(lp0
(dp1
S'line'
p2
S'Furthermore, Ye were found exclusively associated with CD103(+) DCs in the MLNs from wild-type mice, but not from CCR7(-/-) mice, demonstrating a CCR7 dependent transport of Ye by CD103(+) DCs from LP to the MLNs.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I55
sS'uniprot'
p8
VP38570
p9
sS'lengthInChars'
p10
I12
sS'name'
p11
VCD103(+) DCs
p12
sS'lengthInWords'
p13
I2
sa(dp14
g7
I55
sg8
VP38570
p15
sg10
I12
sg11
VCD103(+) DCs
p16
sg13
I2
sa(dp17
g7
I114
sg8
VP32248
p18
sg10
I4
sg11
VCCR7
p19
sg13
I1
sa(dp20
g7
I114
sg8
VP32248
p21
sg10
I4
sg11
VCCR7
p22
sg13
I1
sasS'diseases'
p23
(lp24
(dp25
g7
I75
sS'cui'
p26
VC0026691
p27
sg10
I4
sg11
VMLNs
p28
sg13
I1
sa(dp29
g7
I75
sg26
VC0026691
p30
sg10
I4
sg11
VMLNs
p31
sg13
I1
sa(dp32
g7
I64
sg26
VC0268238
p33
sg10
I3
sg11
VDCs
p34
sg13
I1
sa(dp35
g7
I64
sg26
VC0268238
p36
sg10
I3
sg11
VDCs
p37
sg13
I1
sasa(dp38
g2
S'Although extensive studies have demonstrated the importance of the mesenteric lymph nodes (MLNs) and intestinal CD103(+) dendritic cells (DCs) in driving small intestinal tolerance to protein antigen, the structural and immunological basis of colonic tolerance remain poorly understood.\n'
p39
sg4
(lp40
sg23
(lp41
(dp42
g7
I171
sg26
VC0020963
p43
sg10
I9
sg11
Vtolerance
p44
sg13
I1
sa(dp45
g7
I67
sg26
VC0026691
p46
sg10
I22
sg11
Vmesenteric lymph nodes
p47
sg13
I3
sa(dp48
g7
I138
sg26
VC0268238
p49
sg10
I3
sg11
VDCs
p50
sg13
I1
sa(dp51
g7
I91
sg26
VC0026691
p52
sg10
I4
sg11
VMLNs
p53
sg13
I1
sa(dp54
g7
I171
sg26
VC0020963
p55
sg10
I9
sg11
Vtolerance
p56
sg13
I1
sa(dp57
g7
I121
sg26
VC0268238
p58
sg10
I15
sg11
Vdendritic cells
p59
sg13
I2
sasa(dp60
g2
S'Despite tolerance development, CD103(+)CD11b(+) DCs, which are the major migratory DC population in the MLNs, and the tolerance-related retinoic acid-generating enzyme RALDH2 were virtually absent from the ILNs.\n'
p61
sg4
(lp62
(dp63
g7
I168
sg8
S''
p64
sg10
I6
sg11
VRALDH2
p65
sg13
I1
sa(dp66
g7
I31
sg8
VP38570
p67
sg10
I20
sg11
VCD103(+)CD11b(+) DCs
p68
sg13
I2
sasg23
(lp69
(dp70
g7
I8
sg26
VC0020963
p71
sg10
I9
sg11
Vtolerance
p72
sg13
I1
sa(dp73
g7
I48
sg26
VC0268238
p74
sg10
I3
sg11
VDCs
p75
sg13
I1
sa(dp76
g7
I8
sg26
VC0020963
p77
sg10
I9
sg11
Vtolerance
p78
sg13
I1
sa(dp79
g7
I104
sg26
VC0026691
p80
sg10
I4
sg11
VMLNs
p81
sg13
I1
sasa(dp82
g2
S'Here, we demonstrate that GVHD markedly enhances alloantigen presentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103(+)CD11b(-) dendritic cells (DCs) that migrate from the colon under the influence of CCR7.\n'
p83
sg4
(lp84
(dp85
g7
I224
sg8
VP32248
p86
sg10
I4
sg11
VCCR7
p87
sg13
I1
sa(dp88
g7
I134
sg8
VP38570
p89
sg10
I16
sg11
VCD103(+)CD11b(-)
p90
sg13
I1
sasg23
(lp91
(dp92
g7
I85
sg26
VC0026691
p93
sg10
I22
sg11
Vmesenteric lymph nodes
p94
sg13
I3
sa(dp95
g7
I168
sg26
VC0268238
p96
sg10
I3
sg11
VDCs
p97
sg13
I1
sa(dp98
g7
I26
sg26
VC0018133
p99
sg10
I4
sg11
VGVHD
p100
sg13
I1
sa(dp101
g7
I109
sg26
VC0026691
p102
sg10
I4
sg11
VmLNs
p103
sg13
I1
sa(dp104
g7
I151
sg26
VC0268238
p105
sg10
I15
sg11
Vdendritic cells
p106
sg13
I2
sasa(dp107
g2
S'CD103(+) dendritic cells (DCs) continuously migrate from the intestine to the mesenteric lymph nodes (MLNs) and maintain tolerance by driving the development of regulatory T cells (Treg) in the gut.\n'
p108
sg4
(lp109
(dp110
g7
I0
sg8
VP38570
p111
sg10
I5
sg11
VCD103
p112
sg13
I1
sasg23
(lp113
(dp114
g7
I26
sg26
VC0268238
p115
sg10
I3
sg11
VDCs
p116
sg13
I1
sa(dp117
g7
I78
sg26
VC0026691
p118
sg10
I22
sg11
Vmesenteric lymph nodes
p119
sg13
I3
sa(dp120
g7
I121
sg26
VC0020963
p121
sg10
I9
sg11
Vtolerance
p122
sg13
I1
sa(dp123
g7
I102
sg26
VC0026691
p124
sg10
I4
sg11
VMLNs
p125
sg13
I1
sa(dp126
g7
I9
sg26
VC0268238
p127
sg10
I15
sg11
Vdendritic cells
p128
sg13
I2
sasa(dp129
g2
S'Treatment with PBS followed by 1 single dose of VSL#3, 18 h before killing, was associated with a 2-fold increase in CD103(+)CD11c(+) dendritic cells in MLNs and PPs.\n'
p130
sg4
(lp131
(dp132
g7
I117
sg8
VP38570
p133
sg10
I13
sg11
VCD103(+)CD11c
p134
sg13
I1
sasg23
(lp135
(dp136
g7
I162
sg26
VC0265259
p137
sg10
I3
sg11
VPPs
p138
sg13
I1
sa(dp139
g7
I15
sg26
VC1720830
p140
sg10
I3
sg11
VPBS
p141
sg13
I1
sa(dp142
g7
I153
sg26
VC0026691
p143
sg10
I4
sg11
VMLNs
p144
sg13
I1
sasa(dp145
g2
S'Reduced numbers of Th17 cells, suppressed interleukin (IL)-6 production by intestinal explants, and increased Tregs and CD103-positive regulatory dendritic cells in mesenteric lymph nodes (MLNs) were observed.\n'
p146
sg4
(lp147
(dp148
g7
I42
sg8
VP60568
p149
sg10
I18
sg11
Vinterleukin (IL)-6
p150
sg13
I2
sa(dp151
g7
I120
sg8
VP38570
p152
sg10
I5
sg11
VCD103
p153
sg13
I1
sasg23
(lp154
(dp155
g7
I189
sg26
VC0026691
p156
sg10
I4
sg11
VMLNs
p157
sg13
I1
sa(dp158
g7
I165
sg26
VC0026691
p159
sg10
I22
sg11
Vmesenteric lymph nodes
p160
sg13
I3
sasa(dp161
g2
S'Thus, oral administration of C. kefyr ameliorated EAE by altering the microflora, accompanied by increased Tregs and CD103-positive regulatory dendritic cells in MLNs and decreased Th17 cells in the intestinal lamina propria.\n'
p162
sg4
(lp163
(dp164
g7
I117
sg8
VP38570
p165
sg10
I5
sg11
VCD103
p166
sg13
I1
sasg23
(lp167
(dp168
g7
I162
sg26
VC0026691
p169
sg10
I4
sg11
VMLNs
p170
sg13
I1
sasa(dp171
g2
S'The proportion of CD103 DCs in PPs and MLNs and IL-10-expressing CD4 T cells of PPs and the LP increased after indomethacin treatment.\n'
p172
sg4
(lp173
(dp174
g7
I31
sg8
g64
sg10
I3
sg11
VPPs
p175
sg13
I1
sa(dp176
g7
I31
sg8
g64
sg10
I3
sg11
VPPs
p177
sg13
I1
sa(dp178
g7
I48
sg8
VP01730
p179
sg10
I22
sg11
VIL-10-expressing CD4 T
p180
sg13
I3
sa(dp181
g7
I39
sg8
VP12872
p182
sg10
I4
sg11
VMLNs
p183
sg13
I1
sa(dp184
g7
I18
sg8
VP38570
p185
sg10
I9
sg11
VCD103 DCs
p186
sg13
I2
sasg23
(lp187
(dp188
g7
I31
sg26
VC0265259
p189
sg10
I3
sg11
VPPs
p190
sg13
I1
sa(dp191
g7
I24
sg26
VC0268238
p192
sg10
I3
sg11
VDCs
p193
sg13
I1
sa(dp194
g7
I31
sg26
VC0265259
p195
sg10
I3
sg11
VPPs
p196
sg13
I1
sa(dp197
g7
I39
sg26
VC0026691
p198
sg10
I4
sg11
VMLNs
p199
sg13
I1
sasa(dp200
g2
S'The PP-null mice showed greater indomethacin-induced enteropathy, fewer CD103 DCs in their MLNs, and lower proportion of IL-10-expressing CD4 T cells of their LP than WT mice, regardless of commensal bacteria.\n'
p201
sg4
(lp202
(dp203
g7
I72
sg8
VP38570
p204
sg10
I9
sg11
VCD103 DCs
p205
sg13
I2
sa(dp206
g7
I121
sg8
VP01730
p207
sg10
I22
sg11
VIL-10-expressing CD4 T
p208
sg13
I3
sasg23
(lp209
(dp210
g7
I53
sg26
VC0021831
p211
sg10
I11
sg11
Venteropathy
p212
sg13
I1
sa(dp213
g7
I91
sg26
VC0026691
p214
sg10
I4
sg11
VMLNs
p215
sg13
I1
sa(dp216
g7
I78
sg26
VC0268238
p217
sg10
I3
sg11
VDCs
p218
sg13
I1
sasa(dp219
g2
S'Naive splenic CD4 T cells co-cultured with CD103 DCs isolated from the MLNs of indomethacin-injected WT mice produced a higher amount of IL-10 compared with those co-cultured with CD103 DCs.\n'
p220
sg4
(lp221
(dp222
g7
I14
sg8
VP01730
p223
sg10
I3
sg11
VCD4
p224
sg13
I1
sa(dp225
g7
I43
sg8
VP38570
p226
sg10
I9
sg11
VCD103 DCs
p227
sg13
I2
sa(dp228
g7
I43
sg8
VP38570
p229
sg10
I9
sg11
VCD103 DCs
p230
sg13
I2
sasg23
(lp231
(dp232
g7
I71
sg26
VC0026691
p233
sg10
I4
sg11
VMLNs
p234
sg13
I1
sa(dp235
g7
I49
sg26
VC0268238
p236
sg10
I3
sg11
VDCs
p237
sg13
I1
sa(dp238
g7
I49
sg26
VC0268238
p239
sg10
I3
sg11
VDCs
p240
sg13
I1
sasa(dp241
g2
S'In rickets, on the other hand, no PTH/PTHrP receptor gene expression was observed in the growth plate from day 8 of a vitamin D-deficient diet.\n'
p242
sg4
(lp243
(dp244
g7
I38
sg8
VP12272
p245
sg10
I19
sg11
VPTHrP receptor gene
p246
sg13
I3
sa(dp247
g7
I34
sg8
VP01270
p248
sg10
I3
sg11
VPTH
p249
sg13
I1
sasg23
(lp250
(dp251
g7
I3
sg26
VC0035579
p252
sg10
I7
sg11
Vrickets
p253
sg13
I1
sasa(dp254
g2
S'These results suggest that alterations in the PTH/PTHrP receptor gene expression are associated with rickets but not with TD.\n'
p255
sg4
(lp256
(dp257
g7
I50
sg8
VP12272
p258
sg10
I19
sg11
VPTHrP receptor gene
p259
sg13
I3
sa(dp260
g7
I46
sg8
VP01270
p261
sg10
I3
sg11
VPTH
p262
sg13
I1
sasg23
(lp263
(dp264
g7
I101
sg26
VC0035579
p265
sg10
I7
sg11
Vrickets
p266
sg13
I1
sasa(dp267
g2
S'The reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.\n'
p268
sg4
(lp269
(dp270
g7
I21
sg8
VP01270
p271
sg10
I3
sg11
VPTH
p272
sg13
I1
sa(dp273
g7
I25
sg8
VP12272
p274
sg10
I19
sg11
VPTHrP receptor gene
p275
sg13
I3
sa(dp276
g7
I21
sg8
VP01270
p277
sg10
I3
sg11
VPTH
p278
sg13
I1
sasg23
(lp279
(dp280
g7
I59
sg26
VC0035579
p281
sg10
I7
sg11
Vrickets
p282
sg13
I1
sasa(dp283
g2
S'What is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.\n'
p284
sg4
(lp285
(dp286
g7
I105
sg8
g64
sg10
I6
sg11
VSnapin
p287
sg13
I1
sa(dp288
g7
I59
sg8
g64
sg10
I6
sg11
VCav1.3
p289
sg13
I1
sasg23
(lp290
(dp291
g7
I171
sg26
VC0004238
p292
sg10
I2
sg11
VAF
p293
sg13
I1
sa(dp294
g7
I150
sg26
VC0004238
p295
sg10
I19
sg11
Vatrial fibrillation
p296
sg13
I2
sasa(dp297
g2
S'Furthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.\n'
p298
sg4
(lp299
(dp300
g7
I29
sg8
g64
sg10
I15
sg11
VCav1.3 channels
p301
sg13
I2
sasg23
(lp302
(dp303
g7
I59
sg26
VC0155709
p304
sg10
I31
sg11
Vatrial fibrillation and flutter
p305
sg13
I4
sa(dp306
g7
I13
sg26
VC0544461
p307
sg10
I12
sg11
Vinactivation
p308
sg13
I1
sasa(dp309
g2
S'The significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.\n'
p310
sg4
(lp311
(dp312
g7
I139
sg8
g64
sg10
I6
sg11
VCav1.3
p313
sg13
I1
sasg23
(lp314
(dp315
g7
I151
sg26
VC0596988
p316
sg10
I6
sg11
Vmutant
p317
sg13
I1
sa(dp318
g7
I114
sg26
VC0004238
p319
sg10
I19
sg11
Vatrial fibrillation
p320
sg13
I2
sasa(dp321
g2
S'MRS studies (MRI 1.5 T unit) were performed in 49 patients with schizophrenia (30 with auditory hallucinations and 19 without auditory hallucinations) and 37 controls.\n'
p322
sg4
(lp323
sg23
(lp324
(dp325
g7
I87
sg26
VC0233762
p326
sg10
I23
sg11
Vauditory hallucinations
p327
sg13
I2
sa(dp328
g7
I64
sg26
VC0036341
p329
sg10
I13
sg11
Vschizophrenia
p330
sg13
I1
sa(dp331
g7
I87
sg26
VC0233762
p332
sg10
I23
sg11
Vauditory hallucinations
p333
sg13
I2
sa(dp334
g7
I0
sg26
VC0025235
p335
sg10
I3
sg11
VMRS
p336
sg13
I1
sasa(dp337
g2
S'As a first step towards understanding the role of OPN in retinal degeneration (RD), we examined changes in OPN expression in a mouse model of RD induced by exposure to a blue light-emitting diode (LED).\n'
p338
sg4
(lp339
(dp340
g7
I50
sg8
VP10451
p341
sg10
I3
sg11
VOPN
p342
sg13
I1
sasg23
(lp343
(dp344
g7
I57
sg26
VC0035304
p345
sg10
I20
sg11
Vretinal degeneration
p346
sg13
I2
sa(dp347
g7
I79
sg26
VC0035304
p348
sg10
I2
sg11
VRD
p349
sg13
I1
sa(dp350
g7
I79
sg26
VC0035304
p351
sg10
I2
sg11
VRD
p352
sg13
I1
sasa(dp353
g2
S'Similarly, those who had retinal disease had higher osteopontin concentrations than those without (16.8+/-2 vs. 12.4+/-3 mg/L; p=0.005).\n'
p354
sg4
(lp355
(dp356
g7
I52
sg8
VP10451
p357
sg10
I11
sg11
Vosteopontin
p358
sg13
I1
sasg23
(lp359
(dp360
g7
I25
sg26
VC0035309
p361
sg10
I15
sg11
Vretinal disease
p362
sg13
I2
sasa(dp363
g2
S'Recent studies show overexpressed ENAH in several cancer types, and ENAH correlates with tumor invasiveness.\n'
p364
sg4
(lp365
(dp366
g7
I34
sg8
g64
sg10
I4
sg11
VENAH
p367
sg13
I1
sasg23
(lp368
(dp369
g7
I50
sg26
VC0006826
p370
sg10
I6
sg11
Vcancer
p371
sg13
I1
sa(dp372
g7
I89
sg26
VC0027651
p373
sg10
I5
sg11
Vtumor
p374
sg13
I1
sasa(dp375
g2
S'This study aimed to investigate the expression and function of ENAH in primary gastric adenocarcinoma, and its prognostic significance.\n'
p376
sg4
(lp377
(dp378
g7
I63
sg8
g64
sg10
I4
sg11
VENAH
p379
sg13
I1
sasg23
(lp380
(dp381
g7
I79
sg26
VC0278701
p382
sg10
I22
sg11
Vgastric adenocarcinoma
p383
sg13
I2
sasa(dp384
g2
S'We found significantly increased mRNA (P = 0.0283) and protein (P = 0.0301) expression of ENAH in gastric cancer tissues.\n'
p385
sg4
(lp386
(dp387
g7
I90
sg8
g64
sg10
I4
sg11
VENAH
p388
sg13
I1
sasg23
(lp389
(dp390
g7
I98
sg26
VC0024623
p391
sg10
I14
sg11
Vgastric cancer
p392
sg13
I2
sasa(dp393
g2
S'We also analyzed data of 155 gastric cancer cases from The Cancer Genome Atlas (TCGA) and found that ENAH expression significantly correlated with age (P = 0.003), T stage (P = 0.023) and prognosis (P = 0.05).\n'
p394
sg4
(lp395
(dp396
g7
I101
sg8
g64
sg10
I4
sg11
VENAH
p397
sg13
I1
sasg23
(lp398
(dp399
g7
I29
sg26
VC0024623
p400
sg10
I14
sg11
Vgastric cancer
p401
sg13
I2
sa(dp402
g7
I59
sg26
VC0006826
p403
sg10
I6
sg11
VCancer
p404
sg13
I1
sasa(dp405
g2
S'Furthermore, the function of ENAH in cell proliferation, colony formation, cell migration and invasion of gastric cancer cells was analyzed in vitro.\n'
p406
sg4
(lp407
(dp408
g7
I29
sg8
g64
sg10
I4
sg11
VENAH
p409
sg13
I1
sasg23
(lp410
(dp411
g7
I42
sg26
VC0334094
p412
sg10
I13
sg11
Vproliferation
p413
sg13
I1
sa(dp414
g7
I94
sg26
VC2699153
p415
sg10
I8
sg11
Vinvasion
p416
sg13
I1
sa(dp417
g7
I106
sg26
VC0024623
p418
sg10
I14
sg11
Vgastric cancer
p419
sg13
I2
sasa(dp420
g2
S'Our research suggests that ENAH might play promoting functions in carcinogenesis and progression of gastric cancer, and may serve as a valuable prognostic marker for primary gastric adenocarcinoma patients.\n'
p421
sg4
(lp422
(dp423
g7
I27
sg8
g64
sg10
I4
sg11
VENAH
p424
sg13
I1
sasg23
(lp425
(dp426
g7
I66
sg26
VC0596263
p427
sg10
I14
sg11
Vcarcinogenesis
p428
sg13
I1
sa(dp429
g7
I100
sg26
VC0024623
p430
sg10
I14
sg11
Vgastric cancer
p431
sg13
I2
sa(dp432
g7
I174
sg26
VC0278701
p433
sg10
I22
sg11
Vgastric adenocarcinoma
p434
sg13
I2
sasa(dp435
g2
S'We discovered and validated novel differences in the splicing of genes known to be relevant to lung cancer biology, such as NFIB, ENAH or SPAG9.\n'
p436
sg4
(lp437
(dp438
g7
I124
sg8
g64
sg10
I4
sg11
VNFIB
p439
sg13
I1
sa(dp440
g7
I130
sg8
g64
sg10
I4
sg11
VENAH
p441
sg13
I1
sasg23
(lp442
(dp443
g7
I95
sg26
VC0684249
p444
sg10
I11
sg11
Vlung cancer
p445
sg13
I2
sasa(dp446
g2
S'The expression of ENAH isoform 11a has been shown to be elevated in breast cancers that express HER2.\n'
p447
sg4
(lp448
(dp449
g7
I96
sg8
VP04626
p450
sg10
I4
sg11
VHER2
p451
sg13
I1
sa(dp452
g7
I18
sg8
g64
sg10
I16
sg11
VENAH isoform 11a
p453
sg13
I3
sasg23
(lp454
(dp455
g7
I68
sg26
VC0006142
p456
sg10
I14
sg11
Vbreast cancers
p457
sg13
I2
sasa(dp458
g2
S'Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).\n'
p459
sg4
(lp460
(dp461
g7
I202
sg8
g64
sg10
I4
sg11
VENAH
p462
sg13
I1
sa(dp463
g7
I8
sg8
VP49760
p464
sg10
I4
sg11
VCLK2
p465
sg13
I1
sa(dp466
g7
I208
sg8
g64
sg10
I4
sg11
VMENA
p467
sg13
I1
sasg23
(lp468
(dp469
g7
I99
sg26
VC0599156
p470
sg10
I10
sg11
Vtransition
p471
sg13
I1
sa(dp472
g7
I24
sg26
VC0678222
p473
sg10
I13
sg11
Vbreast cancer
p474
sg13
I2
sasa(dp475
g2
S'We describe a woman with a metastatic neuroendocrine tumor who developed NME 6 years after diagnosis of the tumor.\n'
p476
sg4
(lp477
sg23
(lp478
(dp479
g7
I53
sg26
VC0027651
p480
sg10
I5
sg11
Vtumor
p481
sg13
I1
sa(dp482
g7
I38
sg26
VC0206754
p483
sg10
I20
sg11
Vneuroendocrine tumor
p484
sg13
I2
sasa(dp485
g2
S'The multiplex amplification reaction includes six STR loci from the European standard set of loci (ESS) for DNA databases (D3S1358, D8S1179, D21S11, THO1, FGA and VWA) as well as four additional STR systems selected for their robustness (D2S1338, D12S391, TPOX and D5S818) together with the sex-specific locus amelogenin.\n'
p486
sg4
(lp487
(dp488
g7
I149
sg8
VP82979
p489
sg10
I4
sg11
VTHO1
p490
sg13
I1
sa(dp491
g7
I50
sg8
VP49675
p492
sg10
I8
sg11
VSTR loci
p493
sg13
I2
sa(dp494
g7
I256
sg8
VP40225
p495
sg10
I4
sg11
VTPOX
p496
sg13
I1
sa(dp497
g7
I155
sg8
VP02671
p498
sg10
I3
sg11
VFGA
p499
sg13
I1
sa(dp500
g7
I291
sg8
g64
sg10
I29
sg11
Vsex-specific locus amelogenin
p501
sg13
I3
sasg23
(lp502
(dp503
g7
I14
sg26
VC1705759
p504
sg10
I13
sg11
Vamplification
p505
sg13
I1
sasa(dp506
g2
S'No statistically significant associations at the genome-wide level were observed with shift work or chronotype, though based on raw P values and absolute effect sizes, there were suggestive associations in genes that have been previously linked with cancer (e.g., BACH2, JRK, RPS6KA2) and type-2 diabetes (e.g., KCNQ1).\n'
p507
sg4
(lp508
(dp509
g7
I312
sg8
VP51787
p510
sg10
I5
sg11
VKCNQ1
p511
sg13
I1
sa(dp512
g7
I271
sg8
VP48549
p513
sg10
I3
sg11
VJRK
p514
sg13
I1
sa(dp515
g7
I264
sg8
g64
sg10
I5
sg11
VBACH2
p516
sg13
I1
sa(dp517
g7
I276
sg8
g64
sg10
I7
sg11
VRPS6KA2
p518
sg13
I1
sasg23
(lp519
(dp520
g7
I296
sg26
VC0011849
p521
sg10
I8
sg11
Vdiabetes
p522
sg13
I1
sa(dp523
g7
I250
sg26
VC0006826
p524
sg10
I6
sg11
Vcancer
p525
sg13
I1
sasa(dp526
g2
S'BACH2, a B-cell-specific transcription factor, plays a critical role in oxidative stress-mediated drug resistance in mantle cell lymphoma (MCL); however, the biological functions of BACH2 and its regulation of B-cell malignancies in chronic hypoxic microenvironment have not been studied.\n'
p527
sg4
(lp528
sg23
(lp529
(dp530
g7
I72
sg26
VC0242606
p531
sg10
I16
sg11
Voxidative stress
p532
sg13
I2
sa(dp533
g7
I139
sg26
VC1708350
p534
sg10
I3
sg11
VMCL
p535
sg13
I1
sa(dp536
g7
I117
sg26
VC0334634
p537
sg10
I20
sg11
Vmantle cell lymphoma
p538
sg13
I3
sa(dp539
g7
I241
sg26
VC0242184
p540
sg10
I7
sg11
Vhypoxic
p541
sg13
I1
sa(dp542
g7
I217
sg26
VC0006826
p543
sg10
I12
sg11
Vmalignancies
p544
sg13
I1
sasa(dp545
g2
S'Next, we analyzed the contribution of BACH2 negativity to aggressiveness in EBV-positive B-cell lymphomas using FL-18 (EBV-negative) and FL-18-EB cells (FL-18 sister cell line, EBV-positive).\n'
p546
sg4
(lp547
sg23
(lp548
(dp549
g7
I58
sg26
VC0001807
p550
sg10
I14
sg11
Vaggressiveness
p551
sg13
I1
sa(dp552
g7
I89
sg26
VC0079731
p553
sg10
I16
sg11
VB-cell lymphomas
p554
sg13
I2
sasa(dp555
g2
S'The mig gene of Streptococcus dysgalactiae, a major bovine mastitis pathogen, encodes two plasma protein-binding receptors, alpha2-macroglobulin (alpha2-M) and immunoglobulin G (IgG).\n'
p556
sg4
(lp557
(dp558
g7
I90
sg8
VP63244
p559
sg10
I32
sg11
Vplasma protein-binding receptors
p560
sg13
I3
sa(dp561
g7
I178
sg8
g64
sg10
I3
sg11
VIgG
p562
sg13
I1
sa(dp563
g7
I146
sg8
VP01023
p564
sg10
I8
sg11
Valpha2-M
p565
sg13
I1
sa(dp566
g7
I160
sg8
g64
sg10
I16
sg11
Vimmunoglobulin G
p567
sg13
I2
sa(dp568
g7
I124
sg8
VP01023
p569
sg10
I20
sg11
Valpha2-macroglobulin
p570
sg13
I1
sasg23
(lp571
(dp572
g7
I52
sg26
VC0024895
p573
sg10
I15
sg11
Vbovine mastitis
p574
sg13
I2
sasa(dp575
g2
S'Two are novel associations (top single-nucleotide polymorphism rs379123 in MYO1D and rs9590614 in VMA8) located within genes that function in cell-cell signaling and cell migration, and five are in loci previously associated with chronic obstructive pulmonary disease susceptibility (HHIP, IREB2/CHRNA3, CYP2A6/ADCK, TGFB2, and MMP12).\n'
p576
sg4
(lp577
(dp578
g7
I75
sg8
g64
sg10
I5
sg11
VMYO1D
p579
sg13
I1
sa(dp580
g7
I317
sg8
VP37173
p581
sg10
I5
sg11
VTGFB2
p582
sg13
I1
sa(dp583
g7
I290
sg8
VP48200
p584
sg10
I5
sg11
VIREB2
p585
sg13
I1
sa(dp586
g7
I284
sg8
g64
sg10
I4
sg11
VHHIP
p587
sg13
I1
sa(dp588
g7
I296
sg8
VP32297
p589
sg10
I6
sg11
VCHRNA3
p590
sg13
I1
sa(dp591
g7
I328
sg8
VP39900
p592
sg10
I5
sg11
VMMP12
p593
sg13
I1
sa(dp594
g7
I98
sg8
g64
sg10
I4
sg11
VVMA8
p595
sg13
I1
sasg23
(lp596
(dp597
g7
I230
sg26
VC0024117
p598
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p599
sg13
I4
sasa(dp600
g2
S"Recent studies have implicated the soluble form of EPCR (sEPCR) in Wegener's granulomatosis, Behcet's disease, and systemic lupus erythematosus.\n"
p601
sg4
(lp602
(dp603
g7
I51
sg8
g64
sg10
I4
sg11
VEPCR
p604
sg13
I1
sasg23
(lp605
(dp606
g7
I93
sg26
VC0004943
p607
sg10
I16
sg11
VBehcet's disease
p608
sg13
I2
sa(dp609
g7
I67
sg26
VC0043092
p610
sg10
I24
sg11
VWegener's granulomatosis
p611
sg13
I2
sa(dp612
g7
I115
sg26
VC0024141
p613
sg10
I28
sg11
Vsystemic lupus erythematosus
p614
sg13
I3
sasa(dp615
g2
S"To assess the relevance of this plasma protein in Wegener's granulomatosis (WG), sEPCR levels were measured in sera obtained from WG patients and related to disease activity, sTM levels, and other known markers of disease activity.\n"
p616
sg4
(lp617
(dp618
g7
I175
sg8
g64
sg10
I3
sg11
VsTM
p619
sg13
I1
sasg23
(lp620
(dp621
g7
I76
sg26
VC0043092
p622
sg10
I2
sg11
VWG
p623
sg13
I1
sa(dp624
g7
I50
sg26
VC0043092
p625
sg10
I24
sg11
VWegener's granulomatosis
p626
sg13
I2
sa(dp627
g7
I76
sg26
VC0043092
p628
sg10
I2
sg11
VWG
p629
sg13
I1
sasa(dp630
g2
S'The authors herein present a case of chronic cicatrizing conjunctivitis, cicatricial entropion, and trichiasis caused by a rare entity called linear IgA bullous dermatosis.\n'
p631
sg4
(lp632
(dp633
g7
I149
sg8
VP11912
p634
sg10
I3
sg11
VIgA
p635
sg13
I1
sasg23
(lp636
(dp637
g7
I100
sg26
VC0221259
p638
sg10
I10
sg11
Vtrichiasis
p639
sg13
I1
sa(dp640
g7
I45
sg26
VC1274790
p641
sg10
I26
sg11
Vcicatrizing conjunctivitis
p642
sg13
I2
sa(dp643
g7
I73
sg26
VC0155191
p644
sg10
I21
sg11
Vcicatricial entropion
p645
sg13
I2
sa(dp646
g7
I142
sg26
VC0406650
p647
sg10
I29
sg11
Vlinear IgA bullous dermatosis
p648
sg13
I4
sasa(dp649
g2
S'The etiology of blepharochalasis has yet to be fully elucidated, but histpathologic examinations indicate that elastolytic activity, immunoglobulin A (IgA), and other inflammatory processes might play a substantial role in the pathogenesis of the disease.\n'
p650
sg4
(lp651
(dp652
g7
I151
sg8
VP11912
p653
sg10
I3
sg11
VIgA
p654
sg13
I1
sa(dp655
g7
I133
sg8
VP11912
p656
sg10
I16
sg11
Vimmunoglobulin A
p657
sg13
I2
sasg23
(lp658
(dp659
g7
I16
sg26
VC0005742
p660
sg10
I16
sg11
Vblepharochalasis
p661
sg13
I1
sa(dp662
g7
I227
sg26
VC0699748
p663
sg10
I12
sg11
Vpathogenesis
p664
sg13
I1
sasa(dp665
g2
S'Neurological symptoms of patients with p.Cys89Tyr mutation in the CD59 gene include recurrent peripheral neuropathy resembling Guillain-Barre syndrome, characterized by sensory-motor demyelinating neuropathy with secondary axonal damage and moderate enhancement of the nerve roots on spine MRI, together with recurrent strokes and retinal involvement.\n'
p666
sg4
(lp667
(dp668
g7
I66
sg8
VP13987
p669
sg10
I9
sg11
VCD59 gene
p670
sg13
I2
sasg23
(lp671
(dp672
g7
I319
sg26
VC0038454
p673
sg10
I7
sg11
Vstrokes
p674
sg13
I1
sa(dp675
g7
I94
sg26
VC0031117
p676
sg10
I21
sg11
Vperipheral neuropathy
p677
sg13
I2
sa(dp678
g7
I0
sg26
VC0235031
p679
sg10
I21
sg11
VNeurological symptoms
p680
sg13
I2
sa(dp681
g7
I127
sg26
VC0018378
p682
sg10
I23
sg11
VGuillain-Barre syndrome
p683
sg13
I2
sa(dp684
g7
I183
sg26
VC0270922
p685
sg10
I24
sg11
Vdemyelinating neuropathy
p686
sg13
I2
sasa(dp687
g2
S'Three additional mutations in CD59, leading to loss of function, have been described, and overall, 12/12 (100%) of patients with any mutation presented with neurological symptoms; 11/12 (92%) patients presented with recurrent peripheral neuropathy, 6/12 (50%) with recurrent strokes, and 1/12 (8%) with retinal involvement.\n'
p688
sg4
(lp689
(dp690
g7
I30
sg8
VP13987
p691
sg10
I4
sg11
VCD59
p692
sg13
I1
sasg23
(lp693
(dp694
g7
I157
sg26
VC0235031
p695
sg10
I21
sg11
Vneurological symptoms
p696
sg13
I2
sa(dp697
g7
I275
sg26
VC0038454
p698
sg10
I7
sg11
Vstrokes
p699
sg13
I1
sa(dp700
g7
I226
sg26
VC0031117
p701
sg10
I21
sg11
Vperipheral neuropathy
p702
sg13
I2
sasa(dp703
g2
S'The Epi4K consortium recently identified four de novo mutations in the Gamma-aminobutyric acid type A (GABAA ) receptor Beta3 subunit gene GABRB3 and one in the Beta1 subunit gene GABRB1 in children with epileptic encephalopathies (EEs) Lennox-Gastaut syndrome (LGS) or infantile spasms (IS).\n'
p704
sg4
(lp705
(dp706
g7
I161
sg8
VP18505
p707
sg10
I25
sg11
VBeta1 subunit gene GABRB1
p708
sg13
I4
sa(dp709
g7
I120
sg8
VP28472
p710
sg10
I25
sg11
VBeta3 subunit gene GABRB3
p711
sg13
I4
sasg23
(lp712
(dp713
g7
I262
sg26
VC0023003
p714
sg10
I3
sg11
VLGS
p715
sg13
I1
sa(dp716
g7
I204
sg26
VC0014544
p717
sg10
I9
sg11
Vepileptic
p718
sg13
I1
sa(dp719
g7
I214
sg26
VC0085584
p720
sg10
I16
sg11
Vencephalopathies
p721
sg13
I1
sa(dp722
g7
I270
sg26
VC0037769
p723
sg10
I16
sg11
Vinfantile spasms
p724
sg13
I2
sa(dp725
g7
I288
sg26
VC0037769
p726
sg10
I2
sg11
VIS
p727
sg13
I1
sa(dp728
g7
I232
sg26
VC0085584
p729
sg10
I3
sg11
VEEs
p730
sg13
I1
sa(dp731
g7
I237
sg26
VC0238111
p732
sg10
I23
sg11
VLennox-Gastaut syndrome
p733
sg13
I2
sasa(dp734
g2
S'A GABA(A) receptor Beta3 subunit mutation, G32R, has been associated with childhood absence epilepsy.\n'
p735
sg4
(lp736
(dp737
g7
I2
sg8
VP18507
p738
sg10
I30
sg11
VGABA(A) receptor Beta3 subunit
p739
sg13
I4
sasg23
(lp740
(dp741
g7
I74
sg26
VC0014553
p742
sg10
I26
sg11
Vchildhood absence epilepsy
p743
sg13
I3
sasa(dp744
g2
S'Foram pesquisados artigos escritos em ingles na base de dados PubMed com as palavras-chave "CPAP", "mask" e "obstructive sleep apnea".\n'
p745
sg4
(lp746
sg23
(lp747
(dp748
g7
I109
sg26
VC0520679
p749
sg10
I23
sg11
Vobstructive sleep apnea
p750
sg13
I3
sasa(dp751
g2
S'Based on these data, we hypothesized that molecular imaging of microglia activation might serve as a tool to predict drug refractoriness of epilepsy.\n'
p752
sg4
(lp753
sg23
(lp754
(dp755
g7
I140
sg26
VC0014544
p756
sg10
I8
sg11
Vepilepsy
p757
sg13
I1
sasa(dp758
g2
S'Mutations in SLC9A6 have been reported in X-linked Christianson syndrome associating severe to profound intellectual deficiency and an Angelman-like phenotype with microcephaly, absent speech, ataxia with progressive cerebellar atrophy, ophthalmoplegia, epilepsy, and neurological regression.\n'
p759
sg4
(lp760
(dp761
g7
I13
sg8
g64
sg10
I6
sg11
VSLC9A6
p762
sg13
I1
sasg23
(lp763
(dp764
g7
I193
sg26
VC0004134
p765
sg10
I6
sg11
Vataxia
p766
sg13
I1
sa(dp767
g7
I64
sg26
VC0039082
p768
sg10
I8
sg11
Vsyndrome
p769
sg13
I1
sa(dp770
g7
I164
sg26
VC0025958
p771
sg10
I12
sg11
Vmicrocephaly
p772
sg13
I1
sa(dp773
g7
I254
sg26
VC0014544
p774
sg10
I8
sg11
Vepilepsy
p775
sg13
I1
sa(dp776
g7
I237
sg26
VC0029089
p777
sg10
I15
sg11
Vophthalmoplegia
p778
sg13
I1
sa(dp779
g7
I104
sg26
VC0683322
p780
sg10
I23
sg11
Vintellectual deficiency
p781
sg13
I2
sa(dp782
g7
I217
sg26
VC0740279
p783
sg10
I18
sg11
Vcerebellar atrophy
p784
sg13
I2
sasa(dp785
g2
S'Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999 in which affected males exhibited profound intellectual disability, autism, drug-resistant epilepsy, ophthalmoplegia, mild craniofacial dysmorphism, microcephaly, and ataxia.\n'
p786
sg4
(lp787
(dp788
g7
I13
sg8
g64
sg10
I6
sg11
VSLC9A6
p789
sg13
I1
sasg23
(lp790
(dp791
g7
I191
sg26
VC0014544
p792
sg10
I8
sg11
Vepilepsy
p793
sg13
I1
sa(dp794
g7
I143
sg26
VC0025362
p795
sg10
I23
sg11
Vintellectual disability
p796
sg13
I2
sa(dp797
g7
I236
sg26
VC1737329
p798
sg10
I11
sg11
Vdysmorphism
p799
sg13
I1
sa(dp800
g7
I168
sg26
VC0004352
p801
sg10
I6
sg11
Vautism
p802
sg13
I1
sa(dp803
g7
I249
sg26
VC0025958
p804
sg10
I12
sg11
Vmicrocephaly
p805
sg13
I1
sa(dp806
g7
I201
sg26
VC0029089
p807
sg10
I15
sg11
Vophthalmoplegia
p808
sg13
I1
sa(dp809
g7
I51
sg26
VC0039082
p810
sg10
I8
sg11
Vsyndrome
p811
sg13
I1
sa(dp812
g7
I267
sg26
VC0004134
p813
sg10
I6
sg11
Vataxia
p814
sg13
I1
sasa(dp815
g2
S'Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).\n'
p816
sg4
(lp817
(dp818
g7
I0
sg8
g64
sg10
I5
sg11
VSocs2
p819
sg13
I1
sa(dp820
g7
I78
sg8
VP42229
p821
sg10
I20
sg11
VStat5 response genes
p822
sg13
I3
sa(dp823
g7
I68
sg8
VP19235
p824
sg10
I4
sg11
VEPOR
p825
sg13
I1
sa(dp826
g7
I73
sg8
g64
sg10
I4
sg11
VJak2
p827
sg13
I1
sasg23
(lp828
(dp829
g7
I146
sg26
VC0002871
p830
sg10
I6
sg11
Vanemia
p831
sg13
I1
sasa(dp832
g2
S'Moreover, in in vivo models of atopic dermatitis and allergen-induced airway inflammation, SOCS2(-/-) mice show significantly elevated IgE, eosinophilia, type 2 responses, and inflammatory pathology relative to wild-type mice.\n'
p833
sg4
(lp834
(dp835
g7
I91
sg8
g64
sg10
I10
sg11
VSOCS2(-/-)
p836
sg13
I1
sa(dp837
g7
I135
sg8
VP01854
p838
sg10
I3
sg11
VIgE
p839
sg13
I1
sasg23
(lp840
(dp841
g7
I31
sg26
VC0011615
p842
sg10
I17
sg11
Vatopic dermatitis
p843
sg13
I2
sa(dp844
g7
I140
sg26
VC0014457
p845
sg10
I12
sg11
Veosinophilia
p846
sg13
I1
sa(dp847
g7
I189
sg26
VC0677042
p848
sg10
I9
sg11
Vpathology
p849
sg13
I1
sa(dp850
g7
I77
sg26
VC0021368
p851
sg10
I12
sg11
Vinflammation
p852
sg13
I1
sa(dp853
g7
I135
sg26
VC0270850
p854
sg10
I3
sg11
VIgE
p855
sg13
I1
sasa(dp856
g2
S'Heterozygous and homozygous disruption of SOCS2 alleles promoted 166 and 441% increases in tumor load in the small intestine, respectively, accelerated development of colon tumors, and caused severe anemia.\n'
p857
sg4
(lp858
(dp859
g7
I42
sg8
g64
sg10
I13
sg11
VSOCS2 alleles
p860
sg13
I2
sasg23
(lp861
(dp862
g7
I192
sg26
VC0238644
p863
sg10
I13
sg11
Vsevere anemia
p864
sg13
I2
sa(dp865
g7
I91
sg26
VC0027651
p866
sg10
I5
sg11
Vtumor
p867
sg13
I1
sa(dp868
g7
I167
sg26
VC0009375
p869
sg10
I12
sg11
Vcolon tumors
p870
sg13
I2
sasa(dp871
g2
S"In myasthenia gravis, anti-Kv1.4 and anti-Lrp4 have been characterized as promising novel autoantibodies for the diagnosis of hitherto 'seronegative' myasthenia gravis.\n"
p872
sg4
(lp873
(dp874
g7
I37
sg8
g64
sg10
I9
sg11
Vanti-Lrp4
p875
sg13
I1
sa(dp876
g7
I22
sg8
VP22459
p877
sg10
I10
sg11
Vanti-Kv1.4
p878
sg13
I1
sasg23
(lp879
(dp880
g7
I3
sg26
VC0026896
p881
sg10
I17
sg11
Vmyasthenia gravis
p882
sg13
I2
sa(dp883
g7
I3
sg26
VC0026896
p884
sg10
I17
sg11
Vmyasthenia gravis
p885
sg13
I2
sasa(dp886
g2
S'To clarify the role of p33ING1b in tumorigenesis and progression of head and neck squamous cell carcinoma (HNSCC), we examined the expression and subcellular localization of p33ING1b in 214 HNSCC cases in parallel with 60 dysplasia samples and 48 normal epithelium samples by immunohistochemistry, and analyzed correlations of expression of p33ING1b in HNSCC cases with clinicopathological variables, apototic index and expression of 14-3-3n, p300, p21 and PCNA.\n'
p887
sg4
(lp888
(dp889
g7
I434
sg8
g64
sg10
I7
sg11
V14-3-3n
p890
sg13
I1
sa(dp891
g7
I457
sg8
VP12004
p892
sg10
I4
sg11
VPCNA
p893
sg13
I1
sa(dp894
g7
I443
sg8
g64
sg10
I4
sg11
Vp300
p895
sg13
I1
sa(dp896
g7
I449
sg8
VP42857
p897
sg10
I3
sg11
Vp21
p898
sg13
I1
sasg23
(lp899
(dp900
g7
I107
sg26
VC1168401
p901
sg10
I5
sg11
VHNSCC
p902
sg13
I1
sa(dp903
g7
I222
sg26
VC0334044
p904
sg10
I9
sg11
Vdysplasia
p905
sg13
I1
sa(dp906
g7
I107
sg26
VC1168401
p907
sg10
I5
sg11
VHNSCC
p908
sg13
I1
sa(dp909
g7
I107
sg26
VC1168401
p910
sg10
I5
sg11
VHNSCC
p911
sg13
I1
sa(dp912
g7
I68
sg26
VC1168401
p913
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p914
sg13
I6
sa(dp915
g7
I35
sg26
VC0007621
p916
sg10
I13
sg11
Vtumorigenesis
p917
sg13
I1
sasa(dp918
g2
S'Of 34 informative cases of head and neck squamous cell carcinoma, 68% of tumors showed loss of heterozygosity at chromosome 13q33-34, where the ING1 gene is located.\n'
p919
sg4
(lp920
sg23
(lp921
(dp922
g7
I27
sg26
VC1168401
p923
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p924
sg13
I6
sa(dp925
g7
I73
sg26
VC0027651
p926
sg10
I6
sg11
Vtumors
p927
sg13
I1
sasa(dp928
g2
S'Because ING1 resides on the long arm of chromosome 13 (13q34) (a region frequently deleted in many tumor types), we sought to characterize its role in head and neck squamous-cell carcinoma (HNSCC).\n'
p929
sg4
(lp930
sg23
(lp931
(dp932
g7
I190
sg26
VC1168401
p933
sg10
I5
sg11
VHNSCC
p934
sg13
I1
sa(dp935
g7
I99
sg26
VC0027651
p936
sg10
I5
sg11
Vtumor
p937
sg13
I1
sa(dp938
g7
I151
sg26
VC1168401
p939
sg10
I37
sg11
Vhead and neck squamous-cell carcinoma
p940
sg13
I5
sasa(dp941
g2
S'To investigate the diagnostic utility of beta 2 microglobulin (B2-M) levels and analyze this correlation with the activity of inflammatory bowel disease (IBD).\n'
p942
sg4
(lp943
(dp944
g7
I63
sg8
VP61769
p945
sg10
I4
sg11
VB2-M
p946
sg13
I1
sa(dp947
g7
I41
sg8
VP61769
p948
sg10
I20
sg11
Vbeta 2 microglobulin
p949
sg13
I3
sasg23
(lp950
(dp951
g7
I126
sg26
VC0021390
p952
sg10
I26
sg11
Vinflammatory bowel disease
p953
sg13
I3
sa(dp954
g7
I154
sg26
VC0021390
p955
sg10
I3
sg11
VIBD
p956
sg13
I1
sasa(dp957
g2
S"We examined B2-M serum levels in 43 ulcerative colitis (UC) patients, 35 with Crohn's disease (CD) and 30 control subjects, using an enzymatic method.\n"
p958
sg4
(lp959
sg23
(lp960
(dp961
g7
I95
sg26
VC0010346
p962
sg10
I2
sg11
VCD
p963
sg13
I1
sa(dp964
g7
I78
sg26
VC0010346
p965
sg10
I15
sg11
VCrohn's disease
p966
sg13
I2
sa(dp967
g7
I56
sg26
VC0009324
p968
sg10
I2
sg11
VUC
p969
sg13
I1
sa(dp970
g7
I36
sg26
VC0009324
p971
sg10
I18
sg11
Vulcerative colitis
p972
sg13
I2
sasa(dp973
g2
S"Mean B2-M values were significantly higher in ulcerative colitis and Crohn's disease patients than in healthy controls (UC 2.41 +/- 0.87 vs 1.71 +/- 0.44, P = 0.002; CD 2.24 +/- 1.01 vs 1.71 +/- 0.44, P = 0.033).\n"
p974
sg4
(lp975
sg23
(lp976
(dp977
g7
I46
sg26
VC0009324
p978
sg10
I18
sg11
Vulcerative colitis
p979
sg13
I2
sa(dp980
g7
I69
sg26
VC0010346
p981
sg10
I15
sg11
VCrohn's disease
p982
sg13
I2
sasa(dp983
g2
S'A sample of 250 AA participants (134 normotensive controls and 116 with SH (including 98 treatment controlled, SCH: severe controlled hypertension, and 18 treatment resistant, SRH: severe resistant hypertension)) from the Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID) in metro Atlanta had blood analyzed for apelin and visfatin and urine for 8-isoprostane.\n'
p984
sg4
(lp985
(dp986
g7
I359
sg8
VP43490
p987
sg10
I8
sg11
Vvisfatin
p988
sg13
I1
sa(dp989
g7
I348
sg8
g64
sg10
I6
sg11
Vapelin
p990
sg13
I1
sasg23
(lp991
(dp992
g7
I134
sg26
VC0020538
p993
sg10
I12
sg11
Vhypertension
p994
sg13
I1
sa(dp995
g7
I134
sg26
VC0020538
p996
sg10
I12
sg11
Vhypertension
p997
sg13
I1
sasa(dp998
g2
S'The most commonly reported drug-related adverse events among patients receiving regorafenib in the GRID trial were hand-foot skin reaction, hypertension, diarrhoea and fatigue.\n'
p999
sg4
(lp1000
sg23
(lp1001
(dp1002
g7
I154
sg26
VC0011991
p1003
sg10
I9
sg11
Vdiarrhoea
p1004
sg13
I1
sa(dp1005
g7
I140
sg26
VC0020538
p1006
sg10
I12
sg11
Vhypertension
p1007
sg13
I1
sa(dp1008
g7
I168
sg26
VC0015672
p1009
sg10
I7
sg11
Vfatigue
p1010
sg13
I1
sasa(dp1011
g2
S'In rats with middle cerebral artery occlusion (MCAo), a model of stroke, the transhemispheric migration of MHP36 cells labelled with the bimodal contrast agent GRID was detected on magnetic resonance images (MRI) up to 4 weeks following transplantation.\n'
p1012
sg4
(lp1013
sg23
(lp1014
(dp1015
g7
I47
sg26
VC0740391
p1016
sg10
I4
sg11
VMCAo
p1017
sg13
I1
sa(dp1018
g7
I13
sg26
VC0740391
p1019
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p1020
sg13
I4
sa(dp1021
g7
I65
sg26
VC0038454
p1022
sg10
I6
sg11
Vstroke
p1023
sg13
I1
sasa(dp1024
g2
S'Results Compared with the ischemia reperfusion group, both serum cTnI content and myocardial infarct size in the PPENK group decreased; the expression of PINK1, parkin, p62 and LC3B were all up-regulated.\n'
p1025
sg4
(lp1026
(dp1027
g7
I65
sg8
VP19429
p1028
sg10
I4
sg11
VcTnI
p1029
sg13
I1
sa(dp1030
g7
I177
sg8
g64
sg10
I4
sg11
VLC3B
p1031
sg13
I1
sa(dp1032
g7
I154
sg8
g64
sg10
I5
sg11
VPINK1
p1033
sg13
I1
sa(dp1034
g7
I169
sg8
VP37198
p1035
sg10
I3
sg11
Vp62
p1036
sg13
I1
sasg23
(lp1037
(dp1038
g7
I82
sg26
VC0027051
p1039
sg10
I18
sg11
Vmyocardial infarct
p1040
sg13
I2
sa(dp1041
g7
I26
sg26
VC0022116
p1042
sg10
I8
sg11
Vischemia
p1043
sg13
I1
sasa(dp1044
g2
S'Early-onset preeclampsia and IUGR had the highest autophagy protein expression levels, while normal pregnancy and late-onset preeclampsia had the highest LC3B/Beclin-1 ratio.\n'
p1045
sg4
(lp1046
(dp1047
g7
I154
sg8
g64
sg10
I4
sg11
VLC3B
p1048
sg13
I1
sa(dp1049
g7
I159
sg8
g64
sg10
I8
sg11
VBeclin-1
p1050
sg13
I1
sasg23
(lp1051
(dp1052
g7
I12
sg26
VC0032914
p1053
sg10
I12
sg11
Vpreeclampsia
p1054
sg13
I1
sa(dp1055
g7
I12
sg26
VC0032914
p1056
sg10
I12
sg11
Vpreeclampsia
p1057
sg13
I1
sa(dp1058
g7
I29
sg26
VC0015934
p1059
sg10
I4
sg11
VIUGR
p1060
sg13
I1
sasa(dp1061
g2
S'Apoptosis, myocardial infarction size, heart function and myocardial LC3B expression were examined in an in vivo I/R model by the TUNEL assay, TTC/Evan blue staining, echocardiography and immunohistochemicalstaining, respectively.\n'
p1062
sg4
(lp1063
(dp1064
g7
I69
sg8
g64
sg10
I4
sg11
VLC3B
p1065
sg13
I1
sasg23
(lp1066
(dp1067
g7
I11
sg26
VC0027051
p1068
sg10
I21
sg11
Vmyocardial infarction
p1069
sg13
I2
sasa(dp1070
g2
S'Likewise, in vivo exosome injections in rats that underwent I/R injury significantly reduced apoptosis and the myocardial infarct size and upregulated myocardial LC3B expression as well as improved heart function.\n'
p1071
sg4
(lp1072
(dp1073
g7
I162
sg8
g64
sg10
I4
sg11
VLC3B
p1074
sg13
I1
sasg23
(lp1075
(dp1076
g7
I111
sg26
VC0027051
p1077
sg10
I18
sg11
Vmyocardial infarct
p1078
sg13
I2
sasa(dp1079
g2
S'The expression of the VAV proto-oncogene in 57 patients with chronic myeloproliferative disease (CMD), B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin Lymphoma (B-NHL), and 61 with B-cell chronic lymphocytic leukaemia (B-CLL) was analysed.\n'
p1080
sg4
(lp1081
(dp1082
g7
I22
sg8
VP15498
p1083
sg10
I18
sg11
VVAV proto-oncogene
p1084
sg13
I2
sasg23
(lp1085
(dp1086
g7
I152
sg26
VC0079731
p1087
sg10
I27
sg11
VB-cell non-Hodgkin Lymphoma
p1088
sg13
I3
sa(dp1089
g7
I103
sg26
VC0006413
p1090
sg10
I36
sg11
VB-cell acute lymphoblastic leukaemia
p1091
sg13
I4
sa(dp1092
g7
I181
sg26
VC0079731
p1093
sg10
I5
sg11
VB-NHL
p1094
sg13
I1
sa(dp1095
g7
I61
sg26
VC1292778
p1096
sg10
I34
sg11
Vchronic myeloproliferative disease
p1097
sg13
I3
sa(dp1098
g7
I141
sg26
VC0006413
p1099
sg10
I5
sg11
VB-ALL
p1100
sg13
I1
sa(dp1101
g7
I97
sg26
VC1852502
p1102
sg10
I3
sg11
VCMD
p1103
sg13
I1
sa(dp1104
g7
I201
sg26
VC0023434
p1105
sg10
I36
sg11
VB-cell chronic lymphocytic leukaemia
p1106
sg13
I4
sa(dp1107
g7
I239
sg26
VC0023434
p1108
sg10
I5
sg11
VB-CLL
p1109
sg13
I1
sasa(dp1110
g2
S'In this regard, we report the identification of a HLA-A*0201 allele-restricted immunogenic DEPDC1-derived epitope, which is able to induce cytotoxic T lymphocytes (CTL) exerting a strong and specific functional response in vitro toward not only peptide-loaded cells but also triple negative breast cancer (TNBC) cells endogenously expressing the DEPDC1 protein.\n'
p1111
sg4
(lp1112
(dp1113
g7
I50
sg8
VP30447
p1114
sg10
I10
sg11
VHLA-A*0201
p1115
sg13
I1
sa(dp1116
g7
I346
sg8
g64
sg10
I14
sg11
VDEPDC1 protein
p1117
sg13
I2
sasg23
(lp1118
(dp1119
g7
I291
sg26
VC0678222
p1120
sg10
I13
sg11
Vbreast cancer
p1121
sg13
I2
sasa(dp1122
g2
S'Cross-species comparative genomics analysis of progression from pre-invasive ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) revealed 16 genes with concomitant genomic alterations, CCNB2, UBE2C, TOP2A, CEP55, TPX2, BIRC5, KIAA0101, SHCBP1, UBE2T, PTTG1, NUSAP1, DEPDC1, HELLS, CCNB1, KIF4A, and RRM2, that may be involved in tumorigenesis and in the processes of invasion and progression of disease.\n'
p1123
sg4
(lp1124
(dp1125
g7
I281
sg8
g64
sg10
I6
sg11
VDEPDC1
p1126
sg13
I1
sa(dp1127
g7
I259
sg8
g64
sg10
I5
sg11
VUBE2T
p1128
sg13
I1
sa(dp1129
g7
I207
sg8
g64
sg10
I5
sg11
VUBE2C
p1130
sg13
I1
sa(dp1131
g7
I214
sg8
g64
sg10
I5
sg11
VTOP2A
p1132
sg13
I1
sa(dp1133
g7
I266
sg8
g64
sg10
I5
sg11
VPTTG1
p1134
sg13
I1
sa(dp1135
g7
I241
sg8
g64
sg10
I8
sg11
VKIAA0101
p1136
sg13
I1
sa(dp1137
g7
I303
sg8
g64
sg10
I5
sg11
VKIF4A
p1138
sg13
I1
sa(dp1139
g7
I251
sg8
g64
sg10
I6
sg11
VSHCBP1
p1140
sg13
I1
sa(dp1141
g7
I273
sg8
g64
sg10
I6
sg11
VNUSAP1
p1142
sg13
I1
sa(dp1143
g7
I221
sg8
g64
sg10
I5
sg11
VCEP55
p1144
sg13
I1
sa(dp1145
g7
I296
sg8
VP14635
p1146
sg10
I5
sg11
VCCNB1
p1147
sg13
I1
sa(dp1148
g7
I200
sg8
g64
sg10
I5
sg11
VCCNB2
p1149
sg13
I1
sa(dp1150
g7
I314
sg8
VP31350
p1151
sg10
I4
sg11
VRRM2
p1152
sg13
I1
sa(dp1153
g7
I228
sg8
g64
sg10
I4
sg11
VTPX2
p1154
sg13
I1
sasg23
(lp1155
(dp1156
g7
I68
sg26
VC1134719
p1157
sg10
I25
sg11
Vinvasive ductal carcinoma
p1158
sg13
I3
sa(dp1159
g7
I344
sg26
VC0007621
p1160
sg10
I13
sg11
Vtumorigenesis
p1161
sg13
I1
sa(dp1162
g7
I103
sg26
VC0007124
p1163
sg10
I4
sg11
VDCIS
p1164
sg13
I1
sa(dp1165
g7
I77
sg26
VC0007124
p1166
sg10
I24
sg11
Vductal carcinoma in situ
p1167
sg13
I4
sa(dp1168
g7
I139
sg26
VC1449563
p1169
sg10
I3
sg11
VIDC
p1170
sg13
I1
sa(dp1171
g7
I68
sg26
VC1134719
p1172
sg10
I25
sg11
Vinvasive ductal carcinoma
p1173
sg13
I3
sa(dp1174
g7
I382
sg26
VC2699153
p1175
sg10
I8
sg11
Vinvasion
p1176
sg13
I1
sasa(dp1177
g2
S'The objective of the study was to compare the diagnostic yield of home-made ELISA tests based on synthetic chimeric fibrin/filaggrin citrullinated peptides (CFFCPs) with CCP3 and CCP3.1 commercial tests to detect anti-citrullinated protein/peptide antibodies (ACPAs) in rheumatoid arthritis (RA) patients.\n'
p1178
sg4
(lp1179
(dp1180
g7
I179
sg8
g64
sg10
I6
sg11
VCCP3.1
p1181
sg13
I1
sa(dp1182
g7
I170
sg8
g64
sg10
I4
sg11
VCCP3
p1183
sg13
I1
sa(dp1184
g7
I116
sg8
VP22087
p1185
sg10
I6
sg11
Vfibrin
p1186
sg13
I1
sa(dp1187
g7
I123
sg8
VP20930
p1188
sg10
I9
sg11
Vfilaggrin
p1189
sg13
I1
sa(dp1190
g7
I147
sg8
g64
sg10
I17
sg11
Vpeptides (CFFCPs)
p1191
sg13
I2
sasg23
(lp1192
(dp1193
g7
I292
sg26
VC0003873
p1194
sg10
I2
sg11
VRA
p1195
sg13
I1
sa(dp1196
g7
I270
sg26
VC0003873
p1197
sg10
I20
sg11
Vrheumatoid arthritis
p1198
sg13
I2
sasa(dp1199
g2
S'In the present study, we aimed to estimate the concentrations of cytokines (interleukin 6, IL-6, tumor necrosis factor-Alfa, TNF-Alfa) and auto-antibodies (rheumatoid factor IgM isotype, IgM-RF, antinuclear auto-antibodies, ANA, anti-cyclic citrullinated peptide antibodies IgG isotype, IgG anti-CCP3.1, anti-cardiolipin IgG isotype, IgG anti-aCL) in serum of patients with eRA (early rheumatoid arthritis) and HCVrA (hepatitis C virus-related arthropathy) and to assess the utility of IL-6, TNF-Alfa together with IgG anti-CCP and IgM-RF in distinguishing between patients with true eRA and HCVrA, in the idea of using them as differential immunomarkers.\n'
p1200
sg4
(lp1201
(dp1202
g7
I334
sg8
VP53396
p1203
sg10
I12
sg11
VIgG anti-aCL
p1204
sg13
I2
sa(dp1205
g7
I229
sg8
g64
sg10
I56
sg11
Vanti-cyclic citrullinated peptide antibodies IgG isotype
p1206
sg13
I6
sa(dp1207
g7
I125
sg8
VP01375
p1208
sg10
I8
sg11
VTNF-Alfa
p1209
sg13
I1
sa(dp1210
g7
I91
sg8
VP05231
p1211
sg10
I4
sg11
VIL-6
p1212
sg13
I1
sa(dp1213
g7
I374
sg8
VP03372
p1214
sg10
I3
sg11
VeRA
p1215
sg13
I1
sa(dp1216
g7
I287
sg8
VP07320
p1217
sg10
I12
sg11
VIgG anti-CCP
p1218
sg13
I2
sa(dp1219
g7
I91
sg8
VP05231
p1220
sg10
I4
sg11
VIL-6
p1221
sg13
I1
sa(dp1222
g7
I287
sg8
g64
sg10
I15
sg11
VIgG anti-CCP3.1
p1223
sg13
I2
sa(dp1224
g7
I379
sg8
VP01116
p1225
sg10
I26
sg11
Vearly rheumatoid arthritis
p1226
sg13
I3
sa(dp1227
g7
I374
sg8
VP03372
p1228
sg10
I3
sg11
VeRA
p1229
sg13
I1
sa(dp1230
g7
I97
sg8
VP01375
p1231
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p1232
sg13
I3
sa(dp1233
g7
I125
sg8
VP01375
p1234
sg10
I8
sg11
VTNF-Alfa
p1235
sg13
I1
sa(dp1236
g7
I156
sg8
VP04207
p1237
sg10
I37
sg11
Vrheumatoid factor IgM isotype, IgM-RF
p1238
sg13
I5
sa(dp1239
g7
I174
sg8
VP29965
p1240
sg10
I3
sg11
VIgM
p1241
sg13
I1
sa(dp1242
g7
I224
sg8
g64
sg10
I3
sg11
VANA
p1243
sg13
I1
sa(dp1244
g7
I76
sg8
VP05231
p1245
sg10
I13
sg11
Vinterleukin 6
p1246
sg13
I2
sasg23
(lp1247
(dp1248
g7
I418
sg26
VC0019196
p1249
sg10
I11
sg11
Vhepatitis C
p1250
sg13
I2
sa(dp1251
g7
I444
sg26
VC0022408
p1252
sg10
I11
sg11
Varthropathy
p1253
sg13
I1
sa(dp1254
g7
I97
sg26
VC0333516
p1255
sg10
I14
sg11
Vtumor necrosis
p1256
sg13
I2
sa(dp1257
g7
I296
sg26
VC1832526
p1258
sg10
I3
sg11
VCCP
p1259
sg13
I1
sa(dp1260
g7
I385
sg26
VC0003873
p1261
sg10
I20
sg11
Vrheumatoid arthritis
p1262
sg13
I2
sasa(dp1263
g2
S'Logistic regressions were used to investigate whether using both tests (anti-CCP2 and anti-CCP3) gives a better prediction of rheumatoid arthritis.\n'
p1264
sg4
(lp1265
(dp1266
g7
I86
sg8
g64
sg10
I9
sg11
Vanti-CCP3
p1267
sg13
I1
sa(dp1268
g7
I72
sg8
g64
sg10
I9
sg11
Vanti-CCP2
p1269
sg13
I1
sasg23
(lp1270
(dp1271
g7
I126
sg26
VC0003873
p1272
sg10
I20
sg11
Vrheumatoid arthritis
p1273
sg13
I2
sa(dp1274
g7
I9
sg26
VC0684320
p1275
sg10
I11
sg11
Vregressions
p1276
sg13
I1
sasa(dp1277
g2
S'Binary logistic regressions indicated that the likelihood of having rheumatoid arthritis (RA) is significantly higher when testing positive on both CCP2 and CCP3 compared to CCP2 or CCP3 alone.\n'
p1278
sg4
(lp1279
(dp1280
g7
I148
sg8
g64
sg10
I4
sg11
VCCP2
p1281
sg13
I1
sa(dp1282
g7
I157
sg8
g64
sg10
I4
sg11
VCCP3
p1283
sg13
I1
sa(dp1284
g7
I148
sg8
g64
sg10
I4
sg11
VCCP2
p1285
sg13
I1
sa(dp1286
g7
I157
sg8
g64
sg10
I4
sg11
VCCP3
p1287
sg13
I1
sasg23
(lp1288
(dp1289
g7
I16
sg26
VC0684320
p1290
sg10
I11
sg11
Vregressions
p1291
sg13
I1
sa(dp1292
g7
I90
sg26
VC0003873
p1293
sg10
I2
sg11
VRA
p1294
sg13
I1
sa(dp1295
g7
I68
sg26
VC0003873
p1296
sg10
I20
sg11
Vrheumatoid arthritis
p1297
sg13
I2
sasa(dp1298
g2
S'The presence of ACPA was determined by the visually read, qualitative rapid CCPoint(R) test (Euro-Diagnostica, Malmoe, Sweden) compared to routinely used ELISA assays (Immunoscan CCPlus(R)-Euro-Diagnostica, Sweden, and QuantLite(R) CCP3-INOVA Diagnostics Inc., USA), in the sera of 184 patients: early RA(n = 38), established RA (n = 84), inflammatory arthritis(n = 34) and systemic lupus erythematosus (SLE) (n = 28).\n'
p1299
sg4
(lp1300
sg23
(lp1301
(dp1302
g7
I339
sg26
VC0003864
p1303
sg10
I22
sg11
Vinflammatory arthritis
p1304
sg13
I2
sa(dp1305
g7
I404
sg26
VC0024141
p1306
sg10
I3
sg11
VSLE
p1307
sg13
I1
sa(dp1308
g7
I374
sg26
VC0024141
p1309
sg10
I28
sg11
Vsystemic lupus erythematosus
p1310
sg13
I3
sasa(dp1311
g2
S'The role of costimulatory OX40-OX40 ligand (OX40L) interactions has been explored in the non-infectious pathology of influenza pneumonia.\n'
p1312
sg4
(lp1313
(dp1314
g7
I44
sg8
VP23510
p1315
sg10
I5
sg11
VOX40L
p1316
sg13
I1
sa(dp1317
g7
I26
sg8
VP43489
p1318
sg10
I16
sg11
VOX40-OX40 ligand
p1319
sg13
I2
sasg23
(lp1320
(dp1321
g7
I93
sg26
VC0009450
p1322
sg10
I10
sg11
Vinfectious
p1323
sg13
I1
sa(dp1324
g7
I117
sg26
VC0155870
p1325
sg10
I19
sg11
Vinfluenza pneumonia
p1326
sg13
I2
sa(dp1327
g7
I104
sg26
VC0677042
p1328
sg10
I9
sg11
Vpathology
p1329
sg13
I1
sasa(dp1330
g2
S'Here, we describe a critical contribution of OX40L to infectious pathology, with OX40L deficiency, but not OX40 deficiency, resulting in decreased susceptibility to influenza viral infection.\n'
p1331
sg4
(lp1332
(dp1333
g7
I45
sg8
VP23510
p1334
sg10
I5
sg11
VOX40L
p1335
sg13
I1
sa(dp1336
g7
I45
sg8
VP23510
p1337
sg10
I5
sg11
VOX40L
p1338
sg13
I1
sa(dp1339
g7
I45
sg8
VP43489
p1340
sg10
I4
sg11
VOX40
p1341
sg13
I1
sasg23
(lp1342
(dp1343
g7
I165
sg26
VC0021400
p1344
sg10
I9
sg11
Vinfluenza
p1345
sg13
I1
sa(dp1346
g7
I65
sg26
VC0677042
p1347
sg10
I9
sg11
Vpathology
p1348
sg13
I1
sa(dp1349
g7
I54
sg26
VC0009450
p1350
sg10
I10
sg11
Vinfectious
p1351
sg13
I1
sa(dp1352
g7
I175
sg26
VC0042769
p1353
sg10
I15
sg11
Vviral infection
p1354
sg13
I2
sasa(dp1355
g2
S'In fact, the specific antibody against the sialylated site of OX40L exhibited therapeutic potency in mitigating the OX40L-mediated susceptibility to influenza.\n'
p1356
sg4
(lp1357
(dp1358
g7
I62
sg8
VP23510
p1359
sg10
I5
sg11
VOX40L
p1360
sg13
I1
sa(dp1361
g7
I62
sg8
VP23510
p1362
sg10
I5
sg11
VOX40L
p1363
sg13
I1
sasg23
(lp1364
(dp1365
g7
I149
sg26
VC0021400
p1366
sg10
I9
sg11
Vinfluenza
p1367
sg13
I1
sasa(dp1368
g2
S'Our data illustrate that the influenza-induced expression of OX40L on bronchiolar progenitors has pathogenic value to develop a novel therapeutic approach against influenza.\n'
p1369
sg4
(lp1370
(dp1371
g7
I61
sg8
VP23510
p1372
sg10
I5
sg11
VOX40L
p1373
sg13
I1
sasg23
(lp1374
(dp1375
g7
I29
sg26
VC0021400
p1376
sg10
I9
sg11
Vinfluenza
p1377
sg13
I1
sa(dp1378
g7
I29
sg26
VC0021400
p1379
sg10
I9
sg11
Vinfluenza
p1380
sg13
I1
sasa(dp1381
g2
S'In total T cell cultures, at low Ag dose, 4-1BBL provided the most potent costimulus for influenza-specific CD8 T cell expansion, followed by B7.1 (CD80) and then OX40L.\n'
p1382
sg4
(lp1383
(dp1384
g7
I163
sg8
VP23510
p1385
sg10
I5
sg11
VOX40L
p1386
sg13
I1
sa(dp1387
g7
I148
sg8
VP33681
p1388
sg10
I4
sg11
VCD80
p1389
sg13
I1
sa(dp1390
g7
I108
sg8
VP01732
p1391
sg10
I5
sg11
VCD8 T
p1392
sg13
I2
sasg23
(lp1393
(dp1394
g7
I89
sg26
VC0021400
p1395
sg10
I9
sg11
Vinfluenza
p1396
sg13
I1
sasa(dp1397
g2
S'Thus, OX40L costimulates human antiviral memory CD8 T cell responses largely through indirect effects and can enhance anti-influenza, anti-EBV, and anti-HIV responses, particularly in combination with 4-1BBL or B7.\n'
p1398
sg4
(lp1399
(dp1400
g7
I48
sg8
VP01732
p1401
sg10
I5
sg11
VCD8 T
p1402
sg13
I2
sa(dp1403
g7
I6
sg8
VP23510
p1404
sg10
I5
sg11
VOX40L
p1405
sg13
I1
sasg23
(lp1406
(dp1407
g7
I123
sg26
VC0021400
p1408
sg10
I9
sg11
Vinfluenza
p1409
sg13
I1
sa(dp1410
g7
I153
sg26
VC0019693
p1411
sg10
I3
sg11
VHIV
p1412
sg13
I1
sasa(dp1413
g2
S'The levels of expression of Bag-1 and Bcl-2 were higher in the cervical cancer group, but Cyto-C, AIF, caspase-3, and p-Akt were lower compared with the other two groups (p &lt; 0.05).\n'
p1414
sg4
(lp1415
(dp1416
g7
I98
sg8
g64
sg10
I3
sg11
VAIF
p1417
sg13
I1
sa(dp1418
g7
I28
sg8
g64
sg10
I5
sg11
VBag-1
p1419
sg13
I1
sa(dp1420
g7
I38
sg8
VP10415
p1421
sg10
I5
sg11
VBcl-2
p1422
sg13
I1
sa(dp1423
g7
I118
sg8
g64
sg10
I5
sg11
Vp-Akt
p1424
sg13
I1
sa(dp1425
g7
I103
sg8
VP42574
p1426
sg10
I9
sg11
Vcaspase-3
p1427
sg13
I1
sasg23
(lp1428
(dp1429
g7
I63
sg26
VC0302592
p1430
sg10
I15
sg11
Vcervical cancer
p1431
sg13
I2
sasa(dp1432
g2
S'The co-chaperone protein Bcl-2-associated athanogene-1 (BAG-1) is overexpressed in breast cancer and has been incorporated in the oncotype DX and PAM50 breast cancer prognostic assays.\n'
p1433
sg4
(lp1434
(dp1435
g7
I25
sg8
VP10415
p1436
sg10
I29
sg11
VBcl-2-associated athanogene-1
p1437
sg13
I2
sa(dp1438
g7
I56
sg8
g64
sg10
I5
sg11
VBAG-1
p1439
sg13
I1
sasg23
(lp1440
(dp1441
g7
I83
sg26
VC0678222
p1442
sg10
I13
sg11
Vbreast cancer
p1443
sg13
I2
sa(dp1444
g7
I83
sg26
VC0678222
p1445
sg10
I13
sg11
Vbreast cancer
p1446
sg13
I2
sasa(dp1447
g2
S'The BAG-1L isoform specifically binds to and increases the transcriptional activity of oestrogen receptor in cells, and in some, but not all studies, BAG-1 expression is predictive of clinical outcome in breast cancer.\n'
p1448
sg4
(lp1449
(dp1450
g7
I4
sg8
g64
sg10
I14
sg11
VBAG-1L isoform
p1451
sg13
I2
sa(dp1452
g7
I87
sg8
VP03372
p1453
sg10
I18
sg11
Voestrogen receptor
p1454
sg13
I2
sa(dp1455
g7
I4
sg8
g64
sg10
I5
sg11
VBAG-1
p1456
sg13
I1
sasg23
(lp1457
(dp1458
g7
I204
sg26
VC0678222
p1459
sg10
I13
sg11
Vbreast cancer
p1460
sg13
I2
sasa(dp1461
g2
S'A systematic review of published studies reporting BAG-1 (mRNA and/or protein) expression and clinical outcome in early breast cancer.\n'
p1462
sg4
(lp1463
sg23
(lp1464
(dp1465
g7
I120
sg26
VC0678222
p1466
sg10
I13
sg11
Vbreast cancer
p1467
sg13
I2
sasa(dp1468
g2
S'Increased levels of BAG-1 are associated with better breast cancer outcomes.\n'
p1469
sg4
(lp1470
(dp1471
g7
I20
sg8
g64
sg10
I5
sg11
VBAG-1
p1472
sg13
I1
sasg23
(lp1473
(dp1474
g7
I53
sg26
VC0678222
p1475
sg10
I13
sg11
Vbreast cancer
p1476
sg13
I2
sasa(dp1477
g2
S'Bcl-2-associated athanogene 1 (Bag-1) is a multifunctional protein overexpressed in breast cancer and ductal carcinoma in situ.\n'
p1478
sg4
(lp1479
(dp1480
g7
I0
sg8
VP10415
p1481
sg10
I29
sg11
VBcl-2-associated athanogene 1
p1482
sg13
I3
sa(dp1483
g7
I31
sg8
g64
sg10
I5
sg11
VBag-1
p1484
sg13
I1
sasg23
(lp1485
(dp1486
g7
I84
sg26
VC0678222
p1487
sg10
I13
sg11
Vbreast cancer
p1488
sg13
I2
sa(dp1489
g7
I102
sg26
VC0007124
p1490
sg10
I24
sg11
Vductal carcinoma in situ
p1491
sg13
I4
sasa(dp1492
g2
S'When present in the nucleus Bag-1 is predictive of clinical outcome in breast cancer.\n'
p1493
sg4
(lp1494
(dp1495
g7
I20
sg8
g64
sg10
I13
sg11
Vnucleus Bag-1
p1496
sg13
I2
sasg23
(lp1497
(dp1498
g7
I71
sg26
VC0678222
p1499
sg10
I13
sg11
Vbreast cancer
p1500
sg13
I2
sasa(dp1501
g2
S'Overexpression of cytoplasmic BAG-1 has been associated with the increased survival and decreased response to treatment with tamoxifen (TAM) in breast cancer.\n'
p1502
sg4
(lp1503
(dp1504
g7
I18
sg8
g64
sg10
I17
sg11
Vcytoplasmic BAG-1
p1505
sg13
I2
sasg23
(lp1506
(dp1507
g7
I125
sg26
VC1834582
p1508
sg10
I9
sg11
Vtamoxifen
p1509
sg13
I1
sa(dp1510
g7
I136
sg26
VC1834582
p1511
sg10
I3
sg11
VTAM
p1512
sg13
I1
sa(dp1513
g7
I144
sg26
VC0678222
p1514
sg10
I13
sg11
Vbreast cancer
p1515
sg13
I2
sasa(dp1516
g2
S'We attempted to assess the expression of BAG-1 in the human breast cancer cells that are resistant to treatment with 4-OH TAM and effect of altered BAG-1 expression on their sensitivity to 4-OH TAM.\n'
p1517
sg4
(lp1518
(dp1519
g7
I41
sg8
g64
sg10
I5
sg11
VBAG-1
p1520
sg13
I1
sa(dp1521
g7
I41
sg8
g64
sg10
I5
sg11
VBAG-1
p1522
sg13
I1
sasg23
(lp1523
(dp1524
g7
I122
sg26
VC1834582
p1525
sg10
I3
sg11
VTAM
p1526
sg13
I1
sa(dp1527
g7
I60
sg26
VC0678222
p1528
sg10
I13
sg11
Vbreast cancer
p1529
sg13
I2
sa(dp1530
g7
I122
sg26
VC1834582
p1531
sg10
I3
sg11
VTAM
p1532
sg13
I1
sasa(dp1533
g2
S'Our study indicated that up and down regulations of the BAG-1 expression were associated with the decreased and increased sensitivity to 4-OH TAM in the estrogen receptor-positive (ER+) human breast cancer cell line MCF-7 respectively, and distinct isoforms of BAG-1 had different anti-apoptotic ability in breast cancer cells treated with the 4-OH TAM.\n'
p1534
sg4
(lp1535
(dp1536
g7
I56
sg8
g64
sg10
I5
sg11
VBAG-1
p1537
sg13
I1
sa(dp1538
g7
I56
sg8
g64
sg10
I5
sg11
VBAG-1
p1539
sg13
I1
sa(dp1540
g7
I153
sg8
VP03372
p1541
sg10
I17
sg11
Vestrogen receptor
p1542
sg13
I2
sasg23
(lp1543
(dp1544
g7
I192
sg26
VC0678222
p1545
sg10
I13
sg11
Vbreast cancer
p1546
sg13
I2
sa(dp1547
g7
I192
sg26
VC0678222
p1548
sg10
I13
sg11
Vbreast cancer
p1549
sg13
I2
sa(dp1550
g7
I142
sg26
VC1834582
p1551
sg10
I3
sg11
VTAM
p1552
sg13
I1
sa(dp1553
g7
I142
sg26
VC1834582
p1554
sg10
I3
sg11
VTAM
p1555
sg13
I1
sasa(dp1556
g2
S'Analysis of BAG1 was performed on archival tumour blocks from patients from the anastrozole and tamoxifen arms of the ATAC trial of 5 years endocrine therapy in postmenopausal women with oestrogen receptor (ER)-positive primary breast cancer.\n'
p1557
sg4
(lp1558
(dp1559
g7
I187
sg8
VP03372
p1560
sg10
I18
sg11
Voestrogen receptor
p1561
sg13
I2
sasg23
(lp1562
(dp1563
g7
I106
sg26
VC0206655
p1564
sg10
I4
sg11
Varms
p1565
sg13
I1
sa(dp1566
g7
I228
sg26
VC0678222
p1567
sg10
I13
sg11
Vbreast cancer
p1568
sg13
I2
sa(dp1569
g7
I43
sg26
VC0027651
p1570
sg10
I6
sg11
Vtumour
p1571
sg13
I1
sasa(dp1572
g2
S'Immunohistochemical examination confirmed the diagnosis of thymic squamous carcinoma positive for CD5.\n'
p1573
sg4
(lp1574
(dp1575
g7
I98
sg8
VP06127
p1576
sg10
I3
sg11
VCD5
p1577
sg13
I1
sasg23
(lp1578
(dp1579
g7
I66
sg26
VC0007137
p1580
sg10
I18
sg11
Vsquamous carcinoma
p1581
sg13
I2
sasa(dp1582
g2
S'Total thyroidectomy was performed and histopathological evaluation revealed squamous cell carcinoma, which was confirmed by immunohistochemistry, showing diffuse positivity for CK7, CK19, CK34BetaE12, galectin-3, EGFR, focal positivity for p63 and negativity for TTF-1 and CD5.\n'
p1583
sg4
(lp1584
(dp1585
g7
I177
sg8
VP08729
p1586
sg10
I3
sg11
VCK7
p1587
sg13
I1
sa(dp1588
g7
I263
sg8
VP43699
p1589
sg10
I5
sg11
VTTF-1
p1590
sg13
I1
sa(dp1591
g7
I240
sg8
g64
sg10
I3
sg11
Vp63
p1592
sg13
I1
sa(dp1593
g7
I201
sg8
VP17931
p1594
sg10
I10
sg11
Vgalectin-3
p1595
sg13
I1
sa(dp1596
g7
I273
sg8
VP06127
p1597
sg10
I3
sg11
VCD5
p1598
sg13
I1
sasg23
(lp1599
(dp1600
g7
I76
sg26
VC0007137
p1601
sg10
I23
sg11
Vsquamous cell carcinoma
p1602
sg13
I3
sasa(dp1603
g2
S'GLUT-1, MUC-1, CD117, CD5, CEA, P63, CK19, CK5/6, CD1a and TdT were evaluated using 16 cases of type B3 thymoma and 20 cases of thymic squamous cell carcinoma.\n'
p1604
sg4
(lp1605
(dp1606
g7
I27
sg8
VP40198
p1607
sg10
I3
sg11
VCEA
p1608
sg13
I1
sa(dp1609
g7
I15
sg8
VP10721
p1610
sg10
I5
sg11
VCD117
p1611
sg13
I1
sa(dp1612
g7
I43
sg8
VP02533
p1613
sg10
I5
sg11
VCK5/6
p1614
sg13
I1
sa(dp1615
g7
I0
sg8
VP11166
p1616
sg10
I6
sg11
VGLUT-1
p1617
sg13
I1
sa(dp1618
g7
I50
sg8
VP15813
p1619
sg10
I4
sg11
VCD1a
p1620
sg13
I1
sa(dp1621
g7
I22
sg8
VP06127
p1622
sg10
I3
sg11
VCD5
p1623
sg13
I1
sa(dp1624
g7
I59
sg8
VP04053
p1625
sg10
I3
sg11
VTdT
p1626
sg13
I1
sa(dp1627
g7
I32
sg8
g64
sg10
I3
sg11
VP63
p1628
sg13
I1
sasg23
(lp1629
(dp1630
g7
I128
sg26
VC1336082
p1631
sg10
I30
sg11
Vthymic squamous cell carcinoma
p1632
sg13
I4
sa(dp1633
g7
I104
sg26
VC0040100
p1634
sg10
I7
sg11
Vthymoma
p1635
sg13
I1
sasa(dp1636
g2
S'The sensitivity of GLUT-1 or MUC-1 for thymic squamous cell carcinomas was highest (100%), followed by CK5/6 (95%), CD117 (90%), P63 (85%), CD5 (80%) and CEA (75%).\n'
p1637
sg4
(lp1638
(dp1639
g7
I103
sg8
VP02533
p1640
sg10
I5
sg11
VCK5/6
p1641
sg13
I1
sa(dp1642
g7
I154
sg8
VP40198
p1643
sg10
I3
sg11
VCEA
p1644
sg13
I1
sa(dp1645
g7
I19
sg8
VP11166
p1646
sg10
I6
sg11
VGLUT-1
p1647
sg13
I1
sa(dp1648
g7
I140
sg8
VP06127
p1649
sg10
I3
sg11
VCD5
p1650
sg13
I1
sa(dp1651
g7
I116
sg8
VP10721
p1652
sg10
I5
sg11
VCD117
p1653
sg13
I1
sasg23
(lp1654
(dp1655
g7
I46
sg26
VC0007137
p1656
sg10
I24
sg11
Vsquamous cell carcinomas
p1657
sg13
I3
sasa(dp1658
g2
S'The specificities of CD5, CD117 and CEA for thymic squamous cell carcinomas all were 100%, next was MUC-1 (56.3%), followed by GLUT-1 (50%), P63 (25%), CK5/6 (12.5%).\n'
p1659
sg4
(lp1660
(dp1661
g7
I152
sg8
VP02533
p1662
sg10
I5
sg11
VCK5/6
p1663
sg13
I1
sa(dp1664
g7
I21
sg8
VP06127
p1665
sg10
I3
sg11
VCD5
p1666
sg13
I1
sa(dp1667
g7
I36
sg8
VP40198
p1668
sg10
I3
sg11
VCEA
p1669
sg13
I1
sa(dp1670
g7
I26
sg8
VP10721
p1671
sg10
I5
sg11
VCD117
p1672
sg13
I1
sasg23
(lp1673
(dp1674
g7
I51
sg26
VC0007137
p1675
sg10
I24
sg11
Vsquamous cell carcinomas
p1676
sg13
I3
sasa(dp1677
g2
S'The reactivity of GLUT-1, MUC-1, CD117, CD5, CEA, CD1a and TdT in thymic squamous cell carcinomas and type B3 thymomas had significant difference.\n'
p1678
sg4
(lp1679
(dp1680
g7
I33
sg8
VP10721
p1681
sg10
I5
sg11
VCD117
p1682
sg13
I1
sa(dp1683
g7
I40
sg8
VP06127
p1684
sg10
I3
sg11
VCD5
p1685
sg13
I1
sa(dp1686
g7
I18
sg8
VP11166
p1687
sg10
I6
sg11
VGLUT-1
p1688
sg13
I1
sa(dp1689
g7
I50
sg8
VP15813
p1690
sg10
I12
sg11
VCD1a and TdT
p1691
sg13
I3
sa(dp1692
g7
I45
sg8
VP40198
p1693
sg10
I3
sg11
VCEA
p1694
sg13
I1
sasg23
(lp1695
(dp1696
g7
I110
sg26
VC0040100
p1697
sg10
I8
sg11
Vthymomas
p1698
sg13
I1
sa(dp1699
g7
I73
sg26
VC0007137
p1700
sg10
I24
sg11
Vsquamous cell carcinomas
p1701
sg13
I3
sasa(dp1702
g2
S'Usually a panel of markers is needed, if we combine GLUT-1 or MUC-1 which sensitivity for thymic squamous cell carcinomas is highest with CD5, CD117, CEA, CD1a or TdT which have high specificity, we can make the differential diagnosis effectively.\n'
p1703
sg4
(lp1704
(dp1705
g7
I150
sg8
VP40198
p1706
sg10
I3
sg11
VCEA
p1707
sg13
I1
sa(dp1708
g7
I155
sg8
VP15813
p1709
sg10
I4
sg11
VCD1a
p1710
sg13
I1
sa(dp1711
g7
I163
sg8
VP04053
p1712
sg10
I3
sg11
VTdT
p1713
sg13
I1
sa(dp1714
g7
I138
sg8
VP06127
p1715
sg10
I3
sg11
VCD5
p1716
sg13
I1
sa(dp1717
g7
I143
sg8
VP10721
p1718
sg10
I5
sg11
VCD117
p1719
sg13
I1
sasg23
(lp1720
(dp1721
g7
I97
sg26
VC0007137
p1722
sg10
I24
sg11
Vsquamous cell carcinomas
p1723
sg13
I3
sasa(dp1724
g2
S'On the 8th (hepatitis) and 29th (cirrhosis) day, serum biochemistry parameters, hepatic concentrations of lipid peroxidation-related substances, protein expressions of Alfa-SMA, TGF-Beta, iNOS, eNOS, p-eNOS-Ser1177, p-eNOS-Thr496, VEGF, VEGFR2, p-VEGFR2, and liver histology were evaluated.\n'
p1725
sg4
(lp1726
(dp1727
g7
I188
sg8
g64
sg10
I4
sg11
ViNOS
p1728
sg13
I1
sa(dp1729
g7
I237
sg8
VP35968
p1730
sg10
I6
sg11
VVEGFR2
p1731
sg13
I1
sa(dp1732
g7
I245
sg8
VP35968
p1733
sg10
I8
sg11
Vp-VEGFR2
p1734
sg13
I1
sa(dp1735
g7
I168
sg8
g64
sg10
I8
sg11
VAlfa-SMA
p1736
sg13
I1
sa(dp1737
g7
I178
sg8
VP18075
p1738
sg10
I8
sg11
VTGF-Beta
p1739
sg13
I1
sasg23
(lp1740
(dp1741
g7
I12
sg26
VC0019159
p1742
sg10
I9
sg11
Vhepatitis
p1743
sg13
I1
sa(dp1744
g7
I173
sg26
VC0026847
p1745
sg10
I3
sg11
VSMA
p1746
sg13
I1
sa(dp1747
g7
I33
sg26
VC0023890
p1748
sg10
I9
sg11
Vcirrhosis
p1749
sg13
I1
sasa(dp1750
g2
S'We aimed study impact of hepatocytic viral load, steatosis, and iron load on fibrosis in chronic hepatitis C and role of VEGF and VEGFR overexpression in cirrhotic cases in evolving HCC.\n'
p1751
sg4
(lp1752
(dp1753
g7
I130
sg8
VP35968
p1754
sg10
I5
sg11
VVEGFR
p1755
sg13
I1
sasg23
(lp1756
(dp1757
g7
I49
sg26
VC0152254
p1758
sg10
I9
sg11
Vsteatosis
p1759
sg13
I1
sa(dp1760
g7
I182
sg26
VC2239176
p1761
sg10
I3
sg11
VHCC
p1762
sg13
I1
sa(dp1763
g7
I89
sg26
VC0524910
p1764
sg10
I19
sg11
Vchronic hepatitis C
p1765
sg13
I3
sa(dp1766
g7
I77
sg26
VC0016059
p1767
sg10
I8
sg11
Vfibrosis
p1768
sg13
I1
sasa(dp1769
g2
S'Antisense noncoding RNA in the INK4 locus (ANRIL), which was coded on the Chr9p21.3 loci, participates in the pathogenesis of tumor, coronary artery disease, type 2 diabetes mellitus, and other diseases.\n'
p1770
sg4
(lp1771
(dp1772
g7
I31
sg8
VP42771
p1773
sg10
I10
sg11
VINK4 locus
p1774
sg13
I2
sasg23
(lp1775
(dp1776
g7
I133
sg26
VC1956346
p1777
sg10
I23
sg11
Vcoronary artery disease
p1778
sg13
I3
sa(dp1779
g7
I126
sg26
VC0027651
p1780
sg10
I5
sg11
Vtumor
p1781
sg13
I1
sa(dp1782
g7
I158
sg26
VC0011860
p1783
sg10
I24
sg11
Vtype 2 diabetes mellitus
p1784
sg13
I4
sa(dp1785
g7
I110
sg26
VC0699748
p1786
sg10
I12
sg11
Vpathogenesis
p1787
sg13
I1
sasa(dp1788
g2
S'Single nucleotide polymorphisms near the Ink4/Arf locus have been associated with type-2 diabetes mellitus.\n'
p1789
sg4
(lp1790
(dp1791
g7
I41
sg8
VP42771
p1792
sg10
I4
sg11
VInk4
p1793
sg13
I1
sa(dp1794
g7
I46
sg8
VP42771
p1795
sg10
I3
sg11
VArf
p1796
sg13
I1
sasg23
(lp1797
(dp1798
g7
I89
sg26
VC0011849
p1799
sg10
I17
sg11
Vdiabetes mellitus
p1800
sg13
I2
sa(dp1801
g7
I46
sg26
VC0264490
p1802
sg10
I3
sg11
VArf
p1803
sg13
I1
sasa(dp1804
g2
S'Three recent studies demonstrate that complex and cancer type-specific interactions between c-Myc, MondoA and HIF-1Alfa underlie metabolism, tumourigenesis and drug response.\n'
p1805
sg4
(lp1806
(dp1807
g7
I99
sg8
g64
sg10
I6
sg11
VMondoA
p1808
sg13
I1
sa(dp1809
g7
I92
sg8
VP12524
p1810
sg10
I5
sg11
Vc-Myc
p1811
sg13
I1
sasg23
(lp1812
(dp1813
g7
I50
sg26
VC0006826
p1814
sg10
I6
sg11
Vcancer
p1815
sg13
I1
sasa(dp1816
g2
S'In triple-negative breast cancer, c-Myc blocks MondoA-dependent activation of TXNIP to stimulate aerobic glycolysis.\n'
p1817
sg4
(lp1818
(dp1819
g7
I34
sg8
VP12524
p1820
sg10
I5
sg11
Vc-Myc
p1821
sg13
I1
sa(dp1822
g7
I47
sg8
g64
sg10
I6
sg11
VMondoA
p1823
sg13
I1
sa(dp1824
g7
I78
sg8
g64
sg10
I5
sg11
VTXNIP
p1825
sg13
I1
sasg23
(lp1826
(dp1827
g7
I19
sg26
VC0678222
p1828
sg10
I13
sg11
Vbreast cancer
p1829
sg13
I2
sasa(dp1830
g2
S'In contrast, in neuroblastoma, N-Myc requires MondoA for metabolic reprogramming and tumourigenesis.\n'
p1831
sg4
(lp1832
sg23
(lp1833
(dp1834
g7
I16
sg26
VC0027819
p1835
sg10
I13
sg11
Vneuroblastoma
p1836
sg13
I1
sasa(dp1837
g2
S'Finally, the therapeutic response of BRAF(V600E) melanoma cells to vemurafenib requires downregulation of c-Myc and HIF-1Alfa and upregulation of MondoA-TXNIP, and the subsequent reprogramming away from aerobic glycolysis.\n'
p1838
sg4
(lp1839
(dp1840
g7
I37
sg8
VP15056
p1841
sg10
I4
sg11
VBRAF
p1842
sg13
I1
sa(dp1843
g7
I106
sg8
VP12524
p1844
sg10
I5
sg11
Vc-Myc
p1845
sg13
I1
sasg23
(lp1846
(dp1847
g7
I49
sg26
VC0025202
p1848
sg10
I8
sg11
Vmelanoma
p1849
sg13
I1
sasa(dp1850
g2
S'In this minireview we highlight the findings in these three studies and present a working model to explain why c-Myc and MondoA function cooperatively in some cancers and antagonistically in others.\n'
p1851
sg4
(lp1852
(dp1853
g7
I121
sg8
g64
sg10
I6
sg11
VMondoA
p1854
sg13
I1
sa(dp1855
g7
I111
sg8
VP12524
p1856
sg10
I5
sg11
Vc-Myc
p1857
sg13
I1
sasg23
(lp1858
(dp1859
g7
I159
sg26
VC0006826
p1860
sg10
I7
sg11
Vcancers
p1861
sg13
I1
sasa(dp1862
g2
S'In this issue of Cancer Cell, Carroll and colleagues describe the role of MondoA, a member of the Myc-Max-Mxd-Mxl transcription factor network (termed the extended Myc network herein), in Myc-mediated alterations in cancer cell metabolism and tumorigenesis.\n'
p1863
sg4
(lp1864
(dp1865
g7
I110
sg8
VP17693
p1866
sg10
I3
sg11
VMxl
p1867
sg13
I1
sa(dp1868
g7
I98
sg8
VP12524
p1869
sg10
I3
sg11
VMyc
p1870
sg13
I1
sa(dp1871
g7
I98
sg8
VP12524
p1872
sg10
I3
sg11
VMyc
p1873
sg13
I1
sa(dp1874
g7
I164
sg8
VP12524
p1875
sg10
I18
sg11
VMyc network herein
p1876
sg13
I3
sasg23
(lp1877
(dp1878
g7
I17
sg26
VC0006826
p1879
sg10
I6
sg11
VCancer
p1880
sg13
I1
sa(dp1881
g7
I243
sg26
VC0007621
p1882
sg10
I13
sg11
Vtumorigenesis
p1883
sg13
I1
sa(dp1884
g7
I216
sg26
VC0006826
p1885
sg10
I6
sg11
Vcancer
p1886
sg13
I1
sasa(dp1887
g2
S'Identification and knockdown of genes coregulated by Myc and MondoA have allowed us to define metabolic functions required by deregulated Myc and demonstrate a critical role for lipid biosynthesis in survival of Myc-driven cancer.\n'
p1888
sg4
(lp1889
(dp1890
g7
I53
sg8
VP12524
p1891
sg10
I3
sg11
VMyc
p1892
sg13
I1
sa(dp1893
g7
I53
sg8
VP12524
p1894
sg10
I3
sg11
VMyc
p1895
sg13
I1
sasg23
(lp1896
(dp1897
g7
I223
sg26
VC0006826
p1898
sg10
I6
sg11
Vcancer
p1899
sg13
I1
sasa(dp1900
g2
S'Furthermore, overexpression of a subset of Myc and MondoA coregulated genes correlates with poor outcome of patients with diverse cancers.\n'
p1901
sg4
(lp1902
sg23
(lp1903
(dp1904
g7
I130
sg26
VC0006826
p1905
sg10
I7
sg11
Vcancers
p1906
sg13
I1
sasa(dp1907
g2
S'Coregulation of cancer metabolism by Myc and MondoA provides the potential for therapeutics aimed at inhibiting MondoA and its target genes.\n'
p1908
sg4
(lp1909
sg23
(lp1910
(dp1911
g7
I16
sg26
VC0006826
p1912
sg10
I6
sg11
Vcancer
p1913
sg13
I1
sasa(dp1914
g2
S'Remarkably, this network of transcription factors, including hypoxia-inducible factor-1Alfa, MYC, and MONDOA (MLXIP), drives glycolysis downstream of BRAF(V600), is critical for responses to BRAF inhibition, and is modulated by BRAF inhibition in clinical melanoma specimens.\n'
p1915
sg4
(lp1916
(dp1917
g7
I93
sg8
VP12524
p1918
sg10
I3
sg11
VMYC
p1919
sg13
I1
sa(dp1920
g7
I110
sg8
g64
sg10
I5
sg11
VMLXIP
p1921
sg13
I1
sa(dp1922
g7
I102
sg8
g64
sg10
I6
sg11
VMONDOA
p1923
sg13
I1
sa(dp1924
g7
I61
sg8
g64
sg10
I30
sg11
Vhypoxia-inducible factor-1Alfa
p1925
sg13
I2
sa(dp1926
g7
I150
sg8
VP15056
p1927
sg10
I4
sg11
VBRAF
p1928
sg13
I1
sa(dp1929
g7
I150
sg8
VP15056
p1930
sg10
I4
sg11
VBRAF
p1931
sg13
I1
sa(dp1932
g7
I150
sg8
VP15056
p1933
sg10
I4
sg11
VBRAF
p1934
sg13
I1
sasg23
(lp1935
(dp1936
g7
I61
sg26
VC0242184
p1937
sg10
I7
sg11
Vhypoxia
p1938
sg13
I1
sa(dp1939
g7
I256
sg26
VC0025202
p1940
sg10
I8
sg11
Vmelanoma
p1941
sg13
I1
sasa(dp1942
g2
S'TOP2A and TLE3 protein expressions were evaluated using immunohistochemistry on 28 samples, obtained by core needle biopsy in patients with locally advanced breast carcinoma, subsequently subjected to epirubicin- and paclitaxel-based neoadjuvant chemotherapy.\n'
p1943
sg4
(lp1944
(dp1945
g7
I0
sg8
g64
sg10
I5
sg11
VTOP2A
p1946
sg13
I1
sa(dp1947
g7
I10
sg8
g64
sg10
I12
sg11
VTLE3 protein
p1948
sg13
I2
sasg23
(lp1949
(dp1950
g7
I157
sg26
VC0678222
p1951
sg10
I16
sg11
Vbreast carcinoma
p1952
sg13
I2
sasa(dp1953
g2
S'Data from the current study suggest that TOP2A and TLE3 warrant further investigation in a larger series as predictors of response to neoadjuvant chemotherapy for locally advanced breast carcinoma.\n'
p1954
sg4
(lp1955
(dp1956
g7
I51
sg8
g64
sg10
I4
sg11
VTLE3
p1957
sg13
I1
sa(dp1958
g7
I41
sg8
g64
sg10
I5
sg11
VTOP2A
p1959
sg13
I1
sasg23
(lp1960
(dp1961
g7
I180
sg26
VC0678222
p1962
sg10
I16
sg11
Vbreast carcinoma
p1963
sg13
I2
sasa(dp1964
g2
S'We studied a series of angiosarcoma with TLE3 immunohistochemistry.\n'
p1965
sg4
(lp1966
(dp1967
g7
I41
sg8
g64
sg10
I4
sg11
VTLE3
p1968
sg13
I1
sasg23
(lp1969
(dp1970
g7
I23
sg26
VC0018923
p1971
sg10
I12
sg11
Vangiosarcoma
p1972
sg13
I1
sasa(dp1973
g2
S'TLE3 reactivity was observed in 0/37 (0%) cutaneous angiosarcomas, in 28/48 (58%) cases from soft tissue/viscera and in 4/13 (31%) post-irradiation angiosarcomas.\n'
p1974
sg4
(lp1975
(dp1976
g7
I0
sg8
g64
sg10
I4
sg11
VTLE3
p1977
sg13
I1
sasg23
(lp1978
(dp1979
g7
I52
sg26
VC0018923
p1980
sg10
I13
sg11
Vangiosarcomas
p1981
sg13
I1
sa(dp1982
g7
I52
sg26
VC0018923
p1983
sg10
I13
sg11
Vangiosarcomas
p1984
sg13
I1
sasa(dp1985
g2
S'A lack of TLE3 expression in cutaneous angiosarcoma may reflect differing pathogenesis.\n'
p1986
sg4
(lp1987
(dp1988
g7
I10
sg8
g64
sg10
I4
sg11
VTLE3
p1989
sg13
I1
sasg23
(lp1990
(dp1991
g7
I74
sg26
VC0699748
p1992
sg10
I12
sg11
Vpathogenesis
p1993
sg13
I1
sa(dp1994
g7
I39
sg26
VC0018923
p1995
sg10
I12
sg11
Vangiosarcoma
p1996
sg13
I1
sasa(dp1997
g2
S'We confirmed that the monoclonal antibody to G-Rg3 can be applied to immunocytochemistry for detection of the treated G-Rg3 inside A549 human lung adenocarcinomas.\n'
p1998
sg4
(lp1999
sg23
(lp2000
(dp2001
g7
I147
sg26
VC0001418
p2002
sg10
I15
sg11
Vadenocarcinomas
p2003
sg13
I1
sasa(dp2004
g2
S'In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, GSDMB gene amplification and protein overexpression indicate a poor response to HER2-targeted therapy.\n'
p2005
sg4
(lp2006
(dp2007
g7
I45
sg8
VP04626
p2008
sg10
I4
sg11
VHER2
p2009
sg13
I1
sa(dp2010
g7
I3
sg8
VP01133
p2011
sg10
I40
sg11
Vhuman epidermal growth factor receptor 2
p2012
sg13
I6
sa(dp2013
g7
I45
sg8
VP04626
p2014
sg10
I4
sg11
VHER2
p2015
sg13
I1
sasg23
(lp2016
(dp2017
g7
I60
sg26
VC0678222
p2018
sg10
I13
sg11
Vbreast cancer
p2019
sg13
I2
sa(dp2020
g7
I81
sg26
VC1705759
p2021
sg10
I18
sg11
Vgene amplification
p2022
sg13
I2
sasa(dp2023
g2
S'We found increased GSDMB1 isoform transcripts in the cancerous and non-cancerous tissues from carriers of the G allele vs. carriers of the A/A genotype.\n'
p2024
sg4
(lp2025
sg23
(lp2026
sa(dp2027
g2
S'Here, using an in silico analysis of data from 2,096 breast tumours, we reveal a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases distal from ERBB2) expression and the pathological and clinical parameters of poor prognosis in HER2-positive breast cancer.\n'
p2028
sg4
(lp2029
(dp2030
g7
I174
sg8
VP04626
p2031
sg10
I5
sg11
VERBB2
p2032
sg13
I1
sa(dp2033
g7
I258
sg8
VP04626
p2034
sg10
I4
sg11
VHER2
p2035
sg13
I1
sa(dp2036
g7
I126
sg8
g64
sg10
I5
sg11
VGSDMB
p2037
sg13
I1
sa(dp2038
g7
I113
sg8
g64
sg10
I11
sg11
VGasdermin B
p2039
sg13
I2
sasg23
(lp2040
(dp2041
g7
I53
sg26
VC1458155
p2042
sg10
I14
sg11
Vbreast tumours
p2043
sg13
I2
sa(dp2044
g7
I272
sg26
VC0678222
p2045
sg10
I13
sg11
Vbreast cancer
p2046
sg13
I2
sasa(dp2047
g2
S'In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.\n'
p2048
sg4
(lp2049
(dp2050
g7
I36
sg8
VP04626
p2051
sg10
I5
sg11
VERBB2
p2052
sg13
I1
sa(dp2053
g7
I72
sg8
g64
sg10
I10
sg11
Vgene GSDMB
p2054
sg13
I2
sa(dp2055
g7
I155
sg8
VP04626
p2056
sg10
I4
sg11
VHER2
p2057
sg13
I1
sasg23
(lp2058
(dp2059
g7
I169
sg26
VC0678222
p2060
sg10
I13
sg11
Vbreast cancer
p2061
sg13
I2
sasa(dp2062
g2
S'Because GSDMB is expressed in many types of cancer, including GC, it is likely that the gene contains a regulatory region that is utilized for therapy of occult PD through cancer cell-specific expression of cytotoxic genes.\n'
p2063
sg4
(lp2064
(dp2065
g7
I8
sg8
g64
sg10
I5
sg11
VGSDMB
p2066
sg13
I1
sasg23
(lp2067
(dp2068
g7
I44
sg26
VC0006826
p2069
sg10
I6
sg11
Vcancer
p2070
sg13
I1
sa(dp2071
g7
I44
sg26
VC0006826
p2072
sg10
I6
sg11
Vcancer
p2073
sg13
I1
sasa(dp2074
g2
S'Gasdermin B expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-expression has been related to tumor progression.\n'
p2075
sg4
(lp2076
(dp2077
g7
I0
sg8
g64
sg10
I11
sg11
VGasdermin B
p2078
sg13
I2
sasg23
(lp2079
(dp2080
g7
I159
sg26
VC0178874
p2081
sg10
I17
sg11
Vtumor progression
p2082
sg13
I2
sa(dp2083
g7
I106
sg26
VC0006826
p2084
sg10
I7
sg11
Vcancers
p2085
sg13
I1
sa(dp2086
g7
I49
sg26
VC0027651
p2087
sg10
I5
sg11
Vtumor
p2088
sg13
I1
sasa(dp2089
g2
S'At least four splicing isoforms of GSDMB have been identified, which may play differential roles in cancer.\n'
p2090
sg4
(lp2091
(dp2092
g7
I35
sg8
g64
sg10
I5
sg11
VGSDMB
p2093
sg13
I1
sasg23
(lp2094
(dp2095
g7
I100
sg26
VC0006826
p2096
sg10
I6
sg11
Vcancer
p2097
sg13
I1
sasa(dp2098
g2
S'Here, we uncover for the first time the functional implication of GSDMB in breast cancer.\n'
p2099
sg4
(lp2100
sg23
(lp2101
(dp2102
g7
I75
sg26
VC0678222
p2103
sg10
I13
sg11
Vbreast cancer
p2104
sg13
I2
sasa(dp2105
g2
S'Our data shows that high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients included in an expression dataset (&gt;1,000 cases).\n'
p2106
sg4
(lp2107
(dp2108
g7
I35
sg8
g64
sg10
I5
sg11
VGSDMB
p2109
sg13
I1
sasg23
(lp2110
(dp2111
g7
I116
sg26
VC0678222
p2112
sg10
I13
sg11
Vbreast cancer
p2113
sg13
I2
sa(dp2114
g7
I102
sg26
VC0027627
p2115
sg10
I10
sg11
Vmetastasis
p2116
sg13
I1
sasa(dp2117
g2
S'In order to evaluate the functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2).\n'
p2118
sg4
(lp2119
(dp2120
g7
I112
sg8
g64
sg10
I7
sg11
VGSDMB-2
p2121
sg13
I1
sa(dp2122
g7
I100
sg8
g64
sg10
I7
sg11
VGSDMB-1
p2123
sg13
I1
sasg23
(lp2124
(dp2125
g7
I53
sg26
VC0678222
p2126
sg10
I13
sg11
Vbreast cancer
p2127
sg13
I2
sasa(dp2128
g2
S'Taken together, our results provide for the first time evidences that GSDMB-2 induces invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic marker in breast cancer.\n'
p2129
sg4
(lp2130
(dp2131
g7
I70
sg8
g64
sg10
I7
sg11
VGSDMB-2
p2132
sg13
I1
sasg23
(lp2133
(dp2134
g7
I86
sg26
VC2699153
p2135
sg10
I8
sg11
Vinvasion
p2136
sg13
I1
sa(dp2137
g7
I216
sg26
VC0678222
p2138
sg10
I13
sg11
Vbreast cancer
p2139
sg13
I2
sa(dp2140
g7
I96
sg26
VC0178874
p2141
sg10
I17
sg11
Vtumor progression
p2142
sg13
I2
sa(dp2143
g7
I118
sg26
VC0027627
p2144
sg10
I10
sg11
Vmetastasis
p2145
sg13
I1
sasa(dp2146
g2
S'Given that GSDMB is highly expressed in cancerous cells and the locus resides in an amplicon, GSDMB may be involved in cancer development and/or progression.\n'
p2147
sg4
(lp2148
(dp2149
g7
I11
sg8
g64
sg10
I5
sg11
VGSDMB
p2150
sg13
I1
sasg23
(lp2151
(dp2152
g7
I40
sg26
VC0006826
p2153
sg10
I6
sg11
Vcancer
p2154
sg13
I1
sasa(dp2155
g2
S'However, only limited information is available on GSDMB expression in tissues, normal and cancerous, from cancer patients.\n'
p2156
sg4
(lp2157
sg23
(lp2158
(dp2159
g7
I90
sg26
VC0006826
p2160
sg10
I6
sg11
Vcancer
p2161
sg13
I1
sasa(dp2162
g2
S"We investigated the spatiotemporal expression patterns of GSDMB in gastric cancer patients and the 5' regulatory sequences upstream of GSDMB.\n"
p2163
sg4
(lp2164
sg23
(lp2165
(dp2166
g7
I67
sg26
VC0024623
p2167
sg10
I14
sg11
Vgastric cancer
p2168
sg13
I2
sasa(dp2169
g2
S'Most pre-cancer samples showed moderate GSDMB expression, and most cancerous samples showed augmented GSDMB expression.\n'
p2170
sg4
(lp2171
sg23
(lp2172
(dp2173
g7
I9
sg26
VC0006826
p2174
sg10
I6
sg11
Vcancer
p2175
sg13
I1
sasa(dp2176
g2
S'Patients were divided into three groups according to the severity of fibrosis on biopsy: mild (F0-1), moderate (F2-4), severe (F5-6) liver disease and into two groups according to the NI grading, low (NI 0-3) and high inflammation (NI &gt;=4).\n'
p2177
sg4
(lp2178
sg23
(lp2179
(dp2180
g7
I133
sg26
VC0023895
p2181
sg10
I13
sg11
Vliver disease
p2182
sg13
I2
sa(dp2183
g7
I218
sg26
VC0021368
p2184
sg10
I12
sg11
Vinflammation
p2185
sg13
I1
sa(dp2186
g7
I69
sg26
VC0016059
p2187
sg10
I8
sg11
Vfibrosis
p2188
sg13
I1
sasa(dp2189
g2
S'The low fibrosis (F1-2) group included 56 patients, the high fibrosis group (F3-6) included 88 patients, and the cirrhosis group (F5-6) included 38 patients.\n'
p2190
sg4
(lp2191
sg23
(lp2192
(dp2193
g7
I8
sg26
VC0016059
p2194
sg10
I8
sg11
Vfibrosis
p2195
sg13
I1
sa(dp2196
g7
I113
sg26
VC0023890
p2197
sg10
I9
sg11
Vcirrhosis
p2198
sg13
I1
sa(dp2199
g7
I8
sg26
VC0016059
p2200
sg10
I8
sg11
Vfibrosis
p2201
sg13
I1
sasa(dp2202
g2
S'The promoter methylation status of UCHL1, FLNC, THBS1, and DLEC1 was assessed by quantitative methylation-specific PCR (QMSP) in the serum of 82 GC patients, 46 chronic atrophic gastritis (CAG) subjects, and 40 healthy controls.\n'
p2203
sg4
(lp2204
(dp2205
g7
I42
sg8
g64
sg10
I4
sg11
VFLNC
p2206
sg13
I1
sa(dp2207
g7
I59
sg8
g64
sg10
I5
sg11
VDLEC1
p2208
sg13
I1
sa(dp2209
g7
I48
sg8
VP07996
p2210
sg10
I5
sg11
VTHBS1
p2211
sg13
I1
sa(dp2212
g7
I35
sg8
VP09936
p2213
sg10
I5
sg11
VUCHL1
p2214
sg13
I1
sasg23
(lp2215
(dp2216
g7
I189
sg26
VC0017154
p2217
sg10
I3
sg11
VCAG
p2218
sg13
I1
sa(dp2219
g7
I161
sg26
VC0017154
p2220
sg10
I26
sg11
Vchronic atrophic gastritis
p2221
sg13
I3
sasa(dp2222
g2
S'Significant fibrosis was defined as F3-6 and cirrhosis as F5-6.\n'
p2223
sg4
(lp2224
sg23
(lp2225
(dp2226
g7
I12
sg26
VC0016059
p2227
sg10
I8
sg11
Vfibrosis
p2228
sg13
I1
sa(dp2229
g7
I45
sg26
VC0023890
p2230
sg10
I9
sg11
Vcirrhosis
p2231
sg13
I1
sasa(dp2232
g2
S'On liver biopsy, 132 (22%) had cirrhosis (Ishak F5-6) in the training set and 19 (18%) in the validation set.\n'
p2233
sg4
(lp2234
sg23
(lp2235
(dp2236
g7
I31
sg26
VC0023890
p2237
sg10
I9
sg11
Vcirrhosis
p2238
sg13
I1
sasa(dp2239
g2
S'Kaplan-Meier analysis demonstrated that steatosis impacted on time to progression to both significant fibrosis (Ishak &gt; or =F3) and cirrhosis (Ishak F5-6) (P = 0.001 and P = 0.049, respectively).\n'
p2240
sg4
(lp2241
sg23
(lp2242
(dp2243
g7
I40
sg26
VC0152254
p2244
sg10
I9
sg11
Vsteatosis
p2245
sg13
I1
sa(dp2246
g7
I50
sg26
VC0040456
p2247
sg10
I8
sg11
Vimpacted
p2248
sg13
I1
sa(dp2249
g7
I102
sg26
VC0016059
p2250
sg10
I8
sg11
Vfibrosis
p2251
sg13
I1
sa(dp2252
g7
I135
sg26
VC0023890
p2253
sg10
I9
sg11
Vcirrhosis
p2254
sg13
I1
sasa(dp2255
g2
S'We aimed to investigate the cellular source of secreted protein acidic and rich in cysteine (SPARC) in gastric cancer tissues and the relationship between SPARC expression and its prognostic significance.\n'
p2256
sg4
(lp2257
(dp2258
g7
I47
sg8
VP09486
p2259
sg10
I44
sg11
Vsecreted protein acidic and rich in cysteine
p2260
sg13
I7
sa(dp2261
g7
I93
sg8
VP09486
p2262
sg10
I5
sg11
VSPARC
p2263
sg13
I1
sasg23
(lp2264
(dp2265
g7
I103
sg26
VC0024623
p2266
sg10
I14
sg11
Vgastric cancer
p2267
sg13
I2
sasa(dp2268
g2
S'The present study aimed to investigate the molecular mechanism of breast cancer to bone metastasis of secreted protein acidic and rich in cysteine (SPARC).\n'
p2269
sg4
(lp2270
sg23
(lp2271
(dp2272
g7
I83
sg26
VC0153690
p2273
sg10
I15
sg11
Vbone metastasis
p2274
sg13
I2
sa(dp2275
g7
I66
sg26
VC0678222
p2276
sg10
I13
sg11
Vbreast cancer
p2277
sg13
I2
sasa(dp2278
g2
S'To investigate tumor microenvironment of metastasis (TMEM) and the expression of SPARC (secreted protein acidic and rich in cysteine) in gastric cancer, and their relationships with hematogenous metastasis.\n'
p2279
sg4
(lp2280
(dp2281
g7
I81
sg8
VP09486
p2282
sg10
I5
sg11
VSPARC
p2283
sg13
I1
sa(dp2284
g7
I88
sg8
VP09486
p2285
sg10
I44
sg11
Vsecreted protein acidic and rich in cysteine
p2286
sg13
I7
sasg23
(lp2287
(dp2288
g7
I137
sg26
VC0024623
p2289
sg10
I14
sg11
Vgastric cancer
p2290
sg13
I2
sa(dp2291
g7
I41
sg26
VC0027627
p2292
sg10
I10
sg11
Vmetastasis
p2293
sg13
I1
sa(dp2294
g7
I15
sg26
VC0027651
p2295
sg10
I5
sg11
Vtumor
p2296
sg13
I1
sa(dp2297
g7
I41
sg26
VC0027627
p2298
sg10
I10
sg11
Vmetastasis
p2299
sg13
I1
sasa(dp2300
g2
S'In this study, we investigated the expression status of secreted protein acidic and rich in cysteine, periostin, fibroblast-activated protein, and the newly developed proCOL11A1 antibody in the stroma of surgically resected pancreatic ductal adenocarcinomas and their prognostic implications.\n'
p2301
sg4
(lp2302
sg23
(lp2303
(dp2304
g7
I242
sg26
VC0001418
p2305
sg10
I15
sg11
Vadenocarcinomas
p2306
sg13
I1
sasa(dp2307
g2
S'Tissue microarrays were constructed from 155 surgically resected pancreatic ductal adenocarcinomas and paired non-neoplastic pancreata and from another independent set of 48 normal/benign pancreata, and immunohistochemical stains were performed for proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin.\n'
p2308
sg4
(lp2309
sg23
(lp2310
(dp2311
g7
I83
sg26
VC0001418
p2312
sg10
I15
sg11
Vadenocarcinomas
p2313
sg13
I1
sasa(dp2314
g2
S'proCOL11A1, fibroblast-activated protein, secreted protein acidic and rich in cysteine, and periostin expression was significantly increased in the intratumoral stroma of pancreatic ductal adenocarcinomas compared to paired non-neoplastic pancreata (proCOL11A1: 145/155 (93.5%) vs 26/154 (16.9%); fibroblast-activated protein: 139/143 (97.2%) vs 82/132 (62.1%); secreted protein acidic and rich in cysteine: 113/150 (75.3%) vs 49/132 (37.1%); periostin: 135/151 (89.4%) vs 45/135 (33.3%); p &lt; 0.001, all).\n'
p2315
sg4
(lp2316
sg23
(lp2317
(dp2318
g7
I189
sg26
VC0001418
p2319
sg10
I15
sg11
Vadenocarcinomas
p2320
sg13
I1
sasa(dp2321
g2
S'Secreted Protein Acidic and Rich in Cysteine (SPARC/osteonectin) is an extracellular matrix-associated glycoprotein involved in the regulation of cell proliferation and cell migration in several types of cancers.\n'
p2322
sg4
(lp2323
(dp2324
g7
I52
sg8
VP09486
p2325
sg10
I11
sg11
Vosteonectin
p2326
sg13
I1
sa(dp2327
g7
I71
sg8
VP36222
p2328
sg10
I44
sg11
Vextracellular matrix-associated glycoprotein
p2329
sg13
I3
sasg23
(lp2330
(dp2331
g7
I204
sg26
VC0006826
p2332
sg10
I7
sg11
Vcancers
p2333
sg13
I1
sa(dp2334
g7
I151
sg26
VC0334094
p2335
sg10
I13
sg11
Vproliferation
p2336
sg13
I1
sasa(dp2337
g2
S'MYCN expression and amplification were studied in five alveolar and five embryonal rhabdomyosarcoma cell lines and in 19 tumour biopsies.\n'
p2338
sg4
(lp2339
(dp2340
g7
I0
sg8
VP04198
p2341
sg10
I4
sg11
VMYCN
p2342
sg13
I1
sasg23
(lp2343
(dp2344
g7
I20
sg26
VC1705759
p2345
sg10
I13
sg11
Vamplification
p2346
sg13
I1
sa(dp2347
g7
I121
sg26
VC0027651
p2348
sg10
I6
sg11
Vtumour
p2349
sg13
I1
sa(dp2350
g7
I73
sg26
VC0206656
p2351
sg10
I26
sg11
Vembryonal rhabdomyosarcoma
p2352
sg13
I2
sasa(dp2353
g2
S'Similarly, MYCN protein was detected in all cell lines by western blot analysis, with higher levels of expression in alveolar than in embryonal rhabdomyosarcoma cells.\n'
p2354
sg4
(lp2355
(dp2356
g7
I11
sg8
VP04198
p2357
sg10
I12
sg11
VMYCN protein
p2358
sg13
I2
sasg23
(lp2359
(dp2360
g7
I134
sg26
VC0206656
p2361
sg10
I26
sg11
Vembryonal rhabdomyosarcoma
p2362
sg13
I2
sasa(dp2363
g2
S'Although MYCN expression was higher in alveolar than in embryonal rhabdomyosarcoma cell lines, no clear relationship between histology and level of MYCN expression could be established in this tumour series.\n'
p2364
sg4
(lp2365
(dp2366
g7
I9
sg8
VP04198
p2367
sg10
I4
sg11
VMYCN
p2368
sg13
I1
sa(dp2369
g7
I9
sg8
VP04198
p2370
sg10
I4
sg11
VMYCN
p2371
sg13
I1
sasg23
(lp2372
(dp2373
g7
I56
sg26
VC0206656
p2374
sg10
I26
sg11
Vembryonal rhabdomyosarcoma
p2375
sg13
I2
sa(dp2376
g7
I193
sg26
VC0027651
p2377
sg10
I6
sg11
Vtumour
p2378
sg13
I1
sasa(dp2379
g2
S'A single, large randomised-controlled-trial (ORACLE Childhood Study II) found an increased risk of childhood cerebral palsy and possibly epilepsy following prophylactic antibiotic use in pregnant women with spontaneous preterm labour.\n'
p2380
sg4
(lp2381
sg23
(lp2382
(dp2383
g7
I137
sg26
VC0014544
p2384
sg10
I8
sg11
Vepilepsy
p2385
sg13
I1
sa(dp2386
g7
I219
sg26
VC0022876
p2387
sg10
I14
sg11
Vpreterm labour
p2388
sg13
I2
sa(dp2389
g7
I109
sg26
VC0007789
p2390
sg10
I14
sg11
Vcerebral palsy
p2391
sg13
I2
sasa(dp2392
g2
S'Inclusion criteria were trials containing remission data on patients with confirmed pure class V (Va and Vb) membranous lupus nephritis.\n'
p2393
sg4
(lp2394
sg23
(lp2395
(dp2396
g7
I42
sg26
VC0687702
p2397
sg10
I9
sg11
Vremission
p2398
sg13
I1
sa(dp2399
g7
I120
sg26
VC0024143
p2400
sg10
I15
sg11
Vlupus nephritis
p2401
sg13
I2
sasa(dp2402
g2
S'Va-Vd), elimination of the normal category (WHO class I), clearer definitions for all classes, a standard approach to sclerotic glomeruli, and the division of lupus nephritis class IV into subcategories based on whether the endocapillary involvement is predominantly segmental (lupus nephritis IV-S) or global (lupus nephritis IV-G).\n'
p2403
sg4
(lp2404
sg23
(lp2405
(dp2406
g7
I118
sg26
VC0036429
p2407
sg10
I9
sg11
Vsclerotic
p2408
sg13
I1
sa(dp2409
g7
I159
sg26
VC0024143
p2410
sg10
I15
sg11
Vlupus nephritis
p2411
sg13
I2
sa(dp2412
g7
I159
sg26
VC0024143
p2413
sg10
I15
sg11
Vlupus nephritis
p2414
sg13
I2
sa(dp2415
g7
I159
sg26
VC0024143
p2416
sg10
I15
sg11
Vlupus nephritis
p2417
sg13
I2
sasa(dp2418
g2
S'The initial creatinine in patients with classes Va and Vb lupus nephritis predicted follow-up renal function.\n'
p2419
sg4
(lp2420
sg23
(lp2421
(dp2422
g7
I58
sg26
VC0024143
p2423
sg10
I15
sg11
Vlupus nephritis
p2424
sg13
I2
sasa(dp2425
g2
S'Nineteen had type Va and the rest type Vb nephritis.\n'
p2426
sg4
(lp2427
sg23
(lp2428
(dp2429
g7
I42
sg26
VC0027697
p2430
sg10
I9
sg11
Vnephritis
p2431
sg13
I1
sasa(dp2432
g2
S'Fifteen cases of epithelioid peritoneal mesothelioma and 40 cases of papillary serous carcinoma of the ovary (25 primary and 15 metastatic to the peritoneum) were immunostained for h-CD, D2-40, calretinin, cytokeratin 5/6, thrombomodulin, estrogen and progesterone receptors (ER and PR), Ber-EP4, B72.3, CA19-9, and CD15.\n'
p2433
sg4
(lp2434
(dp2435
g7
I194
sg8
VP22676
p2436
sg10
I10
sg11
Vcalretinin
p2437
sg13
I1
sa(dp2438
g7
I206
sg8
VP02533
p2439
sg10
I15
sg11
Vcytokeratin 5/6
p2440
sg13
I2
sa(dp2441
g7
I223
sg8
VP07204
p2442
sg10
I14
sg11
Vthrombomodulin
p2443
sg13
I1
sa(dp2444
g7
I239
sg8
VP06401
p2445
sg10
I35
sg11
Vestrogen and progesterone receptors
p2446
sg13
I4
sa(dp2447
g7
I288
sg8
VP35408
p2448
sg10
I7
sg11
VBer-EP4
p2449
sg13
I1
sa(dp2450
g7
I297
sg8
VP42081
p2451
sg10
I5
sg11
VB72.3
p2452
sg13
I1
sa(dp2453
g7
I316
sg8
VP22083
p2454
sg10
I4
sg11
VCD15
p2455
sg13
I1
sasg23
(lp2456
(dp2457
g7
I29
sg26
VC1377610
p2458
sg10
I23
sg11
Vperitoneal mesothelioma
p2459
sg13
I2
sa(dp2460
g7
I79
sg26
VC1335177
p2461
sg10
I29
sg11
Vserous carcinoma of the ovary
p2462
sg13
I5
sasa(dp2463
g2
S'A total of 40 peritoneal epithelioid mesotheliomas and 45 serous carcinomas of the ovary (15 primary, 30 metastatic to the peritoneum) were investigated for the expression of the following markers: D2-40, podoplanin, calretinin, keratin 5/6, thrombomodulin, MOC-31, Ber-EP4, B72.3 (TAG-72), BG-8 (Lewis(Y)), CA19-9, and leu-M1 (CD15).\n'
p2464
sg4
(lp2465
(dp2466
g7
I205
sg8
g64
sg10
I10
sg11
Vpodoplanin
p2467
sg13
I1
sa(dp2468
g7
I320
sg8
VP30740
p2469
sg10
I6
sg11
Vleu-M1
p2470
sg13
I1
sa(dp2471
g7
I217
sg8
VP22676
p2472
sg10
I10
sg11
Vcalretinin
p2473
sg13
I1
sa(dp2474
g7
I242
sg8
VP07204
p2475
sg10
I14
sg11
Vthrombomodulin
p2476
sg13
I1
sa(dp2477
g7
I266
sg8
VP35408
p2478
sg10
I7
sg11
VBer-EP4
p2479
sg13
I1
sa(dp2480
g7
I229
sg8
VP02533
p2481
sg10
I11
sg11
Vkeratin 5/6
p2482
sg13
I2
sa(dp2483
g7
I328
sg8
VP22083
p2484
sg10
I4
sg11
VCD15
p2485
sg13
I1
sa(dp2486
g7
I275
sg8
VP42081
p2487
sg10
I5
sg11
VB72.3
p2488
sg13
I1
sasg23
(lp2489
(dp2490
g7
I65
sg26
VC0007097
p2491
sg10
I10
sg11
Vcarcinomas
p2492
sg13
I1
sa(dp2493
g7
I282
sg26
VC0037293
p2494
sg10
I3
sg11
VTAG
p2495
sg13
I1
sa(dp2496
g7
I37
sg26
VC0025500
p2497
sg10
I13
sg11
Vmesotheliomas
p2498
sg13
I1
sasa(dp2499
g2
S'All 45 (100%) serous carcinomas were positive for Ber-EP4, 98% for MOC-31, 73% for B72.3, 73% for BG-8, 67% for CA19-9, 58% for leu-M1, 31% for keratin 5/6, 31% for calretinin, 13% for D2-40, 13% for podoplanin, and 4% for thrombomodulin.\n'
p2500
sg4
(lp2501
(dp2502
g7
I144
sg8
VP02533
p2503
sg10
I11
sg11
Vkeratin 5/6
p2504
sg13
I2
sa(dp2505
g7
I165
sg8
VP22676
p2506
sg10
I10
sg11
Vcalretinin
p2507
sg13
I1
sa(dp2508
g7
I223
sg8
VP07204
p2509
sg10
I14
sg11
Vthrombomodulin
p2510
sg13
I1
sa(dp2511
g7
I50
sg8
VP35408
p2512
sg10
I7
sg11
VBer-EP4
p2513
sg13
I1
sasg23
(lp2514
(dp2515
g7
I21
sg26
VC0007097
p2516
sg10
I10
sg11
Vcarcinomas
p2517
sg13
I1
sasa(dp2518
g2
S'A retrospective study Tertiary referral center In this study, 13 patients who developed facial paralysis due to temporal bone trauma and undergone decompression by using MCF approach in Department of Otorhinolaryngology of Izmir Katip Celebi University Research and Training Hospital between January 1993 and December 2012 were presented retrospectively.\n'
p2519
sg4
(lp2520
sg23
(lp2521
(dp2522
g7
I88
sg26
VC0015469
p2523
sg10
I16
sg11
Vfacial paralysis
p2524
sg13
I2
sasa(dp2525
g2
S'The SNP rs11628722 in the SERPINA9 gene was previously associated with incident ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study.\n'
p2526
sg4
(lp2527
sg23
(lp2528
(dp2529
g7
I80
sg26
VC3272363
p2530
sg10
I15
sg11
Vischemic stroke
p2531
sg13
I2
sa(dp2532
g7
I103
sg26
VC0004153
p2533
sg10
I15
sg11
VAtherosclerosis
p2534
sg13
I1
sasa(dp2535
g2
S'Replications in other populations are needed to validate findings of this study and to establish the SERPINA9 gene as a candidate in the etiology of carotid atherosclerosis.\n'
p2536
sg4
(lp2537
sg23
(lp2538
(dp2539
g7
I149
sg26
VC0577631
p2540
sg10
I23
sg11
Vcarotid atherosclerosis
p2541
sg13
I2
sasa(dp2542
g2
S'Our results indicate that transcriptions of SsADH4 and SsADH6 were highly induced under furfural and HMF stress conditions, and the proteins encoded by them exhibited NADH- and/or NADPH-dependent activities for furfural and HMF reduction, respectively.\n'
p2543
sg4
(lp2544
sg23
(lp2545
sa(dp2546
g2
S'Crystal structures of SySSADH were determined in their apo form, as a binary complex with NADP(+) and as a ternary complex with succinic semialdehyde and NADPH, providing details about the catalytic mechanism by revealing a covalent adduct of a cofactor with the catalytic cysteine in the binary complex and a proposed thiohemiacetal intermediate in the ternary complex.\n'
p2547
sg4
(lp2548
sg23
(lp2549
sa(dp2550
g2
S'Further, BCO2 is associated with the development of mitochondrial oxidative stress, macular degeneration, anemia, and hepatic steatosis.\n'
p2551
sg4
(lp2552
(dp2553
g7
I9
sg8
g64
sg10
I4
sg11
VBCO2
p2554
sg13
I1
sasg23
(lp2555
(dp2556
g7
I106
sg26
VC0002871
p2557
sg10
I6
sg11
Vanemia
p2558
sg13
I1
sa(dp2559
g7
I84
sg26
VC0242383
p2560
sg10
I20
sg11
Vmacular degeneration
p2561
sg13
I2
sa(dp2562
g7
I118
sg26
VC0015695
p2563
sg10
I17
sg11
Vhepatic steatosis
p2564
sg13
I2
sa(dp2565
g7
I66
sg26
VC0242606
p2566
sg10
I16
sg11
Voxidative stress
p2567
sg13
I2
sasa(dp2568
g2
S'Our findings indicate that specific BCMO1 SNPs should be determined when assessing the effects of carotenoid supplementation on macular pigment and that their expression may be influenced by retinal disease.\n'
p2569
sg4
(lp2570
(dp2571
g7
I36
sg8
g64
sg10
I10
sg11
VBCMO1 SNPs
p2572
sg13
I2
sasg23
(lp2573
(dp2574
g7
I191
sg26
VC0035309
p2575
sg10
I15
sg11
Vretinal disease
p2576
sg13
I2
sasa(dp2577
g2
S'We report quantification by enzyme-linked immunosorbent assay (ELISA) of KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13 and KLK14 in the SC and serum of atopic dermatitis (AD) patients by ELISA, and examine their variation with clinical phenotype, correlation with blood levels of eosinophils, lactate dehydrogenase (LDH) and immunoglobulin E. The overall SC serine protease activities were also measured.\n'
p2578
sg4
(lp2579
(dp2580
g7
I97
sg8
g64
sg10
I5
sg11
VKLK10
p2581
sg13
I1
sa(dp2582
g7
I79
sg8
VP06870
p2583
sg10
I4
sg11
VKLK6
p2584
sg13
I1
sa(dp2585
g7
I104
sg8
g64
sg10
I5
sg11
VKLK11
p2586
sg13
I1
sa(dp2587
g7
I314
sg8
g64
sg10
I3
sg11
VLDH
p2588
sg13
I1
sa(dp2589
g7
I353
sg8
VP57727
p2590
sg10
I18
sg11
VSC serine protease
p2591
sg13
I3
sa(dp2592
g7
I291
sg8
VP49366
p2593
sg10
I21
sg11
Vlactate dehydrogenase
p2594
sg13
I2
sa(dp2595
g7
I323
sg8
VP01854
p2596
sg10
I16
sg11
Vimmunoglobulin E
p2597
sg13
I2
sa(dp2598
g7
I91
sg8
g64
sg10
I4
sg11
VKLK8
p2599
sg13
I1
sa(dp2600
g7
I111
sg8
g64
sg10
I5
sg11
VKLK13
p2601
sg13
I1
sa(dp2602
g7
I85
sg8
VP49862
p2603
sg10
I4
sg11
VKLK7
p2604
sg13
I1
sa(dp2605
g7
I121
sg8
g64
sg10
I5
sg11
VKLK14
p2606
sg13
I1
sa(dp2607
g7
I73
sg8
g64
sg10
I4
sg11
VKLK5
p2608
sg13
I1
sasg23
(lp2609
(dp2610
g7
I150
sg26
VC0011615
p2611
sg10
I17
sg11
Vatopic dermatitis
p2612
sg13
I2
sa(dp2613
g7
I169
sg26
VC0011615
p2614
sg10
I2
sg11
VAD
p2615
sg13
I1
sasa(dp2616
g2
S'Amlexanox increased COL7A1 transcript and the phosphorylation of UPF-1, an RNA helicase associated with nonsense-mediated mRNA decay, suggesting that amlexanox inhibits nonsense-mediated mRNA decay in cells from patients with RDEB that respond to read-through treatment.\n'
p2617
sg4
(lp2618
(dp2619
g7
I65
sg8
g64
sg10
I5
sg11
VUPF-1
p2620
sg13
I1
sa(dp2621
g7
I75
sg8
g64
sg10
I12
sg11
VRNA helicase
p2622
sg13
I2
sasg23
(lp2623
(dp2624
g7
I226
sg26
VC0079474
p2625
sg10
I4
sg11
VRDEB
p2626
sg13
I1
sa(dp2627
g7
I127
sg26
VC1265875
p2628
sg10
I5
sg11
Vdecay
p2629
sg13
I1
sa(dp2630
g7
I127
sg26
VC1265875
p2631
sg10
I5
sg11
Vdecay
p2632
sg13
I1
sasa(dp2633
g2
S'the human homolog of the yeast Upf1 protein), was upregulated in GABEB keratinocytes.\n'
p2634
sg4
(lp2635
(dp2636
g7
I25
sg8
g64
sg10
I18
sg11
Vyeast Upf1 protein
p2637
sg13
I3
sasg23
(lp2638
(dp2639
g7
I65
sg26
VC0079301
p2640
sg10
I5
sg11
VGABEB
p2641
sg13
I1
sasa(dp2642
g2
S'We also analyzed the relationship between the Caspr family and neurodegenerative diseases, multiple sclerosis, and autoimmune encephalitis.\n'
p2643
sg4
(lp2644
(dp2645
g7
I46
sg8
VP78357
p2646
sg10
I12
sg11
VCaspr family
p2647
sg13
I2
sasg23
(lp2648
(dp2649
g7
I91
sg26
VC0026769
p2650
sg10
I18
sg11
Vmultiple sclerosis
p2651
sg13
I2
sa(dp2652
g7
I63
sg26
VC0524851
p2653
sg10
I26
sg11
Vneurodegenerative diseases
p2654
sg13
I2
sa(dp2655
g7
I115
sg26
VC0393639
p2656
sg10
I23
sg11
Vautoimmune encephalitis
p2657
sg13
I2
sasa(dp2658
g2
S"Here we have shown a novel function of Caspr in pathogenesis of Alzheimer's disease (AD).\n"
p2659
sg4
(lp2660
sg23
(lp2661
(dp2662
g7
I48
sg26
VC0699748
p2663
sg10
I12
sg11
Vpathogenesis
p2664
sg13
I1
sa(dp2665
g7
I85
sg26
VC1521724
p2666
sg10
I2
sg11
VAD
p2667
sg13
I1
sa(dp2668
g7
I64
sg26
VC1521724
p2669
sg10
I19
sg11
VAlzheimer's disease
p2670
sg13
I2
sasa(dp2671
g2
S'We analysed by immunohistochemistry on free-floating sections from multiple sclerosis brains the expression and distribution of nodal (Na(v) channels), paranodal (paranodin/Caspr) and juxtaparanodal (K(v) channels and Caspr2) molecules in demyelinated and remyelinated lesions.\n'
p2672
sg4
(lp2673
(dp2674
g7
I218
sg8
g64
sg10
I6
sg11
VCaspr2
p2675
sg13
I1
sasg23
(lp2676
(dp2677
g7
I67
sg26
VC0026769
p2678
sg10
I18
sg11
Vmultiple sclerosis
p2679
sg13
I2
sasa(dp2680
g2
S'In the present study, antibodies to Caspr were used to assess the integrity of paranodal junctions on myelinated axons in brain and spinal cord tissue from subjects with longstanding multiple sclerosis, a neurological disorder that affects both myelin and axons.\n'
p2681
sg4
(lp2682
sg23
(lp2683
(dp2684
g7
I139
sg26
VC0035334
p2685
sg10
I4
sg11
Vcord
p2686
sg13
I1
sa(dp2687
g7
I205
sg26
VC0027765
p2688
sg10
I21
sg11
Vneurological disorder
p2689
sg13
I2
sa(dp2690
g7
I183
sg26
VC0026769
p2691
sg10
I18
sg11
Vmultiple sclerosis
p2692
sg13
I2
sasa(dp2693
g2
S'Triple immunofluorescence combined with confocal laser scanning microscopy showed that axons in the demyelinated centre of the 36 brain and 16 spinal cord multiple sclerosis lesions studied were devoid of Caspr immunoreactivity, suggesting that axons down regulate the expression of Caspr following demyelination.\n'
p2694
sg4
(lp2695
sg23
(lp2696
(dp2697
g7
I155
sg26
VC0026769
p2698
sg10
I18
sg11
Vmultiple sclerosis
p2699
sg13
I2
sa(dp2700
g7
I150
sg26
VC0035334
p2701
sg10
I4
sg11
Vcord
p2702
sg13
I1
sa(dp2703
g7
I299
sg26
VC0011304
p2704
sg10
I13
sg11
Vdemyelination
p2705
sg13
I1
sasa(dp2706
g2
S'Interestingly, alterations in the expression and localization of Caspr were observed in tissue from both subjects with the primary and secondary progressive form of multiple sclerosis.\n'
p2707
sg4
(lp2708
(dp2709
g7
I65
sg8
VP78357
p2710
sg10
I5
sg11
VCaspr
p2711
sg13
I1
sasg23
(lp2712
(dp2713
g7
I165
sg26
VC0026769
p2714
sg10
I18
sg11
Vmultiple sclerosis
p2715
sg13
I2
sasa(dp2716
g2
S'This study was divided into two phases: firstly, marker (miR-95, miR-18a, miR-10b, miR125a, and miR-378) detection by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) in sera from HBV patients with HCC (n = 15) and health subject (n = 15); and, secondly, marker validation by real-time qRT-PCR on HBV patients with HCC (n = 86) or hepatitis or cirrhosis (n = 30), and healthy subject (n = 45).\n'
p2717
sg4
(lp2718
(dp2719
g7
I65
sg8
g64
sg10
I7
sg11
VmiR-18a
p2720
sg13
I1
sa(dp2721
g7
I74
sg8
g64
sg10
I7
sg11
VmiR-10b
p2722
sg13
I1
sa(dp2723
g7
I57
sg8
g64
sg10
I6
sg11
VmiR-95
p2724
sg13
I1
sasg23
(lp2725
(dp2726
g7
I212
sg26
VC0019163
p2727
sg10
I3
sg11
VHBV
p2728
sg13
I1
sa(dp2729
g7
I212
sg26
VC0019163
p2730
sg10
I3
sg11
VHBV
p2731
sg13
I1
sa(dp2732
g7
I230
sg26
VC2239176
p2733
sg10
I3
sg11
VHCC
p2734
sg13
I1
sa(dp2735
g7
I376
sg26
VC0023890
p2736
sg10
I9
sg11
Vcirrhosis
p2737
sg13
I1
sa(dp2738
g7
I230
sg26
VC2239176
p2739
sg10
I3
sg11
VHCC
p2740
sg13
I1
sa(dp2741
g7
I363
sg26
VC0019159
p2742
sg10
I9
sg11
Vhepatitis
p2743
sg13
I1
sasa(dp2744
g2
S'MiR-18a yielded an area under the curve (AUC) of ROC of 0.881 with 86.1 % sensitivity and 75.0 % specificity in discriminating HBV-related HCC from healthy controls, and an AUC of ROC of 0.775 with 77.2 % sensitivity and 70.0 % specificity in discriminating HBV-related HCC from chronic hepatitis or cirrhosis.\n'
p2745
sg4
(lp2746
(dp2747
g7
I0
sg8
g64
sg10
I7
sg11
VMiR-18a
p2748
sg13
I1
sasg23
(lp2749
(dp2750
g7
I127
sg26
VC0019163
p2751
sg10
I3
sg11
VHBV
p2752
sg13
I1
sa(dp2753
g7
I139
sg26
VC2239176
p2754
sg10
I3
sg11
VHCC
p2755
sg13
I1
sa(dp2756
g7
I300
sg26
VC0023890
p2757
sg10
I9
sg11
Vcirrhosis
p2758
sg13
I1
sa(dp2759
g7
I139
sg26
VC2239176
p2760
sg10
I3
sg11
VHCC
p2761
sg13
I1
sa(dp2762
g7
I127
sg26
VC0019163
p2763
sg10
I3
sg11
VHBV
p2764
sg13
I1
sa(dp2765
g7
I279
sg26
VC0019189
p2766
sg10
I17
sg11
Vchronic hepatitis
p2767
sg13
I2
sasa(dp2768
g2
S'These studies suggest that monoclonal antibodies (infliximab and adalimumab) are superior to the soluble TNF receptor fusion protein etanercept for the treatment of scleritis in patients that do not respond to corticosteroids and/or to immunosuppressive treatment.\n'
p2769
sg4
(lp2770
(dp2771
g7
I105
sg8
VP01375
p2772
sg10
I12
sg11
VTNF receptor
p2773
sg13
I2
sasg23
(lp2774
(dp2775
g7
I165
sg26
VC0036416
p2776
sg10
I9
sg11
Vscleritis
p2777
sg13
I1
sasa(dp2778
g2
S'To describe 3 cases of scleritis associated with etanercept use for rheumatoid arthritis (RA) and to review the literature related to inflammatory eye diseases associated with the use of etanercept.\n'
p2779
sg4
(lp2780
sg23
(lp2781
(dp2782
g7
I23
sg26
VC0036416
p2783
sg10
I9
sg11
Vscleritis
p2784
sg13
I1
sa(dp2785
g7
I90
sg26
VC0003873
p2786
sg10
I2
sg11
VRA
p2787
sg13
I1
sa(dp2788
g7
I68
sg26
VC0003873
p2789
sg10
I20
sg11
Vrheumatoid arthritis
p2790
sg13
I2
sa(dp2791
g7
I147
sg26
VC0015397
p2792
sg10
I12
sg11
Veye diseases
p2793
sg13
I2
sasa(dp2794
g2
S'Three cases of severe scleritis during etanercept therapy were analyzed.\n'
p2795
sg4
(lp2796
sg23
(lp2797
(dp2798
g7
I22
sg26
VC0036416
p2799
sg10
I9
sg11
Vscleritis
p2800
sg13
I1
sasa(dp2801
g2
S'Three patients with seropositive RA developed scleritis 7-28 months after initiation of etanercept, for the first time during their long-lasting disease.\n'
p2802
sg4
(lp2803
sg23
(lp2804
(dp2805
g7
I20
sg26
VC0409651
p2806
sg10
I15
sg11
Vseropositive RA
p2807
sg13
I2
sa(dp2808
g7
I46
sg26
VC0036416
p2809
sg10
I9
sg11
Vscleritis
p2810
sg13
I1
sasa(dp2811
g2
S'Forty-two cases of inflammatory eye diseases believed to be associated with the use of etanercept have been reported in the literature: 33 uveitis, 8 scleritis, 1 orbital myositis, concerning 16 patients with RA, 10 with juvenile idiopathic arthritis, 14 with ankylosing spondylitis, and 2 with psoriatic spondyloarthropathy.\n'
p2812
sg4
(lp2813
sg23
(lp2814
(dp2815
g7
I32
sg26
VC0015397
p2816
sg10
I12
sg11
Veye diseases
p2817
sg13
I2
sa(dp2818
g7
I221
sg26
VC0553662
p2819
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p2820
sg13
I3
sa(dp2821
g7
I260
sg26
VC0038013
p2822
sg10
I22
sg11
Vankylosing spondylitis
p2823
sg13
I2
sa(dp2824
g7
I305
sg26
VC0949691
p2825
sg10
I19
sg11
Vspondyloarthropathy
p2826
sg13
I1
sa(dp2827
g7
I163
sg26
VC2350476
p2828
sg10
I16
sg11
Vorbital myositis
p2829
sg13
I2
sa(dp2830
g7
I139
sg26
VC0042164
p2831
sg10
I7
sg11
Vuveitis
p2832
sg13
I1
sa(dp2833
g7
I150
sg26
VC0036416
p2834
sg10
I9
sg11
Vscleritis
p2835
sg13
I1
sasa(dp2836
g2
S'A 55-year-old man with RA, on etanercept and oral methotrexate, was referred with diagnosis of acute stromal keratitis, anterior uveitis, and anterior nodular scleritis in his right eye.\n'
p2837
sg4
(lp2838
sg23
(lp2839
(dp2840
g7
I101
sg26
VC1318020
p2841
sg10
I17
sg11
Vstromal keratitis
p2842
sg13
I2
sa(dp2843
g7
I120
sg26
VC0701807
p2844
sg10
I16
sg11
Vanterior uveitis
p2845
sg13
I2
sa(dp2846
g7
I151
sg26
VC0339194
p2847
sg10
I17
sg11
Vnodular scleritis
p2848
sg13
I2
sasa(dp2849
g2
S'We report three cases of female patients who presented a first episode of unilateral scleritis or acute anterior uveitis while they were treated for 12-16 months by TNF inhibitor: etanercept (Enbrel((R))) 25mg twice weekly for rheumatologic diseases (rheumatoid arthritis or ankylosing spondylitis).\n'
p2850
sg4
(lp2851
(dp2852
g7
I165
sg8
VP01375
p2853
sg10
I3
sg11
VTNF
p2854
sg13
I1
sasg23
(lp2855
(dp2856
g7
I251
sg26
VC0003873
p2857
sg10
I20
sg11
Vrheumatoid arthritis
p2858
sg13
I2
sa(dp2859
g7
I85
sg26
VC0036416
p2860
sg10
I9
sg11
Vscleritis
p2861
sg13
I1
sa(dp2862
g7
I275
sg26
VC0038013
p2863
sg10
I22
sg11
Vankylosing spondylitis
p2864
sg13
I2
sa(dp2865
g7
I98
sg26
VC0701807
p2866
sg10
I22
sg11
Vacute anterior uveitis
p2867
sg13
I3
sasa(dp2868
g2
S'Seventeen cases of inflammatory eye disease (uveitis, scleritis, orbital myositis) believed to be associated with etanercept therapy were found in the recent literature.\n'
p2869
sg4
(lp2870
sg23
(lp2871
(dp2872
g7
I45
sg26
VC0042164
p2873
sg10
I7
sg11
Vuveitis
p2874
sg13
I1
sa(dp2875
g7
I65
sg26
VC2350476
p2876
sg10
I16
sg11
Vorbital myositis
p2877
sg13
I2
sa(dp2878
g7
I32
sg26
VC0015397
p2879
sg10
I11
sg11
Veye disease
p2880
sg13
I2
sa(dp2881
g7
I54
sg26
VC0036416
p2882
sg10
I9
sg11
Vscleritis
p2883
sg13
I1
sasa(dp2884
g2
S'We hypothesized that a cystatin C calculated glomerular filtration rate would be more sensitive than the standard creatinine based modified Schwartz equation to detect renal insufficiency in children with congenital neuropathic bladder.\n'
p2885
sg4
(lp2886
(dp2887
g7
I23
sg8
VP01034
p2888
sg10
I10
sg11
Vcystatin C
p2889
sg13
I2
sasg23
(lp2890
(dp2891
g7
I216
sg26
VC0005697
p2892
sg10
I19
sg11
Vneuropathic bladder
p2893
sg13
I2
sa(dp2894
g7
I168
sg26
VC0035078
p2895
sg10
I19
sg11
Vrenal insufficiency
p2896
sg13
I2
sasa(dp2897
g2
S'We prospectively identified children with congenital neuropathic bladder at a multidisciplinary spina bifida clinic who underwent serum creatinine and serum cystatin C testing.\n'
p2898
sg4
(lp2899
(dp2900
g7
I157
sg8
VP01034
p2901
sg10
I10
sg11
Vcystatin C
p2902
sg13
I2
sasg23
(lp2903
(dp2904
g7
I53
sg26
VC0005697
p2905
sg10
I19
sg11
Vneuropathic bladder
p2906
sg13
I2
sa(dp2907
g7
I96
sg26
VC0080178
p2908
sg10
I12
sg11
Vspina bifida
p2909
sg13
I2
sasa(dp2910
g2
S'In children with neuropathic bladder the cystatin C estimated glomerular filtration rate is a better screening test for early renal insufficiency that is not detected by creatinine based rate calculations.\n'
p2911
sg4
(lp2912
(dp2913
g7
I41
sg8
VP01034
p2914
sg10
I10
sg11
Vcystatin C
p2915
sg13
I2
sasg23
(lp2916
(dp2917
g7
I17
sg26
VC0005697
p2918
sg10
I19
sg11
Vneuropathic bladder
p2919
sg13
I2
sa(dp2920
g7
I126
sg26
VC0035078
p2921
sg10
I19
sg11
Vrenal insufficiency
p2922
sg13
I2
sasa(dp2923
g2
S'The CKD-EPI equation using cystatin C was the most precise method of renal function evaluation in patients with neurogenic bladder.\n'
p2924
sg4
(lp2925
(dp2926
g7
I27
sg8
VP01034
p2927
sg10
I10
sg11
Vcystatin C
p2928
sg13
I2
sasg23
(lp2929
(dp2930
g7
I112
sg26
VC0005697
p2931
sg10
I18
sg11
Vneurogenic bladder
p2932
sg13
I2
sa(dp2933
g7
I8
sg26
VC0267963
p2934
sg10
I3
sg11
VEPI
p2935
sg13
I1
sasa(dp2936
g2
S'Seipin deficiency results in lipodystrophy, diabetes, muscle hypertrophy, and male infertility in both human and mouse.\n'
p2937
sg4
(lp2938
(dp2939
g7
I0
sg8
g64
sg10
I6
sg11
VSeipin
p2940
sg13
I1
sasg23
(lp2941
(dp2942
g7
I44
sg26
VC0011849
p2943
sg10
I8
sg11
Vdiabetes
p2944
sg13
I1
sa(dp2945
g7
I78
sg26
VC0021364
p2946
sg10
I16
sg11
Vmale infertility
p2947
sg13
I2
sa(dp2948
g7
I61
sg26
VC0020564
p2949
sg10
I11
sg11
Vhypertrophy
p2950
sg13
I1
sa(dp2951
g7
I29
sg26
VC0023787
p2952
sg10
I13
sg11
Vlipodystrophy
p2953
sg13
I1
sasa(dp2954
g2
S'The objectives of this study were to 1) characterize the anthocyanin profile of Java plum using HPLC-MS; and 2) determine the anti-proliferative (cell counting and MTT) and pro-apoptotic (TUNEL and caspase 3/7 glo assay) properties of Java plum fruit extract (JPE) using HCT-116 colon cancer cell line and colon CSCs (positive for CD 44, CD 133 and ALDH1b1 markers).\n'
p2955
sg4
(lp2956
(dp2957
g7
I349
sg8
VP30837
p2958
sg10
I7
sg11
VALDH1b1
p2959
sg13
I1
sa(dp2960
g7
I198
sg8
VP42574
p2961
sg10
I15
sg11
Vcaspase 3/7 glo
p2962
sg13
I3
sasg23
(lp2963
(dp2964
g7
I279
sg26
VC0699790
p2965
sg10
I12
sg11
Vcolon cancer
p2966
sg13
I2
sa(dp2967
g7
I131
sg26
VC0334094
p2968
sg10
I13
sg11
Vproliferative
p2969
sg13
I1
sasa(dp2970
g2
S'In summary, our data demonstrate that ALDH1B1 may promote colon cancer tumorigenesis by modulating the Wnt/Beta-catenin, Notch and PI3K/Akt signaling pathways.\n'
p2971
sg4
(lp2972
(dp2973
g7
I136
sg8
g64
sg10
I3
sg11
VAkt
p2974
sg13
I1
sa(dp2975
g7
I38
sg8
VP30837
p2976
sg10
I7
sg11
VALDH1B1
p2977
sg13
I1
sa(dp2978
g7
I131
sg8
VP42336
p2979
sg10
I4
sg11
VPI3K
p2980
sg13
I1
sasg23
(lp2981
(dp2982
g7
I58
sg26
VC0699790
p2983
sg10
I12
sg11
Vcolon cancer
p2984
sg13
I2
sa(dp2985
g7
I71
sg26
VC0007621
p2986
sg10
I13
sg11
Vtumorigenesis
p2987
sg13
I1
sasa(dp2988
g2
S'Selective targeting of ALDH1B1 may represent a novel means to prevent or treat colon cancer.\n'
p2989
sg4
(lp2990
(dp2991
g7
I23
sg8
VP30837
p2992
sg10
I7
sg11
VALDH1B1
p2993
sg13
I1
sasg23
(lp2994
(dp2995
g7
I79
sg26
VC0699790
p2996
sg10
I12
sg11
Vcolon cancer
p2997
sg13
I2
sasa(dp2998
g2
S'Compared to normal colon tissue metastatic colon cancers from different patients were associated with increased ALDH1B1 expression (p=0.001) whereas CD29 expression was higher in normal colonic tissue (p=0.014).\n'
p2999
sg4
(lp3000
(dp3001
g7
I112
sg8
VP30837
p3002
sg10
I7
sg11
VALDH1B1
p3003
sg13
I1
sasg23
(lp3004
(dp3005
g7
I43
sg26
VC0007102
p3006
sg10
I13
sg11
Vcolon cancers
p3007
sg13
I2
sasa(dp3008
g2
S'Our study demonstrates that ALDH1B1 is more profoundly expressed in the adenocarcinomas examined in this study relative to ALDH1A1 and that ALDH1B1 is dramatically upregulated in human colonic adenocarcinoma, making it a potential biomarker for human colon cancer.\n'
p3009
sg4
(lp3010
(dp3011
g7
I28
sg8
VP30837
p3012
sg10
I7
sg11
VALDH1B1
p3013
sg13
I1
sa(dp3014
g7
I123
sg8
VP00352
p3015
sg10
I7
sg11
VALDH1A1
p3016
sg13
I1
sa(dp3017
g7
I28
sg8
VP30837
p3018
sg10
I7
sg11
VALDH1B1
p3019
sg13
I1
sasg23
(lp3020
(dp3021
g7
I72
sg26
VC0001418
p3022
sg10
I15
sg11
Vadenocarcinomas
p3023
sg13
I1
sa(dp3024
g7
I185
sg26
VC0338106
p3025
sg10
I22
sg11
Vcolonic adenocarcinoma
p3026
sg13
I2
sa(dp3027
g7
I251
sg26
VC0699790
p3028
sg10
I12
sg11
Vcolon cancer
p3029
sg13
I2
sasa(dp3030
g2
S"The following combinations of main keywords were used: ('Lymphotoxin-alpha' or 'LTA' or 'tumour necrosis factor beta' or 'TNF-beta') and ('Ischemic stroke or 'cerebral infarction' or 'IS') and ('genetic polymorphism' or 'single nucleotide polymorphisms' or 'SNP').\n"
p3031
sg4
(lp3032
(dp3033
g7
I121
sg8
VP01375
p3034
sg10
I10
sg11
V'TNF-beta'
p3035
sg13
I1
sa(dp3036
g7
I88
sg8
VP01375
p3037
sg10
I29
sg11
V'tumour necrosis factor beta'
p3038
sg13
I4
sasg23
(lp3039
(dp3040
g7
I138
sg26
VC3272363
p3041
sg10
I16
sg11
V'Ischemic stroke
p3042
sg13
I2
sa(dp3043
g7
I158
sg26
VC0038454
p3044
sg10
I20
sg11
V'cerebral infarction
p3045
sg13
I2
sa(dp3046
g7
I88
sg26
VC0333516
p3047
sg10
I16
sg11
V'tumour necrosis
p3048
sg13
I2
sasa(dp3049
g2
S'Associations between variations in the lymphotoxin-alpha gene (LTA) and myocardial infarction, cerebral infarction and type 1 diabetes have previously been reported.\n'
p3050
sg4
(lp3051
(dp3052
g7
I63
sg8
VP10515
p3053
sg10
I3
sg11
VLTA
p3054
sg13
I1
sa(dp3055
g7
I39
sg8
VP01374
p3056
sg10
I22
sg11
Vlymphotoxin-alpha gene
p3057
sg13
I2
sasg23
(lp3058
(dp3059
g7
I95
sg26
VC0038454
p3060
sg10
I19
sg11
Vcerebral infarction
p3061
sg13
I2
sa(dp3062
g7
I119
sg26
VC0011854
p3063
sg10
I15
sg11
Vtype 1 diabetes
p3064
sg13
I3
sa(dp3065
g7
I72
sg26
VC0027051
p3066
sg10
I21
sg11
Vmyocardial infarction
p3067
sg13
I2
sasa(dp3068
g2
S'We investigated two genetic polymorphisms in the TNF locus (TNF-alpha -308 G--&gt;A and TNF-beta +252 A--&gt;G) as risk factors for cerebral infarction (CI) by determining its prevalence in 294 survivors of CI, and in 581 age-, gender-, and race-matched controls.\n'
p3069
sg4
(lp3070
(dp3071
g7
I88
sg8
VP01375
p3072
sg10
I15
sg11
VTNF-beta +252 A
p3073
sg13
I3
sa(dp3074
g7
I49
sg8
VP01375
p3075
sg10
I9
sg11
VTNF locus
p3076
sg13
I2
sa(dp3077
g7
I-1
sg8
VP01375
p3078
sg10
I20
sg11
VTNF-alpha -308 G-->A
p3079
sg13
I3
sasg23
(lp3080
(dp3081
g7
I153
sg26
VC0021308
p3082
sg10
I2
sg11
VCI
p3083
sg13
I1
sa(dp3084
g7
I153
sg26
VC0021308
p3085
sg10
I2
sg11
VCI
p3086
sg13
I1
sa(dp3087
g7
I132
sg26
VC0038454
p3088
sg10
I19
sg11
Vcerebral infarction
p3089
sg13
I2
sasa(dp3090
g2
S'In 17 individuals with autoimmune thrombocytopenic purpura the levels of free haptoglobins were assessed after carefully ruling out microangiopathic hemolysis, systemic lupus erythematosus or overt Evans syndrome.\n'
p3091
sg4
(lp3092
(dp3093
g7
I78
sg8
VP00738
p3094
sg10
I12
sg11
Vhaptoglobins
p3095
sg13
I1
sasg23
(lp3096
(dp3097
g7
I198
sg26
VC0272126
p3098
sg10
I14
sg11
VEvans syndrome
p3099
sg13
I2
sa(dp3100
g7
I149
sg26
VC0019054
p3101
sg10
I9
sg11
Vhemolysis
p3102
sg13
I1
sa(dp3103
g7
I160
sg26
VC0024141
p3104
sg10
I28
sg11
Vsystemic lupus erythematosus
p3105
sg13
I3
sa(dp3106
g7
I23
sg26
VC0043117
p3107
sg10
I35
sg11
Vautoimmune thrombocytopenic purpura
p3108
sg13
I3
sasa(dp3109
g2
S'The differential diagnosis for these extraskeletal osseous and cartilaginous lesions includes soft-tissue sarcoma, benign mesenchymoma, malignant mesenchymoma (rare), calcified tophi in gout, melorheostosis (rare), pilomatricoma (rare), and tumoral calcinosis (rare).\n'
p3110
sg4
(lp3111
sg23
(lp3112
(dp3113
g7
I215
sg26
VC0206711
p3114
sg10
I13
sg11
Vpilomatricoma
p3115
sg13
I1
sa(dp3116
g7
I177
sg26
VC0221248
p3117
sg10
I5
sg11
Vtophi
p3118
sg13
I1
sa(dp3119
g7
I122
sg26
VC0025464
p3120
sg10
I12
sg11
Vmesenchymoma
p3121
sg13
I1
sa(dp3122
g7
I122
sg26
VC0334492
p3123
sg10
I23
sg11
Vmesenchymoma, malignant
p3124
sg13
I2
sa(dp3125
g7
I106
sg26
VC1261473
p3126
sg10
I7
sg11
Vsarcoma
p3127
sg13
I1
sa(dp3128
g7
I192
sg26
VC0025239
p3129
sg10
I14
sg11
Vmelorheostosis
p3130
sg13
I1
sa(dp3131
g7
I186
sg26
VC0018099
p3132
sg10
I4
sg11
Vgout
p3133
sg13
I1
sa(dp3134
g7
I241
sg26
VC0263628
p3135
sg10
I18
sg11
Vtumoral calcinosis
p3136
sg13
I2
sasa(dp3137
g2
S'The human muscleblind-like proteins (MBNL) regulate tissue-specific splicing by targeting cardiac troponin T and other pre-mRNAs; aberrant targeting of CUG and CCUG repeat expansions frequently accompanies the neuromuscular disease myotonic dystrophy.\n'
p3138
sg4
(lp3139
(dp3140
g7
I4
sg8
g64
sg10
I31
sg11
Vhuman muscleblind-like proteins
p3141
sg13
I3
sa(dp3142
g7
I37
sg8
g64
sg10
I4
sg11
VMBNL
p3143
sg13
I1
sa(dp3144
g7
I98
sg8
VP24821
p3145
sg10
I8
sg11
Vtroponin
p3146
sg13
I1
sasg23
(lp3147
(dp3148
g7
I210
sg26
VC0027868
p3149
sg10
I21
sg11
Vneuromuscular disease
p3150
sg13
I2
sa(dp3151
g7
I232
sg26
VC0027126
p3152
sg10
I18
sg11
Vmyotonic dystrophy
p3153
sg13
I2
sasa(dp3154
g2
S'MBNL activity is disrupted in the neuromuscular disease myotonic dystrophy type 1 (DM1), due to the instability of a non-coding microsatellite in the DMPK gene and the expression of CUG expansion (CUGexp) RNAs.\n'
p3155
sg4
(lp3156
(dp3157
g7
I150
sg8
g64
sg10
I9
sg11
VDMPK gene
p3158
sg13
I2
sa(dp3159
g7
I83
sg8
g64
sg10
I3
sg11
VDM1
p3160
sg13
I1
sa(dp3161
g7
I0
sg8
g64
sg10
I4
sg11
VMBNL
p3162
sg13
I1
sa(dp3163
g7
I48
sg8
g64
sg10
I33
sg11
Vdisease myotonic dystrophy type 1
p3164
sg13
I5
sasg23
(lp3165
(dp3166
g7
I34
sg26
VC0027868
p3167
sg10
I21
sg11
Vneuromuscular disease
p3168
sg13
I2
sa(dp3169
g7
I83
sg26
VC2931688
p3170
sg10
I3
sg11
VDM1
p3171
sg13
I1
sa(dp3172
g7
I48
sg26
VC2931688
p3173
sg10
I33
sg11
Vdisease myotonic dystrophy type 1
p3174
sg13
I5
sasa(dp3175
g2
S'Subjects were then administered a CRF1 antagonist, antalarmin.\n'
p3176
sg4
(lp3177
(dp3178
g7
I34
sg8
VP34998
p3179
sg10
I4
sg11
VCRF1
p3180
sg13
I1
sasg23
(lp3181
sa(dp3182
g2
S'EOD-induced alcohol consumption was insensitive to CRFR1 blockade by antalarmin, but subjects with high CSF levels of CRF were more responsive.\n'
p3183
sg4
(lp3184
(dp3185
g7
I99
sg8
VP04141
p3186
sg10
I8
sg11
Vhigh CSF
p3187
sg13
I2
sa(dp3188
g7
I51
sg8
VP34998
p3189
sg10
I5
sg11
VCRFR1
p3190
sg13
I1
sasg23
(lp3191
(dp3192
g7
I51
sg26
VC0022661
p3193
sg10
I3
sg11
VCRF
p3194
sg13
I1
sasa(dp3195
g2
S'The present study evaluated the effect of systemic injection of the CRF1 receptor antagonist R121919, the corticosterone synthesis inhibitor metyrapone and central amygdala (CeA) injections of the nonselective CRF antagonist D-Phe-CRF(12-41) in rats in which binge eating was evoked by stress and cycles of food restriction.\n'
p3196
sg4
(lp3197
(dp3198
g7
I156
sg8
VP40198
p3199
sg10
I16
sg11
Vcentral amygdala
p3200
sg13
I2
sa(dp3201
g7
I174
sg8
VP40198
p3202
sg10
I3
sg11
VCeA
p3203
sg13
I1
sa(dp3204
g7
I68
sg8
VP34998
p3205
sg10
I13
sg11
VCRF1 receptor
p3206
sg13
I2
sasg23
(lp3207
(dp3208
g7
I68
sg26
VC0022661
p3209
sg10
I3
sg11
VCRF
p3210
sg13
I1
sa(dp3211
g7
I259
sg26
VC0006370
p3212
sg10
I12
sg11
Vbinge eating
p3213
sg13
I2
sa(dp3214
g7
I68
sg26
VC0022661
p3215
sg10
I3
sg11
VCRF
p3216
sg13
I1
sasa(dp3217
g2
S'These findings demonstrate that extra-hypothalamic CRF1 receptors, rather than those involved in endocrine functions, are involved in binge eating and the crucial role of CRF receptors in CeA.\n'
p3218
sg4
(lp3219
(dp3220
g7
I32
sg8
VP34998
p3221
sg10
I33
sg11
Vextra-hypothalamic CRF1 receptors
p3222
sg13
I3
sa(dp3223
g7
I171
sg8
VP06850
p3224
sg10
I13
sg11
VCRF receptors
p3225
sg13
I2
sa(dp3226
g7
I188
sg8
VP40198
p3227
sg10
I3
sg11
VCeA
p3228
sg13
I1
sasg23
(lp3229
(dp3230
g7
I134
sg26
VC0006370
p3231
sg10
I12
sg11
Vbinge eating
p3232
sg13
I2
sa(dp3233
g7
I51
sg26
VC0022661
p3234
sg10
I3
sg11
VCRF
p3235
sg13
I1
sasa(dp3236
g2
S'CRF1 receptor antagonism may represent a novel pharmacological treatment for binge-related eating disorders.\n'
p3237
sg4
(lp3238
(dp3239
g7
I0
sg8
VP34998
p3240
sg10
I13
sg11
VCRF1 receptor
p3241
sg13
I2
sasg23
(lp3242
(dp3243
g7
I91
sg26
VC0013473
p3244
sg10
I16
sg11
Veating disorders
p3245
sg13
I2
sa(dp3246
g7
I77
sg26
VC0596170
p3247
sg10
I5
sg11
Vbinge
p3248
sg13
I1
sasa(dp3249
g2
S'Current clinical and pre-clinical data suggest that both cannabinoid agents and blockage of CRF through corticotrophin releasing factor receptor type 1 (CRFr1) may offer therapeutic benefits for post-traumatic stress disorder (PTSD).\n'
p3250
sg4
(lp3251
(dp3252
g7
I153
sg8
VP34998
p3253
sg10
I5
sg11
VCRFr1
p3254
sg13
I1
sa(dp3255
g7
I92
sg8
VP06850
p3256
sg10
I59
sg11
VCRF through corticotrophin releasing factor receptor type 1
p3257
sg13
I8
sasg23
(lp3258
(dp3259
g7
I227
sg26
VC0038436
p3260
sg10
I4
sg11
VPTSD
p3261
sg13
I1
sa(dp3262
g7
I92
sg26
VC0022661
p3263
sg10
I3
sg11
VCRF
p3264
sg13
I1
sa(dp3265
g7
I195
sg26
VC0038436
p3266
sg10
I30
sg11
Vpost-traumatic stress disorder
p3267
sg13
I3
sasa(dp3268
g2
S'Intra-BLA and intra-CA1 microinjection of the CRFr1 antagonist, CP-154,526 attenuated startle response.\n'
p3269
sg4
(lp3270
(dp3271
g7
I46
sg8
VP34998
p3272
sg10
I5
sg11
VCRFr1
p3273
sg13
I1
sasg23
(lp3274
sa(dp3275
g2
S'Finally, mRNA levels of CRF, CRFr1 and CB1r were significantly higher in the BLA of rats exposed to shock and reminders compared to non-shocked rats almost one month after the shock.\n'
p3276
sg4
(lp3277
(dp3278
g7
I24
sg8
VP06850
p3279
sg10
I3
sg11
VCRF
p3280
sg13
I1
sa(dp3281
g7
I29
sg8
VP34998
p3282
sg10
I5
sg11
VCRFr1
p3283
sg13
I1
sasg23
(lp3284
(dp3285
g7
I136
sg26
VC0036974
p3286
sg10
I7
sg11
Vshocked
p3287
sg13
I1
sa(dp3288
g7
I24
sg26
VC0022661
p3289
sg10
I3
sg11
VCRF
p3290
sg13
I1
sasa(dp3291
g2
S'Taken together, the results show that enhancing endocannabinoid signaling in the amygdala and hippocampus produced a more favorable spectrum of effects than those caused by the CRFr1 antagonist.\n'
p3292
sg4
(lp3293
(dp3294
g7
I177
sg8
VP34998
p3295
sg10
I5
sg11
VCRFr1
p3296
sg13
I1
sasg23
(lp3297
sa(dp3298
g2
S'We established that all genes of the CRF system, the ligands CRFa, CRFb, urotensin 1 (UTS1), and urocortin 3 (UCN3); the two receptor subtypes (CRFR1 and CRFR2); and the binding protein (CRFBP) are expressed in the heart of zebrafish: crfr1 &gt; crfr2 = crfbp &gt; crfa &gt; ucn3 &gt; crfb &gt; uts1 In vivo, exposure to 5% O2 saturation for 15 min and 90 min of recovery resulted in four- to five-fold increases in whole heart crfb and ucn3 mRNA levels but did not affect the gene expression of other CRF system components.\n'
p3299
sg4
(lp3300
(dp3301
g7
I275
sg8
g64
sg10
I4
sg11
Vucn3
p3302
sg13
I1
sa(dp3303
g7
I246
sg8
g64
sg10
I5
sg11
Vcrfr2
p3304
sg13
I1
sa(dp3305
g7
I144
sg8
VP34998
p3306
sg10
I5
sg11
VCRFR1
p3307
sg13
I1
sa(dp3308
g7
I154
sg8
g64
sg10
I5
sg11
VCRFR2
p3309
sg13
I1
sa(dp3310
g7
I73
sg8
VP55089
p3311
sg10
I11
sg11
Vurotensin 1
p3312
sg13
I2
sa(dp3313
g7
I235
sg8
VP34998
p3314
sg10
I5
sg11
Vcrfr1
p3315
sg13
I1
sa(dp3316
g7
I437
sg8
g64
sg10
I9
sg11
Vucn3 mRNA
p3317
sg13
I2
sa(dp3318
g7
I86
sg8
VP55089
p3319
sg10
I4
sg11
VUTS1
p3320
sg13
I1
sa(dp3321
g7
I37
sg8
VP06850
p3322
sg10
I3
sg11
VCRF
p3323
sg13
I1
sa(dp3324
g7
I110
sg8
g64
sg10
I4
sg11
VUCN3
p3325
sg13
I1
sa(dp3326
g7
I97
sg8
VP55089
p3327
sg10
I11
sg11
Vurocortin 3
p3328
sg13
I2
sa(dp3329
g7
I187
sg8
VP24387
p3330
sg10
I5
sg11
VCRFBP
p3331
sg13
I1
sasg23
(lp3332
(dp3333
g7
I37
sg26
VC0022661
p3334
sg10
I3
sg11
VCRF
p3335
sg13
I1
sa(dp3336
g7
I37
sg26
VC0022661
p3337
sg10
I3
sg11
VCRF
p3338
sg13
I1
sasa(dp3339
g2
S'The aim of this study was to examine the effects of non-peptide corticotropin-releasing factor receptor 1 (CRF1) antagonist (antalarmin) administration on rat conditioned fear responses and gamma-aminobutyric acid (GABA)-ergic brain activity (GAD67 expression and GABA concentration) in low-anxiety (LR) and high-anxiety (HR) rats.\n'
p3340
sg4
(lp3341
(dp3342
g7
I107
sg8
VP34998
p3343
sg10
I4
sg11
VCRF1
p3344
sg13
I1
sa(dp3345
g7
I56
sg8
VP34998
p3346
sg10
I49
sg11
Vpeptide corticotropin-releasing factor receptor 1
p3347
sg13
I5
sa(dp3348
g7
I243
sg8
VP49419
p3349
sg10
I5
sg11
VGAD67
p3350
sg13
I1
sasg23
(lp3351
sa(dp3352
g2
S'These studies showed that HR rats were more susceptible to the anxiolytic effects of CRF1 antagonist administration, which were associated with increased GABAergic activity in the medial prefrontal cortex and amygdala.\n'
p3353
sg4
(lp3354
(dp3355
g7
I85
sg8
VP34998
p3356
sg10
I4
sg11
VCRF1
p3357
sg13
I1
sasg23
(lp3358
sa(dp3359
g2
S'The noncalcemic analogs showed similar efficacy to 1,25(OH)2D3 in stimulating the expression of neuropeptides, CRF, urocortins and POMC, and their receptors, CRFR1, CRFR2, MC1R, MC2R, MC3R and MC4R.\n'
p3360
sg4
(lp3361
(dp3362
g7
I131
sg8
VP01189
p3363
sg10
I4
sg11
VPOMC
p3364
sg13
I1
sa(dp3365
g7
I158
sg8
VP34998
p3366
sg10
I5
sg11
VCRFR1
p3367
sg13
I1
sa(dp3368
g7
I184
sg8
VP41968
p3369
sg10
I4
sg11
VMC3R
p3370
sg13
I1
sa(dp3371
g7
I116
sg8
VP55089
p3372
sg10
I10
sg11
Vurocortins
p3373
sg13
I1
sa(dp3374
g7
I111
sg8
VP06850
p3375
sg10
I3
sg11
VCRF
p3376
sg13
I1
sa(dp3377
g7
I178
sg8
g64
sg10
I4
sg11
VMC2R
p3378
sg13
I1
sa(dp3379
g7
I165
sg8
g64
sg10
I5
sg11
VCRFR2
p3380
sg13
I1
sa(dp3381
g7
I172
sg8
VP04350
p3382
sg10
I4
sg11
VMC1R
p3383
sg13
I1
sa(dp3384
g7
I193
sg8
VP32245
p3385
sg10
I4
sg11
VMC4R
p3386
sg13
I1
sasg23
(lp3387
(dp3388
g7
I111
sg26
VC0022661
p3389
sg10
I3
sg11
VCRF
p3390
sg13
I1
sasa(dp3391
g2
S'Finally-based on the previously demonstrated role of corticotropin-releasing factor 1 (CRF1) receptor inhibition in blocking WCE-induced cytokine mRNAs-the CRF1 receptor antagonist CP154,526 was administered to a subgroup of stressed rats and found to be inactive against induction of CCL2, TNFAlfa, or IL-1Beta mRNAs.\n'
p3392
sg4
(lp3393
(dp3394
g7
I87
sg8
VP34998
p3395
sg10
I4
sg11
VCRF1
p3396
sg13
I1
sa(dp3397
g7
I156
sg8
VP34998
p3398
sg10
I13
sg11
VCRF1 receptor
p3399
sg13
I2
sa(dp3400
g7
I53
sg8
VP06850
p3401
sg10
I32
sg11
Vcorticotropin-releasing factor 1
p3402
sg13
I3
sa(dp3403
g7
I303
sg8
VP01584
p3404
sg10
I14
sg11
VIL-1Beta mRNAs
p3405
sg13
I2
sa(dp3406
g7
I285
sg8
VP13500
p3407
sg10
I4
sg11
VCCL2
p3408
sg13
I1
sasg23
(lp3409
(dp3410
g7
I116
sg26
VC0233660
p3411
sg10
I8
sg11
Vblocking
p3412
sg13
I1
sasa(dp3413
g2
S'It expresses a variety of neurotransmitters, neuropeptides and receptors such as 5-HT1A, D2 and CRF1 receptors.\n'
p3414
sg4
(lp3415
(dp3416
g7
I81
sg8
VP08908
p3417
sg10
I6
sg11
V5-HT1A
p3418
sg13
I1
sa(dp3419
g7
I96
sg8
VP34998
p3420
sg10
I14
sg11
VCRF1 receptors
p3421
sg13
I2
sasg23
(lp3422
sa(dp3423
g2
S'Activation of corticotropin-releasing factor type 1 receptors (CRF-R1) in the ventral tegmental area (VTA) represents a critical mechanism for social defeat to escalate cocaine self-administration in adult rats.\n'
p3424
sg4
(lp3425
(dp3426
g7
I63
sg8
VP06850
p3427
sg10
I6
sg11
VCRF-R1
p3428
sg13
I1
sa(dp3429
g7
I14
sg8
VP06850
p3430
sg10
I47
sg11
Vcorticotropin-releasing factor type 1 receptors
p3431
sg13
I5
sasg23
(lp3432
(dp3433
g7
I63
sg26
VC0022661
p3434
sg10
I3
sg11
VCRF
p3435
sg13
I1
sasa(dp3436
g2
S'We determined the acute effect of a CRF-R1 antagonist (CP376395) microinfusion into the VTA prior to each episode of social defeat in adolescent rats and determined whether this drug treatment could prevent later escalation of cocaine taking in early adulthood.\n'
p3437
sg4
(lp3438
(dp3439
g7
I36
sg8
VP06850
p3440
sg10
I6
sg11
VCRF-R1
p3441
sg13
I1
sasg23
(lp3442
(dp3443
g7
I36
sg26
VC0022661
p3444
sg10
I3
sg11
VCRF
p3445
sg13
I1
sasa(dp3446
g2
S'Episodes of social defeat stress engender neuroadaptation in CRF-R1s in the VTA that alter coping with social stress and that persist into adulthood.\n'
p3447
sg4
(lp3448
(dp3449
g7
I61
sg8
VP06850
p3450
sg10
I7
sg11
VCRF-R1s
p3451
sg13
I1
sasg23
(lp3452
(dp3453
g7
I61
sg26
VC0022661
p3454
sg10
I3
sg11
VCRF
p3455
sg13
I1
sa(dp3456
g7
I103
sg26
VC0871388
p3457
sg10
I13
sg11
Vsocial stress
p3458
sg13
I2
sasa(dp3459
g2
S'Signaling by the corticotropin-releasing factor receptor type 1 (CRFR1) plays an important role in mediating the autonomic response to stressful challenges.\n'
p3460
sg4
(lp3461
(dp3462
g7
I17
sg8
VP34998
p3463
sg10
I46
sg11
Vcorticotropin-releasing factor receptor type 1
p3464
sg13
I5
sa(dp3465
g7
I65
sg8
VP34998
p3466
sg10
I5
sg11
VCRFR1
p3467
sg13
I1
sasg23
(lp3468
sa(dp3469
g2
S'Although CRFR1 is highly expressed in the arcuate nucleus (Arc) of the hypothalamus, the identity of these neurons and the role of CRFR1 here are presently unknown.\n'
p3470
sg4
(lp3471
(dp3472
g7
I9
sg8
VP34998
p3473
sg10
I5
sg11
VCRFR1
p3474
sg13
I1
sa(dp3475
g7
I9
sg8
VP34998
p3476
sg10
I5
sg11
VCRFR1
p3477
sg13
I1
sasg23
(lp3478
(dp3479
g7
I59
sg26
VC0001857
p3480
sg10
I3
sg11
VArc
p3481
sg13
I1
sa(dp3482
g7
I42
sg26
VC0001857
p3483
sg10
I15
sg11
Varcuate nucleus
p3484
sg13
I2
sasa(dp3485
g2
S'Our studies show that nearly half of Arc-CRFR1 neurons coexpress agouti-related peptide (AgRP), half of which originate from POMC precursors.\n'
p3486
sg4
(lp3487
(dp3488
g7
I125
sg8
VP01189
p3489
sg10
I15
sg11
VPOMC precursors
p3490
sg13
I2
sa(dp3491
g7
I89
sg8
g64
sg10
I4
sg11
VAgRP
p3492
sg13
I1
sa(dp3493
g7
I37
sg8
g64
sg10
I3
sg11
VArc
p3494
sg13
I1
sa(dp3495
g7
I41
sg8
VP34998
p3496
sg10
I5
sg11
VCRFR1
p3497
sg13
I1
sa(dp3498
g7
I65
sg8
VP42127
p3499
sg10
I22
sg11
Vagouti-related peptide
p3500
sg13
I2
sasg23
(lp3501
(dp3502
g7
I37
sg26
VC0001857
p3503
sg10
I3
sg11
VArc
p3504
sg13
I1
sasa(dp3505
g2
S"Arc-CRFR1 neurons are innervated by CRF neurons in the hypothalamic paraventricular nucleus, and CRF application decreases AgRP(+)CRFR1(+) neurons' excitability.\n"
p3506
sg4
(lp3507
(dp3508
g7
I0
sg8
g64
sg10
I3
sg11
VArc
p3509
sg13
I1
sa(dp3510
g7
I4
sg8
VP34998
p3511
sg10
I5
sg11
VCRFR1
p3512
sg13
I1
sa(dp3513
g7
I123
sg8
g64
sg10
I12
sg11
VAgRP(+)CRFR1
p3514
sg13
I1
sa(dp3515
g7
I4
sg8
VP06850
p3516
sg10
I3
sg11
VCRF
p3517
sg13
I1
sasg23
(lp3518
(dp3519
g7
I4
sg26
VC0022661
p3520
sg10
I3
sg11
VCRF
p3521
sg13
I1
sa(dp3522
g7
I0
sg26
VC0001857
p3523
sg10
I3
sg11
VArc
p3524
sg13
I1
sa(dp3525
g7
I148
sg26
VC0235169
p3526
sg10
I12
sg11
Vexcitability
p3527
sg13
I1
sa(dp3528
g7
I4
sg26
VC0022661
p3529
sg10
I3
sg11
VCRF
p3530
sg13
I1
sasa(dp3531
g2
S'Despite similar anatomy in both sexes, only female mice selectively lacking CRFR1 in AgRP neurons showed a maladaptive thermogenic response to cold and reduced hepatic glucose production during fasting.\n'
p3532
sg4
(lp3533
(dp3534
g7
I85
sg8
g64
sg10
I4
sg11
VAgRP
p3535
sg13
I1
sa(dp3536
g7
I76
sg8
VP34998
p3537
sg10
I5
sg11
VCRFR1
p3538
sg13
I1
sasg23
(lp3539
(dp3540
g7
I143
sg26
VC0024117
p3541
sg10
I4
sg11
Vcold
p3542
sg13
I1
sasa(dp3543
g2
S'Thus, CRFR1, in a subset of AgRP neurons, plays a regulatory role that enables appropriate sympathetic nervous system activation and consequently protects the organism from hypothermia and hypoglycemia.\n'
p3544
sg4
(lp3545
(dp3546
g7
I6
sg8
VP34998
p3547
sg10
I5
sg11
VCRFR1
p3548
sg13
I1
sa(dp3549
g7
I28
sg8
g64
sg10
I4
sg11
VAgRP
p3550
sg13
I1
sasg23
(lp3551
(dp3552
g7
I189
sg26
VC0020615
p3553
sg10
I12
sg11
Vhypoglycemia
p3554
sg13
I1
sa(dp3555
g7
I103
sg26
VC0027769
p3556
sg10
I7
sg11
Vnervous
p3557
sg13
I1
sasa(dp3558
g2
S'Finally, immunostaining of thin layer chromatograms with antibodies from patients with cutaneous leishmaniasis suggests that the major GIPLs are highly immunogenic and that the elevated anti-Gal antibodies, commonly seen in leishmaniasis patients, may be directed against terminal Galp(alpha 1-3)Galf residues.\n'
p3559
sg4
(lp3560
(dp3561
g7
I286
sg8
VP25100
p3562
sg10
I9
sg11
Valpha 1-3
p3563
sg13
I2
sa(dp3564
g7
I186
sg8
VP16278
p3565
sg10
I19
sg11
Vanti-Gal antibodies
p3566
sg13
I2
sa(dp3567
g7
I281
sg8
g64
sg10
I4
sg11
VGalp
p3568
sg13
I1
sasg23
(lp3569
(dp3570
g7
I87
sg26
VC0023283
p3571
sg10
I23
sg11
Vcutaneous leishmaniasis
p3572
sg13
I2
sa(dp3573
g7
I97
sg26
VC0023281
p3574
sg10
I13
sg11
Vleishmaniasis
p3575
sg13
I1
sasa(dp3576
g2
S'Here we report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10.\n'
p3577
sg4
(lp3578
(dp3579
g7
I139
sg8
VP46092
p3580
sg10
I5
sg11
VCCR10
p3581
sg13
I1
sasg23
(lp3582
(dp3583
g7
I67
sg26
VC0683278
p3584
sg10
I9
sg11
Vsuffering
p3585
sg13
I1
sa(dp3586
g7
I30
sg26
VC0332448
p3587
sg10
I12
sg11
Vinfiltrating
p3588
sg13
I1
sa(dp3589
g7
I93
sg26
VC0392707
p3590
sg10
I6
sg11
Vatopic
p3591
sg13
I1
sa(dp3592
g7
I112
sg26
VC0011616
p3593
sg10
I18
sg11
Vcontact dermatitis
p3594
sg13
I2
sa(dp3595
g7
I82
sg26
VC0033860
p3596
sg10
I9
sg11
Vpsoriasis
p3597
sg13
I1
sasa(dp3598
g2
S'Knockdown of FOXA1 in RT4 bladder cancer cells resulted in increased expression of UPK1B, UPK2, UPK3A, and UPK3B, decreased E-cadherin expression and significantly increased cell proliferation, while overexpression of FOXA1 in T24 cells increased E-cadherin expression and significantly decreased cell growth and invasion.\n'
p3599
sg4
(lp3600
(dp3601
g7
I107
sg8
g64
sg10
I5
sg11
VUPK3B
p3602
sg13
I1
sa(dp3603
g7
I124
sg8
VP12830
p3604
sg10
I10
sg11
VE-cadherin
p3605
sg13
I1
sa(dp3606
g7
I90
sg8
g64
sg10
I4
sg11
VUPK2
p3607
sg13
I1
sa(dp3608
g7
I13
sg8
VP55317
p3609
sg10
I5
sg11
VFOXA1
p3610
sg13
I1
sa(dp3611
g7
I13
sg8
VP55317
p3612
sg10
I5
sg11
VFOXA1
p3613
sg13
I1
sa(dp3614
g7
I124
sg8
VP12830
p3615
sg10
I10
sg11
VE-cadherin
p3616
sg13
I1
sa(dp3617
g7
I83
sg8
g64
sg10
I5
sg11
VUPK1B
p3618
sg13
I1
sa(dp3619
g7
I96
sg8
g64
sg10
I5
sg11
VUPK3A
p3620
sg13
I1
sasg23
(lp3621
(dp3622
g7
I179
sg26
VC0334094
p3623
sg10
I13
sg11
Vproliferation
p3624
sg13
I1
sa(dp3625
g7
I313
sg26
VC2699153
p3626
sg10
I8
sg11
Vinvasion
p3627
sg13
I1
sa(dp3628
g7
I26
sg26
VC0699885
p3629
sg10
I14
sg11
Vbladder cancer
p3630
sg13
I2
sasa(dp3631
g2
S'Schwartz-Jampel syndrome is a very rare congenital myotonic syndrome with typical phenotypic and electrophysiological features.\n'
p3632
sg4
(lp3633
sg23
(lp3634
(dp3635
g7
I0
sg26
VC0036391
p3636
sg10
I24
sg11
VSchwartz-Jampel syndrome
p3637
sg13
I2
sa(dp3638
g7
I16
sg26
VC0039082
p3639
sg10
I8
sg11
Vsyndrome
p3640
sg13
I1
sasa(dp3641
g2
S'To better understand their role in muscle fibrosis, we investigated expression of decorin and biglycan transcripts and protein in muscle of several forms of muscular dystrophy, and also expression of perlecan, an extracellular proteoglycan unrelated to collagen deposition.\n'
p3642
sg4
(lp3643
(dp3644
g7
I82
sg8
VP07585
p3645
sg10
I7
sg11
Vdecorin
p3646
sg13
I1
sa(dp3647
g7
I94
sg8
VP21810
p3648
sg10
I20
sg11
Vbiglycan transcripts
p3649
sg13
I2
sasg23
(lp3650
(dp3651
g7
I157
sg26
VC0026850
p3652
sg10
I18
sg11
Vmuscular dystrophy
p3653
sg13
I2
sa(dp3654
g7
I35
sg26
VC0877009
p3655
sg10
I15
sg11
Vmuscle fibrosis
p3656
sg13
I2
sasa(dp3657
g2
S'We determined the association between haplotypes of FcGammaRIIA-131Arg/His, FcGammaRIIIA-176F/V and FcGammaRIIIB-NA1/NA2 variants and severe malarial anemia (SMA; hemoglobin &lt; 6.0 g/dL, any density parasitemia) in children (n = 274; aged 6-36 months) presenting for their first hospital visit with P. falciparum malaria in a holoendemic transmission region of western Kenya.\n'
p3658
sg4
(lp3659
(dp3660
g7
I76
sg8
VP08637
p3661
sg10
I17
sg11
VFcGammaRIIIA-176F
p3662
sg13
I1
sa(dp3663
g7
I163
sg8
g64
sg10
I10
sg11
Vhemoglobin
p3664
sg13
I1
sa(dp3665
g7
I100
sg8
VP10909
p3666
sg10
I29
sg11
VFcGammaRIIIB-NA1/NA2 variants
p3667
sg13
I2
sa(dp3668
g7
I52
sg8
VP31995
p3669
sg10
I18
sg11
VFcGammaRIIA-131Arg
p3670
sg13
I1
sasg23
(lp3671
(dp3672
g7
I158
sg26
VC0026847
p3673
sg10
I3
sg11
VSMA
p3674
sg13
I1
sa(dp3675
g7
I304
sg26
VC0024535
p3676
sg10
I18
sg11
Vfalciparum malaria
p3677
sg13
I2
sa(dp3678
g7
I201
sg26
VC0242723
p3679
sg10
I11
sg11
Vparasitemia
p3680
sg13
I1
sa(dp3681
g7
I134
sg26
VC0026847
p3682
sg10
I22
sg11
Vsevere malarial anemia
p3683
sg13
I3
sasa(dp3684
g2
S"In contrast, significantly increased levels of BLyS were only observed in patients with Wegener's granulomatosis (WG), but not in patients with microscopic polyangiitis (mPAN)/Churg-Strauss-syndrome (CSS).\n"
p3685
sg4
(lp3686
(dp3687
g7
I47
sg8
g64
sg10
I4
sg11
VBLyS
p3688
sg13
I1
sasg23
(lp3689
(dp3690
g7
I175
sg26
VC0265338
p3691
sg10
I23
sg11
V/Churg-Strauss-syndrome
p3692
sg13
I1
sa(dp3693
g7
I170
sg26
VC0343192
p3694
sg10
I4
sg11
VmPAN
p3695
sg13
I1
sa(dp3696
g7
I144
sg26
VC0343192
p3697
sg10
I24
sg11
Vmicroscopic polyangiitis
p3698
sg13
I2
sa(dp3699
g7
I200
sg26
VC0265338
p3700
sg10
I3
sg11
VCSS
p3701
sg13
I1
sa(dp3702
g7
I88
sg26
VC0043092
p3703
sg10
I24
sg11
VWegener's granulomatosis
p3704
sg13
I2
sa(dp3705
g7
I114
sg26
VC0043092
p3706
sg10
I2
sg11
VWG
p3707
sg13
I1
sasa(dp3708
g2
S"In humans, BLyS overexpression is common in patients with several rheumatic diseases, including SLE, rheumatoid arthritis (RA), Sjoegren's syndrome, scleroderma, Wegener's granulomatosis, and ANCA-associated vasculitis.\n"
p3709
sg4
(lp3710
(dp3711
g7
I96
sg8
g64
sg10
I3
sg11
VSLE
p3712
sg13
I1
sasg23
(lp3713
(dp3714
g7
I128
sg26
VC1527336
p3715
sg10
I19
sg11
VSjoegren's syndrome
p3716
sg13
I2
sa(dp3717
g7
I123
sg26
VC0003873
p3718
sg10
I2
sg11
VRA
p3719
sg13
I1
sa(dp3720
g7
I149
sg26
VC0011644
p3721
sg10
I11
sg11
Vscleroderma
p3722
sg13
I1
sa(dp3723
g7
I101
sg26
VC0003873
p3724
sg10
I20
sg11
Vrheumatoid arthritis
p3725
sg13
I2
sa(dp3726
g7
I66
sg26
VC0035435
p3727
sg10
I18
sg11
Vrheumatic diseases
p3728
sg13
I2
sa(dp3729
g7
I192
sg26
VC2717865
p3730
sg10
I26
sg11
VANCA-associated vasculitis
p3731
sg13
I2
sa(dp3732
g7
I96
sg26
VC0014060
p3733
sg10
I3
sg11
VSLE
p3734
sg13
I1
sa(dp3735
g7
I162
sg26
VC0043092
p3736
sg10
I24
sg11
VWegener's granulomatosis
p3737
sg13
I2
sasa(dp3738
g2
S'The pathology specimens from the patients were retrieved, their pathologic diagnosis was confirmed, demographic and clinical information were gathered, and sections from vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGFR3).\n'
p3739
sg4
(lp3740
(dp3741
g7
I204
sg8
VP35968
p3742
sg10
I43
sg11
Vvascular endothelial growth factor receptor
p3743
sg13
I5
sa(dp3744
g7
I257
sg8
VP35968
p3745
sg10
I50
sg11
Vvascular endothelial growth factor receptor type 1
p3746
sg13
I7
sa(dp3747
g7
I249
sg8
VP35968
p3748
sg10
I5
sg11
VVEGFR
p3749
sg13
I1
sa(dp3750
g7
I435
sg8
VP35916
p3751
sg10
I6
sg11
VVEGFR3
p3752
sg13
I1
sa(dp3753
g7
I318
sg8
VP35968
p3754
sg10
I50
sg11
Vvascular endothelial growth factor receptor type 2
p3755
sg13
I7
sa(dp3756
g7
I370
sg8
VP35968
p3757
sg10
I6
sg11
VVEGFR2
p3758
sg13
I1
sa(dp3759
g7
I309
sg8
VP17948
p3760
sg10
I6
sg11
VVEGFR1
p3761
sg13
I1
sa(dp3762
g7
I383
sg8
VP35968
p3763
sg10
I50
sg11
Vvascular endothelial growth factor receptor type 3
p3764
sg13
I7
sasg23
(lp3765
(dp3766
g7
I4
sg26
VC0677042
p3767
sg10
I9
sg11
Vpathology
p3768
sg13
I1
sa(dp3769
g7
I170
sg26
VC0282607
p3770
sg10
I15
sg11
Vvascular tumors
p3771
sg13
I2
sasa(dp3772
g2
S'Specifically, this article will focus on the following aspects: (1) pathological and molecular features of epithelioid hemangioendothelioma, including the more common WWTR1-CAMTA1 fusion, as well as the recently described YAP1-TFE3 fusion, identified in a morphological variant of epithelioid hemangioendothelioma; (2) discuss the heterogeneity of angiosarcoma clinical, morphological and genetic spectrum, with particular emphasis of MYC and FLT4 gene amplification in radiation-induced angiosarcoma; and (3) provide a practical guide in the differential diagnosis of epithelioid vascular tumors using molecular testing.\n'
p3773
sg4
(lp3774
(dp3775
g7
I443
sg8
VP35916
p3776
sg10
I9
sg11
VFLT4 gene
p3777
sg13
I2
sa(dp3778
g7
I227
sg8
VP19532
p3779
sg10
I4
sg11
VTFE3
p3780
sg13
I1
sa(dp3781
g7
I173
sg8
g64
sg10
I6
sg11
VCAMTA1
p3782
sg13
I1
sa(dp3783
g7
I435
sg8
VP12524
p3784
sg10
I3
sg11
VMYC
p3785
sg13
I1
sa(dp3786
g7
I167
sg8
g64
sg10
I5
sg11
VWWTR1
p3787
sg13
I1
sa(dp3788
g7
I222
sg8
VP46937
p3789
sg10
I4
sg11
VYAP1
p3790
sg13
I1
sasg23
(lp3791
(dp3792
g7
I581
sg26
VC0282607
p3793
sg10
I15
sg11
Vvascular tumors
p3794
sg13
I2
sa(dp3795
g7
I107
sg26
VC0206732
p3796
sg10
I32
sg11
Vepithelioid hemangioendothelioma
p3797
sg13
I2
sa(dp3798
g7
I107
sg26
VC0206732
p3799
sg10
I32
sg11
Vepithelioid hemangioendothelioma
p3800
sg13
I2
sa(dp3801
g7
I448
sg26
VC1705759
p3802
sg10
I18
sg11
Vgene amplification
p3803
sg13
I2
sa(dp3804
g7
I348
sg26
VC0018923
p3805
sg10
I12
sg11
Vangiosarcoma
p3806
sg13
I1
sa(dp3807
g7
I470
sg26
VC1335661
p3808
sg10
I30
sg11
Vradiation-induced angiosarcoma
p3809
sg13
I2
sasa(dp3810
g2
S'The content of skMLCK and myosin-activating protein kinases: RhaA-activated protein kinase (ROCK), integrin-linked protein kinase (ILK), and zipper-interacting protein kinase (ZIPK) was compared in normal human myocardium and the hearts of patients with dilated cardiomyopathy (DCM).\n'
p3811
sg4
(lp3812
(dp3813
g7
I61
sg8
VP33981
p3814
sg10
I29
sg11
VRhaA-activated protein kinase
p3815
sg13
I3
sa(dp3816
g7
I176
sg8
g64
sg10
I4
sg11
VZIPK
p3817
sg13
I1
sa(dp3818
g7
I141
sg8
g64
sg10
I33
sg11
Vzipper-interacting protein kinase
p3819
sg13
I3
sa(dp3820
g7
I99
sg8
g64
sg10
I30
sg11
Vintegrin-linked protein kinase
p3821
sg13
I3
sa(dp3822
g7
I131
sg8
g64
sg10
I3
sg11
VILK
p3823
sg13
I1
sa(dp3824
g7
I15
sg8
VP56539
p3825
sg10
I6
sg11
VskMLCK
p3826
sg13
I1
sa(dp3827
g7
I92
sg8
g64
sg10
I4
sg11
VROCK
p3828
sg13
I1
sa(dp3829
g7
I26
sg8
VP13535
p3830
sg10
I33
sg11
Vmyosin-activating protein kinases
p3831
sg13
I3
sasg23
(lp3832
(dp3833
g7
I278
sg26
VC0007193
p3834
sg10
I3
sg11
VDCM
p3835
sg13
I1
sa(dp3836
g7
I254
sg26
VC0007193
p3837
sg10
I22
sg11
Vdilated cardiomyopathy
p3838
sg13
I2
sasa(dp3839
g2
S'The lymphoma strongly and diffusely expressed CD158k/KIR3DL2 at the protein and transcript level and NKp46 transcripts, in addition to CD8 and cytotoxic proteins.\n'
p3840
sg4
(lp3841
(dp3842
g7
I46
sg8
VP43627
p3843
sg10
I6
sg11
VCD158k
p3844
sg13
I1
sa(dp3845
g7
I135
sg8
VP01732
p3846
sg10
I3
sg11
VCD8
p3847
sg13
I1
sa(dp3848
g7
I53
sg8
VP43630
p3849
sg10
I7
sg11
VKIR3DL2
p3850
sg13
I1
sa(dp3851
g7
I101
sg8
g64
sg10
I17
sg11
VNKp46 transcripts
p3852
sg13
I2
sasg23
(lp3853
(dp3854
g7
I4
sg26
VC0024299
p3855
sg10
I8
sg11
Vlymphoma
p3856
sg13
I1
sasa(dp3857
g2
S'Notably, 16 (20%) of 82 mature T-cell neoplasms, particularly T-cell large granular lymphocytic leukemia, mycosis fungoides, and ALK+ anaplastic large cell lymphoma, aberrantly expressed CD335.\n'
p3858
sg4
(lp3859
(dp3860
g7
I187
sg8
g64
sg10
I5
sg11
VCD335
p3861
sg13
I1
sa(dp3862
g7
I129
sg8
g64
sg10
I4
sg11
VALK+
p3863
sg13
I1
sasg23
(lp3864
(dp3865
g7
I62
sg26
VC1955861
p3866
sg10
I42
sg11
VT-cell large granular lymphocytic leukemia
p3867
sg13
I5
sa(dp3868
g7
I134
sg26
VC0206180
p3869
sg10
I30
sg11
Vanaplastic large cell lymphoma
p3870
sg13
I4
sa(dp3871
g7
I38
sg26
VC0027651
p3872
sg10
I9
sg11
Vneoplasms
p3873
sg13
I1
sa(dp3874
g7
I106
sg26
VC0026948
p3875
sg10
I17
sg11
Vmycosis fungoides
p3876
sg13
I2
sasa(dp3877
g2
S"Sera from 611 patients with scleroderma, CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), Raynaud's disease, and connective tissue disease control patients were studied by ELISA using the fusion protein CENP-B, by immunofluorescence on dividing HEp-2 cells, and by immunoblotting on chromosomes and CENP-B.\n"
p3878
sg4
(lp3879
(dp3880
g7
I252
sg8
VP07199
p3881
sg10
I6
sg11
VCENP-B
p3882
sg13
I1
sa(dp3883
g7
I252
sg8
VP07199
p3884
sg10
I6
sg11
VCENP-B
p3885
sg13
I1
sasg23
(lp3886
(dp3887
g7
I162
sg26
VC0009782
p3888
sg10
I25
sg11
Vconnective tissue disease
p3889
sg13
I3
sa(dp3890
g7
I48
sg26
VC0006663
p3891
sg10
I10
sg11
Vcalcinosis
p3892
sg13
I1
sa(dp3893
g7
I41
sg26
VC0206138
p3894
sg10
I5
sg11
VCREST
p3895
sg13
I1
sa(dp3896
g7
I82
sg26
VC0014858
p3897
sg10
I22
sg11
Vesophageal dysmotility
p3898
sg13
I2
sa(dp3899
g7
I139
sg26
VC0034734
p3900
sg10
I17
sg11
VRaynaud's disease
p3901
sg13
I2
sa(dp3902
g7
I294
sg26
VC0162569
p3903
sg10
I3
sg11
VHEp
p3904
sg13
I1
sa(dp3905
g7
I60
sg26
VC0034735
p3906
sg10
I20
sg11
VRaynaud's phenomenon
p3907
sg13
I2
sa(dp3908
g7
I106
sg26
VC0150988
p3909
sg10
I13
sg11
Vsclerodactyly
p3910
sg13
I1
sa(dp3911
g7
I121
sg26
VC0039446
p3912
sg10
I15
sg11
Vtelangiectasias
p3913
sg13
I1
sa(dp3914
g7
I28
sg26
VC0011644
p3915
sg10
I11
sg11
Vscleroderma
p3916
sg13
I1
sasa(dp3917
g2
S'Less striking effects for mRNA levels were observed for MTX1 at 1q22 in gastric cardia adenocarcinoma and for JRK at 8q24.3 in diffuse GC.\n'
p3918
sg4
(lp3919
(dp3920
g7
I56
sg8
g64
sg10
I4
sg11
VMTX1
p3921
sg13
I1
sasg23
(lp3922
(dp3923
g7
I72
sg26
VC1333762
p3924
sg10
I29
sg11
Vgastric cardia adenocarcinoma
p3925
sg13
I3
sasa(dp3926
g2
S'To evaluate whether parallel radiofrequency transmission (mTX) can improve the symmetry of the left and right femoral arteries in dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) of prostate and bladder cancer.\n'
p3927
sg4
(lp3928
sg23
(lp3929
(dp3930
g7
I209
sg26
VC0699885
p3931
sg10
I14
sg11
Vbladder cancer
p3932
sg13
I2
sasa(dp3933
g2
S'Subsequently, 21 prostate and 21 bladder cancer patients were scanned using the dual channel mTX upgrade.\n'
p3934
sg4
(lp3935
(dp3936
g7
I93
sg8
g64
sg10
I3
sg11
VmTX
p3937
sg13
I1
sasg23
(lp3938
(dp3939
g7
I33
sg26
VC0699885
p3940
sg10
I14
sg11
Vbladder cancer
p3941
sg13
I2
sasa(dp3942
g2
S'S0_LRasym, and MER_LRasym were 0.21 and 0.19 for prostate cancer patients with mTX, and 0.43 and 0.45 for the ones imaged without it (P &lt; 0.001).\n'
p3943
sg4
(lp3944
(dp3945
g7
I79
sg8
g64
sg10
I3
sg11
VmTX
p3946
sg13
I1
sasg23
(lp3947
(dp3948
g7
I49
sg26
VC0600139
p3949
sg10
I15
sg11
Vprostate cancer
p3950
sg13
I2
sasa(dp3951
g2
S'Also, for the bladder cancer patients, S0_LRasym, and MER_LRasym were 0.11 and 0.9 with mTX, while imaging without it yielded 0.52 and 0.39 (P &lt; 0.001).\n'
p3952
sg4
(lp3953
(dp3954
g7
I88
sg8
g64
sg10
I3
sg11
VmTX
p3955
sg13
I1
sasg23
(lp3956
(dp3957
g7
I14
sg26
VC0699885
p3958
sg10
I14
sg11
Vbladder cancer
p3959
sg13
I2
sasa(dp3960
g2
S'Although methotrexate (mtx) is a widely used agent to treat cancer and inflammatory diseases, its hepatotoxic effect limits for clinical utility.\n'
p3961
sg4
(lp3962
sg23
(lp3963
(dp3964
g7
I60
sg26
VC0006826
p3965
sg10
I6
sg11
Vcancer
p3966
sg13
I1
sasa(dp3967
g2
S'We identified 11 variants significantly associated with disease risk and assessed to have a high level of summary evidence: MUC1 rs2070803 at 1q22 (diffuse carcinoma subgroup), MTX1 rs2075570 at 1q22 (diffuse), PSCA rs2294008 at 8q24.2 (non-cardia), PRKAA1 rs13361707 5p13 (non-cardia), PLCE1 rs2274223 10q23 (cardia), TGFBR2 rs3087465 3p22 (Asian), PKLR rs3762272 1q22 (diffuse), PSCA rs2976392 (intestinal), GSTP1 rs1695 11q13 (Asian), CASP8 rs3834129 2q33 (mixed) and TNF rs1799724 6p21.3 (mixed), with the first nine variants characterised by a low FPRP.\n'
p3968
sg4
(lp3969
(dp3970
g7
I211
sg8
g64
sg10
I4
sg11
VPSCA
p3971
sg13
I1
sa(dp3972
g7
I350
sg8
VP30613
p3973
sg10
I19
sg11
VPKLR rs3762272 1q22
p3974
sg13
I3
sa(dp3975
g7
I250
sg8
g64
sg10
I22
sg11
VPRKAA1 rs13361707 5p13
p3976
sg13
I3
sa(dp3977
g7
I471
sg8
VP01375
p3978
sg10
I20
sg11
VTNF rs1799724 6p21.3
p3979
sg13
I3
sa(dp3980
g7
I410
sg8
VP09211
p3981
sg10
I12
sg11
VGSTP1 rs1695
p3982
sg13
I2
sa(dp3983
g7
I319
sg8
VP37173
p3984
sg10
I16
sg11
VTGFBR2 rs3087465
p3985
sg13
I2
sa(dp3986
g7
I211
sg8
g64
sg10
I14
sg11
VPSCA rs2294008
p3987
sg13
I2
sa(dp3988
g7
I553
sg8
g64
sg10
I4
sg11
VFPRP
p3989
sg13
I1
sa(dp3990
g7
I177
sg8
g64
sg10
I14
sg11
VMTX1 rs2075570
p3991
sg13
I2
sasg23
(lp3992
(dp3993
g7
I156
sg26
VC0007097
p3994
sg10
I9
sg11
Vcarcinoma
p3995
sg13
I1
sasa(dp3996
g2
S'The randomized international trial for childhood anaplastic large cell lymphoma, (ALCL99-R1) involving European study groups and a Japanese group, compared six courses of methotrexate 1 g/m(2) over 24 hours with an intrathecal injection (IT) (MTX1 arm) with six courses of methotrexate 3 g/m(2) over 3 hours without IT (MTX3 arm).\n'
p3997
sg4
(lp3998
(dp3999
g7
I243
sg8
g64
sg10
I4
sg11
VMTX1
p4000
sg13
I1
sasg23
(lp4001
(dp4002
g7
I39
sg26
VC1332942
p4003
sg10
I40
sg11
Vchildhood anaplastic large cell lymphoma
p4004
sg13
I5
sasa(dp4005
g2
S'Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).\n'
p4006
sg4
(lp4007
(dp4008
g7
I165
sg8
g64
sg10
I5
sg11
VPRDM8
p4009
sg13
I1
sa(dp4010
g7
I155
sg8
g64
sg10
I4
sg11
VTESC
p4011
sg13
I1
sa(dp4012
g7
I119
sg8
g64
sg10
I5
sg11
VCNPY1
p4013
sg13
I1
sa(dp4014
g7
I56
sg8
g64
sg10
I5
sg11
VIRAK4
p4015
sg13
I1
sa(dp4016
g7
I66
sg8
g64
sg10
I4
sg11
VESM1
p4017
sg13
I1
sa(dp4018
g7
I147
sg8
g64
sg10
I6
sg11
VIFT140
p4019
sg13
I1
sa(dp4020
g7
I81
sg8
VP38398
p4021
sg10
I5
sg11
VBRCA1
p4022
sg13
I1
sa(dp4023
g7
I91
sg8
g64
sg10
I5
sg11
VLASP1
p4024
sg13
I1
sasg23
(lp4025
(dp4026
g7
I136
sg26
VC0021359
p4027
sg10
I9
sg11
Vfertility
p4028
sg13
I1
sa(dp4029
g7
I33
sg26
VC1155266
p4030
sg10
I21
sg11
Vinflammatory response
p4031
sg13
I2
sa(dp4032
g7
I73
sg26
VC0006826
p4033
sg10
I6
sg11
Vcancer
p4034
sg13
I1
sasa(dp4035
g2
S'We reported previously that tescalcin (TESC) levels were higher in tissue and serum from colorectal cancer (CRC) patients and suggested that TESC was a potential oncotarget in CRC.\n'
p4036
sg4
(lp4037
(dp4038
g7
I28
sg8
g64
sg10
I9
sg11
Vtescalcin
p4039
sg13
I1
sa(dp4040
g7
I39
sg8
g64
sg10
I4
sg11
VTESC
p4041
sg13
I1
sa(dp4042
g7
I39
sg8
g64
sg10
I4
sg11
VTESC
p4043
sg13
I1
sa(dp4044
g7
I89
sg8
VP31749
p4045
sg10
I17
sg11
Vcolorectal cancer
p4046
sg13
I2
sa(dp4047
g7
I108
sg8
VP31749
p4048
sg10
I3
sg11
VCRC
p4049
sg13
I1
sasg23
(lp4050
(dp4051
g7
I108
sg26
VC1527249
p4052
sg10
I3
sg11
VCRC
p4053
sg13
I1
sa(dp4054
g7
I89
sg26
VC1527249
p4055
sg10
I17
sg11
Vcolorectal cancer
p4056
sg13
I2
sa(dp4057
g7
I108
sg26
VC1527249
p4058
sg10
I3
sg11
VCRC
p4059
sg13
I1
sasa(dp4060
g2
S'Tescalcin (TESC) is an EF-hand calcium binding protein that is differentially expressed in several tissues, however it is not reported that the expression and functional roles of TESC in colorectal cancer.\n'
p4061
sg4
(lp4062
(dp4063
g7
I23
sg8
VP31949
p4064
sg10
I31
sg11
VEF-hand calcium binding protein
p4065
sg13
I4
sa(dp4066
g7
I11
sg8
g64
sg10
I4
sg11
VTESC
p4067
sg13
I1
sa(dp4068
g7
I0
sg8
g64
sg10
I9
sg11
VTescalcin
p4069
sg13
I1
sa(dp4070
g7
I11
sg8
g64
sg10
I4
sg11
VTESC
p4071
sg13
I1
sasg23
(lp4072
(dp4073
g7
I187
sg26
VC1527249
p4074
sg10
I17
sg11
Vcolorectal cancer
p4075
sg13
I2
sasa(dp4076
g2
S'Levels of messenger RNA (mRNA) and protein expression of TESC in colorectal cancer tissues were assessed using RT-PCR, real time PCR, immunohistochemistry, and clinicopathologic analyses.\n'
p4077
sg4
(lp4078
(dp4079
g7
I57
sg8
g64
sg10
I4
sg11
VTESC
p4080
sg13
I1
sasg23
(lp4081
(dp4082
g7
I65
sg26
VC1527249
p4083
sg10
I17
sg11
Vcolorectal cancer
p4084
sg13
I2
sasa(dp4085
g2
S'Colorectal cancer cells transfected with TESC small interfering RNA and short hairpin RNA were examined in cell proliferation assays, phospho-MAPK array, and mouse xenograft models.\n'
p4086
sg4
(lp4087
sg23
(lp4088
(dp4089
g7
I112
sg26
VC0334094
p4090
sg10
I13
sg11
Vproliferation
p4091
sg13
I1
sa(dp4092
g7
I0
sg26
VC1527249
p4093
sg10
I17
sg11
VColorectal cancer
p4094
sg13
I2
sasa(dp4095
g2
S'Here we demonstrated that TESC is overexpressed in colorectal cancer (CRC), but was not expressed in normal mucosa and premalignant dysplastic lesions.\n'
p4096
sg4
(lp4097
(dp4098
g7
I26
sg8
g64
sg10
I4
sg11
VTESC
p4099
sg13
I1
sasg23
(lp4100
(dp4101
g7
I119
sg26
VC0032927
p4102
sg10
I12
sg11
Vpremalignant
p4103
sg13
I1
sa(dp4104
g7
I51
sg26
VC1527249
p4105
sg10
I17
sg11
Vcolorectal cancer
p4106
sg13
I2
sa(dp4107
g7
I132
sg26
VC0334044
p4108
sg10
I10
sg11
Vdysplastic
p4109
sg13
I1
sa(dp4110
g7
I70
sg26
VC1527249
p4111
sg10
I3
sg11
VCRC
p4112
sg13
I1
sasa(dp4113
g2
S'Thus, TESC is a potential diagnostic marker and oncotarget in colorectal cancer.\n'
p4114
sg4
(lp4115
(dp4116
g7
I6
sg8
g64
sg10
I4
sg11
VTESC
p4117
sg13
I1
sasg23
(lp4118
(dp4119
g7
I62
sg26
VC1527249
p4120
sg10
I17
sg11
Vcolorectal cancer
p4121
sg13
I2
sasa(dp4122
g2
S'We then investigated tescalcin and CSN activity in human erythroleukemia HEL and promyelocytic leukemia K562 cells and find that phorbol 12-myristate 13-acetate (PMA)-induced differentiation, resulting in the upregulation of tescalcin, coincides with reduced deneddylation of cullin-1 (Cul1) and stabilization of p27(Kip1) - molecular events that are associated with CSN activity.\n'
p4123
sg4
(lp4124
(dp4125
g7
I286
sg8
g64
sg10
I4
sg11
VCul1
p4126
sg13
I1
sa(dp4127
g7
I21
sg8
g64
sg10
I9
sg11
Vtescalcin
p4128
sg13
I1
sa(dp4129
g7
I276
sg8
g64
sg10
I8
sg11
Vcullin-1
p4130
sg13
I1
sa(dp4131
g7
I317
sg8
VP46527
p4132
sg10
I4
sg11
VKip1
p4133
sg13
I1
sa(dp4134
g7
I313
sg8
VP40305
p4135
sg10
I3
sg11
Vp27
p4136
sg13
I1
sasg23
(lp4137
(dp4138
g7
I57
sg26
VC0023440
p4139
sg10
I15
sg11
Verythroleukemia
p4140
sg13
I1
sa(dp4141
g7
I81
sg26
VC2745900
p4142
sg10
I22
sg11
Vpromyelocytic leukemia
p4143
sg13
I2
sasa(dp4144
g2
S'We hypothesized that a gene encoding tescalcin (TESC), known to be upregulated at leukemia progression during continuous sorafenib treatment and activate an Na(+)/H(+) exchanger type-1 (NHE1), may underlie tyrosine kinase inhibitor resistance.\n'
p4145
sg4
(lp4146
(dp4147
g7
I206
sg8
VP29401
p4148
sg10
I15
sg11
Vtyrosine kinase
p4149
sg13
I2
sa(dp4150
g7
I186
sg8
VP19634
p4151
sg10
I4
sg11
VNHE1
p4152
sg13
I1
sa(dp4153
g7
I157
sg8
VP19634
p4154
sg10
I27
sg11
VNa(+)/H(+) exchanger type-1
p4155
sg13
I3
sa(dp4156
g7
I48
sg8
g64
sg10
I4
sg11
VTESC
p4157
sg13
I1
sa(dp4158
g7
I23
sg8
g64
sg10
I23
sg11
Vgene encoding tescalcin
p4159
sg13
I3
sasg23
(lp4160
(dp4161
g7
I82
sg26
VC0023418
p4162
sg10
I8
sg11
Vleukemia
p4163
sg13
I1
sasa(dp4164
g2
S'Here we show that tescalcin is expressed in primary human granulocytes and is upregulated in human promyelocytic leukemia HL-60 cells that have been induced to differentiate along the granulocytic lineage.\n'
p4165
sg4
(lp4166
(dp4167
g7
I18
sg8
g64
sg10
I9
sg11
Vtescalcin
p4168
sg13
I1
sasg23
(lp4169
(dp4170
g7
I99
sg26
VC2745900
p4171
sg10
I22
sg11
Vpromyelocytic leukemia
p4172
sg13
I2
sasa(dp4173
g2
S'The GED-determined geometric parameters (r(h1)) are: rSe-S 219.1(1), rS-C 183.2(1), rC-H 109.6(4) pm; angleS-Se-S 102.9(3), angleSe-S-C 100.6(2), angleS-C-H (mean) 107.4(5), phiS-Se-S-C 87.9(20), phiSe-S-C-H 178.8(19) degrees for Se(SCH(3))(2), and rTe-S 238.1(2), rS-C 184.1(3), rC-H 110.0(6) pm; angleS-Te-S 98.9(6), angleTe-S-C 99.7(4), angleS-C-H (mean) 109.2(9), phiS-Te-S-C 73.0(48), phiTe-S-C-H 180.1(19) degrees for Te(SCH(3))(2).\n'
p4174
sg4
(lp4175
(dp4176
g7
I390
sg8
g64
sg10
I17
sg11
VphiTe-S-C-H 180.1
p4177
sg13
I2
sa(dp4178
g7
I146
sg8
g64
sg10
I10
sg11
VangleS-C-H
p4179
sg13
I1
sa(dp4180
g7
I174
sg8
VP06744
p4181
sg10
I4
sg11
VphiS
p4182
sg13
I1
sa(dp4183
g7
I368
sg8
VP06744
p4184
sg10
I11
sg11
VphiS-Te-S-C
p4185
sg13
I1
sa(dp4186
g7
I146
sg8
g64
sg10
I10
sg11
VangleS-C-H
p4187
sg13
I1
sasg23
(lp4188
sa(dp4189
g2
S'A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.\n'
p4190
sg4
(lp4191
sg23
(lp4192
(dp4193
g7
I185
sg26
VC0149871
p4194
sg10
I22
sg11
Vdeep venous thrombosis
p4195
sg13
I3
sa(dp4196
g7
I218
sg26
VC0034065
p4197
sg10
I18
sg11
Vpulmonary embolism
p4198
sg13
I2
sa(dp4199
g7
I209
sg26
VC0149871
p4200
sg10
I3
sg11
VDVT
p4201
sg13
I1
sa(dp4202
g7
I33
sg26
VC0268382
p4203
sg10
I17
sg11
Vrenal amyloidosis
p4204
sg13
I2
sa(dp4205
g7
I250
sg26
VC0272285
p4206
sg10
I32
sg11
Vheparin-induced thrombocytopenia
p4207
sg13
I2
sasa(dp4208
g2
S'Somatic CSF3R T618I (0/54) and CALR (0/30) mutations were not detected either in aCML or MDS/MPN-U.\n'
p4209
sg4
(lp4210
(dp4211
g7
I8
sg8
g64
sg10
I5
sg11
VCSF3R
p4212
sg13
I1
sasg23
(lp4213
(dp4214
g7
I89
sg26
VC0265219
p4215
sg10
I3
sg11
VMDS
p4216
sg13
I1
sasa(dp4217
g2
S'Microarray analysis of miRNAs expressed by Gtl2((-/+)) teratomas revealed decreased expression of 28 miRNAs encoded by the Dlk1-Dio3 domain, low expression of embryonic stem cell-specific miRNAs and dysregulation of miRNAs involved in tumorigenesis.\n'
p4218
sg4
(lp4219
(dp4220
g7
I43
sg8
g64
sg10
I4
sg11
VGtl2
p4221
sg13
I1
sa(dp4222
g7
I123
sg8
VP80370
p4223
sg10
I16
sg11
VDlk1-Dio3 domain
p4224
sg13
I2
sasg23
(lp4225
(dp4226
g7
I55
sg26
VC0039538
p4227
sg10
I9
sg11
Vteratomas
p4228
sg13
I1
sa(dp4229
g7
I235
sg26
VC0007621
p4230
sg10
I13
sg11
Vtumorigenesis
p4231
sg13
I1
sasa(dp4232
g2
S'This study suggests that downregulation of ncRNAs in the Dlk1-Dio3 domain leads to enhanced teratoma growth and repression of stem cell markers.\n'
p4233
sg4
(lp4234
(dp4235
g7
I57
sg8
VP80370
p4236
sg10
I16
sg11
VDlk1-Dio3 domain
p4237
sg13
I2
sasg23
(lp4238
(dp4239
g7
I92
sg26
VC0039538
p4240
sg10
I8
sg11
Vteratoma
p4241
sg13
I1
sasa(dp4242
g2
S'We selected eight genes, ATM serine/threonine kinase gene (ATM), BRCA2, DNA repair associated gene (BRCA2), checkpoint kinase 2 gene (CHEK2), EGFR, parkin RBR E3 ubiquitin protein ligase gene (PARK2), telomerase reverse transcriptase gene (TERT), tumor protein p53 gene (TP53), and Yes associated protein 1 gene (YAP1), on the basis of prior anecdotal association with lung cancer or genome-wide association studies.\n'
p4243
sg4
(lp4244
(dp4245
g7
I201
sg8
g64
sg10
I37
sg11
Vtelomerase reverse transcriptase gene
p4246
sg13
I4
sa(dp4247
g7
I148
sg8
VP04844
p4248
sg10
I13
sg11
Vparkin RBR E3
p4249
sg13
I3
sa(dp4250
g7
I65
sg8
VP51587
p4251
sg10
I5
sg11
VBRCA2
p4252
sg13
I1
sa(dp4253
g7
I247
sg8
VP14222
p4254
sg10
I64
sg11
Vtumor protein p53 gene (TP53), and Yes associated protein 1 gene
p4255
sg13
I11
sa(dp4256
g7
I25
sg8
g64
sg10
I32
sg11
VATM serine/threonine kinase gene
p4257
sg13
I4
sa(dp4258
g7
I240
sg8
g64
sg10
I4
sg11
VTERT
p4259
sg13
I1
sa(dp4260
g7
I134
sg8
g64
sg10
I5
sg11
VCHEK2
p4261
sg13
I1
sa(dp4262
g7
I25
sg8
g64
sg10
I3
sg11
VATM
p4263
sg13
I1
sa(dp4264
g7
I108
sg8
g64
sg10
I24
sg11
Vcheckpoint kinase 2 gene
p4265
sg13
I4
sa(dp4266
g7
I65
sg8
VP51587
p4267
sg10
I5
sg11
VBRCA2
p4268
sg13
I1
sa(dp4269
g7
I72
sg8
g64
sg10
I26
sg11
VDNA repair associated gene
p4270
sg13
I4
sa(dp4271
g7
I313
sg8
VP46937
p4272
sg10
I4
sg11
VYAP1
p4273
sg13
I1
sa(dp4274
g7
I162
sg8
VP62979
p4275
sg10
I9
sg11
Vubiquitin
p4276
sg13
I1
sasg23
(lp4277
(dp4278
g7
I247
sg26
VC0027651
p4279
sg10
I5
sg11
Vtumor
p4280
sg13
I1
sa(dp4281
g7
I193
sg26
VC1868675
p4282
sg10
I5
sg11
VPARK2
p4283
sg13
I1
sa(dp4284
g7
I369
sg26
VC0684249
p4285
sg10
I11
sg11
Vlung cancer
p4286
sg13
I2
sasa(dp4287
g2
S'Expression level of seven in absentia homolog 2 (SIAH2), an E3 ubiquitin-protein ligase, is upregulated in NSCLC and correlated with tumor grade.\n'
p4288
sg4
(lp4289
(dp4290
g7
I63
sg8
VP49427
p4291
sg10
I24
sg11
Vubiquitin-protein ligase
p4292
sg13
I2
sasg23
(lp4293
(dp4294
g7
I133
sg26
VC0027651
p4295
sg10
I5
sg11
Vtumor
p4296
sg13
I1
sa(dp4297
g7
I107
sg26
VC0007131
p4298
sg10
I5
sg11
VNSCLC
p4299
sg13
I1
sasa(dp4300
g2
S'Tumor protein 53 (TP53), TP63, Ki67, epidermal growth factor receptor (EGFR), minichromosome maintenance complex component 6 (MCM6), MCM7, uncharacterized proteins KIAA1522 and KIAA0317, and ubiquitin-protein ligase UHR1 (ICBP90) frequently presented high expression in bronchial brushing specimens from patients who had lung cancer compared with patients who had benign lung lesions.\n'
p4301
sg4
(lp4302
(dp4303
g7
I31
sg8
VP46013
p4304
sg10
I4
sg11
VKi67
p4305
sg13
I1
sa(dp4306
g7
I126
sg8
g64
sg10
I4
sg11
VMCM6
p4307
sg13
I1
sa(dp4308
g7
I0
sg8
VP42771
p4309
sg10
I16
sg11
VTumor protein 53
p4310
sg13
I3
sa(dp4311
g7
I222
sg8
g64
sg10
I6
sg11
VICBP90
p4312
sg13
I1
sa(dp4313
g7
I191
sg8
VP62979
p4314
sg10
I17
sg11
Vubiquitin-protein
p4315
sg13
I1
sa(dp4316
g7
I18
sg8
VP42771
p4317
sg10
I4
sg11
VTP53
p4318
sg13
I1
sa(dp4319
g7
I133
sg8
VP33993
p4320
sg10
I4
sg11
VMCM7
p4321
sg13
I1
sa(dp4322
g7
I37
sg8
VP01133
p4323
sg10
I87
sg11
Vepidermal growth factor receptor (EGFR), minichromosome maintenance complex component 6
p4324
sg13
I10
sasg23
(lp4325
(dp4326
g7
I321
sg26
VC0684249
p4327
sg10
I11
sg11
Vlung cancer
p4328
sg13
I2
sa(dp4329
g7
I0
sg26
VC0027651
p4330
sg10
I5
sg11
VTumor
p4331
sg13
I1
sasa(dp4332
g2
S'Notch1, Dll-1 and Jagged-1 expression were also assessed in stable Kaiso-depleted colon cancer cells and isolated intestinal epithelial cells using real time PCR and western blotting.\n'
p4333
sg4
(lp4334
(dp4335
g7
I0
sg8
VP46531
p4336
sg10
I6
sg11
VNotch1
p4337
sg13
I1
sasg23
(lp4338
(dp4339
g7
I82
sg26
VC0699790
p4340
sg10
I12
sg11
Vcolon cancer
p4341
sg13
I2
sasa(dp4342
g2
S'To assess Kaiso binding to the DLL1, JAG1 and NOTCH1 promoter regions, chromatin immunoprecipitation was performed on three colon cancer cell lines.\n'
p4343
sg4
(lp4344
(dp4345
g7
I31
sg8
g64
sg10
I4
sg11
VDLL1
p4346
sg13
I1
sa(dp4347
g7
I37
sg8
VP78504
p4348
sg10
I4
sg11
VJAG1
p4349
sg13
I1
sa(dp4350
g7
I46
sg8
VP46531
p4351
sg10
I6
sg11
VNOTCH1
p4352
sg13
I1
sasg23
(lp4353
(dp4354
g7
I124
sg26
VC0699790
p4355
sg10
I12
sg11
Vcolon cancer
p4356
sg13
I2
sasa(dp4357
g2
S'The expressions of Notch1, DLL-1, and p-mTOR were detected in 21 cases of FAP polyps, 20 cases of colorectal inflammatory polyp, and 20 cases of poorly differentiated colorectal cancer by Western blotting and reverse transcription polymerase chain reaction (RT-PCR).\n'
p4358
sg4
(lp4359
(dp4360
g7
I19
sg8
VP46531
p4361
sg10
I6
sg11
VNotch1
p4362
sg13
I1
sa(dp4363
g7
I40
sg8
VP42345
p4364
sg10
I4
sg11
VmTOR
p4365
sg13
I1
sasg23
(lp4366
(dp4367
g7
I98
sg26
VC1333111
p4368
sg10
I29
sg11
Vcolorectal inflammatory polyp
p4369
sg13
I3
sa(dp4370
g7
I74
sg26
VC0032580
p4371
sg10
I3
sg11
VFAP
p4372
sg13
I1
sa(dp4373
g7
I167
sg26
VC1527249
p4374
sg10
I17
sg11
Vcolorectal cancer
p4375
sg13
I2
sa(dp4376
g7
I78
sg26
VC0032584
p4377
sg10
I6
sg11
Vpolyps
p4378
sg13
I1
sasa(dp4379
g2
S'The protein and mRNA expressions of Notch-1, DLL-1, and p-mTOR in the FAP group were significantly higher than those in colorectal adenoma group; furthermore, they were significantly higher in the colorectal cancer group (all p &lt; 0.05).\n'
p4380
sg4
(lp4381
(dp4382
g7
I56
sg8
VP42345
p4383
sg10
I6
sg11
Vp-mTOR
p4384
sg13
I1
sasg23
(lp4385
(dp4386
g7
I70
sg26
VC0032580
p4387
sg10
I3
sg11
VFAP
p4388
sg13
I1
sa(dp4389
g7
I197
sg26
VC1527249
p4390
sg10
I17
sg11
Vcolorectal cancer
p4391
sg13
I2
sa(dp4392
g7
I120
sg26
VC1302401
p4393
sg10
I18
sg11
Vcolorectal adenoma
p4394
sg13
I2
sasa(dp4395
g2
S'Potentially novel GPR81 agonists were identified that suppressed fasting plasma free fatty acid levels in rodents and in addition improved insulin sensitivity in mouse models of insulin resistance and diabetes.\n'
p4396
sg4
(lp4397
(dp4398
g7
I139
sg8
VP01308
p4399
sg10
I7
sg11
Vinsulin
p4400
sg13
I1
sa(dp4401
g7
I18
sg8
g64
sg10
I5
sg11
VGPR81
p4402
sg13
I1
sa(dp4403
g7
I139
sg8
VP01308
p4404
sg10
I7
sg11
Vinsulin
p4405
sg13
I1
sasg23
(lp4406
(dp4407
g7
I201
sg26
VC0011849
p4408
sg10
I8
sg11
Vdiabetes
p4409
sg13
I1
sa(dp4410
g7
I139
sg26
VC0920563
p4411
sg10
I19
sg11
Vinsulin sensitivity
p4412
sg13
I2
sa(dp4413
g7
I178
sg26
VC0021655
p4414
sg10
I18
sg11
Vinsulin resistance
p4415
sg13
I2
sasa(dp4416
g2
S'The GPR81 and GPR109A receptors mediate antilipolytic effects and are potential drug targets for the treatment of metabolic disorders such as dyslipidemia and type 2 diabetes.\n'
p4417
sg4
(lp4418
(dp4419
g7
I14
sg8
g64
sg10
I17
sg11
VGPR109A receptors
p4420
sg13
I2
sa(dp4421
g7
I4
sg8
g64
sg10
I5
sg11
VGPR81
p4422
sg13
I1
sasg23
(lp4423
(dp4424
g7
I142
sg26
VC0242339
p4425
sg10
I12
sg11
Vdyslipidemia
p4426
sg13
I1
sa(dp4427
g7
I114
sg26
VC0025517
p4428
sg10
I19
sg11
Vmetabolic disorders
p4429
sg13
I2
sa(dp4430
g7
I159
sg26
VC0011860
p4431
sg10
I15
sg11
Vtype 2 diabetes
p4432
sg13
I3
sasa(dp4433
g2
S'Similar to GPR109a, the activation of GPR81 by lactate suppresses lipolysis, suggesting that GPR81 may be a potential drug target for treating dyslipidemia.\n'
p4434
sg4
(lp4435
(dp4436
g7
I11
sg8
g64
sg10
I7
sg11
VGPR109a
p4437
sg13
I1
sa(dp4438
g7
I38
sg8
g64
sg10
I5
sg11
VGPR81
p4439
sg13
I1
sa(dp4440
g7
I38
sg8
g64
sg10
I5
sg11
VGPR81
p4441
sg13
I1
sasg23
(lp4442
(dp4443
g7
I143
sg26
VC0242339
p4444
sg10
I12
sg11
Vdyslipidemia
p4445
sg13
I1
sasa(dp4446
g2
S'In addition, the fact that GPR81 is expressed only in adipocytes, whereas GPR109a is expressed in various tissues and cells, including Langerhans cells, which are considered responsible for flushing, indicates that targeting GPR81 could lead to the development of antidyslipidemia agents with a reduced risk of this side effect.\n'
p4447
sg4
(lp4448
(dp4449
g7
I27
sg8
g64
sg10
I5
sg11
VGPR81
p4450
sg13
I1
sa(dp4451
g7
I27
sg8
g64
sg10
I5
sg11
VGPR81
p4452
sg13
I1
sa(dp4453
g7
I74
sg8
g64
sg10
I7
sg11
VGPR109a
p4454
sg13
I1
sasg23
(lp4455
(dp4456
g7
I190
sg26
VC0016382
p4457
sg10
I8
sg11
Vflushing
p4458
sg13
I1
sa(dp4459
g7
I316
sg26
VC0879626
p4460
sg10
I11
sg11
Vside effect
p4461
sg13
I2
sasa(dp4462
g2
S'These results suggest that GPR81 is an attractive drug target for treating dyslipidemia without the risk of flushing.\n'
p4463
sg4
(lp4464
(dp4465
g7
I27
sg8
g64
sg10
I5
sg11
VGPR81
p4466
sg13
I1
sasg23
(lp4467
(dp4468
g7
I75
sg26
VC0242339
p4469
sg10
I12
sg11
Vdyslipidemia
p4470
sg13
I1
sa(dp4471
g7
I108
sg26
VC0016382
p4472
sg10
I8
sg11
Vflushing
p4473
sg13
I1
sasa(dp4474
g2
S'GPR81 expression was decreased in ob/ob mice, an animal model of type 2 diabetes that is characterized by inflammation.\n'
p4475
sg4
(lp4476
(dp4477
g7
I0
sg8
g64
sg10
I5
sg11
VGPR81
p4478
sg13
I1
sasg23
(lp4479
(dp4480
g7
I65
sg26
VC0011860
p4481
sg10
I15
sg11
Vtype 2 diabetes
p4482
sg13
I3
sa(dp4483
g7
I106
sg26
VC0021368
p4484
sg10
I12
sg11
Vinflammation
p4485
sg13
I1
sasa(dp4486
g2
S'GPR81 may thus be an attractive target for the treatment of dyslipidemia and other metabolic disorders.\n'
p4487
sg4
(lp4488
(dp4489
g7
I0
sg8
g64
sg10
I5
sg11
VGPR81
p4490
sg13
I1
sasg23
(lp4491
(dp4492
g7
I60
sg26
VC0242339
p4493
sg10
I12
sg11
Vdyslipidemia
p4494
sg13
I1
sa(dp4495
g7
I83
sg26
VC0025517
p4496
sg10
I19
sg11
Vmetabolic disorders
p4497
sg13
I2
sasa(dp4498
g2
S'Hence, targeting GPR81 may lead to the development of a novel and effective therapy for dyslipidemia and a better side effect profile than nicotinic acid.\n'
p4499
sg4
(lp4500
(dp4501
g7
I17
sg8
g64
sg10
I5
sg11
VGPR81
p4502
sg13
I1
sasg23
(lp4503
(dp4504
g7
I114
sg26
VC0879626
p4505
sg10
I11
sg11
Vside effect
p4506
sg13
I2
sa(dp4507
g7
I88
sg26
VC0242339
p4508
sg10
I12
sg11
Vdyslipidemia
p4509
sg13
I1
sasa(dp4510
g2
S'As a proxy for selectivity, ELISAs against tetanus toxoid and the natural antigens laminin, thyroglobulin, and single-stranded DNA (ssDNA) were utilized to assess the ability of the identified reagents to inhibit additional antibody responses.\n'
p4511
sg4
(lp4512
(dp4513
g7
I92
sg8
g64
sg10
I13
sg11
Vthyroglobulin
p4514
sg13
I1
sa(dp4515
g7
I83
sg8
g64
sg10
I7
sg11
Vlaminin
p4516
sg13
I1
sasg23
(lp4517
(dp4518
g7
I43
sg26
VC0039614
p4519
sg10
I7
sg11
Vtetanus
p4520
sg13
I1
sasa(dp4521
g2
S'One of these, the anti-hypertensive agent clonidine, displayed only minimal inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing natural antibodies against laminin, thyroglobulin, or ssDNA.\n'
p4522
sg4
(lp4523
(dp4524
g7
I191
sg8
g64
sg10
I7
sg11
Vlaminin
p4525
sg13
I1
sa(dp4526
g7
I200
sg8
g64
sg10
I13
sg11
Vthyroglobulin
p4527
sg13
I1
sasg23
(lp4528
(dp4529
g7
I133
sg26
VC0039614
p4530
sg10
I7
sg11
Vtetanus
p4531
sg13
I1
sasa(dp4532
g2
S'We examined the influence of activated platelets on cytokine production by normal human mononuclear cells, induced by tetanus toxoid (TT), human thyroglobulin (TG), Escherichia coli LPS, or intact Porphyromonas gingivalis.\n'
p4533
sg4
(lp4534
(dp4535
g7
I139
sg8
g64
sg10
I19
sg11
Vhuman thyroglobulin
p4536
sg13
I2
sasg23
(lp4537
(dp4538
g7
I182
sg26
VC0175697
p4539
sg10
I3
sg11
VLPS
p4540
sg13
I1
sa(dp4541
g7
I118
sg26
VC0039614
p4542
sg10
I7
sg11
Vtetanus
p4543
sg13
I1
sasa(dp4544
g2
S'With this aim, adult degu females were immunized with four antigens, including two mollusk hemocyanins from Concholepas and Megathura (CCH and KLH, respectively), porcine thyroglobulin and tetanus toxoid.\n'
p4545
sg4
(lp4546
(dp4547
g7
I163
sg8
g64
sg10
I21
sg11
Vporcine thyroglobulin
p4548
sg13
I2
sasg23
(lp4549
(dp4550
g7
I189
sg26
VC0039614
p4551
sg10
I7
sg11
Vtetanus
p4552
sg13
I1
sasa(dp4553
g2
S'Notably, both patient groups and healthy controls exhibited higher proliferative responses to thyroglobulin than to a foreign recall antigen, tetanus toxoid.\n'
p4554
sg4
(lp4555
(dp4556
g7
I94
sg8
g64
sg10
I13
sg11
Vthyroglobulin
p4557
sg13
I1
sasg23
(lp4558
(dp4559
g7
I142
sg26
VC0039614
p4560
sg10
I7
sg11
Vtetanus
p4561
sg13
I1
sa(dp4562
g7
I67
sg26
VC0334094
p4563
sg10
I13
sg11
Vproliferative
p4564
sg13
I1
sasa(dp4565
g2
S'In this study, four different types of carrier molecule were investigated: (a) single and branched amino acid polymers--[poly-(D-glu, D-lys) and poly-(phe, glu)-poly(DL-ala)-poly(lys)]; (b) bacterial toxoids--diphtheria (DT) and tetanus (TT); (c) synthetic T-helper epitopes--derived from malarial circumsporozite protein (CS) and measles virus fusion protein (MVF); and (d) thyroglobulin (Thy)--a large protein.\n'
p4566
sg4
(lp4567
(dp4568
g7
I375
sg8
g64
sg10
I13
sg11
Vthyroglobulin
p4569
sg13
I1
sa(dp4570
g7
I390
sg8
g64
sg10
I3
sg11
VThy
p4571
sg13
I1
sasg23
(lp4572
(dp4573
g7
I229
sg26
VC0039614
p4574
sg10
I7
sg11
Vtetanus
p4575
sg13
I1
sa(dp4576
g7
I331
sg26
VC0025007
p4577
sg10
I7
sg11
Vmeasles
p4578
sg13
I1
sa(dp4579
g7
I209
sg26
VC0012546
p4580
sg10
I10
sg11
Vdiphtheria
p4581
sg13
I1
sa(dp4582
g7
I238
sg26
VC0039614
p4583
sg10
I2
sg11
VTT
p4584
sg13
I1
sasa(dp4585
g2
S'Delayed-type hypersensitivity skin response (DTH); antibody response to hepatitis B, tetanus and diphtheria, and pneumococcal vaccines; and autoantibodies to DNA and thyroglobulin were assessed before and after supplementation.\n'
p4586
sg4
(lp4587
(dp4588
g7
I166
sg8
g64
sg10
I13
sg11
Vthyroglobulin
p4589
sg13
I1
sasg23
(lp4590
(dp4591
g7
I97
sg26
VC0012546
p4592
sg10
I10
sg11
Vdiphtheria
p4593
sg13
I1
sa(dp4594
g7
I45
sg26
VC0020522
p4595
sg10
I3
sg11
VDTH
p4596
sg13
I1
sa(dp4597
g7
I85
sg26
VC0039614
p4598
sg10
I7
sg11
Vtetanus
p4599
sg13
I1
sa(dp4600
g7
I72
sg26
VC0019163
p4601
sg10
I11
sg11
Vhepatitis B
p4602
sg13
I2
sa(dp4603
g7
I0
sg26
VC0020522
p4604
sg10
I43
sg11
VDelayed-type hypersensitivity skin response
p4605
sg13
I4
sasa(dp4606
g2
S'Here, we compare the expression profile of PTPs in CD4 T cells of healthy volunteers and patients submitted to an early arthritis clinic, due to suspicion of rheumatoid arthritis, an autoimmune disease mediated by CD4 T cells.\n'
p4607
sg4
(lp4608
(dp4609
g7
I43
sg8
g64
sg10
I4
sg11
VPTPs
p4610
sg13
I1
sa(dp4611
g7
I51
sg8
VP01730
p4612
sg10
I5
sg11
VCD4 T
p4613
sg13
I2
sa(dp4614
g7
I51
sg8
VP01730
p4615
sg10
I5
sg11
VCD4 T
p4616
sg13
I2
sasg23
(lp4617
(dp4618
g7
I120
sg26
VC0003864
p4619
sg10
I9
sg11
Varthritis
p4620
sg13
I1
sa(dp4621
g7
I183
sg26
VC0004364
p4622
sg10
I18
sg11
Vautoimmune disease
p4623
sg13
I2
sa(dp4624
g7
I158
sg26
VC0003873
p4625
sg10
I20
sg11
Vrheumatoid arthritis
p4626
sg13
I2
sasa(dp4627
g2
S'In addition, while null mutations of Lmo1 or Lmo3 have no discernible phenotype, null mutation of Lmo4 alone causes perinatal lethality due to a severe neural tube defect which occurs in the form of anencephaly or exencephaly.\n'
p4628
sg4
(lp4629
(dp4630
g7
I98
sg8
VP61968
p4631
sg10
I4
sg11
VLmo4
p4632
sg13
I1
sa(dp4633
g7
I37
sg8
VP25800
p4634
sg10
I4
sg11
VLmo1
p4635
sg13
I1
sa(dp4636
g7
I45
sg8
g64
sg10
I4
sg11
VLmo3
p4637
sg13
I1
sasg23
(lp4638
(dp4639
g7
I214
sg26
VC0266453
p4640
sg10
I11
sg11
Vexencephaly
p4641
sg13
I1
sa(dp4642
g7
I199
sg26
VC0002902
p4643
sg10
I11
sg11
Vanencephaly
p4644
sg13
I1
sasa(dp4645
g2
S'Genetic factors including the level of expression of the fingerprint of genes involved in the development of bones and cartilage such as GDF-5 or ESR-Alfa or CALM-1 are known to be strong determinants of the osteoarthritis (OA) in Caucasian and Oriental populations.\n'
p4646
sg4
(lp4647
(dp4648
g7
I146
sg8
VP03372
p4649
sg10
I8
sg11
VESR-Alfa
p4650
sg13
I1
sa(dp4651
g7
I137
sg8
VP43026
p4652
sg10
I5
sg11
VGDF-5
p4653
sg13
I1
sa(dp4654
g7
I158
sg8
g64
sg10
I6
sg11
VCALM-1
p4655
sg13
I1
sasg23
(lp4656
(dp4657
g7
I208
sg26
VC0029408
p4658
sg10
I14
sg11
Vosteoarthritis
p4659
sg13
I1
sa(dp4660
g7
I224
sg26
VC0029408
p4661
sg10
I2
sg11
VOA
p4662
sg13
I1
sasa(dp4663
g2
S"To identify the frequency of the rs143383 SNPin the GDF5 gene, which is located in the 5'-untranslated region of Turkish population with knee osteoarthritis (OA).\n"
p4664
sg4
(lp4665
(dp4666
g7
I52
sg8
VP43026
p4667
sg10
I9
sg11
VGDF5 gene
p4668
sg13
I2
sasg23
(lp4669
(dp4670
g7
I137
sg26
VC0409959
p4671
sg10
I19
sg11
Vknee osteoarthritis
p4672
sg13
I2
sasa(dp4673
g2
S"A functional single nucleotide polymorphism (SNP) +104T/C in the 5'-UTR of GDF5 (rs143383) was reported to be associated with osteoarthritis susceptibility in Han Chinese and Japanese populations.\n"
p4674
sg4
(lp4675
(dp4676
g7
I75
sg8
VP43026
p4677
sg10
I4
sg11
VGDF5
p4678
sg13
I1
sasg23
(lp4679
(dp4680
g7
I126
sg26
VC0029408
p4681
sg10
I14
sg11
Vosteoarthritis
p4682
sg13
I1
sasa(dp4683
g2
S'A new study reports molecular characterization of the GDF5 locus, which is associated with osteoarthritis risk and adult height in humans.\n'
p4684
sg4
(lp4685
(dp4686
g7
I54
sg8
VP43026
p4687
sg10
I10
sg11
VGDF5 locus
p4688
sg13
I2
sasg23
(lp4689
(dp4690
g7
I91
sg26
VC0029408
p4691
sg10
I14
sg11
Vosteoarthritis
p4692
sg13
I1
sasa(dp4693
g2
S'Variants in GDF5 are associated with human arthritis and decreased height, but the causal mutations are still unknown.\n'
p4694
sg4
(lp4695
(dp4696
g7
I12
sg8
VP43026
p4697
sg10
I4
sg11
VGDF5
p4698
sg13
I1
sasg23
(lp4699
(dp4700
g7
I43
sg26
VC0003864
p4701
sg10
I9
sg11
Varthritis
p4702
sg13
I1
sasa(dp4703
g2
S'Our results suggest that an ancient regulatory variant in GROW1 has been repeatedly selected in northern environments and that past selection on growth phenotypes explains the high frequency of a GDF5 haplotype that also increases arthritis susceptibility in many human populations.\n'
p4704
sg4
(lp4705
(dp4706
g7
I196
sg8
VP43026
p4707
sg10
I14
sg11
VGDF5 haplotype
p4708
sg13
I2
sasg23
(lp4709
(dp4710
g7
I231
sg26
VC0003864
p4711
sg10
I9
sg11
Varthritis
p4712
sg13
I1
sasa(dp4713
g2
S'The present case-control study was conducted to detect the genetic association between GDF5 (+104T/C) single-nucleotide polymorphism (SNP) and primary knee osteoarthritis (KOA), as well as the possible association of SNP with the severity of KOA.\n'
p4714
sg4
(lp4715
(dp4716
g7
I87
sg8
VP43026
p4717
sg10
I4
sg11
VGDF5
p4718
sg13
I1
sasg23
(lp4719
(dp4720
g7
I172
sg26
VC0409959
p4721
sg10
I3
sg11
VKOA
p4722
sg13
I1
sa(dp4723
g7
I172
sg26
VC0409959
p4724
sg10
I3
sg11
VKOA
p4725
sg13
I1
sa(dp4726
g7
I151
sg26
VC0409959
p4727
sg10
I19
sg11
Vknee osteoarthritis
p4728
sg13
I2
sasa(dp4729
g2
S'The LAZ3/BCL6 (lymphoma-associated zinc finger 3/B cell lymphomas 6) gene frequently is altered in non-Hodgkin lymphomas.\n'
p4730
sg4
(lp4731
(dp4732
g7
I4
sg8
VP41182
p4733
sg10
I4
sg11
VLAZ3
p4734
sg13
I1
sa(dp4735
g7
I9
sg8
VP41182
p4736
sg10
I4
sg11
VBCL6
p4737
sg13
I1
sasg23
(lp4738
(dp4739
g7
I49
sg26
VC0079731
p4740
sg10
I16
sg11
VB cell lymphomas
p4741
sg13
I3
sa(dp4742
g7
I15
sg26
VC0024299
p4743
sg10
I8
sg11
Vlymphoma
p4744
sg13
I1
sa(dp4745
g7
I103
sg26
VC0019829
p4746
sg10
I17
sg11
VHodgkin lymphomas
p4747
sg13
I2
sasa(dp4748
g2
S"Cross-sectional associations were examined between CVD risk factors and urinary LH, FSH, estrone conjugates, and pregnanediol glucuronide (Pdg) measured across one menstrual cycle or 50 d. Menstruating women (n = 500) who were free from diabetes or past stroke or heart attack enrolled in the Daily Hormone Study-Study of Women's Health across the Nation were studied.\n"
p4749
sg4
(lp4750
(dp4751
g7
I84
sg8
VP01225
p4752
sg10
I3
sg11
VFSH
p4753
sg13
I1
sasg23
(lp4754
(dp4755
g7
I264
sg26
VC0027051
p4756
sg10
I12
sg11
Vheart attack
p4757
sg13
I2
sa(dp4758
g7
I254
sg26
VC0038454
p4759
sg10
I6
sg11
Vstroke
p4760
sg13
I1
sa(dp4761
g7
I237
sg26
VC0011849
p4762
sg10
I8
sg11
Vdiabetes
p4763
sg13
I1
sa(dp4764
g7
I51
sg26
VC0007222
p4765
sg10
I3
sg11
VCVD
p4766
sg13
I1
sasa(dp4767
g2
S'We examined 24-h BP recordings in 434 patients with ischemic stroke (lacunar stroke [LS], n = 205; non-lacunar stroke [NLS], n = 229) and in 178 normotensive subjects.\n'
p4768
sg4
(lp4769
sg23
(lp4770
(dp4771
g7
I69
sg26
VC3178801
p4772
sg10
I14
sg11
Vlacunar stroke
p4773
sg13
I2
sa(dp4774
g7
I119
sg26
VC0265218
p4775
sg10
I3
sg11
VNLS
p4776
sg13
I1
sa(dp4777
g7
I69
sg26
VC3178801
p4778
sg10
I14
sg11
Vlacunar stroke
p4779
sg13
I2
sa(dp4780
g7
I52
sg26
VC3272363
p4781
sg10
I15
sg11
Vischemic stroke
p4782
sg13
I2
sasa(dp4783
g2
S'As the basal activity of the MEK1/2-ERK1/2 pathway is often high in acute myeloid leukemias, and that ATO is known to stimulate MEK1/2-ERK1/2 signaling in leukemia, the authors investigated whether knock down of the downstream effector of ERK1/2, RSK1, could enhance the anti-leukemic activity of ATO.\n'
p4784
sg4
(lp4785
(dp4786
g7
I29
sg8
g64
sg10
I6
sg11
VMEK1/2
p4787
sg13
I1
sa(dp4788
g7
I36
sg8
VP27361
p4789
sg10
I6
sg11
VERK1/2
p4790
sg13
I1
sa(dp4791
g7
I36
sg8
VP27361
p4792
sg10
I4
sg11
VERK1
p4793
sg13
I1
sa(dp4794
g7
I36
sg8
VP27361
p4795
sg10
I6
sg11
VERK1/2
p4796
sg13
I1
sa(dp4797
g7
I247
sg8
g64
sg10
I4
sg11
VRSK1
p4798
sg13
I1
sa(dp4799
g7
I29
sg8
g64
sg10
I6
sg11
VMEK1/2
p4800
sg13
I1
sasg23
(lp4801
(dp4802
g7
I68
sg26
VC0023467
p4803
sg10
I23
sg11
Vacute myeloid leukemias
p4804
sg13
I3
sa(dp4805
g7
I82
sg26
VC0023418
p4806
sg10
I8
sg11
Vleukemia
p4807
sg13
I1
sasa(dp4808
g2
S'One showed growth retardation, craniofacial dysmorphism, syndactyly, developmental delay and a de novo deletion (~8.5Mb) on chromosome 7q21.13-q21.3, including DLX5 and DLX6.\n'
p4809
sg4
(lp4810
(dp4811
g7
I160
sg8
VP56178
p4812
sg10
I4
sg11
VDLX5
p4813
sg13
I1
sa(dp4814
g7
I169
sg8
VP56179
p4815
sg10
I4
sg11
VDLX6
p4816
sg13
I1
sasg23
(lp4817
(dp4818
g7
I57
sg26
VC0039075
p4819
sg10
I10
sg11
Vsyndactyly
p4820
sg13
I1
sa(dp4821
g7
I44
sg26
VC1737329
p4822
sg10
I11
sg11
Vdysmorphism
p4823
sg13
I1
sa(dp4824
g7
I11
sg26
VC0151686
p4825
sg10
I18
sg11
Vgrowth retardation
p4826
sg13
I2
sa(dp4827
g7
I69
sg26
VC0424605
p4828
sg10
I19
sg11
Vdevelopmental delay
p4829
sg13
I2
sasa(dp4830
g2
S'In vitro, DeltaNp63alpha induces transcription from the Dlx5 and Dlx6 promoters, an activity abolished by EEC and SHFM-IV mutations, but not by Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC) mutations.\n'
p4831
sg4
(lp4832
(dp4833
g7
I56
sg8
VP56178
p4834
sg10
I4
sg11
VDlx5
p4835
sg13
I1
sa(dp4836
g7
I65
sg8
VP56179
p4837
sg10
I14
sg11
VDlx6 promoters
p4838
sg13
I2
sasg23
(lp4839
(dp4840
g7
I106
sg26
VC1851841
p4841
sg10
I3
sg11
VEEC
p4842
sg13
I1
sa(dp4843
g7
I144
sg26
VC0406709
p4844
sg10
I51
sg11
VAnkyloblepharon-Ectodermal defects-Cleft lip/palate
p4845
sg13
I3
sa(dp4846
g7
I197
sg26
VC0406709
p4847
sg10
I3
sg11
VAEC
p4848
sg13
I1
sasa(dp4849
g2
S'Collectively, this study indicates that CT-induced intestinal barrier disruption and subsequent TLR-4-NF-KB-mediated COX-2 expression are involved in the pathogenesis of EL-induced diarrhea and represent promising novel therapeutic targets of cholera.\n'
p4850
sg4
(lp4851
(dp4852
g7
I117
sg8
VP35354
p4853
sg10
I5
sg11
VCOX-2
p4854
sg13
I1
sasg23
(lp4855
(dp4856
g7
I181
sg26
VC0011991
p4857
sg10
I8
sg11
Vdiarrhea
p4858
sg13
I1
sa(dp4859
g7
I243
sg26
VC0008354
p4860
sg10
I7
sg11
Vcholera
p4861
sg13
I1
sa(dp4862
g7
I154
sg26
VC0699748
p4863
sg10
I12
sg11
Vpathogenesis
p4864
sg13
I1
sasa(dp4865
g2
S'However, purified V. cholerae LPS preferentially stimulated TLR4, although not as potently as LPS of other Gram-negative bacteria, implying that LPS is not a major immunostimulatory component of KVC.\n'
p4866
sg4
(lp4867
(dp4868
g7
I9
sg8
VP22079
p4869
sg10
I24
sg11
Vpurified V. cholerae LPS
p4870
sg13
I4
sasg23
(lp4871
(dp4872
g7
I30
sg26
VC0175697
p4873
sg10
I3
sg11
VLPS
p4874
sg13
I1
sa(dp4875
g7
I30
sg26
VC0175697
p4876
sg10
I3
sg11
VLPS
p4877
sg13
I1
sa(dp4878
g7
I30
sg26
VC0175697
p4879
sg10
I3
sg11
VLPS
p4880
sg13
I1
sasa(dp4881
g2
S'The anti-HMGB1 monoclonal antibody demonstrated therapeutic potential against albuminuria in lupus nephritis by inhibiting neutrophil recruitment and neutrophil extracellular traps.\n'
p4882
sg4
(lp4883
(dp4884
g7
I4
sg8
VP09429
p4885
sg10
I30
sg11
Vanti-HMGB1 monoclonal antibody
p4886
sg13
I3
sasg23
(lp4887
(dp4888
g7
I134
sg26
VC0271510
p4889
sg10
I11
sg11
Vrecruitment
p4890
sg13
I1
sa(dp4891
g7
I175
sg26
VC1275126
p4892
sg10
I5
sg11
Vtraps
p4893
sg13
I1
sa(dp4894
g7
I93
sg26
VC0024143
p4895
sg10
I15
sg11
Vlupus nephritis
p4896
sg13
I2
sasa(dp4897
g2
S"Changes in the mean levels of high mobility group box-1 (HMGB-1) protein and superoxide dismutase (SOD), duration of vasopressor therapy, incidence of acute renal failure, and 60 days' mortality were secondary endpoints.\n"
p4898
sg4
(lp4899
(dp4900
g7
I30
sg8
VP00390
p4901
sg10
I25
sg11
Vhigh mobility group box-1
p4902
sg13
I4
sa(dp4903
g7
I77
sg8
VP00441
p4904
sg10
I20
sg11
Vsuperoxide dismutase
p4905
sg13
I2
sa(dp4906
g7
I57
sg8
VP00390
p4907
sg10
I6
sg11
VHMGB-1
p4908
sg13
I1
sa(dp4909
g7
I99
sg8
VP00441
p4910
sg10
I3
sg11
VSOD
p4911
sg13
I1
sasg23
(lp4912
(dp4913
g7
I151
sg26
VC0022660
p4914
sg10
I19
sg11
Vacute renal failure
p4915
sg13
I3
sasa(dp4916
g2
S'Serum cathepsin L activity positively associated with age, body mass index, nitrite level, neutrophil count, high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide, high-mobility group box-1 protein (HMGB1) and 24-h proteinuria.\n'
p4917
sg4
(lp4918
(dp4919
g7
I0
sg8
VP07711
p4920
sg10
I17
sg11
VSerum cathepsin L
p4921
sg13
I3
sa(dp4922
g7
I197
sg8
VP00390
p4923
sg10
I33
sg11
Vhigh-mobility group box-1 protein
p4924
sg13
I4
sa(dp4925
g7
I232
sg8
VP09429
p4926
sg10
I5
sg11
VHMGB1
p4927
sg13
I1
sa(dp4928
g7
I126
sg8
VP02741
p4929
sg10
I18
sg11
VC-reactive protein
p4930
sg13
I2
sasg23
(lp4931
sa(dp4932
g2
S'The data also showed patients with statin administration present significantly lower cathepsin L activity (P &lt; 0.01), hs-CRP (P &lt; 0.01), HMGB1 (P &lt; 0.01) and proteinuria (P &lt; 0.01) compared to non-statin treatment group.\n'
p4933
sg4
(lp4934
(dp4935
g7
I35
sg8
g64
sg10
I6
sg11
Vstatin
p4936
sg13
I1
sa(dp4937
g7
I121
sg8
VP02741
p4938
sg10
I6
sg11
Vhs-CRP
p4939
sg13
I1
sa(dp4940
g7
I85
sg8
VP07711
p4941
sg10
I11
sg11
Vcathepsin L
p4942
sg13
I2
sa(dp4943
g7
I143
sg8
VP09429
p4944
sg10
I5
sg11
VHMGB1
p4945
sg13
I1
sasg23
(lp4946
sa(dp4947
g2
S'We confirmed the increased expression of IL-36Alfa in the renal tubular epithelial cells of a mouse model of unilateral ureteral obstruction (UUO) and related cell models using mechanically induced pressure, oxidative stress, or high mobility group box 1.\n'
p4948
sg4
(lp4949
(dp4950
g7
I229
sg8
VP00390
p4951
sg10
I25
sg11
Vhigh mobility group box 1
p4952
sg13
I5
sasg23
(lp4953
(dp4954
g7
I120
sg26
VC0041956
p4955
sg10
I20
sg11
Vureteral obstruction
p4956
sg13
I2
sa(dp4957
g7
I142
sg26
VC0041956
p4958
sg10
I3
sg11
VUUO
p4959
sg13
I1
sa(dp4960
g7
I208
sg26
VC0242606
p4961
sg10
I16
sg11
Voxidative stress
p4962
sg13
I2
sasa(dp4963
g2
S'These findings suggest that serum anti-NCS, anti-GBM and HMGB1 may serve as biomarkers specific for the presence of nephritis in pSLE.\n'
p4964
sg4
(lp4965
(dp4966
g7
I44
sg8
g64
sg10
I8
sg11
Vanti-GBM
p4967
sg13
I1
sa(dp4968
g7
I28
sg8
g64
sg10
I14
sg11
Vserum anti-NCS
p4969
sg13
I2
sa(dp4970
g7
I57
sg8
VP09429
p4971
sg10
I5
sg11
VHMGB1
p4972
sg13
I1
sasg23
(lp4973
(dp4974
g7
I116
sg26
VC0027697
p4975
sg10
I9
sg11
Vnephritis
p4976
sg13
I1
sa(dp4977
g7
I49
sg26
VC0017636
p4978
sg10
I3
sg11
VGBM
p4979
sg13
I1
sasa(dp4980
g2
S'By integrated analysis of our data and publicly available bioinformatics resources, we found that a combination panel consisting of CDH3, PLAU, and LFNG might improve the prognosis of overall pancreatic cancer survival.\n'
p4981
sg4
(lp4982
(dp4983
g7
I138
sg8
VP00749
p4984
sg10
I4
sg11
VPLAU
p4985
sg13
I1
sa(dp4986
g7
I132
sg8
VP22223
p4987
sg10
I4
sg11
VCDH3
p4988
sg13
I1
sa(dp4989
g7
I148
sg8
g64
sg10
I4
sg11
VLFNG
p4990
sg13
I1
sasg23
(lp4991
(dp4992
g7
I192
sg26
VC0235974
p4993
sg10
I17
sg11
Vpancreatic cancer
p4994
sg13
I2
sasa(dp4995
g2
S'Hepatocellular carcinoma etiology had no detectable influence on miR-122 expression, whereas miR-152 was increased in HCV+ tissue samples.\n'
p4996
sg4
(lp4997
(dp4998
g7
I93
sg8
g64
sg10
I7
sg11
VmiR-152
p4999
sg13
I1
sa(dp5000
g7
I65
sg8
g64
sg10
I7
sg11
VmiR-122
p5001
sg13
I1
sasg23
(lp5002
(dp5003
g7
I0
sg26
VC1512411
p5004
sg10
I24
sg11
VHepatocellular carcinoma
p5005
sg13
I2
sasa(dp5006
g2
S'Aberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC).\n'
p5007
sg4
(lp5008
(dp5009
g7
I28
sg8
g64
sg10
I18
sg11
VmiR-148/152 family
p5010
sg13
I2
sa(dp5011
g7
I58
sg8
g64
sg10
I8
sg11
VmiR-148b
p5012
sg13
I1
sa(dp5013
g7
I48
sg8
g64
sg10
I8
sg11
VmiR-148a
p5014
sg13
I1
sasg23
(lp5015
(dp5016
g7
I135
sg26
VC2239176
p5017
sg10
I24
sg11
Vhepatocellular carcinoma
p5018
sg13
I2
sa(dp5019
g7
I110
sg26
VC0027651
p5020
sg10
I5
sg11
Vtumor
p5021
sg13
I1
sa(dp5022
g7
I161
sg26
VC2239176
p5023
sg10
I3
sg11
VHCC
p5024
sg13
I1
sasa(dp5025
g2
S'And high expression of HLA-G further suppressed NK against cancer cells, providing a new concept that miR-152 was involved in HBV-induced hepatocellular carcinoma.\n'
p5026
sg4
(lp5027
(dp5028
g7
I23
sg8
VP30486
p5029
sg10
I3
sg11
VHLA
p5030
sg13
I1
sasg23
(lp5031
(dp5032
g7
I59
sg26
VC0006826
p5033
sg10
I6
sg11
Vcancer
p5034
sg13
I1
sa(dp5035
g7
I138
sg26
VC1512411
p5036
sg10
I24
sg11
Vhepatocellular carcinoma
p5037
sg13
I2
sa(dp5038
g7
I126
sg26
VC0019163
p5039
sg10
I3
sg11
VHBV
p5040
sg13
I1
sasa(dp5041
g2
S'The consistency of our findings suggests AKR1C isoenzymes 2 and 3, and potentially SRD5A1, may play a role in progression of HCV-related liver disease in males.\n'
p5042
sg4
(lp5043
(dp5044
g7
I83
sg8
VP18405
p5045
sg10
I6
sg11
VSRD5A1
p5046
sg13
I1
sasg23
(lp5047
(dp5048
g7
I137
sg26
VC0023895
p5049
sg10
I13
sg11
Vliver disease
p5050
sg13
I2
sasa(dp5051
g2
S'Altogether, our data in this Z-12 cell model suggest that the beneficial effects of treatment with progestin observed in endometriosis patients might arise from decreased pre-receptor metabolism of the protective progesterone by the SRD5A1 and AKR1C enzymes.\n'
p5052
sg4
(lp5053
(dp5054
g7
I233
sg8
VP18405
p5055
sg10
I6
sg11
VSRD5A1
p5056
sg13
I1
sasg23
(lp5057
(dp5058
g7
I121
sg26
VC0014175
p5059
sg10
I13
sg11
Vendometriosis
p5060
sg13
I1
sasa(dp5061
g2
S'The mRNA levels for luteinizing hormone receptor (Lhcgr), scavenger receptor class B member 1 (Scarb1), steroidogenic acute regulatory protein (StAR), cholesterol side chain cleavage enzyme (Cyp11a1), 3Beta-hydroxysteroid dehydrogenase 1 (HSD3Beta1), 17Alfa-hydroxylase/20-lyase (Cyp17a1) and membrane receptor c-kit (kit) were significantly downregulated by cerebral ischemia, while luteinizing hormone, Kit ligand (KitL), 17Beta-hydrosteroid dehydrogenase 3 (HSD17Beta3) and 5Alfa-reductase (Srd5a1) were not affected.\n'
p5062
sg4
(lp5063
(dp5064
g7
I20
sg8
g64
sg10
I19
sg11
Vluteinizing hormone
p5065
sg13
I2
sa(dp5066
g7
I280
sg8
VP05093
p5067
sg10
I7
sg11
VCyp17a1
p5068
sg13
I1
sa(dp5069
g7
I424
sg8
VP49366
p5070
sg10
I35
sg11
V17Beta-hydrosteroid dehydrogenase 3
p5071
sg13
I3
sa(dp5072
g7
I20
sg8
VP22888
p5073
sg10
I28
sg11
Vluteinizing hormone receptor
p5074
sg13
I3
sa(dp5075
g7
I494
sg8
VP18405
p5076
sg10
I6
sg11
VSrd5a1
p5077
sg13
I1
sa(dp5078
g7
I251
sg8
g64
sg10
I27
sg11
V17Alfa-hydroxylase/20-lyase
p5079
sg13
I1
sa(dp5080
g7
I144
sg8
VP49675
p5081
sg10
I4
sg11
VStAR
p5082
sg13
I1
sa(dp5083
g7
I58
sg8
g64
sg10
I35
sg11
Vscavenger receptor class B member 1
p5084
sg13
I6
sa(dp5085
g7
I95
sg8
g64
sg10
I6
sg11
VScarb1
p5086
sg13
I1
sa(dp5087
g7
I104
sg8
VP05108
p5088
sg10
I38
sg11
Vsteroidogenic acute regulatory protein
p5089
sg13
I4
sa(dp5090
g7
I477
sg8
g64
sg10
I15
sg11
V5Alfa-reductase
p5091
sg13
I1
sa(dp5092
g7
I191
sg8
VP05108
p5093
sg10
I7
sg11
VCyp11a1
p5094
sg13
I1
sa(dp5095
g7
I417
sg8
VP21583
p5096
sg10
I4
sg11
VKitL
p5097
sg13
I1
sa(dp5098
g7
I50
sg8
VP22888
p5099
sg10
I5
sg11
VLhcgr
p5100
sg13
I1
sa(dp5101
g7
I311
sg8
VP10721
p5102
sg10
I5
sg11
Vc-kit
p5103
sg13
I1
sa(dp5104
g7
I201
sg8
VP49366
p5105
sg10
I36
sg11
V3Beta-hydroxysteroid dehydrogenase 1
p5106
sg13
I3
sa(dp5107
g7
I405
sg8
VP21583
p5108
sg10
I10
sg11
VKit ligand
p5109
sg13
I2
sa(dp5110
g7
I313
sg8
VP10721
p5111
sg10
I3
sg11
Vkit
p5112
sg13
I1
sasg23
(lp5113
(dp5114
g7
I104
sg26
VC2678045
p5115
sg10
I38
sg11
Vsteroidogenic acute regulatory protein
p5116
sg13
I4
sa(dp5117
g7
I144
sg26
VC2678045
p5118
sg10
I4
sg11
VStAR
p5119
sg13
I1
sa(dp5120
g7
I359
sg26
VC0917798
p5121
sg10
I17
sg11
Vcerebral ischemia
p5122
sg13
I2
sasa(dp5123
g2
S'Patient 1 with SDCCAG8 homozygous deletions showed no ciliopathy-specific extrarenal manifestations, such as retinitis pigmentosa or polydactyly prior to genetic analysis.\n'
p5124
sg4
(lp5125
(dp5126
g7
I15
sg8
g64
sg10
I7
sg11
VSDCCAG8
p5127
sg13
I1
sasg23
(lp5128
(dp5129
g7
I109
sg26
VC0035334
p5130
sg10
I20
sg11
Vretinitis pigmentosa
p5131
sg13
I2
sa(dp5132
g7
I133
sg26
VC0152427
p5133
sg10
I11
sg11
Vpolydactyly
p5134
sg13
I1
sasa(dp5135
g2
S'Antipyrine clearance (AP Cl) in CAH patients with fibrosis (0.246 +/- 0.98 mL/min per kg) was similar to that observed in patients with cirrhosis (0.223 +/- 0.148 mL/min per kg), and both values were significantly lower than that found in CAH patients without fibrosis (0.406 +/- 0.159 mL/min per kg, P &lt; 0.01).\n'
p5136
sg4
(lp5137
sg23
(lp5138
(dp5139
g7
I32
sg26
VC0520463
p5140
sg10
I3
sg11
VCAH
p5141
sg13
I1
sa(dp5142
g7
I32
sg26
VC0520463
p5143
sg10
I3
sg11
VCAH
p5144
sg13
I1
sa(dp5145
g7
I50
sg26
VC0016059
p5146
sg10
I8
sg11
Vfibrosis
p5147
sg13
I1
sa(dp5148
g7
I136
sg26
VC0023890
p5149
sg10
I9
sg11
Vcirrhosis
p5150
sg13
I1
sa(dp5151
g7
I50
sg26
VC0016059
p5152
sg10
I8
sg11
Vfibrosis
p5153
sg13
I1
sasa(dp5154
g2
S'Also Ymax was reduced by 50% in cirrhosis, whereas Tmax was increased by 50%, and both significantly correlated with galactose elimination capacity (GEC; R2 = 0.706 and R2 = 0.505, respectively) and with antipyrine clearance (Ap Cl; R2 = 0.823 and R2 = 0.576, respectively).\n'
p5155
sg4
(lp5156
sg23
(lp5157
(dp5158
g7
I32
sg26
VC0023890
p5159
sg10
I9
sg11
Vcirrhosis
p5160
sg13
I1
sasa(dp5161
g2
S'12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107 +/- 240 ml/min, antipyrine clearance (AP Cl) 47 +/- 10.2 ml/min; x +/- SD), 13 subjects had impaired renal function (mean GFR 38 +/- 11.5 ml/min, AP Cl 39 +/- 4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18 +/- 9.2 ml/min, GFR 92 +/- 8.1 ml/min).\n'
p5162
sg4
(lp5163
sg23
(lp5164
(dp5165
g7
I179
sg26
VC0341697
p5166
sg10
I23
sg11
Vimpaired renal function
p5167
sg13
I3
sa(dp5168
g7
I279
sg26
VC0023890
p5169
sg10
I15
sg11
Vliver cirrhosis
p5170
sg13
I2
sasa(dp5171
g2
S'The prognostic value of Gal-8 has been described for laryngeal carcinoma as well as advanced colon carcinoma.\n'
p5172
sg4
(lp5173
(dp5174
g7
I24
sg8
VP16278
p5175
sg10
I5
sg11
VGal-8
p5176
sg13
I1
sasg23
(lp5177
(dp5178
g7
I53
sg26
VC0595989
p5179
sg10
I19
sg11
Vlaryngeal carcinoma
p5180
sg13
I2
sa(dp5181
g7
I93
sg26
VC0699790
p5182
sg10
I15
sg11
Vcolon carcinoma
p5183
sg13
I2
sasa(dp5184
g2
S'The current study analyzed the prognostic values contributed by galectin-1, galectin-3, galectin-4, and galectin-8 in cases of colon carcinoma.\n'
p5185
sg4
(lp5186
(dp5187
g7
I104
sg8
VP09382
p5188
sg10
I10
sg11
Vgalectin-8
p5189
sg13
I1
sa(dp5190
g7
I76
sg8
VP17931
p5191
sg10
I10
sg11
Vgalectin-3
p5192
sg13
I1
sa(dp5193
g7
I64
sg8
VP09382
p5194
sg10
I10
sg11
Vgalectin-1
p5195
sg13
I1
sa(dp5196
g7
I88
sg8
VP56470
p5197
sg10
I10
sg11
Vgalectin-4
p5198
sg13
I1
sasg23
(lp5199
(dp5200
g7
I127
sg26
VC0699790
p5201
sg10
I15
sg11
Vcolon carcinoma
p5202
sg13
I2
sasa(dp5203
g2
S'The data from the current study strongly suggest that galectins-1, -3, and -4 may be involved in the early stages of human colon carcinoma development and that galectin-8 is involved in the later stages.\n'
p5204
sg4
(lp5205
(dp5206
g7
I160
sg8
VP09382
p5207
sg10
I10
sg11
Vgalectin-8
p5208
sg13
I1
sa(dp5209
g7
I54
sg8
VP09382
p5210
sg10
I15
sg11
Vgalectins-1, -3
p5211
sg13
I2
sasg23
(lp5212
(dp5213
g7
I123
sg26
VC0699790
p5214
sg10
I15
sg11
Vcolon carcinoma
p5215
sg13
I2
sasa(dp5216
g2
S'The present study deals with the quantitative determination of immunohistochemical expression of galectin-8 in normal, benign, and malignant human colon tissue samples and in four human colon cancer models (HCT-15, LoVo, CoLo201, and DLD-1) maintained both in vitro as permanent cell lines and in vivo as nude mice xenografts.\n'
p5217
sg4
(lp5218
(dp5219
g7
I234
sg8
VP98173
p5220
sg10
I5
sg11
VDLD-1
p5221
sg13
I1
sa(dp5222
g7
I97
sg8
VP09382
p5223
sg10
I10
sg11
Vgalectin-8
p5224
sg13
I1
sasg23
(lp5225
(dp5226
g7
I186
sg26
VC0699790
p5227
sg10
I12
sg11
Vcolon cancer
p5228
sg13
I2
sasa(dp5229
g2
S'The presence of galectin-8 mRNA in the four human colon cancer cell lines was examined by reverse transcriptase-polymerase chain reaction.\n'
p5230
sg4
(lp5231
(dp5232
g7
I90
sg8
VP63136
p5233
sg10
I21
sg11
Vreverse transcriptase
p5234
sg13
I2
sa(dp5235
g7
I16
sg8
VP09382
p5236
sg10
I15
sg11
Vgalectin-8 mRNA
p5237
sg13
I2
sasg23
(lp5238
(dp5239
g7
I50
sg26
VC0699790
p5240
sg10
I12
sg11
Vcolon cancer
p5241
sg13
I2
sasa(dp5242
g2
S'In vitro, cellular localisation of exogenously added galectin-8 in the culture media of these colon cancer cells was visualised by fluorescence microscopy.\n'
p5243
sg4
(lp5244
(dp5245
g7
I53
sg8
VP09382
p5246
sg10
I10
sg11
Vgalectin-8
p5247
sg13
I1
sasg23
(lp5248
(dp5249
g7
I94
sg26
VC0699790
p5250
sg10
I12
sg11
Vcolon cancer
p5251
sg13
I2
sasa(dp5252
g2
S'Malignant colon tissue exhibited a significantly lower galectin-8 level than normal or benign tissue colon cancers; those with extensive invasion capacities (T3-4/N+/M+) harboured significantly less galectin-8 than colon cancers with localised invasion capacities (T1-2/N0/M0).\n'
p5253
sg4
(lp5254
(dp5255
g7
I55
sg8
VP09382
p5256
sg10
I10
sg11
Vgalectin-8
p5257
sg13
I1
sa(dp5258
g7
I55
sg8
VP09382
p5259
sg10
I10
sg11
Vgalectin-8
p5260
sg13
I1
sasg23
(lp5261
(dp5262
g7
I101
sg26
VC0007102
p5263
sg10
I13
sg11
Vcolon cancers
p5264
sg13
I2
sa(dp5265
g7
I137
sg26
VC2699153
p5266
sg10
I8
sg11
Vinvasion
p5267
sg13
I1
sa(dp5268
g7
I137
sg26
VC2699153
p5269
sg10
I8
sg11
Vinvasion
p5270
sg13
I1
sa(dp5271
g7
I101
sg26
VC0007102
p5272
sg10
I13
sg11
Vcolon cancers
p5273
sg13
I2
sasa(dp5274
g2
S'Grafting the four experimental human colon cancer models onto nude mice enabled us to show that the immunohistochemical expression of galectin-8 was inversely related to tumour growth rate.\n'
p5275
sg4
(lp5276
(dp5277
g7
I134
sg8
VP09382
p5278
sg10
I10
sg11
Vgalectin-8
p5279
sg13
I1
sasg23
(lp5280
(dp5281
g7
I37
sg26
VC0699790
p5282
sg10
I12
sg11
Vcolon cancer
p5283
sg13
I2
sa(dp5284
g7
I170
sg26
VC0027651
p5285
sg10
I6
sg11
Vtumour
p5286
sg13
I1
sasa(dp5287
g2
S'Our findings indicate that downregulation of Mir30c and subsequent activation of BECN1 promotes autophagy, contributing to the pathogenesis of diabetic cardiomyopathy.\n'
p5288
sg4
(lp5289
(dp5290
g7
I81
sg8
g64
sg10
I5
sg11
VBECN1
p5291
sg13
I1
sasg23
(lp5292
(dp5293
g7
I127
sg26
VC0699748
p5294
sg10
I12
sg11
Vpathogenesis
p5295
sg13
I1
sa(dp5296
g7
I143
sg26
VC0853897
p5297
sg10
I23
sg11
Vdiabetic cardiomyopathy
p5298
sg13
I2
sasa(dp5299
g2
S'Cinnamomum verum is used to make the spice cinnamon and has been used for more than 5000 years by both of the two most ancient forms of medicine in the words: Ayurveda and traditional Chinese herbal medicines for various applications such as adenopathy, rheumatism, dermatosis, dyspepsia, stroke, tumors, elephantiasis, trichomonas, yeast, and virus infections.\n'
p5300
sg4
(lp5301
sg23
(lp5302
(dp5303
g7
I266
sg26
VC0037274
p5304
sg10
I10
sg11
Vdermatosis
p5305
sg13
I1
sa(dp5306
g7
I350
sg26
VC0021311
p5307
sg10
I10
sg11
Vinfections
p5308
sg13
I1
sa(dp5309
g7
I320
sg26
VC0040921
p5310
sg10
I11
sg11
Vtrichomonas
p5311
sg13
I1
sa(dp5312
g7
I254
sg26
VC0035435
p5313
sg10
I10
sg11
Vrheumatism
p5314
sg13
I1
sa(dp5315
g7
I305
sg26
VC0013882
p5316
sg10
I13
sg11
Velephantiasis
p5317
sg13
I1
sa(dp5318
g7
I297
sg26
VC0027651
p5319
sg10
I6
sg11
Vtumors
p5320
sg13
I1
sa(dp5321
g7
I289
sg26
VC0038454
p5322
sg10
I6
sg11
Vstroke
p5323
sg13
I1
sa(dp5324
g7
I278
sg26
VC0013395
p5325
sg10
I9
sg11
Vdyspepsia
p5326
sg13
I1
sasa(dp5327
g2
S'Tissue specific intestinal glucose uptake was measured before and after the treatment period using FDG-PET during euglycemic hyperinsulinemia.\n'
p5328
sg4
(lp5329
sg23
(lp5330
(dp5331
g7
I125
sg26
VC0020459
p5332
sg10
I16
sg11
Vhyperinsulinemia
p5333
sg13
I1
sasa(dp5334
g2
S'Because previous literature showed that via hyperglycemia and hyperinsulinemia glucagon has the effect of increasing FDG uptake in skeletal muscle, the use of glucagon should be avoided just prior to FDG PET, although in our subjects, no statistical proof that glucagon enhances FDG uptake in skeletal muscle was obtained.\n'
p5335
sg4
(lp5336
(dp5337
g7
I79
sg8
VP01275
p5338
sg10
I8
sg11
Vglucagon
p5339
sg13
I1
sa(dp5340
g7
I79
sg8
VP01275
p5341
sg10
I8
sg11
Vglucagon
p5342
sg13
I1
sa(dp5343
g7
I79
sg8
VP01275
p5344
sg10
I8
sg11
Vglucagon
p5345
sg13
I1
sasg23
(lp5346
(dp5347
g7
I44
sg26
VC0020456
p5348
sg10
I13
sg11
Vhyperglycemia
p5349
sg13
I1
sa(dp5350
g7
I62
sg26
VC0020459
p5351
sg10
I16
sg11
Vhyperinsulinemia
p5352
sg13
I1
sasa(dp5353
g2
S'The group of pigs in a fasting state and the group of pigs with euglycemic supraphysiological hyperinsulinemia were scanned by positron emission tomography after a single dose of [(18)F]FDG tracer.\n'
p5354
sg4
(lp5355
sg23
(lp5356
(dp5357
g7
I94
sg26
VC0020459
p5358
sg10
I16
sg11
Vhyperinsulinemia
p5359
sg13
I1
sasa(dp5360
g2
S'We measured regional brain glucose uptake in morbidly obese (n = 19) and normal weighted (n = 16) subjects with 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) positron emission tomography (PET) during euglycemic hyperinsulinemia and with functional magnetic resonance imaging (fMRI) while anticipatory food reward was induced by repeated presentations of appetizing and bland food pictures.\n'
p5361
sg4
(lp5362
sg23
(lp5363
(dp5364
g7
I205
sg26
VC0020459
p5365
sg10
I16
sg11
Vhyperinsulinemia
p5366
sg13
I1
sa(dp5367
g7
I54
sg26
VC0028754
p5368
sg10
I5
sg11
Vobese
p5369
sg13
I1
sasa(dp5370
g2
S'We present a model of diet-induced hyperinsulinemia associated with increased insulin receptor activation in neoplastic tissue and with increased tumor FDG-PET image intensity.\n'
p5371
sg4
(lp5372
(dp5373
g7
I78
sg8
VP01308
p5374
sg10
I16
sg11
Vinsulin receptor
p5375
sg13
I2
sasg23
(lp5376
(dp5377
g7
I68
sg26
VC0020459
p5378
sg10
I17
sg11
Vincreased insulin
p5379
sg13
I2
sa(dp5380
g7
I146
sg26
VC0027651
p5381
sg10
I5
sg11
Vtumor
p5382
sg13
I1
sa(dp5383
g7
I35
sg26
VC0020459
p5384
sg10
I16
sg11
Vhyperinsulinemia
p5385
sg13
I1
sasa(dp5386
g2
S'Fractional extraction of [(18)F]FDG and [(2)H]G was similar (not significant), intercorrelated (r = 0.98, P &lt; .0001), and equally higher during hyperinsulinemia than fasting (P &lt;or= .05), with an LC of 0.98 +/- 0.10 and 1.18 +/- 0.26, respectively.\n'
p5387
sg4
(lp5388
sg23
(lp5389
(dp5390
g7
I147
sg26
VC0020459
p5391
sg10
I16
sg11
Vhyperinsulinemia
p5392
sg13
I1
sasa(dp5393
g2
S'Fourteen pigs were coinjected with (18)F-FDG and 6,6-(2)H-glucose ((2)H-G) during fasting (n = 6) and during physiologic (1.0 mU.kg(-1).min(-1), n = 4) and supraphysiologic (5.0 mU.kg(-1).min(-1), n = 4) euglycemic hyperinsulinemia.\n'
p5394
sg4
(lp5395
sg23
(lp5396
(dp5397
g7
I215
sg26
VC0020459
p5398
sg10
I16
sg11
Vhyperinsulinemia
p5399
sg13
I1
sasa(dp5400
g2
S'IGM (Idiopathic Granulomatous Mastitis) is a rare, chronic, non-malignant and non-life-threatening breast disease.\n'
p5401
sg4
(lp5402
(dp5403
g7
I0
sg8
VP29965
p5404
sg10
I3
sg11
VIGM
p5405
sg13
I1
sa(dp5406
g7
I5
sg8
VP29965
p5407
sg10
I33
sg11
VIdiopathic Granulomatous Mastitis
p5408
sg13
I3
sasg23
(lp5409
(dp5410
g7
I99
sg26
VC0006145
p5411
sg10
I14
sg11
Vbreast disease
p5412
sg13
I2
sa(dp5413
g7
I16
sg26
VC0405469
p5414
sg10
I22
sg11
VGranulomatous Mastitis
p5415
sg13
I2
sasa(dp5416
g2
S'Seven-eight patients with non-lactational mastitis treated in our hospital between September 2013 and May 2015 and 88 healthy women (control) were examined for peripheral blood levels of antinuclear antibody (ANA), anti-histone antibody (AHA), immunoglobulins (IgA, IgM, and IgG) and complements (C3, C4, and total complements).\n'
p5417
sg4
(lp5418
(dp5419
g7
I266
sg8
VP29965
p5420
sg10
I3
sg11
VIgM
p5421
sg13
I1
sa(dp5422
g7
I238
sg8
g64
sg10
I3
sg11
VAHA
p5423
sg13
I1
sa(dp5424
g7
I261
sg8
VP11912
p5425
sg10
I3
sg11
VIgA
p5426
sg13
I1
sa(dp5427
g7
I215
sg8
VP62805
p5428
sg10
I21
sg11
Vanti-histone antibody
p5429
sg13
I2
sa(dp5430
g7
I244
sg8
g64
sg10
I15
sg11
Vimmunoglobulins
p5431
sg13
I1
sasg23
(lp5432
(dp5433
g7
I42
sg26
VC3251795
p5434
sg10
I8
sg11
Vmastitis
p5435
sg13
I1
sasa(dp5436
g2
S'Seventy three patients had idiopathic granulomatous lobular mastitis and 20 patients had specific granulomatous mastitis IGM (18 tuberculosis mastitis, 1 alveolar echinococcosis and 1 silk reaction).\n'
p5437
sg4
(lp5438
sg23
(lp5439
(dp5440
g7
I154
sg26
VC0948954
p5441
sg10
I23
sg11
Valveolar echinococcosis
p5442
sg13
I2
sa(dp5443
g7
I98
sg26
VC0405469
p5444
sg10
I22
sg11
Vgranulomatous mastitis
p5445
sg13
I2
sa(dp5446
g7
I129
sg26
VC0041296
p5447
sg10
I12
sg11
Vtuberculosis
p5448
sg13
I1
sa(dp5449
g7
I60
sg26
VC3251795
p5450
sg10
I8
sg11
Vmastitis
p5451
sg13
I1
sa(dp5452
g7
I60
sg26
VC3251795
p5453
sg10
I8
sg11
Vmastitis
p5454
sg13
I1
sasa(dp5455
g2
S'Lung tissue samples obtained from 27 patients with IIP and 39 patients with CVD-ILD were detected using monoclonal antibodies against CD1a, CD1c, CD83, Langerin and DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN).\n'
p5456
sg4
(lp5457
(dp5458
g7
I140
sg8
VP29017
p5459
sg10
I4
sg11
VCD1c
p5460
sg13
I1
sa(dp5461
g7
I134
sg8
VP15813
p5462
sg10
I4
sg11
VCD1a
p5463
sg13
I1
sa(dp5464
g7
I233
sg8
VP35555
p5465
sg10
I7
sg11
VDC-SIGN
p5466
sg13
I1
sa(dp5467
g7
I152
sg8
g64
sg10
I8
sg11
VLangerin
p5468
sg13
I1
sa(dp5469
g7
I165
sg8
VP32942
p5470
sg10
I66
sg11
VDC-specific intercellular adhesion molecule-3-grabbing nonintegrin
p5471
sg13
I5
sa(dp5472
g7
I146
sg8
g64
sg10
I4
sg11
VCD83
p5473
sg13
I1
sasg23
(lp5474
(dp5475
g7
I191
sg26
VC0001511
p5476
sg10
I8
sg11
Vadhesion
p5477
sg13
I1
sa(dp5478
g7
I76
sg26
VC0007222
p5479
sg10
I3
sg11
VCVD
p5480
sg13
I1
sasa(dp5481
g2
S'Finally, a potential role for ApoA-I in microvascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the inverse relationship between the concentration of ApoA-I and that of hyperadhesive VWF.\n'
p5482
sg4
(lp5483
(dp5484
g7
I30
sg8
VP02647
p5485
sg10
I6
sg11
VApoA-I
p5486
sg13
I1
sa(dp5487
g7
I30
sg8
VP02647
p5488
sg10
I6
sg11
VApoA-I
p5489
sg13
I1
sasg23
(lp5490
(dp5491
g7
I120
sg26
VC0243026
p5492
sg10
I6
sg11
Vsepsis
p5493
sg13
I1
sa(dp5494
g7
I80
sg26
VC0034155
p5495
sg10
I35
sg11
Vthrombotic thrombocytopenic purpura
p5496
sg13
I3
sa(dp5497
g7
I54
sg26
VC0028778
p5498
sg10
I9
sg11
Vocclusion
p5499
sg13
I1
sasa(dp5500
g2
S'The objective of the study was to evaluate anti-apolipoprotein A-I (Apo A-I) and carotid intima-media thickness (cIMT) as cardiovascular risk factors in Egyptian women with systemic lupus erythematosus (SLE).\n'
p5501
sg4
(lp5502
(dp5503
g7
I68
sg8
VP02647
p5504
sg10
I7
sg11
VApo A-I
p5505
sg13
I2
sa(dp5506
g7
I43
sg8
VP02647
p5507
sg10
I23
sg11
Vanti-apolipoprotein A-I
p5508
sg13
I2
sasg23
(lp5509
(dp5510
g7
I203
sg26
VC0024141
p5511
sg10
I3
sg11
VSLE
p5512
sg13
I1
sa(dp5513
g7
I173
sg26
VC0024141
p5514
sg10
I28
sg11
Vsystemic lupus erythematosus
p5515
sg13
I3
sasa(dp5516
g2
S'Ten of sixteen variants previously associated with iron traits generalized to HCHS/SOL, including variants at the transferrin (TF), hemochromatosis (HFE), fatty acid desaturase 2 (FADS2)/myelin regulatory factor (MYRF), transmembrane protease, serine 6 (TMPRSS6), transferrin receptor (TFR2), N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ABO blood group (ABO), and GRB2 associated binding protein 3 (GAB3) loci.\n'
p5517
sg4
(lp5518
(dp5519
g7
I114
sg8
VP02787
p5520
sg10
I11
sg11
Vtransferrin
p5521
sg13
I1
sa(dp5522
g7
I316
sg8
VP18440
p5523
sg10
I29
sg11
Varylamine N-acetyltransferase
p5524
sg13
I2
sa(dp5525
g7
I127
sg8
VP02787
p5526
sg10
I2
sg11
VTF
p5527
sg13
I1
sa(dp5528
g7
I382
sg8
g64
sg10
I33
sg11
VGRB2 associated binding protein 3
p5529
sg13
I5
sa(dp5530
g7
I348
sg8
VP18440
p5531
sg10
I4
sg11
VNAT2
p5532
sg13
I1
sa(dp5533
g7
I417
sg8
g64
sg10
I4
sg11
VGAB3
p5534
sg13
I1
sa(dp5535
g7
I180
sg8
g64
sg10
I5
sg11
VFADS2
p5536
sg13
I1
sa(dp5537
g7
I264
sg8
VP02787
p5538
sg10
I20
sg11
Vtransferrin receptor
p5539
sg13
I2
sa(dp5540
g7
I244
sg8
VP30740
p5541
sg10
I8
sg11
Vserine 6
p5542
sg13
I2
sa(dp5543
g7
I187
sg8
g64
sg10
I55
sg11
Vmyelin regulatory factor (MYRF), transmembrane protease
p5544
sg13
I6
sa(dp5545
g7
I293
sg8
VP18440
p5546
sg10
I21
sg11
VN-acetyltransferase 2
p5547
sg13
I2
sa(dp5548
g7
I155
sg8
g64
sg10
I23
sg11
Vfatty acid desaturase 2
p5549
sg13
I4
sa(dp5550
g7
I286
sg8
g64
sg10
I4
sg11
VTFR2
p5551
sg13
I1
sa(dp5552
g7
I83
sg8
g64
sg10
I3
sg11
VSOL
p5553
sg13
I1
sa(dp5554
g7
I78
sg8
VP22607
p5555
sg10
I4
sg11
VHCHS
p5556
sg13
I1
sa(dp5557
g7
I254
sg8
g64
sg10
I7
sg11
VTMPRSS6
p5558
sg13
I1
sasg23
(lp5559
(dp5560
g7
I132
sg26
VC0018995
p5561
sg10
I15
sg11
Vhemochromatosis
p5562
sg13
I1
sasa(dp5563
g2
S'In the liver, TFR2 forms a complex with HFE, a hereditary hemochromatosis-associated protein, and acts as an iron sensor.\n'
p5564
sg4
(lp5565
(dp5566
g7
I14
sg8
g64
sg10
I4
sg11
VTFR2
p5567
sg13
I1
sasg23
(lp5568
(dp5569
g7
I47
sg26
VC0392514
p5570
sg10
I26
sg11
Vhereditary hemochromatosis
p5571
sg13
I2
sasa(dp5572
g2
S"Mutations in VCP are associated with two neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) and inclusion body myopathy with Paget's disease of the bone and frontotemporal dementia (IBMPFD), and extensive study has revealed crucial functions of VCP within neurons.\n"
p5573
sg4
(lp5574
sg23
(lp5575
(dp5576
g7
I124
sg26
VC0026848
p5577
sg10
I8
sg11
Vmyopathy
p5578
sg13
I1
sa(dp5579
g7
I69
sg26
VC0002736
p5580
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p5581
sg13
I3
sa(dp5582
g7
I195
sg26
VC1833662
p5583
sg10
I6
sg11
VIBMPFD
p5584
sg13
I1
sa(dp5585
g7
I170
sg26
VC0338451
p5586
sg10
I23
sg11
Vfrontotemporal dementia
p5587
sg13
I2
sa(dp5588
g7
I138
sg26
VC0029401
p5589
sg10
I27
sg11
VPaget's disease of the bone
p5590
sg13
I5
sa(dp5591
g7
I41
sg26
VC0524851
p5592
sg10
I26
sg11
Vneurodegenerative diseases
p5593
sg13
I2
sa(dp5594
g7
I100
sg26
VC0002736
p5595
sg10
I3
sg11
VALS
p5596
sg13
I1
sasa(dp5597
g2
S'Here, we analyzed a cohort of German patients with sporadic amyotrophic lateral sclerosis and frontotemporal lobar degeneration comorbidity (ALS/FTD) for VCP and WASH complex gene mutations.\n'
p5598
sg4
(lp5599
(dp5600
g7
I162
sg8
g64
sg10
I17
sg11
VWASH complex gene
p5601
sg13
I3
sa(dp5602
g7
I154
sg8
VP55072
p5603
sg10
I3
sg11
VVCP
p5604
sg13
I1
sasg23
(lp5605
(dp5606
g7
I141
sg26
VC0002736
p5607
sg10
I3
sg11
VALS
p5608
sg13
I1
sa(dp5609
g7
I94
sg26
VC0751072
p5610
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p5611
sg13
I3
sa(dp5612
g7
I145
sg26
VC0338451
p5613
sg10
I3
sg11
VFTD
p5614
sg13
I1
sa(dp5615
g7
I60
sg26
VC0002736
p5616
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p5617
sg13
I3
sasa(dp5618
g2
S'Multisystem proteinopathy (MSP), a newly proposed syndrome including inclusion body myopathy (IBM), PDB, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), is mainly caused by mutation in VCP gene.\n'
p5619
sg4
(lp5620
(dp5621
g7
I209
sg8
VP55072
p5622
sg10
I8
sg11
VVCP gene
p5623
sg13
I2
sa(dp5624
g7
I100
sg8
g64
sg10
I3
sg11
VPDB
p5625
sg13
I1
sasg23
(lp5626
(dp5627
g7
I130
sg26
VC0338451
p5628
sg10
I3
sg11
VFTD
p5629
sg13
I1
sa(dp5630
g7
I105
sg26
VC0338451
p5631
sg10
I23
sg11
Vfrontotemporal dementia
p5632
sg13
I2
sa(dp5633
g7
I69
sg26
VC0238190
p5634
sg10
I23
sg11
Vinclusion body myopathy
p5635
sg13
I3
sa(dp5636
g7
I94
sg26
VC0238190
p5637
sg10
I3
sg11
VIBM
p5638
sg13
I1
sa(dp5639
g7
I171
sg26
VC0002736
p5640
sg10
I3
sg11
VALS
p5641
sg13
I1
sa(dp5642
g7
I50
sg26
VC0039082
p5643
sg10
I8
sg11
Vsyndrome
p5644
sg13
I1
sa(dp5645
g7
I100
sg26
VC0029401
p5646
sg10
I3
sg11
VPDB
p5647
sg13
I1
sa(dp5648
g7
I140
sg26
VC0002736
p5649
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p5650
sg13
I3
sasa(dp5651
g2
S'Mutations in the gene encoding valosin-containing protein (VCP) lead to multisystem proteinopathies including frontotemporal dementia.\n'
p5652
sg4
(lp5653
(dp5654
g7
I59
sg8
VP55072
p5655
sg10
I3
sg11
VVCP
p5656
sg13
I1
sa(dp5657
g7
I31
sg8
VP55072
p5658
sg10
I26
sg11
Vvalosin-containing protein
p5659
sg13
I2
sasg23
(lp5660
(dp5661
g7
I110
sg26
VC0338451
p5662
sg10
I23
sg11
Vfrontotemporal dementia
p5663
sg13
I2
sasa(dp5664
g2
S'The production of mature pRNA is essential since it guides the repressor TIP5 to rRNA genes, and IGS-rRNA abolishes this process.\n'
p5665
sg4
(lp5666
(dp5667
g7
I97
sg8
g64
sg10
I8
sg11
VIGS-rRNA
p5668
sg13
I1
sa(dp5669
g7
I73
sg8
g64
sg10
I4
sg11
VTIP5
p5670
sg13
I1
sasg23
(lp5671
(dp5672
g7
I97
sg26
VC1306856
p5673
sg10
I3
sg11
VIGS
p5674
sg13
I1
sasa(dp5675
g2
S'Remarkably, ESCs depleted of DHX9 are unable to differentiate and this phenotype is reverted by the addition of pRNA, whereas providing IGS-rRNA and pRNA mutants deficient for TIP5 binding are not sufficient.\n'
p5676
sg4
(lp5677
(dp5678
g7
I149
sg8
g64
sg10
I12
sg11
VpRNA mutants
p5679
sg13
I2
sa(dp5680
g7
I12
sg8
g64
sg10
I4
sg11
VESCs
p5681
sg13
I1
sa(dp5682
g7
I136
sg8
g64
sg10
I8
sg11
VIGS-rRNA
p5683
sg13
I1
sa(dp5684
g7
I176
sg8
g64
sg10
I4
sg11
VTIP5
p5685
sg13
I1
sa(dp5686
g7
I29
sg8
g64
sg10
I4
sg11
VDHX9
p5687
sg13
I1
sasg23
(lp5688
(dp5689
g7
I12
sg26
VC1849394
p5690
sg10
I4
sg11
VESCs
p5691
sg13
I1
sa(dp5692
g7
I136
sg26
VC1306856
p5693
sg10
I3
sg11
VIGS
p5694
sg13
I1
sasa(dp5695
g2
S'This study was to investigate the relationships of genetic variants in TLR2 and TLR3 with hepatitis B virus (HBV) natural clearance and HBV-related hepatocellular carcinoma (HCC) risk in a Chinese male population.\n'
p5696
sg4
(lp5697
(dp5698
g7
I71
sg8
g64
sg10
I4
sg11
VTLR2
p5699
sg13
I1
sa(dp5700
g7
I80
sg8
g64
sg10
I4
sg11
VTLR3
p5701
sg13
I1
sasg23
(lp5702
(dp5703
g7
I90
sg26
VC0019163
p5704
sg10
I17
sg11
Vhepatitis B virus
p5705
sg13
I3
sa(dp5706
g7
I174
sg26
VC2239176
p5707
sg10
I3
sg11
VHCC
p5708
sg13
I1
sa(dp5709
g7
I109
sg26
VC0019163
p5710
sg10
I3
sg11
VHBV
p5711
sg13
I1
sa(dp5712
g7
I109
sg26
VC0019163
p5713
sg10
I3
sg11
VHBV
p5714
sg13
I1
sa(dp5715
g7
I148
sg26
VC2239176
p5716
sg10
I24
sg11
Vhepatocellular carcinoma
p5717
sg13
I2
sasa(dp5718
g2
S'The study aimed to investigate mRNA expression levels of TLR2 and TLR3 in Hepatitis B virus (HBV) mediated chronic hepatitis B (CHB), cirrhosis (CIRR), and hepatocellular carcinoma (HCC), and to correlate viral load with severity of these diseases and expression of TLRs.\n'
p5719
sg4
(lp5720
(dp5721
g7
I66
sg8
g64
sg10
I4
sg11
VTLR3
p5722
sg13
I1
sa(dp5723
g7
I57
sg8
g64
sg10
I4
sg11
VTLR2
p5724
sg13
I1
sasg23
(lp5725
(dp5726
g7
I182
sg26
VC2239176
p5727
sg10
I3
sg11
VHCC
p5728
sg13
I1
sa(dp5729
g7
I156
sg26
VC2239176
p5730
sg10
I24
sg11
Vhepatocellular carcinoma
p5731
sg13
I2
sa(dp5732
g7
I74
sg26
VC0019163
p5733
sg10
I17
sg11
VHepatitis B virus
p5734
sg13
I3
sa(dp5735
g7
I107
sg26
VC0524909
p5736
sg10
I19
sg11
Vchronic hepatitis B
p5737
sg13
I3
sa(dp5738
g7
I145
sg26
VC0023890
p5739
sg10
I4
sg11
VCIRR
p5740
sg13
I1
sa(dp5741
g7
I93
sg26
VC0019163
p5742
sg10
I3
sg11
VHBV
p5743
sg13
I1
sa(dp5744
g7
I128
sg26
VC0151517
p5745
sg10
I3
sg11
VCHB
p5746
sg13
I1
sa(dp5747
g7
I134
sg26
VC0023890
p5748
sg10
I9
sg11
Vcirrhosis
p5749
sg13
I1
sasa(dp5750
g2
S'Indeed, exogenous histones promote both hepatocellular carcinoma (HCC) cell migration and invasion through toll-like receptor (TLR)4, but not TLR2 or the receptor for advanced glycosylation end product.\n'
p5751
sg4
(lp5752
(dp5753
g7
I8
sg8
VP62805
p5754
sg10
I18
sg11
Vexogenous histones
p5755
sg13
I2
sa(dp5756
g7
I107
sg8
g64
sg10
I18
sg11
Vtoll-like receptor
p5757
sg13
I2
sa(dp5758
g7
I127
sg8
g64
sg10
I3
sg11
VTLR
p5759
sg13
I1
sa(dp5760
g7
I142
sg8
g64
sg10
I4
sg11
VTLR2
p5761
sg13
I1
sasg23
(lp5762
(dp5763
g7
I66
sg26
VC2239176
p5764
sg10
I3
sg11
VHCC
p5765
sg13
I1
sa(dp5766
g7
I90
sg26
VC2699153
p5767
sg10
I8
sg11
Vinvasion
p5768
sg13
I1
sa(dp5769
g7
I40
sg26
VC2239176
p5770
sg10
I24
sg11
Vhepatocellular carcinoma
p5771
sg13
I2
sasa(dp5772
g2
S'Multiple TLRs such as TLR2, TLR3, TLR4, and TLR9, as well as other receptors, can be expressed in cirrhosis and hepatocellular carcinoma.\n'
p5773
sg4
(lp5774
(dp5775
g7
I22
sg8
g64
sg10
I4
sg11
VTLR2
p5776
sg13
I1
sa(dp5777
g7
I44
sg8
g64
sg10
I4
sg11
VTLR9
p5778
sg13
I1
sa(dp5779
g7
I28
sg8
g64
sg10
I4
sg11
VTLR3
p5780
sg13
I1
sasg23
(lp5781
(dp5782
g7
I112
sg26
VC1512411
p5783
sg10
I24
sg11
Vhepatocellular carcinoma
p5784
sg13
I2
sa(dp5785
g7
I98
sg26
VC0023890
p5786
sg10
I9
sg11
Vcirrhosis
p5787
sg13
I1
sasa(dp5788
g2
S'To explore the relationship between innate immunity and hepatitis C Virus (HCV) in determining the risk of cirrhosis (CIR), hepatocellular carcinoma (HCC), mixed cryoglobulinemia syndrome (MCS) and non-Hodgkin lymphoma (NHL), we investigated the impact of the toll-like receptor-2 (TLR2) and interleukin-28B (IL28B) genetic variants.\n'
p5789
sg4
(lp5790
(dp5791
g7
I282
sg8
g64
sg10
I4
sg11
VTLR2
p5792
sg13
I1
sa(dp5793
g7
I292
sg8
g64
sg10
I15
sg11
Vinterleukin-28B
p5794
sg13
I1
sa(dp5795
g7
I309
sg8
g64
sg10
I5
sg11
VIL28B
p5796
sg13
I1
sa(dp5797
g7
I260
sg8
g64
sg10
I20
sg11
Vtoll-like receptor-2
p5798
sg13
I2
sasg23
(lp5799
(dp5800
g7
I124
sg26
VC2239176
p5801
sg10
I24
sg11
Vhepatocellular carcinoma
p5802
sg13
I2
sa(dp5803
g7
I198
sg26
VC0024305
p5804
sg10
I20
sg11
Vnon-Hodgkin lymphoma
p5805
sg13
I2
sa(dp5806
g7
I118
sg26
VC0023890
p5807
sg10
I3
sg11
VCIR
p5808
sg13
I1
sa(dp5809
g7
I189
sg26
VC0036221
p5810
sg10
I3
sg11
VMCS
p5811
sg13
I1
sa(dp5812
g7
I107
sg26
VC0023890
p5813
sg10
I9
sg11
Vcirrhosis
p5814
sg13
I1
sa(dp5815
g7
I156
sg26
VC0036221
p5816
sg10
I31
sg11
Vmixed cryoglobulinemia syndrome
p5817
sg13
I3
sa(dp5818
g7
I56
sg26
VC0019196
p5819
sg10
I11
sg11
Vhepatitis C
p5820
sg13
I2
sa(dp5821
g7
I220
sg26
VC0024305
p5822
sg10
I3
sg11
VNHL
p5823
sg13
I1
sa(dp5824
g7
I150
sg26
VC2239176
p5825
sg10
I3
sg11
VHCC
p5826
sg13
I1
sasa(dp5827
g2
S'The present study was conducted to investigate the expression of COX-2 and IL-32 in primary gastric B-cell lymphoma in order to define their clinical significance and their association with Helicobacter pylori (Hp) infection.\n'
p5828
sg4
(lp5829
(dp5830
g7
I65
sg8
VP35354
p5831
sg10
I5
sg11
VCOX-2
p5832
sg13
I1
sasg23
(lp5833
(dp5834
g7
I100
sg26
VC0079731
p5835
sg10
I15
sg11
VB-cell lymphoma
p5836
sg13
I2
sa(dp5837
g7
I215
sg26
VC0009450
p5838
sg10
I9
sg11
Vinfection
p5839
sg13
I1
sasa(dp5840
g2
S'COX-2 and IL-32 protein expression was detected in 31 primary gastric B-cell lymphoma patients and 19 chronic gastritis patients with immunohistochemistry.\n'
p5841
sg4
(lp5842
(dp5843
g7
I0
sg8
VP35354
p5844
sg10
I5
sg11
VCOX-2
p5845
sg13
I1
sasg23
(lp5846
(dp5847
g7
I70
sg26
VC0079731
p5848
sg10
I15
sg11
VB-cell lymphoma
p5849
sg13
I2
sa(dp5850
g7
I102
sg26
VC0085695
p5851
sg10
I17
sg11
Vchronic gastritis
p5852
sg13
I2
sasa(dp5853
g2
S'These results suggested that Hp infection and the expression of COX-2 and IL-32 were closely linked with each other, and that the overexpression of COX-2 and IL-32 was correlated with tumor progression in primary gastric B-cell lymphoma, thus indicating potential novel therapeutic target.\n'
p5854
sg4
(lp5855
(dp5856
g7
I64
sg8
VP35354
p5857
sg10
I5
sg11
VCOX-2
p5858
sg13
I1
sa(dp5859
g7
I64
sg8
VP35354
p5860
sg10
I5
sg11
VCOX-2
p5861
sg13
I1
sasg23
(lp5862
(dp5863
g7
I221
sg26
VC0079731
p5864
sg10
I15
sg11
VB-cell lymphoma
p5865
sg13
I2
sa(dp5866
g7
I184
sg26
VC0178874
p5867
sg10
I17
sg11
Vtumor progression
p5868
sg13
I2
sa(dp5869
g7
I32
sg26
VC0009450
p5870
sg10
I9
sg11
Vinfection
p5871
sg13
I1
sasa(dp5872
g2
S'Using skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.\n'
p5873
sg4
(lp5874
(dp5875
g7
I175
sg8
VP24001
p5876
sg10
I9
sg11
VIL32 mRNA
p5877
sg13
I2
sasg23
(lp5878
(dp5879
g7
I116
sg26
VC0011615
p5880
sg10
I17
sg11
Vatopic dermatitis
p5881
sg13
I2
sa(dp5882
g7
I38
sg26
VC0026948
p5883
sg10
I17
sg11
Vmycosis fungoides
p5884
sg13
I2
sa(dp5885
g7
I336
sg26
VC0242656
p5886
sg10
I19
sg11
Vdisease progression
p5887
sg13
I2
sa(dp5888
g7
I147
sg26
VC0033860
p5889
sg10
I9
sg11
Vpsoriasis
p5890
sg13
I1
sa(dp5891
g7
I38
sg26
VC0026948
p5892
sg10
I17
sg11
Vmycosis fungoides
p5893
sg13
I2
sa(dp5894
g7
I287
sg26
VC0037274
p5895
sg10
I13
sg11
Vskin diseases
p5896
sg13
I2
sasa(dp5897
g2
S'By IHC and immunofluorescence, we confirmed IL32 protein expression in many CD3(+)CD4(+) T cells and some epidermotropic T cells in mycosis fungoides lesions.\n'
p5898
sg4
(lp5899
(dp5900
g7
I44
sg8
VP24001
p5901
sg10
I12
sg11
VIL32 protein
p5902
sg13
I2
sa(dp5903
g7
I76
sg8
VP01730
p5904
sg10
I9
sg11
VCD3(+)CD4
p5905
sg13
I1
sasg23
(lp5906
(dp5907
g7
I132
sg26
VC0026948
p5908
sg10
I17
sg11
Vmycosis fungoides
p5909
sg13
I2
sasa(dp5910
g2
S'MyLa cells (a mycosis fungoides cell line) express IL32, which, in turn, could promote cellular proliferation and viability in a dose-dependent fashion.\n'
p5911
sg4
(lp5912
(dp5913
g7
I51
sg8
VP24001
p5914
sg10
I4
sg11
VIL32
p5915
sg13
I1
sasg23
(lp5916
(dp5917
g7
I14
sg26
VC0026948
p5918
sg10
I17
sg11
Vmycosis fungoides
p5919
sg13
I2
sa(dp5920
g7
I87
sg26
VC0020507
p5921
sg10
I22
sg11
Vcellular proliferation
p5922
sg13
I2
sasa(dp5923
g2
S'Of the major "polarizing" T-cell cytokines, only IFNGamma mRNA increases with mycosis fungoides progression and positively correlates with IL32 mRNA expression.\n'
p5924
sg4
(lp5925
(dp5926
g7
I139
sg8
VP24001
p5927
sg10
I9
sg11
VIL32 mRNA
p5928
sg13
I2
sasg23
(lp5929
(dp5930
g7
I78
sg26
VC0026948
p5931
sg10
I17
sg11
Vmycosis fungoides
p5932
sg13
I2
sasa(dp5933
g2
S'Th2 cytokines do not positively correlate with IL32 mRNA expression or mycosis fungoides progression.\n'
p5934
sg4
(lp5935
(dp5936
g7
I0
sg8
VP01374
p5937
sg10
I13
sg11
VTh2 cytokines
p5938
sg13
I2
sa(dp5939
g7
I47
sg8
VP24001
p5940
sg10
I9
sg11
VIL32 mRNA
p5941
sg13
I2
sasg23
(lp5942
(dp5943
g7
I71
sg26
VC0026948
p5944
sg10
I17
sg11
Vmycosis fungoides
p5945
sg13
I2
sasa(dp5946
g2
S'In conclusion, we have identified IL32(+) cells as the likely tumor cells in mycosis fungoides, and demonstrated that IL32 mRNA expression increases with mycosis fungoides progression and is significantly higher than mRNA expression in other skin diseases, and that some IL32(+) T cells are independent from the defined Th subsets.\n'
p5947
sg4
(lp5948
(dp5949
g7
I118
sg8
VP24001
p5950
sg10
I9
sg11
VIL32 mRNA
p5951
sg13
I2
sasg23
(lp5952
(dp5953
g7
I77
sg26
VC0026948
p5954
sg10
I17
sg11
Vmycosis fungoides
p5955
sg13
I2
sa(dp5956
g7
I242
sg26
VC0037274
p5957
sg10
I13
sg11
Vskin diseases
p5958
sg13
I2
sa(dp5959
g7
I77
sg26
VC0026948
p5960
sg10
I17
sg11
Vmycosis fungoides
p5961
sg13
I2
sa(dp5962
g7
I62
sg26
VC0027651
p5963
sg10
I5
sg11
Vtumor
p5964
sg13
I1
sasa(dp5965
g2
S'Thus, IL32 may play a unique role in mycosis fungoides progression as an autocrine cytokine.\n'
p5966
sg4
(lp5967
(dp5968
g7
I6
sg8
VP24001
p5969
sg10
I4
sg11
VIL32
p5970
sg13
I1
sasg23
(lp5971
(dp5972
g7
I37
sg26
VC0026948
p5973
sg10
I17
sg11
Vmycosis fungoides
p5974
sg13
I2
sasa(dp5975
g2
S'In this study, we examined the role of IL-32 in cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sezary syndrome (SS).\n'
p5976
sg4
(lp5977
sg23
(lp5978
(dp5979
g7
I75
sg26
VC0079773
p5980
sg10
I4
sg11
VCTCL
p5981
sg13
I1
sa(dp5982
g7
I111
sg26
VC0026948
p5983
sg10
I2
sg11
VMF
p5984
sg13
I1
sa(dp5985
g7
I48
sg26
VC0079773
p5986
sg10
I25
sg11
Vcutaneous T-cell lymphoma
p5987
sg13
I3
sa(dp5988
g7
I92
sg26
VC0026948
p5989
sg10
I17
sg11
Vmycosis fungoides
p5990
sg13
I2
sa(dp5991
g7
I136
sg26
VC0036920
p5992
sg10
I2
sg11
VSS
p5993
sg13
I1
sa(dp5994
g7
I119
sg26
VC0036920
p5995
sg10
I15
sg11
VSezary syndrome
p5996
sg13
I2
sasa(dp5997
g2
S'Microarray analysis showed nonstatistical twofold downregulation of collagen-coding genes (COL4A4, COL8A2, and COL21A1) and a twofold upregulation of the COL6A1, laminin Alfa3 gene LAMA3, and integrin subunit Alfa10 gene ITGA10 in FECD cells.\n'
p5998
sg4
(lp5999
(dp6000
g7
I162
sg8
g64
sg10
I24
sg11
Vlaminin Alfa3 gene LAMA3
p6001
sg13
I4
sa(dp6002
g7
I91
sg8
VP53420
p6003
sg10
I6
sg11
VCOL4A4
p6004
sg13
I1
sa(dp6005
g7
I154
sg8
VP12109
p6006
sg10
I6
sg11
VCOL6A1
p6007
sg13
I1
sa(dp6008
g7
I68
sg8
VP01893
p6009
sg10
I21
sg11
Vcollagen-coding genes
p6010
sg13
I2
sa(dp6011
g7
I111
sg8
g64
sg10
I7
sg11
VCOL21A1
p6012
sg13
I1
sa(dp6013
g7
I99
sg8
VP25067
p6014
sg10
I6
sg11
VCOL8A2
p6015
sg13
I1
sa(dp6016
g7
I192
sg8
g64
sg10
I35
sg11
Vintegrin subunit Alfa10 gene ITGA10
p6017
sg13
I5
sasg23
(lp6018
sa(dp6019
g2
S'To investigate whether the tag single nucleotide polymorphisms (tSNPs) in VSX1, COL4A3, COL4A4, IL1A and IL1B genes were associated with keratoconus (KTCN) in the Han Chinese population.\n'
p6020
sg4
(lp6021
(dp6022
g7
I96
sg8
VP01584
p6023
sg10
I4
sg11
VIL1A
p6024
sg13
I1
sa(dp6025
g7
I88
sg8
VP53420
p6026
sg10
I6
sg11
VCOL4A4
p6027
sg13
I1
sa(dp6028
g7
I105
sg8
VP01584
p6029
sg10
I10
sg11
VIL1B genes
p6030
sg13
I2
sasg23
(lp6031
(dp6032
g7
I150
sg26
VC0022578
p6033
sg10
I4
sg11
VKTCN
p6034
sg13
I1
sa(dp6035
g7
I27
sg26
VC0037293
p6036
sg10
I3
sg11
Vtag
p6037
sg13
I1
sa(dp6038
g7
I137
sg26
VC0022578
p6039
sg10
I11
sg11
Vkeratoconus
p6040
sg13
I1
sasa(dp6041
g2
S'Therefore, a novel liquid chromatography-tandem mass spectrometry assay demonstrated that nitration of the STAT1-Tyr701 occurs in PBMC derived from both pancreatic cancer and melanoma patients.\n'
p6042
sg4
(lp6043
(dp6044
g7
I107
sg8
VP42224
p6045
sg10
I12
sg11
VSTAT1-Tyr701
p6046
sg13
I1
sasg23
(lp6047
(dp6048
g7
I153
sg26
VC0235974
p6049
sg10
I17
sg11
Vpancreatic cancer
p6050
sg13
I2
sa(dp6051
g7
I175
sg26
VC0025202
p6052
sg10
I8
sg11
Vmelanoma
p6053
sg13
I1
sasa(dp6054
g2
S'JAK-STAT inhibitor Ruxolitinib selectively inhibits STAT1 and STAT3 activation and increases CTL infiltration to induce a Tc1/Th1 immune response in the tumor microenvironment in an orthotopic pancreatic cancer mouse model.\n'
p6055
sg4
(lp6056
(dp6057
g7
I4
sg8
g64
sg10
I4
sg11
VSTAT
p6058
sg13
I1
sa(dp6059
g7
I62
sg8
VP40763
p6060
sg10
I5
sg11
VSTAT3
p6061
sg13
I1
sa(dp6062
g7
I52
sg8
VP42224
p6063
sg10
I5
sg11
VSTAT1
p6064
sg13
I1
sa(dp6065
g7
I122
sg8
VP20061
p6066
sg10
I3
sg11
VTc1
p6067
sg13
I1
sasg23
(lp6068
(dp6069
g7
I97
sg26
VC0332448
p6070
sg10
I12
sg11
Vinfiltration
p6071
sg13
I1
sa(dp6072
g7
I193
sg26
VC0235974
p6073
sg10
I17
sg11
Vpancreatic cancer
p6074
sg13
I2
sa(dp6075
g7
I153
sg26
VC0027651
p6076
sg10
I5
sg11
Vtumor
p6077
sg13
I1
sasa(dp6078
g2
S'Bazedoxifene also inhibited STAT3 phosphorylation induced by IL6 and IL11, but not by OSM or STAT1 phosphorylation induced by INFGamma in pancreatic cancer cells, suggesting that Bazedoxifene inhibits the GP130/STAT3 pathway mediated by IL6 and IL11.\n'
p6079
sg4
(lp6080
(dp6081
g7
I205
sg8
VP40189
p6082
sg10
I5
sg11
VGP130
p6083
sg13
I1
sa(dp6084
g7
I86
sg8
VP13725
p6085
sg10
I3
sg11
VOSM
p6086
sg13
I1
sa(dp6087
g7
I69
sg8
VP20809
p6088
sg10
I4
sg11
VIL11
p6089
sg13
I1
sa(dp6090
g7
I69
sg8
VP20809
p6091
sg10
I4
sg11
VIL11
p6092
sg13
I1
sa(dp6093
g7
I28
sg8
VP40763
p6094
sg10
I5
sg11
VSTAT3
p6095
sg13
I1
sa(dp6096
g7
I61
sg8
VP05231
p6097
sg10
I3
sg11
VIL6
p6098
sg13
I1
sa(dp6099
g7
I93
sg8
VP42224
p6100
sg10
I5
sg11
VSTAT1
p6101
sg13
I1
sa(dp6102
g7
I61
sg8
VP05231
p6103
sg10
I3
sg11
VIL6
p6104
sg13
I1
sa(dp6105
g7
I28
sg8
VP40763
p6106
sg10
I5
sg11
VSTAT3
p6107
sg13
I1
sasg23
(lp6108
(dp6109
g7
I138
sg26
VC0235974
p6110
sg10
I17
sg11
Vpancreatic cancer
p6111
sg13
I2
sasa(dp6112
g2
S'In response to cetuximab-coated pancreatic tumor cells, IL-21-treated NK cells secreted significantly higher levels of IFN-Gamma and chemokines, increased chemotaxis of T cells, and enhanced NK cell signal transduction via activation of ERK and STAT1.\n'
p6113
sg4
(lp6114
(dp6115
g7
I245
sg8
VP42224
p6116
sg10
I5
sg11
VSTAT1
p6117
sg13
I1
sa(dp6118
g7
I119
sg8
VP01579
p6119
sg10
I24
sg11
VIFN-Gamma and chemokines
p6120
sg13
I3
sa(dp6121
g7
I237
sg8
VP29323
p6122
sg10
I3
sg11
VERK
p6123
sg13
I1
sasg23
(lp6124
(dp6125
g7
I32
sg26
VC0030297
p6126
sg10
I16
sg11
Vpancreatic tumor
p6127
sg13
I2
sasa(dp6128
g2
S'All patients underwent standardised cycloplegia measurements first by the Pediatric Autorefractor plusoptiX A 08 in 1 metre working distance, then adding an infrared filter to reduce interferences, followed by the Retinomax K-plus 3 in 5 cm working distance and retinoscopy as reference on the right eye.\n'
p6129
sg4
(lp6130
sg23
(lp6131
(dp6132
g7
I36
sg26
VC0235238
p6133
sg10
I11
sg11
Vcycloplegia
p6134
sg13
I1
sasa(dp6135
g2
S'To characterise the presence of a hyperautofluorescent (HAF) ring associated with choroidal neovascularisation (CNV) complex in patients with wet age-related macular degeneration (AMD).\n'
p6136
sg4
(lp6137
sg23
(lp6138
(dp6139
g7
I82
sg26
VC0600518
p6140
sg10
I28
sg11
Vchoroidal neovascularisation
p6141
sg13
I2
sa(dp6142
g7
I146
sg26
VC0242383
p6143
sg10
I32
sg11
Vage-related macular degeneration
p6144
sg13
I3
sa(dp6145
g7
I112
sg26
VC0600518
p6146
sg10
I3
sg11
VCNV
p6147
sg13
I1
sa(dp6148
g7
I180
sg26
VC0242383
p6149
sg10
I3
sg11
VAMD
p6150
sg13
I1
sasa(dp6151
g2
S'In contrast, the role of other plasma enzymes such as kallikrein-kinin-bradykinin, the Hageman factor, peptides and coagulation proteins in drusen formation and ARMD has yet to be determined.\n'
p6152
sg4
(lp6153
(dp6154
g7
I54
sg8
VP06870
p6155
sg10
I27
sg11
Vkallikrein-kinin-bradykinin
p6156
sg13
I1
sasg23
(lp6157
(dp6158
g7
I140
sg26
VC1260959
p6159
sg10
I6
sg11
Vdrusen
p6160
sg13
I1
sa(dp6161
g7
I161
sg26
VC0242383
p6162
sg10
I4
sg11
VARMD
p6163
sg13
I1
sasa(dp6164
g2
S'Lamin B2 knockdown upregulates nucleolar specific 45S rRNA and upstream intergenic transcripts (IGS).\n'
p6165
sg4
(lp6166
(dp6167
g7
I0
sg8
VP49815
p6168
sg10
I5
sg11
VLamin
p6169
sg13
I1
sa(dp6170
g7
I31
sg8
g64
sg10
I27
sg11
Vnucleolar specific 45S rRNA
p6171
sg13
I4
sasg23
(lp6172
(dp6173
g7
I72
sg26
VC1306856
p6174
sg10
I22
sg11
Vintergenic transcripts
p6175
sg13
I2
sa(dp6176
g7
I96
sg26
VC1306856
p6177
sg10
I3
sg11
VIGS
p6178
sg13
I1
sasa(dp6179
g2
S'Approximately seven hundred 45S rRNA genes (rDNA) in the Arabidopsis thaliana genome are organised in two 4 Mbp-long arrays of tandem repeats arranged in head-to-tail fashion separated by an intergenic spacer (IGS).\n'
p6180
sg4
(lp6181
sg23
(lp6182
(dp6183
g7
I210
sg26
VC1306856
p6184
sg10
I3
sg11
VIGS
p6185
sg13
I1
sa(dp6186
g7
I191
sg26
VC1306856
p6187
sg10
I17
sg11
Vintergenic spacer
p6188
sg13
I2
sasa(dp6189
g2
S'Intergenic spacer (IGS) in the length of 2670 bp in which transcription of 45s rRNA precursor starts was found to contain three distinct AT-rich (A + T &gt; 75%) regions.\n'
p6190
sg4
(lp6191
sg23
(lp6192
(dp6193
g7
I19
sg26
VC1306856
p6194
sg10
I3
sg11
VIGS
p6195
sg13
I1
sa(dp6196
g7
I0
sg26
VC1306856
p6197
sg10
I17
sg11
VIntergenic spacer
p6198
sg13
I2
sasa(dp6199
g2
S'In the present study, gingival overgrowth was investigated in transplant patients receiving cyclosporin A (cyclosporin A group) and compared with gingival tissues never exposed to the drug (control group) by analyzing the gene expression of the cell-surface heparan sulfate proteoglycans syndecan-2, syndecan-4 and betaglycan.\n'
p6200
sg4
(lp6201
sg23
(lp6202
sa(dp6203
g2
S'In this study, we analyzed the expression of ICAM-1, VCAM-1, E-selectin and annexin V in primary cultures of human umbilical vein endothelial cells (HUVEC) in response to 10% (v/v) serum of control patients (n = 6), patients with systemic lupus erythematosus (SLE) and no APS (n = 4) or APS patients (n = 9) for 24 h. Total RNA was prepared from confluent endothelial cell layers and mRNA expression of ICAM-1, VCAM-1 and E-selectin was analyzed by reverse transcription polymerase-chain reaction (RT-PCR).\n'
p6204
sg4
(lp6205
(dp6206
g7
I45
sg8
VP05362
p6207
sg10
I6
sg11
VICAM-1
p6208
sg13
I1
sa(dp6209
g7
I76
sg8
VP08758
p6210
sg10
I9
sg11
Vannexin V
p6211
sg13
I2
sa(dp6212
g7
I53
sg8
VP19320
p6213
sg10
I6
sg11
VVCAM-1
p6214
sg13
I1
sa(dp6215
g7
I61
sg8
VP16581
p6216
sg10
I10
sg11
VE-selectin
p6217
sg13
I1
sa(dp6218
g7
I53
sg8
VP19320
p6219
sg10
I6
sg11
VVCAM-1
p6220
sg13
I1
sa(dp6221
g7
I45
sg8
VP05362
p6222
sg10
I6
sg11
VICAM-1
p6223
sg13
I1
sa(dp6224
g7
I61
sg8
VP16581
p6225
sg10
I10
sg11
VE-selectin
p6226
sg13
I1
sasg23
(lp6227
(dp6228
g7
I260
sg26
VC0024141
p6229
sg10
I3
sg11
VSLE
p6230
sg13
I1
sa(dp6231
g7
I272
sg26
VC0085409
p6232
sg10
I3
sg11
VAPS
p6233
sg13
I1
sa(dp6234
g7
I272
sg26
VC0085409
p6235
sg10
I3
sg11
VAPS
p6236
sg13
I1
sa(dp6237
g7
I230
sg26
VC0024141
p6238
sg10
I28
sg11
Vsystemic lupus erythematosus
p6239
sg13
I3
sasa(dp6240
g2
S'Chronic pancreatitis was the most common cause of BBS (35%) and cholecystectomy was the most common cause of leaks.\n'
p6241
sg4
(lp6242
sg23
(lp6243
(dp6244
g7
I0
sg26
VC0149521
p6245
sg10
I20
sg11
VChronic pancreatitis
p6246
sg13
I2
sa(dp6247
g7
I50
sg26
VC0398791
p6248
sg10
I3
sg11
VBBS
p6249
sg13
I1
sasa(dp6250
g2
S'Bardet-Biedl syndrome (BBS; MIM 209900) is a recessive heterogeneous ciliopathy characterized by retinitis pigmentosa (RP), postaxial polydactyly, obesity, hypogonadism, cognitive impairment and kidney dysfunction.\n'
p6251
sg4
(lp6252
sg23
(lp6253
(dp6254
g7
I97
sg26
VC0035334
p6255
sg10
I20
sg11
Vretinitis pigmentosa
p6256
sg13
I2
sa(dp6257
g7
I156
sg26
VC0020619
p6258
sg10
I12
sg11
Vhypogonadism
p6259
sg13
I1
sa(dp6260
g7
I195
sg26
VC0151746
p6261
sg10
I18
sg11
Vkidney dysfunction
p6262
sg13
I2
sa(dp6263
g7
I23
sg26
VC0398791
p6264
sg10
I3
sg11
VBBS
p6265
sg13
I1
sa(dp6266
g7
I124
sg26
VC0220697
p6267
sg10
I21
sg11
Vpostaxial polydactyly
p6268
sg13
I2
sa(dp6269
g7
I147
sg26
VC0028754
p6270
sg10
I7
sg11
Vobesity
p6271
sg13
I1
sa(dp6272
g7
I0
sg26
VC0752166
p6273
sg10
I21
sg11
VBardet-Biedl syndrome
p6274
sg13
I2
sa(dp6275
g7
I170
sg26
VC0338656
p6276
sg10
I20
sg11
Vcognitive impairment
p6277
sg13
I2
sa(dp6278
g7
I119
sg26
VC0035334
p6279
sg10
I2
sg11
VRP
p6280
sg13
I1
sasa(dp6281
g2
S'Whole-exome sequencing was performed in a consanguineous family in which two affected children presented typical BBS features (retinitis pigmentosa, postaxial polydactyly, obesity, hypogonadism and cognitive impairment) without any mutation identified in known BBS genes at the time of the study.\n'
p6282
sg4
(lp6283
sg23
(lp6284
(dp6285
g7
I113
sg26
VC0398791
p6286
sg10
I3
sg11
VBBS
p6287
sg13
I1
sa(dp6288
g7
I181
sg26
VC0020619
p6289
sg10
I12
sg11
Vhypogonadism
p6290
sg13
I1
sa(dp6291
g7
I172
sg26
VC0028754
p6292
sg10
I7
sg11
Vobesity
p6293
sg13
I1
sa(dp6294
g7
I198
sg26
VC0338656
p6295
sg10
I20
sg11
Vcognitive impairment
p6296
sg13
I2
sa(dp6297
g7
I127
sg26
VC0035334
p6298
sg10
I20
sg11
Vretinitis pigmentosa
p6299
sg13
I2
sa(dp6300
g7
I113
sg26
VC0398791
p6301
sg10
I3
sg11
VBBS
p6302
sg13
I1
sa(dp6303
g7
I149
sg26
VC0220697
p6304
sg10
I21
sg11
Vpostaxial polydactyly
p6305
sg13
I2
sasa(dp6306
g2
S'Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder characterized by central obesity, mental impairment, rod-cone dystrophy, polydactyly, hypogonadism in males, and renal abnormalities.\n'
p6307
sg4
(lp6308
sg23
(lp6309
(dp6310
g7
I97
sg26
VC1306341
p6311
sg10
I17
sg11
Vmental impairment
p6312
sg13
I2
sa(dp6313
g7
I23
sg26
VC0398791
p6314
sg10
I3
sg11
VBBS
p6315
sg13
I1
sa(dp6316
g7
I80
sg26
VC0311277
p6317
sg10
I15
sg11
Vcentral obesity
p6318
sg13
I2
sa(dp6319
g7
I116
sg26
VC0035334
p6320
sg10
I18
sg11
Vrod-cone dystrophy
p6321
sg13
I2
sa(dp6322
g7
I149
sg26
VC0020619
p6323
sg10
I12
sg11
Vhypogonadism
p6324
sg13
I1
sa(dp6325
g7
I136
sg26
VC0152427
p6326
sg10
I11
sg11
Vpolydactyly
p6327
sg13
I1
sa(dp6328
g7
I0
sg26
VC0752166
p6329
sg10
I21
sg11
VBardet-Biedl syndrome
p6330
sg13
I2
sasa(dp6331
g2
S'BBS was a significant risk factor for post-ERCP pancreatitis and cholangitis based on a multivariate analysis (OR, 10.732; P=0.0022; OR, 6.443; P=0.0260).\n'
p6332
sg4
(lp6333
sg23
(lp6334
(dp6335
g7
I48
sg26
VC0030305
p6336
sg10
I12
sg11
Vpancreatitis
p6337
sg13
I1
sa(dp6338
g7
I65
sg26
VC0008311
p6339
sg10
I11
sg11
Vcholangitis
p6340
sg13
I1
sa(dp6341
g7
I0
sg26
VC0398791
p6342
sg10
I3
sg11
VBBS
p6343
sg13
I1
sasa(dp6344
g2
S'When a breakdown by etiology of stricture was performed, 14 of 15 (93.3%) patients with chronic pancreatitis, 17 of 19 (89.5%) with gall stone-related disease, 4 of 4 (100%) with surgical procedures, and 2 of 2 (100%) with BBSs of other etiology had resolution at FCSEMS removal.\n'
p6345
sg4
(lp6346
sg23
(lp6347
(dp6348
g7
I88
sg26
VC0149521
p6349
sg10
I20
sg11
Vchronic pancreatitis
p6350
sg13
I2
sa(dp6351
g7
I7
sg26
VC1265875
p6352
sg10
I9
sg11
Vbreakdown
p6353
sg13
I1
sa(dp6354
g7
I32
sg26
VC1261287
p6355
sg10
I9
sg11
Vstricture
p6356
sg13
I1
sasa(dp6357
g2
S'The majority of recent studies of benign biliary strictures (BBSs) have reported on treatment of stenotic injuries following cholecystectomy, orthotopic liver transplantation, living donor liver transplantation, chronic pancreatitis, and different inflammatory conditions such as common bile-duct-related strictures.\n'
p6358
sg4
(lp6359
sg23
(lp6360
(dp6361
g7
I49
sg26
VC1261287
p6362
sg10
I10
sg11
Vstrictures
p6363
sg13
I1
sa(dp6364
g7
I212
sg26
VC0149521
p6365
sg10
I20
sg11
Vchronic pancreatitis
p6366
sg13
I2
sa(dp6367
g7
I41
sg26
VC0597984
p6368
sg10
I18
sg11
Vbiliary strictures
p6369
sg13
I2
sasa(dp6370
g2
S'Bardet-Biedl syndrome (BBS, OMIM 209900) is a rare genetic disorder characterized by obesity, retinitis pigmentosa, post axial polydactyly, cognitive impairment, renal anomalies and hypogonadism.\n'
p6371
sg4
(lp6372
sg23
(lp6373
(dp6374
g7
I127
sg26
VC0152427
p6375
sg10
I11
sg11
Vpolydactyly
p6376
sg13
I1
sa(dp6377
g7
I94
sg26
VC0035334
p6378
sg10
I20
sg11
Vretinitis pigmentosa
p6379
sg13
I2
sa(dp6380
g7
I23
sg26
VC0398791
p6381
sg10
I3
sg11
VBBS
p6382
sg13
I1
sa(dp6383
g7
I162
sg26
VC0266292
p6384
sg10
I15
sg11
Vrenal anomalies
p6385
sg13
I2
sa(dp6386
g7
I0
sg26
VC0752166
p6387
sg10
I21
sg11
VBardet-Biedl syndrome
p6388
sg13
I2
sa(dp6389
g7
I140
sg26
VC0338656
p6390
sg10
I20
sg11
Vcognitive impairment
p6391
sg13
I2
sa(dp6392
g7
I85
sg26
VC0028754
p6393
sg10
I7
sg11
Vobesity
p6394
sg13
I1
sa(dp6395
g7
I51
sg26
VC0019247
p6396
sg10
I16
sg11
Vgenetic disorder
p6397
sg13
I2
sa(dp6398
g7
I182
sg26
VC0020619
p6399
sg10
I12
sg11
Vhypogonadism
p6400
sg13
I1
sasa(dp6401
g2
S'GP 78668A (GP-78) infected BALB/c mouse model of encephalitis and gel zymography was performed for MMP-2 and MMP-9 activities.\n'
p6402
sg4
(lp6403
(dp6404
g7
I109
sg8
VP14780
p6405
sg10
I5
sg11
VMMP-9
p6406
sg13
I1
sa(dp6407
g7
I99
sg8
VP08253
p6408
sg10
I5
sg11
VMMP-2
p6409
sg13
I1
sasg23
(lp6410
(dp6411
g7
I49
sg26
VC0014038
p6412
sg10
I12
sg11
Vencephalitis
p6413
sg13
I1
sasa(dp6414
g2
S"Aging studies in the senescence-accelerated mouse strain (SAM) prone/8 (SAMP8), an animal model of Alzheimer's disease (AD), revealed significantly decreased mRNA and protein expression of AMF and AMFR in the hippocampus.\n"
p6415
sg4
(lp6416
sg23
(lp6417
(dp6418
g7
I58
sg26
VC1563296
p6419
sg10
I3
sg11
VSAM
p6420
sg13
I1
sa(dp6421
g7
I21
sg26
VC1563296
p6422
sg10
I35
sg11
Vsenescence-accelerated mouse strain
p6423
sg13
I3
sa(dp6424
g7
I120
sg26
VC1521724
p6425
sg10
I2
sg11
VAD
p6426
sg13
I1
sa(dp6427
g7
I99
sg26
VC1521724
p6428
sg10
I19
sg11
VAlzheimer's disease
p6429
sg13
I2
sasa(dp6430
g2
S'It also had a full blown clinical picture of neonatal tetanus including: masseter spasm; generalized rigidity; a high pitched cry: and intermittent opisthotonos posturing.\n'
p6431
sg4
(lp6432
sg23
(lp6433
(dp6434
g7
I82
sg26
VC0037763
p6435
sg10
I5
sg11
Vspasm
p6436
sg13
I1
sa(dp6437
g7
I161
sg26
VC0872410
p6438
sg10
I9
sg11
Vposturing
p6439
sg13
I1
sa(dp6440
g7
I101
sg26
VC0026837
p6441
sg10
I8
sg11
Vrigidity
p6442
sg13
I1
sa(dp6443
g7
I148
sg26
VC0151818
p6444
sg10
I12
sg11
Vopisthotonos
p6445
sg13
I1
sa(dp6446
g7
I54
sg26
VC0039614
p6447
sg10
I7
sg11
Vtetanus
p6448
sg13
I1
sasa(dp6449
g2
S'The aim of this study was to investigate the expression of some main components of Wnt/Beta-catenin signaling including WNT7a, DKK-1, Beta-catenin, and GSK-3Beta in eutopic endometrium and peritoneal endometriotic lesions of endometriosis patients compared to healthy endometrium in the mid-secretory phase of menstrual cycle.\n'
p6450
sg4
(lp6451
(dp6452
g7
I152
sg8
VP49841
p6453
sg10
I9
sg11
VGSK-3Beta
p6454
sg13
I1
sa(dp6455
g7
I87
sg8
VP35222
p6456
sg10
I12
sg11
VBeta-catenin
p6457
sg13
I1
sa(dp6458
g7
I127
sg8
g64
sg10
I5
sg11
VDKK-1
p6459
sg13
I1
sa(dp6460
g7
I120
sg8
g64
sg10
I5
sg11
VWNT7a
p6461
sg13
I1
sa(dp6462
g7
I87
sg8
VP35222
p6463
sg10
I12
sg11
VBeta-catenin
p6464
sg13
I1
sasg23
(lp6465
(dp6466
g7
I225
sg26
VC0014175
p6467
sg10
I13
sg11
Vendometriosis
p6468
sg13
I1
sasa(dp6469
g2
S'We also demonstrated that the expression of non-phosphorylated Beta-catenin (active form) and phosphorylated GSK-3Beta (inactive form) were up-regulated in endometriosis patients.\n'
p6470
sg4
(lp6471
(dp6472
g7
I63
sg8
VP35222
p6473
sg10
I12
sg11
VBeta-catenin
p6474
sg13
I1
sa(dp6475
g7
I109
sg8
VP49841
p6476
sg10
I9
sg11
VGSK-3Beta
p6477
sg13
I1
sasg23
(lp6478
(dp6479
g7
I156
sg26
VC0014175
p6480
sg10
I13
sg11
Vendometriosis
p6481
sg13
I1
sasa(dp6482
g2
S'The mRNA levels of Beta-catenin, GSK-3Beta, and WNT7a, as well as the protein levels of total Beta-catenin, total GSK-3Beta, and WNT7a in endometriosis group, were not significantly different with those in control group.\n'
p6483
sg4
(lp6484
(dp6485
g7
I48
sg8
g64
sg10
I5
sg11
VWNT7a
p6486
sg13
I1
sa(dp6487
g7
I19
sg8
VP35222
p6488
sg10
I12
sg11
VBeta-catenin
p6489
sg13
I1
sa(dp6490
g7
I33
sg8
VP49841
p6491
sg10
I9
sg11
VGSK-3Beta
p6492
sg13
I1
sa(dp6493
g7
I33
sg8
VP49841
p6494
sg10
I9
sg11
VGSK-3Beta
p6495
sg13
I1
sa(dp6496
g7
I48
sg8
g64
sg10
I5
sg11
VWNT7a
p6497
sg13
I1
sa(dp6498
g7
I19
sg8
VP35222
p6499
sg10
I12
sg11
VBeta-catenin
p6500
sg13
I1
sasg23
(lp6501
(dp6502
g7
I138
sg26
VC0014175
p6503
sg10
I13
sg11
Vendometriosis
p6504
sg13
I1
sasa(dp6505
g2
S'It seems that the aberrant activation of Wnt/Beta-catenin signaling in the secretory phase of the menstrual cycle in endometriosis has two essential elements: excessive inactivation of GSK-3Beta and suppression of the expression of Wnt signaling inhibitor DKK-1.\n'
p6506
sg4
(lp6507
(dp6508
g7
I246
sg8
g64
sg10
I15
sg11
Vinhibitor DKK-1
p6509
sg13
I2
sa(dp6510
g7
I45
sg8
VP35222
p6511
sg10
I12
sg11
VBeta-catenin
p6512
sg13
I1
sa(dp6513
g7
I185
sg8
VP49841
p6514
sg10
I9
sg11
VGSK-3Beta
p6515
sg13
I1
sasg23
(lp6516
(dp6517
g7
I117
sg26
VC0014175
p6518
sg10
I13
sg11
Vendometriosis
p6519
sg13
I1
sa(dp6520
g7
I169
sg26
VC0544461
p6521
sg10
I12
sg11
Vinactivation
p6522
sg13
I1
sa(dp6523
g7
I199
sg26
VC0221103
p6524
sg10
I11
sg11
Vsuppression
p6525
sg13
I1
sasa(dp6526
g2
S'Down-regulation of E-cadherin expression may activate the Wnt/Beta-catenin pathway in endometrial cells, which may together participate in the occurrence of endometriosis.\n'
p6527
sg4
(lp6528
(dp6529
g7
I19
sg8
VP12830
p6530
sg10
I10
sg11
VE-cadherin
p6531
sg13
I1
sasg23
(lp6532
(dp6533
g7
I157
sg26
VC0014175
p6534
sg10
I13
sg11
Vendometriosis
p6535
sg13
I1
sasa(dp6536
g2
S'Additionally, genetic mutations including PTEN, PIK3CA, ARID1A, Wnt/Beta-catenin, microsatellite instability, Src, and KRAS have been shown to be critical in the pathogenesis of endometriosis associated ovarian cancers.\n'
p6537
sg4
(lp6538
(dp6539
g7
I42
sg8
VP60484
p6540
sg10
I4
sg11
VPTEN
p6541
sg13
I1
sa(dp6542
g7
I48
sg8
VP42336
p6543
sg10
I6
sg11
VPIK3CA
p6544
sg13
I1
sa(dp6545
g7
I119
sg8
VP01116
p6546
sg10
I4
sg11
VKRAS
p6547
sg13
I1
sa(dp6548
g7
I68
sg8
VP35222
p6549
sg10
I12
sg11
VBeta-catenin
p6550
sg13
I1
sa(dp6551
g7
I110
sg8
VP12931
p6552
sg10
I3
sg11
VSrc
p6553
sg13
I1
sa(dp6554
g7
I82
sg8
g64
sg10
I26
sg11
Vmicrosatellite instability
p6555
sg13
I2
sasg23
(lp6556
(dp6557
g7
I178
sg26
VC0014175
p6558
sg10
I13
sg11
Vendometriosis
p6559
sg13
I1
sa(dp6560
g7
I162
sg26
VC0699748
p6561
sg10
I12
sg11
Vpathogenesis
p6562
sg13
I1
sa(dp6563
g7
I82
sg26
VC0920269
p6564
sg10
I26
sg11
Vmicrosatellite instability
p6565
sg13
I2
sa(dp6566
g7
I203
sg26
VC1140680
p6567
sg10
I15
sg11
Vovarian cancers
p6568
sg13
I2
sasa(dp6569
g2
S'The present study investigated the role of S100A6 in endometriosis and its interaction with Beta-catenin by transfecting eutopic endometrial stromal cells with a recombinant lentivirus containing S100A6-specific small interfering RNA.\n'
p6570
sg4
(lp6571
(dp6572
g7
I43
sg8
VP06703
p6573
sg10
I6
sg11
VS100A6
p6574
sg13
I1
sa(dp6575
g7
I43
sg8
VP06703
p6576
sg10
I6
sg11
VS100A6
p6577
sg13
I1
sa(dp6578
g7
I92
sg8
VP35222
p6579
sg10
I12
sg11
VBeta-catenin
p6580
sg13
I1
sasg23
(lp6581
(dp6582
g7
I53
sg26
VC0014175
p6583
sg10
I13
sg11
Vendometriosis
p6584
sg13
I1
sasa(dp6585
g2
S'When the cAMP-PDIE inhibitor 1-methyl-3-isobutyl xanthine (MIX) was added to the above incubation, VP caused a significant increase in cAMP levels in MCT from both NDI mice and control mice.\n'
p6586
sg4
(lp6587
(dp6588
g7
I9
sg8
VP49913
p6589
sg10
I9
sg11
VcAMP-PDIE
p6590
sg13
I1
sasg23
(lp6591
(dp6592
g7
I164
sg26
VC1563705
p6593
sg10
I3
sg11
VNDI
p6594
sg13
I1
sasa(dp6595
g2
S'Under the present experimental setting, VP and other stimulating factors (MIX, cholera toxin) did not change cAMP levels in MAL from either control mice or from NDI mice.\n'
p6596
sg4
(lp6597
sg23
(lp6598
(dp6599
g7
I161
sg26
VC1563705
p6600
sg10
I3
sg11
VNDI
p6601
sg13
I1
sa(dp6602
g7
I79
sg26
VC0008354
p6603
sg10
I7
sg11
Vcholera
p6604
sg13
I1
sasa(dp6605
g2
S'Even when the cAMP response to AVP is partly corrected by cAMP-PDIE inhibitor 1-methyl-3-isobutylxanthine (MIX), under all tested conditions the cAMP levels in MCT of NDI mice remained much lower than in controls (B.\n'
p6606
sg4
(lp6607
(dp6608
g7
I58
sg8
VP49913
p6609
sg10
I9
sg11
VcAMP-PDIE
p6610
sg13
I1
sa(dp6611
g7
I31
sg8
VP01185
p6612
sg10
I3
sg11
VAVP
p6613
sg13
I1
sasg23
(lp6614
(dp6615
g7
I167
sg26
VC1563705
p6616
sg10
I3
sg11
VNDI
p6617
sg13
I1
sasa(dp6618
g2
S'In the presence of 1 microM AVP and 0.05 mM MIX, the cAMP levels accumulated in MCT of NDI mice were four times lower compared with controls, but the levels of ATP and NAD were not different.\n'
p6619
sg4
(lp6620
(dp6621
g7
I21
sg8
VP01185
p6622
sg10
I10
sg11
VmicroM AVP
p6623
sg13
I2
sasg23
(lp6624
(dp6625
g7
I87
sg26
VC1563705
p6626
sg10
I3
sg11
VNDI
p6627
sg13
I1
sa(dp6628
g7
I168
sg26
VC1850380
p6629
sg10
I3
sg11
VNAD
p6630
sg13
I1
sasa(dp6631
g2
S'In turn in the pylorus we have observed 15.91% +/- 0.58% nNOS containing neurons in control animals and 35.38% +/- 1.54% in the diabetes group (increase by 122.37%).\n'
p6632
sg4
(lp6633
sg23
(lp6634
(dp6635
g7
I128
sg26
VC0011849
p6636
sg10
I8
sg11
Vdiabetes
p6637
sg13
I1
sasa(dp6638
g2
S'To determine the effects of supervised structured aerobic exercise training (SSAET) program on interleukin-6 (IL-6), nitric oxide synthase 1 (NOS-1), and cyclooxygenase-2 (COX-2) in type 2 diabetes mellitus (T2DM).\n'
p6639
sg4
(lp6640
(dp6641
g7
I110
sg8
VP05231
p6642
sg10
I4
sg11
VIL-6
p6643
sg13
I1
sa(dp6644
g7
I154
sg8
VP35354
p6645
sg10
I16
sg11
Vcyclooxygenase-2
p6646
sg13
I1
sa(dp6647
g7
I172
sg8
VP35354
p6648
sg10
I5
sg11
VCOX-2
p6649
sg13
I1
sa(dp6650
g7
I142
sg8
g64
sg10
I5
sg11
VNOS-1
p6651
sg13
I1
sa(dp6652
g7
I117
sg8
VP29475
p6653
sg10
I23
sg11
Vnitric oxide synthase 1
p6654
sg13
I4
sa(dp6655
g7
I95
sg8
VP05231
p6656
sg10
I13
sg11
Vinterleukin-6
p6657
sg13
I1
sasg23
(lp6658
(dp6659
g7
I208
sg26
VC0011860
p6660
sg10
I4
sg11
VT2DM
p6661
sg13
I1
sa(dp6662
g7
I182
sg26
VC0011860
p6663
sg10
I24
sg11
Vtype 2 diabetes mellitus
p6664
sg13
I4
sasa(dp6665
g2
S'The pathogenesis of diabetes-associated motility disorders are multifactorial and attributed to abnormalities in extrinsic and intrinsic innervation, and a decrease in the number of interstitial cells of Cajal, and nNOS expression and activity.\n'
p6666
sg4
(lp6667
(dp6668
g7
I215
sg8
VP29475
p6669
sg10
I4
sg11
VnNOS
p6670
sg13
I1
sasg23
(lp6671
(dp6672
g7
I20
sg26
VC0011849
p6673
sg10
I8
sg11
Vdiabetes
p6674
sg13
I1
sa(dp6675
g7
I4
sg26
VC0699748
p6676
sg10
I12
sg11
Vpathogenesis
p6677
sg13
I1
sasa(dp6678
g2
S'Differentially methylated genes were enriched in several neuroendocrine signaling pathways including dopamine-DARPP32 feedback (appetite, reward pathways), corticotrophin releasing hormone signaling, nNOS, neuregulin signaling, mTOR signaling, and type II diabetes mellitus signaling.\n'
p6679
sg4
(lp6680
(dp6681
g7
I228
sg8
VP42345
p6682
sg10
I4
sg11
VmTOR
p6683
sg13
I1
sa(dp6684
g7
I156
sg8
VP01189
p6685
sg10
I32
sg11
Vcorticotrophin releasing hormone
p6686
sg13
I3
sa(dp6687
g7
I200
sg8
VP29475
p6688
sg10
I4
sg11
VnNOS
p6689
sg13
I1
sa(dp6690
g7
I206
sg8
g64
sg10
I10
sg11
Vneuregulin
p6691
sg13
I1
sa(dp6692
g7
I101
sg8
g64
sg10
I16
sg11
Vdopamine-DARPP32
p6693
sg13
I1
sasg23
(lp6694
(dp6695
g7
I248
sg26
VC0011860
p6696
sg10
I25
sg11
Vtype II diabetes mellitus
p6697
sg13
I4
sasa(dp6698
g2
S'Altogether, our data support the hypothesis that a dysregulation in the NO production in brain areas as AMY, HIP and dlPAG may contribute to the mechanisms that link anxiety and diabetes, and the prevention of nNOS brain expression changes induced by a prolonged treatment with FO may be an important mechanism related to its anxiolytic-like effect.\n'
p6699
sg4
(lp6700
(dp6701
g7
I109
sg8
VP47914
p6702
sg10
I3
sg11
VHIP
p6703
sg13
I1
sa(dp6704
g7
I104
sg8
g64
sg10
I3
sg11
VAMY
p6705
sg13
I1
sasg23
(lp6706
(dp6707
g7
I178
sg26
VC0011849
p6708
sg10
I8
sg11
Vdiabetes
p6709
sg13
I1
sasa(dp6710
g2
S'The aim of this study was to determine the effect of melatonin on brain apoptosis, oxidative stress, and CD200 molecule in mice and neuroblastoma cultures infected by Venezuelan equine encephalitis virus.\n'
p6711
sg4
(lp6712
(dp6713
g7
I105
sg8
VP41217
p6714
sg10
I14
sg11
VCD200 molecule
p6715
sg13
I2
sasg23
(lp6716
(dp6717
g7
I132
sg26
VC0027819
p6718
sg10
I13
sg11
Vneuroblastoma
p6719
sg13
I1
sa(dp6720
g7
I83
sg26
VC0242606
p6721
sg10
I16
sg11
Voxidative stress
p6722
sg13
I2
sa(dp6723
g7
I167
sg26
VC0014078
p6724
sg10
I30
sg11
VVenezuelan equine encephalitis
p6725
sg13
I3
sasa(dp6726
g2
S'In addition, infected neuroblastoma cell cultures (multiplicity of infection [MOI]: 1) were treated with 0, 0.1, 0.5, and 1 mM of melatonin and analyzed at 2, 4, and 6 h. CD200 and apoptosis expressions were analyzed by immunohistochemistry and TUNEL assay, respectively.\n'
p6727
sg4
(lp6728
(dp6729
g7
I171
sg8
VP41217
p6730
sg10
I5
sg11
VCD200
p6731
sg13
I1
sasg23
(lp6732
(dp6733
g7
I67
sg26
VC0009450
p6734
sg10
I9
sg11
Vinfection
p6735
sg13
I1
sa(dp6736
g7
I22
sg26
VC0027819
p6737
sg10
I13
sg11
Vneuroblastoma
p6738
sg13
I1
sasa(dp6739
g2
S"A number of pathogens have been found to modulate the CD200-CD200R pathway during infection, including human herpesvirus 8 (HHV-8), the causative agent of Kaposi's sarcoma and B cell neoplasms in AIDS patients, and a closely related primate virus, rhesus macaque rhadinovirus (RRV), which infects and induces disease in rhesus macaque monkeys.\n"
p6740
sg4
(lp6741
(dp6742
g7
I54
sg8
VP41217
p6743
sg10
I5
sg11
VCD200
p6744
sg13
I1
sasg23
(lp6745
(dp6746
g7
I155
sg26
VC0036220
p6747
sg10
I16
sg11
VKaposi's sarcoma
p6748
sg13
I2
sa(dp6749
g7
I183
sg26
VC0027651
p6750
sg10
I9
sg11
Vneoplasms
p6751
sg13
I1
sa(dp6752
g7
I82
sg26
VC0009450
p6753
sg10
I9
sg11
Vinfection
p6754
sg13
I1
sasa(dp6755
g2
S"Through the study of the viral OX2 (vOX2) immunoregulator encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), we have identified a T cell-attenuating role both for this protein and for CD200, a cellular orthologue of the viral vOX2 protein.\n"
p6756
sg4
(lp6757
(dp6758
g7
I192
sg8
VP41217
p6759
sg10
I5
sg11
VCD200
p6760
sg13
I1
sa(dp6761
g7
I36
sg8
VP41217
p6762
sg10
I4
sg11
VvOX2
p6763
sg13
I1
sa(dp6764
g7
I25
sg8
VP41217
p6765
sg10
I9
sg11
Vviral OX2
p6766
sg13
I2
sa(dp6767
g7
I36
sg8
VP41217
p6768
sg10
I4
sg11
VvOX2
p6769
sg13
I1
sasg23
(lp6770
(dp6771
g7
I69
sg26
VC0036220
p6772
sg10
I16
sg11
VKaposi's sarcoma
p6773
sg13
I2
sasa(dp6774
g2
S'CD200 protein was expressed on the surface of 5/8 ovarian cancer, 2/4 melanoma, 2/2 neuroblastoma and 2/3 renal carcinoma cell lines tested, but CD200 was absent on prostate, lung, breast, astrocytoma, or glioblastoma cell lines.\n'
p6775
sg4
(lp6776
(dp6777
g7
I0
sg8
VP41217
p6778
sg10
I5
sg11
VCD200
p6779
sg13
I1
sa(dp6780
g7
I0
sg8
VP41217
p6781
sg10
I13
sg11
VCD200 protein
p6782
sg13
I2
sasg23
(lp6783
(dp6784
g7
I106
sg26
VC0007134
p6785
sg10
I15
sg11
Vrenal carcinoma
p6786
sg13
I2
sa(dp6787
g7
I70
sg26
VC0025202
p6788
sg10
I8
sg11
Vmelanoma
p6789
sg13
I1
sa(dp6790
g7
I205
sg26
VC0017636
p6791
sg10
I12
sg11
Vglioblastoma
p6792
sg13
I1
sa(dp6793
g7
I189
sg26
VC0004114
p6794
sg10
I11
sg11
Vastrocytoma
p6795
sg13
I1
sa(dp6796
g7
I50
sg26
VC1140680
p6797
sg10
I14
sg11
Vovarian cancer
p6798
sg13
I2
sa(dp6799
g7
I84
sg26
VC0027819
p6800
sg10
I13
sg11
Vneuroblastoma
p6801
sg13
I1
sasa(dp6802
g2
S'Within hPIV4 cases, distributions of diseases were; pneumonia (21 %, 95 % CI 17.1-25.7), bronchiolitis (18 %, 95 % CI 14.3-22.5), croup (2 %, 95 % CI 0.8-3.9), mixed illness of any of pneumonia, bronchiolitis or croup (4 %, 95 % CI 2.5-7.0) or other respiratory diseases (54 %, 95 % CI 49.1-59.6).\n'
p6803
sg4
(lp6804
sg23
(lp6805
(dp6806
g7
I130
sg26
VC0010380
p6807
sg10
I5
sg11
Vcroup
p6808
sg13
I1
sa(dp6809
g7
I52
sg26
VC0032285
p6810
sg10
I9
sg11
Vpneumonia
p6811
sg13
I1
sa(dp6812
g7
I52
sg26
VC0032285
p6813
sg10
I9
sg11
Vpneumonia
p6814
sg13
I1
sa(dp6815
g7
I130
sg26
VC0010380
p6816
sg10
I5
sg11
Vcroup
p6817
sg13
I1
sa(dp6818
g7
I89
sg26
VC0006271
p6819
sg10
I13
sg11
Vbronchiolitis
p6820
sg13
I1
sa(dp6821
g7
I250
sg26
VC0035204
p6822
sg10
I20
sg11
Vrespiratory diseases
p6823
sg13
I2
sa(dp6824
g7
I89
sg26
VC0006271
p6825
sg10
I13
sg11
Vbronchiolitis
p6826
sg13
I1
sasa(dp6827
g2
S'Of these, 43 (37.4 %) hospitalized patients [26 males (60.5 %, 95 % CI 45.9 %-75.1 %) and 17 females (39.5 %, 95 % CI 24.9 %-54.1 %)] with mean age of 66.2 +/- 13.4 years had pneumonia triggered by S. marcescens, while 20 (17.4 %) patients [14 males (70 %, 95 % CI 49.9 %-90.1 %) and 6 females (30 %, 95 % CI 9.9 %-50.1 %)] with a mean age of 64.6 +/- 12.8 years had pneumonia caused by P. mirabilis.\n'
p6828
sg4
(lp6829
sg23
(lp6830
(dp6831
g7
I175
sg26
VC0032285
p6832
sg10
I9
sg11
Vpneumonia
p6833
sg13
I1
sa(dp6834
g7
I175
sg26
VC0032285
p6835
sg10
I9
sg11
Vpneumonia
p6836
sg13
I1
sasa(dp6837
g2
S'Moreover, HBD3-C15 showed antimicrobial activity by inhibiting biofilm formation by S. mutans and other dentinophilic bacteria such as Enterococcus faecalis and Streptococcus gordonii, which are associated with dental caries and endodontic infection, on human dentin slices.\n'
p6838
sg4
(lp6839
(dp6840
g7
I15
sg8
g64
sg10
I3
sg11
VC15
p6841
sg13
I1
sa(dp6842
g7
I10
sg8
VP81534
p6843
sg10
I4
sg11
VHBD3
p6844
sg13
I1
sasg23
(lp6845
(dp6846
g7
I240
sg26
VC0009450
p6847
sg10
I9
sg11
Vinfection
p6848
sg13
I1
sa(dp6849
g7
I211
sg26
VC0333519
p6850
sg10
I13
sg11
Vdental caries
p6851
sg13
I2
sasa(dp6852
g2
S'Therefore, we suggest that HBD3-C15 is a potential alternative or additive disinfectant that can be used for the treatment of oral infectious diseases, including dental caries and endodontic infections.\n'
p6853
sg4
(lp6854
(dp6855
g7
I27
sg8
VP81534
p6856
sg10
I4
sg11
VHBD3
p6857
sg13
I1
sa(dp6858
g7
I32
sg8
g64
sg10
I3
sg11
VC15
p6859
sg13
I1
sasg23
(lp6860
(dp6861
g7
I131
sg26
VC0009450
p6862
sg10
I19
sg11
Vinfectious diseases
p6863
sg13
I2
sa(dp6864
g7
I162
sg26
VC0333519
p6865
sg10
I13
sg11
Vdental caries
p6866
sg13
I2
sa(dp6867
g7
I191
sg26
VC0021311
p6868
sg10
I10
sg11
Vinfections
p6869
sg13
I1
sasa(dp6870
g2
S'HBD-3 may potentially be applied in the treatment of periodontitis and may function as osteogenic promoter via its anti-inflammatory effect.\n'
p6871
sg4
(lp6872
(dp6873
g7
I0
sg8
VP81534
p6874
sg10
I5
sg11
VHBD-3
p6875
sg13
I1
sasg23
(lp6876
(dp6877
g7
I53
sg26
VC0031099
p6878
sg10
I13
sg11
Vperiodontitis
p6879
sg13
I1
sa(dp6880
g7
I0
sg26
VC1840321
p6881
sg10
I3
sg11
VHBD
p6882
sg13
I1
sasa(dp6883
g2
S'The present study assessed the effects of hBD3 as a monotherapy for periodontitis in mice and explored its potential mechanism.\n'
p6884
sg4
(lp6885
(dp6886
g7
I42
sg8
VP81534
p6887
sg10
I4
sg11
VhBD3
p6888
sg13
I1
sasg23
(lp6889
(dp6890
g7
I68
sg26
VC0031099
p6891
sg10
I13
sg11
Vperiodontitis
p6892
sg13
I1
sasa(dp6893
g2
S'In vivo, hBD3 inhibited the levels of tumour necrosis factor (TNF)-Alfa, interleukin-6, and matrix metalloprotease-9 in periodontium exposed to Porphyromonas gingivalis (P.g) in a mouse periodontitis model; reduced osteoclast formation and lower alveolar bone loss were also observed.\n'
p6894
sg4
(lp6895
(dp6896
g7
I38
sg8
VP01375
p6897
sg10
I33
sg11
Vtumour necrosis factor (TNF)-Alfa
p6898
sg13
I4
sa(dp6899
g7
I92
sg8
g64
sg10
I24
sg11
Vmatrix metalloprotease-9
p6900
sg13
I2
sa(dp6901
g7
I73
sg8
VP05231
p6902
sg10
I13
sg11
Vinterleukin-6
p6903
sg13
I1
sa(dp6904
g7
I9
sg8
VP81534
p6905
sg10
I4
sg11
VhBD3
p6906
sg13
I1
sasg23
(lp6907
(dp6908
g7
I38
sg26
VC0333516
p6909
sg10
I15
sg11
Vtumour necrosis
p6910
sg13
I2
sa(dp6911
g7
I186
sg26
VC0031099
p6912
sg10
I13
sg11
Vperiodontitis
p6913
sg13
I1
sa(dp6914
g7
I246
sg26
VC0002382
p6915
sg10
I18
sg11
Valveolar bone loss
p6916
sg13
I3
sasa(dp6917
g2
S'In conclusion, hBD3 exhibits potent anti-periodontitis properties both in vitro and in vivo, and this effect may be correlated to inhibition of the nuclear factor-KB pathway and macrophage polarization.\n'
p6918
sg4
(lp6919
(dp6920
g7
I15
sg8
VP81534
p6921
sg10
I4
sg11
VhBD3
p6922
sg13
I1
sasg23
(lp6923
(dp6924
g7
I41
sg26
VC0031099
p6925
sg10
I13
sg11
Vperiodontitis
p6926
sg13
I1
sasa(dp6927
g2
S'The expression of epithelium- and neutrophil-derived host defense peptides (HDPs) (LL-37 and human Beta-defensin-3), which activate mast cells via Mas-related G protein-coupled receptor X2 (MRGPRX2), is increased in periodontitis.\n'
p6928
sg4
(lp6929
(dp6930
g7
I190
sg8
g64
sg10
I7
sg11
VMRGPRX2
p6931
sg13
I1
sa(dp6932
g7
I147
sg8
g64
sg10
I41
sg11
VMas-related G protein-coupled receptor X2
p6933
sg13
I5
sa(dp6934
g7
I99
sg8
VP81534
p6935
sg10
I15
sg11
VBeta-defensin-3
p6936
sg13
I1
sasg23
(lp6937
(dp6938
g7
I147
sg26
VC0242292
p6939
sg10
I3
sg11
VMas
p6940
sg13
I1
sa(dp6941
g7
I216
sg26
VC0031099
p6942
sg10
I13
sg11
Vperiodontitis
p6943
sg13
I1
sasa(dp6944
g2
S'The lentiviral vector containing HBD-3 resulted in broad-spectrum antimicrobial activity against a variety of oral organisms, and could potentially be applied in the treatment of oral infectious diseases, including periodontitis.\n'
p6945
sg4
(lp6946
(dp6947
g7
I33
sg8
VP81534
p6948
sg10
I5
sg11
VHBD-3
p6949
sg13
I1
sasg23
(lp6950
(dp6951
g7
I33
sg26
VC1840321
p6952
sg10
I3
sg11
VHBD
p6953
sg13
I1
sa(dp6954
g7
I215
sg26
VC0031099
p6955
sg10
I13
sg11
Vperiodontitis
p6956
sg13
I1
sa(dp6957
g7
I184
sg26
VC0009450
p6958
sg10
I19
sg11
Vinfectious diseases
p6959
sg13
I2
sasa(dp6960
g2
S'In mice infected with the A/E pathogen Citrobacter rodentium, co-infection with Giardia muris significantly attenuated weight loss, macro- and microscopic signs of colitis, bacterial colonization and translocation, while concurrently enhancing the production and secretion of antimicrobial peptides (AMPs) mouse Beta-defensin 3 and trefoil factor 3 (TFF3).\n'
p6961
sg4
(lp6962
(dp6963
g7
I312
sg8
VP81534
p6964
sg10
I15
sg11
VBeta-defensin 3
p6965
sg13
I2
sa(dp6966
g7
I332
sg8
g64
sg10
I16
sg11
Vtrefoil factor 3
p6967
sg13
I3
sa(dp6968
g7
I350
sg8
g64
sg10
I4
sg11
VTFF3
p6969
sg13
I1
sasg23
(lp6970
(dp6971
g7
I164
sg26
VC0009319
p6972
sg10
I7
sg11
Vcolitis
p6973
sg13
I1
sa(dp6974
g7
I200
sg26
VC0040715
p6975
sg10
I13
sg11
Vtranslocation
p6976
sg13
I1
sa(dp6977
g7
I62
sg26
VC0275524
p6978
sg10
I12
sg11
Vco-infection
p6979
sg13
I1
sa(dp6980
g7
I80
sg26
VC0017536
p6981
sg10
I7
sg11
VGiardia
p6982
sg13
I1
sasa(dp6983
g2
S'Our results indicate that vitamin D specifically enhances the production of the human-Beta-defensin 3 antimicrobial peptide and exerts an inhibitory effect on the pro-inflammatory cytokines, thus suggesting that vitamin D may offer possible therapeutic applications for periodontitis.\n'
p6984
sg4
(lp6985
(dp6986
g7
I80
sg8
VP81534
p6987
sg10
I21
sg11
Vhuman-Beta-defensin 3
p6988
sg13
I2
sasg23
(lp6989
(dp6990
g7
I270
sg26
VC0031099
p6991
sg10
I13
sg11
Vperiodontitis
p6992
sg13
I1
sasa(dp6993
g2
S'When the ARTEMIS scale, which is specific to peripheral arterial occlusive disease, was developed in 1993, there were 400 scales in existence.\n'
p6994
sg4
(lp6995
sg23
(lp6996
(dp6997
g7
I45
sg26
VC1306889
p6998
sg10
I37
sg11
Vperipheral arterial occlusive disease
p6999
sg13
I4
sasa(dp7000
g2
S'The ARTEMIS questionnaire was validated in 177 patients with intermittent claudication (phases IIa and IIb of the Leriche and Fontaine classification).\n'
p7001
sg4
(lp7002
sg23
(lp7003
(dp7004
g7
I61
sg26
VC0021775
p7005
sg10
I25
sg11
Vintermittent claudication
p7006
sg13
I2
sasa(dp7007
g2
S'The objective of this study was to investigate if there is a correlation between the levels of PIMs in disc material and myelopathy associated with cervical intervertebral disc herniation and spondylosis.\n'
p7008
sg4
(lp7009
sg23
(lp7010
(dp7011
g7
I192
sg26
VC0038019
p7012
sg10
I11
sg11
Vspondylosis
p7013
sg13
I1
sa(dp7014
g7
I121
sg26
VC0037928
p7015
sg10
I10
sg11
Vmyelopathy
p7016
sg13
I1
sa(dp7017
g7
I157
sg26
VC0242362
p7018
sg10
I30
sg11
Vintervertebral disc herniation
p7019
sg13
I3
sasa(dp7020
g2
S'However, the possible relationship between PIMs and myelopathy related to cervical disc herniation and spondylosis has not been investigated before.\n'
p7021
sg4
(lp7022
sg23
(lp7023
(dp7024
g7
I74
sg26
VC0410619
p7025
sg10
I24
sg11
Vcervical disc herniation
p7026
sg13
I3
sa(dp7027
g7
I103
sg26
VC0038019
p7028
sg10
I11
sg11
Vspondylosis
p7029
sg13
I1
sa(dp7030
g7
I52
sg26
VC0037928
p7031
sg10
I10
sg11
Vmyelopathy
p7032
sg13
I1
sasa(dp7033
g2
S'This study has demonstrated that PIMs are involved in cervical intervertebral disc degeneration with higher concentrations in the samples associated with myelopathy.\n'
p7034
sg4
(lp7035
sg23
(lp7036
(dp7037
g7
I63
sg26
VC0158266
p7038
sg10
I32
sg11
Vintervertebral disc degeneration
p7039
sg13
I3
sa(dp7040
g7
I154
sg26
VC0037928
p7041
sg10
I10
sg11
Vmyelopathy
p7042
sg13
I1
sasa(dp7043
g2
S'The main aetiologies of acute myelopathy (AM) are: multiple sclerosis, systemic disease (SD), spinal cord infarct (SCI), parainfectious myelopathy (PIM) and delayed radiation myelopathy (DRM).\n'
p7044
sg4
(lp7045
sg23
(lp7046
(dp7047
g7
I94
sg26
VC2314994
p7048
sg10
I19
sg11
Vspinal cord infarct
p7049
sg13
I3
sa(dp7050
g7
I30
sg26
VC0037928
p7051
sg10
I10
sg11
Vmyelopathy
p7052
sg13
I1
sa(dp7053
g7
I60
sg26
VC0036421
p7054
sg10
I19
sg11
Vsclerosis, systemic
p7055
sg13
I2
sa(dp7056
g7
I187
sg26
VC1832370
p7057
sg10
I3
sg11
VDRM
p7058
sg13
I1
sa(dp7059
g7
I157
sg26
VC1832370
p7060
sg10
I28
sg11
Vdelayed radiation myelopathy
p7061
sg13
I3
sa(dp7062
g7
I30
sg26
VC0037928
p7063
sg10
I10
sg11
Vmyelopathy
p7064
sg13
I1
sa(dp7065
g7
I115
sg26
VC2314994
p7066
sg10
I3
sg11
VSCI
p7067
sg13
I1
sasa(dp7068
g2
S'Our findings indicate that parainfectious myelitis (PIM) selectively involving conus medullaris is an important cause of unexplained acute or sub-acute urinary symptoms in adolescent and adult patients.\n'
p7069
sg4
(lp7070
sg23
(lp7071
(dp7072
g7
I152
sg26
VC0426359
p7073
sg10
I16
sg11
Vurinary symptoms
p7074
sg13
I2
sa(dp7075
g7
I42
sg26
VC0026975
p7076
sg10
I8
sg11
Vmyelitis
p7077
sg13
I1
sasa(dp7078
g2
S'The WNT6 rs6747776 homozygous minor allele (CC) was associated with increased risk of colorectal adenoma (OR = 2.75, 95% CI: 1.03-7.31).\n'
p7079
sg4
(lp7080
(dp7081
g7
I4
sg8
g64
sg10
I14
sg11
VWNT6 rs6747776
p7082
sg13
I2
sasg23
(lp7083
(dp7084
g7
I86
sg26
VC1302401
p7085
sg10
I18
sg11
Vcolorectal adenoma
p7086
sg13
I2
sasa(dp7087
g2
S'The incidence of leukemia in these mice varied from 5% to 50%, dependent on the Cre-driving promoter (Cd19, Mb1, or Mx1) used to induce E2A-PBX1 expression.\n'
p7088
sg4
(lp7089
(dp7090
g7
I136
sg8
VP15923
p7091
sg10
I3
sg11
VE2A
p7092
sg13
I1
sa(dp7093
g7
I102
sg8
VP15391
p7094
sg10
I4
sg11
VCd19
p7095
sg13
I1
sa(dp7096
g7
I80
sg8
g64
sg10
I20
sg11
VCre-driving promoter
p7097
sg13
I2
sa(dp7098
g7
I108
sg8
VP11912
p7099
sg10
I3
sg11
VMb1
p7100
sg13
I1
sa(dp7101
g7
I140
sg8
VP40424
p7102
sg10
I4
sg11
VPBX1
p7103
sg13
I1
sa(dp7104
g7
I116
sg8
VP20591
p7105
sg10
I3
sg11
VMx1
p7106
sg13
I1
sasg23
(lp7107
(dp7108
g7
I17
sg26
VC0023418
p7109
sg10
I8
sg11
Vleukemia
p7110
sg13
I1
sasa(dp7111
g2
S'Mutation in FOXN1 was reported to cause a rare disorder characterized by rudimentary thymus gland, T-cell immunodeficiency, congenital alopecia and nail dystrophy within an Italian community.\n'
p7112
sg4
(lp7113
(dp7114
g7
I12
sg8
g64
sg10
I5
sg11
VFOXN1
p7115
sg13
I1
sasg23
(lp7116
(dp7117
g7
I99
sg26
VC1866426
p7118
sg10
I63
sg11
VT-cell immunodeficiency, congenital alopecia and nail dystrophy
p7119
sg13
I7
sa(dp7120
g7
I42
sg26
VC0678236
p7121
sg10
I13
sg11
Vrare disorder
p7122
sg13
I2
sasa(dp7123
g2
S'Alterations in the transcription factor FOXN1 gene, expressed in the mature thymic and skin epithelia, are responsible for human and murine athymia and prevent the development of the T-cell compartment associated to ectodermal abnormalities such as alopecia and nail dystrophy.\n'
p7124
sg4
(lp7125
(dp7126
g7
I19
sg8
g64
sg10
I31
sg11
Vtranscription factor FOXN1 gene
p7127
sg13
I4
sasg23
(lp7128
(dp7129
g7
I262
sg26
VC0221260
p7130
sg10
I14
sg11
Vnail dystrophy
p7131
sg13
I2
sa(dp7132
g7
I140
sg26
VC0599540
p7133
sg10
I7
sg11
Vathymia
p7134
sg13
I1
sasa(dp7135
g2
S'Investigation of a patient with a rare homozygous FOXN1 mutation (R255X), leading to alopecia universalis and thymus aplasia, unexpectedly revealed non-maternal circulating T-cells, and, strikingly, large numbers of aberrant double-negative AlfaBeta T-cells (CD4negCD8neg, DN) and regulatory-like T-cells.\n'
p7136
sg4
(lp7137
(dp7138
g7
I50
sg8
g64
sg10
I14
sg11
VFOXN1 mutation
p7139
sg13
I2
sasg23
(lp7140
(dp7141
g7
I117
sg26
VC0243065
p7142
sg10
I7
sg11
Vaplasia
p7143
sg13
I1
sa(dp7144
g7
I85
sg26
VC0263505
p7145
sg10
I20
sg11
Valopecia universalis
p7146
sg13
I2
sasa(dp7147
g2
S'We show that the alopecia exhibited by both the Hoxc13(tm1Mrc) and Foxn1(nu) mice is because of strikingly similar defects in hair shaft differentiation and that both mutants suffer from a severe nail dystrophy.\n'
p7148
sg4
(lp7149
(dp7150
g7
I48
sg8
VP31276
p7151
sg10
I14
sg11
VHoxc13(tm1Mrc)
p7152
sg13
I1
sa(dp7153
g7
I67
sg8
g64
sg10
I5
sg11
VFoxn1
p7154
sg13
I1
sasg23
(lp7155
(dp7156
g7
I175
sg26
VC0683278
p7157
sg10
I6
sg11
Vsuffer
p7158
sg13
I1
sa(dp7159
g7
I196
sg26
VC0221260
p7160
sg10
I14
sg11
Vnail dystrophy
p7161
sg13
I2
sasa(dp7162
g2
S'FOXN1 deficiency is a primary immunodeficiency characterized by athymia, alopecia totalis, and nail dystrophy.\n'
p7163
sg4
(lp7164
(dp7165
g7
I0
sg8
g64
sg10
I5
sg11
VFOXN1
p7166
sg13
I1
sasg23
(lp7167
(dp7168
g7
I73
sg26
VC0263504
p7169
sg10
I16
sg11
Valopecia totalis
p7170
sg13
I2
sa(dp7171
g7
I64
sg26
VC0599540
p7172
sg10
I7
sg11
Vathymia
p7173
sg13
I1
sa(dp7174
g7
I95
sg26
VC0221260
p7175
sg10
I14
sg11
Vnail dystrophy
p7176
sg13
I2
sa(dp7177
g7
I22
sg26
VC0398686
p7178
sg10
I24
sg11
Vprimary immunodeficiency
p7179
sg13
I2
sasa(dp7180
g2
S'In this study, we examined the time course changes in the blood levels of HMGB1, C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA) in patients with secondary peritonitis who developed SIRS or sepsis.\n'
p7181
sg4
(lp7182
(dp7183
g7
I81
sg8
VP02741
p7184
sg10
I18
sg11
VC-reactive protein
p7185
sg13
I2
sa(dp7186
g7
I122
sg8
VP06132
p7187
sg10
I3
sg11
VPCT
p7188
sg13
I1
sa(dp7189
g7
I101
sg8
VP02741
p7190
sg10
I3
sg11
VCRP
p7191
sg13
I1
sa(dp7192
g7
I107
sg8
VP06132
p7193
sg10
I13
sg11
Vprocalcitonin
p7194
sg13
I1
sa(dp7195
g7
I74
sg8
VP09429
p7196
sg10
I5
sg11
VHMGB1
p7197
sg13
I1
sa(dp7198
g7
I148
sg8
VP35542
p7199
sg10
I3
sg11
VSAA
p7200
sg13
I1
sa(dp7201
g7
I131
sg8
VP35542
p7202
sg10
I15
sg11
Vserum amyloid A
p7203
sg13
I3
sasg23
(lp7204
(dp7205
g7
I137
sg26
VC0011560
p7206
sg10
I7
sg11
Vamyloid
p7207
sg13
I1
sa(dp7208
g7
I214
sg26
VC0243026
p7209
sg10
I6
sg11
Vsepsis
p7210
sg13
I1
sa(dp7211
g7
I107
sg26
VC0162566
p7212
sg10
I13
sg11
Vprocalcitonin
p7213
sg13
I1
sa(dp7214
g7
I206
sg26
VC0242966
p7215
sg10
I4
sg11
VSIRS
p7216
sg13
I1
sa(dp7217
g7
I122
sg26
VC0162566
p7218
sg10
I3
sg11
VPCT
p7219
sg13
I1
sa(dp7220
g7
I170
sg26
VC1449647
p7221
sg10
I21
sg11
Vsecondary peritonitis
p7222
sg13
I2
sasa(dp7223
g2
S'Serum levels of HMGB1, CRP, PCT, and SAA were determined on admission in all the patients, and monitored daily in patients with peritonitis until discharge from hospital.\n'
p7224
sg4
(lp7225
(dp7226
g7
I16
sg8
VP09429
p7227
sg10
I5
sg11
VHMGB1
p7228
sg13
I1
sa(dp7229
g7
I23
sg8
VP02741
p7230
sg10
I3
sg11
VCRP
p7231
sg13
I1
sasg23
(lp7232
(dp7233
g7
I128
sg26
VC0031154
p7234
sg10
I11
sg11
Vperitonitis
p7235
sg13
I1
sa(dp7236
g7
I28
sg26
VC0162566
p7237
sg10
I3
sg11
VPCT
p7238
sg13
I1
sasa(dp7239
g2
S'Preoperative HMGB1, CRP, PCT and SAA levels were statistically highly significantly increased in patients with peritonitis compared to patients with inguinal hernia, and significantly higher in patients with sepsis compared to those with SIRS.\n'
p7240
sg4
(lp7241
(dp7242
g7
I25
sg8
VP06132
p7243
sg10
I3
sg11
VPCT
p7244
sg13
I1
sa(dp7245
g7
I20
sg8
VP02741
p7246
sg10
I3
sg11
VCRP
p7247
sg13
I1
sa(dp7248
g7
I13
sg8
VP09429
p7249
sg10
I5
sg11
VHMGB1
p7250
sg13
I1
sa(dp7251
g7
I33
sg8
VP35542
p7252
sg10
I3
sg11
VSAA
p7253
sg13
I1
sasg23
(lp7254
(dp7255
g7
I25
sg26
VC0162566
p7256
sg10
I3
sg11
VPCT
p7257
sg13
I1
sa(dp7258
g7
I208
sg26
VC0243026
p7259
sg10
I6
sg11
Vsepsis
p7260
sg13
I1
sa(dp7261
g7
I149
sg26
VC0019294
p7262
sg10
I15
sg11
Vinguinal hernia
p7263
sg13
I2
sa(dp7264
g7
I111
sg26
VC0031154
p7265
sg10
I11
sg11
Vperitonitis
p7266
sg13
I1
sa(dp7267
g7
I238
sg26
VC0242966
p7268
sg10
I4
sg11
VSIRS
p7269
sg13
I1
sasa(dp7270
g2
S'HMGB1 and SAA temporal patterns might be useful in distinguishing sepsis from noninfectious SIRS in secondary peritonitis.\n'
p7271
sg4
(lp7272
(dp7273
g7
I10
sg8
VP35542
p7274
sg10
I3
sg11
VSAA
p7275
sg13
I1
sa(dp7276
g7
I0
sg8
VP09429
p7277
sg10
I5
sg11
VHMGB1
p7278
sg13
I1
sasg23
(lp7279
(dp7280
g7
I66
sg26
VC0243026
p7281
sg10
I6
sg11
Vsepsis
p7282
sg13
I1
sa(dp7283
g7
I100
sg26
VC1449647
p7284
sg10
I21
sg11
Vsecondary peritonitis
p7285
sg13
I2
sa(dp7286
g7
I92
sg26
VC0242966
p7287
sg10
I4
sg11
VSIRS
p7288
sg13
I1
sasa(dp7289
g2
S'U ovoj studiji smo ispitivali promenu nivoa u krvi HMGB1, Creaktivnog proteina (CRP), prokalcitonina (PCT) i serumskog proteina amiloid A (SAA) kroz vreme kod pacijenata sa sekundarnim peritonitisom koji su razvili SIRS ili sepsu.\n'
p7290
sg4
(lp7291
(dp7292
g7
I0
sg8
g64
sg10
I56
sg11
VU ovoj studiji smo ispitivali promenu nivoa u krvi HMGB1
p7293
sg13
I10
sa(dp7294
g7
I58
sg8
VP02741
p7295
sg10
I20
sg11
VCreaktivnog proteina
p7296
sg13
I2
sa(dp7297
g7
I80
sg8
VP02741
p7298
sg10
I3
sg11
VCRP
p7299
sg13
I1
sasg23
(lp7300
(dp7301
g7
I215
sg26
VC0242966
p7302
sg10
I4
sg11
VSIRS
p7303
sg13
I1
sa(dp7304
g7
I102
sg26
VC0162566
p7305
sg10
I3
sg11
VPCT
p7306
sg13
I1
sa(dp7307
g7
I86
sg26
VC0162566
p7308
sg10
I14
sg11
Vprokalcitonina
p7309
sg13
I1
sasa(dp7310
g2
S'Svim pacijentima su odreaivane vrednosti HMGB1, CRP, PCT, SAA u serumu na prijemu u bolnicu, dok je u grupi sa peritonitisom nastavljeno postoperativno merenje ovih parametara svakog dana do otpusta iz bolnice.\n'
p7311
sg4
(lp7312
(dp7313
g7
I53
sg8
VP06132
p7314
sg10
I3
sg11
VPCT
p7315
sg13
I1
sa(dp7316
g7
I58
sg8
VP35542
p7317
sg10
I33
sg11
VSAA u serumu na prijemu u bolnicu
p7318
sg13
I7
sa(dp7319
g7
I93
sg8
g64
sg10
I8
sg11
Vdok je u
p7320
sg13
I3
sa(dp7321
g7
I17
sg8
VP09429
p7322
sg10
I29
sg11
Vsu odreaivane vrednosti HMGB1
p7323
sg13
I4
sa(dp7324
g7
I48
sg8
VP02741
p7325
sg10
I3
sg11
VCRP
p7326
sg13
I1
sasg23
(lp7327
(dp7328
g7
I53
sg26
VC0162566
p7329
sg10
I3
sg11
VPCT
p7330
sg13
I1
sasa(dp7331
g2
S'Preoperativne vrednosti HMGB1, CRP, PCT, SAA bile su statisticki znacajno vise kod pacijenata sa peritonitisom u odnosu na pacijente sa ingvinalnim kilama, i statisticki znacajno vise kod pacijenata sa sepsom u odnosu na one sa SIRS-om.\n'
p7332
sg4
(lp7333
(dp7334
g7
I41
sg8
VP35542
p7335
sg10
I3
sg11
VSAA
p7336
sg13
I1
sa(dp7337
g7
I31
sg8
VP02741
p7338
sg10
I3
sg11
VCRP
p7339
sg13
I1
sa(dp7340
g7
I36
sg8
VP06132
p7341
sg10
I3
sg11
VPCT
p7342
sg13
I1
sa(dp7343
g7
I24
sg8
VP09429
p7344
sg10
I5
sg11
VHMGB1
p7345
sg13
I1
sasg23
(lp7346
(dp7347
g7
I228
sg26
VC0242966
p7348
sg10
I4
sg11
VSIRS
p7349
sg13
I1
sa(dp7350
g7
I36
sg26
VC0162566
p7351
sg10
I3
sg11
VPCT
p7352
sg13
I1
sasa(dp7353
g2
S'Vremenski obrasci nivoa HMGB1 i SAA mogli bi da budu korisni u razlikovanju sepse i SIRS-a bez infekcije u sekundarnom peritonitisu.\n'
p7354
sg4
(lp7355
(dp7356
g7
I24
sg8
VP09429
p7357
sg10
I20
sg11
VHMGB1 i SAA mogli bi
p7358
sg13
I5
sasg23
(lp7359
(dp7360
g7
I84
sg26
VC0242966
p7361
sg10
I4
sg11
VSIRS
p7362
sg13
I1
sasa(dp7363
g2
S'Using a murine model of polymicrobial septic peritonitis, we demonstrated that treatment with anti-HMGB1 Ab significantly diminished sepsis-induced dysfunction of neutrophil NADPH oxidase activity.\n'
p7364
sg4
(lp7365
(dp7366
g7
I94
sg8
VP09429
p7367
sg10
I13
sg11
Vanti-HMGB1 Ab
p7368
sg13
I2
sa(dp7369
g7
I174
sg8
VP30043
p7370
sg10
I13
sg11
VNADPH oxidase
p7371
sg13
I2
sasg23
(lp7372
(dp7373
g7
I45
sg26
VC0031154
p7374
sg10
I11
sg11
Vperitonitis
p7375
sg13
I1
sa(dp7376
g7
I133
sg26
VC0243026
p7377
sg10
I6
sg11
Vsepsis
p7378
sg13
I1
sasa(dp7379
g2
S'The aim of our study was to test high mobility group box 1 (HMGB1) in PD patients, evaluating its role as precocious marker of peritoneum damage during peritonitis.\n'
p7380
sg4
(lp7381
(dp7382
g7
I33
sg8
VP00390
p7383
sg10
I25
sg11
Vhigh mobility group box 1
p7384
sg13
I5
sa(dp7385
g7
I60
sg8
VP09429
p7386
sg10
I5
sg11
VHMGB1
p7387
sg13
I1
sasg23
(lp7388
(dp7389
g7
I152
sg26
VC0031154
p7390
sg10
I11
sg11
Vperitonitis
p7391
sg13
I1
sasa(dp7392
g2
S'In patients with acute peritonitis, the highest serum and peritoneal HMGB1 values (64 +/- 3.6 and 70 +/- 5.3 ng/mL, respectively) were assessed, with a progressive decrease of their levels at the resolution time (T-end: sHMGB1:36 +/- 2.5; pHMGB1:30.5 +/- 7.0 ng/mL).\n'
p7393
sg4
(lp7394
(dp7395
g7
I58
sg8
VP09429
p7396
sg10
I16
sg11
Vperitoneal HMGB1
p7397
sg13
I2
sasg23
(lp7398
(dp7399
g7
I17
sg26
VC0267750
p7400
sg10
I17
sg11
Vacute peritonitis
p7401
sg13
I2
sasa(dp7402
g2
S'However, the potential role and source of HMGB1 in the peritoneal dialysis (PD) effluence of patients with peritonitis are unknown.\n'
p7403
sg4
(lp7404
(dp7405
g7
I42
sg8
VP09429
p7406
sg10
I5
sg11
VHMGB1
p7407
sg13
I1
sasg23
(lp7408
(dp7409
g7
I107
sg26
VC0031154
p7410
sg10
I11
sg11
Vperitonitis
p7411
sg13
I1
sasa(dp7412
g2
S'By animal model, inhibition of HMGB1 with glycyrrhizin was performed to determine the effects of HMGB1 in LPS-induced mice peritonitis.\n'
p7413
sg4
(lp7414
(dp7415
g7
I31
sg8
VP09429
p7416
sg10
I5
sg11
VHMGB1
p7417
sg13
I1
sa(dp7418
g7
I31
sg8
VP09429
p7419
sg10
I5
sg11
VHMGB1
p7420
sg13
I1
sasg23
(lp7421
(dp7422
g7
I106
sg26
VC0175697
p7423
sg10
I3
sg11
VLPS
p7424
sg13
I1
sa(dp7425
g7
I123
sg26
VC0031154
p7426
sg10
I11
sg11
Vperitonitis
p7427
sg13
I1
sasa(dp7428
g2
S'The results showed that the levels of HMGB1 in PDE were higher in patients with peritonitis than those in controls, and gradually declined during the period of effective antibiotic treatments.\n'
p7429
sg4
(lp7430
(dp7431
g7
I38
sg8
VP09429
p7432
sg10
I12
sg11
VHMGB1 in PDE
p7433
sg13
I3
sasg23
(lp7434
(dp7435
g7
I80
sg26
VC0031154
p7436
sg10
I11
sg11
Vperitonitis
p7437
sg13
I1
sa(dp7438
g7
I47
sg26
VC1849508
p7439
sg10
I3
sg11
VPDE
p7440
sg13
I1
sasa(dp7441
g2
S'Our study demonstrates that elevated HMGB1 levels in PDE during PD-related peritonitis, at least partially, from peritoneal mesothelial cells, which may be involved in the process of PD-related peritonitis and play a critical role in acute peritoneal dysfunction.\n'
p7442
sg4
(lp7443
(dp7444
g7
I53
sg8
VP49419
p7445
sg10
I3
sg11
VPDE
p7446
sg13
I1
sa(dp7447
g7
I37
sg8
VP09429
p7448
sg10
I5
sg11
VHMGB1
p7449
sg13
I1
sasg23
(lp7450
(dp7451
g7
I75
sg26
VC0031154
p7452
sg10
I11
sg11
Vperitonitis
p7453
sg13
I1
sa(dp7454
g7
I75
sg26
VC0031154
p7455
sg10
I11
sg11
Vperitonitis
p7456
sg13
I1
sa(dp7457
g7
I53
sg26
VC1849508
p7458
sg10
I3
sg11
VPDE
p7459
sg13
I1
sasa(dp7460
g2
S'We investigated lncRNAs with stimulus specific immunomodulatory activity as potential marker genes: LINC00595, SBF2-AS1 (A.fumigatus) and RP11-588G21.2, RP11-394l13.1 (C.albicans) might be detectable in the early phase of infection and serve as therapeutic targets in the future.\n'
p7461
sg4
(lp7462
(dp7463
g7
I138
sg8
g64
sg10
I13
sg11
VRP11-588G21.2
p7464
sg13
I1
sa(dp7465
g7
I153
sg8
g64
sg10
I13
sg11
VRP11-394l13.1
p7466
sg13
I1
sa(dp7467
g7
I116
sg8
g64
sg10
I3
sg11
VAS1
p7468
sg13
I1
sasg23
(lp7469
(dp7470
g7
I222
sg26
VC0009450
p7471
sg10
I9
sg11
Vinfection
p7472
sg13
I1
sa(dp7473
g7
I138
sg26
VC1838601
p7474
sg10
I4
sg11
VRP11
p7475
sg13
I1
sa(dp7476
g7
I138
sg26
VC1838601
p7477
sg10
I4
sg11
VRP11
p7478
sg13
I1
sa(dp7479
g7
I116
sg26
VC1846534
p7480
sg10
I3
sg11
VAS1
p7481
sg13
I1
sasa(dp7482
g2
S'It included three steroid-treated adult asthma groups (severe nonsmokers (SAn group), severe current/ex-smokers (SAs/ex group) and those with mild-moderate disease (MMA group)) and healthy controls (HC group).\n'
p7483
sg4
(lp7484
sg23
(lp7485
(dp7486
g7
I165
sg26
VC0276096
p7487
sg10
I3
sg11
VMMA
p7488
sg13
I1
sa(dp7489
g7
I40
sg26
VC0004096
p7490
sg10
I6
sg11
Vasthma
p7491
sg13
I1
sasa(dp7492
g2
S'Immunohistochemical analysis of glycol methacrylate resin-embedded biopsies showed there were more mast cells in submucosa of the HC group (33.6 mm-2) compared with both severe asthma groups (SAn: 17.4 mm-2, p&lt;0.001; SAs/ex: 22.2 mm-2, p=0.01) and with the MMA group (21.2 mm-2, p=0.01).\n'
p7493
sg4
(lp7494
sg23
(lp7495
(dp7496
g7
I260
sg26
VC0276096
p7497
sg10
I3
sg11
VMMA
p7498
sg13
I1
sa(dp7499
g7
I177
sg26
VC0004096
p7500
sg10
I6
sg11
Vasthma
p7501
sg13
I1
sasa(dp7502
g2
S'In 66 adults asthma was categorized as steroid-naive (SN, n = 17), mild to moderate (MMA, n = 33), and refractory treated with oral corticosteroids (RA, n = 16).\n'
p7503
sg4
(lp7504
sg23
(lp7505
(dp7506
g7
I85
sg26
VC0276096
p7507
sg10
I3
sg11
VMMA
p7508
sg13
I1
sa(dp7509
g7
I67
sg26
VC0276096
p7510
sg10
I16
sg11
Vmild to moderate
p7511
sg13
I3
sa(dp7512
g7
I13
sg26
VC0004096
p7513
sg10
I6
sg11
Vasthma
p7514
sg13
I1
sasa(dp7515
g2
S'To examine the relationship between the HEDIS Medication Management for people with Asthma (MMA) measure and asthma outcomes.\n'
p7516
sg4
(lp7517
sg23
(lp7518
(dp7519
g7
I92
sg26
VC0276096
p7520
sg10
I3
sg11
VMMA
p7521
sg13
I1
sa(dp7522
g7
I109
sg26
VC0004096
p7523
sg10
I6
sg11
Vasthma
p7524
sg13
I1
sa(dp7525
g7
I57
sg26
VC0276096
p7526
sg10
I33
sg11
VManagement for people with Asthma
p7527
sg13
I5
sasa(dp7528
g2
S'The association between MMA compliance in 2012 and asthma outcomes in 2013 was determined.\n'
p7529
sg4
(lp7530
sg23
(lp7531
(dp7532
g7
I24
sg26
VC0276096
p7533
sg10
I3
sg11
VMMA
p7534
sg13
I1
sa(dp7535
g7
I51
sg26
VC0004096
p7536
sg10
I6
sg11
Vasthma
p7537
sg13
I1
sasa(dp7538
g2
S'Patients who were 75% or 50% MMA compliant in 2012 showed no clinically meaningful difference in asthma-related hospitalizations, emergency department visits, or rescue inhaler dispensing in 2013 compared with those who were noncompliant.\n'
p7539
sg4
(lp7540
sg23
(lp7541
(dp7542
g7
I130
sg26
VC2745965
p7543
sg10
I9
sg11
Vemergency
p7544
sg13
I1
sa(dp7545
g7
I97
sg26
VC0004096
p7546
sg10
I6
sg11
Vasthma
p7547
sg13
I1
sa(dp7548
g7
I29
sg26
VC0276096
p7549
sg10
I3
sg11
VMMA
p7550
sg13
I1
sasa(dp7551
g2
S'Stepwise comparison of patients who were 75% or more, 50% to 74%, and less than 50% MMA compliant showed no meaningful difference in asthma outcomes between groups.\n'
p7552
sg4
(lp7553
sg23
(lp7554
(dp7555
g7
I84
sg26
VC0276096
p7556
sg10
I3
sg11
VMMA
p7557
sg13
I1
sa(dp7558
g7
I133
sg26
VC0004096
p7559
sg10
I6
sg11
Vasthma
p7560
sg13
I1
sasa(dp7561
g2
S'Compliance with the HEDIS MMA measure is not related to improvement in the asthma outcomes assessed (rescue inhaler dispensing, asthma-coded hospitalizations, or asthma-coded emergency department visits).\n'
p7562
sg4
(lp7563
sg23
(lp7564
(dp7565
g7
I175
sg26
VC2745965
p7566
sg10
I9
sg11
Vemergency
p7567
sg13
I1
sa(dp7568
g7
I75
sg26
VC0004096
p7569
sg10
I6
sg11
Vasthma
p7570
sg13
I1
sa(dp7571
g7
I26
sg26
VC0276096
p7572
sg10
I3
sg11
VMMA
p7573
sg13
I1
sa(dp7574
g7
I75
sg26
VC0004096
p7575
sg10
I6
sg11
Vasthma
p7576
sg13
I1
sa(dp7577
g7
I75
sg26
VC0004096
p7578
sg10
I6
sg11
Vasthma
p7579
sg13
I1
sasa(dp7580
g2
S'neutrophils were the main cell lineage of IL-1Beta to take part in the innate anti-fungi immunity in the cornea; IL-1Beta generation induced by fungal infection might not be through the pre-excitation in the classical signal pathway; TLR4/TRIF pathway was not involved in pro-IL-1Beta generation; while Dectin-1/syk pathway was involved in IL-1Beta generation in the fungal keratitis; Caspase-l participated in the modification of IL-1Beta to change from the precursor into the mature body; but NLRP3 inflammasome and ASC inflammasome were not involved in IL-1Beta generation; Caspase-11 was involved in IL-1Beta generation through regulating the modified process of Caspase-l to turning from precursor into mature body.\n'
p7581
sg4
(lp7582
(dp7583
g7
I42
sg8
VP01584
p7584
sg10
I8
sg11
VIL-1Beta
p7585
sg13
I1
sa(dp7586
g7
I239
sg8
g64
sg10
I4
sg11
VTRIF
p7587
sg13
I1
sa(dp7588
g7
I312
sg8
VP43405
p7589
sg10
I3
sg11
Vsyk
p7590
sg13
I1
sa(dp7591
g7
I42
sg8
VP01584
p7592
sg10
I8
sg11
VIL-1Beta
p7593
sg13
I1
sa(dp7594
g7
I42
sg8
VP01584
p7595
sg10
I8
sg11
VIL-1Beta
p7596
sg13
I1
sa(dp7597
g7
I42
sg8
VP01584
p7598
sg10
I8
sg11
VIL-1Beta
p7599
sg13
I1
sa(dp7600
g7
I42
sg8
VP01584
p7601
sg10
I8
sg11
VIL-1Beta
p7602
sg13
I1
sa(dp7603
g7
I272
sg8
VP01584
p7604
sg10
I12
sg11
Vpro-IL-1Beta
p7605
sg13
I1
sa(dp7606
g7
I577
sg8
VP39880
p7607
sg10
I10
sg11
VCaspase-11
p7608
sg13
I1
sa(dp7609
g7
I42
sg8
VP01584
p7610
sg10
I8
sg11
VIL-1Beta
p7611
sg13
I1
sa(dp7612
g7
I385
sg8
VP39880
p7613
sg10
I9
sg11
VCaspase-l
p7614
sg13
I1
sa(dp7615
g7
I385
sg8
VP39880
p7616
sg10
I9
sg11
VCaspase-l
p7617
sg13
I1
sa(dp7618
g7
I518
sg8
VP08842
p7619
sg10
I16
sg11
VASC inflammasome
p7620
sg13
I2
sasg23
(lp7621
(dp7622
g7
I367
sg26
VC1262117
p7623
sg10
I16
sg11
Vfungal keratitis
p7624
sg13
I2
sa(dp7625
g7
I144
sg26
VC0026946
p7626
sg10
I16
sg11
Vfungal infection
p7627
sg13
I2
sasa(dp7628
g2
S'To explore the relationship between LOX-1 and TLR4 in Aspergillus fumigatus (A. fumigatus) keratitis.\n'
p7629
sg4
(lp7630
(dp7631
g7
I36
sg8
VP78380
p7632
sg10
I5
sg11
VLOX-1
p7633
sg13
I1
sasg23
(lp7634
(dp7635
g7
I91
sg26
VC0022568
p7636
sg10
I9
sg11
Vkeratitis
p7637
sg13
I1
sasa(dp7638
g2
S'To determine LOX-1 and TLR4 can affect each other and regulate inflammation through regulation of the generation of reactive oxygen species (ROS) in A. fumigatus keratitis.\n'
p7639
sg4
(lp7640
(dp7641
g7
I13
sg8
VP78380
p7642
sg10
I5
sg11
VLOX-1
p7643
sg13
I1
sasg23
(lp7644
(dp7645
g7
I63
sg26
VC0021368
p7646
sg10
I12
sg11
Vinflammation
p7647
sg13
I1
sa(dp7648
g7
I162
sg26
VC0022568
p7649
sg10
I9
sg11
Vkeratitis
p7650
sg13
I1
sasa(dp7651
g2
S'LOX-1 and TLR4 can affect each other and regulate the generation of ROS in A. fumigatus keratitis.\n'
p7652
sg4
(lp7653
(dp7654
g7
I0
sg8
VP78380
p7655
sg10
I5
sg11
VLOX-1
p7656
sg13
I1
sasg23
(lp7657
(dp7658
g7
I88
sg26
VC0022568
p7659
sg10
I9
sg11
Vkeratitis
p7660
sg13
I1
sasa(dp7661
g2
S'Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC).\n'
p7662
sg4
(lp7663
sg23
(lp7664
(dp7665
g7
I220
sg26
VC0007131
p7666
sg10
I26
sg11
Vnon-small cell lung cancer
p7667
sg13
I4
sa(dp7668
g7
I248
sg26
VC0007131
p7669
sg10
I5
sg11
VNSCLC
p7670
sg13
I1
sasa(dp7671
g2
S'Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P &lt; 0.001).\n'
p7672
sg4
(lp7673
(dp7674
g7
I70
sg8
VP07992
p7675
sg10
I10
sg11
VERCC1 mRNA
p7676
sg13
I2
sasg23
(lp7677
(dp7678
g7
I91
sg26
VC0007131
p7679
sg10
I5
sg11
VNSCLC
p7680
sg13
I1
sasa(dp7681
g2
S'The present study aimed to investigate the effects of excision repair cross-complementation 1 (ERCC1) expression on the prognosis of patients with non-small cell lung cancer (NSCLC).\n'
p7682
sg4
(lp7683
(dp7684
g7
I54
sg8
g64
sg10
I39
sg11
Vexcision repair cross-complementation 1
p7685
sg13
I4
sa(dp7686
g7
I95
sg8
VP07992
p7687
sg10
I5
sg11
VERCC1
p7688
sg13
I1
sasg23
(lp7689
(dp7690
g7
I147
sg26
VC0007131
p7691
sg10
I26
sg11
Vnon-small cell lung cancer
p7692
sg13
I4
sa(dp7693
g7
I175
sg26
VC0007131
p7694
sg10
I5
sg11
VNSCLC
p7695
sg13
I1
sasa(dp7696
g2
S'Multivariate analysis demonstrated that ERCC1 expression, pathological staging, and tumor staging were important prognostic factors for NSCLC.\n'
p7697
sg4
(lp7698
(dp7699
g7
I40
sg8
VP07992
p7700
sg10
I5
sg11
VERCC1
p7701
sg13
I1
sasg23
(lp7702
(dp7703
g7
I136
sg26
VC0007131
p7704
sg10
I5
sg11
VNSCLC
p7705
sg13
I1
sa(dp7706
g7
I84
sg26
VC0027651
p7707
sg10
I5
sg11
Vtumor
p7708
sg13
I1
sasa(dp7709
g2
S'The results of the present study suggest that ERCC1 expression is an important prognostic indicator for NSCLC, particularly for patients with stage II-III tumors who receive systematic platinum-based adjuvant chemotherapy.\n'
p7710
sg4
(lp7711
(dp7712
g7
I46
sg8
VP07992
p7713
sg10
I5
sg11
VERCC1
p7714
sg13
I1
sasg23
(lp7715
(dp7716
g7
I155
sg26
VC0027651
p7717
sg10
I6
sg11
Vtumors
p7718
sg13
I1
sa(dp7719
g7
I104
sg26
VC0007131
p7720
sg10
I5
sg11
VNSCLC
p7721
sg13
I1
sasa(dp7722
g2
S'A SNP of the ERCC1 gene (T19007C) has been reported as a prognostic marker in platinum-treated non-small-cell lung cancer (NSCLC).\n'
p7723
sg4
(lp7724
(dp7725
g7
I13
sg8
VP07992
p7726
sg10
I10
sg11
VERCC1 gene
p7727
sg13
I2
sasg23
(lp7728
(dp7729
g7
I123
sg26
VC0007131
p7730
sg10
I5
sg11
VNSCLC
p7731
sg13
I1
sa(dp7732
g7
I95
sg26
VC0007131
p7733
sg10
I26
sg11
Vnon-small-cell lung cancer
p7734
sg13
I3
sasa(dp7735
g2
S'The endonuclease ERCC1-XPF has an important role in the repair of DNA damage caused by a variety of chemotherapeutic agents and there has been intense interest in the use of ERCC1 as a predictive marker of therapeutic response in non-small cell lung carcinoma, squamous cell carcinoma and ovarian cancer.\n'
p7736
sg4
(lp7737
(dp7738
g7
I17
sg8
VP07992
p7739
sg10
I5
sg11
VERCC1
p7740
sg13
I1
sa(dp7741
g7
I4
sg8
VP39748
p7742
sg10
I22
sg11
Vendonuclease ERCC1-XPF
p7743
sg13
I2
sasg23
(lp7744
(dp7745
g7
I230
sg26
VC0007131
p7746
sg10
I29
sg11
Vnon-small cell lung carcinoma
p7747
sg13
I4
sa(dp7748
g7
I289
sg26
VC1140680
p7749
sg10
I14
sg11
Vovarian cancer
p7750
sg13
I2
sa(dp7751
g7
I66
sg26
VC0012860
p7752
sg10
I10
sg11
VDNA damage
p7753
sg13
I2
sa(dp7754
g7
I23
sg26
VC0268140
p7755
sg10
I3
sg11
VXPF
p7756
sg13
I1
sa(dp7757
g7
I261
sg26
VC0007137
p7758
sg10
I23
sg11
Vsquamous cell carcinoma
p7759
sg13
I3
sasa(dp7760
g2
S'The study demonstrated poor methodological quality of SRs/meta-analysis assessing the predictive value of ERCC1 in chemotherapy among the NSCLC patients, especially the high performance bias.\n'
p7761
sg4
(lp7762
(dp7763
g7
I106
sg8
VP07992
p7764
sg10
I5
sg11
VERCC1
p7765
sg13
I1
sasg23
(lp7766
(dp7767
g7
I54
sg26
VC0175693
p7768
sg10
I3
sg11
VSRs
p7769
sg13
I1
sa(dp7770
g7
I138
sg26
VC0007131
p7771
sg10
I5
sg11
VNSCLC
p7772
sg13
I1
sasa(dp7773
g2
S'The expression of ERCC1 and TUBB3 proteins was also evaluated in 50 patients who underwent curative resection for non-small cell lung cancer (NSCLC).\n'
p7774
sg4
(lp7775
(dp7776
g7
I18
sg8
VP07992
p7777
sg10
I5
sg11
VERCC1
p7778
sg13
I1
sa(dp7779
g7
I28
sg8
VP04350
p7780
sg10
I14
sg11
VTUBB3 proteins
p7781
sg13
I2
sasg23
(lp7782
(dp7783
g7
I114
sg26
VC0007131
p7784
sg10
I26
sg11
Vnon-small cell lung cancer
p7785
sg13
I4
sa(dp7786
g7
I142
sg26
VC0007131
p7787
sg10
I5
sg11
VNSCLC
p7788
sg13
I1
sasa(dp7789
g2
S'ERCC1 was expressed in 21 cases (42%), while TUBB3 was expressed in 27 cases (54%), among the 50 NSCLC patients evaluated in the present study.\n'
p7790
sg4
(lp7791
(dp7792
g7
I45
sg8
VP04350
p7793
sg10
I5
sg11
VTUBB3
p7794
sg13
I1
sa(dp7795
g7
I0
sg8
VP07992
p7796
sg10
I5
sg11
VERCC1
p7797
sg13
I1
sasg23
(lp7798
(dp7799
g7
I97
sg26
VC0007131
p7800
sg10
I5
sg11
VNSCLC
p7801
sg13
I1
sasa(dp7802
g2
S'The expression of ERCC1 and TUBB3 proteins in the thymic carcinoma cases was lower than that in the NSCLC cases.\n'
p7803
sg4
(lp7804
(dp7805
g7
I18
sg8
VP07992
p7806
sg10
I5
sg11
VERCC1
p7807
sg13
I1
sa(dp7808
g7
I28
sg8
VP04350
p7809
sg10
I14
sg11
VTUBB3 proteins
p7810
sg13
I2
sasg23
(lp7811
(dp7812
g7
I50
sg26
VC0205969
p7813
sg10
I16
sg11
Vthymic carcinoma
p7814
sg13
I2
sa(dp7815
g7
I100
sg26
VC0007131
p7816
sg10
I5
sg11
VNSCLC
p7817
sg13
I1
sasa(dp7818
g2
S'The pairwise meta-analysis indicated that in terms of overall response ratio (ORR), ERCC1 (rs11615), XRCC1 (rs25487, rs1799782), and XPD (rs13181) polymorphisms are associated with the efficacy of platinum-based chemotherapy in NSCLC.\n'
p7819
sg4
(lp7820
(dp7821
g7
I101
sg8
VP18887
p7822
sg10
I5
sg11
VXRCC1
p7823
sg13
I1
sa(dp7824
g7
I84
sg8
VP07992
p7825
sg10
I5
sg11
VERCC1
p7826
sg13
I1
sasg23
(lp7827
(dp7828
g7
I228
sg26
VC0007131
p7829
sg10
I5
sg11
VNSCLC
p7830
sg13
I1
sa(dp7831
g7
I133
sg26
VC0268138
p7832
sg10
I3
sg11
VXPD
p7833
sg13
I1
sasa(dp7834
g2
S'ERCC1(rs11615), XRCC1(rs25487, rs1799782) and XPD(rs13181) polymorphisms were better predictors in evaluating the efficacy of platinum-based chemotherapy in NSCLC patients.\n'
p7835
sg4
(lp7836
(dp7837
g7
I16
sg8
VP18887
p7838
sg10
I5
sg11
VXRCC1
p7839
sg13
I1
sa(dp7840
g7
I0
sg8
VP07992
p7841
sg10
I5
sg11
VERCC1
p7842
sg13
I1
sasg23
(lp7843
(dp7844
g7
I46
sg26
VC0268138
p7845
sg10
I3
sg11
VXPD
p7846
sg13
I1
sa(dp7847
g7
I157
sg26
VC0007131
p7848
sg10
I5
sg11
VNSCLC
p7849
sg13
I1
sasa(dp7850
g2
S'KRAS mutations have been found in duodenal adenocarcinomas and may have prognostic significance.\n'
p7851
sg4
(lp7852
(dp7853
g7
I0
sg8
VP01116
p7854
sg10
I4
sg11
VKRAS
p7855
sg13
I1
sasg23
(lp7856
(dp7857
g7
I43
sg26
VC0001418
p7858
sg10
I15
sg11
Vadenocarcinomas
p7859
sg13
I1
sasa(dp7860
g2
S'The purpose of this study was to classify clinicopathological characteristics, microsatellite instability and KRAS mutations and identify possible prognostic role of KRAS mutations in duodenal adenocarcinomas.\n'
p7861
sg4
(lp7862
(dp7863
g7
I110
sg8
VP01116
p7864
sg10
I4
sg11
VKRAS
p7865
sg13
I1
sa(dp7866
g7
I110
sg8
VP01116
p7867
sg10
I4
sg11
VKRAS
p7868
sg13
I1
sasg23
(lp7869
(dp7870
g7
I193
sg26
VC0001418
p7871
sg10
I15
sg11
Vadenocarcinomas
p7872
sg13
I1
sa(dp7873
g7
I79
sg26
VC0920269
p7874
sg10
I26
sg11
Vmicrosatellite instability
p7875
sg13
I2
sasa(dp7876
g2
S'In conclusion, KRAS G&gt;A mutation correlates significantly with late stage and poor tumor differentiation in duodenal adenocarcinoma.\n'
p7877
sg4
(lp7878
(dp7879
g7
I15
sg8
VP01116
p7880
sg10
I6
sg11
VKRAS G
p7881
sg13
I2
sasg23
(lp7882
(dp7883
g7
I86
sg26
VC0027651
p7884
sg10
I5
sg11
Vtumor
p7885
sg13
I1
sa(dp7886
g7
I111
sg26
VC0278804
p7887
sg10
I23
sg11
Vduodenal adenocarcinoma
p7888
sg13
I2
sasa(dp7889
g2
S'Among patients who undergo a curative resection of duodenal adenocarcinoma, KRAS G&gt;A mutation carriers will more likely experience distant relapse but may not exhibit a poor prognosis.\n'
p7890
sg4
(lp7891
(dp7892
g7
I76
sg8
VP01116
p7893
sg10
I6
sg11
VKRAS G
p7894
sg13
I2
sasg23
(lp7895
(dp7896
g7
I142
sg26
VC0277556
p7897
sg10
I7
sg11
Vrelapse
p7898
sg13
I1
sa(dp7899
g7
I51
sg26
VC0278804
p7900
sg10
I23
sg11
Vduodenal adenocarcinoma
p7901
sg13
I2
sasa(dp7902
g2
S'The purpose was to identify possible subsets of duodenal adenocarcinomas based on microsatellite instability (MSI), DNA methylation, mutations in the KRAS and BRAF genes, clinicopathologic features, and prognosis.\n'
p7903
sg4
(lp7904
(dp7905
g7
I150
sg8
VP01116
p7906
sg10
I4
sg11
VKRAS
p7907
sg13
I1
sa(dp7908
g7
I159
sg8
VP15056
p7909
sg10
I10
sg11
VBRAF genes
p7910
sg13
I2
sasg23
(lp7911
(dp7912
g7
I57
sg26
VC0001418
p7913
sg10
I15
sg11
Vadenocarcinomas
p7914
sg13
I1
sa(dp7915
g7
I82
sg26
VC0920269
p7916
sg10
I26
sg11
Vmicrosatellite instability
p7917
sg13
I2
sa(dp7918
g7
I110
sg26
VC0920269
p7919
sg10
I3
sg11
VMSI
p7920
sg13
I1
sasa(dp7921
g2
S'CIMP(+) was detected in 27 of 99 (27.3%) duodenal adenocarcinomas and was associated with MSI (P = 0.011) and MLH1 methylation (P &lt; 0.001), but not with KRAS mutations (P = 0.114), as compared with CIMP(-) tumors.\n'
p7922
sg4
(lp7923
(dp7924
g7
I110
sg8
VP40692
p7925
sg10
I4
sg11
VMLH1
p7926
sg13
I1
sa(dp7927
g7
I156
sg8
VP01116
p7928
sg10
I4
sg11
VKRAS
p7929
sg13
I1
sasg23
(lp7930
(dp7931
g7
I209
sg26
VC0027651
p7932
sg10
I6
sg11
Vtumors
p7933
sg13
I1
sa(dp7934
g7
I90
sg26
VC0920269
p7935
sg10
I3
sg11
VMSI
p7936
sg13
I1
sa(dp7937
g7
I50
sg26
VC0001418
p7938
sg10
I15
sg11
Vadenocarcinomas
p7939
sg13
I1
sasa(dp7940
g2
S'Each small intestine K-ras mutation was found in a duodenal adenocarcinoma (4 of 12 cases, 33%), whereas none occurred in 16 other jejunal or ileal adenocarcinomas.\n'
p7941
sg4
(lp7942
(dp7943
g7
I5
sg8
VP01127
p7944
sg10
I17
sg11
Vsmall intestine K
p7945
sg13
I3
sa(dp7946
g7
I23
sg8
VP01116
p7947
sg10
I3
sg11
Vras
p7948
sg13
I1
sasg23
(lp7949
(dp7950
g7
I51
sg26
VC0278804
p7951
sg10
I23
sg11
Vduodenal adenocarcinoma
p7952
sg13
I2
sa(dp7953
g7
I148
sg26
VC0001418
p7954
sg10
I15
sg11
Vadenocarcinomas
p7955
sg13
I1
sasa(dp7956
g2
S'K-ras mutations appear to play a significant role in the pathogenesis of duodenal adenocarcinomas, but they do not appear to be important in the development of jejunal or ileal adenocarcinomas or of carcinoid tumors of the small intestine.\n'
p7957
sg4
(lp7958
(dp7959
g7
I0
sg8
VP01116
p7960
sg10
I5
sg11
VK-ras
p7961
sg13
I1
sasg23
(lp7962
(dp7963
g7
I57
sg26
VC0699748
p7964
sg10
I12
sg11
Vpathogenesis
p7965
sg13
I1
sa(dp7966
g7
I82
sg26
VC0001418
p7967
sg10
I15
sg11
Vadenocarcinomas
p7968
sg13
I1
sa(dp7969
g7
I199
sg26
VC0007095
p7970
sg10
I16
sg11
Vcarcinoid tumors
p7971
sg13
I2
sa(dp7972
g7
I82
sg26
VC0001418
p7973
sg10
I15
sg11
Vadenocarcinomas
p7974
sg13
I1
sasa(dp7975
g2
S'The qRT-PCR showed that miR-5703 and miR-1246 expression was significantly higher in ovarian cancer cells than in normal control cells, whereas the miR-424-5p level was significantly lower.\n'
p7976
sg4
(lp7977
(dp7978
g7
I24
sg8
g64
sg10
I8
sg11
VmiR-5703
p7979
sg13
I1
sa(dp7980
g7
I148
sg8
g64
sg10
I10
sg11
VmiR-424-5p
p7981
sg13
I1
sa(dp7982
g7
I37
sg8
g64
sg10
I8
sg11
VmiR-1246
p7983
sg13
I1
sasg23
(lp7984
(dp7985
g7
I85
sg26
VC1140680
p7986
sg10
I14
sg11
Vovarian cancer
p7987
sg13
I2
sasa(dp7988
g2
S'Decreased expression of miR-424-5p in ovarian carcinoma might be a putative biomarker for distant metastasis in ovarian carcinoma.\n'
p7989
sg4
(lp7990
(dp7991
g7
I24
sg8
g64
sg10
I10
sg11
VmiR-424-5p
p7992
sg13
I1
sasg23
(lp7993
(dp7994
g7
I38
sg26
VC0029925
p7995
sg10
I17
sg11
Vovarian carcinoma
p7996
sg13
I2
sa(dp7997
g7
I98
sg26
VC0027627
p7998
sg10
I10
sg11
Vmetastasis
p7999
sg13
I1
sa(dp8000
g7
I38
sg26
VC0029925
p8001
sg10
I17
sg11
Vovarian carcinoma
p8002
sg13
I2
sasa(dp8003
g2
S'Our studies show that miR-424 levels are suppressed in cell lines that stably maintain HPV 31 or 16 episomes as well as cervical cancer lines that contain integrated genomes such as SiHa.\n'
p8004
sg4
(lp8005
(dp8006
g7
I22
sg8
g64
sg10
I7
sg11
VmiR-424
p8007
sg13
I1
sasg23
(lp8008
(dp8009
g7
I120
sg26
VC0302592
p8010
sg10
I15
sg11
Vcervical cancer
p8011
sg13
I2
sasa(dp8012
g2
S'miRNA expression profiles demonstrate that miR-424 was markedly downregulated in cervical cancer tissue.\n'
p8013
sg4
(lp8014
(dp8015
g7
I43
sg8
g64
sg10
I7
sg11
VmiR-424
p8016
sg13
I1
sasg23
(lp8017
(dp8018
g7
I81
sg26
VC0302592
p8019
sg10
I15
sg11
Vcervical cancer
p8020
sg13
I2
sasa(dp8021
g2
S'Finally, lowered expression of miR-424 could recover the tumor-suppressive effects of PVT1 knockdown in cervical cancer cell lines.\n'
p8022
sg4
(lp8023
(dp8024
g7
I31
sg8
g64
sg10
I7
sg11
VmiR-424
p8025
sg13
I1
sasg23
(lp8026
(dp8027
g7
I57
sg26
VC0027651
p8028
sg10
I5
sg11
Vtumor
p8029
sg13
I1
sa(dp8030
g7
I104
sg26
VC0302592
p8031
sg10
I15
sg11
Vcervical cancer
p8032
sg13
I2
sasa(dp8033
g2
S'Our results reveal a tumor-promoting role for PVT1, acting as a competing endogenous RNA (ceRNA) or a molecular sponge in negatively modulating miR-424, which might provide a novel therapeutic target for cervical cancer.\n'
p8034
sg4
(lp8035
(dp8036
g7
I144
sg8
g64
sg10
I7
sg11
VmiR-424
p8037
sg13
I1
sasg23
(lp8038
(dp8039
g7
I21
sg26
VC0027651
p8040
sg10
I5
sg11
Vtumor
p8041
sg13
I1
sa(dp8042
g7
I204
sg26
VC0302592
p8043
sg10
I15
sg11
Vcervical cancer
p8044
sg13
I2
sasa(dp8045
g2
S'Here, we investigated the role of DCLK1 and microRNA-424 (miR-424) in ovarian clear cell carcinoma (OCCC), a histopathologically distinct subtype of epithelial ovarian cancer associated with poor prognosis and chemotherapy resistance.\n'
p8046
sg4
(lp8047
(dp8048
g7
I44
sg8
g64
sg10
I12
sg11
VmicroRNA-424
p8049
sg13
I1
sa(dp8050
g7
I58
sg8
g64
sg10
I7
sg11
VmiR-424
p8051
sg13
I1
sa(dp8052
g7
I34
sg8
g64
sg10
I5
sg11
VDCLK1
p8053
sg13
I1
sasg23
(lp8054
(dp8055
g7
I149
sg26
VC0677886
p8056
sg10
I25
sg11
Vepithelial ovarian cancer
p8057
sg13
I3
sa(dp8058
g7
I78
sg26
VC0206681
p8059
sg10
I20
sg11
Vclear cell carcinoma
p8060
sg13
I3
sasa(dp8061
g2
S'Analysis of samples from 30 OCCC patients showed that DCLK1 was upregulated and miR-424 was downregulated in tumors compared with adjacent non-tumor tissues.\n'
p8062
sg4
(lp8063
(dp8064
g7
I80
sg8
g64
sg10
I7
sg11
VmiR-424
p8065
sg13
I1
sa(dp8066
g7
I54
sg8
g64
sg10
I5
sg11
VDCLK1
p8067
sg13
I1
sasg23
(lp8068
(dp8069
g7
I109
sg26
VC0027651
p8070
sg10
I6
sg11
Vtumors
p8071
sg13
I1
sa(dp8072
g7
I109
sg26
VC0027651
p8073
sg10
I5
sg11
Vtumor
p8074
sg13
I1
sasa(dp8075
g2
S'Taken together, these data demonstrate that miR-424 has the capacity to suppress cell invasion and EMT in OCCC by downregulating DCLK1, suggesting potential therapeutic targets and strategies for the treatment of this disease.\n'
p8076
sg4
(lp8077
(dp8078
g7
I44
sg8
g64
sg10
I7
sg11
VmiR-424
p8079
sg13
I1
sa(dp8080
g7
I99
sg8
g64
sg10
I3
sg11
VEMT
p8081
sg13
I1
sa(dp8082
g7
I129
sg8
g64
sg10
I5
sg11
VDCLK1
p8083
sg13
I1
sasg23
(lp8084
(dp8085
g7
I81
sg26
VC2699153
p8086
sg10
I13
sg11
Vcell invasion
p8087
sg13
I2
sasa(dp8088
g2
S'This research aimed to investigate the function and underlying mechanisms of miR424-5p in cervical cancer cell growth.\n'
p8089
sg4
(lp8090
sg23
(lp8091
(dp8092
g7
I99
sg26
VC1516170
p8093
sg10
I18
sg11
Vcancer cell growth
p8094
sg13
I3
sasa(dp8095
g2
S'After transfection with miR424-5p mimics or inhibitor, cervical cancer cell proliferation and apoptosis were evaluated by WST-1 and flow cytometry assay, respectively.\n'
p8096
sg4
(lp8097
sg23
(lp8098
(dp8099
g7
I76
sg26
VC0334094
p8100
sg10
I13
sg11
Vproliferation
p8101
sg13
I1
sa(dp8102
g7
I55
sg26
VC0302592
p8103
sg10
I15
sg11
Vcervical cancer
p8104
sg13
I2
sasa(dp8105
g2
S'Expression of miR424-5p was notably decreased in cervical cancer tissues and cells.\n'
p8106
sg4
(lp8107
sg23
(lp8108
(dp8109
g7
I49
sg26
VC0302592
p8110
sg10
I15
sg11
Vcervical cancer
p8111
sg13
I2
sasa(dp8112
g2
S'This research suggests that miR424-5p may act as a novel anti-oncogene in cervical cancer by blocking cell growth through targeting KDM5B-Notch pathway.\n'
p8113
sg4
(lp8114
(dp8115
g7
I132
sg8
g64
sg10
I5
sg11
VKDM5B
p8116
sg13
I1
sa(dp8117
g7
I57
sg8
VP35125
p8118
sg10
I13
sg11
Vanti-oncogene
p8119
sg13
I1
sasg23
(lp8120
(dp8121
g7
I74
sg26
VC0302592
p8122
sg10
I15
sg11
Vcervical cancer
p8123
sg13
I2
sa(dp8124
g7
I93
sg26
VC0233660
p8125
sg10
I8
sg11
Vblocking
p8126
sg13
I1
sasa(dp8127
g2
S'Here, we identified significantly decreased miR-424 expression in radioresistant cervical cancer cells and specimens from cervical cancer patients with radioresistance compared to their radiosensitive parental cells and specimens from radiosensitive patients, respectively.\n'
p8128
sg4
(lp8129
sg23
(lp8130
(dp8131
g7
I81
sg26
VC0302592
p8132
sg10
I15
sg11
Vcervical cancer
p8133
sg13
I2
sa(dp8134
g7
I81
sg26
VC0302592
p8135
sg10
I15
sg11
Vcervical cancer
p8136
sg13
I2
sasa(dp8137
g2
S'Ectopic expression of miR-424 significantly increased radiation-induced DNA damage, cell apoptosis and G2/M cell cycle arrest in radioresistant cervical cancer cells.\n'
p8138
sg4
(lp8139
(dp8140
g7
I22
sg8
g64
sg10
I7
sg11
VmiR-424
p8141
sg13
I1
sasg23
(lp8142
(dp8143
g7
I54
sg26
VC1514688
p8144
sg10
I28
sg11
Vradiation-induced DNA damage
p8145
sg13
I3
sa(dp8146
g7
I144
sg26
VC0302592
p8147
sg10
I15
sg11
Vcervical cancer
p8148
sg13
I2
sasa(dp8149
g2
S'Notably, miR-424 agomiR treatment can sensitize radioresistant cervical cancer cells to radiation in a xenograft model.\n'
p8150
sg4
(lp8151
(dp8152
g7
I9
sg8
g64
sg10
I14
sg11
VmiR-424 agomiR
p8153
sg13
I2
sasg23
(lp8154
(dp8155
g7
I63
sg26
VC0302592
p8156
sg10
I15
sg11
Vcervical cancer
p8157
sg13
I2
sasa(dp8158
g2
S'Taken together, these findings suggest that miR-424 acts as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant cervical cancers.\n'
p8159
sg4
(lp8160
sg23
(lp8161
(dp8162
g7
I142
sg26
VC0007847
p8163
sg10
I16
sg11
Vcervical cancers
p8164
sg13
I2
sasa(dp8165
g2
S'When comparing cytogenetic effects of encephalitis shows: the young patients tick-borne encephalitis level by routine cytogenetics abnormal cells was significantly higher in carriers of inactive forms of gene GSTM1 (0)/GSTT1 (0) than containing active homozygous variants of these genes.\n'
p8166
sg4
(lp8167
(dp8168
g7
I219
sg8
VP30711
p8169
sg10
I5
sg11
VGSTT1
p8170
sg13
I1
sa(dp8171
g7
I204
sg8
VP09488
p8172
sg10
I10
sg11
Vgene GSTM1
p8173
sg13
I2
sasg23
(lp8174
(dp8175
g7
I38
sg26
VC0014038
p8176
sg10
I12
sg11
Vencephalitis
p8177
sg13
I1
sa(dp8178
g7
I77
sg26
VC0014061
p8179
sg10
I23
sg11
Vtick-borne encephalitis
p8180
sg13
I2
sasa(dp8181
g2
S'Individuals with GSTT1-null and GSTM1-null genotypes showed higher risk of hepatotoxicity with advanced stage of (CD4&lt;200) of HIV infection (P=0.18, OR=1.39; P=0.63, OR=1.13).\n'
p8182
sg4
(lp8183
(dp8184
g7
I17
sg8
VP30711
p8185
sg10
I10
sg11
VGSTT1-null
p8186
sg13
I1
sa(dp8187
g7
I114
sg8
VP01730
p8188
sg10
I3
sg11
VCD4
p8189
sg13
I1
sa(dp8190
g7
I32
sg8
VP09488
p8191
sg10
I5
sg11
VGSTM1
p8192
sg13
I1
sasg23
(lp8193
(dp8194
g7
I129
sg26
VC0019693
p8195
sg10
I13
sg11
VHIV infection
p8196
sg13
I2
sasa(dp8197
g2
S'We analysed the distribution of GSTM1 and GSTT1 gene polymorphisms in Egyptian patients with chronic hepatitis C, and investigated their relationship to the clinical outcome of chronic hepatitis C virus (HCV) infection.\n'
p8198
sg4
(lp8199
(dp8200
g7
I42
sg8
VP30711
p8201
sg10
I10
sg11
VGSTT1 gene
p8202
sg13
I2
sa(dp8203
g7
I32
sg8
VP09488
p8204
sg10
I5
sg11
VGSTM1
p8205
sg13
I1
sasg23
(lp8206
(dp8207
g7
I93
sg26
VC0524910
p8208
sg10
I19
sg11
Vchronic hepatitis C
p8209
sg13
I3
sa(dp8210
g7
I209
sg26
VC0009450
p8211
sg10
I9
sg11
Vinfection
p8212
sg13
I1
sa(dp8213
g7
I93
sg26
VC0524910
p8214
sg10
I19
sg11
Vchronic hepatitis C
p8215
sg13
I3
sasa(dp8216
g2
S'To study the relationship between glutathione S-transferase genes GSTT1 and GSTM1 polymorphisms and the susceptibility to infectious mononucleosis (IM) and acute lymphocytic leukemia (ALL) in children.\n'
p8217
sg4
(lp8218
(dp8219
g7
I34
sg8
VP09488
p8220
sg10
I25
sg11
Vglutathione S-transferase
p8221
sg13
I2
sa(dp8222
g7
I66
sg8
VP30711
p8223
sg10
I5
sg11
VGSTT1
p8224
sg13
I1
sa(dp8225
g7
I76
sg8
VP09488
p8226
sg10
I5
sg11
VGSTM1
p8227
sg13
I1
sasg23
(lp8228
(dp8229
g7
I148
sg26
VC0021345
p8230
sg10
I2
sg11
VIM
p8231
sg13
I1
sa(dp8232
g7
I122
sg26
VC0021345
p8233
sg10
I24
sg11
Vinfectious mononucleosis
p8234
sg13
I2
sa(dp8235
g7
I156
sg26
VC1961102
p8236
sg10
I26
sg11
Vacute lymphocytic leukemia
p8237
sg13
I3
sa(dp8238
g7
I184
sg26
VC1961102
p8239
sg10
I3
sg11
VALL
p8240
sg13
I1
sasa(dp8241
g2
S'To investigate the effects of GSTT1, GSTM1 and GSTP1 gene polymorphism on the stage of hepatitis B infection.\n'
p8242
sg4
(lp8243
(dp8244
g7
I47
sg8
VP09211
p8245
sg10
I10
sg11
VGSTP1 gene
p8246
sg13
I2
sa(dp8247
g7
I30
sg8
VP30711
p8248
sg10
I5
sg11
VGSTT1
p8249
sg13
I1
sa(dp8250
g7
I37
sg8
VP09488
p8251
sg10
I5
sg11
VGSTM1
p8252
sg13
I1
sasg23
(lp8253
(dp8254
g7
I87
sg26
VC0019163
p8255
sg10
I21
sg11
Vhepatitis B infection
p8256
sg13
I3
sasa(dp8257
g2
S'The study included normal fetuses and fetuses with syndromes associated with known mandible pathology: Pierre Robin sequence or complex (n = 8); hemifacial microsomia (Treacher-Collins syndrome, n = 3); postaxial acrofacial dysostosis (n = 1).\n'
p8258
sg4
(lp8259
sg23
(lp8260
(dp8261
g7
I51
sg26
VC0039082
p8262
sg10
I9
sg11
Vsyndromes
p8263
sg13
I1
sa(dp8264
g7
I103
sg26
VC0031900
p8265
sg10
I21
sg11
VPierre Robin sequence
p8266
sg13
I3
sa(dp8267
g7
I168
sg26
VC0242387
p8268
sg10
I25
sg11
VTreacher-Collins syndrome
p8269
sg13
I2
sa(dp8270
g7
I145
sg26
VC1306710
p8271
sg10
I21
sg11
Vhemifacial microsomia
p8272
sg13
I2
sa(dp8273
g7
I92
sg26
VC0677042
p8274
sg10
I9
sg11
Vpathology
p8275
sg13
I1
sa(dp8276
g7
I203
sg26
VC0265257
p8277
sg10
I31
sg11
Vpostaxial acrofacial dysostosis
p8278
sg13
I3
sasa(dp8279
g2
S'Hyperglycemia (HG) exacerbates myocardial ischemia/reperfusion (I/R) injury and renders protective strategies ineffective by amplified inflammatory response via enhanced high-mobility group box-1 (HMGB1) release.\n'
p8280
sg4
(lp8281
(dp8282
g7
I197
sg8
VP09429
p8283
sg10
I5
sg11
VHMGB1
p8284
sg13
I1
sa(dp8285
g7
I170
sg8
VP00390
p8286
sg10
I25
sg11
Vhigh-mobility group box-1
p8287
sg13
I3
sasg23
(lp8288
(dp8289
g7
I135
sg26
VC1155266
p8290
sg10
I21
sg11
Vinflammatory response
p8291
sg13
I2
sa(dp8292
g7
I0
sg26
VC0020456
p8293
sg10
I13
sg11
VHyperglycemia
p8294
sg13
I1
sa(dp8295
g7
I31
sg26
VC0151744
p8296
sg10
I19
sg11
Vmyocardial ischemia
p8297
sg13
I2
sa(dp8298
g7
I15
sg26
VC0020456
p8299
sg10
I2
sg11
VHG
p8300
sg13
I1
sasa(dp8301
g2
S'In this review, we look at the mechanisms of secretion of HMGB1, the role of receptors, MMP enzymes, hypoglycaemia, atherosclerosis, oedema, angiogenesis as well as neuroimmunological reactions and post ischemic brain recovery in IS.\n'
p8302
sg4
(lp8303
(dp8304
g7
I88
sg8
g64
sg10
I11
sg11
VMMP enzymes
p8305
sg13
I2
sa(dp8306
g7
I58
sg8
VP09429
p8307
sg10
I5
sg11
VHMGB1
p8308
sg13
I1
sasg23
(lp8309
(dp8310
g7
I101
sg26
VC0020615
p8311
sg10
I13
sg11
Vhypoglycaemia
p8312
sg13
I1
sa(dp8313
g7
I133
sg26
VC0013604
p8314
sg10
I6
sg11
Voedema
p8315
sg13
I1
sa(dp8316
g7
I116
sg26
VC0004153
p8317
sg10
I15
sg11
Vatherosclerosis
p8318
sg13
I1
sasa(dp8319
g2
S'In the present study, we examined whether alleviation of diabetes-attendant oxidative stress and ensuing change in HMGB1 expression influence the dynamic equilibrium between apoptosis/autophagy and liver damage.\n'
p8320
sg4
(lp8321
(dp8322
g7
I115
sg8
VP09429
p8323
sg10
I5
sg11
VHMGB1
p8324
sg13
I1
sasg23
(lp8325
(dp8326
g7
I198
sg26
VC0151763
p8327
sg10
I12
sg11
Vliver damage
p8328
sg13
I2
sa(dp8329
g7
I76
sg26
VC0242606
p8330
sg10
I16
sg11
Voxidative stress
p8331
sg13
I2
sa(dp8332
g7
I57
sg26
VC0011849
p8333
sg10
I8
sg11
Vdiabetes
p8334
sg13
I1
sasa(dp8335
g2
S'Since reduced HMGB1 binds to RAGE but not to TLR4, redox modification of HMGB1 as a mechanism regulating the cross-talk between apoptosis and autophagy in diabetes is discussed.\n'
p8336
sg4
(lp8337
(dp8338
g7
I29
sg8
g64
sg10
I4
sg11
VRAGE
p8339
sg13
I1
sa(dp8340
g7
I14
sg8
VP09429
p8341
sg10
I5
sg11
VHMGB1
p8342
sg13
I1
sa(dp8343
g7
I14
sg8
VP09429
p8344
sg10
I5
sg11
VHMGB1
p8345
sg13
I1
sasg23
(lp8346
(dp8347
g7
I155
sg26
VC0011849
p8348
sg10
I8
sg11
Vdiabetes
p8349
sg13
I1
sasa(dp8350
g2
S'We evaluated the role of GSTM1 polymorphisms in modifying the association between indoor pesticide exposure and cutaneous melanoma.\n'
p8351
sg4
(lp8352
(dp8353
g7
I25
sg8
VP09488
p8354
sg10
I5
sg11
VGSTM1
p8355
sg13
I1
sasg23
(lp8356
(dp8357
g7
I112
sg26
VC0025202
p8358
sg10
I18
sg11
Vcutaneous melanoma
p8359
sg13
I2
sasa(dp8360
g2
S'After adjustment for sex, age, education, hair colour, skin photo-type, solar lentigines, number of nevi and sunburns episodes in childhood, a 2.76-fold (95% CI: 1.08-7.08) increase in the risk of cutaneous melanoma was observed for GSTM1 null individuals highly exposed to indoor pesticides (&gt;=2 times/year) in comparison with GSTM1 active individuals who received low exposure (&lt;2 times/year).\n'
p8361
sg4
(lp8362
(dp8363
g7
I233
sg8
VP09488
p8364
sg10
I5
sg11
VGSTM1
p8365
sg13
I1
sa(dp8366
g7
I233
sg8
VP09488
p8367
sg10
I5
sg11
VGSTM1
p8368
sg13
I1
sasg23
(lp8369
(dp8370
g7
I197
sg26
VC0025202
p8371
sg10
I18
sg11
Vcutaneous melanoma
p8372
sg13
I2
sa(dp8373
g7
I100
sg26
VC0027962
p8374
sg10
I4
sg11
Vnevi
p8375
sg13
I1
sa(dp8376
g7
I78
sg26
VC0023321
p8377
sg10
I10
sg11
Vlentigines
p8378
sg13
I1
sasa(dp8379
g2
S'Participants exposed to these products for 10 years or more and with GSTM1 null genotype also had an increased risk of cutaneous melanoma (odds ratio: 2.78; 95% CI: 1.01-7.66) in comparison with participants with a low duration of exposure (&lt;10 years) and active GSTM1.\n'
p8380
sg4
(lp8381
(dp8382
g7
I69
sg8
VP09488
p8383
sg10
I5
sg11
VGSTM1
p8384
sg13
I1
sa(dp8385
g7
I69
sg8
VP09488
p8386
sg10
I5
sg11
VGSTM1
p8387
sg13
I1
sasg23
(lp8388
(dp8389
g7
I119
sg26
VC0025202
p8390
sg10
I18
sg11
Vcutaneous melanoma
p8391
sg13
I2
sasa(dp8392
g2
S'These findings suggest that the GSTM1 null genotype is a risk modifier for cutaneous melanoma.\n'
p8393
sg4
(lp8394
(dp8395
g7
I32
sg8
VP09488
p8396
sg10
I5
sg11
VGSTM1
p8397
sg13
I1
sasg23
(lp8398
(dp8399
g7
I75
sg26
VC0025202
p8400
sg10
I18
sg11
Vcutaneous melanoma
p8401
sg13
I2
sasa(dp8402
g2
S'EPHX1 Tyr113His, XPD C156A, and GSTT1 null genotypes were associated with skin cancer risk (OR = 2.99, 95% CI = 1.01-8.83; OR = 2.04, 95% CI = 0.99-4.27; OR = 1.74, 95% CI = 1.00-3.02, resp.'
p8403
sg4
(lp8404
(dp8405
g7
I17
sg8
VP18074
p8406
sg10
I9
sg11
VXPD C156A
p8407
sg13
I2
sa(dp8408
g7
I32
sg8
VP30711
p8409
sg10
I5
sg11
VGSTT1
p8410
sg13
I1
sasg23
(lp8411
(dp8412
g7
I17
sg26
VC0268138
p8413
sg10
I3
sg11
VXPD
p8414
sg13
I1
sa(dp8415
g7
I74
sg26
VC0007114
p8416
sg10
I11
sg11
Vskin cancer
p8417
sg13
I2
sasa(dp8418
g2
S').\n'
p8419
sg4
(lp8420
sg23
(lp8421
sa(dp8422
g2
S'Individuals carrying three risk polymorphisms of EPHX1 Tyr113His, XPD C156A, and GSTs presented a 400% increased skin cancer risk when compared to those with less than or equal to one polymorphism.\n'
p8423
sg4
(lp8424
(dp8425
g7
I81
sg8
g64
sg10
I4
sg11
VGSTs
p8426
sg13
I1
sa(dp8427
g7
I66
sg8
VP18074
p8428
sg10
I9
sg11
VXPD C156A
p8429
sg13
I2
sasg23
(lp8430
(dp8431
g7
I66
sg26
VC0268138
p8432
sg10
I3
sg11
VXPD
p8433
sg13
I1
sa(dp8434
g7
I113
sg26
VC0007114
p8435
sg10
I11
sg11
Vskin cancer
p8436
sg13
I2
sasa(dp8437
g2
S'In conclusion, GSTs, EPHX1, and XPD are potential genetic factors for arsenic-induced skin cancers.\n'
p8438
sg4
(lp8439
(dp8440
g7
I32
sg8
VP18074
p8441
sg10
I3
sg11
VXPD
p8442
sg13
I1
sa(dp8443
g7
I15
sg8
g64
sg10
I4
sg11
VGSTs
p8444
sg13
I1
sasg23
(lp8445
(dp8446
g7
I32
sg26
VC0268138
p8447
sg10
I3
sg11
VXPD
p8448
sg13
I1
sa(dp8449
g7
I86
sg26
VC0007114
p8450
sg10
I12
sg11
Vskin cancers
p8451
sg13
I2
sasa(dp8452
g2
S'Numerous epidemiological studies have evaluated the association of Glutathione S-transferase P1 (GSTP1) Ile105Val polymorphism with the risk of skin cancer.\n'
p8453
sg4
(lp8454
(dp8455
g7
I97
sg8
VP09211
p8456
sg10
I5
sg11
VGSTP1
p8457
sg13
I1
sa(dp8458
g7
I67
sg8
VP14222
p8459
sg10
I28
sg11
VGlutathione S-transferase P1
p8460
sg13
I3
sasg23
(lp8461
(dp8462
g7
I144
sg26
VC0007114
p8463
sg10
I11
sg11
Vskin cancer
p8464
sg13
I2
sasa(dp8465
g2
S'To derive a more precise estimation of the association between the GSTP1 Ile105Val polymorphism and skin cancer risk, a meta-analysis was performed.\n'
p8466
sg4
(lp8467
(dp8468
g7
I67
sg8
VP09211
p8469
sg10
I15
sg11
VGSTP1 Ile105Val
p8470
sg13
I2
sasg23
(lp8471
(dp8472
g7
I100
sg26
VC0007114
p8473
sg10
I11
sg11
Vskin cancer
p8474
sg13
I2
sasa(dp8475
g2
S'We used odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the association of GSTP1 Ile105Val polymorphism with skin cancer risk.\n'
p8476
sg4
(lp8477
(dp8478
g7
I92
sg8
VP09211
p8479
sg10
I15
sg11
VGSTP1 Ile105Val
p8480
sg13
I2
sasg23
(lp8481
(dp8482
g7
I58
sg26
VC0007099
p8483
sg10
I3
sg11
VCIs
p8484
sg13
I1
sa(dp8485
g7
I126
sg26
VC0007114
p8486
sg10
I11
sg11
Vskin cancer
p8487
sg13
I2
sa(dp8488
g7
I36
sg26
VC0007099
p8489
sg10
I20
sg11
Vconfidence intervals
p8490
sg13
I2
sasa(dp8491
g2
S'Overall, we found that GSTP1 Ile105Val polymorphism was not associated with skin cancer risk.\n'
p8492
sg4
(lp8493
(dp8494
g7
I23
sg8
VP09211
p8495
sg10
I15
sg11
VGSTP1 Ile105Val
p8496
sg13
I2
sasg23
(lp8497
(dp8498
g7
I76
sg26
VC0007114
p8499
sg10
I11
sg11
Vskin cancer
p8500
sg13
I2
sasa(dp8501
g2
S'As no previous meta-analyses have examined the association of polymorphisms at GSTT1, GSTP1 Ile105Val with skin cancer risk and independently published studies have produced inconsistent conclusions, we were promoted to estimate the associations in the largest study to date.\n'
p8502
sg4
(lp8503
(dp8504
g7
I79
sg8
VP30711
p8505
sg10
I5
sg11
VGSTT1
p8506
sg13
I1
sa(dp8507
g7
I86
sg8
VP09211
p8508
sg10
I15
sg11
VGSTP1 Ile105Val
p8509
sg13
I2
sasg23
(lp8510
(dp8511
g7
I107
sg26
VC0007114
p8512
sg10
I11
sg11
Vskin cancer
p8513
sg13
I2
sasa(dp8514
g2
S'Computer-assisted searches were carried out to systematically identify the studies of GST polymorphisms and skin cancer.\n'
p8515
sg4
(lp8516
(dp8517
g7
I86
sg8
g64
sg10
I3
sg11
VGST
p8518
sg13
I1
sasg23
(lp8519
(dp8520
g7
I108
sg26
VC0007114
p8521
sg10
I11
sg11
Vskin cancer
p8522
sg13
I2
sasa(dp8523
g2
S'The fixed effects meta-analysis of 15 studies suggested no overall association between GSTT1 null and skin cancer.\n'
p8524
sg4
(lp8525
(dp8526
g7
I87
sg8
VP30711
p8527
sg10
I5
sg11
VGSTT1
p8528
sg13
I1
sasg23
(lp8529
(dp8530
g7
I102
sg26
VC0007114
p8531
sg10
I11
sg11
Vskin cancer
p8532
sg13
I2
sasa(dp8533
g2
S'These statistical data demonstrate that Ile105Val polymorphism of the GSTP1 gene may have genetic contribution to the development of skin cancer, MM in particular.\n'
p8534
sg4
(lp8535
(dp8536
g7
I70
sg8
VP09211
p8537
sg10
I10
sg11
VGSTP1 gene
p8538
sg13
I2
sasg23
(lp8539
(dp8540
g7
I133
sg26
VC0007114
p8541
sg10
I11
sg11
Vskin cancer
p8542
sg13
I2
sasa(dp8543
g2
S'Several human GSTs, including GSTM1 and GSTT1, are polymorphic, and null polymorphisms have been associated with increased UVB erythemal sensitivity and skin cancer risk.\n'
p8544
sg4
(lp8545
(dp8546
g7
I8
sg8
g64
sg10
I10
sg11
Vhuman GSTs
p8547
sg13
I2
sa(dp8548
g7
I30
sg8
VP09488
p8549
sg10
I5
sg11
VGSTM1
p8550
sg13
I1
sa(dp8551
g7
I40
sg8
VP30711
p8552
sg10
I5
sg11
VGSTT1
p8553
sg13
I1
sasg23
(lp8554
(dp8555
g7
I153
sg26
VC0007114
p8556
sg10
I11
sg11
Vskin cancer
p8557
sg13
I2
sasa(dp8558
g2
S'However, the expression of GST isozymes in skin cancer is not known.\n'
p8559
sg4
(lp8560
(dp8561
g7
I27
sg8
g64
sg10
I12
sg11
VGST isozymes
p8562
sg13
I2
sasg23
(lp8563
(dp8564
g7
I43
sg26
VC0007114
p8565
sg10
I11
sg11
Vskin cancer
p8566
sg13
I2
sasa(dp8567
g2
S'Our results suggest that altered phenotypic expression of GST isozymes may be a useful marker for skin cancer.\n'
p8568
sg4
(lp8569
(dp8570
g7
I58
sg8
g64
sg10
I12
sg11
VGST isozymes
p8571
sg13
I2
sasg23
(lp8572
(dp8573
g7
I98
sg26
VC0007114
p8574
sg10
I11
sg11
Vskin cancer
p8575
sg13
I2
sasa(dp8576
g2
S'This study focused on the possible involvement of GSTM1 and GSTT1 polymorphisms in risk modulation of cutaneous melanoma.\n'
p8577
sg4
(lp8578
(dp8579
g7
I60
sg8
VP30711
p8580
sg10
I5
sg11
VGSTT1
p8581
sg13
I1
sa(dp8582
g7
I50
sg8
VP09488
p8583
sg10
I5
sg11
VGSTM1
p8584
sg13
I1
sasg23
(lp8585
(dp8586
g7
I102
sg26
VC0025202
p8587
sg10
I18
sg11
Vcutaneous melanoma
p8588
sg13
I2
sasa(dp8589
g2
S'Within a case-control study, the presence of the null polymorphism at GSTM1 and GSTT1 was investigated in 188 cases of cutaneous melanoma and 152 controls.\n'
p8590
sg4
(lp8591
(dp8592
g7
I70
sg8
VP09488
p8593
sg10
I5
sg11
VGSTM1
p8594
sg13
I1
sa(dp8595
g7
I80
sg8
VP30711
p8596
sg10
I5
sg11
VGSTT1
p8597
sg13
I1
sasg23
(lp8598
(dp8599
g7
I119
sg26
VC0025202
p8600
sg10
I18
sg11
Vcutaneous melanoma
p8601
sg13
I2
sasa(dp8602
g2
S'Voclosporin is a relatively new calcineurin inhibitor that has been used successfully in humans for the treatment of plaque psoriasis.\n'
p8603
sg4
(lp8604
sg23
(lp8605
(dp8606
g7
I117
sg26
VC0406317
p8607
sg10
I16
sg11
Vplaque psoriasis
p8608
sg13
I2
sasa(dp8609
g2
S'Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis.\n'
p8610
sg4
(lp8611
sg23
(lp8612
(dp8613
g7
I77
sg26
VC0033860
p8614
sg10
I9
sg11
Vpsoriasis
p8615
sg13
I1
sasa(dp8616
g2
S"To investigate the possibility that gliosis causes the increased Mr 60,000 protein phosphorylation, cases of Pick's disease and multi-infarct dementia were also studied.\n"
p8617
sg4
(lp8618
sg23
(lp8619
(dp8620
g7
I36
sg26
VC0017639
p8621
sg10
I7
sg11
Vgliosis
p8622
sg13
I1
sa(dp8623
g7
I109
sg26
VC0236642
p8624
sg10
I14
sg11
VPick's disease
p8625
sg13
I2
sa(dp8626
g7
I128
sg26
VC0011263
p8627
sg10
I22
sg11
Vmulti-infarct dementia
p8628
sg13
I2
sasa(dp8629
g2
S'Because the hepatic receptor presents avidity for the carbohydrates of IgA1, a protein deposited in the glomerulus of patients with IgA nephropathy, the interaction of IgA1 with the mesangial ASGP-R was explored.\n'
p8630
sg4
(lp8631
(dp8632
g7
I71
sg8
VP01876
p8633
sg10
I4
sg11
VIgA1
p8634
sg13
I1
sa(dp8635
g7
I71
sg8
VP11912
p8636
sg10
I3
sg11
VIgA
p8637
sg13
I1
sa(dp8638
g7
I71
sg8
VP01876
p8639
sg10
I4
sg11
VIgA1
p8640
sg13
I1
sa(dp8641
g7
I192
sg8
VP07307
p8642
sg10
I6
sg11
VASGP-R
p8643
sg13
I1
sasg23
(lp8644
(dp8645
g7
I132
sg26
VC0017661
p8646
sg10
I15
sg11
VIgA nephropathy
p8647
sg13
I2
sasa(dp8648
g2
S'Interestingly, mutations in a PTP-PEST- and PTP-HSCF-interacting protein, PSTPIP1, were identified in humans with pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome and familial recurrent arthritis, two autoinflammatory diseases.\n'
p8649
sg4
(lp8650
(dp8651
g7
I74
sg8
g64
sg10
I7
sg11
VPSTPIP1
p8652
sg13
I1
sa(dp8653
g7
I30
sg8
g64
sg10
I42
sg11
VPTP-PEST- and PTP-HSCF-interacting protein
p8654
sg13
I4
sasg23
(lp8655
(dp8656
g7
I114
sg26
VC1858361
p8657
sg10
I58
sg11
Vpyogenic sterile arthritis, pyoderma gangrenosum, and acne
p8658
sg13
I7
sa(dp8659
g7
I34
sg26
VC0032064
p8660
sg10
I4
sg11
VPEST
p8661
sg13
I1
sa(dp8662
g7
I193
sg26
VC1858361
p8663
sg10
I28
sg11
Vfamilial recurrent arthritis
p8664
sg13
I3
sa(dp8665
g7
I180
sg26
VC0039082
p8666
sg10
I8
sg11
Vsyndrome
p8667
sg13
I1
sa(dp8668
g7
I30
sg26
VC0398648
p8669
sg10
I3
sg11
VPTP
p8670
sg13
I1
sa(dp8671
g7
I30
sg26
VC0398648
p8672
sg10
I3
sg11
VPTP
p8673
sg13
I1
sa(dp8674
g7
I174
sg26
VC0220697
p8675
sg10
I4
sg11
VPAPA
p8676
sg13
I1
sasa(dp8677
g2
S'Bruck Syndrome is a connective tissue disease associated with inactivating mutations in lysyl hydroxylase 2 (LH2/PLOD2) or FK506 binding protein 65 (FKBP65/FKBP10).\n'
p8678
sg4
(lp8679
(dp8680
g7
I113
sg8
g64
sg10
I5
sg11
VPLOD2
p8681
sg13
I1
sa(dp8682
g7
I149
sg8
g64
sg10
I6
sg11
VFKBP65
p8683
sg13
I1
sa(dp8684
g7
I156
sg8
g64
sg10
I6
sg11
VFKBP10
p8685
sg13
I1
sa(dp8686
g7
I109
sg8
VP50458
p8687
sg10
I3
sg11
VLH2
p8688
sg13
I1
sa(dp8689
g7
I88
sg8
g64
sg10
I19
sg11
Vlysyl hydroxylase 2
p8690
sg13
I3
sasg23
(lp8691
(dp8692
g7
I20
sg26
VC0009782
p8693
sg10
I25
sg11
Vconnective tissue disease
p8694
sg13
I3
sa(dp8695
g7
I0
sg26
VC0432253
p8696
sg10
I14
sg11
VBruck Syndrome
p8697
sg13
I2
sasa(dp8698
g2
S'The phenotype overlaps with that seen with mutations in PLOD2 (Bruck syndrome II), which encodes LH2, the enzyme that hydroxylates the telopeptide lysyl residues.\n'
p8699
sg4
(lp8700
(dp8701
g7
I97
sg8
VP50458
p8702
sg10
I3
sg11
VLH2
p8703
sg13
I1
sa(dp8704
g7
I56
sg8
g64
sg10
I5
sg11
VPLOD2
p8705
sg13
I1
sasg23
(lp8706
(dp8707
g7
I63
sg26
VC0432253
p8708
sg10
I14
sg11
VBruck syndrome
p8709
sg13
I2
sasa(dp8710
g2
S'PLOD2 and FKBP10 are genes mutated in Bruck syndrome (BS), a condition resembling osteogenesis imperfecta (OI), but that is also typically associated with congenital joint contractures.\n'
p8711
sg4
(lp8712
(dp8713
g7
I10
sg8
g64
sg10
I6
sg11
VFKBP10
p8714
sg13
I1
sa(dp8715
g7
I0
sg8
g64
sg10
I5
sg11
VPLOD2
p8716
sg13
I1
sasg23
(lp8717
(dp8718
g7
I155
sg26
VC1393851
p8719
sg10
I29
sg11
Vcongenital joint contractures
p8720
sg13
I3
sa(dp8721
g7
I54
sg26
VC0432253
p8722
sg10
I2
sg11
VBS
p8723
sg13
I1
sa(dp8724
g7
I107
sg26
VC0029434
p8725
sg10
I2
sg11
VOI
p8726
sg13
I1
sa(dp8727
g7
I61
sg26
VC0012634
p8728
sg10
I9
sg11
Vcondition
p8729
sg13
I1
sa(dp8730
g7
I82
sg26
VC0029434
p8731
sg10
I23
sg11
Vosteogenesis imperfecta
p8732
sg13
I2
sa(dp8733
g7
I38
sg26
VC0432253
p8734
sg10
I14
sg11
VBruck syndrome
p8735
sg13
I2
sasa(dp8736
g2
S'Because of (i) absence of COL1A1/2 mutations, (ii) a consanguineous pedigree with a similarly affected sibling and (iii) the existence of congenital joint contractures with absence of recessive variants in PLOD2, mutation analysis was performed of the FKBP10 gene, recently associated with Bruck syndrome and/or recessive OI.\n'
p8737
sg4
(lp8738
(dp8739
g7
I206
sg8
g64
sg10
I5
sg11
VPLOD2
p8740
sg13
I1
sa(dp8741
g7
I252
sg8
g64
sg10
I11
sg11
VFKBP10 gene
p8742
sg13
I2
sasg23
(lp8743
(dp8744
g7
I138
sg26
VC1393851
p8745
sg10
I29
sg11
Vcongenital joint contractures
p8746
sg13
I3
sa(dp8747
g7
I290
sg26
VC0432253
p8748
sg10
I14
sg11
VBruck syndrome
p8749
sg13
I2
sasa(dp8750
g2
S'Bruck syndrome is a recessive disorder featuring congenital contractures in addition to bone fragility; Bruck syndrome type 2 is caused by mutations in PLOD2 encoding collagen lysyl hydroxylase, whereas Bruck syndrome type 1 has been mapped to chromosome 17, with evidence suggesting region 17p12, but the gene has remained elusive so far.\n'
p8751
sg4
(lp8752
(dp8753
g7
I167
sg8
g64
sg10
I26
sg11
Vcollagen lysyl hydroxylase
p8754
sg13
I3
sa(dp8755
g7
I152
sg8
g64
sg10
I5
sg11
VPLOD2
p8756
sg13
I1
sasg23
(lp8757
(dp8758
g7
I49
sg26
VC0332878
p8759
sg10
I23
sg11
Vcongenital contractures
p8760
sg13
I2
sa(dp8761
g7
I0
sg26
VC0432253
p8762
sg10
I14
sg11
VBruck syndrome
p8763
sg13
I2
sa(dp8764
g7
I0
sg26
VC0432253
p8765
sg10
I14
sg11
VBruck syndrome
p8766
sg13
I2
sa(dp8767
g7
I0
sg26
VC0432253
p8768
sg10
I14
sg11
VBruck syndrome
p8769
sg13
I2
sa(dp8770
g7
I88
sg26
VC1390474
p8771
sg10
I14
sg11
Vbone fragility
p8772
sg13
I2
sasa(dp8773
g2
S'This suggested that the association of Nck to tyrosine 361 in Dok1 is necessary for the JNK and c-Jun activation by glial cell line-derived neurotrophic factor or RET-MEN2B.\n'
p8774
sg4
(lp8775
(dp8776
g7
I62
sg8
g64
sg10
I4
sg11
VDok1
p8777
sg13
I1
sa(dp8778
g7
I88
sg8
VP53779
p8779
sg10
I3
sg11
VJNK
p8780
sg13
I1
sa(dp8781
g7
I96
sg8
VP05412
p8782
sg10
I5
sg11
Vc-Jun
p8783
sg13
I1
sa(dp8784
g7
I46
sg8
VP14679
p8785
sg10
I12
sg11
Vtyrosine 361
p8786
sg13
I2
sa(dp8787
g7
I39
sg8
VP16333
p8788
sg10
I3
sg11
VNck
p8789
sg13
I1
sa(dp8790
g7
I163
sg8
VP07949
p8791
sg10
I9
sg11
VRET-MEN2B
p8792
sg13
I1
sasg23
(lp8793
(dp8794
g7
I167
sg26
VC0025269
p8795
sg10
I5
sg11
VMEN2B
p8796
sg13
I1
sasa(dp8797
g2
S'Because a high level of the JNK phosphorylation was observed in the cells expressing RET-MEN2B, its strong activation via Nck binding to Dok1 may be responsible for aggressive properties of medullary thyroid carcinoma developed in MEN 2B.\n'
p8798
sg4
(lp8799
(dp8800
g7
I85
sg8
VP07949
p8801
sg10
I3
sg11
VRET
p8802
sg13
I1
sa(dp8803
g7
I28
sg8
VP53779
p8804
sg10
I3
sg11
VJNK
p8805
sg13
I1
sa(dp8806
g7
I122
sg8
VP16333
p8807
sg10
I3
sg11
VNck
p8808
sg13
I1
sa(dp8809
g7
I137
sg8
g64
sg10
I4
sg11
VDok1
p8810
sg13
I1
sa(dp8811
g7
I89
sg8
VP07949
p8812
sg10
I5
sg11
VMEN2B
p8813
sg13
I1
sasg23
(lp8814
(dp8815
g7
I165
sg26
VC0001807
p8816
sg10
I10
sg11
Vaggressive
p8817
sg13
I1
sa(dp8818
g7
I89
sg26
VC0025269
p8819
sg10
I5
sg11
VMEN2B
p8820
sg13
I1
sa(dp8821
g7
I231
sg26
VC0025269
p8822
sg10
I6
sg11
VMEN 2B
p8823
sg13
I2
sa(dp8824
g7
I190
sg26
VC0238462
p8825
sg10
I27
sg11
Vmedullary thyroid carcinoma
p8826
sg13
I3
sasa(dp8827
g2
S'In this report, using a constitutively activated Ret TK form, Ret-ptc 2, we demonstrate that the MEN 2B as the activated WT Ret TK binds to several SH2 signalling proteins such as Shc, Grb-2, Phospholipase Cgamma, Crk and Nck.\n'
p8828
sg4
(lp8829
(dp8830
g7
I214
sg8
VP46108
p8831
sg10
I3
sg11
VCrk
p8832
sg13
I1
sa(dp8833
g7
I222
sg8
VP16333
p8834
sg10
I3
sg11
VNck
p8835
sg13
I1
sa(dp8836
g7
I185
sg8
VP62993
p8837
sg10
I5
sg11
VGrb-2
p8838
sg13
I1
sa(dp8839
g7
I97
sg8
g64
sg10
I6
sg11
VMEN 2B
p8840
sg13
I2
sa(dp8841
g7
I192
sg8
VP04054
p8842
sg10
I20
sg11
VPhospholipase Cgamma
p8843
sg13
I2
sa(dp8844
g7
I148
sg8
VP02649
p8845
sg10
I23
sg11
VSH2 signalling proteins
p8846
sg13
I3
sa(dp8847
g7
I62
sg8
g64
sg10
I9
sg11
VRet-ptc 2
p8848
sg13
I2
sa(dp8849
g7
I111
sg8
VP29401
p8850
sg10
I19
sg11
Vactivated WT Ret TK
p8851
sg13
I4
sa(dp8852
g7
I49
sg8
VP29401
p8853
sg10
I6
sg11
VRet TK
p8854
sg13
I2
sasg23
(lp8855
(dp8856
g7
I97
sg26
VC0025269
p8857
sg10
I6
sg11
VMEN 2B
p8858
sg13
I2
sa(dp8859
g7
I66
sg26
VC0238463
p8860
sg10
I3
sg11
Vptc
p8861
sg13
I1
sasa(dp8862
g2
S'However, in contrast to the activated WT form, expression of the MEN 2B mutated Ret-ptc 2 results in the tyrosine phosphorylation of a panel of proteins which interestingly interact with Crk and Nck.\n'
p8863
sg4
(lp8864
(dp8865
g7
I195
sg8
VP16333
p8866
sg10
I3
sg11
VNck
p8867
sg13
I1
sa(dp8868
g7
I187
sg8
VP46108
p8869
sg10
I3
sg11
VCrk
p8870
sg13
I1
sa(dp8871
g7
I65
sg8
g64
sg10
I24
sg11
VMEN 2B mutated Ret-ptc 2
p8872
sg13
I5
sasg23
(lp8873
(dp8874
g7
I84
sg26
VC0238463
p8875
sg10
I3
sg11
Vptc
p8876
sg13
I1
sa(dp8877
g7
I65
sg26
VC0025269
p8878
sg10
I6
sg11
VMEN 2B
p8879
sg13
I2
sasa(dp8880
g2
S'Of the 43 patients with advanced anal carcinoma evaluable for PD-L1 expression, 32 (74%) had PD-L1-positive tumors as assessed with the 22C3 prototype assay, of whom 25 were enrolled between April and September 2014.\n'
p8881
sg4
(lp8882
sg23
(lp8883
(dp8884
g7
I33
sg26
VC0349534
p8885
sg10
I14
sg11
Vanal carcinoma
p8886
sg13
I2
sa(dp8887
g7
I108
sg26
VC0027651
p8888
sg10
I6
sg11
Vtumors
p8889
sg13
I1
sa(dp8890
g7
I48
sg26
VC1516986
p8891
sg10
I9
sg11
Vevaluable
p8892
sg13
I1
sasa(dp8893
g2
S'In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity.\n'
p8894
sg4
(lp8895
sg23
(lp8896
(dp8897
g7
I60
sg26
VC1412036
p8898
sg10
I28
sg11
Vsquamous cell anal carcinoma
p8899
sg13
I4
sasa(dp8900
g2
S'To evaluate the expression of programmed cell death-ligand 1 (PD-L1) in anal cancer.\n'
p8901
sg4
(lp8902
sg23
(lp8903
(dp8904
g7
I72
sg26
VC0153446
p8905
sg10
I11
sg11
Vanal cancer
p8906
sg13
I2
sasa(dp8907
g2
S'SIOD is rare disorder related to SMARCAL1 or SMARCAL2 gene mutation, including (among other comorbidities) T-cell immunodeficiency, nephrotic syndrome, and renal failure.\n'
p8908
sg4
(lp8909
(dp8910
g7
I0
sg8
VP29377
p8911
sg10
I4
sg11
VSIOD
p8912
sg13
I1
sa(dp8913
g7
I33
sg8
g64
sg10
I8
sg11
VSMARCAL1
p8914
sg13
I1
sasg23
(lp8915
(dp8916
g7
I107
sg26
VC1274233
p8917
sg10
I23
sg11
VT-cell immunodeficiency
p8918
sg13
I2
sa(dp8919
g7
I156
sg26
VC0035078
p8920
sg10
I13
sg11
Vrenal failure
p8921
sg13
I2
sa(dp8922
g7
I0
sg26
VC0877024
p8923
sg10
I4
sg11
VSIOD
p8924
sg13
I1
sa(dp8925
g7
I132
sg26
VC0027726
p8926
sg10
I18
sg11
Vnephrotic syndrome
p8927
sg13
I2
sa(dp8928
g7
I8
sg26
VC0678236
p8929
sg10
I13
sg11
Vrare disorder
p8930
sg13
I2
sasa(dp8931
g2
S'Schimke immuno-osseous dysplasia (SIOD) is a pleiotropic disorder caused by mutations in the SWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like-1 (SMARCAL1) gene, with multiple clinical features, notably end-stage renal disease.\n'
p8932
sg4
(lp8933
(dp8934
g7
I97
sg8
VP51532
p8935
sg10
I31
sg11
VSNF2-related, matrix-associated
p8936
sg13
I2
sa(dp8937
g7
I190
sg8
g64
sg10
I8
sg11
VSMARCAL1
p8938
sg13
I1
sa(dp8939
g7
I93
sg8
VP28370
p8940
sg10
I3
sg11
VSWI
p8941
sg13
I1
sasg23
(lp8942
(dp8943
g7
I34
sg26
VC0877024
p8944
sg10
I4
sg11
VSIOD
p8945
sg13
I1
sa(dp8946
g7
I247
sg26
VC0022661
p8947
sg10
I23
sg11
Vend-stage renal disease
p8948
sg13
I3
sa(dp8949
g7
I0
sg26
VC0877024
p8950
sg10
I32
sg11
VSchimke immuno-osseous dysplasia
p8951
sg13
I3
sasa(dp8952
g2
S'SIOD, which is caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal dysplasia, T cell deficiency, and renal failure.\n'
p8953
sg4
(lp8954
(dp8955
g7
I0
sg8
VP29377
p8956
sg10
I4
sg11
VSIOD
p8957
sg13
I1
sa(dp8958
g7
I38
sg8
g64
sg10
I8
sg11
VSMARCAL1
p8959
sg13
I1
sasg23
(lp8960
(dp8961
g7
I163
sg26
VC0035078
p8962
sg10
I13
sg11
Vrenal failure
p8963
sg13
I2
sa(dp8964
g7
I120
sg26
VC0410528
p8965
sg10
I18
sg11
Vskeletal dysplasia
p8966
sg13
I2
sa(dp8967
g7
I0
sg26
VC0877024
p8968
sg10
I4
sg11
VSIOD
p8969
sg13
I1
sa(dp8970
g7
I140
sg26
VC1744558
p8971
sg10
I17
sg11
VT cell deficiency
p8972
sg13
I3
sasa(dp8973
g2
S'For example, mutations in SMARCAL1 (also named HARP) cause Schimke immuno-osseous dysplasia (SIOD); a multi-system disorder characterized by growth defects, immune deficiencies, renal failure and other complex phenotypes.\n'
p8974
sg4
(lp8975
(dp8976
g7
I47
sg8
VP21246
p8977
sg10
I4
sg11
VHARP
p8978
sg13
I1
sa(dp8979
g7
I26
sg8
g64
sg10
I8
sg11
VSMARCAL1
p8980
sg13
I1
sasg23
(lp8981
(dp8982
g7
I93
sg26
VC0877024
p8983
sg10
I4
sg11
VSIOD
p8984
sg13
I1
sa(dp8985
g7
I178
sg26
VC0035078
p8986
sg10
I13
sg11
Vrenal failure
p8987
sg13
I2
sa(dp8988
g7
I59
sg26
VC0877024
p8989
sg10
I32
sg11
VSchimke immuno-osseous dysplasia
p8990
sg13
I3
sasa(dp8991
g2
S'Mutations in SMARCAL1 cause Schimke Immuno-Osseous Dysplasia (SIOD), an autosomal recessive multisystem developmental disease characterized by growth retardation, T-cell deficiency, bone marrow failure, anemia and renal failure.\n'
p8992
sg4
(lp8993
(dp8994
g7
I13
sg8
g64
sg10
I8
sg11
VSMARCAL1
p8995
sg13
I1
sasg23
(lp8996
(dp8997
g7
I182
sg26
VC0030312
p8998
sg10
I19
sg11
Vbone marrow failure
p8999
sg13
I3
sa(dp9000
g7
I203
sg26
VC0002871
p9001
sg10
I6
sg11
Vanemia
p9002
sg13
I1
sa(dp9003
g7
I143
sg26
VC0151686
p9004
sg10
I18
sg11
Vgrowth retardation
p9005
sg13
I2
sa(dp9006
g7
I62
sg26
VC0877024
p9007
sg10
I4
sg11
VSIOD
p9008
sg13
I1
sa(dp9009
g7
I163
sg26
VC1744558
p9010
sg10
I17
sg11
VT-cell deficiency
p9011
sg13
I2
sa(dp9012
g7
I28
sg26
VC0877024
p9013
sg10
I32
sg11
VSchimke Immuno-Osseous Dysplasia
p9014
sg13
I3
sa(dp9015
g7
I214
sg26
VC0035078
p9016
sg10
I13
sg11
Vrenal failure
p9017
sg13
I2
sasa(dp9018
g2
S'We hypothesized that common polymorphisms in the five human lysyl oxidase genes (LOX, LOXL1, LOXL2, LOXL3, and LOXL4) may be associated with the phenotype of adolescent idiopathic scoliosis.\n'
p9019
sg4
(lp9020
(dp9021
g7
I81
sg8
VP28300
p9022
sg10
I3
sg11
VLOX
p9023
sg13
I1
sa(dp9024
g7
I86
sg8
g64
sg10
I5
sg11
VLOXL1
p9025
sg13
I1
sa(dp9026
g7
I111
sg8
g64
sg10
I5
sg11
VLOXL4
p9027
sg13
I1
sa(dp9028
g7
I54
sg8
VP28300
p9029
sg10
I25
sg11
Vhuman lysyl oxidase genes
p9030
sg13
I4
sa(dp9031
g7
I100
sg8
VP58215
p9032
sg10
I5
sg11
VLOXL3
p9033
sg13
I1
sa(dp9034
g7
I93
sg8
g64
sg10
I5
sg11
VLOXL2
p9035
sg13
I1
sasg23
(lp9036
(dp9037
g7
I158
sg26
VC0410702
p9038
sg10
I31
sg11
Vadolescent idiopathic scoliosis
p9039
sg13
I3
sasa(dp9040
g2
S'No evidence for significant association was found between coding or tag SNPs in LOX, LOXL1, LOXL2, LOXL3, and LOXL4 and the phenotype of adolescent idiopathic scoliosis.\n'
p9041
sg4
(lp9042
(dp9043
g7
I99
sg8
VP58215
p9044
sg10
I5
sg11
VLOXL3
p9045
sg13
I1
sa(dp9046
g7
I80
sg8
VP28300
p9047
sg10
I3
sg11
VLOX
p9048
sg13
I1
sa(dp9049
g7
I92
sg8
g64
sg10
I5
sg11
VLOXL2
p9050
sg13
I1
sa(dp9051
g7
I85
sg8
g64
sg10
I5
sg11
VLOXL1
p9052
sg13
I1
sa(dp9053
g7
I110
sg8
g64
sg10
I5
sg11
VLOXL4
p9054
sg13
I1
sasg23
(lp9055
(dp9056
g7
I68
sg26
VC0037293
p9057
sg10
I3
sg11
Vtag
p9058
sg13
I1
sa(dp9059
g7
I137
sg26
VC0410702
p9060
sg10
I31
sg11
Vadolescent idiopathic scoliosis
p9061
sg13
I3
sasa(dp9062
g2
S'The transcription factor Ets1 is expressed at low levels in epidermal keratinocytes under physiological conditions, but is over-expressed in cutaneous squamous cell carcinoma (SCC).\n'
p9063
sg4
(lp9064
(dp9065
g7
I25
sg8
VP14921
p9066
sg10
I4
sg11
VEts1
p9067
sg13
I1
sasg23
(lp9068
(dp9069
g7
I141
sg26
VC0553723
p9070
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p9071
sg13
I4
sasa(dp9072
g2
S'We aimed to evaluate the role of ETS-1 in the invasiveness and progression of laryngeal squamous carcinoma, as well as to determine the correlations between clinicopathological characteristics and expression of this molecule.\n'
p9073
sg4
(lp9074
(dp9075
g7
I33
sg8
VP14921
p9076
sg10
I5
sg11
VETS-1
p9077
sg13
I1
sasg23
(lp9078
(dp9079
g7
I88
sg26
VC0007137
p9080
sg10
I18
sg11
Vsquamous carcinoma
p9081
sg13
I2
sasa(dp9082
g2
S'We assessed the levels of ETS-1 in a total of 96 laryngeal specimens of varying degrees of dysplasia, microinvasive squamous carcinoma (8), and invasive squamous carcinoma (60), using normal mucosal epithelium (10) as a positive control.\n'
p9083
sg4
(lp9084
(dp9085
g7
I26
sg8
VP14921
p9086
sg10
I5
sg11
VETS-1
p9087
sg13
I1
sasg23
(lp9088
(dp9089
g7
I91
sg26
VC0334044
p9090
sg10
I9
sg11
Vdysplasia
p9091
sg13
I1
sa(dp9092
g7
I116
sg26
VC0007137
p9093
sg10
I18
sg11
Vsquamous carcinoma
p9094
sg13
I2
sa(dp9095
g7
I102
sg26
VC0205622
p9096
sg10
I13
sg11
Vmicroinvasive
p9097
sg13
I1
sa(dp9098
g7
I116
sg26
VC0007137
p9099
sg10
I18
sg11
Vsquamous carcinoma
p9100
sg13
I2
sasa(dp9101
g2
S'We found a significantly higher ETS-1 expression in invasive laryngeal squamous cell carcinomas than in dysplasia (P&lt;0.001).\n'
p9102
sg4
(lp9103
(dp9104
g7
I32
sg8
VP14921
p9105
sg10
I5
sg11
VETS-1
p9106
sg13
I1
sasg23
(lp9107
(dp9108
g7
I71
sg26
VC0007137
p9109
sg10
I24
sg11
Vsquamous cell carcinomas
p9110
sg13
I3
sa(dp9111
g7
I104
sg26
VC0334044
p9112
sg10
I9
sg11
Vdysplasia
p9113
sg13
I1
sasa(dp9114
g2
S'This data suggest that ETS-1 expression may play an important role in tumor invasion, and may function in the initiation of the invasive process in laryngeal squamous cell carcinoma.\n'
p9115
sg4
(lp9116
(dp9117
g7
I23
sg8
VP14921
p9118
sg10
I5
sg11
VETS-1
p9119
sg13
I1
sasg23
(lp9120
(dp9121
g7
I70
sg26
VC0027651
p9122
sg10
I5
sg11
Vtumor
p9123
sg13
I1
sa(dp9124
g7
I76
sg26
VC2699153
p9125
sg10
I8
sg11
Vinvasion
p9126
sg13
I1
sa(dp9127
g7
I148
sg26
VC0280324
p9128
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p9129
sg13
I4
sasa(dp9130
g2
S'Immunohistochemical staining showed Ets-1 expression in 82 cases of 156 carcinomas (53%): 36 of 52 (69%) squamous cell carcinomas, 41 of 96 (43%) adenocarcinomas, and 5 of 8 (63%) other carcinomas.\n'
p9131
sg4
(lp9132
(dp9133
g7
I36
sg8
VP14921
p9134
sg10
I5
sg11
VEts-1
p9135
sg13
I1
sasg23
(lp9136
(dp9137
g7
I146
sg26
VC0001418
p9138
sg10
I15
sg11
Vadenocarcinomas
p9139
sg13
I1
sa(dp9140
g7
I72
sg26
VC0007097
p9141
sg10
I10
sg11
Vcarcinomas
p9142
sg13
I1
sa(dp9143
g7
I105
sg26
VC0007137
p9144
sg10
I24
sg11
Vsquamous cell carcinomas
p9145
sg13
I3
sa(dp9146
g7
I72
sg26
VC0007097
p9147
sg10
I10
sg11
Vcarcinomas
p9148
sg13
I1
sasa(dp9149
g2
S'Etamicastat is a dopamine Beta-hydroxylase (DBetaH) inhibitor currently in clinical development for the treatment of hypertension and heart failure.\n'
p9150
sg4
(lp9151
(dp9152
g7
I17
sg8
VP09172
p9153
sg10
I25
sg11
Vdopamine Beta-hydroxylase
p9154
sg13
I2
sa(dp9155
g7
I44
sg8
VP09172
p9156
sg10
I6
sg11
VDBetaH
p9157
sg13
I1
sasg23
(lp9158
(dp9159
g7
I117
sg26
VC0020538
p9160
sg10
I12
sg11
Vhypertension
p9161
sg13
I1
sa(dp9162
g7
I134
sg26
VC0018802
p9163
sg10
I13
sg11
Vheart failure
p9164
sg13
I2
sasa(dp9165
g2
S'Etamicastat is a new dopamine-Beta-hydroxylase (DBetaH) inhibitor currently in clinical development for the treatment of hypertension and heart failure.\n'
p9166
sg4
(lp9167
(dp9168
g7
I21
sg8
VP09172
p9169
sg10
I25
sg11
Vdopamine-Beta-hydroxylase
p9170
sg13
I1
sa(dp9171
g7
I48
sg8
VP09172
p9172
sg10
I6
sg11
VDBetaH
p9173
sg13
I1
sasg23
(lp9174
(dp9175
g7
I138
sg26
VC0018802
p9176
sg10
I13
sg11
Vheart failure
p9177
sg13
I2
sa(dp9178
g7
I121
sg26
VC0020538
p9179
sg10
I12
sg11
Vhypertension
p9180
sg13
I1
sasa(dp9181
g2
S'In this Review, we discuss how SSEs are controlled as part of genome maintenance pathways in eukaryotes, with an emphasis on the elaborate mechanisms that regulate the members of the major SSE families - including the xeroderma pigmentosum group F-complementing protein (XPF) and MMS and UV-sensitive protein 81 (MUS81)-dependent nucleases, and the flap endonuclease 1 (FEN1), XPG and XPG-like endonuclease 1 (GEN1) enzymes - during processes such as DNA adduct repair, Holliday junction processing and replication stress.\n'
p9182
sg4
(lp9183
(dp9184
g7
I313
sg8
g64
sg10
I5
sg11
VMUS81
p9185
sg13
I1
sa(dp9186
g7
I271
sg8
g64
sg10
I3
sg11
VXPF
p9187
sg13
I1
sa(dp9188
g7
I349
sg8
VP39748
p9189
sg10
I19
sg11
Vflap endonuclease 1
p9190
sg13
I3
sa(dp9191
g7
I370
sg8
VP39748
p9192
sg10
I4
sg11
VFEN1
p9193
sg13
I1
sa(dp9194
g7
I410
sg8
g64
sg10
I4
sg11
VGEN1
p9195
sg13
I1
sa(dp9196
g7
I385
sg8
VP28715
p9197
sg10
I23
sg11
VXPG-like endonuclease 1
p9198
sg13
I3
sa(dp9199
g7
I377
sg8
VP28715
p9200
sg10
I3
sg11
VXPG
p9201
sg13
I1
sa(dp9202
g7
I218
sg8
VP00390
p9203
sg10
I51
sg11
Vxeroderma pigmentosum group F-complementing protein
p9204
sg13
I5
sa(dp9205
g7
I280
sg8
g64
sg10
I31
sg11
VMMS and UV-sensitive protein 81
p9206
sg13
I5
sasg23
(lp9207
(dp9208
g7
I377
sg26
VC0268141
p9209
sg10
I3
sg11
VXPG
p9210
sg13
I1
sa(dp9211
g7
I271
sg26
VC0268140
p9212
sg10
I3
sg11
VXPF
p9213
sg13
I1
sa(dp9214
g7
I218
sg26
VC0268140
p9215
sg10
I51
sg11
Vxeroderma pigmentosum group F-complementing protein
p9216
sg13
I5
sa(dp9217
g7
I377
sg26
VC0268141
p9218
sg10
I3
sg11
VXPG
p9219
sg13
I1
sasa(dp9220
g2
S"The human HJ resolvase GEN1 is a member of the XPG/Rad2 family of 5'-flap endonucleases.\n"
p9221
sg4
(lp9222
(dp9223
g7
I47
sg8
VP28715
p9224
sg10
I3
sg11
VXPG
p9225
sg13
I1
sa(dp9226
g7
I51
sg8
VP39748
p9227
sg10
I4
sg11
VRad2
p9228
sg13
I1
sa(dp9229
g7
I4
sg8
g64
sg10
I23
sg11
Vhuman HJ resolvase GEN1
p9230
sg13
I4
sasg23
(lp9231
(dp9232
g7
I47
sg26
VC0268141
p9233
sg10
I3
sg11
VXPG
p9234
sg13
I1
sasa(dp9235
g2
S'The structure of the GEN1 protein reveals it to have an elaborated FEN-XPG family fold that is modified for its role in four-way junction resolution.\n'
p9236
sg4
(lp9237
(dp9238
g7
I21
sg8
g64
sg10
I12
sg11
VGEN1 protein
p9239
sg13
I2
sasg23
(lp9240
(dp9241
g7
I71
sg26
VC0268141
p9242
sg10
I3
sg11
VXPG
p9243
sg13
I1
sasa(dp9244
g2
S'The GEN1 core is similar to other Rad2/XPG nucleases.\n'
p9245
sg4
(lp9246
(dp9247
g7
I39
sg8
VP28715
p9248
sg10
I13
sg11
VXPG nucleases
p9249
sg13
I2
sa(dp9250
g7
I34
sg8
VP39748
p9251
sg10
I4
sg11
VRad2
p9252
sg13
I1
sa(dp9253
g7
I4
sg8
g64
sg10
I9
sg11
VGEN1 core
p9254
sg13
I2
sasg23
(lp9255
(dp9256
g7
I39
sg26
VC0268141
p9257
sg10
I3
sg11
VXPG
p9258
sg13
I1
sasa(dp9259
g2
S'Comparison with FEN superfamily members, including XPG, EXO1, and GEN1, identifies superfamily motifs such as the helical gateway that select for ss-dsDNA junctions and provides key biological insights into nuclease specificity and regulation.\n'
p9260
sg4
(lp9261
(dp9262
g7
I66
sg8
g64
sg10
I4
sg11
VGEN1
p9263
sg13
I1
sa(dp9264
g7
I56
sg8
g64
sg10
I4
sg11
VEXO1
p9265
sg13
I1
sa(dp9266
g7
I51
sg8
VP28715
p9267
sg10
I3
sg11
VXPG
p9268
sg13
I1
sasg23
(lp9269
(dp9270
g7
I51
sg26
VC0268141
p9271
sg10
I3
sg11
VXPG
p9272
sg13
I1
sasa(dp9273
g2
S"Superfamily members, such as flap endonucleases, exonuclease 1, DNA repair protein XPG, endonuclease GEN1 and the 5'-3'-exoribonucleases, play key roles in many cellular processes such as DNA replication and repair, recombination, transcription, RNA turnover and RNA interference.\n"
p9274
sg4
(lp9275
(dp9276
g7
I29
sg8
VP20292
p9277
sg10
I33
sg11
Vflap endonucleases, exonuclease 1
p9278
sg13
I4
sa(dp9279
g7
I88
sg8
VP39748
p9280
sg10
I17
sg11
Vendonuclease GEN1
p9281
sg13
I2
sa(dp9282
g7
I64
sg8
VP07992
p9283
sg10
I22
sg11
VDNA repair protein XPG
p9284
sg13
I4
sasg23
(lp9285
(dp9286
g7
I83
sg26
VC0268141
p9287
sg10
I3
sg11
VXPG
p9288
sg13
I1
sasa(dp9289
g2
S"It is a member of the 5' structure-specific nuclease family of exonucleases and endonucleases that includes FEN-1, XPG, and GEN1.\n"
p9290
sg4
(lp9291
(dp9292
g7
I108
sg8
VP39748
p9293
sg10
I5
sg11
VFEN-1
p9294
sg13
I1
sa(dp9295
g7
I22
sg8
g64
sg10
I71
sg11
V5' structure-specific nuclease family of exonucleases and endonucleases
p9296
sg13
I8
sa(dp9297
g7
I124
sg8
g64
sg10
I4
sg11
VGEN1
p9298
sg13
I1
sa(dp9299
g7
I115
sg8
VP28715
p9300
sg10
I3
sg11
VXPG
p9301
sg13
I1
sasg23
(lp9302
(dp9303
g7
I115
sg26
VC0268141
p9304
sg10
I3
sg11
VXPG
p9305
sg13
I1
sasa(dp9306
g2
S"FEN1 5' nuclease superfamily members acting in nucleotide excision repair (XPG), mismatch repair (EXO1), and homologous recombination (GEN1) paradoxically incise structurally distinct bubbles, ends, or Holliday junctions, respectively.\n"
p9307
sg4
(lp9308
(dp9309
g7
I135
sg8
g64
sg10
I4
sg11
VGEN1
p9310
sg13
I1
sa(dp9311
g7
I0
sg8
VP39748
p9312
sg10
I36
sg11
VFEN1 5' nuclease superfamily members
p9313
sg13
I5
sa(dp9314
g7
I81
sg8
g64
sg10
I22
sg11
Vmismatch repair (EXO1)
p9315
sg13
I3
sasg23
(lp9316
(dp9317
g7
I75
sg26
VC0268141
p9318
sg10
I3
sg11
VXPG
p9319
sg13
I1
sasa(dp9320
g2
S'The current study sought to localise the sites of CpG methylation within Prm1 and Prm3, and to identify the main transcription factors regulating TPBeta expression through Prm3 in the prostate adenocarcinoma PC-3 and LNCaP cell lines.\n'
p9321
sg4
(lp9322
(dp9323
g7
I193
sg8
g64
sg10
I19
sg11
Vadenocarcinoma PC-3
p9324
sg13
I2
sa(dp9325
g7
I82
sg8
g64
sg10
I4
sg11
VPrm3
p9326
sg13
I1
sa(dp9327
g7
I73
sg8
VP04553
p9328
sg10
I4
sg11
VPrm1
p9329
sg13
I1
sa(dp9330
g7
I82
sg8
g64
sg10
I4
sg11
VPrm3
p9331
sg13
I1
sasg23
(lp9332
(dp9333
g7
I184
sg26
VC0007112
p9334
sg10
I23
sg11
Vprostate adenocarcinoma
p9335
sg13
I2
sasa(dp9336
g2
S'Mechanistically, we recently discovered that both TPAlfa and TPBeta form functional signalling complexes with members of the protein kinase C-related kinase (PRK) family, AGC- kinases essential for the epigenetic regulation of androgen receptor (AR)-dependent transcription and promising therapeutic targets for treatment of castrate-resistant prostate cancer (CRPC).\n'
p9337
sg4
(lp9338
(dp9339
g7
I158
sg8
g64
sg10
I3
sg11
VPRK
p9340
sg13
I1
sa(dp9341
g7
I125
sg8
VP17252
p9342
sg10
I31
sg11
Vprotein kinase C-related kinase
p9343
sg13
I4
sa(dp9344
g7
I246
sg8
VP10275
p9345
sg10
I2
sg11
VAR
p9346
sg13
I1
sa(dp9347
g7
I227
sg8
VP10275
p9348
sg10
I17
sg11
Vandrogen receptor
p9349
sg13
I2
sa(dp9350
g7
I171
sg8
VP20794
p9351
sg10
I12
sg11
VAGC- kinases
p9352
sg13
I2
sasg23
(lp9353
(dp9354
g7
I344
sg26
VC0600139
p9355
sg10
I15
sg11
Vprostate cancer
p9356
sg13
I2
sasa(dp9357
g2
S'Despite exhibiting several functional and regulatory differences, the role of the individual TP isoforms in neoplastic diseases is largely unknown.This study evaluated expression of the TPAlfa and TPBeta isoforms in tumour microarrays of the benign prostate and different pathological (Gleason) grades of prostate cancer (PCa).\n'
p9358
sg4
(lp9359
(dp9360
g7
I197
sg8
VP38606
p9361
sg10
I15
sg11
VTPBeta isoforms
p9362
sg13
I2
sasg23
(lp9363
(dp9364
g7
I322
sg26
VC0268398
p9365
sg10
I3
sg11
VPCa
p9366
sg13
I1
sa(dp9367
g7
I216
sg26
VC0027651
p9368
sg10
I6
sg11
Vtumour
p9369
sg13
I1
sa(dp9370
g7
I305
sg26
VC0600139
p9371
sg10
I15
sg11
Vprostate cancer
p9372
sg13
I2
sasa(dp9373
g2
S'Hence, focusing on the setting of prostate cancer, this study investigated whether TPAlfa and/or TPBeta might also complex with PRK2 and PRK3 to regulate their activity and neoplastic responses.\n'
p9374
sg4
(lp9375
(dp9376
g7
I128
sg8
g64
sg10
I4
sg11
VPRK2
p9377
sg13
I1
sasg23
(lp9378
(dp9379
g7
I34
sg26
VC0600139
p9380
sg10
I15
sg11
Vprostate cancer
p9381
sg13
I2
sasa(dp9382
g2
S'Previous data by our laboratory demonstrated amplified thromboxane-A2 signaling was associated with poor prognoses in bladder cancer patients and overexpression of the thromboxane-A2 isoform-Beta receptor (TPBeta), but not TPAlfa, induced malignant transformation of immortalized bladder cells in vivo.\n'
p9383
sg4
(lp9384
(dp9385
g7
I168
sg8
VP38606
p9386
sg10
I36
sg11
Vthromboxane-A2 isoform-Beta receptor
p9387
sg13
I3
sasg23
(lp9388
(dp9389
g7
I118
sg26
VC0699885
p9390
sg10
I14
sg11
Vbladder cancer
p9391
sg13
I2
sa(dp9392
g7
I239
sg26
VC1608408
p9393
sg10
I24
sg11
Vmalignant transformation
p9394
sg13
I2
sasa(dp9395
g2
S'Interestingly, in contrast to the stimulatory effect of ERAlfa on HADHB enzyme activity observed in the previous study, silencing of ERBeta enhanced the enzyme activity of HADHB in the present study, suggesting that ERBeta plays an inhibitory role in HADHB enzyme activity in the breast cancer cells.\n'
p9396
sg4
(lp9397
(dp9398
g7
I66
sg8
VP55084
p9399
sg10
I12
sg11
VHADHB enzyme
p9400
sg13
I2
sa(dp9401
g7
I66
sg8
VP55084
p9402
sg10
I5
sg11
VHADHB
p9403
sg13
I1
sa(dp9404
g7
I66
sg8
VP55084
p9405
sg10
I12
sg11
VHADHB enzyme
p9406
sg13
I2
sasg23
(lp9407
(dp9408
g7
I280
sg26
VC0678222
p9409
sg10
I13
sg11
Vbreast cancer
p9410
sg13
I2
sasa(dp9411
g2
S'IMMP2L, the gene encoding the inner mitochondrial membrane peptidase subunit 2-like protein, has been reported as a candidate gene for Tourette syndrome, autism spectrum disorder (ASD) and additional neurodevelopmental disorders.\n'
p9412
sg4
(lp9413
(dp9414
g7
I59
sg8
g64
sg10
I32
sg11
Vpeptidase subunit 2-like protein
p9415
sg13
I4
sa(dp9416
g7
I0
sg8
g64
sg10
I6
sg11
VIMMP2L
p9417
sg13
I1
sasg23
(lp9418
(dp9419
g7
I135
sg26
VC0040517
p9420
sg10
I17
sg11
VTourette syndrome
p9421
sg13
I2
sa(dp9422
g7
I180
sg26
VC1510586
p9423
sg10
I3
sg11
VASD
p9424
sg13
I1
sa(dp9425
g7
I154
sg26
VC1510586
p9426
sg10
I24
sg11
Vautism spectrum disorder
p9427
sg13
I3
sasa(dp9428
g2
S'Here we genotyped 100 trio families with an index proband with autism spectrum disorder in Han Chinese population and found three cases with rare exonic IMMP2L deletions.\n'
p9429
sg4
(lp9430
sg23
(lp9431
(dp9432
g7
I63
sg26
VC1510586
p9433
sg10
I24
sg11
Vautism spectrum disorder
p9434
sg13
I3
sasa(dp9435
g2
S'A study in a Caucasian population has identified two single-nucleotide polymorphisms (SNPs) in ZNF533, one in DOCK4, and two in IMMP2L, which were all significantly associated with autism.\n'
p9436
sg4
(lp9437
(dp9438
g7
I95
sg8
g64
sg10
I6
sg11
VZNF533
p9439
sg13
I1
sa(dp9440
g7
I110
sg8
g64
sg10
I5
sg11
VDOCK4
p9441
sg13
I1
sa(dp9442
g7
I128
sg8
g64
sg10
I6
sg11
VIMMP2L
p9443
sg13
I1
sasg23
(lp9444
(dp9445
g7
I181
sg26
VC0004352
p9446
sg10
I6
sg11
Vautism
p9447
sg13
I1
sasa(dp9448
g2
S'The present study aimed to investigate whether ZNF533, DOCK4, and IMMP2L genes are also associated with autism in a northeastern Chinese Han population.\n'
p9449
sg4
(lp9450
(dp9451
g7
I55
sg8
g64
sg10
I5
sg11
VDOCK4
p9452
sg13
I1
sa(dp9453
g7
I66
sg8
g64
sg10
I12
sg11
VIMMP2L genes
p9454
sg13
I2
sa(dp9455
g7
I47
sg8
g64
sg10
I6
sg11
VZNF533
p9456
sg13
I1
sasg23
(lp9457
(dp9458
g7
I104
sg26
VC0004352
p9459
sg10
I6
sg11
Vautism
p9460
sg13
I1
sasa(dp9461
g2
S'Although no excess CNVs, either deletions or duplications, were found in the ADHD cohort relative to controls, the inherited rare CNV-associated gene set was significantly enriched for genes reported as candidates in studies of autism, schizophrenia and Tourette syndrome, including A2BP1, AUTS2, CNTNAP2 and IMMP2L.\n'
p9462
sg4
(lp9463
(dp9464
g7
I297
sg8
g64
sg10
I7
sg11
VCNTNAP2
p9465
sg13
I1
sa(dp9466
g7
I283
sg8
g64
sg10
I5
sg11
VA2BP1
p9467
sg13
I1
sa(dp9468
g7
I290
sg8
g64
sg10
I5
sg11
VAUTS2
p9469
sg13
I1
sa(dp9470
g7
I309
sg8
g64
sg10
I6
sg11
VIMMP2L
p9471
sg13
I1
sasg23
(lp9472
(dp9473
g7
I77
sg26
VC1263846
p9474
sg10
I4
sg11
VADHD
p9475
sg13
I1
sa(dp9476
g7
I254
sg26
VC0040517
p9477
sg10
I17
sg11
VTourette syndrome
p9478
sg13
I2
sa(dp9479
g7
I228
sg26
VC0004352
p9480
sg10
I6
sg11
Vautism
p9481
sg13
I1
sa(dp9482
g7
I236
sg26
VC0036341
p9483
sg10
I13
sg11
Vschizophrenia
p9484
sg13
I1
sasa(dp9485
g2
S'We screened 39 GTS patients, and, due to the localization of IMMP2L in the critical region for the autistic disorder (AD) locus on chromosome 7q (AUTS1), 95 multiplex AD families; however, no coding mutations were found in either GTS or AD patients.\n'
p9486
sg4
(lp9487
(dp9488
g7
I61
sg8
g64
sg10
I6
sg11
VIMMP2L
p9489
sg13
I1
sasg23
(lp9490
(dp9491
g7
I15
sg26
VC0040517
p9492
sg10
I3
sg11
VGTS
p9493
sg13
I1
sa(dp9494
g7
I15
sg26
VC0040517
p9495
sg10
I3
sg11
VGTS
p9496
sg13
I1
sa(dp9497
g7
I99
sg26
VC0004352
p9498
sg10
I17
sg11
Vautistic disorder
p9499
sg13
I2
sa(dp9500
g7
I118
sg26
VC0004352
p9501
sg10
I2
sg11
VAD
p9502
sg13
I1
sa(dp9503
g7
I118
sg26
VC0004352
p9504
sg10
I2
sg11
VAD
p9505
sg13
I1
sa(dp9506
g7
I118
sg26
VC0004352
p9507
sg10
I2
sg11
VAD
p9508
sg13
I1
sasa(dp9509
g2
S'Northern blot hybridization of RNA from different human brain tumors showed very low amounts of TSC-22 mRNA in most investigated samples of GBM, anaplastic astrocytoma, and some other tumors.\n'
p9510
sg4
(lp9511
(dp9512
g7
I96
sg8
g64
sg10
I11
sg11
VTSC-22 mRNA
p9513
sg13
I2
sasg23
(lp9514
(dp9515
g7
I96
sg26
VC0041341
p9516
sg10
I3
sg11
VTSC
p9517
sg13
I1
sa(dp9518
g7
I56
sg26
VC0006118
p9519
sg10
I12
sg11
Vbrain tumors
p9520
sg13
I2
sa(dp9521
g7
I145
sg26
VC0334579
p9522
sg10
I22
sg11
Vanaplastic astrocytoma
p9523
sg13
I2
sa(dp9524
g7
I140
sg26
VC0017636
p9525
sg10
I3
sg11
VGBM
p9526
sg13
I1
sa(dp9527
g7
I62
sg26
VC0027651
p9528
sg10
I6
sg11
Vtumors
p9529
sg13
I1
sasa(dp9530
g2
S'Human genetic studies have found heterozygous deletions affecting NRXN1 and NRXN2, encoding Alfa-neurexin I (Nrxn1Alfa) and Alfa-neurexin II (Nrxn2Alfa), in individuals with autism spectrum disorders and schizophrenia.\n'
p9531
sg4
(lp9532
(dp9533
g7
I66
sg8
VP58400
p9534
sg10
I5
sg11
VNRXN1
p9535
sg13
I1
sa(dp9536
g7
I124
sg8
VP58401
p9537
sg10
I16
sg11
VAlfa-neurexin II
p9538
sg13
I2
sa(dp9539
g7
I76
sg8
VP58401
p9540
sg10
I5
sg11
VNRXN2
p9541
sg13
I1
sasg23
(lp9542
(dp9543
g7
I204
sg26
VC0036341
p9544
sg10
I13
sg11
Vschizophrenia
p9545
sg13
I1
sa(dp9546
g7
I174
sg26
VC1510586
p9547
sg10
I25
sg11
Vautism spectrum disorders
p9548
sg13
I3
sasa(dp9549
g2
S'To assess whether the heterozygous loss of neurexins results in behaviors relevant to autism or schizophrenia, we used mice with heterozygous (HET) deletion of Nrxn1Alfa or Nrxn2Alfa.\n'
p9550
sg4
(lp9551
(dp9552
g7
I22
sg8
g64
sg10
I12
sg11
Vheterozygous
p9553
sg13
I1
sa(dp9554
g7
I22
sg8
g64
sg10
I12
sg11
Vheterozygous
p9555
sg13
I1
sa(dp9556
g7
I143
sg8
g64
sg10
I3
sg11
VHET
p9557
sg13
I1
sasg23
(lp9558
(dp9559
g7
I96
sg26
VC0036341
p9560
sg10
I13
sg11
Vschizophrenia
p9561
sg13
I1
sa(dp9562
g7
I86
sg26
VC0004352
p9563
sg10
I6
sg11
Vautism
p9564
sg13
I1
sasa(dp9565
g2
S'Our findings demonstrate that the heterozygous loss of Alfa-neurexin I and Alfa-neurexin II in mice leads to phenotypes relevant to autism and schizophrenia.\n'
p9566
sg4
(lp9567
(dp9568
g7
I75
sg8
VP58401
p9569
sg10
I16
sg11
VAlfa-neurexin II
p9570
sg13
I2
sasg23
(lp9571
(dp9572
g7
I132
sg26
VC0004352
p9573
sg10
I6
sg11
Vautism
p9574
sg13
I1
sa(dp9575
g7
I143
sg26
VC0036341
p9576
sg10
I13
sg11
Vschizophrenia
p9577
sg13
I1
sasa(dp9578
g2
S'The deletion contains several genes including PPP2R5B, which has been associated with intellectual disability and overgrowth; NRXN2, which has been associated with intellectual disability and autism spectrum disorder; and CDCA5, which is part of the cohesin pathway, as are all the five known CdLS genes.\n'
p9579
sg4
(lp9580
(dp9581
g7
I126
sg8
VP58401
p9582
sg10
I5
sg11
VNRXN2
p9583
sg13
I1
sa(dp9584
g7
I222
sg8
g64
sg10
I5
sg11
VCDCA5
p9585
sg13
I1
sa(dp9586
g7
I293
sg8
g64
sg10
I10
sg11
VCdLS genes
p9587
sg13
I2
sa(dp9588
g7
I46
sg8
g64
sg10
I7
sg11
VPPP2R5B
p9589
sg13
I1
sasg23
(lp9590
(dp9591
g7
I86
sg26
VC0025362
p9592
sg10
I23
sg11
Vintellectual disability
p9593
sg13
I2
sa(dp9594
g7
I192
sg26
VC1510586
p9595
sg10
I24
sg11
Vautism spectrum disorder
p9596
sg13
I3
sa(dp9597
g7
I86
sg26
VC0025362
p9598
sg10
I23
sg11
Vintellectual disability
p9599
sg13
I2
sa(dp9600
g7
I293
sg26
VC0270972
p9601
sg10
I4
sg11
VCdLS
p9602
sg13
I1
sasa(dp9603
g2
S'Human genetic studies have discovered mutations disrupting exons of the NRXN2 gene, which encodes the synaptic adhesion protein Alfa-neurexin II (Nrxn2Alfa), in two unrelated individuals with autism, but a causal link between NRXN2 and the disorder remains unclear.\n'
p9604
sg4
(lp9605
(dp9606
g7
I72
sg8
VP58401
p9607
sg10
I10
sg11
VNRXN2 gene
p9608
sg13
I2
sa(dp9609
g7
I72
sg8
VP58401
p9610
sg10
I5
sg11
VNRXN2
p9611
sg13
I1
sa(dp9612
g7
I102
sg8
g64
sg10
I42
sg11
Vsynaptic adhesion protein Alfa-neurexin II
p9613
sg13
I5
sasg23
(lp9614
(dp9615
g7
I192
sg26
VC0004352
p9616
sg10
I6
sg11
Vautism
p9617
sg13
I1
sa(dp9618
g7
I111
sg26
VC0001511
p9619
sg10
I8
sg11
Vadhesion
p9620
sg13
I1
sasa(dp9621
g2
S'To begin to test the hypothesis that Nrxn2Alfa deficiency contributes to the symptoms of autism, we employed Nrxn2Alfa knockout (KO) mice that genetically model Nrxn2Alfa deficiency in vivo.\n'
p9622
sg4
(lp9623
sg23
(lp9624
(dp9625
g7
I89
sg26
VC0004352
p9626
sg10
I6
sg11
Vautism
p9627
sg13
I1
sasa(dp9628
g2
S'Our findings demonstrate a causal role for the loss of Nrxn2Alfa in the genesis of autism-related behaviors in mice.\n'
p9629
sg4
(lp9630
sg23
(lp9631
(dp9632
g7
I83
sg26
VC0004352
p9633
sg10
I6
sg11
Vautism
p9634
sg13
I1
sasa(dp9635
g2
S'In the present study, we explored the physiological relevance of Granzyme A in the control of pulmonary Mycobacterium tuberculosis infection in vivo.\n'
p9636
sg4
(lp9637
(dp9638
g7
I65
sg8
VP12544
p9639
sg10
I10
sg11
VGranzyme A
p9640
sg13
I2
sasg23
(lp9641
(dp9642
g7
I118
sg26
VC0041296
p9643
sg10
I22
sg11
Vtuberculosis infection
p9644
sg13
I2
sasa(dp9645
g2
S'Our results show that, even though Granzyme A is expressed by cytotoxic cells from mouse lungs during pulmonary infection, its deficiency in knockout mice does not have an effect in the control of M. tuberculosis infection.\n'
p9646
sg4
(lp9647
(dp9648
g7
I35
sg8
VP12544
p9649
sg10
I10
sg11
VGranzyme A
p9650
sg13
I2
sasg23
(lp9651
(dp9652
g7
I200
sg26
VC0041296
p9653
sg10
I22
sg11
Vtuberculosis infection
p9654
sg13
I2
sa(dp9655
g7
I102
sg26
VC0876973
p9656
sg10
I19
sg11
Vpulmonary infection
p9657
sg13
I2
sasa(dp9658
g2
S'In addition our findings indicate that absence of Granzyme A does not affect the protection conferred by the live-attenuated M. tuberculosis vaccine MTBVAC.\n'
p9659
sg4
(lp9660
(dp9661
g7
I50
sg8
VP12544
p9662
sg10
I10
sg11
VGranzyme A
p9663
sg13
I2
sasg23
(lp9664
(dp9665
g7
I128
sg26
VC0041296
p9666
sg10
I12
sg11
Vtuberculosis
p9667
sg13
I1
sasa(dp9668
g2
S'Altogether, our findings are in apparent contradiction with previously published in vitro results and suggest that Granzyme A does not have a crucial role in vivo in the protective response to tuberculosis.\n'
p9669
sg4
(lp9670
(dp9671
g7
I115
sg8
VP12544
p9672
sg10
I10
sg11
VGranzyme A
p9673
sg13
I2
sasg23
(lp9674
(dp9675
g7
I193
sg26
VC0041296
p9676
sg10
I12
sg11
Vtuberculosis
p9677
sg13
I1
sasa(dp9678
g2
S'The tuberculosis group had a significantly higher concentration of granzyme A than the silicosis and lung cancer groups (P &lt; 0.05), and the silicosis group and lung cancer group had similar protein concentration trends (P &gt; 0.05).\n'
p9679
sg4
(lp9680
(dp9681
g7
I67
sg8
VP12544
p9682
sg10
I10
sg11
Vgranzyme A
p9683
sg13
I2
sasg23
(lp9684
(dp9685
g7
I101
sg26
VC0684249
p9686
sg10
I11
sg11
Vlung cancer
p9687
sg13
I2
sa(dp9688
g7
I87
sg26
VC0037116
p9689
sg10
I9
sg11
Vsilicosis
p9690
sg13
I1
sa(dp9691
g7
I101
sg26
VC0684249
p9692
sg10
I11
sg11
Vlung cancer
p9693
sg13
I2
sa(dp9694
g7
I4
sg26
VC0041296
p9695
sg10
I12
sg11
Vtuberculosis
p9696
sg13
I1
sa(dp9697
g7
I87
sg26
VC0037116
p9698
sg10
I9
sg11
Vsilicosis
p9699
sg13
I1
sasa(dp9700
g2
S'Our results reveal enhanced intra- and extracellular expression of gzmA and B in patients with pulmonary TB, suggesting that gzms are part of the host response to tuberculosis.\n'
p9701
sg4
(lp9702
(dp9703
g7
I67
sg8
VP12544
p9704
sg10
I4
sg11
VgzmA
p9705
sg13
I1
sasg23
(lp9706
(dp9707
g7
I163
sg26
VC0041296
p9708
sg10
I12
sg11
Vtuberculosis
p9709
sg13
I1
sa(dp9710
g7
I95
sg26
VC0041327
p9711
sg10
I12
sg11
Vpulmonary TB
p9712
sg13
I2
sasa(dp9713
g2
S'Our results suggest that granzyme A could be considered another biomarker of TB, that can be used, other than IFN-Gamma, to discriminate between patients with active TB and LTBI subjects in a well characterized cohort of confirmed Mycobacterium tuberculosis-infected individuals.\n'
p9714
sg4
(lp9715
(dp9716
g7
I110
sg8
VP01579
p9717
sg10
I9
sg11
VIFN-Gamma
p9718
sg13
I1
sa(dp9719
g7
I25
sg8
VP12544
p9720
sg10
I10
sg11
Vgranzyme A
p9721
sg13
I2
sasg23
(lp9722
(dp9723
g7
I245
sg26
VC0041296
p9724
sg10
I12
sg11
Vtuberculosis
p9725
sg13
I1
sasa(dp9726
g2
S'Thus, murine transcriptome analysis can be used to predict immunological responses in cattle allowing the prioritisation of CXCLl9, CXCL10, Granzyme A and IL-22 as potential additional readout systems for the ante-mortem diagnosis of bovine tuberculosis.\n'
p9727
sg4
(lp9728
(dp9729
g7
I140
sg8
VP12544
p9730
sg10
I10
sg11
VGranzyme A
p9731
sg13
I2
sa(dp9732
g7
I155
sg8
g64
sg10
I5
sg11
VIL-22
p9733
sg13
I1
sa(dp9734
g7
I132
sg8
VP02778
p9735
sg10
I6
sg11
VCXCL10
p9736
sg13
I1
sasg23
(lp9737
(dp9738
g7
I234
sg26
VC0041307
p9739
sg10
I19
sg11
Vbovine tuberculosis
p9740
sg13
I2
sasa(dp9741
g2
S'Nafamostat, camostat and aprotinin markedly reduced tryptic activity on the apical surface of cystic fibrosis airway epithelial monolayers, suggesting prostasin as the major source of such activity and supporting strategies targeting prostasin for inactivation.\n'
p9742
sg4
(lp9743
(dp9744
g7
I151
sg8
g64
sg10
I9
sg11
Vprostasin
p9745
sg13
I1
sasg23
(lp9746
(dp9747
g7
I94
sg26
VC0010674
p9748
sg10
I15
sg11
Vcystic fibrosis
p9749
sg13
I2
sa(dp9750
g7
I248
sg26
VC0544461
p9751
sg10
I12
sg11
Vinactivation
p9752
sg13
I1
sasa(dp9753
g2
S'Understanding the mechanism by which prostasin and its inhibitors regulate sodium channels has provided a new insight into the treatment of hypertension and some other diseases like cystic fibrosis.\n'
p9754
sg4
(lp9755
(dp9756
g7
I37
sg8
g64
sg10
I9
sg11
Vprostasin
p9757
sg13
I1
sasg23
(lp9758
(dp9759
g7
I140
sg26
VC0020538
p9760
sg10
I12
sg11
Vhypertension
p9761
sg13
I1
sa(dp9762
g7
I182
sg26
VC0010674
p9763
sg10
I15
sg11
Vcystic fibrosis
p9764
sg13
I2
sasa(dp9765
g2
S'Because ENaC-mediated dehydration contributes to cystic fibrosis (CF), prostasin and matriptase are potential therapeutic targets, but their catalytic competence on airway epithelial surfaces has been unclear.\n'
p9766
sg4
(lp9767
(dp9768
g7
I71
sg8
g64
sg10
I9
sg11
Vprostasin
p9769
sg13
I1
sa(dp9770
g7
I85
sg8
g64
sg10
I10
sg11
Vmatriptase
p9771
sg13
I1
sa(dp9772
g7
I8
sg8
VP37088
p9773
sg10
I4
sg11
VENaC
p9774
sg13
I1
sasg23
(lp9775
(dp9776
g7
I22
sg26
VC0011175
p9777
sg10
I11
sg11
Vdehydration
p9778
sg13
I1
sa(dp9779
g7
I66
sg26
VC0010674
p9780
sg10
I2
sg11
VCF
p9781
sg13
I1
sa(dp9782
g7
I49
sg26
VC0010674
p9783
sg10
I15
sg11
Vcystic fibrosis
p9784
sg13
I2
sasa(dp9785
g2
S'As a first step toward understanding the molecular mechanisms of neuroblastoma differentiation we analyzed the expression pattern of the developmentally important Homeobox genes in cells treated with retinoic acid.\n'
p9786
sg4
(lp9787
sg23
(lp9788
(dp9789
g7
I65
sg26
VC0027819
p9790
sg10
I13
sg11
Vneuroblastoma
p9791
sg13
I1
sasa(dp9792
g2
S'The strategy employed involved rapid screening of a cDNA library prepared from retinoic acid treated human LA-N-5 neuroblastoma cells for Homeobox genes by the polymerase chain reaction.\n'
p9793
sg4
(lp9794
(dp9795
g7
I138
sg8
VP52954
p9796
sg10
I14
sg11
VHomeobox genes
p9797
sg13
I2
sasg23
(lp9798
(dp9799
g7
I114
sg26
VC0027819
p9800
sg10
I13
sg11
Vneuroblastoma
p9801
sg13
I1
sasa(dp9802
g2
S'Preliminary studies indicate that there is an induction of Homeobox gene expression in differentiating LA-N-5 neuroblastoma cells.\n'
p9803
sg4
(lp9804
(dp9805
g7
I59
sg8
VP09629
p9806
sg10
I13
sg11
VHomeobox gene
p9807
sg13
I2
sasg23
(lp9808
(dp9809
g7
I110
sg26
VC0027819
p9810
sg10
I13
sg11
Vneuroblastoma
p9811
sg13
I1
sasa(dp9812
g2
S'We hypothesized that Nrf2 modulates progression from acute tubular damage to renal fibrosis.\n'
p9813
sg4
(lp9814
(dp9815
g7
I21
sg8
g64
sg10
I4
sg11
VNrf2
p9816
sg13
I1
sasg23
(lp9817
(dp9818
g7
I77
sg26
VC0151650
p9819
sg10
I14
sg11
Vrenal fibrosis
p9820
sg13
I2
sasa(dp9821
g2
S'We asked whether Nrf2 deletion increases renal injury in mice following unilateral ureteral obstruction (UUO).\n'
p9822
sg4
(lp9823
(dp9824
g7
I17
sg8
g64
sg10
I4
sg11
VNrf2
p9825
sg13
I1
sasg23
(lp9826
(dp9827
g7
I83
sg26
VC0041956
p9828
sg10
I20
sg11
Vureteral obstruction
p9829
sg13
I2
sa(dp9830
g7
I105
sg26
VC0041956
p9831
sg10
I3
sg11
VUUO
p9832
sg13
I1
sasa(dp9833
g2
S'We studied Nrf2 in renal biopsies of patients with acute, subacute and chronic tubulointerstitial nephritis (TIN).\n'
p9834
sg4
(lp9835
sg23
(lp9836
(dp9837
g7
I71
sg26
VC0238304
p9838
sg10
I36
sg11
Vchronic tubulointerstitial nephritis
p9839
sg13
I3
sasa(dp9840
g2
S'The aim of this study was to evaluate the effects of resistance exercise programs on the expression of transcription factors Nrf2 and nuclear factor KB (NF-KB) in CKD patients on hemodialysis (HD).\n'
p9841
sg4
(lp9842
(dp9843
g7
I125
sg8
g64
sg10
I4
sg11
VNrf2
p9844
sg13
I1
sa(dp9845
g7
I134
sg8
VP01160
p9846
sg10
I17
sg11
Vnuclear factor KB
p9847
sg13
I3
sa(dp9848
g7
I153
sg8
VP01160
p9849
sg10
I5
sg11
VNF-KB
p9850
sg13
I1
sasg23
(lp9851
sa(dp9852
g2
S'In conclusion, these data suggest that resistance exercises seem to be capable of inducing Nrf2 activation in CKD patients on HD.\n'
p9853
sg4
(lp9854
(dp9855
g7
I91
sg8
g64
sg10
I4
sg11
VNrf2
p9856
sg13
I1
sasg23
(lp9857
sa(dp9858
g2
S'Activate Nrf2 could inhibit the activation of NLRP3 inflammasome in acute liver injury and severe lupus nephritis.\n'
p9859
sg4
(lp9860
(dp9861
g7
I9
sg8
g64
sg10
I4
sg11
VNrf2
p9862
sg13
I1
sasg23
(lp9863
(dp9864
g7
I98
sg26
VC0024143
p9865
sg10
I15
sg11
Vlupus nephritis
p9866
sg13
I2
sasa(dp9867
g2
S'Here, we show that the loss of Nrf2 suppresses fibrosis and inflammation in a unilateral ureter obstruction (UUO) model of CKD in mice.\n'
p9868
sg4
(lp9869
(dp9870
g7
I31
sg8
g64
sg10
I4
sg11
VNrf2
p9871
sg13
I1
sasg23
(lp9872
(dp9873
g7
I89
sg26
VC0041956
p9874
sg10
I18
sg11
Vureter obstruction
p9875
sg13
I2
sa(dp9876
g7
I109
sg26
VC0041956
p9877
sg10
I3
sg11
VUUO
p9878
sg13
I1
sa(dp9879
g7
I47
sg26
VC0016059
p9880
sg10
I8
sg11
Vfibrosis
p9881
sg13
I1
sa(dp9882
g7
I60
sg26
VC0021368
p9883
sg10
I12
sg11
Vinflammation
p9884
sg13
I1
sasa(dp9885
g2
S'These results demonstrate that Nrf2-related inflammasome activation can promote CKD symptoms via infiltration of M1 macrophages.\n'
p9886
sg4
(lp9887
(dp9888
g7
I31
sg8
g64
sg10
I4
sg11
VNrf2
p9889
sg13
I1
sasg23
(lp9890
(dp9891
g7
I97
sg26
VC0332448
p9892
sg10
I12
sg11
Vinfiltration
p9893
sg13
I1
sasa(dp9894
g2
S'Thus, we have identified the Nrf2 pathway as a promising therapeutic target for CKD.\n'
p9895
sg4
(lp9896
(dp9897
g7
I29
sg8
g64
sg10
I4
sg11
VNrf2
p9898
sg13
I1
sasg23
(lp9899
sa(dp9900
g2
S'Reduced nuclear factor erythroid 2-related factor 2 (NRF2) pathway activity was reported in models of chronic kidney disease (CKD).\n'
p9901
sg4
(lp9902
(dp9903
g7
I53
sg8
g64
sg10
I4
sg11
VNRF2
p9904
sg13
I1
sa(dp9905
g7
I8
sg8
g64
sg10
I43
sg11
Vnuclear factor erythroid 2-related factor 2
p9906
sg13
I6
sasg23
(lp9907
(dp9908
g7
I102
sg26
VC1561643
p9909
sg10
I22
sg11
Vchronic kidney disease
p9910
sg13
I3
sa(dp9911
g7
I126
sg26
VC1561643
p9912
sg10
I3
sg11
VCKD
p9913
sg13
I1
sasa(dp9914
g2
S'We conclude that spontaneous phasic contractions of human sigmoid circular smooth muscle may be mediated by activation of NK2 receptors, calcium release from intracellular stores, and activation of calmodulin and protein kinase C. In ulcerative colitis patients, spontaneous phasic contractions are decreased, and this decrease may be in part due to overproduction of hydrogen peroxide affecting sigmoid circular muscle.\n'
p9915
sg4
(lp9916
(dp9917
g7
I198
sg8
g64
sg10
I10
sg11
Vcalmodulin
p9918
sg13
I1
sa(dp9919
g7
I122
sg8
g64
sg10
I13
sg11
VNK2 receptors
p9920
sg13
I2
sa(dp9921
g7
I213
sg8
VP17252
p9922
sg10
I16
sg11
Vprotein kinase C
p9923
sg13
I3
sasg23
(lp9924
(dp9925
g7
I36
sg26
VC1140999
p9926
sg10
I12
sg11
Vcontractions
p9927
sg13
I1
sa(dp9928
g7
I36
sg26
VC1140999
p9929
sg10
I12
sg11
Vcontractions
p9930
sg13
I1
sa(dp9931
g7
I234
sg26
VC0009324
p9932
sg10
I18
sg11
Vulcerative colitis
p9933
sg13
I2
sasa(dp9934
g2
S'In a prospective, randomized, double-blind study, we enrolled 48 premedicated and calm 2-6-year-old children undergoing inguinal hernia repair.\n'
p9935
sg4
(lp9936
sg23
(lp9937
(dp9938
g7
I37
sg26
VC0456909
p9939
sg10
I5
sg11
Vblind
p9940
sg13
I1
sa(dp9941
g7
I120
sg26
VC0019294
p9942
sg10
I15
sg11
Vinguinal hernia
p9943
sg13
I2
sasa(dp9944
g2
S'We conclude that Ca(2+) stores of HSCM cells may be reduced in ulcerative colitis and that the signal transduction pathway of neurokinin A-induced contraction switches from calmodulin- and protein kinase C-dependent in normal cells to protein kinase C-dependent in ulcerative colitis cells.\n'
p9945
sg4
(lp9946
(dp9947
g7
I189
sg8
VP17252
p9948
sg10
I16
sg11
Vprotein kinase C
p9949
sg13
I3
sa(dp9950
g7
I189
sg8
VP17252
p9951
sg10
I16
sg11
Vprotein kinase C
p9952
sg13
I3
sa(dp9953
g7
I173
sg8
g64
sg10
I10
sg11
Vcalmodulin
p9954
sg13
I1
sasg23
(lp9955
(dp9956
g7
I63
sg26
VC0009324
p9957
sg10
I18
sg11
Vulcerative colitis
p9958
sg13
I2
sa(dp9959
g7
I63
sg26
VC0009324
p9960
sg10
I18
sg11
Vulcerative colitis
p9961
sg13
I2
sa(dp9962
g7
I147
sg26
VC1140999
p9963
sg10
I11
sg11
Vcontraction
p9964
sg13
I1
sasa(dp9965
g2
S'We report suspected ocular albinism in two Japanese sisters, caused by mutations in the HPS6 (Hermansky-Pudlak syndrome 6) gene.\n'
p9966
sg4
(lp9967
(dp9968
g7
I94
sg8
g64
sg10
I27
sg11
VHermansky-Pudlak syndrome 6
p9969
sg13
I3
sa(dp9970
g7
I88
sg8
g64
sg10
I4
sg11
VHPS6
p9971
sg13
I1
sasg23
(lp9972
(dp9973
g7
I20
sg26
VC0078917
p9974
sg10
I15
sg11
Vocular albinism
p9975
sg13
I2
sa(dp9976
g7
I94
sg26
VC0079504
p9977
sg10
I25
sg11
VHermansky-Pudlak syndrome
p9978
sg13
I2
sasa(dp9979
g2
S'Biallelic mutations in the photoreceptor-expressed aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) are associated with autosomal recessive Leber congenital amaurosis (LCA), the most severe form of inherited retinopathy in early childhood.\n'
p9980
sg4
(lp9981
(dp9982
g7
I51
sg8
g64
sg10
I52
sg11
Varyl hydrocarbon receptor interacting protein-like 1
p9983
sg13
I6
sa(dp9984
g7
I105
sg8
g64
sg10
I5
sg11
VAIPL1
p9985
sg13
I1
sasg23
(lp9986
(dp9987
g7
I152
sg26
VC0339527
p9988
sg10
I26
sg11
VLeber congenital amaurosis
p9989
sg13
I3
sa(dp9990
g7
I220
sg26
VC0035309
p9991
sg10
I11
sg11
Vretinopathy
p9992
sg13
I1
sa(dp9993
g7
I180
sg26
VC0339527
p9994
sg10
I3
sg11
VLCA
p9995
sg13
I1
sasa(dp9996
g2
S'Our findings provide insight into the mechanism underlying the co-chaperone role of AIPL1 and will be critical for ensuring an early and effective diagnosis of AIPL1 LCA patients.\n'
p9997
sg4
(lp9998
(dp9999
g7
I84
sg8
g64
sg10
I5
sg11
VAIPL1
p10000
sg13
I1
sa(dp10001
g7
I160
sg8
g64
sg10
I9
sg11
VAIPL1 LCA
p10002
sg13
I2
sasg23
(lp10003
(dp10004
g7
I166
sg26
VC0339527
p10005
sg10
I3
sg11
VLCA
p10006
sg13
I1
sasa(dp10007
g2
S'Malfunction of mutant AIPL1 proteins triggers a severe form of Leber congenital amaurosis and leads to blindness.\n'
p10008
sg4
(lp10009
(dp10010
g7
I15
sg8
g64
sg10
I21
sg11
Vmutant AIPL1 proteins
p10011
sg13
I3
sasg23
(lp10012
(dp10013
g7
I63
sg26
VC0339527
p10014
sg10
I26
sg11
VLeber congenital amaurosis
p10015
sg13
I3
sa(dp10016
g7
I103
sg26
VC0456909
p10017
sg10
I9
sg11
Vblindness
p10018
sg13
I1
sa(dp10019
g7
I15
sg26
VC0596988
p10020
sg10
I6
sg11
Vmutant
p10021
sg13
I1
sasa(dp10022
g2
S'Genetic mutations in aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) cause photoreceptor degeneration associated with Leber congenital amaurosis 4 (LCA4) in human patients.\n'
p10023
sg4
(lp10024
(dp10025
g7
I21
sg8
g64
sg10
I52
sg11
Varyl hydrocarbon receptor interacting protein-like 1
p10026
sg13
I6
sa(dp10027
g7
I161
sg8
g64
sg10
I4
sg11
VLCA4
p10028
sg13
I1
sa(dp10029
g7
I131
sg8
g64
sg10
I28
sg11
VLeber congenital amaurosis 4
p10030
sg13
I4
sa(dp10031
g7
I75
sg8
g64
sg10
I5
sg11
VAIPL1
p10032
sg13
I1
sasg23
(lp10033
(dp10034
g7
I88
sg26
VC1998028
p10035
sg10
I26
sg11
Vphotoreceptor degeneration
p10036
sg13
I2
sa(dp10037
g7
I161
sg26
VC1858386
p10038
sg10
I4
sg11
VLCA4
p10039
sg13
I1
sa(dp10040
g7
I131
sg26
VC1858386
p10041
sg10
I28
sg11
VLeber congenital amaurosis 4
p10042
sg13
I4
sasa(dp10043
g2
S'Mutations in AIPL1, including many missense mutations in the FKBP domain, have been associated with Leber congenital amaurosis, a severe blinding disease.\n'
p10044
sg4
(lp10045
(dp10046
g7
I13
sg8
g64
sg10
I5
sg11
VAIPL1
p10047
sg13
I1
sa(dp10048
g7
I61
sg8
g64
sg10
I11
sg11
VFKBP domain
p10049
sg13
I2
sasg23
(lp10050
(dp10051
g7
I100
sg26
VC0339527
p10052
sg10
I26
sg11
VLeber congenital amaurosis
p10053
sg13
I3
sasa(dp10054
g2
S'Its dysfunction, caused by mutations in either the enzyme itself or AIPL1 (aryl hydrocarbon receptor-interacting protein-like 1), leads to retinal diseases culminating in blindness.\n'
p10055
sg4
(lp10056
(dp10057
g7
I75
sg8
g64
sg10
I52
sg11
Varyl hydrocarbon receptor-interacting protein-like 1
p10058
sg13
I5
sa(dp10059
g7
I68
sg8
g64
sg10
I5
sg11
VAIPL1
p10060
sg13
I1
sasg23
(lp10061
(dp10062
g7
I171
sg26
VC0456909
p10063
sg10
I9
sg11
Vblindness
p10064
sg13
I1
sa(dp10065
g7
I139
sg26
VC0035309
p10066
sg10
I16
sg11
Vretinal diseases
p10067
sg13
I2
sasa(dp10068
g2
S'Undiagnosed human patients with early-onset blindness should be screened for this AIPL1 variant.\n'
p10069
sg4
(lp10070
(dp10071
g7
I82
sg8
g64
sg10
I13
sg11
VAIPL1 variant
p10072
sg13
I2
sasg23
(lp10073
(dp10074
g7
I44
sg26
VC0456909
p10075
sg10
I9
sg11
Vblindness
p10076
sg13
I1
sasa(dp10077
g2
S'Biallelic mutations in AIPL1 cause Leber congenital amaurosis (LCA), a devastating retinal degeneration characterized by the loss or severe impairment of vision within the first few years of life.\n'
p10078
sg4
(lp10079
(dp10080
g7
I23
sg8
g64
sg10
I5
sg11
VAIPL1
p10081
sg13
I1
sasg23
(lp10082
(dp10083
g7
I140
sg26
VC0684336
p10084
sg10
I10
sg11
Vimpairment
p10085
sg13
I1
sa(dp10086
g7
I35
sg26
VC0339527
p10087
sg10
I26
sg11
VLeber congenital amaurosis
p10088
sg13
I3
sa(dp10089
g7
I83
sg26
VC0035304
p10090
sg10
I20
sg11
Vretinal degeneration
p10091
sg13
I2
sa(dp10092
g7
I63
sg26
VC0339527
p10093
sg10
I3
sg11
VLCA
p10094
sg13
I1
sasa(dp10095
g2
S'We also reveal that in-phase exon skipping occurs normally at a low frequency in the retina, but arises abundantly as a consequence of specific AIPL1 variations, suggesting a tolerance threshold for the expression of these alternative transcripts in the retina normally, which is exceeded in LCA.\n'
p10096
sg4
(lp10097
(dp10098
g7
I144
sg8
g64
sg10
I5
sg11
VAIPL1
p10099
sg13
I1
sasg23
(lp10100
(dp10101
g7
I292
sg26
VC0339527
p10102
sg10
I3
sg11
VLCA
p10103
sg13
I1
sa(dp10104
g7
I175
sg26
VC0020963
p10105
sg10
I9
sg11
Vtolerance
p10106
sg13
I1
sasa(dp10107
g2
S'Our data confirm the disease-association of the AIPL1 variations investigated and reveal for the first time that aberrant splicing of AIPL1 is an underlying mechanism of disease in LCA.\n'
p10108
sg4
(lp10109
(dp10110
g7
I48
sg8
g64
sg10
I5
sg11
VAIPL1
p10111
sg13
I1
sa(dp10112
g7
I48
sg8
g64
sg10
I5
sg11
VAIPL1
p10113
sg13
I1
sasg23
(lp10114
(dp10115
g7
I181
sg26
VC0339527
p10116
sg10
I3
sg11
VLCA
p10117
sg13
I1
sasa(dp10118
g2
S'Currently, 21 genes are known to be associated with LCA and recurrent mutations have been observed in AIPL1, CEP290, CRB1 and GUCY2D.\n'
p10119
sg4
(lp10120
(dp10121
g7
I126
sg8
g64
sg10
I6
sg11
VGUCY2D
p10122
sg13
I1
sa(dp10123
g7
I117
sg8
VP82279
p10124
sg10
I4
sg11
VCRB1
p10125
sg13
I1
sa(dp10126
g7
I102
sg8
g64
sg10
I5
sg11
VAIPL1
p10127
sg13
I1
sa(dp10128
g7
I109
sg8
g64
sg10
I6
sg11
VCEP290
p10129
sg13
I1
sasg23
(lp10130
(dp10131
g7
I52
sg26
VC0339527
p10132
sg10
I3
sg11
VLCA
p10133
sg13
I1
sasa(dp10134
g2
S'To investigate the influence of experimental obstructive jaundice and exogenous bombesin (BBS) and neurotensin (NT) administration on the expression of the tight junction (TJ)-protein claudin-4 in intestinal epithelium of rats.\n'
p10135
sg4
(lp10136
(dp10137
g7
I70
sg8
VP07492
p10138
sg10
I18
sg11
Vexogenous bombesin
p10139
sg13
I2
sa(dp10140
g7
I90
sg8
g64
sg10
I3
sg11
VBBS
p10141
sg13
I1
sa(dp10142
g7
I112
sg8
VP30990
p10143
sg10
I2
sg11
VNT
p10144
sg13
I1
sa(dp10145
g7
I99
sg8
VP30990
p10146
sg10
I11
sg11
Vneurotensin
p10147
sg13
I1
sasg23
(lp10148
(dp10149
g7
I90
sg26
VC0398791
p10150
sg10
I3
sg11
VBBS
p10151
sg13
I1
sa(dp10152
g7
I80
sg26
VC0398791
p10153
sg10
I8
sg11
Vbombesin
p10154
sg13
I1
sa(dp10155
g7
I45
sg26
VC0022354
p10156
sg10
I20
sg11
Vobstructive jaundice
p10157
sg13
I2
sasa(dp10158
g2
S'To evaluate the effect of bombesin (BBS) and neurotensin (NT) on intestinal histopathology, intestinal oxidative stress, and endotoxemia in experimental obstructive jaundice.\n'
p10159
sg4
(lp10160
(dp10161
g7
I26
sg8
VP07492
p10162
sg10
I8
sg11
Vbombesin
p10163
sg13
I1
sa(dp10164
g7
I36
sg8
g64
sg10
I3
sg11
VBBS
p10165
sg13
I1
sa(dp10166
g7
I45
sg8
VP30990
p10167
sg10
I11
sg11
Vneurotensin
p10168
sg13
I1
sa(dp10169
g7
I58
sg8
VP30990
p10170
sg10
I2
sg11
VNT
p10171
sg13
I1
sasg23
(lp10172
(dp10173
g7
I26
sg26
VC0398791
p10174
sg10
I8
sg11
Vbombesin
p10175
sg13
I1
sa(dp10176
g7
I36
sg26
VC0398791
p10177
sg10
I3
sg11
VBBS
p10178
sg13
I1
sa(dp10179
g7
I153
sg26
VC0022354
p10180
sg10
I20
sg11
Vobstructive jaundice
p10181
sg13
I2
sa(dp10182
g7
I103
sg26
VC0242606
p10183
sg10
I16
sg11
Voxidative stress
p10184
sg13
I2
sasa(dp10185
g2
S'The MT-1 and MT-2 proteins are encoded by a family of eight genes (MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-IH, MT-1X, and MT-2A), and reverse transcriptase-polymerase chain reaction was used to determine which genes were expressed in the normal bladder and in bladder cancer.\n'
p10186
sg4
(lp10187
(dp10188
g7
I102
sg8
VP80294
p10189
sg10
I5
sg11
VMT-IH
p10190
sg13
I1
sa(dp10191
g7
I4
sg8
g64
sg10
I4
sg11
VMT-1
p10192
sg13
I1
sa(dp10193
g7
I74
sg8
VP07438
p10194
sg10
I5
sg11
VMT-1B
p10195
sg13
I1
sa(dp10196
g7
I13
sg8
VP02795
p10197
sg10
I13
sg11
VMT-2 proteins
p10198
sg13
I2
sa(dp10199
g7
I132
sg8
VP63136
p10200
sg10
I21
sg11
Vreverse transcriptase
p10201
sg13
I2
sa(dp10202
g7
I88
sg8
VP13640
p10203
sg10
I5
sg11
VMT-1F
p10204
sg13
I1
sasg23
(lp10205
(dp10206
g7
I258
sg26
VC0699885
p10207
sg10
I14
sg11
Vbladder cancer
p10208
sg13
I2
sasa(dp10209
g2
S'The expression of MT-1E mRNA was variable in both normal bladder and bladder cancer specimens.\n'
p10210
sg4
(lp10211
sg23
(lp10212
(dp10213
g7
I69
sg26
VC0699885
p10214
sg10
I14
sg11
Vbladder cancer
p10215
sg13
I2
sasa(dp10216
g2
S'Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.\n'
p10217
sg4
(lp10218
(dp10219
g7
I57
sg8
VP35398
p10220
sg10
I36
sg11
VT-cell-specific transcription factor
p10221
sg13
I3
sa(dp10222
g7
I276
sg8
VP11473
p10223
sg10
I18
sg11
Vvitamin D receptor
p10224
sg13
I3
sa(dp10225
g7
I109
sg8
VP00519
p10226
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p10227
sg13
I3
sa(dp10228
g7
I399
sg8
g64
sg10
I31
sg11
VPR domain zinc finger protein 1
p10229
sg13
I6
sa(dp10230
g7
I322
sg8
VP29323
p10231
sg10
I3
sg11
VERK
p10232
sg13
I1
sa(dp10233
g7
I362
sg8
VP20823
p10234
sg10
I35
sg11
Vrunt-related transcription factor 1
p10235
sg13
I4
sa(dp10236
g7
I477
sg8
VP01584
p10237
sg10
I13
sg11
Vinterleukin 1
p10238
sg13
I2
sa(dp10239
g7
I152
sg8
VP12931
p10240
sg10
I8
sg11
Vsarcoma"
p10241
sg13
I1
sa(dp10242
g7
I163
sg8
VP10914
p10243
sg10
I30
sg11
Vinterferon regulatory factor 1
p10244
sg13
I4
sa(dp10245
g7
I227
sg8
VP49336
p10246
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p10247
sg13
I4
sa(dp10248
g7
I296
sg8
VP56524
p10249
sg10
I19
sg11
Vhistone deacetylase
p10250
sg13
I2
sa(dp10251
g7
I95
sg8
VP12931
p10252
sg10
I3
sg11
VSrc
p10253
sg13
I1
sa(dp10254
g7
I217
sg8
VP14635
p10255
sg10
I8
sg11
Vcyclin B
p10256
sg13
I2
sa(dp10257
g7
I334
sg8
VP10415
p10258
sg10
I26
sg11
Vbcl-2-associated X protein
p10259
sg13
I3
sa(dp10260
g7
I317
sg8
VP53779
p10261
sg10
I4
sg11
VMAPK
p10262
sg13
I1
sa(dp10263
g7
I432
sg8
VP09619
p10264
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p10265
sg13
I4
sa(dp10266
g7
I265
sg8
VP29466
p10267
sg10
I9
sg11
Vcaspase-1
p10268
sg13
I1
sa(dp10269
g7
I195
sg8
VP04818
p10270
sg10
I20
sg11
Vthymidylate synthase
p10271
sg13
I2
sa(dp10272
g7
I252
sg8
VP24941
p10273
sg10
I3
sg11
VCDK
p10274
sg13
I1
sasg23
(lp10275
(dp10276
g7
I152
sg26
VC1261473
p10277
sg10
I7
sg11
Vsarcoma
p10278
sg13
I1
sa(dp10279
g7
I362
sg26
VC0013336
p10280
sg10
I4
sg11
Vrunt
p10281
sg13
I1
sasa(dp10282
g2
S'Therefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.\n'
p10283
sg4
(lp10284
(dp10285
g7
I45
sg8
VP11310
p10286
sg10
I4
sg11
VMCAD
p10287
sg13
I1
sa(dp10288
g7
I25
sg8
VP29466
p10289
sg10
I9
sg11
Vcaspase-1
p10290
sg13
I1
sasg23
(lp10291
(dp10292
g7
I173
sg26
VC0178874
p10293
sg10
I18
sg11
Vcancer progression
p10294
sg13
I2
sa(dp10295
g7
I45
sg26
VC0220710
p10296
sg10
I4
sg11
VMCAD
p10297
sg13
I1
sa(dp10298
g7
I129
sg26
VC0027651
p10299
sg10
I5
sg11
VTumor
p10300
sg13
I1
sa(dp10301
g7
I111
sg26
VC0178874
p10302
sg10
I17
sg11
Vtumor progression
p10303
sg13
I2
sasa(dp10304
g2
S'Here, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.\n'
p10305
sg4
(lp10306
(dp10307
g7
I95
sg8
VP49366
p10308
sg10
I22
sg11
Vacyl-CoA dehydrogenase
p10309
sg13
I2
sa(dp10310
g7
I27
sg8
VP29466
p10311
sg10
I9
sg11
Vcaspase-1
p10312
sg13
I1
sasg23
(lp10313
(dp10314
g7
I100
sg26
VC2678439
p10315
sg10
I3
sg11
VCoA
p10316
sg13
I1
sa(dp10317
g7
I231
sg26
VC0678222
p10318
sg10
I13
sg11
Vbreast cancer
p10319
sg13
I2
sa(dp10320
g7
I171
sg26
VC0221103
p10321
sg10
I11
sg11
Vsuppression
p10322
sg13
I1
sa(dp10323
g7
I186
sg26
VC0027651
p10324
sg10
I6
sg11
Vtumour
p10325
sg13
I1
sasa(dp10326
g2
S"In the 20 patients, the pathological diagnosis of underlying non-Hodgkin's lymphoma (NHL) comprised follicular lymphoma (FL, n = 12), diffuse large B cell lymphoma (DLBCL, n = 4), mantle cell lymphoma (MCL, n = 2), enteropathy associated T cell lymphoma (ETL, n = 1) and anaplastic large cell lymphoma (ALCL, n = 1).\n"
p10327
sg4
(lp10328
sg23
(lp10329
(dp10330
g7
I215
sg26
VC0456889
p10331
sg10
I38
sg11
Venteropathy associated T cell lymphoma
p10332
sg13
I5
sa(dp10333
g7
I121
sg26
VC0024301
p10334
sg10
I2
sg11
VFL
p10335
sg13
I1
sa(dp10336
g7
I165
sg26
VC0079744
p10337
sg10
I5
sg11
VDLBCL
p10338
sg13
I1
sa(dp10339
g7
I85
sg26
VC0024305
p10340
sg10
I3
sg11
VNHL
p10341
sg13
I1
sa(dp10342
g7
I303
sg26
VC0206180
p10343
sg10
I4
sg11
VALCL
p10344
sg13
I1
sa(dp10345
g7
I271
sg26
VC0206180
p10346
sg10
I30
sg11
Vanaplastic large cell lymphoma
p10347
sg13
I4
sa(dp10348
g7
I202
sg26
VC1708350
p10349
sg10
I3
sg11
VMCL
p10350
sg13
I1
sa(dp10351
g7
I255
sg26
VC0456889
p10352
sg10
I3
sg11
VETL
p10353
sg13
I1
sa(dp10354
g7
I100
sg26
VC0024301
p10355
sg10
I19
sg11
Vfollicular lymphoma
p10356
sg13
I2
sa(dp10357
g7
I134
sg26
VC0079744
p10358
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p10359
sg13
I5
sa(dp10360
g7
I61
sg26
VC0024305
p10361
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p10362
sg13
I2
sa(dp10363
g7
I180
sg26
VC0334634
p10364
sg10
I20
sg11
Vmantle cell lymphoma
p10365
sg13
I3
sasa(dp10366
g2
S'50 patients with non-Hodgkin (n = 27) and Hodgkin lymphoma (n = 23) were examined with a plain T2-weighted TSE sequence (parameters: TE 90 ms, TR &gt;2.500 ms, slice thickness 8 mm, slice interval 0.8 mm, ETL 20, NEX 4), and with spiral CT following oral and intravenous administration of contrast agent.\n'
p10367
sg4
(lp10368
(dp10369
g7
I205
sg8
g64
sg10
I6
sg11
VETL 20
p10370
sg13
I2
sasg23
(lp10371
(dp10372
g7
I42
sg26
VC0019829
p10373
sg10
I16
sg11
VHodgkin lymphoma
p10374
sg13
I2
sasa(dp10375
g2
S'The methylation status of septin-9 gene in plasma has been developed as a promising biomarker to aid in the diagnosis of colorectal cancer (CRC).\n'
p10376
sg4
(lp10377
(dp10378
g7
I26
sg8
g64
sg10
I13
sg11
Vseptin-9 gene
p10379
sg13
I2
sasg23
(lp10380
(dp10381
g7
I140
sg26
VC1527249
p10382
sg10
I3
sg11
VCRC
p10383
sg13
I1
sa(dp10384
g7
I121
sg26
VC1527249
p10385
sg10
I17
sg11
Vcolorectal cancer
p10386
sg13
I2
sasa(dp10387
g2
S'The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening.\n'
p10388
sg4
(lp10389
sg23
(lp10390
(dp10391
g7
I75
sg26
VC1527249
p10392
sg10
I17
sg11
Vcolorectal cancer
p10393
sg13
I2
sa(dp10394
g7
I94
sg26
VC1527249
p10395
sg10
I3
sg11
VCRC
p10396
sg13
I1
sasa(dp10397
g2
S'This study aims to examine the influence of algorithm and subject-related factors, including cancer stage, age, sex, and cancer location, on the performance of the SEPT9 gene methylation test, an assay approved by the US FDA for colorectal cancer (CRC) screening.\n'
p10398
sg4
(lp10399
sg23
(lp10400
(dp10401
g7
I229
sg26
VC1527249
p10402
sg10
I17
sg11
Vcolorectal cancer
p10403
sg13
I2
sa(dp10404
g7
I93
sg26
VC0006826
p10405
sg10
I6
sg11
Vcancer
p10406
sg13
I1
sa(dp10407
g7
I93
sg26
VC0006826
p10408
sg10
I6
sg11
Vcancer
p10409
sg13
I1
sa(dp10410
g7
I248
sg26
VC1527249
p10411
sg10
I3
sg11
VCRC
p10412
sg13
I1
sasa(dp10413
g2
S'The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy.\n'
p10414
sg4
(lp10415
sg23
(lp10416
(dp10417
g7
I157
sg26
VC1527249
p10418
sg10
I17
sg11
Vcolorectal cancer
p10419
sg13
I2
sasa(dp10420
g2
S'Clinically, we observed a positive correlation between stromal expression of FAP, p-STAT3, and CCL2 in human intrahepatic cholangiocarcinoma, a highly aggressive liver cancer with dense desmoplastic stroma, where elevated levels of stromal FAP predicted a poor survival outcome.\n'
p10421
sg4
(lp10422
(dp10423
g7
I95
sg8
VP13500
p10424
sg10
I4
sg11
VCCL2
p10425
sg13
I1
sa(dp10426
g7
I82
sg8
VP40763
p10427
sg10
I7
sg11
Vp-STAT3
p10428
sg13
I1
sa(dp10429
g7
I77
sg8
VP25054
p10430
sg10
I3
sg11
VFAP
p10431
sg13
I1
sasg23
(lp10432
(dp10433
g7
I151
sg26
VC0001807
p10434
sg10
I10
sg11
Vaggressive
p10435
sg13
I1
sa(dp10436
g7
I109
sg26
VC0345905
p10437
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p10438
sg13
I2
sa(dp10439
g7
I77
sg26
VC0032580
p10440
sg10
I3
sg11
VFAP
p10441
sg13
I1
sa(dp10442
g7
I77
sg26
VC0032580
p10443
sg10
I3
sg11
VFAP
p10444
sg13
I1
sa(dp10445
g7
I162
sg26
VC0345904
p10446
sg10
I12
sg11
Vliver cancer
p10447
sg13
I2
sa(dp10448
g7
I186
sg26
VC1511789
p10449
sg10
I12
sg11
Vdesmoplastic
p10450
sg13
I1
sasa(dp10451
g2
S'We previously discovered that polymorphisms in or near CELF6 may be associated with autism spectrum disorder (ASD) in humans and that the deletion of this gene in mice results in a partial ASD-like phenotype.\n'
p10452
sg4
(lp10453
(dp10454
g7
I189
sg8
VP51689
p10455
sg10
I8
sg11
VASD-like
p10456
sg13
I1
sa(dp10457
g7
I55
sg8
g64
sg10
I5
sg11
VCELF6
p10458
sg13
I1
sasg23
(lp10459
(dp10460
g7
I110
sg26
VC1510586
p10461
sg10
I3
sg11
VASD
p10462
sg13
I1
sa(dp10463
g7
I84
sg26
VC1510586
p10464
sg10
I24
sg11
Vautism spectrum disorder
p10465
sg13
I3
sa(dp10466
g7
I110
sg26
VC1510586
p10467
sg10
I3
sg11
VASD
p10468
sg13
I1
sasa(dp10469
g2
S'Analysis of common variants near the corresponding genes in the AGRE collection implicated the RNA binding protein CELF6 in autism risk.\n'
p10470
sg4
(lp10471
(dp10472
g7
I95
sg8
g64
sg10
I25
sg11
VRNA binding protein CELF6
p10473
sg13
I4
sasg23
(lp10474
(dp10475
g7
I124
sg26
VC0004352
p10476
sg10
I6
sg11
Vautism
p10477
sg13
I1
sasa(dp10478
g2
S'The Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data were mined to verify the change of NDUFA4L2 expression level in ccRCC tissues.\n'
p10479
sg4
(lp10480
(dp10481
g7
I109
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10482
sg13
I1
sasg23
(lp10483
(dp10484
g7
I42
sg26
VC0006826
p10485
sg10
I6
sg11
VCancer
p10486
sg13
I1
sasa(dp10487
g2
S'NDUFA4L2 was verified to be overexpressed in ccRCC tissues and its expression level was increased accordingly as the American Joint Committee on Cancer (AJCC) stage progressed.\n'
p10488
sg4
(lp10489
(dp10490
g7
I0
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10491
sg13
I1
sasg23
(lp10492
(dp10493
g7
I145
sg26
VC0006826
p10494
sg10
I6
sg11
VCancer
p10495
sg13
I1
sasa(dp10496
g2
S'NDUFA4L2 is overexpressed in VHL-deficient cell lines and neuroblastoma.\n'
p10497
sg4
(lp10498
(dp10499
g7
I29
sg8
VP40337
p10500
sg10
I3
sg11
VVHL
p10501
sg13
I1
sa(dp10502
g7
I0
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10503
sg13
I1
sasg23
(lp10504
(dp10505
g7
I58
sg26
VC0027819
p10506
sg10
I13
sg11
Vneuroblastoma
p10507
sg13
I1
sa(dp10508
g7
I29
sg26
VC0019562
p10509
sg10
I3
sg11
VVHL
p10510
sg13
I1
sasa(dp10511
g2
S'The clinical significance of NDUFA4L2 in clear cell renal cell carcinoma (ccRCC) has not been well studied.\n'
p10512
sg4
(lp10513
(dp10514
g7
I29
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10515
sg13
I1
sasg23
(lp10516
(dp10517
g7
I41
sg26
VC0279702
p10518
sg10
I31
sg11
Vclear cell renal cell carcinoma
p10519
sg13
I5
sa(dp10520
g7
I74
sg26
VC0279702
p10521
sg10
I5
sg11
VccRCC
p10522
sg13
I1
sasa(dp10523
g2
S'Our study has provided the first clinical relevance of NDUFA4L2 in human cancer and suggested that HCC patients with NDUFA4L2 overexpression may be suitable candidates for HIF inhibitor treatment.\n'
p10524
sg4
(lp10525
(dp10526
g7
I55
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10527
sg13
I1
sa(dp10528
g7
I55
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10529
sg13
I1
sasg23
(lp10530
(dp10531
g7
I99
sg26
VC2239176
p10532
sg10
I3
sg11
VHCC
p10533
sg13
I1
sa(dp10534
g7
I73
sg26
VC0006826
p10535
sg10
I6
sg11
Vcancer
p10536
sg13
I1
sasa(dp10537
g2
S'We delineated the functions of the hypoxia-inducible factor-1Alfa (HIF1Alfa) target NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4-like 2 (NDUFA4L2) in clear cell renal cell carcinoma (ccRCC) and characterized NDUFA4L2 as a novel molecular target for ccRCC treatment.\n'
p10538
sg4
(lp10539
(dp10540
g7
I145
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10541
sg13
I1
sa(dp10542
g7
I145
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10543
sg13
I1
sa(dp10544
g7
I35
sg8
VP49366
p10545
sg10
I108
sg11
Vhypoxia-inducible factor-1Alfa (HIF1Alfa) target NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4-like 2
p10546
sg13
I12
sasg23
(lp10547
(dp10548
g7
I191
sg26
VC0279702
p10549
sg10
I5
sg11
VccRCC
p10550
sg13
I1
sa(dp10551
g7
I191
sg26
VC0279702
p10552
sg10
I5
sg11
VccRCC
p10553
sg13
I1
sa(dp10554
g7
I35
sg26
VC0242184
p10555
sg10
I7
sg11
Vhypoxia
p10556
sg13
I1
sa(dp10557
g7
I158
sg26
VC0279702
p10558
sg10
I31
sg11
Vclear cell renal cell carcinoma
p10559
sg13
I5
sasa(dp10560
g2
S'We evaluated normal kidney and ccRCC patient microarray and RNAseq data from Oncomine and The Cancer Genome Atlas for NDUFA4L2 mRNA levels and the clinical implications of high NDUFA4L2 expression.\n'
p10561
sg4
(lp10562
(dp10563
g7
I118
sg8
g64
sg10
I13
sg11
VNDUFA4L2 mRNA
p10564
sg13
I2
sa(dp10565
g7
I118
sg8
g64
sg10
I8
sg11
VNDUFA4L2
p10566
sg13
I1
sasg23
(lp10567
(dp10568
g7
I94
sg26
VC0006826
p10569
sg10
I6
sg11
VCancer
p10570
sg13
I1
sasa(dp10571
g2
S'The purpose of this study is to test whether miR-497 can modulate macrophage foam cell formation, an initiating event in atherosclerosis.\n'
p10572
sg4
(lp10573
sg23
(lp10574
(dp10575
g7
I121
sg26
VC0004153
p10576
sg10
I15
sg11
Vatherosclerosis
p10577
sg13
I1
sasa(dp10578
g2
S'In conclusion, miR-497 contributes to oxLDL-induced lipid deposition in macrophages largely via targeting of apelin and thus represents a potential therapeutic target for atherosclerosis.\n'
p10579
sg4
(lp10580
(dp10581
g7
I15
sg8
g64
sg10
I7
sg11
VmiR-497
p10582
sg13
I1
sa(dp10583
g7
I109
sg8
g64
sg10
I6
sg11
Vapelin
p10584
sg13
I1
sasg23
(lp10585
(dp10586
g7
I171
sg26
VC0004153
p10587
sg10
I15
sg11
Vatherosclerosis
p10588
sg13
I1
sasa(dp10589
g2
S'However, to date, no information about the role of miR-497 in the development of atherosclerosis has been reported.\n'
p10590
sg4
(lp10591
sg23
(lp10592
(dp10593
g7
I81
sg26
VC0004153
p10594
sg10
I15
sg11
Vatherosclerosis
p10595
sg13
I1
sasa(dp10596
g2
S'This study investigated the possible role of miR-497 in vascular endothelial cell injury during the early stage of atherosclerosis.\n'
p10597
sg4
(lp10598
sg23
(lp10599
(dp10600
g7
I115
sg26
VC0004153
p10601
sg10
I15
sg11
Vatherosclerosis
p10602
sg13
I1
sa(dp10603
g7
I77
sg26
VC0599732
p10604
sg10
I11
sg11
Vcell injury
p10605
sg13
I2
sasa(dp10606
g2
S'Overall, our study shows that miR-497 might play a role in the development of atherosclerosis by inducing apoptosis and suppressing the proliferation of vascular endothelial cells.\n'
p10607
sg4
(lp10608
(dp10609
g7
I30
sg8
g64
sg10
I7
sg11
VmiR-497
p10610
sg13
I1
sasg23
(lp10611
(dp10612
g7
I136
sg26
VC0334094
p10613
sg10
I13
sg11
Vproliferation
p10614
sg13
I1
sa(dp10615
g7
I78
sg26
VC0004153
p10616
sg10
I15
sg11
Vatherosclerosis
p10617
sg13
I1
sasa(dp10618
g2
S'Therefore, miR-497 could be a potential therapeutic target for the treatment of atherosclerosis.\n'
p10619
sg4
(lp10620
(dp10621
g7
I11
sg8
g64
sg10
I7
sg11
VmiR-497
p10622
sg13
I1
sasg23
(lp10623
(dp10624
g7
I80
sg26
VC0004153
p10625
sg10
I15
sg11
Vatherosclerosis
p10626
sg13
I1
sasa(dp10627
g2
S'miR-34a-5p and miR-497-5p were increasingly up-regulated, while miR-434-3p was progressively down-regulated when atherosclerosis progressed.\n'
p10628
sg4
(lp10629
(dp10630
g7
I0
sg8
g64
sg10
I10
sg11
VmiR-34a-5p
p10631
sg13
I1
sa(dp10632
g7
I15
sg8
g64
sg10
I10
sg11
VmiR-497-5p
p10633
sg13
I1
sa(dp10634
g7
I64
sg8
g64
sg10
I10
sg11
VmiR-434-3p
p10635
sg13
I1
sasg23
(lp10636
(dp10637
g7
I113
sg26
VC0004153
p10638
sg10
I15
sg11
Vatherosclerosis
p10639
sg13
I1
sasa(dp10640
g2
S'However, the expression of VASH-1 and its clinical value in bladder cancer remain unknown.\n'
p10641
sg4
(lp10642
(dp10643
g7
I27
sg8
g64
sg10
I6
sg11
VVASH-1
p10644
sg13
I1
sasg23
(lp10645
(dp10646
g7
I60
sg26
VC0699885
p10647
sg10
I14
sg11
Vbladder cancer
p10648
sg13
I2
sasa(dp10649
g2
S'The current study analyzed the expression of VASH-1, as well as the expression of the angiogenesis-related factors vascular endothelial growth factor-A, hypoxia inducible factor-1Alfa and cluster of differentiation 34 in bladder cancer tissues from 50 patients using immunohistochemistry.\n'
p10650
sg4
(lp10651
(dp10652
g7
I45
sg8
g64
sg10
I6
sg11
VVASH-1
p10653
sg13
I1
sa(dp10654
g7
I115
sg8
g64
sg10
I36
sg11
Vvascular endothelial growth factor-A
p10655
sg13
I4
sa(dp10656
g7
I153
sg8
g64
sg10
I30
sg11
Vhypoxia inducible factor-1Alfa
p10657
sg13
I3
sasg23
(lp10658
(dp10659
g7
I153
sg26
VC0242184
p10660
sg10
I7
sg11
Vhypoxia
p10661
sg13
I1
sa(dp10662
g7
I221
sg26
VC0699885
p10663
sg10
I14
sg11
Vbladder cancer
p10664
sg13
I2
sasa(dp10665
g2
S'The current study demonstrated that VASH-1 is primarily expressed in the cytoplasm of bladder cancer cells and in a fraction of vascular endothelial cells.\n'
p10666
sg4
(lp10667
(dp10668
g7
I36
sg8
g64
sg10
I6
sg11
VVASH-1
p10669
sg13
I1
sasg23
(lp10670
(dp10671
g7
I86
sg26
VC0699885
p10672
sg10
I14
sg11
Vbladder cancer
p10673
sg13
I2
sasa(dp10674
g2
S'Collectively, the results of the current study suggest that VASH-1 is clinically significant in bladder cancer and its high expression may predict the progression and prognosis of patients with bladder cancer.\n'
p10675
sg4
(lp10676
(dp10677
g7
I60
sg8
g64
sg10
I6
sg11
VVASH-1
p10678
sg13
I1
sasg23
(lp10679
(dp10680
g7
I96
sg26
VC0699885
p10681
sg10
I14
sg11
Vbladder cancer
p10682
sg13
I2
sa(dp10683
g7
I96
sg26
VC0699885
p10684
sg10
I14
sg11
Vbladder cancer
p10685
sg13
I2
sasa(dp10686
g2
S'Several studies have demonstrated that VASH1 plays important roles in tumor angiogenesis but the role of this angiogenic inhibitor in renal cell carcinoma (RCC) has not been elucidated.\n'
p10687
sg4
(lp10688
(dp10689
g7
I39
sg8
g64
sg10
I5
sg11
VVASH1
p10690
sg13
I1
sasg23
(lp10691
(dp10692
g7
I134
sg26
VC0007134
p10693
sg10
I20
sg11
Vrenal cell carcinoma
p10694
sg13
I3
sa(dp10695
g7
I70
sg26
VC1519670
p10696
sg10
I18
sg11
Vtumor angiogenesis
p10697
sg13
I2
sa(dp10698
g7
I156
sg26
VC0007134
p10699
sg10
I3
sg11
VRCC
p10700
sg13
I1
sasa(dp10701
g2
S'Renal cell carcinoma is highly vascularised, but the significance of endogenous VASH1 in renal cell carcinoma has not been defined.\n'
p10702
sg4
(lp10703
(dp10704
g7
I80
sg8
g64
sg10
I5
sg11
VVASH1
p10705
sg13
I1
sasg23
(lp10706
(dp10707
g7
I89
sg26
VC0007134
p10708
sg10
I20
sg11
Vrenal cell carcinoma
p10709
sg13
I3
sa(dp10710
g7
I0
sg26
VC0007134
p10711
sg10
I20
sg11
VRenal cell carcinoma
p10712
sg13
I3
sasa(dp10713
g2
S'To identify VASH1 expression and its possible relationship with various clinicopathological factors and prognosis in renal cell carcinoma.\n'
p10714
sg4
(lp10715
(dp10716
g7
I12
sg8
g64
sg10
I5
sg11
VVASH1
p10717
sg13
I1
sasg23
(lp10718
(dp10719
g7
I117
sg26
VC0007134
p10720
sg10
I20
sg11
Vrenal cell carcinoma
p10721
sg13
I3
sasa(dp10722
g2
S'VASH1 expression may be useful for estimating the prognosis of renal cell carcinoma.\n'
p10723
sg4
(lp10724
(dp10725
g7
I0
sg8
g64
sg10
I5
sg11
VVASH1
p10726
sg13
I1
sasg23
(lp10727
(dp10728
g7
I63
sg26
VC0007134
p10729
sg10
I20
sg11
Vrenal cell carcinoma
p10730
sg13
I3
sasa(dp10731
g2
S'Further studies of the role of VASH1 in renal cell carcinoma involving larger sample sizes are warranted.\n'
p10732
sg4
(lp10733
(dp10734
g7
I31
sg8
g64
sg10
I5
sg11
VVASH1
p10735
sg13
I1
sasg23
(lp10736
(dp10737
g7
I40
sg26
VC0007134
p10738
sg10
I20
sg11
Vrenal cell carcinoma
p10739
sg13
I3
sasa(dp10740
g2
S'Several studies have demonstrated that VASH1 plays important roles in tumor angiogenesis but the role of this angiogenic inhibitor in renal cell carcinoma (RCC) has not been elucidated until now.\n'
p10741
sg4
(lp10742
(dp10743
g7
I39
sg8
g64
sg10
I5
sg11
VVASH1
p10744
sg13
I1
sasg23
(lp10745
(dp10746
g7
I134
sg26
VC0007134
p10747
sg10
I20
sg11
Vrenal cell carcinoma
p10748
sg13
I3
sa(dp10749
g7
I70
sg26
VC1519670
p10750
sg10
I18
sg11
Vtumor angiogenesis
p10751
sg13
I2
sa(dp10752
g7
I156
sg26
VC0007134
p10753
sg10
I3
sg11
VRCC
p10754
sg13
I1
sasa(dp10755
g2
S'CYP17A1 and CYP11B1 were positive in 21 (100%) and 17 (81%) adenomas, respectively.\n'
p10756
sg4
(lp10757
(dp10758
g7
I12
sg8
VP15538
p10759
sg10
I7
sg11
VCYP11B1
p10760
sg13
I1
sa(dp10761
g7
I0
sg8
VP05093
p10762
sg10
I7
sg11
VCYP17A1
p10763
sg13
I1
sasg23
(lp10764
(dp10765
g7
I60
sg26
VC0001430
p10766
sg10
I8
sg11
Vadenomas
p10767
sg13
I1
sasa(dp10768
g2
S'F-DST significantly decreased after adrenalectomy, and most of the adenomas were immunohistochemically positive for CYP17A1 and CYP11B1 as well as CYP11B2.\n'
p10769
sg4
(lp10770
(dp10771
g7
I147
sg8
VP19099
p10772
sg10
I7
sg11
VCYP11B2
p10773
sg13
I1
sa(dp10774
g7
I116
sg8
VP05093
p10775
sg10
I7
sg11
VCYP17A1
p10776
sg13
I1
sa(dp10777
g7
I128
sg8
VP15538
p10778
sg10
I7
sg11
VCYP11B1
p10779
sg13
I1
sasg23
(lp10780
(dp10781
g7
I67
sg26
VC0001430
p10782
sg10
I8
sg11
Vadenomas
p10783
sg13
I1
sasa(dp10784
g2
S'The aims of our study were to determine whether the CYP11B1 expression was regulated through DNA methylation in hypercortisolemia with cortisol-producing adenoma (CPA), and to investigate a possible relationship between DNA methylation and somatic mutations identified in CPA.\n'
p10785
sg4
(lp10786
(dp10787
g7
I52
sg8
VP15538
p10788
sg10
I7
sg11
VCYP11B1
p10789
sg13
I1
sasg23
(lp10790
(dp10791
g7
I240
sg26
VC0544886
p10792
sg10
I17
sg11
Vsomatic mutations
p10793
sg13
I2
sa(dp10794
g7
I135
sg26
VC0001430
p10795
sg10
I26
sg11
Vcortisol-producing adenoma
p10796
sg13
I2
sa(dp10797
g7
I163
sg26
VC0001430
p10798
sg10
I3
sg11
VCPA
p10799
sg13
I1
sa(dp10800
g7
I163
sg26
VC0001430
p10801
sg10
I3
sg11
VCPA
p10802
sg13
I1
sa(dp10803
g7
I112
sg26
VC0598639
p10804
sg10
I17
sg11
Vhypercortisolemia
p10805
sg13
I1
sasa(dp10806
g2
S'Four familial forms of primary aldosteronism (FH-I to FH-IV) have been described.\n'
p10807
sg4
(lp10808
sg23
(lp10809
(dp10810
g7
I23
sg26
VC1384514
p10811
sg10
I21
sg11
Vprimary aldosteronism
p10812
sg13
I2
sasa(dp10813
g2
S'We also analyzed the expression of cortisol-producing CYP11B1 and aldosterone-producing CYP11B2 enzymes in adenoma tissue from 57 patients with aldosterone-producing adenoma, employing immunohistochemistry with digital image analysis.\n'
p10814
sg4
(lp10815
(dp10816
g7
I54
sg8
VP15538
p10817
sg10
I7
sg11
VCYP11B1
p10818
sg13
I1
sa(dp10819
g7
I88
sg8
VP19099
p10820
sg10
I15
sg11
VCYP11B2 enzymes
p10821
sg13
I2
sasg23
(lp10822
(dp10823
g7
I107
sg26
VC0001430
p10824
sg10
I7
sg11
Vadenoma
p10825
sg13
I1
sa(dp10826
g7
I107
sg26
VC0001430
p10827
sg10
I7
sg11
Vadenoma
p10828
sg13
I1
sasa(dp10829
g2
S'Four APAs showed a predominant (&gt;=50%) zona fasciculata-like cell pattern: one tumor had CYP11B1 H-score = 150, no detectable CYP11B2 expression, and harbored a PRKACA p.Leu206Arg mutation (that we have reported previously elsewhere), one had no CYP11B1 expression, CYP11B2 H-score = 40, and no mutations; the remaining two adenomas had high CYP11B1 H-score (160 and 240, respectively) and low CYP11B2 H-score (30 and 15, respectively), with the latter harboring a CTNNB1 p.Ser45Phe activating mutation.\n'
p10830
sg4
(lp10831
(dp10832
g7
I269
sg8
VP19099
p10833
sg10
I9
sg11
VCYP11B2 H
p10834
sg13
I2
sa(dp10835
g7
I92
sg8
VP15538
p10836
sg10
I9
sg11
VCYP11B1 H
p10837
sg13
I2
sa(dp10838
g7
I129
sg8
VP19099
p10839
sg10
I7
sg11
VCYP11B2
p10840
sg13
I1
sa(dp10841
g7
I468
sg8
VP35222
p10842
sg10
I8
sg11
VCTNNB1 p
p10843
sg13
I2
sa(dp10844
g7
I92
sg8
VP15538
p10845
sg10
I9
sg11
VCYP11B1 H
p10846
sg13
I2
sa(dp10847
g7
I269
sg8
VP19099
p10848
sg10
I9
sg11
VCYP11B2 H
p10849
sg13
I2
sa(dp10850
g7
I92
sg8
VP15538
p10851
sg10
I7
sg11
VCYP11B1
p10852
sg13
I1
sasg23
(lp10853
(dp10854
g7
I327
sg26
VC0001430
p10855
sg10
I8
sg11
Vadenomas
p10856
sg13
I1
sa(dp10857
g7
I82
sg26
VC0027651
p10858
sg10
I5
sg11
Vtumor
p10859
sg13
I1
sa(dp10860
g7
I42
sg26
VC0019360
p10861
sg10
I4
sg11
Vzona
p10862
sg13
I1
sasa(dp10863
g2
S'One of five aldosterone-producing adenomas had a predominant zona glomerulosa-like pattern, CYP11B1 H-score = 15, CYP11B2 H-score = 180, and no mutations.\n'
p10864
sg4
(lp10865
(dp10866
g7
I92
sg8
VP15538
p10867
sg10
I7
sg11
VCYP11B1
p10868
sg13
I1
sa(dp10869
g7
I114
sg8
VP19099
p10870
sg10
I9
sg11
VCYP11B2 H
p10871
sg13
I2
sasg23
(lp10872
(dp10873
g7
I61
sg26
VC0019360
p10874
sg10
I4
sg11
Vzona
p10875
sg13
I1
sa(dp10876
g7
I34
sg26
VC0001430
p10877
sg10
I8
sg11
Vadenomas
p10878
sg13
I1
sasa(dp10879
g2
S'The majority of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion were composed mainly of zona fasciculata-like cells, while CYP11B1 and CYP11B2 immunostaining demonstrated clear heterogeneity.\n'
p10880
sg4
(lp10881
(dp10882
g7
I170
sg8
VP19099
p10883
sg10
I7
sg11
VCYP11B2
p10884
sg13
I1
sa(dp10885
g7
I158
sg8
VP15538
p10886
sg10
I7
sg11
VCYP11B1
p10887
sg13
I1
sasg23
(lp10888
(dp10889
g7
I38
sg26
VC0001430
p10890
sg10
I8
sg11
Vadenomas
p10891
sg13
I1
sa(dp10892
g7
I123
sg26
VC0019360
p10893
sg10
I4
sg11
Vzona
p10894
sg13
I1
sasa(dp10895
g2
S'Hydrolethalus can also be difficult to distinguish from certain skeletal dysplasias such as the short rib-polydactyly syndromes and campomelic dysplasia.\n'
p10896
sg4
(lp10897
sg23
(lp10898
(dp10899
g7
I132
sg26
VC1861922
p10900
sg10
I20
sg11
Vcampomelic dysplasia
p10901
sg13
I2
sa(dp10902
g7
I96
sg26
VC0036996
p10903
sg10
I31
sg11
Vshort rib-polydactyly syndromes
p10904
sg13
I3
sa(dp10905
g7
I73
sg26
VC0334044
p10906
sg10
I10
sg11
Vdysplasias
p10907
sg13
I1
sasa(dp10908
g2
S'It is proposed that cases of hydrolethalus syndrome with short limbs constitute a separate type of lethal osteochondrodysplasia mimicking short rib-polydactyly syndromes.\n'
p10909
sg4
(lp10910
sg23
(lp10911
(dp10912
g7
I138
sg26
VC0036996
p10913
sg10
I31
sg11
Vshort rib-polydactyly syndromes
p10914
sg13
I3
sa(dp10915
g7
I29
sg26
VC2931104
p10916
sg10
I22
sg11
Vhydrolethalus syndrome
p10917
sg13
I2
sa(dp10918
g7
I106
sg26
VC0026707
p10919
sg10
I21
sg11
Vosteochondrodysplasia
p10920
sg13
I1
sasa(dp10921
g2
S'miR-145 and miR-20a-5p previously reported as diagnosis biomarker in treatment naive RRMS patients and their expression after IFN-Beta therapy might be indicative of molecular mechanism of IFN-Beta.\n'
p10922
sg4
(lp10923
(dp10924
g7
I126
sg8
VP01574
p10925
sg10
I8
sg11
VIFN-Beta
p10926
sg13
I1
sa(dp10927
g7
I0
sg8
g64
sg10
I7
sg11
VmiR-145
p10928
sg13
I1
sa(dp10929
g7
I12
sg8
g64
sg10
I10
sg11
VmiR-20a-5p
p10930
sg13
I1
sa(dp10931
g7
I126
sg8
VP01574
p10932
sg10
I8
sg11
VIFN-Beta
p10933
sg13
I1
sasg23
(lp10934
sa(dp10935
g2
S'Here, in order to clarify the ambiguous molecular mechanism of IFN-Beta and evaluate the potential use of them as a biomarker for monitoring of therapy, we investigated the expression of miR-145 and miR-20a-5p in blood sample of 15 treatment naive RRMS patients, 15 IFN-Beta-treated RRMS patients, and 15 healthy volunteers (HVs).\n'
p10936
sg4
(lp10937
(dp10938
g7
I63
sg8
VP01574
p10939
sg10
I8
sg11
VIFN-Beta
p10940
sg13
I1
sa(dp10941
g7
I199
sg8
g64
sg10
I10
sg11
VmiR-20a-5p
p10942
sg13
I1
sa(dp10943
g7
I187
sg8
g64
sg10
I7
sg11
VmiR-145
p10944
sg13
I1
sa(dp10945
g7
I63
sg8
VP01574
p10946
sg10
I8
sg11
VIFN-Beta
p10947
sg13
I1
sasg23
(lp10948
sa(dp10949
g2
S'In this study, we have focused our investigation on miR-20a, a member of the miR-17-92 cluster, whose expression is decreased in patients suffering from multiple sclerosis.\n'
p10950
sg4
(lp10951
(dp10952
g7
I77
sg8
g64
sg10
I17
sg11
VmiR-17-92 cluster
p10953
sg13
I2
sa(dp10954
g7
I52
sg8
g64
sg10
I7
sg11
VmiR-20a
p10955
sg13
I1
sasg23
(lp10956
(dp10957
g7
I153
sg26
VC0026769
p10958
sg10
I18
sg11
Vmultiple sclerosis
p10959
sg13
I2
sa(dp10960
g7
I138
sg26
VC0683278
p10961
sg10
I9
sg11
Vsuffering
p10962
sg13
I1
sasa(dp10963
g2
S"Seven miRNAs (miR-206, miR-132, miR-193b, miR-130b, miR-20a, miR-296, and miR-329) related to Alzheimer's disease (AD) were detected in serum using a quantitative real-time PCR (qRT-PCR) method.\n"
p10964
sg4
(lp10965
(dp10966
g7
I52
sg8
g64
sg10
I7
sg11
VmiR-20a
p10967
sg13
I1
sa(dp10968
g7
I32
sg8
g64
sg10
I8
sg11
VmiR-193b
p10969
sg13
I1
sa(dp10970
g7
I23
sg8
g64
sg10
I7
sg11
VmiR-132
p10971
sg13
I1
sa(dp10972
g7
I61
sg8
g64
sg10
I7
sg11
VmiR-296
p10973
sg13
I1
sa(dp10974
g7
I14
sg8
g64
sg10
I7
sg11
VmiR-206
p10975
sg13
I1
sa(dp10976
g7
I42
sg8
g64
sg10
I8
sg11
VmiR-130b
p10977
sg13
I1
sasg23
(lp10978
(dp10979
g7
I94
sg26
VC1521724
p10980
sg10
I19
sg11
VAlzheimer's disease
p10981
sg13
I2
sa(dp10982
g7
I115
sg26
VC1521724
p10983
sg10
I2
sg11
VAD
p10984
sg13
I1
sasa(dp10985
g2
S'This study identifies a set of miRNAs deregulated in CIS/RRMS and reconfirms the previously reported underexpression of hsa-miR-20a-5p in MS. hsa-miR-20a-5p and the other validated miRNAs may represent promising candidates for future evaluation as biomarkers for MS and could be of relevance in the pathophysiology of this disease.\n'
p10986
sg4
(lp10987
(dp10988
g7
I120
sg8
g64
sg10
I14
sg11
Vhsa-miR-20a-5p
p10989
sg13
I1
sa(dp10990
g7
I53
sg8
VP12821
p10991
sg10
I3
sg11
VCIS
p10992
sg13
I1
sa(dp10993
g7
I120
sg8
g64
sg10
I14
sg11
Vhsa-miR-20a-5p
p10994
sg13
I1
sa(dp10995
g7
I57
sg8
g64
sg10
I4
sg11
VRRMS
p10996
sg13
I1
sasg23
(lp10997
(dp10998
g7
I120
sg26
VC0393754
p10999
sg10
I3
sg11
Vhsa
p11000
sg13
I1
sa(dp11001
g7
I53
sg26
VC0007099
p11002
sg10
I3
sg11
VCIS
p11003
sg13
I1
sa(dp11004
g7
I120
sg26
VC0393754
p11005
sg10
I3
sg11
Vhsa
p11006
sg13
I1
sasa(dp11007
g2
S'We found that Tiam1-mediated Rac signaling functions in various aspects of tumorigenicity including the formation and progression of Ras-induced skin tumors and Wnt-induced intestinal tumors.\n'
p11008
sg4
(lp11009
(dp11010
g7
I133
sg8
VP01116
p11011
sg10
I3
sg11
VRas
p11012
sg13
I1
sa(dp11013
g7
I29
sg8
VP31749
p11014
sg10
I3
sg11
VRac
p11015
sg13
I1
sa(dp11016
g7
I14
sg8
g64
sg10
I5
sg11
VTiam1
p11017
sg13
I1
sasg23
(lp11018
(dp11019
g7
I75
sg26
VC1519697
p11020
sg10
I14
sg11
Vtumorigenicity
p11021
sg13
I1
sa(dp11022
g7
I145
sg26
VC0037286
p11023
sg10
I11
sg11
Vskin tumors
p11024
sg13
I2
sa(dp11025
g7
I173
sg26
VC0021841
p11026
sg10
I17
sg11
Vintestinal tumors
p11027
sg13
I2
sasa(dp11028
g2
S'Here we show that Tiam1, a selective Rac GTPase activator, is a Wnt-responsive gene expressed in the base of intestinal crypts and up-regulated in mouse intestinal tumors and human colon adenomas.\n'
p11029
sg4
(lp11030
(dp11031
g7
I37
sg8
VP31749
p11032
sg10
I10
sg11
VRac GTPase
p11033
sg13
I2
sa(dp11034
g7
I18
sg8
g64
sg10
I5
sg11
VTiam1
p11035
sg13
I1
sasg23
(lp11036
(dp11037
g7
I187
sg26
VC0001430
p11038
sg10
I8
sg11
Vadenomas
p11039
sg13
I1
sa(dp11040
g7
I153
sg26
VC0021841
p11041
sg10
I17
sg11
Vintestinal tumors
p11042
sg13
I2
sasa(dp11043
g2
S'However, invasion of malignant intestinal tumors is enhanced by a lack of Tiam1.\n'
p11044
sg4
(lp11045
(dp11046
g7
I74
sg8
g64
sg10
I5
sg11
VTiam1
p11047
sg13
I1
sasg23
(lp11048
(dp11049
g7
I21
sg26
VC0346627
p11050
sg10
I27
sg11
Vmalignant intestinal tumors
p11051
sg13
I3
sa(dp11052
g7
I9
sg26
VC2699153
p11053
sg10
I8
sg11
Vinvasion
p11054
sg13
I1
sasa(dp11055
g2
S'Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) modulate the genesis and activity of osteoclasts, however their role in renal osteodystrophy pathogenesis has not been clarified so far.\n'
p11056
sg4
(lp11057
(dp11058
g7
I62
sg8
g64
sg10
I6
sg11
VRANK-L
p11059
sg13
I1
sa(dp11060
g7
I0
sg8
g64
sg10
I15
sg11
VOsteoprotegerin
p11061
sg13
I1
sa(dp11062
g7
I26
sg8
g64
sg10
I34
sg11
Vreceptor activator of NF-kB ligand
p11063
sg13
I5
sa(dp11064
g7
I17
sg8
g64
sg10
I3
sg11
VOPG
p11065
sg13
I1
sasg23
(lp11066
(dp11067
g7
I163
sg26
VC0699748
p11068
sg10
I12
sg11
Vpathogenesis
p11069
sg13
I1
sa(dp11070
g7
I142
sg26
VC0035086
p11071
sg10
I20
sg11
Vrenal osteodystrophy
p11072
sg13
I2
sasa(dp11073
g2
S'Here, using an integrative approach, we have dissected the metabolic fingerprints of lung adenocarcinomas, and we show that Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine biosynthesis, is highly expressed in a adenocarcinoma subset with poor prognosis.\n'
p11074
sg4
(lp11075
(dp11076
g7
I156
sg8
g64
sg10
I5
sg11
VPHGDH
p11077
sg13
I1
sa(dp11078
g7
I124
sg8
VP49366
p11079
sg10
I30
sg11
VPhosphoglycerate dehydrogenase
p11080
sg13
I2
sasg23
(lp11081
(dp11082
g7
I90
sg26
VC0001418
p11083
sg10
I15
sg11
Vadenocarcinomas
p11084
sg13
I1
sa(dp11085
g7
I90
sg26
VC0001418
p11086
sg10
I14
sg11
Vadenocarcinoma
p11087
sg13
I1
sasa(dp11088
g2
S'Our study provides evidence that a unique metabolic program is activated in a lung adenocarcinoma subset, described by PHGDH, which confers growth and survival and may have therapeutic implications.\n'
p11089
sg4
(lp11090
sg23
(lp11091
(dp11092
g7
I78
sg26
VC0152013
p11093
sg10
I19
sg11
Vlung adenocarcinoma
p11094
sg13
I2
sasa(dp11095
g2
S'Mice with colon-specific carcinoma--caused by either chromosomal (CDX2P 9.5-NLS Cre;Apc(+/flox), abbreviated to CPC;Apc) or microsatellite (CDX2P9.5-G19Cre;Apc(flox/flox) and CDX2P9.5-G22Cre;Apc(flox/flox)) instability, respectively--were administered chlorinated (10.0 mg/L chlorine) or tap (0.7 mg/L chlorine) water and evaluated for colon polyp formation.\n'
p11096
sg4
(lp11097
(dp11098
g7
I84
sg8
VP25054
p11099
sg10
I3
sg11
VApc
p11100
sg13
I1
sa(dp11101
g7
I124
sg8
g64
sg10
I31
sg11
Vmicrosatellite (CDX2P9.5-G19Cre
p11102
sg13
I2
sa(dp11103
g7
I84
sg8
VP25054
p11104
sg10
I3
sg11
VApc
p11105
sg13
I1
sa(dp11106
g7
I84
sg8
VP25054
p11107
sg10
I3
sg11
VApc
p11108
sg13
I1
sa(dp11109
g7
I66
sg8
VP09936
p11110
sg10
I17
sg11
VCDX2P 9.5-NLS Cre
p11111
sg13
I3
sasg23
(lp11112
(dp11113
g7
I25
sg26
VC0007097
p11114
sg10
I9
sg11
Vcarcinoma
p11115
sg13
I1
sa(dp11116
g7
I336
sg26
VC0009376
p11117
sg10
I11
sg11
Vcolon polyp
p11118
sg13
I2
sa(dp11119
g7
I76
sg26
VC0265218
p11120
sg10
I3
sg11
VNLS
p11121
sg13
I1
sa(dp11122
g7
I84
sg26
VC0033036
p11123
sg10
I3
sg11
VApc
p11124
sg13
I1
sa(dp11125
g7
I84
sg26
VC0033036
p11126
sg10
I3
sg11
VApc
p11127
sg13
I1
sa(dp11128
g7
I84
sg26
VC0033036
p11129
sg10
I3
sg11
VApc
p11130
sg13
I1
sa(dp11131
g7
I84
sg26
VC0033036
p11132
sg10
I3
sg11
VApc
p11133
sg13
I1
sasa(dp11134
g2
S'In this study, total lipids (TLs) from silver carp brain were isolated into polar lipids (PLs) and neutral lipids (NLs), and the anticancer potential of the lipid fractions (LFs) was investigated using the human cervical carcinoma HeLa cell line.\n'
p11135
sg4
(lp11136
sg23
(lp11137
(dp11138
g7
I76
sg26
VC0030360
p11139
sg10
I12
sg11
Vpolar lipids
p11140
sg13
I2
sa(dp11141
g7
I212
sg26
VC0302592
p11142
sg10
I18
sg11
Vcervical carcinoma
p11143
sg13
I2
sa(dp11144
g7
I115
sg26
VC0265218
p11145
sg10
I3
sg11
VNLs
p11146
sg13
I1
sa(dp11147
g7
I90
sg26
VC0030360
p11148
sg10
I3
sg11
VPLs
p11149
sg13
I1
sa(dp11150
g7
I99
sg26
VC0265218
p11151
sg10
I14
sg11
Vneutral lipids
p11152
sg13
I2
sa(dp11153
g7
I46
sg26
VC0263385
p11154
sg10
I4
sg11
Vcarp
p11155
sg13
I1
sasa(dp11156
g2
S'Among the TLs, PLs have proven to be more effective in inducing cervical carcinoma cell death than NLs.\n'
p11157
sg4
(lp11158
sg23
(lp11159
(dp11160
g7
I99
sg26
VC0265218
p11161
sg10
I3
sg11
VNLs
p11162
sg13
I1
sa(dp11163
g7
I15
sg26
VC0030360
p11164
sg10
I3
sg11
VPLs
p11165
sg13
I1
sa(dp11166
g7
I64
sg26
VC0302592
p11167
sg10
I18
sg11
Vcervical carcinoma
p11168
sg13
I2
sasa(dp11169
g2
S'We have previously shown that plasmonic nanoparticles conjugated with nuclear-targeting and cytoplasm-targeting peptides (NLS and RGD, respectively) are capable of altering the cell cycle of human oral squamous carcinoma cells (HSC-3).\n'
p11170
sg4
(lp11171
(dp11172
g7
I228
sg8
VP19526
p11173
sg10
I5
sg11
VHSC-3
p11174
sg13
I1
sasg23
(lp11175
(dp11176
g7
I202
sg26
VC0007137
p11177
sg10
I18
sg11
Vsquamous carcinoma
p11178
sg13
I2
sa(dp11179
g7
I122
sg26
VC0265218
p11180
sg10
I3
sg11
VNLS
p11181
sg13
I1
sasa(dp11182
g2
S'To determine the expression patterns of phosphoglycerate dehydrogenase (PHGDH) and serum squamous cell carcinoma antigen (SCC-Ag) in cervical cancer andtheir clinical significance and to explore their relationship with clinicopathological parameters.\n'
p11183
sg4
(lp11184
(dp11185
g7
I40
sg8
VP49366
p11186
sg10
I30
sg11
Vphosphoglycerate dehydrogenase
p11187
sg13
I2
sa(dp11188
g7
I72
sg8
g64
sg10
I5
sg11
VPHGDH
p11189
sg13
I1
sasg23
(lp11190
(dp11191
g7
I89
sg26
VC0007137
p11192
sg10
I23
sg11
Vsquamous cell carcinoma
p11193
sg13
I3
sa(dp11194
g7
I133
sg26
VC0302592
p11195
sg10
I15
sg11
Vcervical cancer
p11196
sg13
I2
sasa(dp11197
g2
S'In the present work, we utilized the plasmonic scattering property and the ability of nuclear-targeted silver nanoparticles (NLS/RGD-AgNPs) to induce programmed cell death in order to image in real-time the behavior of human oral squamous carcinoma (HSC-3) cell communities during and after the induction of apoptosis.\n'
p11198
sg4
(lp11199
sg23
(lp11200
(dp11201
g7
I125
sg26
VC0265218
p11202
sg10
I3
sg11
VNLS
p11203
sg13
I1
sa(dp11204
g7
I230
sg26
VC0007137
p11205
sg10
I18
sg11
Vsquamous carcinoma
p11206
sg13
I2
sasa(dp11207
g2
S'Mice carrying a CDX2P-NLS Cre recombinase transgene and a loxP-targeted Apc allele developed mainly colorectal tumors, with carcinomas seen in 6 of 36 (17%) of mice followed for 300 days.\n'
p11208
sg4
(lp11209
(dp11210
g7
I58
sg8
VP25054
p11211
sg10
I24
sg11
VloxP-targeted Apc allele
p11212
sg13
I3
sa(dp11213
g7
I16
sg8
g64
sg10
I35
sg11
VCDX2P-NLS Cre recombinase transgene
p11214
sg13
I4
sasg23
(lp11215
(dp11216
g7
I100
sg26
VC0009404
p11217
sg10
I17
sg11
Vcolorectal tumors
p11218
sg13
I2
sa(dp11219
g7
I22
sg26
VC0265218
p11220
sg10
I3
sg11
VNLS
p11221
sg13
I1
sa(dp11222
g7
I124
sg26
VC0007097
p11223
sg10
I10
sg11
Vcarcinomas
p11224
sg13
I1
sa(dp11225
g7
I72
sg26
VC0033036
p11226
sg10
I3
sg11
VApc
p11227
sg13
I1
sasa(dp11228
g2
S"La ragione per procedere alla fenestrazione con il laser e per il migliore controllo endoscopico delle estensione della resezione, e si puo visualizzare direttamente il collasso dell'ureterocele.\n"
p11229
sg4
(lp11230
sg23
(lp11231
(dp11232
g7
I178
sg26
VC0041960
p11233
sg10
I16
sg11
Vdell'ureterocele
p11234
sg13
I1
sa(dp11235
g7
I136
sg26
VC0856281
p11236
sg10
I3
sg11
Vpuo
p11237
sg13
I1
sasa(dp11238
g2
S'It seems a new signaling axis, SIRT1-SFRS10-LPIN1 axis, acting in the pathogenesis of AFLD exists.\n'
p11239
sg4
(lp11240
(dp11241
g7
I31
sg8
g64
sg10
I5
sg11
VSIRT1
p11242
sg13
I1
sa(dp11243
g7
I44
sg8
g64
sg10
I5
sg11
VLPIN1
p11244
sg13
I1
sa(dp11245
g7
I37
sg8
VP62995
p11246
sg10
I6
sg11
VSFRS10
p11247
sg13
I1
sasg23
(lp11248
(dp11249
g7
I70
sg26
VC0699748
p11250
sg10
I12
sg11
Vpathogenesis
p11251
sg13
I1
sasa(dp11252
g2
S'SIRT1, SFRS10, and LIPIN1 had been separately reported to participate in lipid metabolism and the pathogenesis of AFLD.\n'
p11253
sg4
(lp11254
(dp11255
g7
I7
sg8
VP62995
p11256
sg10
I6
sg11
VSFRS10
p11257
sg13
I1
sa(dp11258
g7
I0
sg8
g64
sg10
I5
sg11
VSIRT1
p11259
sg13
I1
sasg23
(lp11260
(dp11261
g7
I98
sg26
VC0699748
p11262
sg10
I12
sg11
Vpathogenesis
p11263
sg13
I1
sasa(dp11264
g2
S'It seems a new signaling axis, SIRT1-SFRS10-LIPIN1 axis, acting in the pathogenesis of AFLD exists.\n'
p11265
sg4
(lp11266
(dp11267
g7
I31
sg8
g64
sg10
I5
sg11
VSIRT1
p11268
sg13
I1
sa(dp11269
g7
I37
sg8
VP62995
p11270
sg10
I6
sg11
VSFRS10
p11271
sg13
I1
sasg23
(lp11272
(dp11273
g7
I71
sg26
VC0699748
p11274
sg10
I12
sg11
Vpathogenesis
p11275
sg13
I1
sasa(dp11276
g2
S'Further study aimed at SIRT1-SFRS10-LIPIN1 signaling system will possibly offer a more effective therapeutic target for AFLD.\n'
p11277
sg4
(lp11278
(dp11279
g7
I23
sg8
g64
sg10
I5
sg11
VSIRT1
p11280
sg13
I1
sa(dp11281
g7
I29
sg8
VP62995
p11282
sg10
I6
sg11
VSFRS10
p11283
sg13
I1
sasg23
(lp11284
sa(dp11285
g2
S'Emerging evidence suggests a pivotal role of lipin-1 as a crucial downstream regulator of SIRT1-AMPK signaling system that is likely to be ultimately responsible for development and progression of AFLD.\n'
p11286
sg4
(lp11287
(dp11288
g7
I96
sg8
VP54646
p11289
sg10
I4
sg11
VAMPK
p11290
sg13
I1
sa(dp11291
g7
I90
sg8
g64
sg10
I5
sg11
VSIRT1
p11292
sg13
I1
sa(dp11293
g7
I45
sg8
g64
sg10
I7
sg11
Vlipin-1
p11294
sg13
I1
sasg23
(lp11295
sa(dp11296
g2
S'This review summarizes current knowledge about the role of lipin-1 in the pathogenesis of AFLD and its potential signal transduction mechanisms.\n'
p11297
sg4
(lp11298
(dp11299
g7
I59
sg8
g64
sg10
I7
sg11
Vlipin-1
p11300
sg13
I1
sasg23
(lp11301
(dp11302
g7
I74
sg26
VC0699748
p11303
sg10
I12
sg11
Vpathogenesis
p11304
sg13
I1
sasa(dp11305
g2
S'The aim of this review was to focus on the knowledge of the role of lipin-1 in the pathogenesis of alcoholic fatty liver.\n'
p11306
sg4
(lp11307
(dp11308
g7
I68
sg8
g64
sg10
I7
sg11
Vlipin-1
p11309
sg13
I1
sasg23
(lp11310
(dp11311
g7
I99
sg26
VC0015696
p11312
sg10
I21
sg11
Valcoholic fatty liver
p11313
sg13
I3
sa(dp11314
g7
I83
sg26
VC0699748
p11315
sg10
I12
sg11
Vpathogenesis
p11316
sg13
I1
sasa(dp11317
g2
S'Systematic review of animal clinical and cell level studies related to the function of lipin-1 on alcoholic fatty liver, alcoholic hepatitis and alcoholic liver cirrhosis disease.\n'
p11318
sg4
(lp11319
(dp11320
g7
I87
sg8
g64
sg10
I7
sg11
Vlipin-1
p11321
sg13
I1
sasg23
(lp11322
(dp11323
g7
I131
sg26
VC0019159
p11324
sg10
I9
sg11
Vhepatitis
p11325
sg13
I1
sa(dp11326
g7
I108
sg26
VC0015696
p11327
sg10
I22
sg11
Vfatty liver, alcoholic
p11328
sg13
I3
sa(dp11329
g7
I145
sg26
VC0023891
p11330
sg10
I25
sg11
Valcoholic liver cirrhosis
p11331
sg13
I3
sasa(dp11332
g2
S'In hepatocytes of alcoholic fatty liver disease (AFLD), ethanol increases the expression of lipin-1 through the AMPK-SREBP-1 signaling and the Lpin1Beta/Alfa ratio by SIRT1-SFRS10- Lpin1Beta/Alfa axis.\n'
p11333
sg4
(lp11334
(dp11335
g7
I173
sg8
VP62995
p11336
sg10
I6
sg11
VSFRS10
p11337
sg13
I1
sa(dp11338
g7
I167
sg8
g64
sg10
I5
sg11
VSIRT1
p11339
sg13
I1
sa(dp11340
g7
I112
sg8
VP36956
p11341
sg10
I12
sg11
VAMPK-SREBP-1
p11342
sg13
I1
sa(dp11343
g7
I92
sg8
g64
sg10
I7
sg11
Vlipin-1
p11344
sg13
I1
sasg23
(lp11345
(dp11346
g7
I18
sg26
VC0015696
p11347
sg10
I21
sg11
Valcoholic fatty liver
p11348
sg13
I3
sasa(dp11349
g2
S'We discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan\'s anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan\'s anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).\n'
p11350
sg4
(lp11351
(dp11352
g7
I623
sg8
VP01308
p11353
sg10
I7
sg11
Vinsulin
p11354
sg13
I1
sa(dp11355
g7
I586
sg8
g64
sg10
I9
sg11
Vgene LIPE
p11356
sg13
I2
sa(dp11357
g7
I478
sg8
g64
sg10
I4
sg11
VATGL
p11358
sg13
I1
sa(dp11359
g7
I581
sg8
g64
sg10
I3
sg11
VHSL
p11360
sg13
I1
sa(dp11361
g7
I484
sg8
g64
sg10
I11
sg11
Vgene PNPLA2
p11362
sg13
I2
sa(dp11363
g7
I555
sg8
g64
sg10
I24
sg11
Vhormone-sensitive lipase
p11364
sg13
I2
sa(dp11365
g7
I321
sg8
g64
sg10
I5
sg11
VABHD5
p11366
sg13
I1
sa(dp11367
g7
I271
sg8
g64
sg10
I11
sg11
Vperilipin 1
p11368
sg13
I2
sa(dp11369
g7
I234
sg8
g64
sg10
I5
sg11
VDGAT1
p11370
sg13
I1
sa(dp11371
g7
I67
sg8
g64
sg10
I6
sg11
VAGPAT2
p11372
sg13
I1
sa(dp11373
g7
I449
sg8
VP04118
p11374
sg10
I27
sg11
Vadipose triglyceride lipase
p11375
sg13
I3
sa(dp11376
g7
I113
sg8
g64
sg10
I5
sg11
VLPIN1
p11377
sg13
I1
sasg23
(lp11378
(dp11379
g7
I507
sg26
VC0026848
p11380
sg10
I8
sg11
Vmyopathy
p11381
sg13
I1
sa(dp11382
g7
I359
sg26
VC0268238
p11383
sg10
I4
sg11
VNLSD
p11384
sg13
I1
sa(dp11385
g7
I181
sg26
VC1864997
p11386
sg10
I15
sg11
VMajeed syndrome
p11387
sg13
I2
sa(dp11388
g7
I359
sg26
VC0268238
p11389
sg10
I4
sg11
VNLSD
p11390
sg13
I1
sa(dp11391
g7
I370
sg26
VC0020758
p11392
sg10
I10
sg11
Vichthyosis
p11393
sg13
I1
sa(dp11394
g7
I328
sg26
VC0268238
p11395
sg10
I29
sg11
Vneutral lipid storage disease
p11396
sg13
I4
sa(dp11397
g7
I517
sg26
VC0878544
p11398
sg10
I14
sg11
Vcardiomyopathy
p11399
sg13
I1
sa(dp11400
g7
I130
sg26
VC0035410
p11401
sg10
I14
sg11
Vrhabdomyolysis
p11402
sg13
I1
sa(dp11403
g7
I85
sg26
VC0221032
p11404
sg10
I25
sg11
Vgeneralized lipodystrophy
p11405
sg13
I2
sa(dp11406
g7
I257
sg26
VC0021831
p11407
sg10
I11
sg11
Venteropathy
p11408
sg13
I1
sa(dp11409
g7
I170
sg26
VC0012634
p11410
sg10
I9
sg11
Vcondition
p11411
sg13
I1
sa(dp11412
g7
I284
sg26
VC0220989
p11413
sg10
I21
sg11
Vpartial lipodystrophy
p11414
sg13
I2
sa(dp11415
g7
I623
sg26
VC0021655
p11416
sg10
I18
sg11
Vinsulin resistance
p11417
sg13
I2
sasa(dp11418
g2
S'Transcripts were found and quantified for several isoforms of epithelial calcium channels (TRPV5, TRPV6), calcium buffer proteins (calbindin-D9K, calbindin-D28K), sodium-calcium exchangers (NCX1, NCX2, NCX3) and plasma membrane Ca2+-ATPase (PMCA1, PMCA2, PMCA3, and PMCA4) in native SCCD, cochlear lateral wall (LW) and stria vascularis (SV) of adult rat as well as Ca2+ channels in neonatal SCCD.\n'
p11419
sg4
(lp11420
(dp11421
g7
I131
sg8
VP05937
p11422
sg10
I13
sg11
Vcalbindin-D9K
p11423
sg13
I1
sa(dp11424
g7
I98
sg8
g64
sg10
I5
sg11
VTRPV6
p11425
sg13
I1
sa(dp11426
g7
I248
sg8
g64
sg10
I5
sg11
VPMCA2
p11427
sg13
I1
sa(dp11428
g7
I266
sg8
VP23634
p11429
sg10
I5
sg11
VPMCA4
p11430
sg13
I1
sa(dp11431
g7
I241
sg8
VP20020
p11432
sg10
I5
sg11
VPMCA1
p11433
sg13
I1
sa(dp11434
g7
I212
sg8
g64
sg10
I27
sg11
Vplasma membrane Ca2+-ATPase
p11435
sg13
I3
sa(dp11436
g7
I202
sg8
VP57103
p11437
sg10
I4
sg11
VNCX3
p11438
sg13
I1
sa(dp11439
g7
I196
sg8
VP57103
p11440
sg10
I4
sg11
VNCX2
p11441
sg13
I1
sa(dp11442
g7
I91
sg8
g64
sg10
I5
sg11
VTRPV5
p11443
sg13
I1
sa(dp11444
g7
I62
sg8
VP12830
p11445
sg10
I27
sg11
Vepithelial calcium channels
p11446
sg13
I3
sa(dp11447
g7
I146
sg8
VP05937
p11448
sg10
I14
sg11
Vcalbindin-D28K
p11449
sg13
I1
sasg23
(lp11450
(dp11451
g7
I283
sg26
VC0271287
p11452
sg10
I4
sg11
VSCCD
p11453
sg13
I1
sa(dp11454
g7
I283
sg26
VC0271287
p11455
sg10
I4
sg11
VSCCD
p11456
sg13
I1
sasa(dp11457
g2
S'We found transcripts in primary cultures of semicircular canal duct (SCCD) epithelial cells from neonatal rats representing a complete transport system for transepithelial absorption of Ca2+ that is comprised of the epithelial Ca2+ channels ECaC1 (CaT2, TRPV5) and ECaC2 (CaT1, TRPV6), calbindin (calbindin-D9k, calbindin-D28k), Na+/Ca2+ exchanger (NCX1, NCX2, and NCX3), and plasma membrane Ca2+-ATPase (PMCA1, PMCA3, and PMCA4) by RT-PCR.\n'
p11458
sg4
(lp11459
(dp11460
g7
I329
sg8
VP00918
p11461
sg10
I18
sg11
VNa+/Ca2+ exchanger
p11462
sg13
I2
sa(dp11463
g7
I376
sg8
g64
sg10
I27
sg11
Vplasma membrane Ca2+-ATPase
p11464
sg13
I3
sa(dp11465
g7
I423
sg8
VP23634
p11466
sg10
I5
sg11
VPMCA4
p11467
sg13
I1
sa(dp11468
g7
I365
sg8
VP57103
p11469
sg10
I4
sg11
VNCX3
p11470
sg13
I1
sa(dp11471
g7
I355
sg8
VP57103
p11472
sg10
I4
sg11
VNCX2
p11473
sg13
I1
sa(dp11474
g7
I278
sg8
g64
sg10
I5
sg11
VTRPV6
p11475
sg13
I1
sa(dp11476
g7
I272
sg8
VP41208
p11477
sg10
I4
sg11
VCaT1
p11478
sg13
I1
sa(dp11479
g7
I286
sg8
VP05937
p11480
sg10
I9
sg11
Vcalbindin
p11481
sg13
I1
sa(dp11482
g7
I312
sg8
VP05937
p11483
sg10
I14
sg11
Vcalbindin-D28k
p11484
sg13
I1
sa(dp11485
g7
I405
sg8
VP20020
p11486
sg10
I5
sg11
VPMCA1
p11487
sg13
I1
sa(dp11488
g7
I216
sg8
VP12830
p11489
sg10
I30
sg11
Vepithelial Ca2+ channels ECaC1
p11490
sg13
I4
sa(dp11491
g7
I248
sg8
g64
sg10
I4
sg11
VCaT2
p11492
sg13
I1
sa(dp11493
g7
I286
sg8
VP05937
p11494
sg10
I9
sg11
Vcalbindin
p11495
sg13
I1
sa(dp11496
g7
I265
sg8
VP43155
p11497
sg10
I5
sg11
VECaC2
p11498
sg13
I1
sa(dp11499
g7
I254
sg8
g64
sg10
I5
sg11
VTRPV5
p11500
sg13
I1
sasg23
(lp11501
(dp11502
g7
I69
sg26
VC0271287
p11503
sg10
I4
sg11
VSCCD
p11504
sg13
I1
sa(dp11505
g7
I44
sg26
VC0271287
p11506
sg10
I23
sg11
Vsemicircular canal duct
p11507
sg13
I3
sasa(dp11508
g2
S'The five receptors bind the natural peptides with high affinity, but only sst2, sst5, and sst3 bind the short synthetic analogs used to treat acromegaly and neuroendocrine tumors.\n'
p11509
sg4
(lp11510
(dp11511
g7
I74
sg8
VP30874
p11512
sg10
I4
sg11
Vsst2
p11513
sg13
I1
sa(dp11514
g7
I90
sg8
g64
sg10
I4
sg11
Vsst3
p11515
sg13
I1
sasg23
(lp11516
(dp11517
g7
I157
sg26
VC0206754
p11518
sg10
I21
sg11
Vneuroendocrine tumors
p11519
sg13
I2
sa(dp11520
g7
I142
sg26
VC0001206
p11521
sg10
I10
sg11
Vacromegaly
p11522
sg13
I1
sasa(dp11523
g2
S'We further identified 35 genes with differential expression in WLs from 0 to 12 months (long-term) weight loss, with 20 showing opposite expression patterns in acquired obesity, and 16/35 genes with significant expression-DNA methylation correlations.\n'
p11524
sg4
(lp11525
sg23
(lp11526
(dp11527
g7
I169
sg26
VC0028754
p11528
sg10
I7
sg11
Vobesity
p11529
sg13
I1
sasa(dp11530
g2
S'The number of patients developing ferritin or vitamin B12 deficiency was significantly lower with WLS Forte compared with sMVS (P &lt; 0.05).\n'
p11531
sg4
(lp11532
(dp11533
g7
I34
sg8
VP02794
p11534
sg10
I8
sg11
Vferritin
p11535
sg13
I1
sasg23
(lp11536
(dp11537
g7
I46
sg26
VC0042847
p11538
sg10
I22
sg11
Vvitamin B12 deficiency
p11539
sg13
I3
sasa(dp11540
g2
S'Over 90% of responders believe that WLS is an effective WL option and is more effective than self-directed diet and medical management of obesity.\n'
p11541
sg4
(lp11542
sg23
(lp11543
(dp11544
g7
I138
sg26
VC0028754
p11545
sg10
I7
sg11
Vobesity
p11546
sg13
I1
sasa(dp11547
g2
S'This study examined the anti-obesity and anti-diabetic effects of fucoxanthin-rich wakame lipids (WLs) on high fat (HF) diet-induced obesity in mice.\n'
p11548
sg4
(lp11549
sg23
(lp11550
(dp11551
g7
I29
sg26
VC0028754
p11552
sg10
I7
sg11
Vobesity
p11553
sg13
I1
sa(dp11554
g7
I29
sg26
VC0028754
p11555
sg10
I7
sg11
Vobesity
p11556
sg13
I1
sasa(dp11557
g2
S'There is therefore a biochemical and nutritional basis for the application of fucoxanthin-rich WLs as a functional food to prevent obesity and diabetes-related disorders.\n'
p11558
sg4
(lp11559
sg23
(lp11560
(dp11561
g7
I143
sg26
VC0011849
p11562
sg10
I8
sg11
Vdiabetes
p11563
sg13
I1
sa(dp11564
g7
I131
sg26
VC0028754
p11565
sg10
I7
sg11
Vobesity
p11566
sg13
I1
sasa(dp11567
g2
S'We investigated the effects of a traditional Chinese herbal formula, Wulingsan (WLS), on renal stone prevention using an ethylene glycol-induced nephrocalcinosis rat model.\n'
p11568
sg4
(lp11569
sg23
(lp11570
(dp11571
g7
I145
sg26
VC0027709
p11572
sg10
I16
sg11
Vnephrocalcinosis
p11573
sg13
I1
sa(dp11574
g7
I89
sg26
VC0022650
p11575
sg10
I11
sg11
Vrenal stone
p11576
sg13
I2
sasa(dp11577
g2
S'The mRNA expression of genes involved in the induction of autophagy in response to toxin (Esr1 and Pik3C3) and coregulators of autophagy and apoptosis (Bax and Cyld) were significantly upregulated in cdtB(+)wt S. Javiana-infected macrophages.\n'
p11578
sg4
(lp11579
(dp11580
g7
I99
sg8
g64
sg10
I6
sg11
VPik3C3
p11581
sg13
I1
sa(dp11582
g7
I160
sg8
g64
sg10
I4
sg11
VCyld
p11583
sg13
I1
sa(dp11584
g7
I90
sg8
VP03372
p11585
sg10
I4
sg11
VEsr1
p11586
sg13
I1
sa(dp11587
g7
I83
sg8
g64
sg10
I5
sg11
Vtoxin
p11588
sg13
I1
sasg23
(lp11589
(dp11590
g7
I71
sg26
VC1154712
p11591
sg10
I17
sg11
Vresponse to toxin
p11592
sg13
I3
sa(dp11593
g7
I200
sg26
VC1562894
p11594
sg10
I4
sg11
VcdtB
p11595
sg13
I1
sasa(dp11596
g2
S'To determine the respective roles of epithelial versus stromal ERalpha in this response, the following tissue recombinants were constructed with prostatic epithelium (PRE) and stroma (S) from wild-type (wt) and ERalpha knockout (alphaERKO) mice: wt-S + wt-PRE, alphaERKO-S + alphaERKO-PRE, wt-S + alphaERKO-PRE and alphaERKO-S + wt-PRE.\n'
p11597
sg4
(lp11598
(dp11599
g7
I315
sg8
VP58743
p11600
sg10
I20
sg11
ValphaERKO-S + wt-PRE
p11601
sg13
I3
sa(dp11602
g7
I63
sg8
VP03372
p11603
sg10
I7
sg11
VERalpha
p11604
sg13
I1
sa(dp11605
g7
I261
sg8
VP58743
p11606
sg10
I27
sg11
ValphaERKO-S + alphaERKO-PRE
p11607
sg13
I3
sa(dp11608
g7
I290
sg8
VP58743
p11609
sg10
I20
sg11
Vwt-S + alphaERKO-PRE
p11610
sg13
I3
sa(dp11611
g7
I63
sg8
VP03372
p11612
sg10
I7
sg11
VERalpha
p11613
sg13
I1
sa(dp11614
g7
I246
sg8
VP58743
p11615
sg10
I13
sg11
Vwt-S + wt-PRE
p11616
sg13
I3
sasg23
(lp11617
sa(dp11618
g2
S'In order to determine the respective roles of epithelial and stromal ERalpha in this response, the following tissue recombinants were constructed with prostatic epithelia (E) and stroma (S) from wt and ERKO mice: wt-S+wt-E, alphaERKO-S+alphaERKO-E, wt-S+alphaERKO-E, and alphaERKO-S+wt-E. A metaplastic response to DES was observed in wt-S+wt-E tissue recombinants.\n'
p11619
sg4
(lp11620
(dp11621
g7
I46
sg8
VP12830
p11622
sg10
I30
sg11
Vepithelial and stromal ERalpha
p11623
sg13
I4
sasg23
(lp11624
(dp11625
g7
I315
sg26
VC0394006
p11626
sg10
I3
sg11
VDES
p11627
sg13
I1
sasa(dp11628
g2
S'In response to E2 treatment, grafts prepared with wt-S (wt-S + wt-E and wt-S + ko-E) showed similar large increases in epithelial labeling index, indicating that E2 stimulated epithelial proliferation despite a lack of epithelial ER alpha in wt-S + ko-E tissue recombinants.\n'
p11629
sg4
(lp11630
(dp11631
g7
I219
sg8
VP12830
p11632
sg10
I19
sg11
Vepithelial ER alpha
p11633
sg13
I3
sasg23
(lp11634
(dp11635
g7
I176
sg26
VC0334097
p11636
sg10
I24
sg11
Vepithelial proliferation
p11637
sg13
I2
sasa(dp11638
g2
S'Mutations in REEP1 have been identified in three types of neurological disorders, autosomal dominant form of Hereditary Spastic Paraplegia type 31 (SPG31), autosomal dominant distal hereditary motor neuronopathy type VB (HMN5B), and autosomal recessive form of congenital axonal neuropathy and diaphragmatic palsy.\n'
p11639
sg4
(lp11640
(dp11641
g7
I13
sg8
g64
sg10
I5
sg11
VREEP1
p11642
sg13
I1
sasg23
(lp11643
(dp11644
g7
I272
sg26
VC0270921
p11645
sg10
I17
sg11
Vaxonal neuropathy
p11646
sg13
I2
sa(dp11647
g7
I58
sg26
VC0027765
p11648
sg10
I22
sg11
Vneurological disorders
p11649
sg13
I2
sa(dp11650
g7
I148
sg26
VC1853247
p11651
sg10
I5
sg11
VSPG31
p11652
sg13
I1
sa(dp11653
g7
I120
sg26
VC1853247
p11654
sg10
I26
sg11
VSpastic Paraplegia type 31
p11655
sg13
I4
sa(dp11656
g7
I109
sg26
VC0037773
p11657
sg10
I29
sg11
VHereditary Spastic Paraplegia
p11658
sg13
I3
sasa(dp11659
g2
S'Our study demonstrated further evidence of allelic heterogeneity in SPG31, mutant REEP1 mRNA dosage effects through NMD and intra-familial phenotype variability.\n'
p11660
sg4
(lp11661
(dp11662
g7
I68
sg8
g64
sg10
I5
sg11
VSPG31
p11663
sg13
I1
sa(dp11664
g7
I75
sg8
g64
sg10
I17
sg11
Vmutant REEP1 mRNA
p11665
sg13
I3
sasg23
(lp11666
(dp11667
g7
I68
sg26
VC1853247
p11668
sg10
I5
sg11
VSPG31
p11669
sg13
I1
sa(dp11670
g7
I75
sg26
VC0596988
p11671
sg10
I6
sg11
Vmutant
p11672
sg13
I1
sasa(dp11673
g2
S'Mutations in spastin, strumpellin, or REEP1 cause hereditary spastic paraplegia (HSP), a disease characterized by axonal degeneration.\n'
p11674
sg4
(lp11675
(dp11676
g7
I13
sg8
g64
sg10
I7
sg11
Vspastin
p11677
sg13
I1
sa(dp11678
g7
I38
sg8
g64
sg10
I5
sg11
VREEP1
p11679
sg13
I1
sasg23
(lp11680
(dp11681
g7
I81
sg26
VC0034152
p11682
sg10
I3
sg11
VHSP
p11683
sg13
I1
sa(dp11684
g7
I50
sg26
VC0037773
p11685
sg10
I29
sg11
Vhereditary spastic paraplegia
p11686
sg13
I3
sa(dp11687
g7
I121
sg26
VC0011164
p11688
sg10
I12
sg11
Vdegeneration
p11689
sg13
I1
sasa(dp11690
g2
S'We describe the clinical presentation and pathogeny of HSP through a report of a case due to a novel mutation of the REEP1 gene (SPG31).\n'
p11691
sg4
(lp11692
(dp11693
g7
I117
sg8
g64
sg10
I10
sg11
VREEP1 gene
p11694
sg13
I2
sa(dp11695
g7
I129
sg8
g64
sg10
I5
sg11
VSPG31
p11696
sg13
I1
sasg23
(lp11697
(dp11698
g7
I95
sg26
VC2985438
p11699
sg10
I14
sg11
Vnovel mutation
p11700
sg13
I2
sa(dp11701
g7
I55
sg26
VC0034152
p11702
sg10
I3
sg11
VHSP
p11703
sg13
I1
sa(dp11704
g7
I129
sg26
VC1853247
p11705
sg10
I5
sg11
VSPG31
p11706
sg13
I1
sasa(dp11707
g2
S'Hereditary spastic paraplegia, SPG31, is a rare neurological disorder caused by mutations in REEP1 gene encoding the microtubule-interacting protein, REEP1.\n'
p11708
sg4
(lp11709
(dp11710
g7
I31
sg8
g64
sg10
I5
sg11
VSPG31
p11711
sg13
I1
sa(dp11712
g7
I93
sg8
g64
sg10
I10
sg11
VREEP1 gene
p11713
sg13
I2
sa(dp11714
g7
I117
sg8
g64
sg10
I31
sg11
Vmicrotubule-interacting protein
p11715
sg13
I2
sa(dp11716
g7
I93
sg8
g64
sg10
I5
sg11
VREEP1
p11717
sg13
I1
sasg23
(lp11718
(dp11719
g7
I31
sg26
VC1853247
p11720
sg10
I5
sg11
VSPG31
p11721
sg13
I1
sa(dp11722
g7
I0
sg26
VC0037773
p11723
sg10
I29
sg11
VHereditary spastic paraplegia
p11724
sg13
I3
sa(dp11725
g7
I48
sg26
VC0027765
p11726
sg10
I21
sg11
Vneurological disorder
p11727
sg13
I2
sasa(dp11728
g2
S'Hereditary spastic paraplegias (HSPs; SPG1-76 plus others) are length-dependent disorders affecting long corticospinal axons, and the most common autosomal dominant forms are caused by mutations in genes that encode the spastin (SPG4), atlastin-1 (SPG3A) and REEP1 (SPG31) proteins.\n'
p11729
sg4
(lp11730
(dp11731
g7
I236
sg8
g64
sg10
I10
sg11
Vatlastin-1
p11732
sg13
I1
sa(dp11733
g7
I38
sg8
VP32004
p11734
sg10
I7
sg11
VSPG1-76
p11735
sg13
I1
sa(dp11736
g7
I266
sg8
g64
sg10
I5
sg11
VSPG31
p11737
sg13
I1
sa(dp11738
g7
I229
sg8
g64
sg10
I4
sg11
VSPG4
p11739
sg13
I1
sa(dp11740
g7
I259
sg8
g64
sg10
I5
sg11
VREEP1
p11741
sg13
I1
sa(dp11742
g7
I248
sg8
g64
sg10
I5
sg11
VSPG3A
p11743
sg13
I1
sa(dp11744
g7
I220
sg8
g64
sg10
I7
sg11
Vspastin
p11745
sg13
I1
sasg23
(lp11746
(dp11747
g7
I32
sg26
VC0037773
p11748
sg10
I4
sg11
VHSPs
p11749
sg13
I1
sa(dp11750
g7
I38
sg26
VC0795953
p11751
sg10
I4
sg11
VSPG1
p11752
sg13
I1
sa(dp11753
g7
I0
sg26
VC0037773
p11754
sg10
I30
sg11
VHereditary spastic paraplegias
p11755
sg13
I3
sa(dp11756
g7
I266
sg26
VC1853247
p11757
sg10
I5
sg11
VSPG31
p11758
sg13
I1
sa(dp11759
g7
I229
sg26
VC1866855
p11760
sg10
I4
sg11
VSPG4
p11761
sg13
I1
sa(dp11762
g7
I248
sg26
VC2931355
p11763
sg10
I5
sg11
VSPG3A
p11764
sg13
I1
sasa(dp11765
g2
S'To date, only dominant REEP1 mutations have been reported to be associated with a slowly progressive hereditary spastic paraplegia.\n'
p11766
sg4
(lp11767
(dp11768
g7
I14
sg8
g64
sg10
I24
sg11
Vdominant REEP1 mutations
p11769
sg13
I3
sasg23
(lp11770
(dp11771
g7
I101
sg26
VC0037773
p11772
sg10
I29
sg11
Vhereditary spastic paraplegia
p11773
sg13
I3
sasa(dp11774
g2
S'Here we report that upon transplantation of a well-defined aggressive murine B220+CD5+ Chronic Lymphocytic Leukemia (CLL) cell clone, TCL1-192, into SCID mice one injection of a monoclonal antibody directed against SLAMF6 (AlfaSlamf6) abrogates tumor progression in the spleen, bone marrow and blood.\n'
p11775
sg4
(lp11776
(dp11777
g7
I215
sg8
g64
sg10
I6
sg11
VSLAMF6
p11778
sg13
I1
sa(dp11779
g7
I134
sg8
VP56279
p11780
sg10
I8
sg11
VTCL1-192
p11781
sg13
I1
sasg23
(lp11782
(dp11783
g7
I117
sg26
VC0023434
p11784
sg10
I3
sg11
VCLL
p11785
sg13
I1
sa(dp11786
g7
I245
sg26
VC0178874
p11787
sg10
I17
sg11
Vtumor progression
p11788
sg13
I2
sa(dp11789
g7
I149
sg26
VC0085110
p11790
sg10
I4
sg11
VSCID
p11791
sg13
I1
sa(dp11792
g7
I87
sg26
VC0023434
p11793
sg10
I28
sg11
VChronic Lymphocytic Leukemia
p11794
sg13
I3
sa(dp11795
g7
I59
sg26
VC0001807
p11796
sg10
I10
sg11
Vaggressive
p11797
sg13
I1
sasa(dp11798
g2
S'Similarly, progression of a murine B cell lymphoma, LMP2A/LambdaMyc, was also eliminated by AlfaSlamf6.\n'
p11799
sg4
(lp11800
sg23
(lp11801
(dp11802
g7
I35
sg26
VC0079731
p11803
sg10
I15
sg11
VB cell lymphoma
p11804
sg13
I3
sasa(dp11805
g2
S'Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects.\n'
p11806
sg4
(lp11807
(dp11808
g7
I78
sg8
VP09326
p11809
sg10
I4
sg11
VCD48
p11810
sg13
I1
sa(dp11811
g7
I84
sg8
g64
sg10
I5
sg11
VCD229
p11812
sg13
I1
sa(dp11813
g7
I71
sg8
g64
sg10
I5
sg11
VCD150
p11814
sg13
I1
sa(dp11815
g7
I128
sg8
VP61073
p11816
sg10
I5
sg11
VCD184
p11817
sg13
I1
sa(dp11818
g7
I118
sg8
VP41217
p11819
sg10
I5
sg11
VCD200
p11820
sg13
I1
sa(dp11821
g7
I98
sg8
g64
sg10
I5
sg11
VCD319
p11822
sg13
I1
sa(dp11823
g7
I105
sg8
g64
sg10
I5
sg11
VCD272
p11824
sg13
I1
sa(dp11825
g7
I112
sg8
VP42081
p11826
sg10
I4
sg11
VCD86
p11827
sg13
I1
sasg23
(lp11828
(dp11829
g7
I216
sg26
VC1704423
p11830
sg10
I3
sg11
VPCL
p11831
sg13
I1
sa(dp11832
g7
I194
sg26
VC0023484
p11833
sg10
I20
sg11
Vplasma cell leukemia
p11834
sg13
I3
sasa(dp11835
g2
S'Finally, this tumor did not express the PVR (CD155) and nectin-2 (CD112) ligands for the DNAM-1 activating NK receptor, which plays a crucial role in NK/neuroblastoma interactions.\n'
p11836
sg4
(lp11837
(dp11838
g7
I56
sg8
g64
sg10
I8
sg11
Vnectin-2
p11839
sg13
I1
sa(dp11840
g7
I40
sg8
VP15151
p11841
sg10
I3
sg11
VPVR
p11842
sg13
I1
sa(dp11843
g7
I45
sg8
VP15151
p11844
sg10
I5
sg11
VCD155
p11845
sg13
I1
sa(dp11846
g7
I89
sg8
g64
sg10
I6
sg11
VDNAM-1
p11847
sg13
I1
sa(dp11848
g7
I107
sg8
VP43630
p11849
sg10
I11
sg11
VNK receptor
p11850
sg13
I2
sa(dp11851
g7
I66
sg8
g64
sg10
I5
sg11
VCD112
p11852
sg13
I1
sasg23
(lp11853
(dp11854
g7
I153
sg26
VC0027819
p11855
sg10
I13
sg11
Vneuroblastoma
p11856
sg13
I1
sa(dp11857
g7
I14
sg26
VC0027651
p11858
sg10
I5
sg11
Vtumor
p11859
sg13
I1
sa(dp11860
g7
I40
sg26
VC1860404
p11861
sg10
I3
sg11
VPVR
p11862
sg13
I1
sasa(dp11863
g2
S'As for the males with varicocele, Ig A and Ig M decrease is noticeable relative to the control group, 1,06+/-0,21 g/l and 0,61+/-0,19 g/l respectively (p&lt;0,05).\n'
p11864
sg4
(lp11865
sg23
(lp11866
(dp11867
g7
I22
sg26
VC0042341
p11868
sg10
I10
sg11
Vvaricocele
p11869
sg13
I1
sasa(dp11870
g2
S'Detection of IgG and IgA sperm antibodies were negative in both man with and without varicocele.\n'
p11871
sg4
(lp11872
(dp11873
g7
I21
sg8
VP11912
p11874
sg10
I20
sg11
VIgA sperm antibodies
p11875
sg13
I3
sasg23
(lp11876
(dp11877
g7
I85
sg26
VC0042341
p11878
sg10
I10
sg11
Vvaricocele
p11879
sg13
I1
sasa(dp11880
g2
S'A significant quantitative difference between the varicocele and control groups was also observed for serum IgA, seminal plasma IgA and IgM, and sperm-bound IgG, IgA, and IgM.\n'
p11881
sg4
(lp11882
(dp11883
g7
I108
sg8
VP11912
p11884
sg10
I3
sg11
VIgA
p11885
sg13
I1
sa(dp11886
g7
I136
sg8
VP29965
p11887
sg10
I3
sg11
VIgM
p11888
sg13
I1
sa(dp11889
g7
I113
sg8
VP11912
p11890
sg10
I18
sg11
Vseminal plasma IgA
p11891
sg13
I3
sa(dp11892
g7
I136
sg8
VP29965
p11893
sg10
I3
sg11
VIgM
p11894
sg13
I1
sa(dp11895
g7
I102
sg8
VP11912
p11896
sg10
I9
sg11
Vserum IgA
p11897
sg13
I2
sasg23
(lp11898
(dp11899
g7
I50
sg26
VC0042341
p11900
sg10
I10
sg11
Vvaricocele
p11901
sg13
I1
sasa(dp11902
g2
S'DHGA-D also significantly induced G1 cell cycle arrest, together with the suppression of glycogen synthase kinase 3Beta and retinoblastoma phosphorylation and cyclin D1 expression.\n'
p11903
sg4
(lp11904
(dp11905
g7
I159
sg8
VP24385
p11906
sg10
I9
sg11
Vcyclin D1
p11907
sg13
I2
sa(dp11908
g7
I89
sg8
VP13807
p11909
sg10
I30
sg11
Vglycogen synthase kinase 3Beta
p11910
sg13
I4
sasg23
(lp11911
(dp11912
g7
I74
sg26
VC0221103
p11913
sg10
I11
sg11
Vsuppression
p11914
sg13
I1
sa(dp11915
g7
I124
sg26
VC0035335
p11916
sg10
I14
sg11
Vretinoblastoma
p11917
sg13
I1
sasa(dp11918
g2
S'C1P induced phosphorylation of glycogen synthase kinase-3Beta and the product of retinoblastoma gene, and enhanced cyclin D1 protein levels.\n'
p11919
sg4
(lp11920
(dp11921
g7
I115
sg8
VP24385
p11922
sg10
I17
sg11
Vcyclin D1 protein
p11923
sg13
I3
sa(dp11924
g7
I81
sg8
g64
sg10
I19
sg11
Vretinoblastoma gene
p11925
sg13
I2
sa(dp11926
g7
I31
sg8
VP13807
p11927
sg10
I30
sg11
Vglycogen synthase kinase-3Beta
p11928
sg13
I3
sasg23
(lp11929
(dp11930
g7
I81
sg26
VC0035335
p11931
sg10
I14
sg11
Vretinoblastoma
p11932
sg13
I1
sasa(dp11933
g2
S'Replacement of distention with pharmacological relaxation reduced the increase in cyclin D1 expression, phosphorylation of retinoblastoma, Akt-Thr(308), glycogen synthase kinase 3 beta and p38, but not extracellular signal-regulated kinases.\n'
p11934
sg4
(lp11935
(dp11936
g7
I82
sg8
VP24385
p11937
sg10
I9
sg11
Vcyclin D1
p11938
sg13
I2
sa(dp11939
g7
I189
sg8
VP46108
p11940
sg10
I3
sg11
Vp38
p11941
sg13
I1
sa(dp11942
g7
I153
sg8
VP49841
p11943
sg10
I31
sg11
Vglycogen synthase kinase 3 beta
p11944
sg13
I5
sa(dp11945
g7
I123
sg8
g64
sg10
I28
sg11
Vretinoblastoma, Akt-Thr(308)
p11946
sg13
I2
sasg23
(lp11947
(dp11948
g7
I123
sg26
VC0035335
p11949
sg10
I14
sg11
Vretinoblastoma
p11950
sg13
I1
sa(dp11951
g7
I15
sg26
VC0012359
p11952
sg10
I10
sg11
Vdistention
p11953
sg13
I1
sasa(dp11954
g2
S'Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as VEGF-B and placental growth factor inhibitor, might improve the clinical outcome in patients with CRVO who respond insufficiently to ranibizumab/bevacizumab.\n'
p11955
sg4
(lp11956
(dp11957
g7
I86
sg8
g64
sg10
I6
sg11
VVEGF-A
p11958
sg13
I1
sa(dp11959
g7
I127
sg8
VP49763
p11960
sg10
I23
sg11
Vplacental growth factor
p11961
sg13
I3
sa(dp11962
g7
I48
sg8
g64
sg10
I36
sg11
Vvascular endothelial growth factor-A
p11963
sg13
I4
sa(dp11964
g7
I116
sg8
VP49765
p11965
sg10
I6
sg11
VVEGF-B
p11966
sg13
I1
sasg23
(lp11967
sa(dp11968
g2
S'In this study, the expression of bFGF, vimentin, CD 34, c-kit (or CD 117), desmin, S-100 protein, and alpha-smooth muscle actin (alpha-SMA) in SFTs, hemangiopericytomas (HPC), gastrointestinal stromal tumors (GIST), and dermatofibrosarcoma protuberans (DFSP) were evaluated to assess their usefulness in the differential diagnosis of these lesions.\n'
p11969
sg4
(lp11970
(dp11971
g7
I33
sg8
VP53370
p11972
sg10
I4
sg11
VbFGF
p11973
sg13
I1
sa(dp11974
g7
I75
sg8
VP98155
p11975
sg10
I6
sg11
Vdesmin
p11976
sg13
I1
sa(dp11977
g7
I102
sg8
VP63267
p11978
sg10
I25
sg11
Valpha-smooth muscle actin
p11979
sg13
I3
sa(dp11980
g7
I83
sg8
VP04271
p11981
sg10
I13
sg11
VS-100 protein
p11982
sg13
I2
sa(dp11983
g7
I129
sg8
g64
sg10
I9
sg11
Valpha-SMA
p11984
sg13
I1
sa(dp11985
g7
I56
sg8
VP10721
p11986
sg10
I5
sg11
Vc-kit
p11987
sg13
I1
sasg23
(lp11988
(dp11989
g7
I253
sg26
VC0392784
p11990
sg10
I4
sg11
VDFSP
p11991
sg13
I1
sa(dp11992
g7
I209
sg26
VC0238198
p11993
sg10
I4
sg11
VGIST
p11994
sg13
I1
sa(dp11995
g7
I170
sg26
VC0238339
p11996
sg10
I3
sg11
VHPC
p11997
sg13
I1
sa(dp11998
g7
I176
sg26
VC0238198
p11999
sg10
I31
sg11
Vgastrointestinal stromal tumors
p12000
sg13
I3
sa(dp12001
g7
I149
sg26
VC0018922
p12002
sg10
I19
sg11
Vhemangiopericytomas
p12003
sg13
I1
sa(dp12004
g7
I135
sg26
VC0026847
p12005
sg10
I3
sg11
VSMA
p12006
sg13
I1
sa(dp12007
g7
I220
sg26
VC0392784
p12008
sg10
I31
sg11
Vdermatofibrosarcoma protuberans
p12009
sg13
I2
sasa(dp12010
g2
S'Glomerulopathy with fibronectin deposits (GFND) is a rare autosomal dominant disease characterized by massive fibronectin deposits, leading to end-stage renal failure.\n'
p12011
sg4
(lp12012
sg23
(lp12013
(dp12014
g7
I143
sg26
VC0022661
p12015
sg10
I23
sg11
Vend-stage renal failure
p12016
sg13
I3
sa(dp12017
g7
I0
sg26
VC1866075
p12018
sg10
I40
sg11
VGlomerulopathy with fibronectin deposits
p12019
sg13
I4
sa(dp12020
g7
I42
sg26
VC1866075
p12021
sg10
I4
sg11
VGFND
p12022
sg13
I1
sasa(dp12023
g2
S'Glomerulopathy with fibronectin (FN) deposits (GFND) is an autosomal dominant disease with age-related penetrance, characterized by proteinuria, microscopic hematuria, hypertension, and massive glomerular deposits of FN that lead to end-stage renal failure.\n'
p12024
sg4
(lp12025
sg23
(lp12026
(dp12027
g7
I145
sg26
VC0239937
p12028
sg10
I21
sg11
Vmicroscopic hematuria
p12029
sg13
I2
sa(dp12030
g7
I233
sg26
VC0022661
p12031
sg10
I23
sg11
Vend-stage renal failure
p12032
sg13
I3
sa(dp12033
g7
I168
sg26
VC0020538
p12034
sg10
I12
sg11
Vhypertension
p12035
sg13
I1
sa(dp12036
g7
I0
sg26
VC0268731
p12037
sg10
I14
sg11
VGlomerulopathy
p12038
sg13
I1
sasa(dp12039
g2
S'Fibronectin glomerulopathy (GFND) is a newly recognized autosomal dominant disease of the kidney that results in albuminuria, microscopic hematuria, hypertension, renal tubular acidosis type IV, and end-stage renal disease in the 2d to 6th decade of life.\n'
p12040
sg4
(lp12041
sg23
(lp12042
(dp12043
g7
I126
sg26
VC0239937
p12044
sg10
I21
sg11
Vmicroscopic hematuria
p12045
sg13
I2
sa(dp12046
g7
I163
sg26
VC0376185
p12047
sg10
I30
sg11
Vrenal tubular acidosis type IV
p12048
sg13
I5
sa(dp12049
g7
I199
sg26
VC0022661
p12050
sg10
I23
sg11
Vend-stage renal disease
p12051
sg13
I3
sa(dp12052
g7
I0
sg26
VC1866075
p12053
sg10
I26
sg11
VFibronectin glomerulopathy
p12054
sg13
I2
sasa(dp12055
g2
S'Multilocus linkage analysis has suggested that the Waardenburg syndrome type 1 (WS1) locus is flanked by placental alkaline phosphatase (ALPP) and fibronectin 1 (FN1).\n'
p12056
sg4
(lp12057
(dp12058
g7
I137
sg8
VP10696
p12059
sg10
I4
sg11
VALPP
p12060
sg13
I1
sa(dp12061
g7
I105
sg8
g64
sg10
I30
sg11
Vplacental alkaline phosphatase
p12062
sg13
I3
sa(dp12063
g7
I80
sg8
VP23760
p12064
sg10
I3
sg11
VWS1
p12065
sg13
I1
sa(dp12066
g7
I51
sg8
g64
sg10
I27
sg11
VWaardenburg syndrome type 1
p12067
sg13
I4
sasg23
(lp12068
(dp12069
g7
I80
sg26
VC1847800
p12070
sg10
I3
sg11
VWS1
p12071
sg13
I1
sa(dp12072
g7
I51
sg26
VC1847800
p12073
sg10
I27
sg11
VWaardenburg syndrome type 1
p12074
sg13
I4
sasa(dp12075
g2
S'Furthermore, Ehd3(-/-); Ehd4(-/-) mice provide a unique model to elucidate mechanisms of glomerular endothelial injury which is observed in a wide variety of human renal and extra-renal diseases.\n'
p12076
sg4
(lp12077
(dp12078
g7
I24
sg8
g64
sg10
I4
sg11
VEhd4
p12079
sg13
I1
sa(dp12080
g7
I13
sg8
g64
sg10
I9
sg11
VEhd3(-/-)
p12081
sg13
I1
sasg23
(lp12082
(dp12083
g7
I180
sg26
VC0022658
p12084
sg10
I14
sg11
Vrenal diseases
p12085
sg13
I2
sasa(dp12086
g2
S"Defective apoptosis of lamina propria T cells (LPTs) is involved in the pathogenesis of Crohn's disease.\n"
p12087
sg4
(lp12088
sg23
(lp12089
(dp12090
g7
I88
sg26
VC0010346
p12091
sg10
I15
sg11
VCrohn's disease
p12092
sg13
I2
sa(dp12093
g7
I72
sg26
VC0699748
p12094
sg10
I12
sg11
Vpathogenesis
p12095
sg13
I1
sasa(dp12096
g2
S"LPTs were isolated from mucosal samples of patients with Crohn's disease or ulcerative colitis and healthy individuals (controls).\n"
p12097
sg4
(lp12098
sg23
(lp12099
(dp12100
g7
I76
sg26
VC0009324
p12101
sg10
I18
sg11
Vulcerative colitis
p12102
sg13
I2
sa(dp12103
g7
I57
sg26
VC0010346
p12104
sg10
I15
sg11
VCrohn's disease
p12105
sg13
I2
sasa(dp12106
g2
S"LPTs from patients with Crohn's disease had higher levels of survivin than LPTs from patients with ulcerative colitis or controls.\n"
p12107
sg4
(lp12108
sg23
(lp12109
(dp12110
g7
I24
sg26
VC0010346
p12111
sg10
I15
sg11
VCrohn's disease
p12112
sg13
I2
sa(dp12113
g7
I99
sg26
VC0009324
p12114
sg10
I18
sg11
Vulcerative colitis
p12115
sg13
I2
sasa(dp12116
g2
S'Levels of survivin were low in LPTs from patients with ulcerative colitis and controls as a result of ubiquitin-mediated proteasome degradation.\n'
p12117
sg4
(lp12118
(dp12119
g7
I102
sg8
VP62979
p12120
sg10
I9
sg11
Vubiquitin
p12121
sg13
I1
sasg23
(lp12122
(dp12123
g7
I55
sg26
VC0009324
p12124
sg10
I18
sg11
Vulcerative colitis
p12125
sg13
I2
sasa(dp12126
g2
S"In LPTs from patients with Crohn's disease, survivin bound to the heat shock protein (HSP)90, and therefore was resistant to proteasome degradation.\n"
p12127
sg4
(lp12128
(dp12129
g7
I66
sg8
VP34931
p12130
sg10
I26
sg11
Vheat shock protein (HSP)90
p12131
sg13
I4
sasg23
(lp12132
(dp12133
g7
I66
sg26
VC0034152
p12134
sg10
I18
sg11
Vheat shock protein
p12135
sg13
I3
sa(dp12136
g7
I86
sg26
VC0034152
p12137
sg10
I3
sg11
VHSP
p12138
sg13
I1
sa(dp12139
g7
I27
sg26
VC0010346
p12140
sg10
I15
sg11
VCrohn's disease
p12141
sg13
I2
sasa(dp12142
g2
S"Levels of survivin are increased in LPTs from patients with Crohn's disease (compared with ulcerative colitis and controls) because survivin interacts with HSP90 and prevents proteasome degradation.\n"
p12143
sg4
(lp12144
(dp12145
g7
I156
sg8
VP07900
p12146
sg10
I5
sg11
VHSP90
p12147
sg13
I1
sasg23
(lp12148
(dp12149
g7
I60
sg26
VC0010346
p12150
sg10
I15
sg11
VCrohn's disease
p12151
sg13
I2
sa(dp12152
g7
I91
sg26
VC0009324
p12153
sg10
I18
sg11
Vulcerative colitis
p12154
sg13
I2
sasa(dp12155
g2
S'With the advantage of the low risk of hypoglycemia, DPP-IV attracted the attention of medicinal chemists as a new target for oral hypoglycemics.\n'
p12156
sg4
(lp12157
(dp12158
g7
I52
sg8
g64
sg10
I6
sg11
VDPP-IV
p12159
sg13
I1
sasg23
(lp12160
(dp12161
g7
I38
sg26
VC0020615
p12162
sg10
I12
sg11
Vhypoglycemia
p12163
sg13
I1
sasa(dp12164
g2
S'Efficacy and safety studies of dipetidyl peptidase inhibitors (DPP-IV), sitagliptin, vildagliptin and linagliptin provide similar improvements in HbA1c levels when compared with metformin, sulfonylureas or glitazones without contributing to weight gain and hypoglycemia.\n'
p12165
sg4
(lp12166
(dp12167
g7
I31
sg8
g64
sg10
I19
sg11
Vdipetidyl peptidase
p12168
sg13
I2
sa(dp12169
g7
I63
sg8
g64
sg10
I6
sg11
VDPP-IV
p12170
sg13
I1
sasg23
(lp12171
(dp12172
g7
I257
sg26
VC0020615
p12173
sg10
I12
sg11
Vhypoglycemia
p12174
sg13
I1
sasa(dp12175
g2
S'Dipeptidyl peptase 4 (DPP-IV) inhibitors and glucagon-like peptide 1 (GLP1) analogues as insulin secretagogues have a lower risk for hypoglycemia than sulfonylurea and insulin.\n'
p12176
sg4
(lp12177
(dp12178
g7
I22
sg8
g64
sg10
I6
sg11
VDPP-IV
p12179
sg13
I1
sa(dp12180
g7
I89
sg8
VP01308
p12181
sg10
I7
sg11
Vinsulin
p12182
sg13
I1
sa(dp12183
g7
I89
sg8
VP01308
p12184
sg10
I7
sg11
Vinsulin
p12185
sg13
I1
sa(dp12186
g7
I70
sg8
VP0C6A0
p12187
sg10
I4
sg11
VGLP1
p12188
sg13
I1
sa(dp12189
g7
I45
sg8
VP01275
p12190
sg10
I23
sg11
Vglucagon-like peptide 1
p12191
sg13
I3
sasg23
(lp12192
(dp12193
g7
I133
sg26
VC0020615
p12194
sg10
I12
sg11
Vhypoglycemia
p12195
sg13
I1
sasa(dp12196
g2
S'For hypoglycaemia, MH-OR, 95%CI = 0.13 [0.09, 0.19], p &lt; 0.00001(DPP-IV inhibitors + met vs. su + met).\n'
p12197
sg4
(lp12198
sg23
(lp12199
(dp12200
g7
I4
sg26
VC0020615
p12201
sg10
I13
sg11
Vhypoglycaemia
p12202
sg13
I1
sasa(dp12203
g2
S'To investigate the role of insulin-like growth factor-1 (IGF-1), in localized osteosarcoma, serum levels of IGF-1, IGFBP-2, and IGFBP-3 were measured in 224 similarly treated, newly diagnosed patients.\n'
p12204
sg4
(lp12205
(dp12206
g7
I27
sg8
VP01308
p12207
sg10
I28
sg11
Vinsulin-like growth factor-1
p12208
sg13
I3
sa(dp12209
g7
I57
sg8
VP01343
p12210
sg10
I5
sg11
VIGF-1
p12211
sg13
I1
sa(dp12212
g7
I128
sg8
VP17936
p12213
sg10
I7
sg11
VIGFBP-3
p12214
sg13
I1
sa(dp12215
g7
I57
sg8
VP01343
p12216
sg10
I5
sg11
VIGF-1
p12217
sg13
I1
sa(dp12218
g7
I115
sg8
VP18065
p12219
sg10
I7
sg11
VIGFBP-2
p12220
sg13
I1
sasg23
(lp12221
(dp12222
g7
I68
sg26
VC0278511
p12223
sg10
I22
sg11
Vlocalized osteosarcoma
p12224
sg13
I2
sasa(dp12225
g2
S'Calreticulin, a phagocytic "eat me" signal carried by placental EVs significantly inhibited ovarian cancer growth (P = 0.001).\n'
p12226
sg4
(lp12227
(dp12228
g7
I0
sg8
VP27797
p12229
sg10
I12
sg11
VCalreticulin
p12230
sg13
I1
sasg23
(lp12231
(dp12232
g7
I92
sg26
VC1140680
p12233
sg10
I14
sg11
Vovarian cancer
p12234
sg13
I2
sasa(dp12235
g2
S'We confirm that treatment with DNMT inhibitors upregulates expression of the antigen processing and presentation molecules B2M, CALR, CD58, PSMB8, PSMB9 at the RNA and protein level in a wider range of colon and ovarian cancer cell lines and treatment time points than had been described previously.\n'
p12236
sg4
(lp12237
(dp12238
g7
I128
sg8
VP27797
p12239
sg10
I4
sg11
VCALR
p12240
sg13
I1
sa(dp12241
g7
I134
sg8
VP19256
p12242
sg10
I4
sg11
VCD58
p12243
sg13
I1
sa(dp12244
g7
I147
sg8
VP28065
p12245
sg10
I5
sg11
VPSMB9
p12246
sg13
I1
sa(dp12247
g7
I140
sg8
VP28062
p12248
sg10
I5
sg11
VPSMB8
p12249
sg13
I1
sa(dp12250
g7
I123
sg8
VP61769
p12251
sg10
I3
sg11
VB2M
p12252
sg13
I1
sasg23
(lp12253
(dp12254
g7
I212
sg26
VC1140680
p12255
sg10
I14
sg11
Vovarian cancer
p12256
sg13
I2
sasa(dp12257
g2
S'Here, we analyzed the impact of CALR expression levels detected by microarray finding a positive correlation between CALR and the expression of a metagene indicating the presence of cytotoxic T lymphocytes (CTL) in NSCLC and ovarian cancer.\n'
p12258
sg4
(lp12259
(dp12260
g7
I32
sg8
VP27797
p12261
sg10
I4
sg11
VCALR
p12262
sg13
I1
sasg23
(lp12263
(dp12264
g7
I225
sg26
VC1140680
p12265
sg10
I14
sg11
Vovarian cancer
p12266
sg13
I2
sa(dp12267
g7
I215
sg26
VC0007131
p12268
sg10
I5
sg11
VNSCLC
p12269
sg13
I1
sasa(dp12270
g2
S'Combination of two parameters (CALR + DC (dendritic cell) in NSCL and CALR + aDC in ovarian cancer) or three parameters (CALR + CTL + DC in NSCL and CALR + CTL + aDC in ovarian cancer) had a significant impact on overall patient survival in NSCL (Adenoconsortium) and ovarian cancer (TCGA collection), allowing the stratification of patients in high-risk and low-risk groups.\n'
p12271
sg4
(lp12272
(dp12273
g7
I149
sg8
VP27797
p12274
sg10
I16
sg11
VCALR + CTL + aDC
p12275
sg13
I5
sa(dp12276
g7
I61
sg8
g64
sg10
I4
sg11
VNSCL
p12277
sg13
I1
sa(dp12278
g7
I70
sg8
VP27797
p12279
sg10
I10
sg11
VCALR + aDC
p12280
sg13
I3
sa(dp12281
g7
I61
sg8
g64
sg10
I4
sg11
VNSCL
p12282
sg13
I1
sasg23
(lp12283
(dp12284
g7
I84
sg26
VC1140680
p12285
sg10
I14
sg11
Vovarian cancer
p12286
sg13
I2
sa(dp12287
g7
I84
sg26
VC1140680
p12288
sg10
I14
sg11
Vovarian cancer
p12289
sg13
I2
sa(dp12290
g7
I84
sg26
VC1140680
p12291
sg10
I14
sg11
Vovarian cancer
p12292
sg13
I2
sasa(dp12293
g2
S'In addition, CALR and aDC alone have a significant impact on overall survival in ovarian cancer.\n'
p12294
sg4
(lp12295
(dp12296
g7
I22
sg8
VP20711
p12297
sg10
I3
sg11
VaDC
p12298
sg13
I1
sa(dp12299
g7
I13
sg8
VP27797
p12300
sg10
I4
sg11
VCALR
p12301
sg13
I1
sasg23
(lp12302
(dp12303
g7
I81
sg26
VC1140680
p12304
sg10
I14
sg11
Vovarian cancer
p12305
sg13
I2
sasa(dp12306
g2
S'Remarkably, we found that tumoural CALRhigh-phenotype was predictive of positive clinical responses to therapy with ICD inducers (radiotherapy and paclitaxel) in lung and ovarian cancer patients, respectively.\n'
p12307
sg4
(lp12308
sg23
(lp12309
(dp12310
g7
I171
sg26
VC1140680
p12311
sg10
I14
sg11
Vovarian cancer
p12312
sg13
I2
sa(dp12313
g7
I116
sg26
VC0020725
p12314
sg10
I3
sg11
VICD
p12315
sg13
I1
sasa(dp12316
g2
S'Adenovirus expressing calreticulin-E7 (Ad-CRT-E7) has shown promising results in the cervical cancer murine model.\n'
p12317
sg4
(lp12318
(dp12319
g7
I22
sg8
VP27797
p12320
sg10
I12
sg11
Vcalreticulin
p12321
sg13
I1
sa(dp12322
g7
I39
sg8
VP27797
p12323
sg10
I6
sg11
VAd-CRT
p12324
sg13
I1
sasg23
(lp12325
(dp12326
g7
I0
sg26
VC0001486
p12327
sg10
I10
sg11
VAdenovirus
p12328
sg13
I1
sa(dp12329
g7
I85
sg26
VC0302592
p12330
sg10
I15
sg11
Vcervical cancer
p12331
sg13
I2
sasa(dp12332
g2
S'Considering that Baihui (GV20), Dazhui (GV14), Quchi (LI11) and Yongquan (KI1) are commonly used in clinics for stroke treatment and are easy to locate, we chose the above four acupoints as the combination for electro acupuncture treatment which was performed once a day for different time periods.\n'
p12333
sg4
(lp12334
sg23
(lp12335
(dp12336
g7
I112
sg26
VC0038454
p12337
sg10
I6
sg11
Vstroke
p12338
sg13
I1
sasa(dp12339
g2
S'B oTAaneHHoM nocneonepamyNoHHoM nepNoAe (4epe3 1 roA) y 32 namyNeHToB NMena MecTo HopMoToHNR (BTO cocTaBnRno B cpeAHeM 16,0+/-2,3 MM pT.cT.\n'
p12340
sg4
(lp12341
sg23
(lp12342
sa(dp12343
g2
S'4epe3 1 roA cywecTBeHHblx N3MeHeHNN cpeAHNx BenN4NH onToMeTpN4ecKNx noKa3aTeneN no cpaBHeHNh c noKa3aTenRMN 6-MecR4Horo nepNoAa He HabnhAanocb.\n'
p12344
sg4
(lp12345
sg23
(lp12346
sa(dp12347
g2
S'Nocne Ha4ana npNeMa BHyTpb ceneKTNBHblx &amp;#x03B2;-bnoKaTopoB npoBoANnocb noBTopHoe obcneAoBaHNe B cpoKN 4epe3 2, 4 HeA, 3 Mec, 6 Mec, 4epe3 1 roA.\n'
p12348
sg4
(lp12349
(dp12350
g7
I-1
sg8
g64
sg10
I137
sg11
VNocne Ha4ana npNeMa BHyTpb ceneKTNBHblx \u03b2-bnoKaTopoB npoBoANnocb noBTopHoe obcneAoBaHNe B cpoKN 4epe3 2, 4 HeA, 3 Mec, 6 Mec, 4epe3 1 roA
p12351
sg13
I22
sasg23
(lp12352
sa(dp12353
g2
S'Bo 2-N (NccneAyeMoN) rpynne cpeAHNe noKa3aTenN MKO3 N obweN cBeToBoN 4yBcTBNTenbHocTN myeHTpanbHoN obnacTN ceT4aTKN Ao ne4eHNR cocTaBNnN 0,08+/-0,02 N 4,23+/-0,2 AB, 4epe3 1 Mec nocne BBeAeHNR NMnnaHTaTa c AeKcaMeTa3oHoM - 0,21+/-0,04 N 11,77+/-0,98 AB, 4epe3 1 roA - 0,23+/-0,17 N 5,2+/-0,78 AB cooTBeTcTBeHHo.\n'
p12354
sg4
(lp12355
(dp12356
g7
I153
sg8
g64
sg10
I78
sg11
V23+/-0,2 AB, 4epe3 1 Mec nocne BBeAeHNR NMnnaHTaTa c AeKcaMeTa3oHoM - 0,21+/-0
p12357
sg13
I12
sasg23
(lp12358
sa(dp12359
g2
S'OmyeHKa Nx cocToRHNR npoBoANnacb npN obpaweHNN namyNeHTa c ocHoBHoN XanoboN Ha ronoBHyh bonb (BN3NT 1), 4epe3 6 Mec (BN3NT 2), 4epe3 1roA (BN3NT 3).\n'
p12360
sg4
(lp12361
(dp12362
g7
I104
sg8
g64
sg10
I42
sg11
V4epe3 6 Mec (BN3NT 2), 4epe3 1roA (BN3NT 3
p12363
sg13
I9
sasg23
(lp12364
sa(dp12365
g2
S'OmyeHKa Nx cocToRHNR npoBoANnacb npN obpaweHNN namyNeHTa c ocHoBHoN XanoboN Ha ronoBHyh bonb (BN3NT 1), 4epe3 6 Mec (BN3NT 2), 4epe3 1roA (BN3NT 3).\n'
p12366
sg4
(lp12367
(dp12368
g7
I104
sg8
g64
sg10
I42
sg11
V4epe3 6 Mec (BN3NT 2), 4epe3 1roA (BN3NT 3
p12369
sg13
I9
sasg23
(lp12370
sa(dp12371
g2
S'MeToAaMN onTN4ecKoN KorepeHTHoN ToMorpaoNN N MNKponepNMeTpNN obcneAoBaHbl B ANHaMNKe 78 bonbHblx (82 rna3a) c npo3pa4HblMN onTN4ecKNMN cpeAaMN KaK B Ha4ane (4epe3 1 Mec nocne ycnewHoN onepamyNN no noBoAy NMP), TaK N B KoHmye cpoKa HabnhAeHNR (He MeHee 1 roAa).\n'
p12372
sg4
(lp12373
(dp12374
g7
I108
sg8
g64
sg10
I150
sg11
Vc npo3pa4HblMN onTN4ecKNMN cpeAaMN KaK B Ha4ane (4epe3 1 Mec nocne ycnewHoN onepamyNN no noBoAy NMP), TaK N B KoHmye cpoKa HabnhAeHNR (He MeHee 1 roAa
p12375
sg13
I26
sasg23
(lp12376
sa(dp12377
g2
S'We report the effectiveness of a less-invasive treatment for intractable LBP from superior cluneal nerve entrapment neuropathy (SCN-EN) and gluteus medius muscle (GMeM) pain.\n'
p12378
sg4
(lp12379
(dp12380
g7
I163
sg8
VP24821
p12381
sg10
I4
sg11
VGMeM
p12382
sg13
I1
sa(dp12383
g7
I140
sg8
VP24821
p12384
sg10
I21
sg11
Vgluteus medius muscle
p12385
sg13
I3
sa(dp12386
g7
I128
sg8
VP30626
p12387
sg10
I6
sg11
VSCN-EN
p12388
sg13
I1
sa(dp12389
g7
I73
sg8
VP18428
p12390
sg10
I3
sg11
VLBP
p12391
sg13
I1
sa(dp12392
g7
I82
sg8
VP30626
p12393
sg10
I44
sg11
Vsuperior cluneal nerve entrapment neuropathy
p12394
sg13
I5
sasg23
(lp12395
(dp12396
g7
I105
sg26
VC1510429
p12397
sg10
I21
sg11
Ventrapment neuropathy
p12398
sg13
I2
sa(dp12399
g7
I73
sg26
VC0024031
p12400
sg10
I3
sg11
VLBP
p12401
sg13
I1
sasa(dp12402
g2
S'Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p &lt;0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.\n'
p12403
sg4
(lp12404
(dp12405
g7
I211
sg8
VP62736
p12406
sg10
I5
sg11
VACTA2
p12407
sg13
I1
sa(dp12408
g7
I323
sg8
VP05937
p12409
sg10
I5
sg11
VCALB1
p12410
sg13
I1
sa(dp12411
g7
I225
sg8
VP15018
p12412
sg10
I3
sg11
VLIF
p12413
sg13
I1
sa(dp12414
g7
I218
sg8
g64
sg10
I5
sg11
VPOSTN
p12415
sg13
I1
sa(dp12416
g7
I252
sg8
g64
sg10
I4
sg11
VHEY2
p12417
sg13
I1
sa(dp12418
g7
I29
sg8
VP09936
p12419
sg10
I9
sg11
VUCHL1 KDs
p12420
sg13
I2
sa(dp12421
g7
I245
sg8
g64
sg10
I5
sg11
VGDF15
p12422
sg13
I1
sa(dp12423
g7
I304
sg8
VP78363
p12424
sg10
I5
sg11
VABCA4
p12425
sg13
I1
sa(dp12426
g7
I237
sg8
g64
sg10
I6
sg11
VFBXW11
p12427
sg13
I1
sa(dp12428
g7
I317
sg8
VP55087
p12429
sg10
I4
sg11
VAQP4
p12430
sg13
I1
sa(dp12431
g7
I334
sg8
g64
sg10
I3
sg11
VALK
p12432
sg13
I1
sa(dp12433
g7
I230
sg8
g64
sg10
I5
sg11
VFBXL7
p12434
sg13
I1
sa(dp12435
g7
I311
sg8
g64
sg10
I4
sg11
VAQP3
p12436
sg13
I1
sasg23
(lp12437
(dp12438
g7
I199
sg26
VC0006826
p12439
sg10
I6
sg11
Vcancer
p12440
sg13
I1
sasa(dp12441
g2
S'This case demonstrates that blastoid morphology in cyclin D1-negative MCL with IGL-CCND2 translocation indicates progression to a more aggressive neoplasm, similar to cyclin D1-positive MCL.\n'
p12442
sg4
(lp12443
(dp12444
g7
I51
sg8
VP24385
p12445
sg10
I9
sg11
Vcyclin D1
p12446
sg13
I2
sa(dp12447
g7
I51
sg8
VP24385
p12448
sg10
I9
sg11
Vcyclin D1
p12449
sg13
I2
sa(dp12450
g7
I79
sg8
VP15814
p12451
sg10
I3
sg11
VIGL
p12452
sg13
I1
sa(dp12453
g7
I83
sg8
VP30279
p12454
sg10
I5
sg11
VCCND2
p12455
sg13
I1
sasg23
(lp12456
(dp12457
g7
I146
sg26
VC0027651
p12458
sg10
I8
sg11
Vneoplasm
p12459
sg13
I1
sa(dp12460
g7
I70
sg26
VC1708350
p12461
sg10
I3
sg11
VMCL
p12462
sg13
I1
sa(dp12463
g7
I135
sg26
VC0001807
p12464
sg10
I10
sg11
Vaggressive
p12465
sg13
I1
sa(dp12466
g7
I89
sg26
VC0040715
p12467
sg10
I13
sg11
Vtranslocation
p12468
sg13
I1
sa(dp12469
g7
I70
sg26
VC1708350
p12470
sg10
I3
sg11
VMCL
p12471
sg13
I1
sasa(dp12472
g2
S"For the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).\n"
p12473
sg4
(lp12474
(dp12475
g7
I220
sg8
VP42830
p12476
sg10
I5
sg11
VCXCL5
p12477
sg13
I1
sa(dp12478
g7
I170
sg8
VP01591
p12479
sg10
I3
sg11
VIGJ
p12480
sg13
I1
sa(dp12481
g7
I230
sg8
VP10147
p12482
sg10
I4
sg11
VCCL3
p12483
sg13
I1
sa(dp12484
g7
I428
sg8
g64
sg10
I4
sg11
VNBPF
p12485
sg13
I1
sa(dp12486
g7
I395
sg8
g64
sg10
I31
sg11
Vneuroblastoma breakpoint family
p12487
sg13
I3
sa(dp12488
g7
I131
sg8
VP11717
p12489
sg10
I5
sg11
VIGF2R
p12490
sg13
I1
sa(dp12491
g7
I94
sg8
VP01308
p12492
sg10
I35
sg11
Vinsulin-like growth factor receptor
p12493
sg13
I4
sa(dp12494
g7
I84
sg8
g64
sg10
I4
sg11
VLRP1
p12495
sg13
I1
sa(dp12496
g7
I155
sg8
VP15814
p12497
sg10
I10
sg11
VIGL family
p12498
sg13
I2
sasg23
(lp12499
(dp12500
g7
I63
sg26
VC1521724
p12501
sg10
I19
sg11
VAlzheimer's disease
p12502
sg13
I2
sa(dp12503
g7
I197
sg26
VC0021368
p12504
sg10
I21
sg11
Vinflammatory reaction
p12505
sg13
I2
sa(dp12506
g7
I293
sg26
VC0796085
p12507
sg10
I3
sg11
VNHS
p12508
sg13
I1
sa(dp12509
g7
I395
sg26
VC0027819
p12510
sg10
I13
sg11
Vneuroblastoma
p12511
sg13
I1
sasa(dp12512
g2
S'For those who screened positive, standard treatment for TB or preemptive treatment for cryptococcal infection was initiated, followed by ART 2 weeks later.\n'
p12513
sg4
(lp12514
sg23
(lp12515
(dp12516
g7
I100
sg26
VC0009450
p12517
sg10
I9
sg11
Vinfection
p12518
sg13
I1
sasa(dp12519
g2
S'Glial fibrillary acidic protein, AQP1, and AQP4-biomarkers of Muller cell activity-are significantly increased in human eyes with diabetes, confirming that Muller cells are precociously affected by diabetes mellitus.\n'
p12520
sg4
(lp12521
(dp12522
g7
I0
sg8
VP05230
p12523
sg10
I31
sg11
VGlial fibrillary acidic protein
p12524
sg13
I4
sa(dp12525
g7
I33
sg8
VP29972
p12526
sg10
I4
sg11
VAQP1
p12527
sg13
I1
sa(dp12528
g7
I43
sg8
VP55087
p12529
sg10
I4
sg11
VAQP4
p12530
sg13
I1
sasg23
(lp12531
(dp12532
g7
I130
sg26
VC0011849
p12533
sg10
I8
sg11
Vdiabetes
p12534
sg13
I1
sa(dp12535
g7
I198
sg26
VC0011849
p12536
sg10
I17
sg11
Vdiabetes mellitus
p12537
sg13
I2
sasa(dp12538
g2
S'Diabetes produced a decrease in claudin-5 expression in the hippocampus and striatum and reduced AQP4 in the hippocampus.\n'
p12539
sg4
(lp12540
(dp12541
g7
I97
sg8
VP55087
p12542
sg10
I4
sg11
VAQP4
p12543
sg13
I1
sasg23
(lp12544
(dp12545
g7
I0
sg26
VC0011849
p12546
sg10
I8
sg11
VDiabetes
p12547
sg13
I1
sasa(dp12548
g2
S'The reduction of AQP4 levels produced by diabetes was not reversed by exercise.\n'
p12549
sg4
(lp12550
(dp12551
g7
I17
sg8
VP55087
p12552
sg10
I4
sg11
VAQP4
p12553
sg13
I1
sasg23
(lp12554
(dp12555
g7
I41
sg26
VC0011849
p12556
sg10
I8
sg11
Vdiabetes
p12557
sg13
I1
sasa(dp12558
g2
S'However, Qctn treatments inhibited diabetes-induced increases in GFAP and AQP4 expression.\n'
p12559
sg4
(lp12560
(dp12561
g7
I74
sg8
VP55087
p12562
sg10
I4
sg11
VAQP4
p12563
sg13
I1
sasg23
(lp12564
(dp12565
g7
I35
sg26
VC0011849
p12566
sg10
I8
sg11
Vdiabetes
p12567
sg13
I1
sasa(dp12568
g2
S'In a mouse model of Coxsackievirus B3 (CVB3)-induced chronic myocarditis, the delivery of the adenovirus-containing IL-17 receptor A (Ad-IL17RA:Fc) reduced IL-17A production and decreased the number of Th17 cells in the spleen and heart, leading to the down-regulation of systemic TNF-Alfa and IL-6 production.\n'
p12569
sg4
(lp12570
(dp12571
g7
I272
sg8
VP01375
p12572
sg10
I17
sg11
Vsystemic TNF-Alfa
p12573
sg13
I2
sa(dp12574
g7
I294
sg8
VP05231
p12575
sg10
I4
sg11
VIL-6
p12576
sg13
I1
sa(dp12577
g7
I116
sg8
g64
sg10
I16
sg11
VIL-17 receptor A
p12578
sg13
I3
sa(dp12579
g7
I134
sg8
g64
sg10
I9
sg11
VAd-IL17RA
p12580
sg13
I1
sasg23
(lp12581
(dp12582
g7
I61
sg26
VC0027059
p12583
sg10
I11
sg11
Vmyocarditis
p12584
sg13
I1
sa(dp12585
g7
I94
sg26
VC0001486
p12586
sg10
I10
sg11
Vadenovirus
p12587
sg13
I1
sasa(dp12588
g2
S'Ad-IL17R:Fc reduced the left ventricle dilation and decreased the mortality in viral myocarditis, leading to DCM (56% in the Ad-IL17R:Fc versus 76% in the Ad-null group).\n'
p12589
sg4
(lp12590
(dp12591
g7
I3
sg8
g64
sg10
I5
sg11
VIL17R
p12592
sg13
I1
sa(dp12593
g7
I0
sg8
g64
sg10
I8
sg11
VAd-IL17R
p12594
sg13
I1
sasg23
(lp12595
(dp12596
g7
I39
sg26
VC0012359
p12597
sg10
I8
sg11
Vdilation
p12598
sg13
I1
sa(dp12599
g7
I79
sg26
VC0276138
p12600
sg10
I17
sg11
Vviral myocarditis
p12601
sg13
I2
sasa(dp12602
g2
S'We determined that the delivery of IL-17-RA:Fc reduces cardiac remodeling, improves function, and decreases mortality in viral myocarditis leading to DCM, possibly by suppressing fibrosis.\n'
p12603
sg4
(lp12604
sg23
(lp12605
(dp12606
g7
I179
sg26
VC0016059
p12607
sg10
I8
sg11
Vfibrosis
p12608
sg13
I1
sa(dp12609
g7
I121
sg26
VC0276138
p12610
sg10
I17
sg11
Vviral myocarditis
p12611
sg13
I2
sasa(dp12612
g2
S'Macrophages expressing IL-17 receptors were observed infiltrating the hearts of mice with myocarditis, and genetic ablation of IL-17RA altered MPhi recruitment.\n'
p12613
sg4
(lp12614
(dp12615
g7
I143
sg8
VP34972
p12616
sg10
I4
sg11
VMPhi
p12617
sg13
I1
sa(dp12618
g7
I23
sg8
g64
sg10
I15
sg11
VIL-17 receptors
p12619
sg13
I2
sasg23
(lp12620
(dp12621
g7
I53
sg26
VC0332448
p12622
sg10
I12
sg11
Vinfiltrating
p12623
sg13
I1
sa(dp12624
g7
I148
sg26
VC0271510
p12625
sg10
I11
sg11
Vrecruitment
p12626
sg13
I1
sa(dp12627
g7
I90
sg26
VC0027059
p12628
sg10
I11
sg11
Vmyocarditis
p12629
sg13
I1
sasa(dp12630
g2
S'Serum BNP (brain naturiuretic peptide) and ANP (atrial natriuretic peptide) levels are reportedly elevated in patients with thyrotoxicosis.\n'
p12631
sg4
(lp12632
sg23
(lp12633
(dp12634
g7
I124
sg26
VC0040156
p12635
sg10
I14
sg11
Vthyrotoxicosis
p12636
sg13
I1
sasa(dp12637
g2
S'We measured serum ANP and BNP levels in 130 patients with thyrotoxicosis and correlated them with HF severity and thyroid function.\n'
p12638
sg4
(lp12639
(dp12640
g7
I12
sg8
VP16066
p12641
sg10
I9
sg11
Vserum ANP
p12642
sg13
I2
sa(dp12643
g7
I26
sg8
VP16860
p12644
sg10
I3
sg11
VBNP
p12645
sg13
I1
sasg23
(lp12646
(dp12647
g7
I58
sg26
VC0040156
p12648
sg10
I14
sg11
Vthyrotoxicosis
p12649
sg13
I1
sasa(dp12650
g2
S'These data suggest that the cardiovascular condition is the major factor responsible for the elevated serum BNP and ANP levels in thyrotoxic patients, while thyrotoxicosis itself is an independent but minor contributing factor.\n'
p12651
sg4
(lp12652
(dp12653
g7
I102
sg8
VP16860
p12654
sg10
I9
sg11
Vserum BNP
p12655
sg13
I2
sa(dp12656
g7
I116
sg8
VP16066
p12657
sg10
I3
sg11
VANP
p12658
sg13
I1
sasg23
(lp12659
(dp12660
g7
I157
sg26
VC0040156
p12661
sg10
I14
sg11
Vthyrotoxicosis
p12662
sg13
I1
sa(dp12663
g7
I43
sg26
VC0012634
p12664
sg10
I9
sg11
Vcondition
p12665
sg13
I1
sasa(dp12666
g2
S'Plasma ANP levels are impaired in several endocrine diseases : the plasma hormone levels increase in hypercortisolism, hyperaldosteronism, thyrotoxicosis and inappropriate antidiuretic hormone secretion; it decreases in hypothyroidism.\n'
p12667
sg4
(lp12668
(dp12669
g7
I0
sg8
VP16066
p12670
sg10
I10
sg11
VPlasma ANP
p12671
sg13
I2
sasg23
(lp12672
(dp12673
g7
I139
sg26
VC0040156
p12674
sg10
I14
sg11
Vthyrotoxicosis
p12675
sg13
I1
sa(dp12676
g7
I22
sg26
VC0684336
p12677
sg10
I8
sg11
Vimpaired
p12678
sg13
I1
sa(dp12679
g7
I158
sg26
VC0021141
p12680
sg10
I44
sg11
Vinappropriate antidiuretic hormone secretion
p12681
sg13
I4
sa(dp12682
g7
I101
sg26
VC0010481
p12683
sg10
I16
sg11
Vhypercortisolism
p12684
sg13
I1
sa(dp12685
g7
I42
sg26
VC0014130
p12686
sg10
I18
sg11
Vendocrine diseases
p12687
sg13
I2
sa(dp12688
g7
I220
sg26
VC0020676
p12689
sg10
I14
sg11
Vhypothyroidism
p12690
sg13
I1
sa(dp12691
g7
I119
sg26
VC0020428
p12692
sg10
I18
sg11
Vhyperaldosteronism
p12693
sg13
I1
sasa(dp12694
g2
S'Further, the CT genotype of the RAD23B Ala249Val was associated with increased esophageal cancer risk (OR = 1.44; 95% CI = 1.05-1.97), whereas the poly-AT-/+ genotype of the XPC intron 9 conferred a decreased risk (OR = 0.71, 95% CI = 0.51-0.97).\n'
p12695
sg4
(lp12696
(dp12697
g7
I174
sg8
g64
sg10
I12
sg11
VXPC intron 9
p12698
sg13
I3
sa(dp12699
g7
I32
sg8
VP54727
p12700
sg10
I6
sg11
VRAD23B
p12701
sg13
I1
sasg23
(lp12702
(dp12703
g7
I174
sg26
VC2752147
p12704
sg10
I3
sg11
VXPC
p12705
sg13
I1
sa(dp12706
g7
I79
sg26
VC0014859
p12707
sg10
I17
sg11
Vesophageal cancer
p12708
sg13
I2
sasa(dp12709
g2
S'The present study aimed to systemically review the evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and systemic lupus erythematosus (SLE), as well as the associations between several polymorphisms in the MIF gene and SLE susceptibility.\n'
p12710
sg4
(lp12711
(dp12712
g7
I264
sg8
VP05109
p12713
sg10
I8
sg11
VMIF gene
p12714
sg13
I2
sa(dp12715
g7
I277
sg8
g64
sg10
I18
sg11
VSLE susceptibility
p12716
sg13
I2
sasg23
(lp12717
(dp12718
g7
I193
sg26
VC0024141
p12719
sg10
I3
sg11
VSLE
p12720
sg13
I1
sa(dp12721
g7
I163
sg26
VC0024141
p12722
sg10
I28
sg11
Vsystemic lupus erythematosus
p12723
sg13
I3
sa(dp12724
g7
I193
sg26
VC0024141
p12725
sg10
I3
sg11
VSLE
p12726
sg13
I1
sasa(dp12727
g2
S'Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus.\n'
p12728
sg4
(lp12729
sg23
(lp12730
(dp12731
g7
I144
sg26
VC0028754
p12732
sg10
I7
sg11
Vobesity
p12733
sg13
I1
sa(dp12734
g7
I97
sg26
VC0443146
p12735
sg10
I10
sg11
Vautoimmune
p12736
sg13
I1
sa(dp12737
g7
I179
sg26
VC0024141
p12738
sg10
I28
sg11
Vsystemic lupus erythematosus
p12739
sg13
I3
sa(dp12740
g7
I153
sg26
VC0003873
p12741
sg10
I20
sg11
Vrheumatoid arthritis
p12742
sg13
I2
sasa(dp12743
g2
S'Macrophage migration inhibitory factor (MIF) is a key regulator of both atherosclerosis and systemic lupus erythematosus (SLE), yet factors leading to its overproduction remain unclear.\n'
p12744
sg4
(lp12745
sg23
(lp12746
(dp12747
g7
I122
sg26
VC0024141
p12748
sg10
I3
sg11
VSLE
p12749
sg13
I1
sa(dp12750
g7
I72
sg26
VC0004153
p12751
sg10
I15
sg11
Vatherosclerosis
p12752
sg13
I1
sa(dp12753
g7
I92
sg26
VC0024141
p12754
sg10
I28
sg11
Vsystemic lupus erythematosus
p12755
sg13
I3
sasa(dp12756
g2
S'To investigate the mRNA level of glucocorticoid receptor Alfa (GRAlfa) and heat shock protein 90 (HSP90) in peripheral blood mononuclear cells (PBMCs) and the plasma protein level of macrophage migration inhibitory factor (MIF) in patients with systemic lupus erythematosus (SLE) and to analyze their association with glucocorticoid (GC) resistance.\n'
p12757
sg4
(lp12758
(dp12759
g7
I98
sg8
VP07900
p12760
sg10
I5
sg11
VHSP90
p12761
sg13
I1
sa(dp12762
g7
I33
sg8
VP04150
p12763
sg10
I63
sg11
Vglucocorticoid receptor Alfa (GRAlfa) and heat shock protein 90
p12764
sg13
I9
sasg23
(lp12765
(dp12766
g7
I245
sg26
VC0024141
p12767
sg10
I28
sg11
Vsystemic lupus erythematosus
p12768
sg13
I3
sa(dp12769
g7
I275
sg26
VC0024141
p12770
sg10
I3
sg11
VSLE
p12771
sg13
I1
sasa(dp12772
g2
S'To study the effect of the innate cytokine macrophage migration inhibitory factor (MIF) on the susceptibility and severity of systemic lupus erythematosus (SLE) in a multinational population of 1,369 Caucasian and African American patients.\n'
p12773
sg4
(lp12774
(dp12775
g7
I34
sg8
VP14174
p12776
sg10
I47
sg11
Vcytokine macrophage migration inhibitory factor
p12777
sg13
I5
sa(dp12778
g7
I83
sg8
VP05109
p12779
sg10
I3
sg11
VMIF
p12780
sg13
I1
sasg23
(lp12781
(dp12782
g7
I126
sg26
VC0024141
p12783
sg10
I28
sg11
Vsystemic lupus erythematosus
p12784
sg13
I3
sa(dp12785
g7
I156
sg26
VC0024141
p12786
sg10
I3
sg11
VSLE
p12787
sg13
I1
sasa(dp12788
g2
S'Minimal change disease and focal segmental glomerular sclerosis showed minimal or none expression of FcRn (1/8, 0/4 respectively) and not statistically difference from that of normal controls.\n'
p12789
sg4
(lp12790
sg23
(lp12791
(dp12792
g7
I0
sg26
VC1704320
p12793
sg10
I22
sg11
VMinimal change disease
p12794
sg13
I3
sa(dp12795
g7
I43
sg26
VC0178664
p12796
sg10
I20
sg11
Vglomerular sclerosis
p12797
sg13
I2
sasa(dp12798
g2
S'There was a higher production profile of TNF-Alfa and TSLP in nasal secretion in the patients with perennial allergic rhinitis and additional high sensitization to SEs.\n'
p12799
sg4
(lp12800
(dp12801
g7
I41
sg8
VP01375
p12802
sg10
I17
sg11
VTNF-Alfa and TSLP
p12803
sg13
I3
sasg23
(lp12804
(dp12805
g7
I99
sg26
VC0035457
p12806
sg10
I27
sg11
Vperennial allergic rhinitis
p12807
sg13
I3
sasa(dp12808
g2
S'We found that house dust mite (HDM) extract induced TSLP production by nasal epithelial cells, suggesting that TSLP may be involved in development of HDM-induced allergic rhinitis (AR).\n'
p12809
sg4
(lp12810
(dp12811
g7
I52
sg8
g64
sg10
I4
sg11
VTSLP
p12812
sg13
I1
sasg23
(lp12813
(dp12814
g7
I181
sg26
VC2607914
p12815
sg10
I2
sg11
VAR
p12816
sg13
I1
sa(dp12817
g7
I162
sg26
VC2607914
p12818
sg10
I17
sg11
Vallergic rhinitis
p12819
sg13
I2
sasa(dp12820
g2
S'We investigated changes in large aggregating (versican [VS]), basement membrane (heparan sulfate proteoglycan [HSPG]), and small (biglycan and fibromodulin) PGs during the development of BM-induced pulmonary fibrosis.\n'
p12821
sg4
(lp12822
(dp12823
g7
I143
sg8
g64
sg10
I12
sg11
Vfibromodulin
p12824
sg13
I1
sa(dp12825
g7
I111
sg8
VP34741
p12826
sg10
I4
sg11
VHSPG
p12827
sg13
I1
sasg23
(lp12828
(dp12829
g7
I198
sg26
VC0034069
p12830
sg10
I18
sg11
Vpulmonary fibrosis
p12831
sg13
I2
sa(dp12832
g7
I157
sg26
VC0796254
p12833
sg10
I3
sg11
VPGs
p12834
sg13
I1
sasa(dp12835
g2
S'Fourteen patients aged 1 to 15 years with medulloblastoma (six patients), low-grade astrocytoma (four patients), and high-grade astrocytoma (four patients) were treated with carboplatin and etoposide (JET regimen).\n'
p12836
sg4
(lp12837
sg23
(lp12838
(dp12839
g7
I84
sg26
VC0004114
p12840
sg10
I11
sg11
Vastrocytoma
p12841
sg13
I1
sa(dp12842
g7
I42
sg26
VC0025149
p12843
sg10
I15
sg11
Vmedulloblastoma
p12844
sg13
I1
sa(dp12845
g7
I84
sg26
VC0004114
p12846
sg10
I11
sg11
Vastrocytoma
p12847
sg13
I1
sasa(dp12848
g2
S'Although predominantly present in hepatocytes, CYP2E1 has also been found in hematopoietic stem cells and subtypes of acute myeloid leukemia with unknown clinical significance except for the metabolism of anti-fungal drugs.\n'
p12849
sg4
(lp12850
(dp12851
g7
I47
sg8
VP05181
p12852
sg10
I6
sg11
VCYP2E1
p12853
sg13
I1
sasg23
(lp12854
(dp12855
g7
I118
sg26
VC0023467
p12856
sg10
I22
sg11
Vacute myeloid leukemia
p12857
sg13
I3
sasa(dp12858
g2
S'The aim of the present study was to analyze the roles of T lymphoma invasion and metastasis 1 (Tiam1) in nasopharyngeal carcinoma (NPC) progression and its correlation with clinicopathological features, including the survival of patients with NPC.\n'
p12859
sg4
(lp12860
(dp12861
g7
I57
sg8
VP41162
p12862
sg10
I36
sg11
VT lymphoma invasion and metastasis 1
p12863
sg13
I6
sa(dp12864
g7
I95
sg8
g64
sg10
I5
sg11
VTiam1
p12865
sg13
I1
sasg23
(lp12866
(dp12867
g7
I68
sg26
VC2699153
p12868
sg10
I8
sg11
Vinvasion
p12869
sg13
I1
sa(dp12870
g7
I131
sg26
VC2931822
p12871
sg10
I3
sg11
VNPC
p12872
sg13
I1
sa(dp12873
g7
I81
sg26
VC0027627
p12874
sg10
I10
sg11
Vmetastasis
p12875
sg13
I1
sa(dp12876
g7
I131
sg26
VC2931822
p12877
sg10
I3
sg11
VNPC
p12878
sg13
I1
sa(dp12879
g7
I105
sg26
VC2931822
p12880
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12881
sg13
I2
sa(dp12882
g7
I59
sg26
VC0024299
p12883
sg10
I8
sg11
Vlymphoma
p12884
sg13
I1
sasa(dp12885
g2
S'Rac1) and Tiam1-Rac1 pathway affects the migration and invasion of many tumors, such as nasopharyngeal carcinoma, breast cancer and retinoblastoma.\n'
p12886
sg4
(lp12887
(dp12888
g7
I0
sg8
VP63000
p12889
sg10
I4
sg11
VRac1
p12890
sg13
I1
sa(dp12891
g7
I10
sg8
g64
sg10
I5
sg11
VTiam1
p12892
sg13
I1
sa(dp12893
g7
I0
sg8
VP63000
p12894
sg10
I4
sg11
VRac1
p12895
sg13
I1
sasg23
(lp12896
(dp12897
g7
I88
sg26
VC2931822
p12898
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12899
sg13
I2
sa(dp12900
g7
I132
sg26
VC0035335
p12901
sg10
I14
sg11
Vretinoblastoma
p12902
sg13
I1
sa(dp12903
g7
I72
sg26
VC0027651
p12904
sg10
I6
sg11
Vtumors
p12905
sg13
I1
sa(dp12906
g7
I55
sg26
VC2699153
p12907
sg10
I8
sg11
Vinvasion
p12908
sg13
I1
sa(dp12909
g7
I114
sg26
VC0678222
p12910
sg10
I13
sg11
Vbreast cancer
p12911
sg13
I2
sasa(dp12912
g2
S'To explore biological aspects of Tiam1 gene expression in nasopharyngeal carcinoma cells.\n'
p12913
sg4
(lp12914
(dp12915
g7
I33
sg8
g64
sg10
I10
sg11
VTiam1 gene
p12916
sg13
I2
sasg23
(lp12917
(dp12918
g7
I58
sg26
VC2931822
p12919
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12920
sg13
I2
sasa(dp12921
g2
S'Tiam1/C1199HA expression plasmids were transfected into nasopharyngeal carcinoma cells of C666-1 and CNE1 by lipofectamine2000.\n'
p12922
sg4
(lp12923
(dp12924
g7
I101
sg8
g64
sg10
I4
sg11
VCNE1
p12925
sg13
I1
sa(dp12926
g7
I0
sg8
g64
sg10
I5
sg11
VTiam1
p12927
sg13
I1
sasg23
(lp12928
(dp12929
g7
I56
sg26
VC2931822
p12930
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12931
sg13
I2
sasa(dp12932
g2
S'Tiam1 expression correlates with the invasion and metastasis of nasopharyngeal carcinoma cells.\n'
p12933
sg4
(lp12934
(dp12935
g7
I0
sg8
g64
sg10
I5
sg11
VTiam1
p12936
sg13
I1
sasg23
(lp12937
(dp12938
g7
I50
sg26
VC0027627
p12939
sg10
I10
sg11
Vmetastasis
p12940
sg13
I1
sa(dp12941
g7
I64
sg26
VC2931822
p12942
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12943
sg13
I2
sa(dp12944
g7
I37
sg26
VC2699153
p12945
sg10
I8
sg11
Vinvasion
p12946
sg13
I1
sasa(dp12947
g2
S'This study is designed to investigate the roles of Tiam1 and Rac1 in nasopharyngeal carcinoma (NPC).\n'
p12948
sg4
(lp12949
(dp12950
g7
I61
sg8
VP63000
p12951
sg10
I4
sg11
VRac1
p12952
sg13
I1
sa(dp12953
g7
I51
sg8
g64
sg10
I5
sg11
VTiam1
p12954
sg13
I1
sasg23
(lp12955
(dp12956
g7
I69
sg26
VC2931822
p12957
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12958
sg13
I2
sa(dp12959
g7
I95
sg26
VC2931822
p12960
sg10
I3
sg11
VNPC
p12961
sg13
I1
sasa(dp12962
g2
S'To investigate the relationship between the protein expression of T-lymphoma invasion and metastasis gene 1 (Tiam-1) and the biological behaviors of nasopharyngeal carcinoma (NPC).\n'
p12963
sg4
(lp12964
sg23
(lp12965
(dp12966
g7
I68
sg26
VC0024299
p12967
sg10
I8
sg11
Vlymphoma
p12968
sg13
I1
sa(dp12969
g7
I77
sg26
VC2699153
p12970
sg10
I8
sg11
Vinvasion
p12971
sg13
I1
sa(dp12972
g7
I175
sg26
VC2931822
p12973
sg10
I3
sg11
VNPC
p12974
sg13
I1
sa(dp12975
g7
I90
sg26
VC0027627
p12976
sg10
I10
sg11
Vmetastasis
p12977
sg13
I1
sa(dp12978
g7
I149
sg26
VC2931822
p12979
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12980
sg13
I2
sasa(dp12981
g2
S'To study the relation between T lymphoma invasion/metastasis1 (Tiam1) gene and nasopharyngeal carcinoma progression.\n'
p12982
sg4
(lp12983
(dp12984
g7
I63
sg8
g64
sg10
I5
sg11
VTiam1
p12985
sg13
I1
sa(dp12986
g7
I30
sg8
g64
sg10
I31
sg11
VT lymphoma invasion/metastasis1
p12987
sg13
I3
sasg23
(lp12988
(dp12989
g7
I41
sg26
VC2699153
p12990
sg10
I8
sg11
Vinvasion
p12991
sg13
I1
sa(dp12992
g7
I79
sg26
VC2931822
p12993
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12994
sg13
I2
sa(dp12995
g7
I32
sg26
VC0024299
p12996
sg10
I8
sg11
Vlymphoma
p12997
sg13
I1
sasa(dp12998
g2
S'Average expression of the Tiam1 gene in nasopharyngeal carcinoma tissue (1.183 +/- 0.73) is higher than in normal nasopharyngeal tissue (0.87 +/- 0.45) (P &lt; 0.01).\n'
p12999
sg4
(lp13000
(dp13001
g7
I26
sg8
g64
sg10
I10
sg11
VTiam1 gene
p13002
sg13
I2
sasg23
(lp13003
(dp13004
g7
I40
sg26
VC2931822
p13005
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13006
sg13
I2
sasa(dp13007
g2
S'Average expression of the Tiam1 gene in nasopharyngeal carcinoma tissue is higher than in normal nasopharyngeal tissue.\n'
p13008
sg4
(lp13009
(dp13010
g7
I26
sg8
g64
sg10
I10
sg11
VTiam1 gene
p13011
sg13
I2
sasg23
(lp13012
(dp13013
g7
I40
sg26
VC2931822
p13014
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13015
sg13
I2
sasa(dp13016
g2
S'Our data suggest that the overexpression of the Tiam1 gene correlates invasion and metastasis of nasopharyngeal carcinoma.\n'
p13017
sg4
(lp13018
(dp13019
g7
I48
sg8
g64
sg10
I10
sg11
VTiam1 gene
p13020
sg13
I2
sasg23
(lp13021
(dp13022
g7
I83
sg26
VC0027627
p13023
sg10
I10
sg11
Vmetastasis
p13024
sg13
I1
sa(dp13025
g7
I70
sg26
VC2699153
p13026
sg10
I8
sg11
Vinvasion
p13027
sg13
I1
sa(dp13028
g7
I97
sg26
VC2931822
p13029
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13030
sg13
I2
sasa(dp13031
g2
S'In the present study, an initial staging FDG PET/CT showed intense FDG uptake in a patient with liver carcinosarcoma composed of hepatocellular carcinoma and rhabdomyosarcoma.\n'
p13032
sg4
(lp13033
sg23
(lp13034
(dp13035
g7
I158
sg26
VC0035412
p13036
sg10
I16
sg11
Vrhabdomyosarcoma
p13037
sg13
I1
sa(dp13038
g7
I129
sg26
VC1512411
p13039
sg10
I24
sg11
Vhepatocellular carcinoma
p13040
sg13
I2
sa(dp13041
g7
I96
sg26
VC2007076
p13042
sg10
I20
sg11
Vliver carcinosarcoma
p13043
sg13
I2
sasa(dp13044
g2
S'Workup of urinary retention after a previously treated squamous cell carcinoma of the prostate led to a transurethral prostate resection revealing carcinosarcoma of the prostate, which on F-FDG PET/CT demonstrated moderate to high avidity of this atypical prostate cancer, with partial obstruction of the urinary system and lung metastases.\n'
p13045
sg4
(lp13046
sg23
(lp13047
(dp13048
g7
I324
sg26
VC0153676
p13049
sg10
I15
sg11
Vlung metastases
p13050
sg13
I2
sa(dp13051
g7
I278
sg26
VC0333169
p13052
sg10
I19
sg11
Vpartial obstruction
p13053
sg13
I2
sa(dp13054
g7
I147
sg26
VC0007140
p13055
sg10
I14
sg11
Vcarcinosarcoma
p13056
sg13
I1
sa(dp13057
g7
I256
sg26
VC0600139
p13058
sg10
I15
sg11
Vprostate cancer
p13059
sg13
I2
sa(dp13060
g7
I55
sg26
VC1302530
p13061
sg10
I39
sg11
Vsquamous cell carcinoma of the prostate
p13062
sg13
I6
sasa(dp13063
g2
S'In the present study, we report a case of gastric carcinosarcoma composed of rhabdomyosarcoma and adenocarcinoma on F-FDG PET/CT.\n'
p13064
sg4
(lp13065
sg23
(lp13066
(dp13067
g7
I50
sg26
VC0007140
p13068
sg10
I14
sg11
Vcarcinosarcoma
p13069
sg13
I1
sa(dp13070
g7
I98
sg26
VC0001418
p13071
sg10
I14
sg11
Vadenocarcinoma
p13072
sg13
I1
sa(dp13073
g7
I77
sg26
VC0035412
p13074
sg10
I16
sg11
Vrhabdomyosarcoma
p13075
sg13
I1
sasa(dp13076
g2
S'This is the rare reported case of esophageal carcinosarcoma that showed increased accumulation of tracer on FDG-PET.\n'
p13077
sg4
(lp13078
sg23
(lp13079
(dp13080
g7
I34
sg26
VC2987252
p13081
sg10
I25
sg11
Vesophageal carcinosarcoma
p13082
sg13
I2
sasa(dp13083
g2
S'We report a case of tissue-proven carcinosarcoma of the uterine corpus in a 65-year-old woman with elevated serum alpha-fetoprotein (AFP), whose 18F-FDG PET/CT showed a 10.3-cm mass in the uterus with uneven high FDG uptake.\n'
p13084
sg4
(lp13085
(dp13086
g7
I133
sg8
VP02771
p13087
sg10
I3
sg11
VAFP
p13088
sg13
I1
sa(dp13089
g7
I108
sg8
VP02771
p13090
sg10
I23
sg11
Vserum alpha-fetoprotein
p13091
sg13
I2
sasg23
(lp13092
(dp13093
g7
I34
sg26
VC1704376
p13094
sg10
I36
sg11
Vcarcinosarcoma of the uterine corpus
p13095
sg13
I5
sasa(dp13096
g2
S'Overexpression of meprin Beta is implicated in fibrosis, inflammatory diseases and cancers.\n'
p13097
sg4
(lp13098
sg23
(lp13099
(dp13100
g7
I47
sg26
VC0016059
p13101
sg10
I8
sg11
Vfibrosis
p13102
sg13
I1
sa(dp13103
g7
I83
sg26
VC0006826
p13104
sg10
I7
sg11
Vcancers
p13105
sg13
I1
sasa(dp13106
g2
S'However, selective meprin Beta inhibition is crucial to reduce cancer metastasis and adverse effects in inflammation.\n'
p13107
sg4
(lp13108
sg23
(lp13109
(dp13110
g7
I104
sg26
VC0021368
p13111
sg10
I12
sg11
Vinflammation
p13112
sg13
I1
sa(dp13113
g7
I70
sg26
VC0027627
p13114
sg10
I10
sg11
Vmetastasis
p13115
sg13
I1
sa(dp13116
g7
I85
sg26
VC0879626
p13117
sg10
I15
sg11
Vadverse effects
p13118
sg13
I2
sa(dp13119
g7
I63
sg26
VC0006826
p13120
sg10
I6
sg11
Vcancer
p13121
sg13
I1
sasa(dp13122
g2
S"Moreover, meprin Beta cleaves amyloid precursor protein, thought to be involved in the progression of Alzheimer's disease.\n"
p13123
sg4
(lp13124
(dp13125
g7
I30
sg8
VP17342
p13126
sg10
I25
sg11
Vamyloid precursor protein
p13127
sg13
I3
sasg23
(lp13128
(dp13129
g7
I87
sg26
VC1735366
p13130
sg10
I34
sg11
Vprogression of Alzheimer's disease
p13131
sg13
I4
sa(dp13132
g7
I30
sg26
VC0011560
p13133
sg10
I7
sg11
Vamyloid
p13134
sg13
I1
sasa(dp13135
g2
S'Therefore, meprin Beta inhibitors are considered to be emerging therapeutics with paramount importance in the treatment of kidney failure, fibrosis, inflammatory bowel diseases and cancer.\n'
p13136
sg4
(lp13137
sg23
(lp13138
(dp13139
g7
I123
sg26
VC0035078
p13140
sg10
I14
sg11
Vkidney failure
p13141
sg13
I2
sa(dp13142
g7
I139
sg26
VC0016059
p13143
sg10
I8
sg11
Vfibrosis
p13144
sg13
I1
sa(dp13145
g7
I181
sg26
VC0006826
p13146
sg10
I6
sg11
Vcancer
p13147
sg13
I1
sa(dp13148
g7
I149
sg26
VC0021390
p13149
sg10
I27
sg11
Vinflammatory bowel diseases
p13150
sg13
I3
sasa(dp13151
g2
S'Meprin (EC 3.4.24.18), an astacin-like metalloprotease, is expressed in the epithelium of the intestine and kidney tubules and has been related to cancer, but the mechanistic links are unknown.\n'
p13152
sg4
(lp13153
(dp13154
g7
I39
sg8
g64
sg10
I15
sg11
Vmetalloprotease
p13155
sg13
I1
sasg23
(lp13156
(dp13157
g7
I147
sg26
VC0006826
p13158
sg10
I6
sg11
Vcancer
p13159
sg13
I1
sasa(dp13160
g2
S'The zinc endopeptidase meprin (EC 3.4.24.18) is expressed in brush border membranes of intestine and kidney tubules, intestinal leukocytes, and certain cancer cells, suggesting a role in epithelial differentiation and cell migration.\n'
p13161
sg4
(lp13162
sg23
(lp13163
(dp13164
g7
I152
sg26
VC0006826
p13165
sg10
I6
sg11
Vcancer
p13166
sg13
I1
sasa(dp13167
g2
S'This investigation tested the hypothesis that variations in the structural or regulatory regions of the MEP1B gene are related to susceptibility to diabetic nephropathy in the Pima Indian population.\n'
p13168
sg4
(lp13169
(dp13170
g7
I104
sg8
g64
sg10
I10
sg11
VMEP1B gene
p13171
sg13
I2
sasg23
(lp13172
(dp13173
g7
I148
sg26
VC0011881
p13174
sg10
I20
sg11
Vdiabetic nephropathy
p13175
sg13
I2
sasa(dp13176
g2
S'The present study demonstrates significant within-family association for SNPs in MEP1B gene with diabetic nephropathy.\n'
p13177
sg4
(lp13178
(dp13179
g7
I73
sg8
g64
sg10
I4
sg11
VSNPs
p13180
sg13
I1
sa(dp13181
g7
I81
sg8
g64
sg10
I10
sg11
VMEP1B gene
p13182
sg13
I2
sasg23
(lp13183
(dp13184
g7
I97
sg26
VC0011881
p13185
sg10
I20
sg11
Vdiabetic nephropathy
p13186
sg13
I2
sasa(dp13187
g2
S"The chemokine CCL20 is over-produced in epithelium of Crohn's disease [CD] patients and contributes to recruiting immune cells to inflamed gut.\n"
p13188
sg4
(lp13189
(dp13190
g7
I14
sg8
VP78556
p13191
sg10
I5
sg11
VCCL20
p13192
sg13
I1
sasg23
(lp13193
(dp13194
g7
I54
sg26
VC0010346
p13195
sg10
I15
sg11
VCrohn's disease
p13196
sg13
I2
sasa(dp13197
g2
S'The stage of liver cirrhosis correlated with an increase in plasma levels of pro-inflammatory cytokines (IL-6) and chemotactic chemokines involved in immune cell trafficking (MIP-3Alfa/CCL20).\n'
p13198
sg4
(lp13199
(dp13200
g7
I175
sg8
g64
sg10
I9
sg11
VMIP-3Alfa
p13201
sg13
I1
sa(dp13202
g7
I185
sg8
VP78556
p13203
sg10
I5
sg11
VCCL20
p13204
sg13
I1
sa(dp13205
g7
I105
sg8
VP05231
p13206
sg10
I4
sg11
VIL-6
p13207
sg13
I1
sasg23
(lp13208
(dp13209
g7
I13
sg26
VC0023890
p13210
sg10
I15
sg11
Vliver cirrhosis
p13211
sg13
I2
sa(dp13212
g7
I175
sg26
VC1851100
p13213
sg10
I3
sg11
VMIP
p13214
sg13
I1
sasa(dp13215
g2
S'Probiotic administration in patients with liver cirrhosis led to modulation of plasma levels of several molecules and compounds measured (MIP-3Alfa/CCL20, NO, big-endothelin, TXB2 and MPO).\n'
p13216
sg4
(lp13217
(dp13218
g7
I184
sg8
VP05164
p13219
sg10
I3
sg11
VMPO
p13220
sg13
I1
sa(dp13221
g7
I138
sg8
g64
sg10
I9
sg11
VMIP-3Alfa
p13222
sg13
I1
sa(dp13223
g7
I148
sg8
VP78556
p13224
sg10
I5
sg11
VCCL20
p13225
sg13
I1
sasg23
(lp13226
(dp13227
g7
I42
sg26
VC0023890
p13228
sg10
I15
sg11
Vliver cirrhosis
p13229
sg13
I2
sa(dp13230
g7
I138
sg26
VC1851100
p13231
sg10
I3
sg11
VMIP
p13232
sg13
I1
sasa(dp13233
g2
S'Conversely, eight genes associated with carcinogenesis had higher expression in fibrosarcomas: FHL2, PLAGL1, FNBP1L, BAG2, HK1, CSK and Cox5A.\n'
p13234
sg4
(lp13235
(dp13236
g7
I128
sg8
VP41240
p13237
sg10
I3
sg11
VCSK
p13238
sg13
I1
sa(dp13239
g7
I123
sg8
VP22459
p13240
sg10
I3
sg11
VHK1
p13241
sg13
I1
sa(dp13242
g7
I117
sg8
g64
sg10
I4
sg11
VBAG2
p13243
sg13
I1
sa(dp13244
g7
I136
sg8
VP20674
p13245
sg10
I5
sg11
VCox5A
p13246
sg13
I1
sa(dp13247
g7
I109
sg8
g64
sg10
I6
sg11
VFNBP1L
p13248
sg13
I1
sa(dp13249
g7
I95
sg8
VP14222
p13250
sg10
I4
sg11
VFHL2
p13251
sg13
I1
sa(dp13252
g7
I101
sg8
g64
sg10
I6
sg11
VPLAGL1
p13253
sg13
I1
sasg23
(lp13254
(dp13255
g7
I95
sg26
VC1863727
p13256
sg10
I4
sg11
VFHL2
p13257
sg13
I1
sa(dp13258
g7
I40
sg26
VC0596263
p13259
sg10
I14
sg11
Vcarcinogenesis
p13260
sg13
I1
sa(dp13261
g7
I80
sg26
VC0016057
p13262
sg10
I13
sg11
Vfibrosarcomas
p13263
sg13
I1
sasa(dp13264
g2
S'Analysis of microarray data showed elevated expression of MEST, PLAGL1, PEG3, DLK1, and IGF2 in various embryonal cancers, especially rhabdomyosarcoma, as compared to nonembryonal cancers and normal tissues.\n'
p13265
sg4
(lp13266
(dp13267
g7
I64
sg8
g64
sg10
I6
sg11
VPLAGL1
p13268
sg13
I1
sa(dp13269
g7
I58
sg8
g64
sg10
I4
sg11
VMEST
p13270
sg13
I1
sa(dp13271
g7
I72
sg8
g64
sg10
I4
sg11
VPEG3
p13272
sg13
I1
sa(dp13273
g7
I78
sg8
VP80370
p13274
sg10
I4
sg11
VDLK1
p13275
sg13
I1
sa(dp13276
g7
I88
sg8
VP01344
p13277
sg10
I4
sg11
VIGF2
p13278
sg13
I1
sasg23
(lp13279
(dp13280
g7
I134
sg26
VC0035412
p13281
sg10
I16
sg11
Vrhabdomyosarcoma
p13282
sg13
I1
sa(dp13283
g7
I104
sg26
VC0751364
p13284
sg10
I17
sg11
Vembryonal cancers
p13285
sg13
I2
sa(dp13286
g7
I114
sg26
VC0006826
p13287
sg10
I7
sg11
Vcancers
p13288
sg13
I1
sasa(dp13289
g2
S'Furthermore, siRNA-mediated knockdown of MEST, PLAGL1, PEG3, and IGF2 expression inhibited proliferation in Rh30 rhabdomyosarcoma cells.\n'
p13290
sg4
(lp13291
(dp13292
g7
I65
sg8
VP01344
p13293
sg10
I4
sg11
VIGF2
p13294
sg13
I1
sa(dp13295
g7
I47
sg8
g64
sg10
I6
sg11
VPLAGL1
p13296
sg13
I1
sa(dp13297
g7
I55
sg8
g64
sg10
I4
sg11
VPEG3
p13298
sg13
I1
sa(dp13299
g7
I41
sg8
g64
sg10
I4
sg11
VMEST
p13300
sg13
I1
sasg23
(lp13301
(dp13302
g7
I91
sg26
VC0334094
p13303
sg10
I13
sg11
Vproliferation
p13304
sg13
I1
sa(dp13305
g7
I113
sg26
VC0035412
p13306
sg10
I16
sg11
Vrhabdomyosarcoma
p13307
sg13
I1
sasa(dp13308
g2
S'This case is the first reported of a heterozygous C3 mutation associated with lupus nephritis and autoantibodies against complement alternative pathway proteins (Factor I, Factor B, C3 and Properdin).These autoantibodies cause activation of this pathway and this fact could explain that the tissue damage is restricted to the kidney.\n'
p13309
sg4
(lp13310
(dp13311
g7
I172
sg8
g64
sg10
I8
sg11
VFactor B
p13312
sg13
I2
sa(dp13313
g7
I121
sg8
g64
sg10
I39
sg11
Vcomplement alternative pathway proteins
p13314
sg13
I4
sa(dp13315
g7
I162
sg8
VP05156
p13316
sg10
I8
sg11
VFactor I
p13317
sg13
I2
sa(dp13318
g7
I189
sg8
VP27918
p13319
sg10
I9
sg11
VProperdin
p13320
sg13
I1
sasg23
(lp13321
(dp13322
g7
I78
sg26
VC0024143
p13323
sg10
I15
sg11
Vlupus nephritis
p13324
sg13
I2
sasa(dp13325
g2
S'Such deficiencies are caused by primary congenital immunodeficiency of a complement protein, properdin or mannose binding lectin, or are secondary to consumption of complement by systemic lupus erythematosus (SLE) or membranoproliferative glomerulonephritis (MPGN).\n'
p13326
sg4
(lp13327
(dp13328
g7
I93
sg8
VP27918
p13329
sg10
I9
sg11
Vproperdin
p13330
sg13
I1
sa(dp13331
g7
I106
sg8
VP63244
p13332
sg10
I22
sg11
Vmannose binding lectin
p13333
sg13
I3
sa(dp13334
g7
I73
sg8
g64
sg10
I18
sg11
Vcomplement protein
p13335
sg13
I2
sasg23
(lp13336
(dp13337
g7
I259
sg26
VC0017662
p13338
sg10
I4
sg11
VMPGN
p13339
sg13
I1
sa(dp13340
g7
I40
sg26
VC0853602
p13341
sg10
I27
sg11
Vcongenital immunodeficiency
p13342
sg13
I2
sa(dp13343
g7
I179
sg26
VC0024141
p13344
sg10
I28
sg11
Vsystemic lupus erythematosus
p13345
sg13
I3
sa(dp13346
g7
I209
sg26
VC0024141
p13347
sg10
I3
sg11
VSLE
p13348
sg13
I1
sa(dp13349
g7
I217
sg26
VC0017662
p13350
sg10
I40
sg11
Vmembranoproliferative glomerulonephritis
p13351
sg13
I2
sasa(dp13352
g2
S'Our results identify RefGenes as a powerful tool for the identification of valid RGs and suggest GUSB as the most reliable RG for KCs.\n'
p13353
sg4
(lp13354
(dp13355
g7
I97
sg8
VP08236
p13356
sg10
I4
sg11
VGUSB
p13357
sg13
I1
sasg23
(lp13358
(dp13359
g7
I81
sg26
VC0265341
p13360
sg10
I3
sg11
VRGs
p13361
sg13
I1
sa(dp13362
g7
I130
sg26
VC0022575
p13363
sg10
I3
sg11
VKCs
p13364
sg13
I1
sasa(dp13365
g2
S'CDCA-3G (CDCA-3-glucuronide) and -24G, LCA-3G and -24G, and HDCA-6G and -24G were enzymatically formed by using microsomes from human liver, purified by liquid chromatography, digested with recombinant beta-glucuronidase, and quantified by liquid chromatography/electrospray ionization coupled to mass spectrometry (LC-ESI/MS).\n'
p13366
sg4
(lp13367
(dp13368
g7
I39
sg8
VP09496
p13369
sg10
I6
sg11
VLCA-3G
p13370
sg13
I1
sa(dp13371
g7
I190
sg8
VP08236
p13372
sg10
I30
sg11
Vrecombinant beta-glucuronidase
p13373
sg13
I2
sasg23
(lp13374
(dp13375
g7
I39
sg26
VC0339527
p13376
sg10
I3
sg11
VLCA
p13377
sg13
I1
sasa(dp13378
g2
S'Backgroud/Aims: Previous studies have shown that miR-501 is involved in the development of hepatocellular carcinoma (HCC) by promoting cell proliferation through CYLD.\n'
p13379
sg4
(lp13380
(dp13381
g7
I162
sg8
g64
sg10
I4
sg11
VCYLD
p13382
sg13
I1
sa(dp13383
g7
I49
sg8
g64
sg10
I7
sg11
VmiR-501
p13384
sg13
I1
sasg23
(lp13385
(dp13386
g7
I91
sg26
VC2239176
p13387
sg10
I24
sg11
Vhepatocellular carcinoma
p13388
sg13
I2
sa(dp13389
g7
I117
sg26
VC2239176
p13390
sg10
I3
sg11
VHCC
p13391
sg13
I1
sa(dp13392
g7
I140
sg26
VC0334094
p13393
sg10
I13
sg11
Vproliferation
p13394
sg13
I1
sasa(dp13395
g2
S'Previous studies have shown that the micro-ribonucleic acid miR-501-5p is upregulated in hepatocellular carcinoma cells and tissues with high hepatitis B virus replication, and that miR-501 overexpression significantly promotes hepatitis B virus replication.\n'
p13396
sg4
(lp13397
(dp13398
g7
I60
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13399
sg13
I1
sasg23
(lp13400
(dp13401
g7
I142
sg26
VC0019163
p13402
sg10
I11
sg11
Vhepatitis B
p13403
sg13
I2
sa(dp13404
g7
I89
sg26
VC1512411
p13405
sg10
I24
sg11
Vhepatocellular carcinoma
p13406
sg13
I2
sa(dp13407
g7
I142
sg26
VC0019163
p13408
sg10
I11
sg11
Vhepatitis B
p13409
sg13
I2
sasa(dp13410
g2
S'We further analysed a published microarray-based high-throughput dataset (NCBI/GEO/GSE36915) and found that miR-501-5p was upregulated in hepatocellular carcinoma tumour tissues.\n'
p13411
sg4
(lp13412
(dp13413
g7
I108
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13414
sg13
I1
sasg23
(lp13415
(dp13416
g7
I138
sg26
VC1512411
p13417
sg10
I24
sg11
Vhepatocellular carcinoma
p13418
sg13
I2
sa(dp13419
g7
I163
sg26
VC0027651
p13420
sg10
I6
sg11
Vtumour
p13421
sg13
I1
sasa(dp13422
g2
S'We therefore investigated the possible function of miR-501-5p during the development of hepatocellular carcinoma.\n'
p13423
sg4
(lp13424
(dp13425
g7
I51
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13426
sg13
I1
sasg23
(lp13427
(dp13428
g7
I88
sg26
VC1512411
p13429
sg10
I24
sg11
Vhepatocellular carcinoma
p13430
sg13
I2
sasa(dp13431
g2
S'Expression of miR-501-5p in human hepatocellular carcinoma specimens and cell lines was assessed, using real-time polymerase chain reaction.\n'
p13432
sg4
(lp13433
(dp13434
g7
I14
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13435
sg13
I1
sasg23
(lp13436
(dp13437
g7
I34
sg26
VC1512411
p13438
sg10
I24
sg11
Vhepatocellular carcinoma
p13439
sg13
I2
sasa(dp13440
g2
S"MiR-501-5p was upregulated in hepatocellular carcinoma specimens and cell lines, and directly targeted the 3' untranslated region of CYLD.\n"
p13441
sg4
(lp13442
(dp13443
g7
I0
sg8
g64
sg10
I10
sg11
VMiR-501-5p
p13444
sg13
I1
sa(dp13445
g7
I133
sg8
g64
sg10
I4
sg11
VCYLD
p13446
sg13
I1
sasg23
(lp13447
(dp13448
g7
I30
sg26
VC1512411
p13449
sg10
I24
sg11
Vhepatocellular carcinoma
p13450
sg13
I2
sasa(dp13451
g2
S'MiR-501-5p upregulation corresponded with a downregulation of CYLD in the same tissues and cell lines, and overexpression of MiR-501-5p decreased CYLD expression, increased expression of cyclin D1 and c-myc and promoted the proliferation of hepatocellular carcinoma cells in vitro.\n'
p13452
sg4
(lp13453
(dp13454
g7
I0
sg8
g64
sg10
I10
sg11
VMiR-501-5p
p13455
sg13
I1
sa(dp13456
g7
I187
sg8
VP24385
p13457
sg10
I9
sg11
Vcyclin D1
p13458
sg13
I2
sa(dp13459
g7
I0
sg8
g64
sg10
I10
sg11
VMiR-501-5p
p13460
sg13
I1
sa(dp13461
g7
I201
sg8
VP12524
p13462
sg10
I5
sg11
Vc-myc
p13463
sg13
I1
sa(dp13464
g7
I62
sg8
g64
sg10
I4
sg11
VCYLD
p13465
sg13
I1
sa(dp13466
g7
I62
sg8
g64
sg10
I4
sg11
VCYLD
p13467
sg13
I1
sasg23
(lp13468
(dp13469
g7
I241
sg26
VC1512411
p13470
sg10
I24
sg11
Vhepatocellular carcinoma
p13471
sg13
I2
sa(dp13472
g7
I224
sg26
VC0334094
p13473
sg10
I13
sg11
Vproliferation
p13474
sg13
I1
sasa(dp13475
g2
S'This study suggests that miR-501-5p may play an important role in the development of hepatocellular carcinoma by promoting cell proliferation, and indicates that miR-501-5p may represent a novel therapeutic target for hepatocellular carcinoma.\n'
p13476
sg4
(lp13477
(dp13478
g7
I25
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13479
sg13
I1
sa(dp13480
g7
I25
sg8
g64
sg10
I10
sg11
VmiR-501-5p
p13481
sg13
I1
sasg23
(lp13482
(dp13483
g7
I128
sg26
VC0334094
p13484
sg10
I13
sg11
Vproliferation
p13485
sg13
I1
sa(dp13486
g7
I85
sg26
VC1512411
p13487
sg10
I24
sg11
Vhepatocellular carcinoma
p13488
sg13
I2
sa(dp13489
g7
I85
sg26
VC1512411
p13490
sg10
I24
sg11
Vhepatocellular carcinoma
p13491
sg13
I2
sasa(dp13492
g2
S'miR-501 expression was significantly up-regulated in hepatocellular carcinoma tissues, where HBV replication kept high.\n'
p13493
sg4
(lp13494
sg23
(lp13495
(dp13496
g7
I93
sg26
VC0019163
p13497
sg10
I3
sg11
VHBV
p13498
sg13
I1
sa(dp13499
g7
I53
sg26
VC1512411
p13500
sg10
I24
sg11
Vhepatocellular carcinoma
p13501
sg13
I2
sasa(dp13502
g2
S'Screening of celiac disease by anti-tissue transglutaminase antibody should be completed as a routine investigation in patients with iron-deficiency anemia.\n'
p13503
sg4
(lp13504
(dp13505
g7
I31
sg8
VP21980
p13506
sg10
I37
sg11
Vanti-tissue transglutaminase antibody
p13507
sg13
I3
sasg23
(lp13508
(dp13509
g7
I133
sg26
VC0162316
p13510
sg10
I22
sg11
Viron-deficiency anemia
p13511
sg13
I2
sa(dp13512
g7
I13
sg26
VC0007570
p13513
sg10
I14
sg11
Vceliac disease
p13514
sg13
I2
sasa(dp13515
g2
S'Tissue transglutaminase antibodies were positive in 13 (8 %) patients with iron-deficiency anemia of obscure origin and 4 (2.5 %) in control group (p = 0.026) (odds ratio 3.42; 95 % confidence interval [CI]: 1.092-10.743).\n'
p13516
sg4
(lp13517
(dp13518
g7
I0
sg8
VP21980
p13519
sg10
I34
sg11
VTissue transglutaminase antibodies
p13520
sg13
I3
sasg23
(lp13521
(dp13522
g7
I75
sg26
VC0162316
p13523
sg10
I22
sg11
Viron-deficiency anemia
p13524
sg13
I2
sasa(dp13525
g2
S'Iron deficiency anemia and celiac disease were diagnosed on the basis of low serum ferritin, elevated serum level of IgA endomysial and tissue transglutaminase anti-bodies and histologic findings in small bowel biopsies.\n'
p13526
sg4
(lp13527
(dp13528
g7
I83
sg8
VP02794
p13529
sg10
I8
sg11
Vferritin
p13530
sg13
I1
sa(dp13531
g7
I117
sg8
VP11912
p13532
sg10
I3
sg11
VIgA
p13533
sg13
I1
sasg23
(lp13534
(dp13535
g7
I27
sg26
VC0007570
p13536
sg10
I14
sg11
Vceliac disease
p13537
sg13
I2
sa(dp13538
g7
I0
sg26
VC0162316
p13539
sg10
I22
sg11
VIron deficiency anemia
p13540
sg13
I3
sasa(dp13541
g2
S'These results suggest that in proliferating intestinal neoplasms, Bmi1- or Lgr5-positive cells represent a population of cancer stem cells, whereas Lgr5-positive cells also function as cells-of-origin for intestinal tumors.\n'
p13542
sg4
(lp13543
(dp13544
g7
I66
sg8
VP35226
p13545
sg10
I4
sg11
VBmi1
p13546
sg13
I1
sa(dp13547
g7
I75
sg8
g64
sg10
I5
sg11
VLgr5-
p13548
sg13
I1
sa(dp13549
g7
I75
sg8
g64
sg10
I4
sg11
VLgr5
p13550
sg13
I1
sasg23
(lp13551
(dp13552
g7
I121
sg26
VC0006826
p13553
sg10
I6
sg11
Vcancer
p13554
sg13
I1
sa(dp13555
g7
I44
sg26
VC0021841
p13556
sg10
I20
sg11
Vintestinal neoplasms
p13557
sg13
I2
sa(dp13558
g7
I205
sg26
VC0021841
p13559
sg10
I17
sg11
Vintestinal tumors
p13560
sg13
I2
sasa(dp13561
g2
S'After fluorescence activated cell sorting, real-time polymerase chain reaction (PCR) and western blot confirmed Bmi-1 was differentially expressed in CD133 sorted laryngeal tumor cells.\n'
p13562
sg4
(lp13563
(dp13564
g7
I112
sg8
VP35226
p13565
sg10
I5
sg11
VBmi-1
p13566
sg13
I1
sa(dp13567
g7
I150
sg8
g64
sg10
I5
sg11
VCD133
p13568
sg13
I1
sasg23
(lp13569
(dp13570
g7
I163
sg26
VC0023055
p13571
sg10
I15
sg11
Vlaryngeal tumor
p13572
sg13
I2
sasa(dp13573
g2
S'Our data indicate that Bmi-1 expression is central to the tumorigenicity of CD133(+) cells, which functions as a pleiotropic regulator that maintains the viability and proliferative capacity of human laryngeal tumor.\n'
p13574
sg4
(lp13575
(dp13576
g7
I23
sg8
VP35226
p13577
sg10
I5
sg11
VBmi-1
p13578
sg13
I1
sa(dp13579
g7
I76
sg8
g64
sg10
I5
sg11
VCD133
p13580
sg13
I1
sasg23
(lp13581
(dp13582
g7
I168
sg26
VC0334094
p13583
sg10
I13
sg11
Vproliferative
p13584
sg13
I1
sa(dp13585
g7
I58
sg26
VC1519697
p13586
sg10
I14
sg11
Vtumorigenicity
p13587
sg13
I1
sa(dp13588
g7
I200
sg26
VC0023055
p13589
sg10
I15
sg11
Vlaryngeal tumor
p13590
sg13
I2
sasa(dp13591
g2
S'Thus, we conclude that Bmi1 deficiency impairs the progression and maintenance of small intestinal tumors in a cell autonomous and highly Arf-dependent manner.\n'
p13592
sg4
(lp13593
(dp13594
g7
I23
sg8
VP35226
p13595
sg10
I4
sg11
VBmi1
p13596
sg13
I1
sa(dp13597
g7
I138
sg8
VP42771
p13598
sg10
I3
sg11
VArf
p13599
sg13
I1
sasg23
(lp13600
(dp13601
g7
I88
sg26
VC0021841
p13602
sg10
I17
sg11
Vintestinal tumors
p13603
sg13
I2
sa(dp13604
g7
I138
sg26
VC0264490
p13605
sg10
I3
sg11
VArf
p13606
sg13
I1
sasa(dp13607
g2
S'Here, we demonstrate that Id1 is strongly expressed in human and mouse liver tumors and in hepatocellular carcinoma (HCC) cell lines, whereas its expression is very low or undetectable in normal liver tissues.\n'
p13608
sg4
(lp13609
(dp13610
g7
I26
sg8
VP29372
p13611
sg10
I3
sg11
VId1
p13612
sg13
I1
sasg23
(lp13613
(dp13614
g7
I91
sg26
VC2239176
p13615
sg10
I24
sg11
Vhepatocellular carcinoma
p13616
sg13
I2
sa(dp13617
g7
I71
sg26
VC0023903
p13618
sg10
I12
sg11
Vliver tumors
p13619
sg13
I2
sa(dp13620
g7
I117
sg26
VC2239176
p13621
sg10
I3
sg11
VHCC
p13622
sg13
I1
sasa(dp13623
g2
S'Together, our findings indicate a prominent novel role for Id1 in liver cancer cell metabolic adaptation.\n'
p13624
sg4
(lp13625
(dp13626
g7
I59
sg8
VP29372
p13627
sg10
I3
sg11
VId1
p13628
sg13
I1
sasg23
(lp13629
(dp13630
g7
I66
sg26
VC0345904
p13631
sg10
I12
sg11
Vliver cancer
p13632
sg13
I2
sasa(dp13633
g2
S'In the liver cancer cell line HepG2, BMP9 triggers Smad1,5,8 phosphorylation and inhibitor of DNA binding 1 (Id1) expression up- regulation.\n'
p13634
sg4
(lp13635
(dp13636
g7
I109
sg8
VP29372
p13637
sg10
I3
sg11
VId1
p13638
sg13
I1
sa(dp13639
g7
I51
sg8
VP41250
p13640
sg10
I56
sg11
VSmad1,5,8 phosphorylation and inhibitor of DNA binding 1
p13641
sg13
I8
sa(dp13642
g7
I37
sg8
VP43026
p13643
sg10
I4
sg11
VBMP9
p13644
sg13
I1
sasg23
(lp13645
(dp13646
g7
I7
sg26
VC0345904
p13647
sg10
I12
sg11
Vliver cancer
p13648
sg13
I2
sasa(dp13649
g2
S'Cross-sectional study including all chronic hemodialysis patients with hepatitis C virus, in two public hemodialysis centers of Fez.\n'
p13650
sg4
(lp13651
sg23
(lp13652
(dp13653
g7
I71
sg26
VC0019196
p13654
sg10
I11
sg11
Vhepatitis C
p13655
sg13
I2
sasa(dp13656
g2
S'Consecutive patients with investigated ulcer or non-ulcer dyspepsia were prospectively enrolled in the Hassan II University Hospital of Fez.\n'
p13657
sg4
(lp13658
sg23
(lp13659
(dp13660
g7
I58
sg26
VC0013395
p13661
sg10
I9
sg11
Vdyspepsia
p13662
sg13
I1
sa(dp13663
g7
I39
sg26
VC0041582
p13664
sg10
I5
sg11
Vulcer
p13665
sg13
I1
sa(dp13666
g7
I39
sg26
VC0041582
p13667
sg10
I5
sg11
Vulcer
p13668
sg13
I1
sasa(dp13669
g2
S'Pendrin/NCC double KO (pendrin/NCC-dKO) mice display severe salt wasting under basal conditions and develop profound volume depletion, prerenal renal failure, and metabolic alkalosis and are growth retarded.\n'
p13670
sg4
(lp13671
(dp13672
g7
I23
sg8
g64
sg10
I7
sg11
Vpendrin
p13673
sg13
I1
sa(dp13674
g7
I0
sg8
g64
sg10
I7
sg11
VPendrin
p13675
sg13
I1
sasg23
(lp13676
(dp13677
g7
I65
sg26
VC0235394
p13678
sg10
I7
sg11
Vwasting
p13679
sg13
I1
sa(dp13680
g7
I191
sg26
VC0151686
p13681
sg10
I15
sg11
Vgrowth retarded
p13682
sg13
I2
sa(dp13683
g7
I144
sg26
VC0035078
p13684
sg10
I13
sg11
Vrenal failure
p13685
sg13
I2
sa(dp13686
g7
I163
sg26
VC0220983
p13687
sg10
I19
sg11
Vmetabolic alkalosis
p13688
sg13
I2
sasa(dp13689
g2
S"Further experiments used mice with blunted ENaC endocytosis and degradation (Liddle's syndrome) to explore the significance of pendrin-dependent changes in ENaC open probability.\n"
p13690
sg4
(lp13691
(dp13692
g7
I127
sg8
g64
sg10
I7
sg11
Vpendrin
p13693
sg13
I1
sa(dp13694
g7
I43
sg8
VP37088
p13695
sg10
I4
sg11
VENaC
p13696
sg13
I1
sasg23
(lp13697
(dp13698
g7
I77
sg26
VC0221043
p13699
sg10
I17
sg11
VLiddle's syndrome
p13700
sg13
I2
sasa(dp13701
g2
S"In mouse models of Liddle's syndrome, pendrin gene ablation did not change ENaC subunit total protein abundance, subcellular distribution, or channel density, but markedly reduced channel open probability.\n"
p13702
sg4
(lp13703
(dp13704
g7
I38
sg8
g64
sg10
I12
sg11
Vpendrin gene
p13705
sg13
I2
sasg23
(lp13706
(dp13707
g7
I19
sg26
VC0221043
p13708
sg10
I17
sg11
VLiddle's syndrome
p13709
sg13
I2
sasa(dp13710
g2
S"In a mouse model of Liddle's syndrome, however, pendrin gene ablation reduces channel activity mainly through changes in open probability.\n"
p13711
sg4
(lp13712
(dp13713
g7
I48
sg8
g64
sg10
I12
sg11
Vpendrin gene
p13714
sg13
I2
sasg23
(lp13715
(dp13716
g7
I20
sg26
VC0221043
p13717
sg10
I17
sg11
VLiddle's syndrome
p13718
sg13
I2
sasa(dp13719
g2
S'We propose that the combined inhibition of pendrin and NCC can provide a strong diuretic regimen without causing hypokalemia for patients with fluid overload, including patients with congestive heart failure, nephrotic syndrome, diuretic resistance, or generalized edema.\n'
p13720
sg4
(lp13721
(dp13722
g7
I43
sg8
g64
sg10
I7
sg11
Vpendrin
p13723
sg13
I1
sasg23
(lp13724
(dp13725
g7
I209
sg26
VC0027726
p13726
sg10
I18
sg11
Vnephrotic syndrome
p13727
sg13
I2
sa(dp13728
g7
I253
sg26
VC0151603
p13729
sg10
I17
sg11
Vgeneralized edema
p13730
sg13
I2
sa(dp13731
g7
I183
sg26
VC0018802
p13732
sg10
I24
sg11
Vcongestive heart failure
p13733
sg13
I3
sa(dp13734
g7
I143
sg26
VC0546817
p13735
sg10
I14
sg11
Vfluid overload
p13736
sg13
I2
sasa(dp13737
g2
S'We propose that pharmacologic inhibition of pendrin and NCC can provide a novel and strong diuretic regimen for patients with fluid overload, including those with congestive heart failure, nephrotic syndrome or renal failure.\n'
p13738
sg4
(lp13739
(dp13740
g7
I44
sg8
g64
sg10
I7
sg11
Vpendrin
p13741
sg13
I1
sasg23
(lp13742
(dp13743
g7
I189
sg26
VC0027726
p13744
sg10
I18
sg11
Vnephrotic syndrome
p13745
sg13
I2
sa(dp13746
g7
I211
sg26
VC0035078
p13747
sg10
I13
sg11
Vrenal failure
p13748
sg13
I2
sa(dp13749
g7
I126
sg26
VC0546817
p13750
sg10
I14
sg11
Vfluid overload
p13751
sg13
I2
sa(dp13752
g7
I163
sg26
VC0018802
p13753
sg10
I24
sg11
Vcongestive heart failure
p13754
sg13
I3
sasa(dp13755
g2
S'Furthermore, experimental validation was carried out with MIP-1Beta-induced U937 cell model and collagen induced arthritis (CIA) rat model.\n'
p13756
sg4
(lp13757
(dp13758
g7
I58
sg8
g64
sg10
I9
sg11
VMIP-1Beta
p13759
sg13
I1
sasg23
(lp13760
(dp13761
g7
I113
sg26
VC0003864
p13762
sg10
I9
sg11
Varthritis
p13763
sg13
I1
sa(dp13764
g7
I58
sg26
VC1851100
p13765
sg10
I3
sg11
VMIP
p13766
sg13
I1
sasa(dp13767
g2
S"ROMK knockout mice (KO) show a similar phenotype to Bartter's syndrome of salt wasting and dehydration due to reduced Na-2Cl-K-cotransporter activity but not in ROMK1 KO.\n"
p13768
sg4
(lp13769
(dp13770
g7
I118
sg8
g64
sg10
I22
sg11
VNa-2Cl-K-cotransporter
p13771
sg13
I1
sa(dp13772
g7
I161
sg8
VP48048
p13773
sg10
I8
sg11
VROMK1 KO
p13774
sg13
I2
sa(dp13775
g7
I0
sg8
VP48048
p13776
sg10
I4
sg11
VROMK
p13777
sg13
I1
sasg23
(lp13778
(dp13779
g7
I91
sg26
VC0011175
p13780
sg10
I11
sg11
Vdehydration
p13781
sg13
I1
sa(dp13782
g7
I52
sg26
VC0004775
p13783
sg10
I18
sg11
VBartter's syndrome
p13784
sg13
I2
sa(dp13785
g7
I79
sg26
VC0235394
p13786
sg10
I7
sg11
Vwasting
p13787
sg13
I1
sasa(dp13788
g2
S'Mutations in the ROMK1 potassium channel gene (KCNJ1) cause antenatal/neonatal Bartter syndrome type II (aBS II), a renal disorder that begins in utero, accounting for the polyhydramnios and premature delivery that is typical in affected infants, who develop massive renal salt wasting, hypokalaemic metabolic alkalosis, secondary hyperreninaemic hyperaldosteronism, hypercalciuria and nephrocalcinosis.\n'
p13789
sg4
(lp13790
(dp13791
g7
I47
sg8
VP48048
p13792
sg10
I5
sg11
VKCNJ1
p13793
sg13
I1
sa(dp13794
g7
I17
sg8
VP48048
p13795
sg10
I28
sg11
VROMK1 potassium channel gene
p13796
sg13
I4
sasg23
(lp13797
(dp13798
g7
I116
sg26
VC0022658
p13799
sg10
I14
sg11
Vrenal disorder
p13800
sg13
I2
sa(dp13801
g7
I172
sg26
VC0020224
p13802
sg10
I14
sg11
Vpolyhydramnios
p13803
sg13
I1
sa(dp13804
g7
I347
sg26
VC0020428
p13805
sg10
I18
sg11
Vhyperaldosteronism
p13806
sg13
I1
sa(dp13807
g7
I278
sg26
VC0235394
p13808
sg10
I7
sg11
Vwasting
p13809
sg13
I1
sa(dp13810
g7
I300
sg26
VC0220983
p13811
sg10
I19
sg11
Vmetabolic alkalosis
p13812
sg13
I2
sa(dp13813
g7
I79
sg26
VC0004775
p13814
sg10
I16
sg11
VBartter syndrome
p13815
sg13
I2
sa(dp13816
g7
I191
sg26
VC0151526
p13817
sg10
I18
sg11
Vpremature delivery
p13818
sg13
I2
sa(dp13819
g7
I367
sg26
VC0020438
p13820
sg10
I14
sg11
Vhypercalciuria
p13821
sg13
I1
sa(dp13822
g7
I386
sg26
VC0027709
p13823
sg10
I16
sg11
Vnephrocalcinosis
p13824
sg13
I1
sasa(dp13825
g2
S'Type II Bartter syndrome is caused by mutations in the renal outer medullary potassium (ROMK) channel, but the molecular mechanisms underlying this disease are poorly defined.\n'
p13826
sg4
(lp13827
(dp13828
g7
I88
sg8
VP48048
p13829
sg10
I4
sg11
VROMK
p13830
sg13
I1
sasg23
(lp13831
(dp13832
g7
I8
sg26
VC0004775
p13833
sg10
I16
sg11
VBartter syndrome
p13834
sg13
I2
sasa(dp13835
g2
S'These findings indicate that the underlying pathology for at least a subset of patients with type II Bartter syndrome is linked to the ERAD pathway and that future therapeutic strategies should focus on correcting deficiencies in ROMK folding.\n'
p13836
sg4
(lp13837
(dp13838
g7
I230
sg8
VP48048
p13839
sg10
I4
sg11
VROMK
p13840
sg13
I1
sasg23
(lp13841
(dp13842
g7
I44
sg26
VC0677042
p13843
sg10
I9
sg11
Vpathology
p13844
sg13
I1
sa(dp13845
g7
I101
sg26
VC0004775
p13846
sg10
I16
sg11
VBartter syndrome
p13847
sg13
I2
sasa(dp13848
g2
S"This idea is supported by the phenotype of antenatal Bartter's syndrome type II associated with loss-of-function mutations in the human ROMK channel, as well as, by cardiovascular studies of heterozygous carriers of channel mutations associated with type II Bartter's syndrome.\n"
p13849
sg4
(lp13850
sg23
(lp13851
(dp13852
g7
I53
sg26
VC0004775
p13853
sg10
I18
sg11
VBartter's syndrome
p13854
sg13
I2
sa(dp13855
g7
I53
sg26
VC0004775
p13856
sg10
I18
sg11
VBartter's syndrome
p13857
sg13
I2
sasa(dp13858
g2
S"In addition, Bartter's syndrome type II features are manifested on exposure to ROMK inhibitors.\n"
p13859
sg4
(lp13860
(dp13861
g7
I79
sg8
VP48048
p13862
sg10
I4
sg11
VROMK
p13863
sg13
I1
sasg23
(lp13864
(dp13865
g7
I13
sg26
VC0004775
p13866
sg10
I18
sg11
VBartter's syndrome
p13867
sg13
I2
sasa(dp13868
g2
S'Romk knock-out mice show a similar phenotype to Bartter syndrome of salt wasting and dehydration due to reduced Na-K-2Cl-cotransporter activity.\n'
p13869
sg4
(lp13870
(dp13871
g7
I112
sg8
g64
sg10
I22
sg11
VNa-K-2Cl-cotransporter
p13872
sg13
I1
sasg23
(lp13873
(dp13874
g7
I48
sg26
VC0004775
p13875
sg10
I16
sg11
VBartter syndrome
p13876
sg13
I2
sa(dp13877
g7
I85
sg26
VC0011175
p13878
sg10
I11
sg11
Vdehydration
p13879
sg13
I1
sa(dp13880
g7
I73
sg26
VC0235394
p13881
sg10
I7
sg11
Vwasting
p13882
sg13
I1
sasa(dp13883
g2
S'KCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.\n'
p13884
sg4
(lp13885
(dp13886
g7
I0
sg8
VP48048
p13887
sg10
I5
sg11
VKCNJ1
p13888
sg13
I1
sasg23
(lp13889
(dp13890
g7
I72
sg26
VC0004775
p13891
sg10
I16
sg11
VBartter syndrome
p13892
sg13
I2
sa(dp13893
g7
I93
sg26
VC0011849
p13894
sg10
I8
sg11
Vdiabetes
p13895
sg13
I1
sasa(dp13896
g2
S'The identification of human mutations suggests that MPDZ plays a role in human retinal disease, but the precise nature of this role remains to be determined.\n'
p13897
sg4
(lp13898
(dp13899
g7
I52
sg8
g64
sg10
I4
sg11
VMPDZ
p13900
sg13
I1
sasg23
(lp13901
(dp13902
g7
I79
sg26
VC0035309
p13903
sg10
I15
sg11
Vretinal disease
p13904
sg13
I2
sasa(dp13905
g2
S'We aimed to investigate the biological role of miR-367 in uveal melanoma cell growth and migration, and the underlying mechanism responsible.\n'
p13906
sg4
(lp13907
(dp13908
g7
I47
sg8
g64
sg10
I7
sg11
VmiR-367
p13909
sg13
I1
sasg23
(lp13910
(dp13911
g7
I58
sg26
VC0220633
p13912
sg10
I14
sg11
Vuveal melanoma
p13913
sg13
I2
sasa(dp13914
g2
S'Quantitative real-time polymerase chain reaction was performed to evaluate miR-367 expression in uveal melanoma tissue samples and cell lines.\n'
p13915
sg4
(lp13916
sg23
(lp13917
(dp13918
g7
I97
sg26
VC0220633
p13919
sg10
I14
sg11
Vuveal melanoma
p13920
sg13
I2
sasa(dp13921
g2
S'In addition, the role of PTEN in miR-367-mediated uveal melanoma cell growth and migration was evaluated.\n'
p13922
sg4
(lp13923
(dp13924
g7
I33
sg8
g64
sg10
I7
sg11
VmiR-367
p13925
sg13
I1
sa(dp13926
g7
I25
sg8
VP60484
p13927
sg10
I4
sg11
VPTEN
p13928
sg13
I1
sasg23
(lp13929
(dp13930
g7
I50
sg26
VC0220633
p13931
sg10
I14
sg11
Vuveal melanoma
p13932
sg13
I2
sasa(dp13933
g2
S'miR-367 was significantly upregulated in uveal melanoma cells and tissue samples (both P &lt; 0.01).\n'
p13934
sg4
(lp13935
sg23
(lp13936
(dp13937
g7
I41
sg26
VC0220633
p13938
sg10
I14
sg11
Vuveal melanoma
p13939
sg13
I2
sasa(dp13940
g2
S"More importantly, co-transfection with a PTEN construct lacking the 3'-untranslated region mitigated miR-367 mimic-induced promotion of uveal melanoma cell proliferation and migration.\n"
p13941
sg4
(lp13942
(dp13943
g7
I41
sg8
VP60484
p13944
sg10
I4
sg11
VPTEN
p13945
sg13
I1
sasg23
(lp13946
(dp13947
g7
I136
sg26
VC0220633
p13948
sg10
I14
sg11
Vuveal melanoma
p13949
sg13
I2
sa(dp13950
g7
I156
sg26
VC0334094
p13951
sg10
I13
sg11
Vproliferation
p13952
sg13
I1
sasa(dp13953
g2
S'In summary, miR-367 was found to be upregulated in this malignancy, and may promote uveal melanoma cell proliferation and migration, at least in part by regulating PTEN.\n'
p13954
sg4
(lp13955
(dp13956
g7
I164
sg8
VP60484
p13957
sg10
I4
sg11
VPTEN
p13958
sg13
I1
sasg23
(lp13959
(dp13960
g7
I56
sg26
VC0006826
p13961
sg10
I10
sg11
Vmalignancy
p13962
sg13
I1
sa(dp13963
g7
I84
sg26
VC0220633
p13964
sg10
I14
sg11
Vuveal melanoma
p13965
sg13
I2
sa(dp13966
g7
I104
sg26
VC0334094
p13967
sg10
I13
sg11
Vproliferation
p13968
sg13
I1
sasa(dp13969
g2
S'We further constructed an immunocompetent mouse model of acute hepatitis B viral infection to demonstrate that LSECtin significantly delayed the clearance of hepatitis B virus from blood and infected hepatocytes by limiting the frequency of hepatitis B virus-specific IFN-Gamma-producing cells.\n'
p13970
sg4
(lp13971
(dp13972
g7
I268
sg8
VP01579
p13973
sg10
I9
sg11
VIFN-Gamma
p13974
sg13
I1
sa(dp13975
g7
I111
sg8
g64
sg10
I7
sg11
VLSECtin
p13976
sg13
I1
sasg23
(lp13977
(dp13978
g7
I63
sg26
VC0019163
p13979
sg10
I11
sg11
Vhepatitis B
p13980
sg13
I2
sa(dp13981
g7
I63
sg26
VC0019163
p13982
sg10
I11
sg11
Vhepatitis B
p13983
sg13
I2
sa(dp13984
g7
I81
sg26
VC0009450
p13985
sg10
I9
sg11
Vinfection
p13986
sg13
I1
sa(dp13987
g7
I63
sg26
VC0019163
p13988
sg10
I17
sg11
Vhepatitis B viral
p13989
sg13
I3
sasa(dp13990
g2
S'Consistent with this function, LSECtin was upregulated in the liver of mouse models of viral hepatitis.\n'
p13991
sg4
(lp13992
(dp13993
g7
I31
sg8
g64
sg10
I7
sg11
VLSECtin
p13994
sg13
I1
sasg23
(lp13995
(dp13996
g7
I87
sg26
VC0042721
p13997
sg10
I15
sg11
Vviral hepatitis
p13998
sg13
I2
sasa(dp13999
g2
S'Metabolomic analysis revealed that alpha-naphthyl isothiocyanate (ANIT)-induced intrahepatic cholestasis resulted in the accumulation of serum long-chain acylcarnitines and triglyceride, and the reduced expression of four fatty acid Beta-oxidation (Beta-FAO) relevant genes (Cpt1b, Cpt2, Mcad and Hadha), indicating the disruption of Beta-FAO.\n'
p14000
sg4
(lp14001
(dp14002
g7
I275
sg8
g64
sg10
I5
sg11
VCpt1b
p14003
sg13
I1
sa(dp14004
g7
I282
sg8
VP23786
p14005
sg10
I4
sg11
VCpt2
p14006
sg13
I1
sa(dp14007
g7
I297
sg8
VP40939
p14008
sg10
I5
sg11
VHadha
p14009
sg13
I1
sa(dp14010
g7
I137
sg8
g64
sg10
I16
sg11
Vserum long-chain
p14011
sg13
I2
sa(dp14012
g7
I288
sg8
VP11310
p14013
sg10
I4
sg11
VMcad
p14014
sg13
I1
sasg23
(lp14015
(dp14016
g7
I288
sg26
VC0220710
p14017
sg10
I4
sg11
VMcad
p14018
sg13
I1
sa(dp14019
g7
I80
sg26
VC0008372
p14020
sg10
I24
sg11
Vintrahepatic cholestasis
p14021
sg13
I2
sasa(dp14022
g2
S'Furthermore, re-addition of IgA or IgM to the Igs-depleted corona reinstated the low adhesion of PLGA VTCs, as evidenced by ~40-70% reduction relative to particles with an Igs-deficient corona.\n'
p14023
sg4
(lp14024
(dp14025
g7
I35
sg8
VP29965
p14026
sg10
I3
sg11
VIgM
p14027
sg13
I1
sa(dp14028
g7
I46
sg8
g64
sg10
I3
sg11
VIgs
p14029
sg13
I1
sa(dp14030
g7
I46
sg8
g64
sg10
I3
sg11
VIgs
p14031
sg13
I1
sa(dp14032
g7
I28
sg8
VP11912
p14033
sg10
I3
sg11
VIgA
p14034
sg13
I1
sasg23
(lp14035
(dp14036
g7
I85
sg26
VC0001511
p14037
sg10
I8
sg11
Vadhesion
p14038
sg13
I1
sa(dp14039
g7
I46
sg26
VC1306856
p14040
sg10
I3
sg11
VIgs
p14041
sg13
I1
sa(dp14042
g7
I46
sg26
VC1306856
p14043
sg10
I3
sg11
VIgs
p14044
sg13
I1
sasa(dp14045
g2
S'Specific antibody deficiency (SAD) is a primary immunodeficiency disease characterized by normal immunoglobulins (Igs), IgA, IgM, total IgG, and IgG subclass levels, but with recurrent infection and diminished antibody responses to polysaccharide antigens following vaccination.\n'
p14046
sg4
(lp14047
(dp14048
g7
I125
sg8
VP29965
p14049
sg10
I3
sg11
VIgM
p14050
sg13
I1
sa(dp14051
g7
I120
sg8
VP11912
p14052
sg10
I3
sg11
VIgA
p14053
sg13
I1
sa(dp14054
g7
I114
sg8
g64
sg10
I3
sg11
VIgs
p14055
sg13
I1
sa(dp14056
g7
I97
sg8
g64
sg10
I15
sg11
Vimmunoglobulins
p14057
sg13
I1
sasg23
(lp14058
(dp14059
g7
I0
sg26
VC0398711
p14060
sg10
I28
sg11
VSpecific antibody deficiency
p14061
sg13
I3
sa(dp14062
g7
I30
sg26
VC0085159
p14063
sg10
I3
sg11
VSAD
p14064
sg13
I1
sa(dp14065
g7
I185
sg26
VC0009450
p14066
sg10
I9
sg11
Vinfection
p14067
sg13
I1
sa(dp14068
g7
I48
sg26
VC0021051
p14069
sg10
I24
sg11
Vimmunodeficiency disease
p14070
sg13
I2
sa(dp14071
g7
I97
sg26
VC1306856
p14072
sg10
I15
sg11
Vimmunoglobulins
p14073
sg13
I1
sa(dp14074
g7
I114
sg26
VC1306856
p14075
sg10
I3
sg11
VIgs
p14076
sg13
I1
sasa(dp14077
g2
S'GCB IgM and IgT have the prototypical structure when compared to other fish Igs.\n'
p14078
sg4
(lp14079
(dp14080
g7
I71
sg8
g64
sg10
I8
sg11
Vfish Igs
p14081
sg13
I2
sa(dp14082
g7
I0
sg8
VP04062
p14083
sg10
I7
sg11
VGCB IgM
p14084
sg13
I2
sasg23
(lp14085
(dp14086
g7
I76
sg26
VC1306856
p14087
sg10
I3
sg11
VIgs
p14088
sg13
I1
sasa(dp14089
g2
S'Another major factor in SPRY3 repression is late replication; the inactive X and Y alleles of SPRY3 have delayed replication relative to the active X allele, even in ICF syndrome cells where the closely linked SYBL1 gene is reactivated and advanced in replication.\n'
p14090
sg4
(lp14091
(dp14092
g7
I24
sg8
g64
sg10
I5
sg11
VSPRY3
p14093
sg13
I1
sa(dp14094
g7
I24
sg8
g64
sg10
I5
sg11
VSPRY3
p14095
sg13
I1
sa(dp14096
g7
I210
sg8
VP51809
p14097
sg10
I10
sg11
VSYBL1 gene
p14098
sg13
I2
sasg23
(lp14099
(dp14100
g7
I170
sg26
VC0039082
p14101
sg10
I8
sg11
Vsyndrome
p14102
sg13
I1
sasa(dp14103
g2
S'In ICF syndrome, a human disease affecting DNA methylation, SYBL1 escapes from silencing and this correlates with altered patterns of histone methylation and acetylation.\n'
p14104
sg4
(lp14105
(dp14106
g7
I134
sg8
VP62805
p14107
sg10
I7
sg11
Vhistone
p14108
sg13
I1
sa(dp14109
g7
I60
sg8
VP51809
p14110
sg10
I5
sg11
VSYBL1
p14111
sg13
I1
sasg23
(lp14112
(dp14113
g7
I7
sg26
VC0039082
p14114
sg10
I8
sg11
Vsyndrome
p14115
sg13
I1
sasa(dp14116
g2
S'Pseudoachondroplasia (PSACH) is an autosomal dominant osteochondrodysplasia caused by mutations in the gene encoding cartilage oligomeric matrix protein (COMP).\n'
p14117
sg4
(lp14118
(dp14119
g7
I154
sg8
VP49747
p14120
sg10
I4
sg11
VCOMP
p14121
sg13
I1
sa(dp14122
g7
I103
sg8
VP49747
p14123
sg10
I49
sg11
Vgene encoding cartilage oligomeric matrix protein
p14124
sg13
I6
sasg23
(lp14125
(dp14126
g7
I54
sg26
VC0026707
p14127
sg10
I21
sg11
Vosteochondrodysplasia
p14128
sg13
I1
sa(dp14129
g7
I0
sg26
VC0410538
p14130
sg10
I20
sg11
VPseudoachondroplasia
p14131
sg13
I1
sa(dp14132
g7
I22
sg26
VC0410538
p14133
sg10
I5
sg11
VPSACH
p14134
sg13
I1
sasa(dp14135
g2
S'GAC repeat expansion from five to seven in the exonic region of the gene for cartilage oligomeric matrix protein (COMP) leads to pseudoachondroplasia, a skeletal abnormality.\n'
p14136
sg4
(lp14137
(dp14138
g7
I77
sg8
VP49747
p14139
sg10
I35
sg11
Vcartilage oligomeric matrix protein
p14140
sg13
I4
sa(dp14141
g7
I114
sg8
VP49747
p14142
sg10
I4
sg11
VCOMP
p14143
sg13
I1
sasg23
(lp14144
(dp14145
g7
I129
sg26
VC0410538
p14146
sg10
I20
sg11
Vpseudoachondroplasia
p14147
sg13
I1
sasa(dp14148
g2
S'The phenotypic spectrum associated with heterozygous mutations in cartilage oligomeric matrix protein gene (COMP) range from a mild form of multiple epiphyseal dysplasia (MED) to pseudoachondroplasia (PSACH).\n'
p14149
sg4
(lp14150
(dp14151
g7
I108
sg8
VP49747
p14152
sg10
I4
sg11
VCOMP
p14153
sg13
I1
sa(dp14154
g7
I53
sg8
VP49747
p14155
sg10
I53
sg11
Vmutations in cartilage oligomeric matrix protein gene
p14156
sg13
I7
sasg23
(lp14157
(dp14158
g7
I140
sg26
VC0026760
p14159
sg10
I29
sg11
Vmultiple epiphyseal dysplasia
p14160
sg13
I3
sa(dp14161
g7
I171
sg26
VC0026760
p14162
sg10
I3
sg11
VMED
p14163
sg13
I1
sa(dp14164
g7
I201
sg26
VC0410538
p14165
sg10
I5
sg11
VPSACH
p14166
sg13
I1
sa(dp14167
g7
I179
sg26
VC0410538
p14168
sg10
I20
sg11
Vpseudoachondroplasia
p14169
sg13
I1
sasa(dp14170
g2
S'Pseudoachondroplasia (PSACH), a severe short-limbed dwarfing condition, is associated with life-long joint pain and early onset osteoarthritis.\n'
p14171
sg4
(lp14172
sg23
(lp14173
(dp14174
g7
I128
sg26
VC0029408
p14175
sg10
I14
sg11
Vosteoarthritis
p14176
sg13
I1
sa(dp14177
g7
I0
sg26
VC0410538
p14178
sg10
I20
sg11
VPseudoachondroplasia
p14179
sg13
I1
sa(dp14180
g7
I61
sg26
VC0012634
p14181
sg10
I9
sg11
Vcondition
p14182
sg13
I1
sa(dp14183
g7
I101
sg26
VC0003862
p14184
sg10
I10
sg11
Vjoint pain
p14185
sg13
I2
sa(dp14186
g7
I22
sg26
VC0410538
p14187
sg10
I5
sg11
VPSACH
p14188
sg13
I1
sasa(dp14189
g2
S'Mutations in cartilage oligomeric matrix protein cause pseudoachondroplasia, a severe disproportionate short stature disorder.\n'
p14190
sg4
(lp14191
sg23
(lp14192
(dp14193
g7
I55
sg26
VC0410538
p14194
sg10
I20
sg11
Vpseudoachondroplasia
p14195
sg13
I1
sa(dp14196
g7
I103
sg26
VC0013336
p14197
sg10
I22
sg11
Vshort stature disorder
p14198
sg13
I3
sasa(dp14199
g2
S'We demonstrate delivery of human cartilage oligomeric matrix protein-specific antisense oligonucleotides to cartilage and reduction of cartilage oligomeric matrix protein expression, which largely alleviates pseudoachondroplasia growth plate chondrocyte pathology.\n'
p14200
sg4
(lp14201
sg23
(lp14202
(dp14203
g7
I208
sg26
VC0410538
p14204
sg10
I20
sg11
Vpseudoachondroplasia
p14205
sg13
I1
sa(dp14206
g7
I254
sg26
VC0677042
p14207
sg10
I9
sg11
Vpathology
p14208
sg13
I1
sasa(dp14209
g2
S'We report the case of a 40-year-old woman with pseudoachondroplasia (PSACH), with a heterozygous mutation (c.806A &gt; G, p.Asp269Gly) located in the Type 3 repeats domain of the cartilage oligomeric matrix protein gene, who complained of the unusual symptom of painful locking of the wrist.\n'
p14210
sg4
(lp14211
sg23
(lp14212
(dp14213
g7
I47
sg26
VC0410538
p14214
sg10
I20
sg11
Vpseudoachondroplasia
p14215
sg13
I1
sa(dp14216
g7
I69
sg26
VC0410538
p14217
sg10
I5
sg11
VPSACH
p14218
sg13
I1
sa(dp14219
g7
I262
sg26
VC0030193
p14220
sg10
I7
sg11
Vpainful
p14221
sg13
I1
sa(dp14222
g7
I251
sg26
VC1457887
p14223
sg10
I7
sg11
Vsymptom
p14224
sg13
I1
sasa(dp14225
g2
S'Pseudoachondroplasia (PSACH; MIM no.\n'
p14226
sg4
(lp14227
(dp14228
g7
I0
sg8
VP49747
p14229
sg10
I20
sg11
VPseudoachondroplasia
p14230
sg13
I1
sa(dp14231
g7
I29
sg8
g64
sg10
I3
sg11
VMIM
p14232
sg13
I1
sa(dp14233
g7
I22
sg8
VP49747
p14234
sg10
I5
sg11
VPSACH
p14235
sg13
I1
sasg23
(lp14236
(dp14237
g7
I0
sg26
VC0410538
p14238
sg10
I20
sg11
VPseudoachondroplasia
p14239
sg13
I1
sa(dp14240
g7
I22
sg26
VC0410538
p14241
sg10
I5
sg11
VPSACH
p14242
sg13
I1
sasa(dp14243
g2
S'Pseudoachondroplasia (PSACH) is a rare and severe genetic disease; therefore, an accurate molecular diagnosis is essential for appropriate disease treatment and family planning.\n'
p14244
sg4
(lp14245
sg23
(lp14246
(dp14247
g7
I50
sg26
VC0019247
p14248
sg10
I15
sg11
Vgenetic disease
p14249
sg13
I2
sa(dp14250
g7
I0
sg26
VC0410538
p14251
sg10
I20
sg11
VPseudoachondroplasia
p14252
sg13
I1
sa(dp14253
g7
I22
sg26
VC0410538
p14254
sg10
I5
sg11
VPSACH
p14255
sg13
I1
sasa(dp14256
g2
S'To uncover the genetic associations with Ebstein anomaly, we have searched chromosomal imbalances using standard cytogenetic and array-CGH analysis, and single gene conditions associated with syndromic Ebstein anomaly (with extracardiac anomalies), and screened GATA4 and NKX2.5 mutations in nonsyndromic patients (without extracardiac anomalies).\n'
p14257
sg4
(lp14258
(dp14259
g7
I262
sg8
VP43694
p14260
sg10
I5
sg11
VGATA4
p14261
sg13
I1
sa(dp14262
g7
I272
sg8
VP52952
p14263
sg10
I16
sg11
VNKX2.5 mutations
p14264
sg13
I2
sasg23
(lp14265
(dp14266
g7
I135
sg26
VC1855900
p14267
sg10
I3
sg11
VCGH
p14268
sg13
I1
sa(dp14269
g7
I41
sg26
VC0013481
p14270
sg10
I15
sg11
VEbstein anomaly
p14271
sg13
I2
sa(dp14272
g7
I41
sg26
VC0013481
p14273
sg10
I15
sg11
VEbstein anomaly
p14274
sg13
I2
sasa(dp14275
g2
S'Candidate genes include the GATA4 gene (in patients with del 8p23.1), NKX2.5 (based on published patients with isolated Ebstein anomaly) and a hypothetical gene in patients with del 1p36).\n'
p14276
sg4
(lp14277
(dp14278
g7
I70
sg8
VP52952
p14279
sg10
I6
sg11
VNKX2.5
p14280
sg13
I1
sa(dp14281
g7
I28
sg8
VP43694
p14282
sg10
I10
sg11
VGATA4 gene
p14283
sg13
I2
sasg23
(lp14284
(dp14285
g7
I120
sg26
VC0013481
p14286
sg10
I15
sg11
VEbstein anomaly
p14287
sg13
I2
sasa(dp14288
g2
S"In this study, we evaluated the presence and frequency of mutations in the NKX2.5 gene on 159 unrelated patients with a diverse range of non-syndromic congenital heart defects (conotruncal anomalies, septal defects, left-sided lesions, right-sided lesions, patent ductus arteriosus and Ebstein's anomaly).\n"
p14289
sg4
(lp14290
(dp14291
g7
I75
sg8
VP52952
p14292
sg10
I11
sg11
VNKX2.5 gene
p14293
sg13
I2
sasg23
(lp14294
(dp14295
g7
I286
sg26
VC0013481
p14296
sg10
I17
sg11
VEbstein's anomaly
p14297
sg13
I2
sa(dp14298
g7
I200
sg26
VC0018816
p14299
sg10
I14
sg11
Vseptal defects
p14300
sg13
I2
sa(dp14301
g7
I151
sg26
VC0018798
p14302
sg10
I24
sg11
Vcongenital heart defects
p14303
sg13
I3
sa(dp14304
g7
I257
sg26
VC0013274
p14305
sg10
I24
sg11
Vpatent ductus arteriosus
p14306
sg13
I3
sasa(dp14307
g2
S'The current data suggest that haploinsufficiency of NKX2-5 cause Ebstein anomaly and support previous results showing that NKX2-5 mutations cause ASD and AV conduction defect.\n'
p14308
sg4
(lp14309
(dp14310
g7
I123
sg8
VP52952
p14311
sg10
I16
sg11
VNKX2-5 mutations
p14312
sg13
I2
sa(dp14313
g7
I52
sg8
VP52952
p14314
sg10
I6
sg11
VNKX2-5
p14315
sg13
I1
sasg23
(lp14316
(dp14317
g7
I65
sg26
VC0013481
p14318
sg10
I15
sg11
VEbstein anomaly
p14319
sg13
I2
sa(dp14320
g7
I157
sg26
VC0264886
p14321
sg10
I17
sg11
Vconduction defect
p14322
sg13
I2
sa(dp14323
g7
I146
sg26
VC1510586
p14324
sg10
I3
sg11
VASD
p14325
sg13
I1
sasa(dp14326
g2
S"Heterozygous mutation of human CSX/NKX2.5 has been associated with various congenital heart diseases such as atrial septal defect (ASD), ventricular septal defect, tetralogy of Fallot, and tricuspid valve abnormalities, including Ebstein's anomaly.\n"
p14327
sg4
(lp14328
(dp14329
g7
I35
sg8
VP52952
p14330
sg10
I4
sg11
VNKX2
p14331
sg13
I1
sa(dp14332
g7
I13
sg8
VP52952
p14333
sg10
I21
sg11
Vmutation of human CSX
p14334
sg13
I4
sasg23
(lp14335
(dp14336
g7
I164
sg26
VC0039685
p14337
sg10
I19
sg11
Vtetralogy of Fallot
p14338
sg13
I3
sa(dp14339
g7
I230
sg26
VC0013481
p14340
sg10
I17
sg11
VEbstein's anomaly
p14341
sg13
I2
sa(dp14342
g7
I109
sg26
VC0018817
p14343
sg10
I20
sg11
Vatrial septal defect
p14344
sg13
I3
sa(dp14345
g7
I131
sg26
VC1510586
p14346
sg10
I3
sg11
VASD
p14347
sg13
I1
sa(dp14348
g7
I86
sg26
VC0018799
p14349
sg10
I14
sg11
Vheart diseases
p14350
sg13
I2
sa(dp14351
g7
I137
sg26
VC0018818
p14352
sg10
I25
sg11
Vventricular septal defect
p14353
sg13
I3
sasa(dp14354
g2
S'We found that patients with lung squamous cell carcinoma with low p53 acetylation and SIRT1 expression mostly showed low HIC1 expression, confirming deregulation of HIC1-SIRT1-p53 circular loop in the clinical model.\n'
p14355
sg4
(lp14356
(dp14357
g7
I86
sg8
g64
sg10
I5
sg11
VSIRT1
p14358
sg13
I1
sa(dp14359
g7
I121
sg8
g64
sg10
I4
sg11
VHIC1
p14360
sg13
I1
sa(dp14361
g7
I66
sg8
VP42771
p14362
sg10
I3
sg11
Vp53
p14363
sg13
I1
sa(dp14364
g7
I86
sg8
g64
sg10
I5
sg11
VSIRT1
p14365
sg13
I1
sa(dp14366
g7
I66
sg8
VP42771
p14367
sg10
I3
sg11
Vp53
p14368
sg13
I1
sa(dp14369
g7
I121
sg8
g64
sg10
I4
sg11
VHIC1
p14370
sg13
I1
sasg23
(lp14371
(dp14372
g7
I28
sg26
VC0149782
p14373
sg10
I28
sg11
Vlung squamous cell carcinoma
p14374
sg13
I4
sasa(dp14375
g2
S'Distinct status of p53 acetylation/deacetylation and HIC1 alteration mechanism result from different SIRT1-DBC1 control and epigenetic alteration in lung squamous cell carcinoma and lung adenocarcinoma.\n'
p14376
sg4
(lp14377
(dp14378
g7
I107
sg8
g64
sg10
I4
sg11
VDBC1
p14379
sg13
I1
sa(dp14380
g7
I53
sg8
g64
sg10
I4
sg11
VHIC1
p14381
sg13
I1
sa(dp14382
g7
I101
sg8
g64
sg10
I5
sg11
VSIRT1
p14383
sg13
I1
sa(dp14384
g7
I19
sg8
VP42771
p14385
sg10
I3
sg11
Vp53
p14386
sg13
I1
sasg23
(lp14387
(dp14388
g7
I182
sg26
VC0152013
p14389
sg10
I19
sg11
Vlung adenocarcinoma
p14390
sg13
I2
sa(dp14391
g7
I149
sg26
VC0149782
p14392
sg10
I28
sg11
Vlung squamous cell carcinoma
p14393
sg13
I4
sasa(dp14394
g2
S'We investigated promoter hypermethylation of six genes, p16, APC, HIC-1, death-associated protein kinase (DAPK), O(6)-methylguanine-DNA-methyltransferase (MGMT), and E-cadherin, in uterine cervical carcinoma from 53 patients including 31 cases of squamous cell carcinoma (SCC) and 22 cases of adenocarcinoma (AC).\n'
p14395
sg4
(lp14396
(dp14397
g7
I56
sg8
VP42771
p14398
sg10
I3
sg11
Vp16
p14399
sg13
I1
sa(dp14400
g7
I106
sg8
VP53355
p14401
sg10
I4
sg11
VDAPK
p14402
sg13
I1
sa(dp14403
g7
I66
sg8
g64
sg10
I38
sg11
VHIC-1, death-associated protein kinase
p14404
sg13
I4
sa(dp14405
g7
I166
sg8
VP12830
p14406
sg10
I10
sg11
VE-cadherin
p14407
sg13
I1
sa(dp14408
g7
I155
sg8
VP16455
p14409
sg10
I4
sg11
VMGMT
p14410
sg13
I1
sa(dp14411
g7
I61
sg8
VP25054
p14412
sg10
I3
sg11
VAPC
p14413
sg13
I1
sa(dp14414
g7
I113
sg8
g64
sg10
I40
sg11
VO(6)-methylguanine-DNA-methyltransferase
p14415
sg13
I1
sasg23
(lp14416
(dp14417
g7
I189
sg26
VC0302592
p14418
sg10
I18
sg11
Vcervical carcinoma
p14419
sg13
I2
sa(dp14420
g7
I272
sg26
VC0007137
p14421
sg10
I3
sg11
VSCC
p14422
sg13
I1
sa(dp14423
g7
I309
sg26
VC0001418
p14424
sg10
I2
sg11
VAC
p14425
sg13
I1
sa(dp14426
g7
I247
sg26
VC0007137
p14427
sg10
I23
sg11
Vsquamous cell carcinoma
p14428
sg13
I3
sa(dp14429
g7
I61
sg26
VC0033036
p14430
sg10
I3
sg11
VAPC
p14431
sg13
I1
sa(dp14432
g7
I293
sg26
VC0001418
p14433
sg10
I14
sg11
Vadenocarcinoma
p14434
sg13
I1
sasa(dp14435
g2
S'The aim of this study was to evaluate the influence of PNPLA3 p.I148M and APOC3 rs2854116 and rs2854117 polymorphisms on the clinical and histological presentation of chronic hepatitis C in an Italian population and their relationship with viral and anthropometric parameters.\n'
p14436
sg4
(lp14437
(dp14438
g7
I55
sg8
g64
sg10
I14
sg11
VPNPLA3 p.I148M
p14439
sg13
I2
sa(dp14440
g7
I74
sg8
VP02656
p14441
sg10
I15
sg11
VAPOC3 rs2854116
p14442
sg13
I2
sasg23
(lp14443
(dp14444
g7
I167
sg26
VC0524910
p14445
sg10
I19
sg11
Vchronic hepatitis C
p14446
sg13
I3
sasa(dp14447
g2
S'To explore the gene polymorphisms of ApoAI-75 Msp1, ApoB Msp1, ApoCIII Sst1, LRP5, and ApoE genotypes in two pairs of semi different modes of hepatitis B for HBV markers.\n'
p14448
sg4
(lp14449
(dp14450
g7
I37
sg8
VP02647
p14451
sg10
I13
sg11
VApoAI-75 Msp1
p14452
sg13
I2
sa(dp14453
g7
I77
sg8
g64
sg10
I4
sg11
VLRP5
p14454
sg13
I1
sa(dp14455
g7
I52
sg8
g64
sg10
I9
sg11
VApoB Msp1
p14456
sg13
I2
sa(dp14457
g7
I87
sg8
VP02649
p14458
sg10
I14
sg11
VApoE genotypes
p14459
sg13
I2
sa(dp14460
g7
I63
sg8
VP02656
p14461
sg10
I12
sg11
VApoCIII Sst1
p14462
sg13
I2
sasg23
(lp14463
(dp14464
g7
I142
sg26
VC0019163
p14465
sg10
I11
sg11
Vhepatitis B
p14466
sg13
I2
sa(dp14467
g7
I158
sg26
VC0019163
p14468
sg10
I3
sg11
VHBV
p14469
sg13
I1
sasa(dp14470
g2
S"There was association between gene polymorphisms of ApoAI-75Msp1 and ApoE and different modes of two pairs of semi-hepatitis B (P &lt; 0.05), while there wasn't any association between gene polymorphisms of ApoB-Msp1, ApoCIII-Sst1, LRP5 and different modes of two pairs of semi-hepatitis B (P &gt; 0.05).\n"
p14471
sg4
(lp14472
(dp14473
g7
I218
sg8
VP02656
p14474
sg10
I7
sg11
VApoCIII
p14475
sg13
I1
sa(dp14476
g7
I226
sg8
VP30872
p14477
sg10
I4
sg11
VSst1
p14478
sg13
I1
sa(dp14479
g7
I232
sg8
g64
sg10
I4
sg11
VLRP5
p14480
sg13
I1
sa(dp14481
g7
I60
sg8
g64
sg10
I4
sg11
VMsp1
p14482
sg13
I1
sa(dp14483
g7
I69
sg8
VP02649
p14484
sg10
I4
sg11
VApoE
p14485
sg13
I1
sa(dp14486
g7
I52
sg8
VP02647
p14487
sg10
I12
sg11
VApoAI-75Msp1
p14488
sg13
I1
sasg23
(lp14489
(dp14490
g7
I115
sg26
VC0019163
p14491
sg10
I11
sg11
Vhepatitis B
p14492
sg13
I2
sa(dp14493
g7
I115
sg26
VC0019163
p14494
sg10
I11
sg11
Vhepatitis B
p14495
sg13
I2
sasa(dp14496
g2
S'AQP8 expression was highest in CIN2-3 (91.7%), but levels in cervical carcinoma were also higher than in mild cervicitis.\n'
p14497
sg4
(lp14498
(dp14499
g7
I0
sg8
g64
sg10
I4
sg11
VAQP8
p14500
sg13
I1
sasg23
(lp14501
(dp14502
g7
I61
sg26
VC0302592
p14503
sg10
I18
sg11
Vcervical carcinoma
p14504
sg13
I2
sa(dp14505
g7
I110
sg26
VC0007860
p14506
sg10
I10
sg11
Vcervicitis
p14507
sg13
I1
sasa(dp14508
g2
S'Connective tissue abnormalities are not generally recognised as a part of NF1 microdeletion syndrome, but mitral valve prolapse, joint laxity, and/or soft skin on the palms have been reported in a few patients.\n'
p14509
sg4
(lp14510
(dp14511
g7
I74
sg8
VP21359
p14512
sg10
I3
sg11
VNF1
p14513
sg13
I1
sasg23
(lp14514
(dp14515
g7
I74
sg26
VC3150928
p14516
sg10
I26
sg11
VNF1 microdeletion syndrome
p14517
sg13
I3
sa(dp14518
g7
I106
sg26
VC0026267
p14519
sg10
I21
sg11
Vmitral valve prolapse
p14520
sg13
I3
sa(dp14521
g7
I129
sg26
VC0086437
p14522
sg10
I12
sg11
Vjoint laxity
p14523
sg13
I2
sasa(dp14524
g2
S"Thus, our present work links ApoE and PPP2R5E expression to a reduction in the PP2A catalytic activity that has implications for Alzheimer's disease.\n"
p14525
sg4
(lp14526
(dp14527
g7
I38
sg8
g64
sg10
I7
sg11
VPPP2R5E
p14528
sg13
I1
sa(dp14529
g7
I79
sg8
g64
sg10
I4
sg11
VPP2A
p14530
sg13
I1
sa(dp14531
g7
I29
sg8
VP02649
p14532
sg10
I4
sg11
VApoE
p14533
sg13
I1
sasg23
(lp14534
(dp14535
g7
I129
sg26
VC1521724
p14536
sg10
I19
sg11
VAlzheimer's disease
p14537
sg13
I2
sasa(dp14538
g2
S'Quantification of circulating fetal and total cell-free DNA (cfDNA) and soluble human leucocyte antigen (HLAG) in gestational hypertension and pre-eclampsia.\n'
p14539
sg4
(lp14540
(dp14541
g7
I105
sg8
VP17693
p14542
sg10
I4
sg11
VHLAG
p14543
sg13
I1
sa(dp14544
g7
I72
sg8
VP35558
p14545
sg10
I31
sg11
Vsoluble human leucocyte antigen
p14546
sg13
I4
sasg23
(lp14547
(dp14548
g7
I143
sg26
VC0032914
p14549
sg10
I13
sg11
Vpre-eclampsia
p14550
sg13
I1
sa(dp14551
g7
I114
sg26
VC0341934
p14552
sg10
I24
sg11
Vgestational hypertension
p14553
sg13
I2
sasa(dp14554
g2
S'Soluble HLAG levels were lower in pre-eclamptics than controls and gestational hypertension (p &lt; 0.05).\n'
p14555
sg4
(lp14556
(dp14557
g7
I8
sg8
VP17693
p14558
sg10
I4
sg11
VHLAG
p14559
sg13
I1
sasg23
(lp14560
(dp14561
g7
I67
sg26
VC0341934
p14562
sg10
I24
sg11
Vgestational hypertension
p14563
sg13
I2
sasa(dp14564
g2
S'Circulating fetal and total cfDNA were increased, while soluble HLAG was decreased in pre-eclampsia.\n'
p14565
sg4
(lp14566
(dp14567
g7
I64
sg8
VP17693
p14568
sg10
I4
sg11
VHLAG
p14569
sg13
I1
sasg23
(lp14570
(dp14571
g7
I86
sg26
VC0032914
p14572
sg10
I13
sg11
Vpre-eclampsia
p14573
sg13
I1
sasa(dp14574
g2
S'The effect of HLA-G 14 bp Ins/Del polymorphism (rs371194629) on the risk of preeclampsia has been assessed in several populations, yet the results are still conflicting.\n'
p14575
sg4
(lp14576
(dp14577
g7
I30
sg8
VP01719
p14578
sg10
I3
sg11
VDel
p14579
sg13
I1
sa(dp14580
g7
I14
sg8
VP01308
p14581
sg10
I15
sg11
VHLA-G 14 bp Ins
p14582
sg13
I4
sasg23
(lp14583
(dp14584
g7
I76
sg26
VC0032914
p14585
sg10
I12
sg11
Vpreeclampsia
p14586
sg13
I1
sa(dp14587
g7
I26
sg26
VC1533172
p14588
sg10
I3
sg11
VIns
p14589
sg13
I1
sasa(dp14590
g2
S'This well-powered study clearly demonstrates that the maternal HLA-G 14-bp Ins/Del polymorphism is not associated with preeclampsia risk.\n'
p14591
sg4
(lp14592
(dp14593
g7
I63
sg8
VP01308
p14594
sg10
I15
sg11
VHLA-G 14-bp Ins
p14595
sg13
I3
sa(dp14596
g7
I79
sg8
VP01719
p14597
sg10
I3
sg11
VDel
p14598
sg13
I1
sasg23
(lp14599
(dp14600
g7
I119
sg26
VC0032914
p14601
sg10
I12
sg11
Vpreeclampsia
p14602
sg13
I1
sa(dp14603
g7
I75
sg26
VC1533172
p14604
sg10
I3
sg11
VIns
p14605
sg13
I1
sasa(dp14606
g2
S'Ten genes (ABI3BP, C7, HLA-G, IL2RB, KRBOX1, LRRC15, METTL7B, MPP5, RFLNB and SLC20A) had a &gt;=+/-1 fold expression difference in severe early-onset preeclampsia group compared to early controls.\n'
p14607
sg4
(lp14608
(dp14609
g7
I30
sg8
VP14784
p14610
sg10
I5
sg11
VIL2RB
p14611
sg13
I1
sa(dp14612
g7
I62
sg8
g64
sg10
I4
sg11
VMPP5
p14613
sg13
I1
sa(dp14614
g7
I53
sg8
g64
sg10
I7
sg11
VMETTL7B
p14615
sg13
I1
sa(dp14616
g7
I23
sg8
VP17693
p14617
sg10
I5
sg11
VHLA-G
p14618
sg13
I1
sa(dp14619
g7
I45
sg8
g64
sg10
I6
sg11
VLRRC15
p14620
sg13
I1
sa(dp14621
g7
I11
sg8
g64
sg10
I6
sg11
VABI3BP
p14622
sg13
I1
sa(dp14623
g7
I0
sg8
VP24821
p14624
sg10
I9
sg11
VTen genes
p14625
sg13
I2
sasg23
(lp14626
(dp14627
g7
I151
sg26
VC0032914
p14628
sg10
I12
sg11
Vpreeclampsia
p14629
sg13
I1
sasa(dp14630
g2
S'There were 362 genes that had a &gt;=+/-1 fold expression difference in severe early-onset preeclampsia group compared to late-onset preeclampsia group including ABI3BP, C7, HLA-G and IL2RB.\n'
p14631
sg4
(lp14632
(dp14633
g7
I174
sg8
VP17693
p14634
sg10
I5
sg11
VHLA-G
p14635
sg13
I1
sa(dp14636
g7
I162
sg8
g64
sg10
I6
sg11
VABI3BP
p14637
sg13
I1
sa(dp14638
g7
I184
sg8
VP14784
p14639
sg10
I5
sg11
VIL2RB
p14640
sg13
I1
sasg23
(lp14641
(dp14642
g7
I91
sg26
VC0032914
p14643
sg10
I12
sg11
Vpreeclampsia
p14644
sg13
I1
sa(dp14645
g7
I91
sg26
VC0032914
p14646
sg10
I12
sg11
Vpreeclampsia
p14647
sg13
I1
sasa(dp14648
g2
S'ABI3BP, C7, HLA-G and IL2RB might contribute to the development of early form of severe preeclampsia.\n'
p14649
sg4
(lp14650
(dp14651
g7
I22
sg8
VP14784
p14652
sg10
I5
sg11
VIL2RB
p14653
sg13
I1
sa(dp14654
g7
I0
sg8
g64
sg10
I6
sg11
VABI3BP
p14655
sg13
I1
sa(dp14656
g7
I12
sg8
VP17693
p14657
sg10
I5
sg11
VHLA-G
p14658
sg13
I1
sasg23
(lp14659
(dp14660
g7
I81
sg26
VC0341950
p14661
sg10
I19
sg11
Vsevere preeclampsia
p14662
sg13
I2
sasa(dp14663
g2
S'168 healthy normal weight women and 59 overweight/obese women; to avoid the effect of preeclampsia on sHLA-G concentrations, cases were further divided in two groups: 42 with normotensive pregnancy and 17 who developed preeclampsia.\n'
p14664
sg4
(lp14665
sg23
(lp14666
(dp14667
g7
I50
sg26
VC0028754
p14668
sg10
I5
sg11
Vobese
p14669
sg13
I1
sa(dp14670
g7
I86
sg26
VC0032914
p14671
sg10
I12
sg11
Vpreeclampsia
p14672
sg13
I1
sa(dp14673
g7
I86
sg26
VC0032914
p14674
sg10
I12
sg11
Vpreeclampsia
p14675
sg13
I1
sa(dp14676
g7
I39
sg26
VC0497406
p14677
sg10
I10
sg11
Voverweight
p14678
sg13
I1
sasa(dp14679
g2
S'Maternal concentrations of sHLA-G in the two trimesters and before delivery were significantly lower among subjects who developed preeclampsia than in controls (p&lt;0.001) or in obese subjects with normotensive pregnancies (p&lt;0.001).\n'
p14680
sg4
(lp14681
sg23
(lp14682
(dp14683
g7
I130
sg26
VC0032914
p14684
sg10
I12
sg11
Vpreeclampsia
p14685
sg13
I1
sa(dp14686
g7
I179
sg26
VC0028754
p14687
sg10
I5
sg11
Vobese
p14688
sg13
I1
sasa(dp14689
g2
S'Obesity influences maternal and fetal sHLA-G concentrations during pregnancy, to optimize the reproductive success, while preeclampsia impairs the mother-offspring antinflammatory response.\n'
p14690
sg4
(lp14691
sg23
(lp14692
(dp14693
g7
I0
sg26
VC0028754
p14694
sg10
I7
sg11
VObesity
p14695
sg13
I1
sa(dp14696
g7
I122
sg26
VC0032914
p14697
sg10
I12
sg11
Vpreeclampsia
p14698
sg13
I1
sasa(dp14699
g2
S'Our results showed that the content of GABA and the expression of GABAA and GABAC receptors of retina were up-regulated during the development of myopia, and this up-regulation was inhibited by applying EA to Hegu (LI4) and Taiyang (EX-HN5) acupoints.\n'
p14700
sg4
(lp14701
sg23
(lp14702
(dp14703
g7
I146
sg26
VC0027092
p14704
sg10
I6
sg11
Vmyopia
p14705
sg13
I1
sa(dp14706
g7
I215
sg26
VC3151377
p14707
sg10
I3
sg11
VLI4
p14708
sg13
I1
sasa(dp14709
g2
S'Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.\n'
p14710
sg4
(lp14711
(dp14712
g7
I57
sg8
VP35398
p14713
sg10
I36
sg11
VT-cell-specific transcription factor
p14714
sg13
I3
sa(dp14715
g7
I276
sg8
VP11473
p14716
sg10
I18
sg11
Vvitamin D receptor
p14717
sg13
I3
sa(dp14718
g7
I109
sg8
VP00519
p14719
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p14720
sg13
I3
sa(dp14721
g7
I399
sg8
g64
sg10
I31
sg11
VPR domain zinc finger protein 1
p14722
sg13
I6
sa(dp14723
g7
I322
sg8
VP29323
p14724
sg10
I3
sg11
VERK
p14725
sg13
I1
sa(dp14726
g7
I362
sg8
VP20823
p14727
sg10
I35
sg11
Vrunt-related transcription factor 1
p14728
sg13
I4
sa(dp14729
g7
I477
sg8
VP01584
p14730
sg10
I13
sg11
Vinterleukin 1
p14731
sg13
I2
sa(dp14732
g7
I152
sg8
VP12931
p14733
sg10
I8
sg11
Vsarcoma"
p14734
sg13
I1
sa(dp14735
g7
I163
sg8
VP10914
p14736
sg10
I30
sg11
Vinterferon regulatory factor 1
p14737
sg13
I4
sa(dp14738
g7
I227
sg8
VP49336
p14739
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p14740
sg13
I4
sa(dp14741
g7
I296
sg8
VP56524
p14742
sg10
I19
sg11
Vhistone deacetylase
p14743
sg13
I2
sa(dp14744
g7
I95
sg8
VP12931
p14745
sg10
I3
sg11
VSrc
p14746
sg13
I1
sa(dp14747
g7
I217
sg8
VP14635
p14748
sg10
I8
sg11
Vcyclin B
p14749
sg13
I2
sa(dp14750
g7
I334
sg8
VP10415
p14751
sg10
I26
sg11
Vbcl-2-associated X protein
p14752
sg13
I3
sa(dp14753
g7
I317
sg8
VP53779
p14754
sg10
I4
sg11
VMAPK
p14755
sg13
I1
sa(dp14756
g7
I432
sg8
VP09619
p14757
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p14758
sg13
I4
sa(dp14759
g7
I265
sg8
VP29466
p14760
sg10
I9
sg11
Vcaspase-1
p14761
sg13
I1
sa(dp14762
g7
I195
sg8
VP04818
p14763
sg10
I20
sg11
Vthymidylate synthase
p14764
sg13
I2
sa(dp14765
g7
I252
sg8
VP24941
p14766
sg10
I3
sg11
VCDK
p14767
sg13
I1
sasg23
(lp14768
(dp14769
g7
I152
sg26
VC1261473
p14770
sg10
I7
sg11
Vsarcoma
p14771
sg13
I1
sa(dp14772
g7
I362
sg26
VC0013336
p14773
sg10
I4
sg11
Vrunt
p14774
sg13
I1
sasa(dp14775
g2
S'To study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.\n'
p14776
sg4
(lp14777
(dp14778
g7
I61
sg8
g64
sg10
I6
sg11
VBlimp1
p14779
sg13
I1
sa(dp14780
g7
I44
sg8
VP17980
p14781
sg10
I16
sg11
Vmature protein-1
p14782
sg13
I2
sasg23
(lp14783
(dp14784
g7
I147
sg26
VC0026764
p14785
sg10
I16
sg11
Vmultiple myeloma
p14786
sg13
I2
sasa(dp14787
g2
S'Bcl6 (B-cell lymphoma 6) is a transcriptional repressor and critical mediator of the germinal center reaction during a T-cell-dependent antibody response, where it enables somatic hypermutation of immunoglobulin genes and inhibits terminal differentiation via repression of Blimp1.\n'
p14788
sg4
(lp14789
(dp14790
g7
I274
sg8
g64
sg10
I6
sg11
VBlimp1
p14791
sg13
I1
sa(dp14792
g7
I0
sg8
VP41182
p14793
sg10
I4
sg11
VBcl6
p14794
sg13
I1
sa(dp14795
g7
I197
sg8
g64
sg10
I20
sg11
Vimmunoglobulin genes
p14796
sg13
I2
sa(dp14797
g7
I6
sg8
VP41182
p14798
sg10
I17
sg11
VB-cell lymphoma 6
p14799
sg13
I3
sasg23
(lp14800
(dp14801
g7
I6
sg26
VC0079731
p14802
sg10
I15
sg11
VB-cell lymphoma
p14803
sg13
I2
sasa(dp14804
g2
S'We report that a SEC component, the Eleven -nineteen Lysine-rich leukemia (ELL) family member 3 (ELL3) is dynamically up-regulated in mature and activated human B cells followed by suppression as B cells transition to plasma cells in part mediated by the transcription repressor PRDM1.\n'
p14805
sg4
(lp14806
(dp14807
g7
I97
sg8
g64
sg10
I4
sg11
VELL3
p14808
sg13
I1
sa(dp14809
g7
I65
sg8
VP55199
p14810
sg10
I30
sg11
Vleukemia (ELL) family member 3
p14811
sg13
I5
sa(dp14812
g7
I279
sg8
g64
sg10
I5
sg11
VPRDM1
p14813
sg13
I1
sasg23
(lp14814
(dp14815
g7
I65
sg26
VC0023418
p14816
sg10
I8
sg11
Vleukemia
p14817
sg13
I1
sa(dp14818
g7
I204
sg26
VC0599156
p14819
sg10
I10
sg11
Vtransition
p14820
sg13
I1
sa(dp14821
g7
I181
sg26
VC0221103
p14822
sg10
I11
sg11
Vsuppression
p14823
sg13
I1
sasa(dp14824
g2
S'The expression of PR domain zinc finger protein 1 (Blimp1) and B-cell lymphoma 6 (Bcl6) were analyzed by western blotting.\n'
p14825
sg4
(lp14826
(dp14827
g7
I51
sg8
g64
sg10
I6
sg11
VBlimp1
p14828
sg13
I1
sa(dp14829
g7
I82
sg8
VP41182
p14830
sg10
I4
sg11
VBcl6
p14831
sg13
I1
sa(dp14832
g7
I18
sg8
g64
sg10
I31
sg11
VPR domain zinc finger protein 1
p14833
sg13
I6
sa(dp14834
g7
I63
sg8
VP41182
p14835
sg10
I17
sg11
VB-cell lymphoma 6
p14836
sg13
I3
sasg23
(lp14837
(dp14838
g7
I63
sg26
VC0079731
p14839
sg10
I15
sg11
VB-cell lymphoma
p14840
sg13
I2
sasa(dp14841
g2
S'These results indicated that Mda-7/IL-24 could induce terminal differentiation of B lymphoma cells by regulating the expression of Blimp1 and Bcl6 via altering the P38 MAPK signaling pathway, suggesting that Mda-7/IL-24 may therefore be a potential differentiation therapeutic agent to be applied in clinical treatment of B cell lymphoma.\n'
p14842
sg4
(lp14843
(dp14844
g7
I29
sg8
g64
sg10
I11
sg11
VMda-7/IL-24
p14845
sg13
I1
sa(dp14846
g7
I29
sg8
g64
sg10
I11
sg11
VMda-7/IL-24
p14847
sg13
I1
sa(dp14848
g7
I142
sg8
VP41182
p14849
sg10
I4
sg11
VBcl6
p14850
sg13
I1
sa(dp14851
g7
I164
sg8
VP46108
p14852
sg10
I8
sg11
VP38 MAPK
p14853
sg13
I2
sa(dp14854
g7
I131
sg8
g64
sg10
I6
sg11
VBlimp1
p14855
sg13
I1
sasg23
(lp14856
(dp14857
g7
I322
sg26
VC0079731
p14858
sg10
I15
sg11
VB cell lymphoma
p14859
sg13
I3
sa(dp14860
g7
I84
sg26
VC0024299
p14861
sg10
I8
sg11
Vlymphoma
p14862
sg13
I1
sasa(dp14863
g2
S'B lymphocyte-induced maturation protein-1 (Blimp-1) ensures B-cell differentiation into the plasma cell stage, and its instability constitutes a crucial oncogenic element in certain aggressive cases of activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL).\n'
p14864
sg4
(lp14865
(dp14866
g7
I0
sg8
g64
sg10
I41
sg11
VB lymphocyte-induced maturation protein-1
p14867
sg13
I4
sa(dp14868
g7
I43
sg8
g64
sg10
I7
sg11
VBlimp-1
p14869
sg13
I1
sasg23
(lp14870
(dp14871
g7
I182
sg26
VC0001807
p14872
sg10
I10
sg11
Vaggressive
p14873
sg13
I1
sa(dp14874
g7
I224
sg26
VC0079744
p14875
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p14876
sg13
I4
sasa(dp14877
g2
S'Mechanistically, whereas wild-type Blimp-1 metabolism is triggered in the nucleus through PML-mediated sumoylation, the degradation of lymphoma-associated mutants is accelerated by subversion of this pathway to Hrd1-mediated cytoplasmic sequestration and ubiquitination.\n'
p14878
sg4
(lp14879
(dp14880
g7
I211
sg8
g64
sg10
I4
sg11
VHrd1
p14881
sg13
I1
sasg23
(lp14882
(dp14883
g7
I135
sg26
VC0024299
p14884
sg10
I8
sg11
Vlymphoma
p14885
sg13
I1
sa(dp14886
g7
I90
sg26
VC0023524
p14887
sg10
I3
sg11
VPML
p14888
sg13
I1
sasa(dp14889
g2
S'Therefore, HSP70-Hrd1 axis represents a potential therapeutic target for restoring the oncorepressor activity of unstable lymphoma-associated Blimp-1 mutants.The transcriptional repressor Blimp-1 has an important role in B-cell differentiation.\n'
p14890
sg4
(lp14891
(dp14892
g7
I142
sg8
g64
sg10
I7
sg11
VBlimp-1
p14893
sg13
I1
sa(dp14894
g7
I11
sg8
VP34932
p14895
sg10
I5
sg11
VHSP70
p14896
sg13
I1
sa(dp14897
g7
I17
sg8
g64
sg10
I4
sg11
VHrd1
p14898
sg13
I1
sasg23
(lp14899
(dp14900
g7
I122
sg26
VC0024299
p14901
sg10
I8
sg11
Vlymphoma
p14902
sg13
I1
sasa(dp14903
g2
S'Here the authors show that lymphoma-associated Blimp-1 mutants are selectively recognized by HSP70-Hrd1, which leads to their accelerated degradation and propose HSP70 inhibition as a therapeutic approach for certain lymphomas.\n'
p14904
sg4
(lp14905
(dp14906
g7
I93
sg8
VP34932
p14907
sg10
I5
sg11
VHSP70
p14908
sg13
I1
sa(dp14909
g7
I99
sg8
g64
sg10
I4
sg11
VHrd1
p14910
sg13
I1
sa(dp14911
g7
I154
sg8
VP34932
p14912
sg10
I13
sg11
Vpropose HSP70
p14913
sg13
I2
sasg23
(lp14914
(dp14915
g7
I27
sg26
VC0024299
p14916
sg10
I8
sg11
Vlymphoma
p14917
sg13
I1
sa(dp14918
g7
I217
sg26
VC0024299
p14919
sg10
I9
sg11
Vlymphomas
p14920
sg13
I1
sasa(dp14921
g2
S'These findings support a model in which upregulation of BLIMP1 links microenvironmental cues to a metastatic stem cell character.Significance: PDAC is an almost uniformly lethal cancer, largely due to its tendency for metastasis.\n'
p14922
sg4
(lp14923
(dp14924
g7
I56
sg8
g64
sg10
I6
sg11
VBLIMP1
p14925
sg13
I1
sasg23
(lp14926
(dp14927
g7
I178
sg26
VC0006826
p14928
sg10
I6
sg11
Vcancer
p14929
sg13
I1
sa(dp14930
g7
I218
sg26
VC0027627
p14931
sg10
I10
sg11
Vmetastasis
p14932
sg13
I1
sasa(dp14933
g2
S'Expression of several cytokines and chemokines were significantly increased in plasma from EV71-infected patients compared to healthy controls, which further indicated that: (1) GM-CSF, MIP-1Beta, IL-2, IL-33, and IL-23 secretion was elevated in patients who rapidly developed disease and presented with uncomplicated neurological damage; (2) G-CSF and MCP-1 were distinguishably secreted in EV71 infected very severe patients presenting with acute respiratory failure; (3) IP-10, MCP-1, IL-6, IL-8, and G-CSF levels were much higher in cerebrospinal fluid than in plasma from patients with neurological damage; (4) FACS analysis revealed that the frequency of CD19(+)HLADR(+) mature B cells dynamically changed over time during the course of hospitalization and was accompanied by dramatically increased EV71-specific antibodies.\n'
p14934
sg4
(lp14935
(dp14936
g7
I353
sg8
VP41597
p14937
sg10
I5
sg11
VMCP-1
p14938
sg13
I1
sa(dp14939
g7
I178
sg8
VP04141
p14940
sg10
I6
sg11
VGM-CSF
p14941
sg13
I1
sa(dp14942
g7
I343
sg8
VP09919
p14943
sg10
I5
sg11
VG-CSF
p14944
sg13
I1
sa(dp14945
g7
I197
sg8
VP60568
p14946
sg10
I4
sg11
VIL-2
p14947
sg13
I1
sa(dp14948
g7
I353
sg8
VP41597
p14949
sg10
I5
sg11
VMCP-1
p14950
sg13
I1
sa(dp14951
g7
I214
sg8
g64
sg10
I5
sg11
VIL-23
p14952
sg13
I1
sa(dp14953
g7
I661
sg8
VP15391
p14954
sg10
I12
sg11
VCD19(+)HLADR
p14955
sg13
I1
sa(dp14956
g7
I186
sg8
g64
sg10
I9
sg11
VMIP-1Beta
p14957
sg13
I1
sa(dp14958
g7
I343
sg8
VP09919
p14959
sg10
I5
sg11
VG-CSF
p14960
sg13
I1
sa(dp14961
g7
I488
sg8
VP05231
p14962
sg10
I4
sg11
VIL-6
p14963
sg13
I1
sasg23
(lp14964
(dp14965
g7
I443
sg26
VC0264490
p14966
sg10
I25
sg11
Vacute respiratory failure
p14967
sg13
I3
sa(dp14968
g7
I186
sg26
VC1851100
p14969
sg10
I3
sg11
VMIP
p14970
sg13
I1
sasa(dp14971
g2
S'Using an immunoblotting assay (ImBA), several immuno-crossreactive antigenic components (ImCRAC-myc) have been identified in the whole sonicates of M. bovis-BCG, and M. tuberculosis (Mtb) and M. leprae (ML) whereby the sera of 100% lepromatous leprosy (L-Lep) reacted to 29/33 KD doublet and that of 100% tuberculoid leprosy (T-Lep) reacted to 64 KD bands.\n'
p14972
sg4
(lp14973
(dp14974
g7
I326
sg8
VP41159
p14975
sg10
I5
sg11
VT-Lep
p14976
sg13
I1
sa(dp14977
g7
I96
sg8
VP12524
p14978
sg10
I3
sg11
Vmyc
p14979
sg13
I1
sa(dp14980
g7
I253
sg8
VP41159
p14981
sg10
I5
sg11
VL-Lep
p14982
sg13
I1
sasg23
(lp14983
(dp14984
g7
I169
sg26
VC0041296
p14985
sg10
I12
sg11
Vtuberculosis
p14986
sg13
I1
sa(dp14987
g7
I305
sg26
VC0023351
p14988
sg10
I19
sg11
Vtuberculoid leprosy
p14989
sg13
I2
sa(dp14990
g7
I232
sg26
VC0023348
p14991
sg10
I19
sg11
Vlepromatous leprosy
p14992
sg13
I2
sasa(dp14993
g2
S'These two complement effectors, C5a and C5b-9, generated from C5 cleavage, are key components of the complement system responsible for propagating and/or initiating pathology in different diseases, including paroxysmal nocturnal hemoglobinuria, rheumatoid arthritis, ischemia-reperfusion injuries and neurodegenerative diseases.\n'
p14994
sg4
(lp14995
(dp14996
g7
I32
sg8
VP21730
p14997
sg10
I3
sg11
VC5a
p14998
sg13
I1
sasg23
(lp14999
(dp15000
g7
I208
sg26
VC0024790
p15001
sg10
I35
sg11
Vparoxysmal nocturnal hemoglobinuria
p15002
sg13
I3
sa(dp15003
g7
I245
sg26
VC0003873
p15004
sg10
I20
sg11
Vrheumatoid arthritis
p15005
sg13
I2
sa(dp15006
g7
I165
sg26
VC0677042
p15007
sg10
I9
sg11
Vpathology
p15008
sg13
I1
sa(dp15009
g7
I267
sg26
VC0022116
p15010
sg10
I8
sg11
Vischemia
p15011
sg13
I1
sa(dp15012
g7
I301
sg26
VC0524851
p15013
sg10
I26
sg11
Vneurodegenerative diseases
p15014
sg13
I2
sasa(dp15015
g2
S'Our findings further suggest that Rab1A is a valuable biomarker for prognosis and personalized mTORC1-targeted therapy in liver cancer.\n'
p15016
sg4
(lp15017
(dp15018
g7
I34
sg8
VP62820
p15019
sg10
I5
sg11
VRab1A
p15020
sg13
I1
sasg23
(lp15021
(dp15022
g7
I122
sg26
VC0345904
p15023
sg10
I12
sg11
Vliver cancer
p15024
sg13
I2
sasa(dp15025
g2
S'They should also be of importance in the knowledge of inherited genetic deficiencies, such as glycogen storage disease type 1 (Von Gierke disease) and the Fanconi-Bickel and glucose-galactose malabsorption syndromes.\n'
p15026
sg4
(lp15027
sg23
(lp15028
(dp15029
g7
I206
sg26
VC0039082
p15030
sg10
I9
sg11
Vsyndromes
p15031
sg13
I1
sa(dp15032
g7
I174
sg26
VC0268186
p15033
sg10
I31
sg11
Vglucose-galactose malabsorption
p15034
sg13
I2
sa(dp15035
g7
I94
sg26
VC0017919
p15036
sg10
I24
sg11
Vglycogen storage disease
p15037
sg13
I3
sa(dp15038
g7
I127
sg26
VC0017920
p15039
sg10
I18
sg11
VVon Gierke disease
p15040
sg13
I3
sasa(dp15041
g2
S'MicroRNA-224 (miR-224) is one of the most commonly up-regulated microRNAs in hepatocellular carcinoma (HCC), which affects crucial cellular processes such as apoptosis and cell proliferation.\n'
p15042
sg4
(lp15043
(dp15044
g7
I14
sg8
g64
sg10
I7
sg11
VmiR-224
p15045
sg13
I1
sa(dp15046
g7
I0
sg8
g64
sg10
I12
sg11
VMicroRNA-224
p15047
sg13
I1
sasg23
(lp15048
(dp15049
g7
I77
sg26
VC2239176
p15050
sg10
I24
sg11
Vhepatocellular carcinoma
p15051
sg13
I2
sa(dp15052
g7
I103
sg26
VC2239176
p15053
sg10
I3
sg11
VHCC
p15054
sg13
I1
sa(dp15055
g7
I177
sg26
VC0334094
p15056
sg10
I13
sg11
Vproliferation
p15057
sg13
I1
sasa(dp15058
g2
S'Examples include glycogen in the case of Pompe disease, glycosaminoglycans in the case of the mucopolysaccharidoses, glycoproteins in the cases of the oligosaccharidoses, and sphingolipids in the cases of Niemann-Pick disease types A and B, Gaucher disease, Tay-Sachs disease, Krabbe disease, and metachromatic leukodystrophy.\n'
p15059
sg4
(lp15060
sg23
(lp15061
(dp15062
g7
I297
sg26
VC0023522
p15063
sg10
I28
sg11
Vmetachromatic leukodystrophy
p15064
sg13
I2
sa(dp15065
g7
I205
sg26
VC0028064
p15066
sg10
I20
sg11
VNiemann-Pick disease
p15067
sg13
I2
sa(dp15068
g7
I41
sg26
VC0017921
p15069
sg10
I13
sg11
VPompe disease
p15070
sg13
I2
sa(dp15071
g7
I277
sg26
VC0023521
p15072
sg10
I14
sg11
VKrabbe disease
p15073
sg13
I2
sa(dp15074
g7
I94
sg26
VC0026703
p15075
sg10
I21
sg11
Vmucopolysaccharidoses
p15076
sg13
I1
sa(dp15077
g7
I249
sg26
VC0039373
p15078
sg10
I18
sg11
Vdisease, Tay-Sachs
p15079
sg13
I2
sasa(dp15080
g2
S'Examples include imiglucerase, taliglucerase and velaglucerase for Gaucher disease, laronidase for Hurler disease, idursulfase for Hunter disease, elosulfase for Morquio disease, galsulfase for Maroteaux-Lamy disease, alglucosidase alfa for Pompe disease, and agalsidase alfa and beta for Fabry disease.\n'
p15081
sg4
(lp15082
(dp15083
g7
I260
sg8
VP06280
p15084
sg10
I24
sg11
Vagalsidase alfa and beta
p15085
sg13
I4
sa(dp15086
g7
I17
sg8
VP02774
p15087
sg10
I12
sg11
Vimiglucerase
p15088
sg13
I1
sasg23
(lp15089
(dp15090
g7
I241
sg26
VC0017921
p15091
sg10
I13
sg11
VPompe disease
p15092
sg13
I2
sa(dp15093
g7
I131
sg26
VC0026705
p15094
sg10
I14
sg11
VHunter disease
p15095
sg13
I2
sa(dp15096
g7
I162
sg26
VC0026707
p15097
sg10
I15
sg11
VMorquio disease
p15098
sg13
I2
sa(dp15099
g7
I99
sg26
VC0086795
p15100
sg10
I14
sg11
VHurler disease
p15101
sg13
I2
sa(dp15102
g7
I194
sg26
VC0026709
p15103
sg10
I22
sg11
VMaroteaux-Lamy disease
p15104
sg13
I2
sa(dp15105
g7
I67
sg26
VC0017205
p15106
sg10
I15
sg11
VGaucher disease
p15107
sg13
I2
sa(dp15108
g7
I289
sg26
VC0002986
p15109
sg10
I13
sg11
VFabry disease
p15110
sg13
I2
sasa(dp15111
g2
S'The advent of treatment options for some of these disorders has led to newborn screening pilot studies, and ultimately to the addition of Pompe disease and Hurler disease to the Recommended Uniform Screening Panel (RUSP) in 2015 and 2016, respectively.\n'
p15112
sg4
(lp15113
sg23
(lp15114
(dp15115
g7
I156
sg26
VC0086795
p15116
sg10
I14
sg11
VHurler disease
p15117
sg13
I2
sa(dp15118
g7
I138
sg26
VC0017921
p15119
sg10
I13
sg11
VPompe disease
p15120
sg13
I2
sasa(dp15121
g2
S'We report an informatics solution proven to minimize these issues.MethodsThe Kentucky Department for Public Health outsourced testing for mucopolysaccharidosis type I (MPS I) and Pompe disease, conditions recently added to the recommended uniform screening panel, plus Krabbe disease, which was added by legislative mandate.\n'
p15122
sg4
(lp15123
sg23
(lp15124
(dp15125
g7
I269
sg26
VC0023521
p15126
sg10
I14
sg11
VKrabbe disease
p15127
sg13
I2
sa(dp15128
g7
I168
sg26
VC0023786
p15129
sg10
I5
sg11
VMPS I
p15130
sg13
I2
sa(dp15131
g7
I179
sg26
VC0017921
p15132
sg10
I13
sg11
VPompe disease
p15133
sg13
I2
sa(dp15134
g7
I138
sg26
VC0023786
p15135
sg10
I28
sg11
Vmucopolysaccharidosis type I
p15136
sg13
I3
sasa(dp15137
g2
S'Testing by tandem mass spectrometry was integrated with multivariate pattern recognition software (Collaborative Laboratory Integrated Reports), which is freely available to newborn screening programs for selection of cases for which a biochemical second-tier test is needed.ResultsOf five presumptive positive cases, one was affected with infantile Krabbe disease, two with Pompe disease, and one with MPS I.\n'
p15138
sg4
(lp15139
(dp15140
g7
I403
sg8
VP05164
p15141
sg10
I5
sg11
VMPS I
p15142
sg13
I2
sasg23
(lp15143
(dp15144
g7
I340
sg26
VC0751273
p15145
sg10
I24
sg11
Vinfantile Krabbe disease
p15146
sg13
I3
sa(dp15147
g7
I375
sg26
VC0017921
p15148
sg10
I13
sg11
VPompe disease
p15149
sg13
I2
sa(dp15150
g7
I403
sg26
VC0023786
p15151
sg10
I5
sg11
VMPS I
p15152
sg13
I2
sasa(dp15153
g2
S'Pompe disease, a rare lysosomal storage disease caused by deficiency of the lysosomal acid Alfa-glucosidase (GAA), is characterized by glycogen accumulation, triggering severe secondary cellular damage and resulting in progressive motor handicap and premature death.\n'
p15154
sg4
(lp15155
(dp15156
g7
I76
sg8
g64
sg10
I31
sg11
Vlysosomal acid Alfa-glucosidase
p15157
sg13
I3
sa(dp15158
g7
I109
sg8
VP10253
p15159
sg10
I3
sg11
VGAA
p15160
sg13
I1
sasg23
(lp15161
(dp15162
g7
I22
sg26
VC0085078
p15163
sg10
I25
sg11
Vlysosomal storage disease
p15164
sg13
I3
sa(dp15165
g7
I0
sg26
VC0017921
p15166
sg10
I13
sg11
VPompe disease
p15167
sg13
I2
sasa(dp15168
g2
S'Pompe disease is a lysosomal storage disorder caused by acid-Alfa-glucosidase (GAA) deficiency, leading to glycogen storage.\n'
p15169
sg4
(lp15170
(dp15171
g7
I79
sg8
VP10253
p15172
sg10
I3
sg11
VGAA
p15173
sg13
I1
sa(dp15174
g7
I61
sg8
g64
sg10
I16
sg11
VAlfa-glucosidase
p15175
sg13
I1
sasg23
(lp15176
(dp15177
g7
I19
sg26
VC0085078
p15178
sg10
I26
sg11
Vlysosomal storage disorder
p15179
sg13
I3
sa(dp15180
g7
I0
sg26
VC0017921
p15181
sg10
I13
sg11
VPompe disease
p15182
sg13
I2
sasa(dp15183
g2
S'Although RUFY3 (RUN and FYVE domain containing 3)/SINGAR1 (single axon-related1)/RIPX (Rap2 interacting protein X) has an important role in neuronal development, its pathophysiologic role and relevance to cancer are still largely unknown.\n'
p15184
sg4
(lp15185
(dp15186
g7
I59
sg8
g64
sg10
I20
sg11
Vsingle axon-related1
p15187
sg13
I2
sa(dp15188
g7
I50
sg8
g64
sg10
I7
sg11
VSINGAR1
p15189
sg13
I1
sa(dp15190
g7
I16
sg8
g64
sg10
I32
sg11
VRUN and FYVE domain containing 3
p15191
sg13
I6
sa(dp15192
g7
I81
sg8
g64
sg10
I4
sg11
VRIPX
p15193
sg13
I1
sa(dp15194
g7
I9
sg8
g64
sg10
I5
sg11
VRUFY3
p15195
sg13
I1
sa(dp15196
g7
I87
sg8
g64
sg10
I26
sg11
VRap2 interacting protein X
p15197
sg13
I4
sasg23
(lp15198
(dp15199
g7
I205
sg26
VC0006826
p15200
sg10
I6
sg11
Vcancer
p15201
sg13
I1
sasa(dp15202
g2
S'The purpose of this study was to elucidate the molecular mechanisms by which RUFY3 involves in gastric cancer cell migration and invasion.\n'
p15203
sg4
(lp15204
(dp15205
g7
I77
sg8
g64
sg10
I5
sg11
VRUFY3
p15206
sg13
I1
sasg23
(lp15207
(dp15208
g7
I95
sg26
VC0024623
p15209
sg10
I14
sg11
Vgastric cancer
p15210
sg13
I2
sa(dp15211
g7
I129
sg26
VC2699153
p15212
sg10
I8
sg11
Vinvasion
p15213
sg13
I1
sasa(dp15214
g2
S'Here, our data show that overexpression of RUFY3 leads to the formation of F-actin-enriched protrusive structures at the cell periphery and induces gastric cancer cell migration.\n'
p15215
sg4
(lp15216
(dp15217
g7
I43
sg8
g64
sg10
I5
sg11
VRUFY3
p15218
sg13
I1
sasg23
(lp15219
(dp15220
g7
I148
sg26
VC0024623
p15221
sg10
I14
sg11
Vgastric cancer
p15222
sg13
I2
sasa(dp15223
g2
S'Furthermore, P21-activated kinase-1 (PAK1) interacts with RUFY3, and promotes RUFY3 expression and RUFY3-induced gastric cancer cell migration; inhibition of PAK1 attenuates RUFY3-induced SGC-7901 cell migration and invasion.\n'
p15224
sg4
(lp15225
(dp15226
g7
I58
sg8
g64
sg10
I5
sg11
VRUFY3
p15227
sg13
I1
sa(dp15228
g7
I13
sg8
VP42857
p15229
sg10
I22
sg11
VP21-activated kinase-1
p15230
sg13
I2
sa(dp15231
g7
I37
sg8
g64
sg10
I4
sg11
VPAK1
p15232
sg13
I1
sa(dp15233
g7
I58
sg8
g64
sg10
I5
sg11
VRUFY3
p15234
sg13
I1
sa(dp15235
g7
I58
sg8
g64
sg10
I5
sg11
VRUFY3
p15236
sg13
I1
sa(dp15237
g7
I37
sg8
g64
sg10
I4
sg11
VPAK1
p15238
sg13
I1
sa(dp15239
g7
I58
sg8
g64
sg10
I5
sg11
VRUFY3
p15240
sg13
I1
sasg23
(lp15241
(dp15242
g7
I113
sg26
VC0024623
p15243
sg10
I14
sg11
Vgastric cancer
p15244
sg13
I2
sa(dp15245
g7
I216
sg26
VC2699153
p15246
sg10
I8
sg11
Vinvasion
p15247
sg13
I1
sasa(dp15248
g2
S'Strikingly, we found significant upregulation of RUFY3 in gastric cancer samples with invasive carcinoma at pathologic TNM III and TNM IV stages, compared with their non-tumor counterparts.\n'
p15249
sg4
(lp15250
(dp15251
g7
I119
sg8
g64
sg10
I7
sg11
VTNM III
p15252
sg13
I2
sa(dp15253
g7
I49
sg8
g64
sg10
I5
sg11
VRUFY3
p15254
sg13
I1
sa(dp15255
g7
I131
sg8
g64
sg10
I6
sg11
VTNM IV
p15256
sg13
I2
sasg23
(lp15257
(dp15258
g7
I58
sg26
VC0024623
p15259
sg10
I14
sg11
Vgastric cancer
p15260
sg13
I2
sa(dp15261
g7
I170
sg26
VC0027651
p15262
sg10
I5
sg11
Vtumor
p15263
sg13
I1
sa(dp15264
g7
I86
sg26
VC1334274
p15265
sg10
I18
sg11
Vinvasive carcinoma
p15266
sg13
I2
sasa(dp15267
g2
S'Moreover, an obvious positive correlation was observed between the protein expression of RUFY3 and PAK1 in 40 pairs of gastric cancer samples.\n'
p15268
sg4
(lp15269
(dp15270
g7
I89
sg8
g64
sg10
I5
sg11
VRUFY3
p15271
sg13
I1
sa(dp15272
g7
I99
sg8
g64
sg10
I4
sg11
VPAK1
p15273
sg13
I1
sasg23
(lp15274
(dp15275
g7
I119
sg26
VC0024623
p15276
sg10
I14
sg11
Vgastric cancer
p15277
sg13
I2
sasa(dp15278
g2
S'Therefore, these findings provide important evidence that PAK1 can positively regulate RUFY3 expression, which contribute to the metastatic potential of gastric cancer cells, maybe blocking PAK1-RUFY3 signaling would become a potential metastasis therapeutic strategy for gastric cancer.\n'
p15279
sg4
(lp15280
(dp15281
g7
I87
sg8
g64
sg10
I5
sg11
VRUFY3
p15282
sg13
I1
sa(dp15283
g7
I58
sg8
g64
sg10
I4
sg11
VPAK1
p15284
sg13
I1
sa(dp15285
g7
I87
sg8
g64
sg10
I5
sg11
VRUFY3
p15286
sg13
I1
sa(dp15287
g7
I58
sg8
g64
sg10
I4
sg11
VPAK1
p15288
sg13
I1
sasg23
(lp15289
(dp15290
g7
I153
sg26
VC0024623
p15291
sg10
I14
sg11
Vgastric cancer
p15292
sg13
I2
sa(dp15293
g7
I236
sg26
VC0027627
p15294
sg10
I10
sg11
Vmetastasis
p15295
sg13
I1
sa(dp15296
g7
I153
sg26
VC0024623
p15297
sg10
I14
sg11
Vgastric cancer
p15298
sg13
I2
sa(dp15299
g7
I181
sg26
VC0233660
p15300
sg10
I8
sg11
Vblocking
p15301
sg13
I1
sasa(dp15302
g2
S'After mRNA transcription of meningioma (WHO grade I-III) and meningeal tissue from three different experimental sample types (fresh tissue, primary cell cultures and FFPE tissue), 13 candidate reference genes (ACTB, B2M, HPRT, VIM, GAPDH, YWHAZ, EIF4A2, MUC1, ATP5B, GNB2L, TUBB, CYC1, RPL13A) were chosen for quantitative expression analysis.\n'
p15303
sg4
(lp15304
(dp15305
g7
I232
sg8
VP04406
p15306
sg10
I5
sg11
VGAPDH
p15307
sg13
I1
sa(dp15308
g7
I260
sg8
VP06576
p15309
sg10
I5
sg11
VATP5B
p15310
sg13
I1
sa(dp15311
g7
I286
sg8
VP40429
p15312
sg10
I6
sg11
VRPL13A
p15313
sg13
I1
sa(dp15314
g7
I210
sg8
VP63261
p15315
sg10
I4
sg11
VACTB
p15316
sg13
I1
sa(dp15317
g7
I246
sg8
g64
sg10
I6
sg11
VEIF4A2
p15318
sg13
I1
sa(dp15319
g7
I221
sg8
VP00492
p15320
sg10
I4
sg11
VHPRT
p15321
sg13
I1
sa(dp15322
g7
I216
sg8
VP61769
p15323
sg10
I3
sg11
VB2M
p15324
sg13
I1
sa(dp15325
g7
I274
sg8
VP04350
p15326
sg10
I4
sg11
VTUBB
p15327
sg13
I1
sa(dp15328
g7
I280
sg8
VP08574
p15329
sg10
I4
sg11
VCYC1
p15330
sg13
I1
sasg23
(lp15331
(dp15332
g7
I28
sg26
VC0025286
p15333
sg10
I10
sg11
Vmeningioma
p15334
sg13
I1
sasa(dp15335
g2
S'YAP and 14-3-3Zeta expression exhibited a negative correlation in gastric cancer (GC) tissues.\n'
p15336
sg4
(lp15337
(dp15338
g7
I0
sg8
VP46937
p15339
sg10
I3
sg11
VYAP
p15340
sg13
I1
sasg23
(lp15341
(dp15342
g7
I66
sg26
VC0024623
p15343
sg10
I14
sg11
Vgastric cancer
p15344
sg13
I2
sa(dp15345
g7
I82
sg26
VC0024623
p15346
sg10
I2
sg11
VGC
p15347
sg13
I1
sasa(dp15348
g2
S'Remarkably, the expression of YWHAZ is inversely correlated with the level of miR-451 in human breast cancer samples.\n'
p15349
sg4
(lp15350
(dp15351
g7
I78
sg8
g64
sg10
I7
sg11
VmiR-451
p15352
sg13
I1
sasg23
(lp15353
(dp15354
g7
I95
sg26
VC0678222
p15355
sg10
I13
sg11
Vbreast cancer
p15356
sg13
I2
sasa(dp15357
g2
S'To define the functional impact of 14-3-3Zeta proteasomal binding in myeloma cells, silencing and overexpression experiments are performed.\n'
p15358
sg4
(lp15359
sg23
(lp15360
(dp15361
g7
I69
sg26
VC0026764
p15362
sg10
I7
sg11
Vmyeloma
p15363
sg13
I1
sasa(dp15364
g2
S'We find that downregulation of 14-3-3Zeta impairs myeloma cell growth and confers resistance to clinically used proteasome inhibitors.\n'
p15365
sg4
(lp15366
sg23
(lp15367
(dp15368
g7
I50
sg26
VC0026764
p15369
sg10
I7
sg11
Vmyeloma
p15370
sg13
I1
sasa(dp15371
g2
S'In a large cohort of newly diagnosed myeloma patients, elevated expression of 14-3-3Zeta is associated with high risk myeloma genetic subtypes and worse prognosis overall.\n'
p15372
sg4
(lp15373
sg23
(lp15374
(dp15375
g7
I37
sg26
VC0026764
p15376
sg10
I7
sg11
Vmyeloma
p15377
sg13
I1
sa(dp15378
g7
I37
sg26
VC0026764
p15379
sg10
I7
sg11
Vmyeloma
p15380
sg13
I1
sasa(dp15381
g2
S'Our work demonstrates the important role of 14-3-3Zeta in regulating proteasome function, myeloma cell growth and sensitivity to therapeutics, and suggests regulation of 14-3-3Zeta as a new approach in myeloma therapy.Leukemia advance online publication, 17 October 2017; doi:10.1038/leu.2017.288.\n'
p15382
sg4
(lp15383
sg23
(lp15384
(dp15385
g7
I218
sg26
VC0023418
p15386
sg10
I8
sg11
VLeukemia
p15387
sg13
I1
sa(dp15388
g7
I90
sg26
VC0026764
p15389
sg10
I7
sg11
Vmyeloma
p15390
sg13
I1
sa(dp15391
g7
I90
sg26
VC0026764
p15392
sg10
I7
sg11
Vmyeloma
p15393
sg13
I1
sasa(dp15394
g2
S'Among them, Rab-GDIBeta, aldehyde dehydrogenase 2 (ALDH2) and 14-3-3 zeta/delta were important since they were previously reported to be associated with cancer and their expression levels were found to be lower in BCG-treated group in comparison to the non-treated group.\n'
p15395
sg4
(lp15396
(dp15397
g7
I62
sg8
VP27348
p15398
sg10
I17
sg11
V14-3-3 zeta/delta
p15399
sg13
I2
sa(dp15400
g7
I12
sg8
VP49366
p15401
sg10
I37
sg11
VRab-GDIBeta, aldehyde dehydrogenase 2
p15402
sg13
I4
sa(dp15403
g7
I51
sg8
VP05091
p15404
sg10
I5
sg11
VALDH2
p15405
sg13
I1
sasg23
(lp15406
(dp15407
g7
I153
sg26
VC0006826
p15408
sg10
I6
sg11
Vcancer
p15409
sg13
I1
sasa(dp15410
g2
S'Overexpression of MUC1 is found to induce epithelial-mesenchymal transition and promote metastasis of lung cancer cells, while knockdown of 14-3-3Zeta can completely abolish the oncogenic function of MUC1.Furthermore, we unraveled a novel mechanism that 14-3-3Zeta activates NF-KB signaling pathway, and therefore enhanced MUC1/NF-KB feedback loop to upregulate MUC1 expression.\n'
p15411
sg4
(lp15412
sg23
(lp15413
(dp15414
g7
I102
sg26
VC0684249
p15415
sg10
I11
sg11
Vlung cancer
p15416
sg13
I2
sa(dp15417
g7
I65
sg26
VC0599156
p15418
sg10
I10
sg11
Vtransition
p15419
sg13
I1
sa(dp15420
g7
I88
sg26
VC0027627
p15421
sg10
I10
sg11
Vmetastasis
p15422
sg13
I1
sasa(dp15423
g2
S'14-3-3Zeta and MUC1 is a promising prognostic biomarker for lung cancer patients and therapeutic targeting of 14-3-3Zeta and MUC1 may be a potential treatment option for patients with LAC.\n'
p15424
sg4
(lp15425
sg23
(lp15426
(dp15427
g7
I60
sg26
VC0684249
p15428
sg10
I11
sg11
Vlung cancer
p15429
sg13
I2
sasa(dp15430
g2
S'14-3-3Zeta expression is amplified in over 40% breast cancer patients and is associated with a poor prognosis.\n'
p15431
sg4
(lp15432
sg23
(lp15433
(dp15434
g7
I47
sg26
VC0678222
p15435
sg10
I13
sg11
Vbreast cancer
p15436
sg13
I2
sasa(dp15437
g2
S'Various in vitro and xenograft models have suggested that attenuating 14-3-3Zeta expression may provide therapeutic benefits but there has been no study looking at tumor onset and metastasis in breast cancer mouse models with a targeted deletion of 14-3-3Zeta.\n'
p15438
sg4
(lp15439
sg23
(lp15440
(dp15441
g7
I194
sg26
VC0678222
p15442
sg10
I13
sg11
Vbreast cancer
p15443
sg13
I2
sa(dp15444
g7
I180
sg26
VC0027627
p15445
sg10
I10
sg11
Vmetastasis
p15446
sg13
I1
sa(dp15447
g7
I164
sg26
VC0027651
p15448
sg10
I5
sg11
Vtumor
p15449
sg13
I1
sasa(dp15450
g2
S'We generated a 14-3-3Zeta knockout mouse model to characterize the role of 14-3-3Zeta in breast cancer progression.\n'
p15451
sg4
(lp15452
sg23
(lp15453
(dp15454
g7
I96
sg26
VC0178874
p15455
sg10
I18
sg11
Vcancer progression
p15456
sg13
I2
sasa(dp15457
g2
S'Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).\n'
p15458
sg4
(lp15459
(dp15460
g7
I496
sg8
g64
sg10
I4
sg11
VPAK1
p15461
sg13
I1
sa(dp15462
g7
I459
sg8
VP49336
p15463
sg10
I4
sg11
VCDK8
p15464
sg13
I1
sa(dp15465
g7
I363
sg8
g64
sg10
I6
sg11
VDFF-45
p15466
sg13
I1
sa(dp15467
g7
I394
sg8
VP45983
p15468
sg10
I5
sg11
VMAPK8
p15469
sg13
I1
sa(dp15470
g7
I355
sg8
VP55210
p15471
sg10
I6
sg11
VCASP-7
p15472
sg13
I1
sa(dp15473
g7
I479
sg8
VP49841
p15474
sg10
I10
sg11
VGSK-3 beta
p15475
sg13
I2
sa(dp15476
g7
I465
sg8
g64
sg10
I5
sg11
VCHEK1
p15477
sg13
I1
sa(dp15478
g7
I260
sg8
VP60484
p15479
sg10
I4
sg11
VPTEN
p15480
sg13
I1
sa(dp15481
g7
I265
sg8
VP42336
p15482
sg10
I4
sg11
VPI3K
p15483
sg13
I1
sa(dp15484
g7
I347
sg8
VP39880
p15485
sg10
I6
sg11
VCASP-9
p15486
sg13
I1
sa(dp15487
g7
I388
sg8
g64
sg10
I4
sg11
VPAX2
p15488
sg13
I1
sa(dp15489
g7
I447
sg8
VP06493
p15490
sg10
I4
sg11
VCDK1
p15491
sg13
I1
sa(dp15492
g7
I453
sg8
VP24941
p15493
sg10
I4
sg11
VCDK2
p15494
sg13
I1
sa(dp15495
g7
I383
sg8
VP12931
p15496
sg10
I3
sg11
VSrc
p15497
sg13
I1
sa(dp15498
g7
I371
sg8
g64
sg10
I3
sg11
VNPM
p15499
sg13
I1
sa(dp15500
g7
I270
sg8
g64
sg10
I3
sg11
VAkt
p15501
sg13
I1
sa(dp15502
g7
I371
sg8
g64
sg10
I3
sg11
VNPM
p15503
sg13
I1
sa(dp15504
g7
I502
sg8
VP35813
p15505
sg10
I10
sg11
VPP2C-alpha
p15506
sg13
I1
sasg23
(lp15507
(dp15508
g7
I427
sg26
VC0178874
p15509
sg10
I18
sg11
Vcancer progression
p15510
sg13
I2
sasa(dp15511
g2
S'The 14-3-3Zeta protein acts as a molecular switch in regulating the TGF-Beta pathway, which alters from a tumor suppressor in the early stage of breast cancer to a promoter of metastasis in the late stage.\n'
p15512
sg4
(lp15513
(dp15514
g7
I68
sg8
VP18075
p15515
sg10
I8
sg11
VTGF-Beta
p15516
sg13
I1
sasg23
(lp15517
(dp15518
g7
I176
sg26
VC0027627
p15519
sg10
I10
sg11
Vmetastasis
p15520
sg13
I1
sa(dp15521
g7
I145
sg26
VC0678222
p15522
sg10
I13
sg11
Vbreast cancer
p15523
sg13
I2
sa(dp15524
g7
I106
sg26
VC0027651
p15525
sg10
I5
sg11
Vtumor
p15526
sg13
I1
sasa(dp15527
g2
S'This change is due to the binding of 14-3-3Zeta with YAP1 and Beta-TRCP in premalignant and cancer cells, respectively.\n'
p15528
sg4
(lp15529
(dp15530
g7
I62
sg8
g64
sg10
I9
sg11
VBeta-TRCP
p15531
sg13
I1
sa(dp15532
g7
I53
sg8
VP46937
p15533
sg10
I4
sg11
VYAP1
p15534
sg13
I1
sasg23
(lp15535
(dp15536
g7
I92
sg26
VC0006826
p15537
sg10
I6
sg11
Vcancer
p15538
sg13
I1
sa(dp15539
g7
I75
sg26
VC0032927
p15540
sg10
I12
sg11
Vpremalignant
p15541
sg13
I1
sasa(dp15542
g2
S'Owing to this inappropriate role of 14-3-3Zeta when involved in cancer and metastasis, we predicted that Gln15, Glu17, Tyr211, and Gln219 are hotspot residues of 14-3-3Zeta during its interaction with YAP1 protein.\n'
p15543
sg4
(lp15544
(dp15545
g7
I201
sg8
VP46937
p15546
sg10
I12
sg11
VYAP1 protein
p15547
sg13
I2
sasg23
(lp15548
(dp15549
g7
I64
sg26
VC0006826
p15550
sg10
I6
sg11
Vcancer
p15551
sg13
I1
sa(dp15552
g7
I75
sg26
VC0027627
p15553
sg10
I10
sg11
Vmetastasis
p15554
sg13
I1
sasa(dp15555
g2
S'Targeting these residues of 14-3-3Zeta can prevent cancer and metastasis caused by malfunctioning of the TGF-Beta pathway.\n'
p15556
sg4
(lp15557
(dp15558
g7
I105
sg8
VP18075
p15559
sg10
I8
sg11
VTGF-Beta
p15560
sg13
I1
sasg23
(lp15561
(dp15562
g7
I51
sg26
VC0006826
p15563
sg10
I6
sg11
Vcancer
p15564
sg13
I1
sa(dp15565
g7
I62
sg26
VC0027627
p15566
sg10
I10
sg11
Vmetastasis
p15567
sg13
I1
sasa(dp15568
g2
S'The objective of this study was to evaluate the accuracy of non-invasive detection of fetal trisomy 18 using the unmethylated-maspin (U-maspin) gene as a cell-free fetal DNA marker and the methylated-maspin (M-maspin) gene as a cell-free total DNA marker in the first trimester of pregnancy.\n'
p15569
sg4
(lp15570
sg23
(lp15571
(dp15572
g7
I92
sg26
VC0152096
p15573
sg10
I10
sg11
Vtrisomy 18
p15574
sg13
I2
sasa(dp15575
g2
S'Median U-maspin concentrations were significantly elevated in women with trisomy 18 fetuses compared with controls (27.2 vs. 6.7 copies/mL; P&lt;0.001).\n'
p15576
sg4
(lp15577
sg23
(lp15578
(dp15579
g7
I73
sg26
VC0152096
p15580
sg10
I10
sg11
Vtrisomy 18
p15581
sg13
I2
sasa(dp15582
g2
S'Median M-maspin concentrations were also significantly higher in women with trisomy 18 fetuses than in controls (96.9 vs. 19.5 copies/mL, P&lt;0.001).\n'
p15583
sg4
(lp15584
(dp15585
g7
I0
sg8
VP36952
p15586
sg10
I15
sg11
VMedian M-maspin
p15587
sg13
I2
sasg23
(lp15588
(dp15589
g7
I76
sg26
VC0152096
p15590
sg10
I10
sg11
Vtrisomy 18
p15591
sg13
I2
sasa(dp15592
g2
S'The specificities of U-maspin and M-maspin concentrations for non-invasive fetal trisomy 18 detection were 96.4% and 74.5%, respectively, with a sensitivity of 90.9%.\n'
p15593
sg4
(lp15594
sg23
(lp15595
(dp15596
g7
I81
sg26
VC0152096
p15597
sg10
I10
sg11
Vtrisomy 18
p15598
sg13
I2
sasa(dp15599
g2
S'Our results suggest that U-maspin and M-maspin concentrations may be useful as potential biomarkers for non-invasive detection of fetal trisomy 18 in the first trimester of pregnancy, irrespective of the sex and genetic variations of the fetus.\n'
p15600
sg4
(lp15601
(dp15602
g7
I130
sg8
VP14207
p15603
sg10
I16
sg11
Vfetal trisomy 18
p15604
sg13
I3
sasg23
(lp15605
(dp15606
g7
I136
sg26
VC0152096
p15607
sg10
I10
sg11
Vtrisomy 18
p15608
sg13
I2
sasa(dp15609
g2
S'Recently, the SERPINB5 gene on chromosome 18 was shown to exhibit different DNA-methylation patterns in the placenta and maternal blood cells, and the allelic ratio for placenta-derived hypomethylated SERPINB5 in maternal plasma was further shown to be useful for noninvasive detection of fetal trisomy 18.\n'
p15610
sg4
(lp15611
(dp15612
g7
I14
sg8
VP36952
p15613
sg10
I13
sg11
VSERPINB5 gene
p15614
sg13
I2
sa(dp15615
g7
I14
sg8
VP36952
p15616
sg10
I8
sg11
VSERPINB5
p15617
sg13
I1
sasg23
(lp15618
(dp15619
g7
I295
sg26
VC0152096
p15620
sg10
I10
sg11
Vtrisomy 18
p15621
sg13
I2
sasa(dp15622
g2
S'Further studies can shed light on the physiological importance of actin filament aggregation with the peptides of thymopoietin, the systematic release of which from the thymus produces the phenomena characteristic for the serious neuromuscular disease myasthenia gravis.\n'
p15623
sg4
(lp15624
(dp15625
g7
I114
sg8
VP42166
p15626
sg10
I12
sg11
Vthymopoietin
p15627
sg13
I1
sasg23
(lp15628
(dp15629
g7
I252
sg26
VC0026896
p15630
sg10
I17
sg11
Vmyasthenia gravis
p15631
sg13
I2
sa(dp15632
g7
I230
sg26
VC0027868
p15633
sg10
I21
sg11
Vneuromuscular disease
p15634
sg13
I2
sasa(dp15635
g2
S'The appearance of systemic lupus erythematosus (SLE) as well as thymopoietin (TP3) treatment in a patient who has undergone thymectomy because of myasthenia gravis (MG) is described.\n'
p15636
sg4
(lp15637
(dp15638
g7
I64
sg8
VP42166
p15639
sg10
I12
sg11
Vthymopoietin
p15640
sg13
I1
sasg23
(lp15641
(dp15642
g7
I48
sg26
VC0024141
p15643
sg10
I3
sg11
VSLE
p15644
sg13
I1
sa(dp15645
g7
I165
sg26
VC0026896
p15646
sg10
I2
sg11
VMG
p15647
sg13
I1
sa(dp15648
g7
I146
sg26
VC0026896
p15649
sg10
I17
sg11
Vmyasthenia gravis
p15650
sg13
I2
sa(dp15651
g7
I18
sg26
VC0024141
p15652
sg10
I28
sg11
Vsystemic lupus erythematosus
p15653
sg13
I3
sasa(dp15654
g2
S'M2 (45Kd protein) was synthesized in thymocytes treated with thymopoietin, in cells from a patient with myasthenia gravis, and in a human T cell line.\n'
p15655
sg4
(lp15656
(dp15657
g7
I61
sg8
VP42166
p15658
sg10
I12
sg11
Vthymopoietin
p15659
sg13
I1
sa(dp15660
g7
I4
sg8
g64
sg10
I12
sg11
V45Kd protein
p15661
sg13
I2
sasg23
(lp15662
(dp15663
g7
I104
sg26
VC0026896
p15664
sg10
I17
sg11
Vmyasthenia gravis
p15665
sg13
I2
sasa(dp15666
g2
S'The effect of thymopoietin penta- (TP-5), tetra-(TP-4), and tripeptides (TP-3) was studied on the depressed lectin-dependent cell-mediated cytotoxicity (LDCC) against adherent HEp-2 target cells by peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE).\n'
p15667
sg4
(lp15668
(dp15669
g7
I108
sg8
g64
sg10
I6
sg11
Vlectin
p15670
sg13
I1
sasg23
(lp15671
(dp15672
g7
I139
sg26
VC0596402
p15673
sg10
I12
sg11
Vcytotoxicity
p15674
sg13
I1
sa(dp15675
g7
I176
sg26
VC0162569
p15676
sg10
I3
sg11
VHEp
p15677
sg13
I1
sa(dp15678
g7
I259
sg26
VC0024141
p15679
sg10
I28
sg11
Vsystemic lupus erythematosus
p15680
sg13
I3
sa(dp15681
g7
I289
sg26
VC0024141
p15682
sg10
I3
sg11
VSLE
p15683
sg13
I1
sasa(dp15684
g2
S'We demonstrated that the E6 proteins of two beta-human papillomaviruses (HPV14 and HPV21) associated with epidermodysplasia verruciformis also interacted with FOXK1/K2 through a motif similar to that of E1A.\n'
p15685
sg4
(lp15686
(dp15687
g7
I25
sg8
VP02649
p15688
sg10
I11
sg11
VE6 proteins
p15689
sg13
I2
sa(dp15690
g7
I159
sg8
VP85037
p15691
sg10
I5
sg11
VFOXK1
p15692
sg13
I1
sasg23
(lp15693
(dp15694
g7
I106
sg26
VC0014522
p15695
sg10
I31
sg11
Vepidermodysplasia verruciformis
p15696
sg13
I2
sasa(dp15697
g2
S'Moreover, induction of oncostatin M was detected in cancer-stimulated ASCs, whereas the downstream S100A7 binding proteins/receptor for advanced glycation endproducts were significantly upregulated in correspondence with S100A7 expression in breast cancer cells after coculture with ASCs.\n'
p15698
sg4
(lp15699
(dp15700
g7
I23
sg8
VP0CE72
p15701
sg10
I12
sg11
Voncostatin M
p15702
sg13
I2
sa(dp15703
g7
I99
sg8
VP31151
p15704
sg10
I32
sg11
VS100A7 binding proteins/receptor
p15705
sg13
I3
sa(dp15706
g7
I99
sg8
VP31151
p15707
sg10
I6
sg11
VS100A7
p15708
sg13
I1
sasg23
(lp15709
(dp15710
g7
I52
sg26
VC0006826
p15711
sg10
I6
sg11
Vcancer
p15712
sg13
I1
sa(dp15713
g7
I242
sg26
VC0678222
p15714
sg10
I13
sg11
Vbreast cancer
p15715
sg13
I2
sasa(dp15716
g2
S'We identified 39 significantly deregulated miRNAs, and the integration between miRNA and mRNA data revealed the importance of immune-related pathways, particularly the Oncostatin M (OSM) signaling, associated with mesenchymal-like breast cancer cells.\n'
p15717
sg4
(lp15718
(dp15719
g7
I168
sg8
VP0CE72
p15720
sg10
I12
sg11
VOncostatin M
p15721
sg13
I2
sa(dp15722
g7
I182
sg8
VP13725
p15723
sg10
I3
sg11
VOSM
p15724
sg13
I1
sasg23
(lp15725
(dp15726
g7
I231
sg26
VC0678222
p15727
sg10
I13
sg11
Vbreast cancer
p15728
sg13
I2
sasa(dp15729
g2
S'OSM levels correlated with genes involved in the inflammatory response, epithelial-to-mesenchymal transition (EMT), and epidermal growth factor (EGF) signaling in human estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative breast cancer.\n'
p15730
sg4
(lp15731
(dp15732
g7
I163
sg8
VP03372
p15733
sg10
I23
sg11
Vhuman estrogen receptor
p15734
sg13
I3
sa(dp15735
g7
I145
sg8
VP01133
p15736
sg10
I3
sg11
VEGF
p15737
sg13
I1
sa(dp15738
g7
I120
sg8
VP01133
p15739
sg10
I23
sg11
Vepidermal growth factor
p15740
sg13
I3
sa(dp15741
g7
I191
sg8
VP04626
p15742
sg10
I50
sg11
V-negative/human epidermal growth factor receptor 2
p15743
sg13
I6
sa(dp15744
g7
I243
sg8
VP04626
p15745
sg10
I4
sg11
VHER2
p15746
sg13
I1
sa(dp15747
g7
I0
sg8
VP13725
p15748
sg10
I3
sg11
VOSM
p15749
sg13
I1
sasg23
(lp15750
(dp15751
g7
I98
sg26
VC0599156
p15752
sg10
I10
sg11
Vtransition
p15753
sg13
I1
sa(dp15754
g7
I49
sg26
VC1155266
p15755
sg10
I21
sg11
Vinflammatory response
p15756
sg13
I2
sa(dp15757
g7
I258
sg26
VC0678222
p15758
sg10
I13
sg11
Vbreast cancer
p15759
sg13
I2
sasa(dp15760
g2
S'The identification of the OSM inflammatory pathway as an important mediator of EMT in triple-negative breast cancer (TNBC) may provide a novel potential opportunity to improve therapeutic strategies.\n'
p15761
sg4
(lp15762
(dp15763
g7
I26
sg8
VP13725
p15764
sg10
I3
sg11
VOSM
p15765
sg13
I1
sa(dp15766
g7
I79
sg8
g64
sg10
I3
sg11
VEMT
p15767
sg13
I1
sasg23
(lp15768
(dp15769
g7
I102
sg26
VC0678222
p15770
sg10
I13
sg11
Vbreast cancer
p15771
sg13
I2
sasa(dp15772
g2
S'Specifically, OSM, expressed by CD45(+) leucocytes in the stromal vascular fraction, induced phosphorylation of STAT3 (pSTAT3-) Y705 and S727 in breast cancer cells and transcription of several STAT3-dependent genes, including S100 family members S100A7, S100A8, and S100A9.\n'
p15773
sg4
(lp15774
(dp15775
g7
I247
sg8
VP31151
p15776
sg10
I6
sg11
VS100A7
p15777
sg13
I1
sa(dp15778
g7
I112
sg8
VP40763
p15779
sg10
I5
sg11
VSTAT3
p15780
sg13
I1
sa(dp15781
g7
I267
sg8
VP06702
p15782
sg10
I6
sg11
VS100A9
p15783
sg13
I1
sa(dp15784
g7
I227
sg8
VP04271
p15785
sg10
I11
sg11
VS100 family
p15786
sg13
I2
sa(dp15787
g7
I32
sg8
VP08575
p15788
sg10
I7
sg11
VCD45(+)
p15789
sg13
I1
sa(dp15790
g7
I255
sg8
VP05109
p15791
sg10
I6
sg11
VS100A8
p15792
sg13
I1
sa(dp15793
g7
I14
sg8
VP13725
p15794
sg10
I3
sg11
VOSM
p15795
sg13
I1
sa(dp15796
g7
I194
sg8
VP40763
p15797
sg10
I21
sg11
VSTAT3-dependent genes
p15798
sg13
I2
sasg23
(lp15799
(dp15800
g7
I145
sg26
VC0678222
p15801
sg10
I13
sg11
Vbreast cancer
p15802
sg13
I2
sasa(dp15803
g2
S'Our work reveals the potential of novel therapeutic strategies targeting the OSM and STAT3 axis in patients with breast cancer harboring nuclear pSTAT3-Y705.\n'
p15804
sg4
(lp15805
(dp15806
g7
I85
sg8
VP40763
p15807
sg10
I5
sg11
VSTAT3
p15808
sg13
I1
sa(dp15809
g7
I77
sg8
VP13725
p15810
sg10
I3
sg11
VOSM
p15811
sg13
I1
sasg23
(lp15812
(dp15813
g7
I113
sg26
VC0678222
p15814
sg10
I13
sg11
Vbreast cancer
p15815
sg13
I2
sasa(dp15816
g2
S'Here, we show that hypoxia-primed cancer cells chemoattract and polarize macrophages to pro-angiogenic M2-polarized subtype via Eotaxin and Oncostatin M. Concordantly, hypoxic regions of human breast-cancer specimen exhibited elevated Eotaxin and Oncostatin M levels with concurrently elevated M2-macrophage content.\n'
p15817
sg4
(lp15818
(dp15819
g7
I140
sg8
VP0CE72
p15820
sg10
I12
sg11
VOncostatin M
p15821
sg13
I2
sa(dp15822
g7
I128
sg8
VP51671
p15823
sg10
I7
sg11
VEotaxin
p15824
sg13
I1
sa(dp15825
g7
I140
sg8
VP0CE72
p15826
sg10
I12
sg11
VOncostatin M
p15827
sg13
I2
sa(dp15828
g7
I128
sg8
VP51671
p15829
sg10
I7
sg11
VEotaxin
p15830
sg13
I1
sasg23
(lp15831
(dp15832
g7
I19
sg26
VC0242184
p15833
sg10
I7
sg11
Vhypoxia
p15834
sg13
I1
sa(dp15835
g7
I34
sg26
VC0006826
p15836
sg10
I6
sg11
Vcancer
p15837
sg13
I1
sa(dp15838
g7
I34
sg26
VC0006826
p15839
sg10
I6
sg11
Vcancer
p15840
sg13
I1
sa(dp15841
g7
I168
sg26
VC0242184
p15842
sg10
I7
sg11
Vhypoxic
p15843
sg13
I1
sasa(dp15844
g2
S'Blockade of Eotaxin/Oncostatin M not only prevented hypoxic breast-cancer cells from recruiting and polarizing macrophages towards an M2-polarized phenotype and retarded tumor progression in 4T1/BALB/c-syngenic-mice-model of breast-cancer but also enhanced the efficacy of anti-angiogenic Bevacizumab.\n'
p15845
sg4
(lp15846
(dp15847
g7
I20
sg8
VP0CE72
p15848
sg10
I12
sg11
VOncostatin M
p15849
sg13
I2
sa(dp15850
g7
I12
sg8
VP51671
p15851
sg10
I7
sg11
VEotaxin
p15852
sg13
I1
sasg23
(lp15853
(dp15854
g7
I67
sg26
VC0006826
p15855
sg10
I6
sg11
Vcancer
p15856
sg13
I1
sa(dp15857
g7
I67
sg26
VC0006826
p15858
sg10
I6
sg11
Vcancer
p15859
sg13
I1
sa(dp15860
g7
I52
sg26
VC0242184
p15861
sg10
I7
sg11
Vhypoxic
p15862
sg13
I1
sa(dp15863
g7
I170
sg26
VC0178874
p15864
sg10
I17
sg11
Vtumor progression
p15865
sg13
I2
sasa(dp15866
g2
S'HB-EGF and OSM are co-expressed by TAM in breast carcinoma patients, and plasma levels of both ligands correlate strongly.\n'
p15867
sg4
(lp15868
(dp15869
g7
I11
sg8
VP13725
p15870
sg10
I3
sg11
VOSM
p15871
sg13
I1
sa(dp15872
g7
I0
sg8
g64
sg10
I6
sg11
VHB-EGF
p15873
sg13
I1
sasg23
(lp15874
(dp15875
g7
I42
sg26
VC0678222
p15876
sg10
I16
sg11
Vbreast carcinoma
p15877
sg13
I2
sa(dp15878
g7
I35
sg26
VC1834582
p15879
sg10
I3
sg11
VTAM
p15880
sg13
I1
sasa(dp15881
g2
S'The purpose of this study was to evaluate the safety and efficacy of Thymosin Beta4 eye drops (RGN-259) as a novel therapy for severe dry eye disease (including that associated with graft vs. host disease).\n'
p15882
sg4
(lp15883
sg23
(lp15884
(dp15885
g7
I138
sg26
VC0015397
p15886
sg10
I11
sg11
Veye disease
p15887
sg13
I2
sa(dp15888
g7
I182
sg26
VC0018133
p15889
sg10
I22
sg11
Vgraft vs. host disease
p15890
sg13
I4
sa(dp15891
g7
I134
sg26
VC0314719
p15892
sg10
I7
sg11
Vdry eye
p15893
sg13
I2
sasa(dp15894
g2
S'The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (TBeta4) as a novel therapy for DES.\n'
p15895
sg4
(lp15896
(dp15897
g7
I155
sg8
VP20962
p15898
sg10
I15
sg11
Vthymosin beta 4
p15899
sg13
I3
sa(dp15900
g7
I172
sg8
VP62328
p15901
sg10
I6
sg11
VTBeta4
p15902
sg13
I1
sasg23
(lp15903
(dp15904
g7
I85
sg26
VC0394006
p15905
sg10
I3
sg11
VDES
p15906
sg13
I1
sa(dp15907
g7
I67
sg26
VC0013238
p15908
sg10
I16
sg11
Vdry eye syndrome
p15909
sg13
I3
sa(dp15910
g7
I85
sg26
VC0394006
p15911
sg10
I3
sg11
VDES
p15912
sg13
I1
sasa(dp15913
g2
S'The present study was conducted to analyze CD39 expression in T cells and B-CLL cells to evaluate its impact on the clinical course of patients with B-CLL and correlate its levels with well-established risk factors.\n'
p15914
sg4
(lp15915
(dp15916
g7
I43
sg8
VP49961
p15917
sg10
I4
sg11
VCD39
p15918
sg13
I1
sasg23
(lp15919
(dp15920
g7
I76
sg26
VC0023434
p15921
sg10
I3
sg11
VCLL
p15922
sg13
I1
sa(dp15923
g7
I76
sg26
VC0023434
p15924
sg10
I3
sg11
VCLL
p15925
sg13
I1
sasa(dp15926
g2
S'Overall, our data indicate that T-cell CD39 expression may identify subsets of patients with B-CLL with an unfavorable clinical outcome.\n'
p15927
sg4
(lp15928
(dp15929
g7
I39
sg8
VP49961
p15930
sg10
I4
sg11
VCD39
p15931
sg13
I1
sasg23
(lp15932
(dp15933
g7
I95
sg26
VC0023434
p15934
sg10
I3
sg11
VCLL
p15935
sg13
I1
sasa(dp15936
g2
S"This paper focuses on the impact of ectonucleotidases, in particular, NTPDase1/CD39 and ecto-5'-nucleotidase/CD73, on allograft rejection, acute GvHD, and graft-versus-leukemia effect, and on possible clinical implications for the modulation of purinergic signalling after transplantation.\n"
p15937
sg4
(lp15938
(dp15939
g7
I79
sg8
VP49961
p15940
sg10
I4
sg11
VCD39
p15941
sg13
I1
sa(dp15942
g7
I88
sg8
VP21589
p15943
sg10
I20
sg11
Vecto-5'-nucleotidase
p15944
sg13
I1
sa(dp15945
g7
I70
sg8
VP49961
p15946
sg10
I8
sg11
VNTPDase1
p15947
sg13
I1
sa(dp15948
g7
I109
sg8
VP21589
p15949
sg10
I4
sg11
VCD73
p15950
sg13
I1
sasg23
(lp15951
(dp15952
g7
I139
sg26
VC0856825
p15953
sg10
I10
sg11
Vacute GvHD
p15954
sg13
I2
sa(dp15955
g7
I168
sg26
VC0023418
p15956
sg10
I8
sg11
Vleukemia
p15957
sg13
I1
sasa(dp15958
g2
S'A population of CCR7(+)CD39(+) T(regs) was significantly associated with chronic lymphocytic leukemia.\n'
p15959
sg4
(lp15960
(dp15961
g7
I16
sg8
VP32248
p15962
sg10
I11
sg11
VCCR7(+)CD39
p15963
sg13
I1
sasg23
(lp15964
(dp15965
g7
I73
sg26
VC0023434
p15966
sg10
I28
sg11
Vchronic lymphocytic leukemia
p15967
sg13
I3
sasa(dp15968
g2
S'We have tested whether the expression of CD39 and CD73 by chronic lymphocytic leukemia (CLL) cells activates an adenosinergic axis affecting growth and survival.\n'
p15969
sg4
(lp15970
(dp15971
g7
I41
sg8
VP49961
p15972
sg10
I4
sg11
VCD39
p15973
sg13
I1
sa(dp15974
g7
I50
sg8
VP21589
p15975
sg10
I4
sg11
VCD73
p15976
sg13
I1
sasg23
(lp15977
(dp15978
g7
I58
sg26
VC0023434
p15979
sg10
I28
sg11
Vchronic lymphocytic leukemia
p15980
sg13
I3
sa(dp15981
g7
I88
sg26
VC0023434
p15982
sg10
I3
sg11
VCLL
p15983
sg13
I1
sasa(dp15984
g2
S'Transcriptional and posttranscriptional levels of CaMKIIin tissue samples and MMP2, MMP9 and TIMP-1 expression in the human colon cancer cell line HCT116 were assessed by qRT-PCR and western blot.\n'
p15985
sg4
(lp15986
(dp15987
g7
I93
sg8
VP01033
p15988
sg10
I6
sg11
VTIMP-1
p15989
sg13
I1
sa(dp15990
g7
I84
sg8
VP14780
p15991
sg10
I4
sg11
VMMP9
p15992
sg13
I1
sa(dp15993
g7
I78
sg8
VP08253
p15994
sg10
I4
sg11
VMMP2
p15995
sg13
I1
sasg23
(lp15996
(dp15997
g7
I124
sg26
VC0699790
p15998
sg10
I12
sg11
Vcolon cancer
p15999
sg13
I2
sasa(dp16000
g2
S'Thus, these findings suggested that TUC.338 acts as a novel oncogene by targeting the TIMP-1 gene thus promoting colorectal cancer cell migration and invasion.\n'
p16001
sg4
(lp16002
(dp16003
g7
I86
sg8
VP01033
p16004
sg10
I11
sg11
VTIMP-1 gene
p16005
sg13
I2
sasg23
(lp16006
(dp16007
g7
I113
sg26
VC1527249
p16008
sg10
I17
sg11
Vcolorectal cancer
p16009
sg13
I2
sa(dp16010
g7
I150
sg26
VC2699153
p16011
sg10
I8
sg11
Vinvasion
p16012
sg13
I1
sasa.